{"PMID":"34449877","Document":["Ipilimumab was the first treatment that improved survival in advanced melanoma.","Efficacy and toxicity in a real-world setting may differ from clinical trials, due to more liberal eligibility criteria and less intensive monitoring.","Moreover, high costs and lack of biomarkers have raised cost-benefit concerns about ipilimumab in national healthcare systems and limited its use.","Here, we report the prospective, interventional study, Ipi4 (NCT02068196), which aimed to investigate the toxicity and efficacy of ipilimumab in a real-world population with advanced melanoma.","This national, multicentre, phase IV trial included 151 patients.","Patients received ipilimumab 3\u00a0mg\/kg intravenously and were followed for at least 5\u2009years or until death.","Treatment interruption or cessation occurred in 38%, most frequently due to disease progression (19%).","Treatment-associated grade 3 to 4 toxicity was observed in 28% of patients, and immune-related toxicity in 56%.","The overall response rate was 9%.","Median overall survival was 12.1\u00a0months (95% CI: 8.3-15.9); and progression-free survival 2.7\u00a0months (95% CI: 2.6-2.8).","After 5\u2009years, 20% of patients were alive.","In a landmark analysis from 6 months, improved survival was associated with objective response (HR 0.16, P\u2009=\u00a0.001) and stable disease (HR 0.49, P\u2009=\u00a0.005) compared to progressive disease.","Poor performance status, elevated lactate dehydrogenase and C-reactive protein were identified as biomarkers.","This prospective trial represents the longest reported follow-up of a real-world melanoma population treated with ipilimumab.","Results indicate safety and efficacy comparable to phase III trials and suggest that the use of ipilimumab can be based on current cost-benefit estimates."],"Aspect":"p","Summary":"The study included 151 patients with advanced melanoma who received ipilimumab treatment.","Indexes":[4],"Sentences":["This national, multicentre, phase IV trial included 151 patients."],"Revise":false}
{"PMID":"36416836","Document":["IMPORTANCE: A key issue for the adjuvant treatment of patients with melanoma is the assessment of the effect of treatment on relapse, survival, and quality of life (QOL).","OBJECTIVE: To compare QOL in patients with resected melanoma at high risk for relapse who were treated with adjuvant pembrolizumab vs standard of care with either ipilimumab or high-dose interferon \u03b1 2b (HDI).","DESIGN, SETTING, AND PARTICIPANTS: The S1404 phase 3 randomized clinical trial was conducted by the SWOG Cancer Research Network at 211 community\/academic sites in the US, Canada, and Ireland.","Patients were enrolled from December 2015 to October 2017.","Data analysis for this QOL substudy was completed in March 2022.","Overall, 832 patients were evaluable for the primary QOL end point.","INTERVENTIONS: Patients were randomized (1:1) to treatment with adjuvant pembrolizumab vs standard of care with ipilimumab\/HDI.","MAIN OUTCOMES AND MEASURES: Quality of life was assessed for patients at baseline and cycles 1, 3, 5, 7, and 9 after randomization using the Functional Assessment of Cancer Therapy (FACT) Biological Response Modifiers (FACT-BRM), FACT-General, Functional Assessment of Chronic Illness Therapy-Diarrhea, and European QOL 5-Dimension 3-Level scales.","The primary end point was the comparison by arm of cycle 3 FACT-BRM trial outcome index (TOI) scores using linear regression.","Linear-mixed models were used to evaluate QOL scores over time.","Regression analyses included adjustments for the baseline score, disease stage, and programmed cell death ligand 1 status.","A clinically meaningful difference of 5 points was targeted.","RESULTS: Among 1303 eligible patients (median [range] age, 56.7 [18.3-86.0] years; 524 women [40.2%]; 779 men [59.8%]; 10 Asian [0.8%], 7 Black [0.5%], 44 Hispanic [3.4%], and 1243 White [95.4%] individuals), 1188 (91.1%) had baseline FACT-BRM TOI scores, and 832 were evaluable at cycle 3 (ipilimumab\/HDI\u2009=\u2009267 [32.1%]; pembrolizumab\u2009=\u2009565 [67.9%]).","Evaluable patients were predominantly younger than 65 years (623 [74.9%]) and male (779 [58.9%]).","Estimates of FACT-BRM TOI cycle 3 compliance did not differ by arm (ipilimumab\/HDI, 96.0% vs pembrolizumab, 98.3%; P\u2009=\u2009.25).","The adjusted cycle 3 FACT-BRM TOI score was 9.6 points (95% CI, 7.9-11.3; P\u2009<\u2009.001) higher (better QOL) for pembrolizumab compared with ipilimumab\/HDI, exceeding the prespecified clinically meaningful difference.","In linear-mixed models, differences by arm exceeded 5 points in favor of pembrolizumab through cycle 7.","In post hoc analyses, FACT-BRM TOI scores favored the pembrolizumab arm compared with the subset of patients receiving ipilimumab (difference, 6.0 points; 95% CI, 4.1-7.8; P\u2009<\u2009.001) or HDI (difference, 17.0 points; 95% CI, 14.6-19.4; P\u2009<\u2009.001).","CONCLUSIONS AND RELEVANCE: This secondary analysis of a phase 3 randomized clinical trial found that adjuvant pembrolizumab improved QOL vs treatment with adjuvant ipilimumab or HDI in patients with high-risk resected melanoma.","TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02506153."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"35862871","Document":["PURPOSE: Combination treatment with BRAF and MEK inhibitors has demonstrated benefits on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the treatment of advanced BRAF V600-mutant melanoma.","Here, we report the 5-year update from the COLUMBUS trial (ClinicalTrials.gov identifier: NCT01909453).","METHODS: Patients with locally advanced unresectable or metastatic BRAF V600-mutant melanoma, untreated or progressed after first-line immunotherapy, were randomly assigned 1:1:1 to encorafenib 450 mg once daily plus binimetinib 45 mg twice daily, vemurafenib 960 mg twice daily, or encorafenib 300 mg once daily.","An updated analysis was conducted 65 months after the last patient was randomly assigned.","RESULTS: Five hundred seventy-seven patients were randomly assigned: 192 to encorafenib plus binimetinib, 191 to vemurafenib, and 194 to encorafenib.","The 5-year PFS and OS rates with encorafenib plus binimetinib were 23% and 35% overall and 31% and 45% in those with normal lactate dehydrogenase levels, respectively.","In comparison, the 5-year PFS and OS rates with vemurafenib were 10% and 21% overall and 12% and 28% in those with normal lactate dehydrogenase levels, respectively.","The median duration of response with encorafenib plus binimetinib was 18.6 months, with disease control achieved in 92.2% of patients.","In comparison, the median duration of response with vemurafenib was 12.3 months, with disease control achieved in 81.2% of patients.","Long-term follow-up showed no new safety concerns, and results were consistent with the known tolerability profile of encorafenib plus binimetinib.","Interactive visualization of the data presented in this article is available at COLUMBUS dashboard.","CONCLUSION: In this 5-year update of part 1 of the COLUMBUS trial, encorafenib plus binimetinib treatment demonstrated continued long-term benefits and a consistent safety profile in patients with BRAF V600-mutant melanoma."],"Aspect":"s","Summary":"Long-term follow-up showed no new safety concerns, and results were consistent with the known tolerability profile of encorafenib plus binimetinib.","Indexes":[9],"Sentences":["Long-term follow-up showed no new safety concerns, and results were consistent with the known tolerability profile of encorafenib plus binimetinib."],"Revise":false}
{"PMID":"35121932","Document":["Generating responses to tumor antigens poses a challenge for immunotherapy.","This phase II trial (NCT02129075) tested fms-like tyrosine kinase 3 (Flt3) ligand pre-treatment enhancement of responses to dendritic cell (DC)-targeting vaccines.","We evaluated a regimen of Flt3L (CDX-301) to increase DCs and other antigen-presenting cells, poly-ICLC (TLR3 agonist that activates DCs) and a vaccine comprising anti-DEC-205-NY-ESO-1, a fusion antibody targeting CD205, linked to NY-ESO-1.","High-risk melanoma patients were randomized to vaccine, with and without CDX-301.","The end point was immune response to NY-ESO-1.","Flt3L increased peripheral monocytes and conventional DCs (cDCs), including cross-presenting cDC1 and cDC2 and plasmacytoid DCs.","Significant increases in humoral and T-cell responses and activation of DCs, natural killer cells and T cells were elicited.","Transcriptional analyses revealed gene signatures associated with CDX-301 induction of an early, durable immune response.","This study reveals in vivo effects of Flt3L on innate immune cells in the setting of vaccination, leading to an immunogenic vaccine regimen."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"31980913","Document":["BACKGROUND: Autologous dendritic cell (DC) vaccines can induce tumor-specific T cells, but their effect can be counteracted by immunosuppressive mechanisms.","Cisplatin has shown immunomodulatory effects in vivo which may enhance efficacy of DC vaccination.","METHODS: This is a prospective, randomized, open-label phase 2 study (NCT02285413) including stage III and IV melanoma patients receiving 3 biweekly vaccinations of gp100 and tyrosinase mRNA-loaded monocyte-derived DCs with or without cisplatin.","Primary objectives were to study immunogenicity and feasibility, and secondary objectives were to assess toxicity and survival.","RESULTS: Twenty-two stage III and 32 stage IV melanoma patients were analyzed.","Antigen-specific CD8+ T cells were found in 44% versus 67% and functional T cell responses in 28% versus 19% of skin-test infiltrating lymphocytes in patients receiving DC vaccination with and without cisplatin, respectively.","Four patients stopped cisplatin because of toxicity and continued DC monotherapy.","No therapy-related grade 3 or 4 adverse events occurred due to DC monotherapy.","During combination therapy, one therapy-related grade 3 adverse event, decompensated heart failure due to fluid overload, occurred.","The clinical outcome parameters did not clearly suggest significant differences.","CONCLUSIONS: Combination of DC vaccination and cisplatin in melanoma patients is feasible and safe, but does not seem to result in more tumor-specific T cell responses or improved clinical outcome, when compared to DC vaccination monotherapy."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"36113242","Document":["BACKGROUND: A phase 1a first-in-human study evaluated the safety\/tolerability, preliminary antitumour activity and pharmacokinetics of the oral MEK1\/2 inhibitor FCN-159 in Chinese patients with advanced, NRAS-mutant melanoma.","PATIENTS AND METHODS: Patients received a single FCN-159 dose at assigned levels, proceeding to continuous dosing (once daily [QD] for 28-day cycles) if no dose-limiting toxicities (DLTs) occurred within the next 3 days.","Dose escalation was initiated after review of data for the previous dose level.","The primary end-point was incidence of DLTs after the first dose.","RESULTS: Thirty-three patients were enrolled across nine FCN-159 dose groups (0.2-15\u00a0mg QD).","One DLT occurred: grade 3 folliculitis in the 15-mg group.","There was one grade &gt;3 treatment-emergent adverse event (TEAE), death of unknown aetiology (not FCN-159 related).","The most common FCN-159-related TEAE was rash (36.4%), and the incidence of grade \u22653 FCN-159-related TEAEs was 15.2%.","Antitumour activity at QD doses &lt;6\u00a0mg was limited; therefore, efficacy data are presented only for doses \u22656\u00a0mg (n\u00a0=\u00a021).","The objective response and clinical benefit rates were 19.0% (four partial responses) and 52.4%, respectively.","Median (95% confidence interval) duration of response and progression-free survival were 4.8 months (2.8-not reached) and 3.8 months (1.8-5.6), respectively.","FCN-159 exposure increased dose-proportionately; geometric mean terminal half-life was 29.9-56.9\u00a0h. CONCLUSIONS: FCN-159 was well tolerated and demonstrated promising antitumour activity at doses \u22656\u00a0mg QD in patients with advanced, NRAS-mutant melanoma.","The recommended phase 2 dose was 12\u00a0mg QD.","GOV IDENTIFIER: NCT03932253.","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03932253."],"Aspect":"m","Summary":"The phase 1a study evaluated the oral MEK1\/2 inhibitor FCN-159 in Chinese patients with advanced, NRAS-mutant melanoma, with doses ranging from 0.2 to 15 mg QD, and the recommended phase 2 dose was 12 mg QD.","Indexes":[0,4,12],"Sentences":["BACKGROUND: A phase 1a first-in-human study evaluated the safety\/tolerability, preliminary antitumour activity and pharmacokinetics of the oral MEK1\/2 inhibitor FCN-159 in Chinese patients with advanced, NRAS-mutant melanoma.","RESULTS: Thirty-three patients were enrolled across nine FCN-159 dose groups (0.2-15\u00a0mg QD).","The recommended phase 2 dose was 12\u00a0mg QD."],"Revise":false}
{"PMID":"34463842","Document":["PURPOSE: To assess the efficacy of a treat-and-extend strategy with intravitreal ranibizumab for radiation-related macular edema.","METHODS: Forty eyes with radiation-induced macular edema and decreased visual acuity were enrolled in the phase IIb, prospective clinical trial and randomized into 3 cohorts: (A) monthly ranibizumab, (B) monthly ranibizumab with targeted retinal photocoagulation (TRP), or (C) as-needed ranibizumab and TRP.","In year 2, all subjects entered a treat-and-extend protocol for ranibizumab.","The primary outcome measure was mean change in early treatment diabetic retinopathy study (ETDRS) best-corrected visual acuity (BCVA) from baseline.","RESULTS: Through year 1, the mean change in ETDRS BCVA was significantly different between the three cohorts (p\u2009<\u20090.001); cohort A saw the largest gain with\u2009+\u20094.0 letters.","Significant anatomic improvements were also seen in all cohorts.","Comparatively, through year 2, cohorts A, B, and C had a mean change in ETDRS BCVA of\u2009-\u20091.9,\u2009-\u20093.9, and\u2009+\u20091.3 letters, respectively; additionally, no significant differences were found in absolute ETDRS BCVA across time (ANOVA, p\u2009=\u20090.123).","Overall, 90% of eyes maintained VA 20\/200 or better and 33.3% of subjects gained at least one line of vision.","There were no significant differences in mean central macular thickness for any cohort compared to baseline (p\u2009=\u20090.09).","The presence of retinal hemorrhage and intraretinal exudates stayed consistent from year 1 to year 2 for all cohorts.","CONCLUSIONS: Among eyes with radiation-related macular edema, a treat-and-extend regimen with ranibizumab may not result in as many visual and anatomic improvements as monthly injections.","However, treat-and-extend still may prevent serious visual complications compared to historical controls.","TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02222610."],"Aspect":"a","Summary":"The study aims to assess the efficacy of a treat-and-extend strategy with intravitreal ranibizumab for radiation-related macular edema.","Indexes":[0],"Sentences":["PURPOSE: To assess the efficacy of a treat-and-extend strategy with intravitreal ranibizumab for radiation-related macular edema."],"Revise":false}
{"PMID":"34551229","Document":["BACKGROUND: Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma.","Data showing a proven overall survival benefit with a systemic treatment are lacking.","Tebentafusp is a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells.","METHODS: In this open-label, phase 3 trial, we randomly assigned previously untreated HLA-A*02:01-positive patients with metastatic uveal melanoma in a 2:1 ratio to receive tebentafusp (tebentafusp group) or the investigator's choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine (control group), stratified according to the lactate dehydrogenase level.","The primary end point was overall survival.","RESULTS: A total of 378 patients were randomly assigned to either the tebentafusp group (252 patients) or the control group (126 patients).","Overall survival at 1 year was 73% in the tebentafusp group and 59% in the control group (hazard ratio for death, 0.51; 95% confidence interval [CI], 0.37 to 0.71; P<0.001) in the intention-to-treat population.","Progression-free survival was also significantly higher in the tebentafusp group than in the control group (31% vs. 19% at 6 months; hazard ratio for disease progression or death, 0.73; 95% CI, 0.58 to 0.94; P\u2009=\u20090.01).","The most common treatment-related adverse events in the tebentafusp group were cytokine-mediated events (due to T-cell activation) and skin-related events (due to glycoprotein 100-positive melanocytes), including rash (83%), pyrexia (76%), and pruritus (69%).","These adverse events decreased in incidence and severity after the first three or four doses and infrequently led to discontinuation of the trial treatment (2%).","No treatment-related deaths were reported.","CONCLUSIONS: Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma.","(Funded by Immunocore; ClinicalTrials.gov number, NCT03070392; EudraCT number, 2015-003153-18.",")."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"33641012","Document":["BACKGROUND: Melanoma therapy has changed dramatically over the last decade with improvements in immunotherapy, yet many patients do not respond to current therapies.","This novel vaccine strategy may prime a patient's immune system against their tumor and work synergistically with immunotherapy against advanced-stage melanoma.","METHODS: This was a prospective, randomized, double-blind, placebo-controlled, phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine administered to prevent recurrence in patients with resected stage III\/IV melanoma.","Patients were enrolled and randomized 2:1 to the TLPLDC vaccine or placebo (empty yeast cell wall particles and autologous dendritic cells).","Both intention-to-treat (ITT) and per treatment (PT) analyses were predefined, with PT analysis including patients who remained disease-free through the primary vaccine\/placebo series (6 months).","RESULTS: A total of 144 patients were randomized (103 vaccine, 41 control).","Therapy was well-tolerated with similar toxicity between treatment arms; one patient in each group experienced related serious adverse events.","While disease-free survival (DFS) was not different between groups in ITT analysis, in PT analysis the vaccine group showed improved 24-month DFS (62.9% vs. 34.8%, p = 0.041).","CONCLUSIONS: This phase IIb trial of TLPLDC vaccine administered to patients with resected stage III\/IV melanoma shows TLPLDC is well-tolerated and improves DFS in patients who complete the primary vaccine series.","This suggests patients who do not recur early benefit from TLPLDC in preventing future recurrence from melanoma.","A phase III trial of TLPLDC + checkpoint inhibitor versus checkpoint inhibitor alone in patients with advanced, surgically resected melanoma is under development.","TRIAL REGISTRATION: NCT02301611."],"Aspect":"o","Summary":"The phase IIb trial of the TLPLDC vaccine showed improved 24-month disease-free survival (DFS) in patients with resected stage III\/IV melanoma who completed the primary vaccine series.","Indexes":[7,8],"Sentences":["While disease-free survival (DFS) was not different between groups in ITT analysis, in PT analysis the vaccine group showed improved 24-month DFS (62.9% vs. 34.8%, p = 0.041).","CONCLUSIONS: This phase IIb trial of TLPLDC vaccine administered to patients with resected stage III\/IV melanoma shows TLPLDC is well-tolerated and improves DFS in patients who complete the primary vaccine series."],"Revise":false}
{"PMID":"32007138","Document":["BACKGROUND: Adjuvant dabrafenib plus trametinib reduced the risk of relapse versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma in the phase 3 COMBI-AD trial.","This prespecified exploratory biomarker analysis aimed to evaluate potential prognostic or predictive factors and mechanisms of resistance to adjuvant targeted therapy.","METHODS: COMBI-AD is a randomised, double-blind, placebo-controlled, phase 3 trial comparing dabrafenib 150 mg orally twice daily plus trametinib 2 mg orally once daily versus two matched placebos.","Study participants were at least 18 years of age and underwent complete resection of stage IIIA (lymph node metastases >1 mm), IIIB, or IIIC cutaneous melanoma, per American Joint Committee on Cancer 7th edition criteria, with a BRAFV600E or BRAFV600K mutation.","Patients were randomly assigned (1:1) to the two treatment groups by an interactive voice response system, stratified by mutation type and disease stage.","Patients, physicians, and the investigators who analysed data were masked to treatment allocation.","The primary outcome was relapse-free survival, defined as the time from randomisation to disease recurrence or death from any cause.","Biomarker assessment was a prespecified exploratory outcome of the trial.","We assessed intrinsic tumour genomic features by use of next-generation DNA sequencing and characteristics of the tumour microenvironment by use of a NanoString RNA assay, which might provide prognostic and predictive information.","This trial is registered with ClinicalTrials.gov, number NCT01682083, and is ongoing but no longer recruiting participants.","FINDINGS: Between Jan 31, 2013, and Dec 11, 2014, 870 patients were enrolled in the trial.","Median follow-up at data cutoff (April 30, 2018) was 44 months (IQR 38-49) in the dabrafenib plus trametinib group and 42 months (21-49) in the placebo group.","Intrinsic tumour genomic features were assessed in 368 patients (DNA sequencing set) and tumour microenvironment characteristics were assessed in 507 patients (NanoString biomarker set).","MAPK pathway genomic alterations at baseline did not affect treatment benefit or clinical outcome.","An IFN\u03b3 gene expression signature higher than the median was prognostic for prolonged relapse-free survival in both treatment groups.","Tumour mutational burden was independently prognostic for relapse-free survival in the placebo group (high TMB, top third; hazard ratio [HR] 0\u00b756, 95% CI 0\u00b737-0\u00b785, p=0\u00b70056), but not in the dabrafenib plus trametinib group (0\u00b783, 95% CI 0\u00b753-1\u00b732, p=0\u00b744).","Patients with tumour mutational burden in the lower two terciles seem to derive a substantial long-term relapse-free survival benefit from targeted therapy (HR [versus placebo] 0\u00b749, 95% CI 0\u00b735-0\u00b768, p<0\u00b70001).","However, patients with high tumour mutational burden seem to have a less pronounced benefit with targeted therapy (HR [versus placebo] 0\u00b775, 95% CI 0\u00b744-1\u00b726, p=0\u00b727), especially if they had an IFN\u03b3 signature lower than the median (HR 0\u00b788 [95% CI 0\u00b740-1\u00b793], p=0\u00b774).","INTERPRETATION: Tumour mutational burden alone or in combination with IFN\u03b3 gene expression signature or other markers for an adaptive immune response might be of relevance for identifying patients with stage III melanoma who might derive clinical benefit from targeted therapy.","Further validation in prospective clinical trials is warranted.","FUNDING: Novartis Pharmaceuticals."],"Aspect":"m","Summary":"The trial compared dabrafenib 150 mg orally twice daily plus trametinib 2 mg orally once daily versus two matched placebos.","Indexes":[2],"Sentences":["METHODS: COMBI-AD is a randomised, double-blind, placebo-controlled, phase 3 trial comparing dabrafenib 150 mg orally twice daily plus trametinib 2 mg orally once daily versus two matched placebos."],"Revise":false}
{"PMID":"34449877","Document":["Ipilimumab was the first treatment that improved survival in advanced melanoma.","Efficacy and toxicity in a real-world setting may differ from clinical trials, due to more liberal eligibility criteria and less intensive monitoring.","Moreover, high costs and lack of biomarkers have raised cost-benefit concerns about ipilimumab in national healthcare systems and limited its use.","Here, we report the prospective, interventional study, Ipi4 (NCT02068196), which aimed to investigate the toxicity and efficacy of ipilimumab in a real-world population with advanced melanoma.","This national, multicentre, phase IV trial included 151 patients.","Patients received ipilimumab 3\u00a0mg\/kg intravenously and were followed for at least 5\u2009years or until death.","Treatment interruption or cessation occurred in 38%, most frequently due to disease progression (19%).","Treatment-associated grade 3 to 4 toxicity was observed in 28% of patients, and immune-related toxicity in 56%.","The overall response rate was 9%.","Median overall survival was 12.1\u00a0months (95% CI: 8.3-15.9); and progression-free survival 2.7\u00a0months (95% CI: 2.6-2.8).","After 5\u2009years, 20% of patients were alive.","In a landmark analysis from 6 months, improved survival was associated with objective response (HR 0.16, P\u2009=\u00a0.001) and stable disease (HR 0.49, P\u2009=\u00a0.005) compared to progressive disease.","Poor performance status, elevated lactate dehydrogenase and C-reactive protein were identified as biomarkers.","This prospective trial represents the longest reported follow-up of a real-world melanoma population treated with ipilimumab.","Results indicate safety and efficacy comparable to phase III trials and suggest that the use of ipilimumab can be based on current cost-benefit estimates."],"Aspect":"i","Summary":"The study, Ipi4 (NCT02068196), investigated the toxicity and efficacy of ipilimumab in a real-world population with advanced melanoma, with patients receiving ipilimumab 3 mg\/kg intravenously and followed for at least 5 years or until death.","Indexes":[3,5],"Sentences":["Here, we report the prospective, interventional study, Ipi4 (NCT02068196), which aimed to investigate the toxicity and efficacy of ipilimumab in a real-world population with advanced melanoma.","Patients received ipilimumab 3\u00a0mg\/kg intravenously and were followed for at least 5\u2009years or until death."],"Revise":false}
{"PMID":"37286303","Document":["BACKGROUND: Immune checkpoint inhibitors have significantly improved outcomes in first line cutaneous melanoma.","However, there is a high unmet need for patients who progress on these therapies and combination therapies are being explored to improve outcomes.","Tebentafusp is a first-in-class gp100\u00d7CD3 ImmTAC bispecific that demonstrated overall survival (OS) benefit (HR 0.51) in metastatic uveal melanoma despite a modest overall response rate of 9%.","This phase 1b trial evaluated the safety and initial efficacy of tebentafusp in combination with durvalumab (anti-programmed death ligand 1 (PDL1)) and\/or tremelimumab (anti-cytotoxic T lymphocyte-associated antigen 4) in patients with metastatic cutaneous melanoma (mCM), the majority of whom progressed on prior checkpoint inhibitors.","METHODS: In this open-label, multicenter, phase 1b, dose-escalation trial, HLA-A*02:01-positive patients with mCM received weekly intravenous tebentafusp with increasing monthly doses of durvalumab and\/or tremelimumab starting day 15 of each cycle.","The primary objective was to identify the maximum tolerated dose (MTD) or recommended phase 2 dose for each combination.","Efficacy analyses were performed in all tebentafusp with durvalumab\u00b1tremelimumab treated patients with a sensitivity analysis in those who progressed on prior anti-PD(L)1 therapy.","RESULTS: 85 patients were assigned to receive tebentafusp in combination with durvalumab (n=43), tremelimumab (n=13), or durvalumab and tremelimumab (n=29).","Patients were heavily pretreated with a median of 3 prior lines of therapy, including 76 (89%) who received prior anti-PD(L)1.","Maximum target doses of tebentafusp (68 mcg) alone or in combination with durvalumab (20\u2009mg\/kg) and tremelimumab (1\u2009mg\/kg) were tolerated; MTD was not formally identified for any arm.","Adverse event profile was consistent with each individual therapy and there were no new safety signals nor treatment-related deaths.","In the efficacy subset (n=72), the response rate was 14%, tumor shrinkage rate was 41% and 1-year OS rate was 76% (95% CI: 70% to 81%).","The 1-year OS for triplet combination (79%; 95%\u2009CI: 71% to 86%) was similar to tebentafusp plus durvalumab (74%; 95%\u2009CI: 67% to 80%).","CONCLUSION: At maximum target doses, the safety of tebentafusp with checkpoint inhibitors was consistent with safety of each individual therapy.","Tebentafusp with durvalumab demonstrated promising efficacy in heavily pretreated patients with mCM, including those who progressed on prior anti-PD(L)1.","TRIAL REGISTRATION NUMBER: NCT02535078."],"Aspect":"s","Summary":"The adverse event profile of tebentafusp with checkpoint inhibitors was consistent with each individual therapy, with no new safety signals nor treatment-related deaths.","Indexes":[10],"Sentences":["Adverse event profile was consistent with each individual therapy and there were no new safety signals nor treatment-related deaths."],"Revise":false}
{"PMID":"38365756","Document":["Both targeted therapies and immunotherapies provide benefit in resected Stage III melanoma.","We hypothesized that the combination of targeted and immunotherapy given prior to therapeutic lymph node dissection (TLND) would be tolerable and drive robust pathologic responses.","In NeoACTIVATE (NCT03554083), a Phase II trial, patients with clinically evident resectable Stage III melanoma received either 12 weeks of neoadjuvant vemurafenib, cobimetinib, and atezolizumab (BRAF-mutated, Cohort A, n\u2009=\u200915), or cobimetinib and atezolizumab (BRAF-wild-type, Cohort B, n\u2009=\u200915) followed by TLND and 24 weeks of adjuvant atezolizumab.","Here, we report outcomes from the neoadjuvant portion of the trial.","Based on intent to treat analysis, pathologic response (\u226450% viable tumor) and major pathologic response (complete or near-complete, \u226410% viable tumor) were observed in 86.7% and 66.7% of BRAF-mutated and 53.3% and 33.3% of BRAF-wild-type patients, respectively (primary outcome); these exceeded pre-specified benchmarks of 50% and 30% for major pathologic response.","Grade 3 and higher toxicities, primarily dermatologic, occurred in 63% during neoadjuvant treatment (secondary outcome).","No surgical delays nor progression to regional unresectability occurred (secondary outcome).","Peripheral blood CD8\u2009+\u2009TCM cell expansion associated with favorable pathologic responses (exploratory outcome)."],"Aspect":"o","Summary":"The NeoACTIVATE trial demonstrated that the combination of targeted and immunotherapy before surgery in patients with Stage III melanoma led to an improved outcome in both BRAF-mutated and BRAF-wild-type disease, with tolerable toxicities.","Indexes":[2,4,5],"Sentences":["In NeoACTIVATE (NCT03554083), a Phase II trial, patients with clinically evident resectable Stage III melanoma received either 12 weeks of neoadjuvant vemurafenib, cobimetinib, and atezolizumab (BRAF-mutated, Cohort A, n\u2009=\u200915), or cobimetinib and atezolizumab (BRAF-wild-type, Cohort B, n\u2009=\u200915) followed by TLND and 24 weeks of adjuvant atezolizumab.","Based on intent to treat analysis, pathologic response (\u226450% viable tumor) and major pathologic response (complete or near-complete, \u226410% viable tumor) were observed in 86.7% and 66.7% of BRAF-mutated and 53.3% and 33.3% of BRAF-wild-type patients, respectively (primary outcome); these exceeded pre-specified benchmarks of 50% and 30% for major pathologic response.","Grade 3 and higher toxicities, primarily dermatologic, occurred in 63% during neoadjuvant treatment (secondary outcome)."],"Revise":true}
{"PMID":"32816891","Document":["PURPOSE: Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain, which redirects T cells to kill gp100-expressing tumor cells.","Here, we report a multicenter phase I\/II trial of tebentafusp in metastatic melanoma (NCT01211262) focusing on the mechanism of action of tebentafusp.","PATIENTS AND METHODS: Eighty-four patients with advanced melanoma received tebentafusp.","Treatment efficacy, treatment-related adverse events, and biomarker assessments were performed for blood-derived and tumor biopsy samples obtained at baseline and on-treatment.","RESULTS: Tebentafusp was generally well-tolerated and active in both patients with metastatic uveal melanoma and patients with metastatic cutaneous melanoma.","A 1-year overall survival rate of 65% was achieved for both patient cohorts.","On-treatment cytokine measurements were consistent with the induction of IFN\u03b3 pathway-related markers in the periphery and tumor.","Notably, tebentafusp induced an increase in serum CXCL10 (a T-cell attractant) and a reduction in circulating CXCR3+ CD8+ T cells together with an increase in cytotoxic T cells in the tumor microenvironment.","Furthermore, increased serum CXCL10 or the appearance of rash (likely due to cytotoxic T cells targeting gp100-expressing skin melanocytes) showed a positive association with patient survival.","CONCLUSIONS: These data suggest that redirecting T cells using a gp100-targeting TCR\/anti-CD3 bispecific fusion protein may provide benefit to patients with metastatic melanoma.","Furthermore, the activity observed in these two molecularly disparate melanoma classes hints at the broad therapeutic potential of tebentafusp."],"Aspect":"m","Summary":"The trial involved tebentafusp, a bispecific fusion protein targeting gp100 and CD3 to redirect T cells to kill tumor cells.","Indexes":[0,1,4],"Sentences":["PURPOSE: Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain, which redirects T cells to kill gp100-expressing tumor cells.","Here, we report a multicenter phase I\/II trial of tebentafusp in metastatic melanoma (NCT01211262) focusing on the mechanism of action of tebentafusp.","RESULTS: Tebentafusp was generally well-tolerated and active in both patients with metastatic uveal melanoma and patients with metastatic cutaneous melanoma."],"Revise":false}
{"PMID":"32376721","Document":["BACKGROUND: CTLA-4 blockade with ipilimumab is Food and Drug Administration-approved for melanoma as a monotherapy and has been shown to modulate the circulating T-cell repertoire.","We have previously reported clinical trials combining CTLA-4 blockade with granulocyte-macrophage colony-stimulating factor (GM-CSF) in metastatic melanoma patients and in metastatic castration resistant prostate cancer (mCRPC) patients.","Here, we investigate the effect that cancer type has on circulating T cells in metastatic melanoma and mCRPC patients, treated with ipilimumab and GM-CSF.","METHODS: We used next-generation sequencing of T-cell receptors (TCR) to compare the circulating T cells of melanoma and mCRPC patients receiving the same treatment with ipilimumab and GM-CSF by Wilcoxon rank sum test.","Flow cytometry was utilized to investigate specific T-cell populations.","TCR sequencing results were correlated with each T-cell subpopulation by Spearman's rank correlation coefficient.","Of note, 14 metastatic melanoma patients had samples available for TCR sequencing and 21 had samples available for flow cytometry analysis; 37 mCRPC patients had samples available for sequencing of whom 22 have TCR data available at both timepoints; 20 of these patients had samples available for flow cytometry analysis and 16 had data available at both timepoints.","RESULTS: While melanoma and mCRPC patients had similar pretreatment circulating T-cell counts, treatment induces greater expansion of circulating T cells in melanoma patients.","Metastatic melanoma patients have a higher proportion of clones that increased more than fourfold after the treatment compared with mCRPC patients (18.9% vs 11.0%, p=0.017).","Additionally, melanoma patients compared with mCRPC patients had a higher ratio of convergent frequency (1.22 vs 0.60, p=0.012).","Decreases in clonality induced by treatment are associated with baseline CD8+ T-cell counts in both patient groups, but are more pronounced in the melanoma patients (r=-0.81, p<0.001\u2009vs r=-0.59, p=0.02).","TRIAL REGISTRATION NUMBERS: NCT00064129; NCT01363206."],"Aspect":"o","Summary":"The results indicate that melanoma patients exhibit greater expansion of circulating T cells and a higher proportion of clones that increased more than fourfold after treatment compared to mCRPC patients, with a stronger correlation between decreases in clonality and baseline CD8+ T-cell counts in melanoma patients.","Indexes":[7,8,9,10],"Sentences":["RESULTS: While melanoma and mCRPC patients had similar pretreatment circulating T-cell counts, treatment induces greater expansion of circulating T cells in melanoma patients.","Metastatic melanoma patients have a higher proportion of clones that increased more than fourfold after the treatment compared with mCRPC patients (18.9% vs 11.0%, p=0.017).","Additionally, melanoma patients compared with mCRPC patients had a higher ratio of convergent frequency (1.22 vs 0.60, p=0.012).","Decreases in clonality induced by treatment are associated with baseline CD8+ T-cell counts in both patient groups, but are more pronounced in the melanoma patients (r=-0.81, p<0.001\u2009vs r=-0.59, p=0.02)."],"Revise":true}
{"PMID":"32761328","Document":["BACKGROUND: Ocular melanoma is the most common primary intraocular malignancy and has a very poor prognosis once liver metastases occur.","The aim of this study was to prospectively assess the efficacy and safety of percutaneous hepatic perfusion with melphalan (M-PHP) using the new second-generation (GEN 2) hemofiltration system in patients with ocular melanoma metastases confined to the liver.","METHODS: Prospective, single-center, single-arm, phase II study including patients with unresectable ocular melanoma metastases confined to the liver.","Treatment consisted of two M-PHP procedures at 6-8 weeks interval.","Procedures were performed using the CHEMOSAT (GEN 2) system with 3 mg\/kg melphalan.","Primary endpoints were overall response rate (ORR) and best overall response (BOR).","Secondary endpoints included overall survival (OS), progression-free survival (PFS), hepatic PFS (hPFS), and safety.","RESULTS: Sixty-four M-PHP procedures were performed in 35 patients between February 2014 and June 2017.","The ORR was 72%.","BOR was as follows: complete response in 3%, partial response in 69%, stable disease in 13%, and progressive disease in 16%.","There was no treatment-related mortality.","Fourteen serious adverse events occurred.","At a median follow-up of 19.1 months (range 5.6-69.5), median OS was 19.1 months and was significantly longer in responders than in nonresponders (27.5 vs. 11.9 months, p < 0.001).","The 1- and 2-year OS was 77% and 43%, respectively.","PFS and hPFS were 7.6 and 11.2 months, respectively.","CONCLUSIONS: M-PHP using the GEN 2 filter can achieve a high ORR and prolonged survival in patients with liver-only ocular melanoma metastases."],"Aspect":"s","Summary":"Fourteen serious adverse events occurred.","Indexes":[11],"Sentences":["Fourteen serious adverse events occurred."],"Revise":false}
{"PMID":"33128473","Document":["In the present study, we demonstrated that borage (Borago officinalis L.) seed oil subjected to immobilized lipase pretreatment are enriched with linoleic acid (LNA, 18:2n-6), \u03b3-linolenic acid (GLA, 18:3n-6), and oleic acid (OLA, 18:1n-9).","We further showed that lipase-treated borage oil (LT-BOL) regulates the activity and degradation of tyrosinase, an important enzyme implicated in the synthesis of melanin in murine melanocytes, B16F10.","LT-BOL and its free fatty acid components reduced the levels of melanin and tyrosinase in melanocytes with GLA exerting similar or stronger effects compared with LNA and OLA.","The brightening efficacy of LT-BOL on melanin metabolism in humans was tested by an 8-week, double-blind, randomized clinical trial, which enrolled 21 Korean female adults (mean age 48.57 \u00b1\u20093.28).","Visual evaluation showed that cream containing 1% LT-BOL significantly decreased (p\u2009<\u20090.05) melasma on the treated skin area after 6 and 8\u2009weeks.","The analysis of the skin brightness using Chromameter CR-400 confirmed that the brightness of the treated area was significantly increased (p\u2009<\u20090.01) after 4, 6, and 8\u2009weeks.","Together, our results suggest that LT-BOL may be suitable as a natural skin whitening cosmeceutical product."],"Aspect":"o","Summary":"The study demonstrated that lipase-treated borage oil (LT-BOL) significantly decreased melasma and increased skin brightness in a clinical trial.","Indexes":[4,5],"Sentences":["Visual evaluation showed that cream containing 1% LT-BOL significantly decreased (p\u2009<\u20090.05) melasma on the treated skin area after 6 and 8\u2009weeks.","The analysis of the skin brightness using Chromameter CR-400 confirmed that the brightness of the treated area was significantly increased (p\u2009<\u20090.01) after 4, 6, and 8\u2009weeks."],"Revise":false}
{"PMID":"34101300","Document":["To evaluate the feasibility of adoptive cell therapy (ACT) using ex vivo-expanded tumor-infiltrating lymphocytes (TILs) in Japanese patients with melanoma who failed immune-checkpoint inhibitor therapy, an open-label, single-arm, pilot study was conducted.","We investigated the immunological and genetic factors of the pretreatment tumor and expanded TILs that may be associated with the clinical response.","The treatment protocol comprised preparation of TIL culture, lympho-depleting non-myeloablative preconditioning with cyclophosphamide and fludarabine, TIL infusion, and intravenous administration of low-dose IL-2.","Three patients of clinical subtypes mucosal, superficial spreading, and acral melanoma underwent TIL-ACT.","Most severe adverse events, including fever and leukopenia, were manageable with the supportive regimen specified in the protocol, suggesting that the TIL-ACT regimen is suitable for Japanese patients with melanoma.","One patient showed a short-term partial response, one relatively long-stable disease, and one experienced disease progression.","Whole-exome and transcriptional sequencing of isolated tumor cells and immunohistochemical analyses before TIL-ACT revealed various immunostimulatory factors, including a high tumor mutation burden and immune cell-recruiting chemokines, as well as various immunosuppressive factors including TGF-\u03b2, VEGF, Wnt\/\u03b2-catenin, and MAPK signaling and epithelial-to-mesenchymal transition, which might influence the efficacy of TIL-ACT.","Our results imply mechanisms for the antitumor effect of and resistance to TIL-ACT.","Further studies of immune-resistant mechanisms of TIL-ACT are warranted.","This study is registered with the UMIN Clinical Trial Registry (UMIN 000011431)."],"Aspect":"m","Summary":"The treatment protocol included lympho-depleting non-myeloablative preconditioning with cyclophosphamide and fludarabine, TIL infusion, and intravenous administration of low-dose IL-2.","Indexes":[2],"Sentences":["The treatment protocol comprised preparation of TIL culture, lympho-depleting non-myeloablative preconditioning with cyclophosphamide and fludarabine, TIL infusion, and intravenous administration of low-dose IL-2."],"Revise":false}
{"PMID":"38723373","Document":["BACKGROUND: Treatment with encorafenib plus binimetinib and encorafenib monotherapy is associated with improved progression-free survival (PFS) and overall survival (OS) compared with vemurafenib in patients with BRAF V600E\/K-mutant metastatic melanoma.","We report results from the 7-year analysis of COLUMBUS part 1 (NCT01909453) at 99.7 months (median duration between randomization and data cutoff).","METHODS: 577 patients with locally advanced unresectable or metastatic BRAF V600E\/K-mutant melanoma who were treatment-naive or progressed after first-line immunotherapy were randomized 1:1:1 to encorafenib 450\u00a0mg once daily (QD) plus binimetinib 45\u00a0mg twice daily (BID) (n\u00a0=\u00a0192), vemurafenib 960\u00a0mg BID (n\u00a0=\u00a0191), or encorafenib monotherapy 300\u00a0mg QD (n\u00a0=\u00a0194).","No prior BRAF\/MEK inhibitor was allowed.","RESULTS: Seven-year PFS and OS rates (95\u00a0% CI) were 21.2\u00a0% (14.7-28.4\u00a0%) and 27.4\u00a0% (21.2-33.9%) in the encorafenib plus binimetinib arm and 6.4\u00a0% (2.1-14.0\u00a0%) and 18.2\u00a0% (12.8-24.3\u00a0%) in the vemurafenib arm, respectively.","Median melanoma-specific survival (95\u00a0% CI) was 36.8 months (27.7-51.5 months) in the encorafenib plus binimetinib arm and 19.3 months (14.8-25.9 months) in the vemurafenib arm.","Thirty-four long-term responders (complete\/partial response ongoing at 7 years) were identified across arms.","CONCLUSIONS: This is the longest follow-up from a phase III trial of BRAF\/MEK inhibitor combination in BRAF V600E\/K-mutant metastatic melanoma.","Safety results were consistent with the known tolerability profile of encorafenib plus binimetinib.","Results support the long-term efficacy and known safety of encorafenib plus binimetinib in this population and provide new insights on long-term responders.","Interactive data visualization is available at the COLUMBUS dashboard (https:\/\/clinical-trials.dimensions.ai\/columbus7\/)."],"Aspect":"i","Summary":"Patients with locally advanced unresectable or metastatic BRAF V600E\/K-mutant melanoma were randomized to receive encorafenib plus binimetinib, vemurafenib, or encorafenib monotherapy to compare their efficacy and safety.","Indexes":[2],"Sentences":["METHODS: 577 patients with locally advanced unresectable or metastatic BRAF V600E\/K-mutant melanoma who were treatment-naive or progressed after first-line immunotherapy were randomized 1:1:1 to encorafenib 450\u00a0mg once daily (QD) plus binimetinib 45\u00a0mg twice daily (BID) (n\u00a0=\u00a0192), vemurafenib 960\u00a0mg BID (n\u00a0=\u00a0191), or encorafenib monotherapy 300\u00a0mg QD (n\u00a0=\u00a0194)."],"Revise":false}
{"PMID":"36629029","Document":["PURPOSE: Inherited variation in MC1R imparts low to moderate risk of melanoma.","Research on genetic risk recall, factors predicting recall, and whether recall influences adoption of preventive behaviors is limited.","METHODS: Participants (n\u00a0= 447) enrolled in a melanoma precision prevention trial were provided with MC1R risk information (average or higher) and after 6 and 12 months, were asked to recall their genetic risk.","Predictors of recall were identified using backward stepwise selection.","Intervention effects were reassessed after stratifying by recall.","RESULTS: Participants at higher risk were 2 to 3 times more likely to misremember or not recall than participants with average risk.","Misremembering was almost exclusively observed among participants at higher risk.","Among the participants with average risk, lower health numeracy and not completing the telephone follow-up were associated with not recalling or misremembering.","Among the participants at higher risk, lower education was associated with not recalling and lower perceived comparative chance of developing melanoma was associated with misremembering.","In general, participants at higher risk who correctly recalled had modestly stronger intervention effects on sun protection behaviors than those who misremembered or did not recall.","CONCLUSION: Future studies should examine different strategies to increase genetic risk recall, which may result in improved behavioral outcomes, especially among participants with lower education and health numeracy."],"Aspect":"p","Summary":"The study involved 447 participants enrolled in a melanoma precision prevention trial.","Indexes":[2],"Sentences":["METHODS: Participants (n\u00a0= 447) enrolled in a melanoma precision prevention trial were provided with MC1R risk information (average or higher) and after 6 and 12 months, were asked to recall their genetic risk."],"Revise":false}
{"PMID":"31699709","Document":["Given its ability to induce both humoral and cellular immune responses, NY-ESO-1 has been considered a suitable antigen for a cancer vaccine.","Despite promising results from early-phase clinical studies in patients with melanoma, NY-ESO-1 vaccine immunotherapy has not been widely investigated in larger trials; consequently, many questions remain as to the optimal vaccine formulation, predictive biomarkers, and sequencing and timing of vaccines in melanoma treatment.","We conducted an adjuvant phase I\/II clinical trial in high-risk resected melanoma to optimize the delivery of poly-ICLC, a TLR-3\/MDA-5 agonist, as a component of vaccine formulation.","A phase I dose-escalation part was undertaken to identify the MTD of poly-ICLC administered in combination with NY-ESO-1 and montanide.","This was followed by a randomized phase II part investigating the MTD of poly-ICLC with NY-ESO-1 with or without montanide.","The vaccine regimens were generally well tolerated, with no treatment-related grade 3\/4 adverse events.","Both regimens induced integrated NY-ESO-1-specific CD4+ T-cell and humoral responses.","CD8+ T-cell responses were mainly detected in patients receiving montanide.","T-cell avidity toward NY-ESO-1 peptides was higher in patients vaccinated with montanide.","In conclusion, NY-ESO-1 protein in combination with poly-ICLC is safe, well tolerated, and capable of inducing integrated antibody and CD4+ T-cell responses in most patients.","Combination with montanide enhances antigen-specific T-cell avidity and CD8+ T-cell cross-priming in a fraction of patients, indicating that montanide contributes to the induction of specific CD8+ T-cell responses to NY-ESO-1."],"Aspect":"i","Summary":"The study conducted an adjuvant phase I\/II clinical trial in high-risk resected melanoma patients to optimize the delivery of poly-ICLC in combination with NY-ESO-1 and montanide.","Indexes":[2,3,4],"Sentences":["We conducted an adjuvant phase I\/II clinical trial in high-risk resected melanoma to optimize the delivery of poly-ICLC, a TLR-3\/MDA-5 agonist, as a component of vaccine formulation.","A phase I dose-escalation part was undertaken to identify the MTD of poly-ICLC administered in combination with NY-ESO-1 and montanide.","This was followed by a randomized phase II part investigating the MTD of poly-ICLC with NY-ESO-1 with or without montanide."],"Revise":false}
{"PMID":"35190519","Document":["Treatment for advanced melanoma after progression on immunotherapy is limited.","This phase II trial (NCT03422445) was conducted to evaluate the efficacy and safety of apatinib plus temozolomide in patients with advanced melanoma after failure of immunotherapy.","Patients with unresectable stage III or stage IV melanoma after progression on immunotherapy were treated with temozolomide 300 mg on days 1-5 and apatinib 500 mg daily every 28-day cycle until disease progression or intolerable toxicities.","Besides immunotherapy, prior chemotherapy, targeted therapy, and clinical trials were allowed.","The primary endpoint was progression-free survival.","Secondary endpoints were objective response rate, disease control rate, overall survival, and safety.","Of 29 patients, 28 (96.6%) had metastatic diseases, and the predominant subtypes were mucosal [12 (41.4%)] and acral melanoma [eight (27.6%)].","Five (17.2%) patients showed BRAF, CKIT, or NRAS mutation.","Five achieved confirmed partial response, with an objective response rate of 17.2%.","The disease control rate was 82.8%.","The median progression-free survival was 5.0 months [95% confidence interval (CI): 4.7-5.3], and the median overall survival was 10.1 months (95% CI: 5.1-15.0).","Grade 3-4 treatment-related adverse events included proteinuria [four (13.8%)], thrombocytopenia [two (6.9%)], hypertension [one (3.4%)], and hyperbilirubinemia [one (3.4%)].","No treatment-related death occurred.","Apatinib plus temozolomide demonstrated promising efficacy and manageable safety profile in patients with advanced melanoma after progression on immunotherapy."],"Aspect":"o","Summary":"The study found that apatinib plus temozolomide achieved an objective response rate of 17.2% and a median progression-free survival of 5.0 months in patients with advanced melanoma after progression on immunotherapy. ","Indexes":[8,10,13],"Sentences":["Five achieved confirmed partial response, with an objective response rate of 17.2%.","The median progression-free survival was 5.0 months [95% confidence interval (CI): 4.7-5.3], and the median overall survival was 10.1 months (95% CI: 5.1-15.0).","Apatinib plus temozolomide demonstrated promising efficacy and manageable safety profile in patients with advanced melanoma after progression on immunotherapy."],"Revise":true}
{"PMID":"31980913","Document":["BACKGROUND: Autologous dendritic cell (DC) vaccines can induce tumor-specific T cells, but their effect can be counteracted by immunosuppressive mechanisms.","Cisplatin has shown immunomodulatory effects in vivo which may enhance efficacy of DC vaccination.","METHODS: This is a prospective, randomized, open-label phase 2 study (NCT02285413) including stage III and IV melanoma patients receiving 3 biweekly vaccinations of gp100 and tyrosinase mRNA-loaded monocyte-derived DCs with or without cisplatin.","Primary objectives were to study immunogenicity and feasibility, and secondary objectives were to assess toxicity and survival.","RESULTS: Twenty-two stage III and 32 stage IV melanoma patients were analyzed.","Antigen-specific CD8+ T cells were found in 44% versus 67% and functional T cell responses in 28% versus 19% of skin-test infiltrating lymphocytes in patients receiving DC vaccination with and without cisplatin, respectively.","Four patients stopped cisplatin because of toxicity and continued DC monotherapy.","No therapy-related grade 3 or 4 adverse events occurred due to DC monotherapy.","During combination therapy, one therapy-related grade 3 adverse event, decompensated heart failure due to fluid overload, occurred.","The clinical outcome parameters did not clearly suggest significant differences.","CONCLUSIONS: Combination of DC vaccination and cisplatin in melanoma patients is feasible and safe, but does not seem to result in more tumor-specific T cell responses or improved clinical outcome, when compared to DC vaccination monotherapy."],"Aspect":"s","Summary":"One therapy-related grade 3 adverse event, decompensated heart failure due to fluid overload, occurred during combination therapy, and no grade 3 or 4 adverse events occurred due to DC monotherapy.","Indexes":[7,8],"Sentences":["No therapy-related grade 3 or 4 adverse events occurred due to DC monotherapy.","During combination therapy, one therapy-related grade 3 adverse event, decompensated heart failure due to fluid overload, occurred."],"Revise":false}
{"PMID":"34158360","Document":["PURPOSE: The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall survival (OS) with addition of cobimetinib to vemurafenib compared with vemurafenib in patients with previously untreated BRAFV600 mutation-positive advanced melanoma.","We report long-term follow-up of coBRIM, with at least 5 years since the last patient was randomized.","PATIENTS AND METHODS: Eligible patients were randomized 1:1 to receive either oral cobimetinib (60 mg once daily on days 1-21 in each 28-day cycle) or placebo in combination with oral vemurafenib (960 mg twice daily).","RESULTS: 495 patients were randomized to cobimetinib plus vemurafenib (n = 247) or placebo plus vemurafenib (n = 248).","Median follow-up was 21.2 months for cobimetinib plus vemurafenib and 16.6 months for placebo plus vemurafenib.","Median OS was 22.5 months (95% CI, 20.3-28.8) with cobimetinib plus vemurafenib and 17.4 months (95% CI, 15.0-19.8) with placebo plus vemurafenib; 5-year OS rates were 31% and 26%, respectively.","Median PFS was 12.6 months (95% CI, 9.5-14.8) with cobimetinib plus vemurafenib and 7.2 months (95% CI, 5.6-7.5) with placebo plus vemurafenib; 5-year PFS rates were 14% and 10%, respectively.","OS and PFS were longest in patients with normal baseline lactate dehydrogenase levels and low tumor burden, and in those achieving complete response.","The safety profile remained consistent with previously published reports.","CONCLUSIONS: Extended follow-up of coBRIM confirms the long-term clinical benefit and safety profile of cobimetinib plus vemurafenib compared with vemurafenib monotherapy in patients with BRAFV600 mutation-positive advanced melanoma."],"Aspect":"m","Summary":"The trial involved cobimetinib at 60 mg once daily on days 1-21 of each 28-day cycle and vemurafenib at 960 mg twice daily.","Indexes":[2],"Sentences":["PATIENTS AND METHODS: Eligible patients were randomized 1:1 to receive either oral cobimetinib (60 mg once daily on days 1-21 in each 28-day cycle) or placebo in combination with oral vemurafenib (960 mg twice daily)."],"Revise":false}
{"PMID":"33449414","Document":["Immune checkpoint inhibition (ICI) treatments improve outcomes for metastatic melanoma; however, up to 60% of treated patients do not respond to ICI and\/or develop immune-related adverse events (irAEs).","Currently, robust and reliable biomarker to predict response and\/or occurrence of irAEs to ICI are missing.","Herein, we wanted to explore whether germline variants (SNPs) could predict the clinical outcomes of melanoma patients treated with ICIs.","We performed a whole exome sequencing using gDNA isolated from blood, from a discovery cohort of 57 patients with metastatic melanoma.","The top associations were then tested in a validation cohort of 57 patients.","Our work suggests that individual germline genetic variants have no or weak impact on the response to ICIs.","Only, variants in IL1RL1 have a significant impact in treatment response.","The role of IL1RL1 in the immune response against melanoma and as a theranostic marker warrants further investigations."],"Aspect":"i","Summary":"The study performed whole exome sequencing using blood-derived gDNA from patients with metastatic melanoma to explore the predictive power of germline variants (SNPs) on clinical outcomes of ICI treatments.","Indexes":[2,3],"Sentences":["Herein, we wanted to explore whether germline variants (SNPs) could predict the clinical outcomes of melanoma patients treated with ICIs.","We performed a whole exome sequencing using gDNA isolated from blood, from a discovery cohort of 57 patients with metastatic melanoma."],"Revise":false}
{"PMID":"33875611","Document":["BACKGROUND: While programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) antagonists have improved the prognosis for many patients with melanoma, around 60% fail therapy.","PVSRIPO is a non-neurovirulent rhinovirus:poliovirus chimera that facilitates an antitumor immune response following cell entry via the poliovirus receptor CD155, which is expressed on tumor and antigen-presenting cells.","Preclinical studies show that oncolytic virus plus anti-PD-1 therapy leads to a greater antitumor response than either agent alone, warranting clinical investigation.","METHODS: An open-label phase I trial of intratumoral PVSRIPO in patients with unresectable melanoma (American Joint Committee on Cancer V.7 stage IIIB, IIIC, or IV) was performed.","Eligible patients had disease progression on anti-PD-1 and V-raf murine sarcoma viral oncogene homolog B (BRAF)\/mitogen activated protein kinase kinase (MEK) inhibitors (if BRAF mutant).","The primary objective was to characterize the safety and tolerability of PVSRIPO.","Twelve patients in four cohorts received a total of 1, 2 or 3 injections of PVSRIPO monotherapy, with 21 days between injections.","RESULTS: PVSRIPO injections were well tolerated with no serious adverse events (SAEs) or dose-limiting toxicities (DLTs) reported.","All adverse events (AEs) were grade (G) 1 or G2 (G1 pruritus most common at 58%); all but two PVSRIPO-treatment related AEs were localized to the injected or adjacent lesions (n=1\u2009G1 hot flash, n=1\u2009G1 fatigue).","Four out of 12 patients (33%) achieved an objective response per immune-related response criteria (two observations, 4 weeks apart), including 4\/6 (67%) who received three injections.","In the four patients with in-transit disease, a pathological complete response (pCR) was observed in two (50%) patients.","Following study completion, 11\/12 patients (92%) reinitiated immune checkpoint inhibitor-based therapy, and 6\/12 patients (50%) remained without progression at a median follow-up time of 18 months.","CONCLUSION: Intratumoral PVSRIPO was well tolerated.","Despite the limited number of PVSRIPO treatments relative to the overall lesion burden (67% patients>5 lesions), intratumoral PVSRIPO showed promising antitumor activity, with pCR in injected as well as non-injected lesions in select patients.","TRIAL REGISTRATION NUMBER: NCT03712358."],"Aspect":"s","Summary":"All adverse events (AEs) were grade (G) 1 or G2, with the most common being G1 pruritus (58%), and all but two PVSRIPO-treatment related AEs were localized to the injected or adjacent lesions.","Indexes":[8],"Sentences":["All adverse events (AEs) were grade (G) 1 or G2 (G1 pruritus most common at 58%); all but two PVSRIPO-treatment related AEs were localized to the injected or adjacent lesions (n=1\u2009G1 hot flash, n=1\u2009G1 fatigue)."],"Revise":false}
{"PMID":"32669376","Document":["PURPOSE: This open-label, dose-finding phase Ib\/II study reports the safety and activity of the first combination use with BRAF inhibitor (BRAFi) encorafenib plus MEK inhibitor (MEKi) binimetinib in patients with BRAF V600E-mutant solid tumors.","PATIENTS AND METHODS: In phase I, the recommended phase 2 doses (RP2D) were established (primary objective).","In phase II, the clinical activity of the combination at the RP2D was assessed (primary objective) in patients with BRAF-mutant metastatic colorectal cancer (mCRC), BRAFi-treated BRAF-mutant melanoma, and BRAFi-na\u00efve BRAF-mutant melanoma.","RESULTS: A total of 126 patients with BRAF-mutant solid tumors were enrolled (phase I: 47 patients; phase II: 79 patients).","The RP2D was encorafenib 450 mg once daily plus binimetinib 45 mg twice daily and pharmacokinetic data suggest that drug exposures of each agent were similar in combination compared with single-agent studies.","In the phase II cohorts, confirmed responses were seen in two of 11 (18%) evaluable patients with mCRC, 11 of 26 (42%) evaluable patients with BRAFi-pretreated melanoma, and 28 of 42 (67%) BRAFi-na\u00efve patients with melanoma.","The most common grade 3\/4 adverse event in phase II was increased alanine aminotransferase.","CONCLUSIONS: The combination of encorafenib (450 mg) plus binimetinib (45 mg) showed acceptable tolerability and encouraging activity in patients with BRAF V600-mutant tumors, which led to the dose selection for the melanoma COLUMBUS study.","The safety profile of the combination was consistent with other approved BRAFi plus MEKi regimens, with several differences, including lower rates of dose-limiting pyrexia, arthralgia, and photosensitivity."],"Aspect":"a","Summary":"The study aims to assess the safety and activity of the combination use of BRAF inhibitor (BRAFi) encorafenib plus MEK inhibitor (MEKi) binimetinib in patients with BRAF V600E-mutant solid tumors.","Indexes":[0],"Sentences":["PURPOSE: This open-label, dose-finding phase Ib\/II study reports the safety and activity of the first combination use with BRAF inhibitor (BRAFi) encorafenib plus MEK inhibitor (MEKi) binimetinib in patients with BRAF V600E-mutant solid tumors."],"Revise":false}
{"PMID":"32044885","Document":["Predicting the response to PD-1\/PD-L1 immune checkpoint blockade in patients with metastatic melanoma remains challenging.","In this study, we have investigated for the relationships between PD-L1 expression, PD-L1 copy number variations, and the response to anti-PD-1 therapies.","We studied the formalin-fixed paraffin-embedded tumor samples of 36 patients with metastatic melanoma using PD-L1 immunohistochemistry (IHC) and PD-L1\/chromosome 9 fluorescent in situ hybridization (FISH).","PD-L1 IHC was positive in 3 patients (8.33%, with >5% stained tumor cells) and PD-L1 FISH test revealed 5 (13.8%) PD-L1 amplifications, 8 (22.2%) PD-L1 gains, and 2 (5.5%) PD-L1 losses.","Among 14 responders and 13 nonresponders to anti-PD-1 immunotherapy, we concluded that there was no significant relationship between PD-L1 expression, PD-L1 copy number variations, and the response to anti-PD-1 therapies.","In our study, the determination of PD-L1 expression using IHC and PD-L1 copy number using FISH was insufficient to predict the response to PD-1\/PD-L1 immune checkpoint blockade in patients with advanced melanomas."],"Aspect":"m","Summary":"The study investigated anti-PD-1 therapies.","Indexes":[1,4],"Sentences":["In this study, we have investigated for the relationships between PD-L1 expression, PD-L1 copy number variations, and the response to anti-PD-1 therapies.","Among 14 responders and 13 nonresponders to anti-PD-1 immunotherapy, we concluded that there was no significant relationship between PD-L1 expression, PD-L1 copy number variations, and the response to anti-PD-1 therapies."],"Revise":false}
{"PMID":"34400899","Document":["Plant tissue culture holds immense potential for the production of secondary metabolites with various physiological functions.","We recently established a plant tissue culture system capable of producing secondary metabolites from Aster yomena.","This study aimed to uncover the mechanisms underlying the potential therapeutic effects of Aster yomena callus pellet extract (AYC-P-E) on photoaging-induced skin pigmentation.","Excessive melanogenesis was induced in B16F10 melanoma cells using \u03b1-melanocyte stimulating hormone (\u03b1-MSH).","The effects of AYC-P-E treatment on melanin biosynthesis inducers and melanin synthesis inhibition were assessed.","Based on the results, a clinical study was conducted in subjects with skin pigmentation.","AYC-P-E inhibited melanogenesis in \u03b1-MSH-treated B16F10 cells, accompanied by decreased mRNA and protein expression of melanin biosynthesis inducers, including cyclic AMP response element-binding protein (CREB), tyrosinase, microphthalmia-associated transcription factor (MITF), tyrosinase related protein-1 (TRP-1), and TRP-2.","This anti-melanogenic effect was mediated by mitogen-activated protein kinase (MEK)\/extracellular signal-regulated kinase (ERK) and protein kinase B (AKT) phosphorylation.","Treatment of subjects with skin pigmentation with AYC-P-E-containing cream formulations resulted in 3.33%, 7.06%, and 8.68% improvement in the melanin levels at 2, 4, and 8 weeks, respectively.","Our findings suggest that AYC-P-E inhibits excessive melanogenesis by activating MEK\/ERK and AKT signaling, potentiating its cosmetic applications in hyperpigmentation treatment."],"Aspect":"o","Summary":"AYC-P-E inhibits excessive melanogenesis by activating MEK\/ERK and AKT signaling, showing potential for hyperpigmentation treatment.","Indexes":[6,7,9],"Sentences":["AYC-P-E inhibited melanogenesis in \u03b1-MSH-treated B16F10 cells, accompanied by decreased mRNA and protein expression of melanin biosynthesis inducers, including cyclic AMP response element-binding protein (CREB), tyrosinase, microphthalmia-associated transcription factor (MITF), tyrosinase related protein-1 (TRP-1), and TRP-2.","This anti-melanogenic effect was mediated by mitogen-activated protein kinase (MEK)\/extracellular signal-regulated kinase (ERK) and protein kinase B (AKT) phosphorylation.","Our findings suggest that AYC-P-E inhibits excessive melanogenesis by activating MEK\/ERK and AKT signaling, potentiating its cosmetic applications in hyperpigmentation treatment."],"Revise":false}
{"PMID":"39374099","Document":["PURPOSE: Patients with BRAFV600\/NRASQ61 wild-type melanoma who progress after immune checkpoint inhibitors (ICIs) have a poor prognosis.","MEK inhibition has shown activity in this patient population but is associated with treatment-limiting skin toxicity.","Combining a BRAF inhibitor with a MEK inhibitor is associated with less skin toxicity.","METHODS: This phase II trial investigated trametinib (2 mg once daily) in patients with advanced BRAFV600\/NRASQ61 wild-type, ICI-refractory melanoma.","In case of treatment-limiting skin toxicity, low-dose dabrafenib (50 mg twice daily) was added to trametinib.","After a trial amendment, both drugs were combined up-front.","The confirmed objective response rate (cORR) served as the primary end point.","RESULTS: Twenty-four patients were included (50% male; median age 57 years; 92% Eastern Cooperative Oncology Group Performance Status 0-2; 75% stage IV-M1c\/stage IV-M1d; median number of prior therapies: two [range, 1-5]).","Three patients were enrolled before and 21 patients after the amendment, respectively.","Seven confirmed and one unconfirmed partial responses (PRs) were observed (cORR, 29.2%).","The median duration of response was 16.6 weeks (95% CI, 5.5 to 27.7).","Stable disease (SD) was the best response in an additional five patients.","Among the responding patients, genetic alterations causing mitogen-activated protein kinase (MAPK) pathway activation were documented in six patients.","The disease control rate in patients with MAPK pathway-activating alterations was 64.3% (five confirmed PR, one unconfirmed PR, and three SD).","The median progression-free survival was 13.3 weeks (95% CI, 3.5 to 23.1), and the median overall survival was 54.3 weeks (95% CI, 37.9 to 70.6).","Adding low-dose dabrafenib to trametinib effectively mitigated or prevented treatment-limiting trametinib-related skin toxicity.","CONCLUSION: The combination of trametinib plus low-dose dabrafenib demonstrated encouraging efficacy and effective mitigation of skin toxicity in patients with advanced, ICI-pretreated BRAFV600\/NRASQ61 wild-type melanoma patients.","MAPK pathway-activating alterations hold promise as a predictive biomarker."],"Aspect":"m","Summary":"The trial investigated trametinib at a dose of 2 mg once daily, with low-dose dabrafenib at 50 mg twice daily added in case of treatment-limiting skin toxicity.","Indexes":[3,4],"Sentences":["METHODS: This phase II trial investigated trametinib (2 mg once daily) in patients with advanced BRAFV600\/NRASQ61 wild-type, ICI-refractory melanoma.","In case of treatment-limiting skin toxicity, low-dose dabrafenib (50 mg twice daily) was added to trametinib."],"Revise":false}
{"PMID":"38401247","Document":["BACKGROUND: POD1UM-203, an open-label, multicenter, phase II study, evaluated retifanlimab, a humanized monoclonal antibody targeting programmed cell death protein-1 (PD-1) in patients with selected solid tumors where immune checkpoint inhibitor therapies have previously shown efficacy.","PATIENTS AND METHODS: Eligible patients (\u226518 years) had measurable disease and included unresectable or metastatic melanoma, treatment-naive metastatic non-small-cell lung cancer (NSCLC) with high programmed death-ligand 1 (PD-L1) expression (tumor proportion score \u226550%), cisplatin-ineligible locally advanced\/metastatic urothelial carcinoma (UC) with PD-L1 expression (combined positive score \u226510%), or treatment-naive locally advanced\/metastatic clear-cell renal cell carcinoma (RCC).","Retifanlimab 500 mg was administered intravenously every 4 weeks as a 30-min infusion.","The primary endpoint was investigator-assessed overall response rate.","RESULTS: Overall, 121 patients (35 melanoma, 23 NSCLC, 29 UC, 34 RCC) were enrolled and treated.","The overall response rate [95% confidence interval (CI)] was 40.0% (23.9-57.9) in the melanoma cohort, 34.8% (16.4-57.3) in the NSCLC cohort, 37.9% (20.7-57.7) in the UC cohort, and 23.5% (10.7-41.2) in the RCC cohort.","Median duration of response was 11.5 months (95% CI 2.2-not reached) in the UC cohort, and was not reached in the other cohorts.","Retifanlimab safety was consistent with previous experience for PD-(L)1 inhibitors.","CONCLUSIONS: Retifanlimab demonstrated durable antitumor activity in patients with melanoma, NSCLC, UC, or RCC.","The efficacy and safety of retifanlimab were as expected for a PD-(L)1 inhibitor.","These data support further study of retifanlimab in solid tumors."],"Aspect":"i","Summary":"The study evaluated retifanlimab, a humanized monoclonal antibody targeting PD-1, administered intravenously every 4 weeks as a 30-min infusion in patients with selected solid tumors who have previously responded to immune checkpoint inhibitor therapies.","Indexes":[0,2],"Sentences":["BACKGROUND: POD1UM-203, an open-label, multicenter, phase II study, evaluated retifanlimab, a humanized monoclonal antibody targeting programmed cell death protein-1 (PD-1) in patients with selected solid tumors where immune checkpoint inhibitor therapies have previously shown efficacy.","Retifanlimab 500 mg was administered intravenously every 4 weeks as a 30-min infusion."],"Revise":true}
{"PMID":"35074903","Document":["BACKGROUND: There are no validated biomarkers that can aid clinicians in selecting who would best benefit from anticytotoxic T lymphocyte-associated antigen 4 monotherapy versus combination checkpoint blockade in patients with advanced melanoma who have progressive disease after programmed death 1 (PD-1) blockade.","METHODS: We conducted a randomized multicenter phase II trial in patients with advanced melanoma.","Patients were randomly assigned to receive either 1\u2009mg\/kg of nivolumab plus 3\u2009mg\/kg of ipilimumab or 3\u2009mg\/kg of ipilimumab every 3 weeks for up to four doses.","Patients were stratified by histological subtype and prior response to PD-1 therapy.","The primary clinical objective was overall response rate by week 18.","Translational biomarker analyses were conducted in patients with blood and tissue samples.","RESULTS: Objective responses were seen in 5 of 9 patients in the ipilimumab arm and 2 of 10 patients in the ipilimumab+nivolumab\u2009arm; disease control rates (DCRs) (66.7% vs 60.0%) and rates of grade 3-4 adverse events (56% vs 50%) were comparable between arms.","In a pooled analysis, patients with clinical benefit (CB), defined as Response Evaluation Criteria in Solid Tumors response or progression-free for 6 months, showed increased circulating CD4+ T cells with higher polyfunctionality and interferon gamma production following treatment.","Tumor profiling revealed enrichment of NRAS mutations and activation of transcriptional programs associated with innate and adaptive immunity in patients with CB.","CONCLUSIONS: In patients with advanced melanoma that previously progressed on PD-1 blockade, objective responses were seen in both arms, with comparable DCRs.","Findings from biomarker analyses provided hypothesis-generating signals for validation in future studies of larger patient cohorts.","TRIAL REGISTRATION NUMBER: NCT02731729."],"Aspect":"m","Summary":"The trial involved ipilimumab administered at a dose of 3 mg\/kg every 3 weeks for up to four doses, either alone or in combination with nivolumab at 1 mg\/kg.","Indexes":[2],"Sentences":["Patients were randomly assigned to receive either 1\u2009mg\/kg of nivolumab plus 3\u2009mg\/kg of ipilimumab or 3\u2009mg\/kg of ipilimumab every 3 weeks for up to four doses."],"Revise":false}
{"PMID":"36113895","Document":["BACKGROUND: Intratumoral (IT) myeloid dendritic cells (myDCs) play a pivotal role in initiating antitumor immune responses and relicensing of anti-tumor cytotoxic T lymphocytes within the tumor microenvironment.","Talimogene laherparepvec (T-VEC) induces immunogenic cell death, thereby providing maturation signals and enhancing the release of tumor antigens that can be captured and processed by CD1c (BDCA-1)+ \/ CD141 (BDCA-3)+ myDCs, in order to reinvigorate the cancer-immunity cycle.","METHODS: In this phase I trial, patients with advanced melanoma who failed standard therapy were eligible for IT injections of \u22651 non-visceral metastases with T-VEC on day 1 followed by IT injection of CD1c (BDCA-1)+ myDCs +\/- CD141 (BDCA-3)+ myDCs on day 2.","T-VEC injections were repeated on day 21 and every 14 days thereafter.","The number of IT administered CD1c (BDCA-1)+ myDCs was escalated from 0.5\u00d7106, to 1\u00d7106, to a maximum of 10\u00d7106 cells in three sequential cohorts.","In cohort 4, all isolated CD1c (BDCA-1)+ \/ CD141 (BDCA-3)+ myDCs were used for IT injection.","Primary objectives were safety and feasibility.","Repetitive biopsies of treated lesions were performed.","RESULTS: In total, 13 patients were enrolled (cohort 1 n=2; cohort 2 n=2; cohort 3 n=3; cohort 4 n=6).","Patients received a median of 6 (range 3-8) T-VEC injections.","The treatment was safe with most frequent adverse events being fatigue (n=11 (85%)), fever (n=8 (62%)), and chills\/influenza-like symptoms (n=6 (46%)).","Nine (69%) and four patients (31%), respectively, experienced pain or redness at the injection-site.","Clinical responses were documented in injected and non-injected lesions.","Two patients (cohort 3) who previously progressed on anti-PD-1 therapy (and one patient also on anti-CTLA-4 therapy) developed a durable, pathologically confirmed complete response that is ongoing at 33 and 35 months following initiation of study treatment.","One additional patient treated (cohort 4) had an unconfirmed partial response as best response; two additional patients had a mixed response (with durable complete responses of some injected and non-injected lesions).","On-treatment biopsies revealed a strong infiltration by inflammatory cells in regressing lesions.","CONCLUSIONS: IT coinjection of autologous CD1c (BDCA-1)+ +\/- CD141 (BDCA-3)+ myDCs with T-VEC is feasible, tolerable and resulted in encouraging early signs of antitumor activity in immune checkpoint inhibitor-refractory melanoma patients.","TRIAL REGISTRATION NUMBER: NCT03747744."],"Aspect":"p","Summary":"The study involved 13 patients with advanced melanoma who had failed standard therapy.","Indexes":[2,8],"Sentences":["METHODS: In this phase I trial, patients with advanced melanoma who failed standard therapy were eligible for IT injections of \u22651 non-visceral metastases with T-VEC on day 1 followed by IT injection of CD1c (BDCA-1)+ myDCs +\/- CD141 (BDCA-3)+ myDCs on day 2.","RESULTS: In total, 13 patients were enrolled (cohort 1 n=2; cohort 2 n=2; cohort 3 n=3; cohort 4 n=6)."],"Revise":false}
{"PMID":"33020648","Document":["Immune and targeted therapies achieve long-term survival in metastatic melanoma; however, new treatment strategies are needed to improve patients' outcomes1,2.","We report on the efficacy, safety and biomarker analysis from the single-arm safety run-in (part 1; n\u2009=\u20099) and biomarker (part 2; n\u2009=\u200927) cohorts of the randomized, placebo-controlled, phase\u20093 COMBI-i trial (NCT02967692) of the anti-PD-1 antibody spartalizumab, in combination with the BRAF inhibitor dabrafenib and MEK inhibitor trametinib.","Patients (n\u2009=\u200936) had previously untreated BRAF V600-mutant unresectable or metastatic melanoma.","In part\u20091, the recommended phase\u20093 regimen was identified based on the incidence of dose-limiting toxicities (DLTs; primary endpoint): 400\u2009mg of spartalizumab every 4\u2009weeks plus 150\u2009mg of dabrafenib twice daily plus 2\u2009mg of trametinib once daily.","Part\u20092 characterized changes in PD-L1 levels and CD8+ cells following treatment (primary endpoint), and analyzed additional biomarkers.","Assessments of efficacy and safety were key secondary endpoints (median follow-up, 24.3\u2009months).","Spartalizumab plus dabrafenib and trametinib led to an objective response rate (ORR) of 78%, including 44% complete responses (CRs).","Grade\u2009\u22653 treatment-related adverse events (TRAEs) were experienced by 72% of patients.","All patients had temporary dose modifications, and 17% permanently discontinued all three study drugs due to TRAEs.","Early progression-free survival (PFS) events were associated with low tumor mutational burden\/T cell-inflamed gene expression signature (GES) or high immunosuppressive tumor microenvironment (TME) GES levels at baseline; an immunosuppressive TME may also preclude CR.","Overall, the efficacy, safety and on-treatment biomarker modulations associated with spartalizumab plus dabrafenib and trametinib are promising, and biomarkers that may predict long-term benefit were identified."],"Aspect":"a","Summary":"The study aims to report on the efficacy, safety, and biomarker analysis of spartalizumab in combination with dabrafenib and trametinib in patients with previously untreated BRAF V600-mutant unresectable or metastatic melanoma.","Indexes":[1,2,4,5],"Sentences":["We report on the efficacy, safety and biomarker analysis from the single-arm safety run-in (part 1; n\u2009=\u20099) and biomarker (part 2; n\u2009=\u200927) cohorts of the randomized, placebo-controlled, phase\u20093 COMBI-i trial (NCT02967692) of the anti-PD-1 antibody spartalizumab, in combination with the BRAF inhibitor dabrafenib and MEK inhibitor trametinib.","Patients (n\u2009=\u200936) had previously untreated BRAF V600-mutant unresectable or metastatic melanoma.","Part\u20092 characterized changes in PD-L1 levels and CD8+ cells following treatment (primary endpoint), and analyzed additional biomarkers.","Assessments of efficacy and safety were key secondary endpoints (median follow-up, 24.3\u2009months)."],"Revise":false}
{"PMID":"38588588","Document":["Gut-microbiota modulation shows promise in improving immune-checkpoint blockade (ICB) response; however, precision biomarker-driven, placebo-controlled trials are lacking.","We performed a multicenter, randomized placebo-controlled, biomarker-stratified phase I trial in patients with ICB-na\u00efve metastatic melanoma using SER-401, an orally delivered Firmicutesenriched spore formulation.","Fecal microbiota signatures were characterized at baseline; patients were stratified by high versus low Ruminococcaceae abundance prior to randomization to the SER-401 arm (oral vancomycin-preconditioning\/SER-401 alone\/nivolumab + SER-401), versus the placebo arm [placebo antibiotic\/placebo microbiome modulation (PMM)\/nivolumab + PMM (NCT03817125)].","Analysis of 14 accrued patients demonstrated that treatment with SER-401 + nivolumab was safe, with an overall response rate of 25% in the SER-401 arm and 67% in the placebo arm (though the study was underpowered related to poor accrual during the COVID-19 pandemic).","Translational analyses demonstrated that vancomycin preconditioning was associated with the disruption of the gut microbiota and impaired immunity, with incomplete recovery at ICB administration (particularly in patients with high baseline Ruminococcaceae).","These results have important implications for future microbiome modulation trials.","Significance: This first-of-its-kind, placebo-controlled, randomized biomarker-driven microbiome modulation trial demonstrated that vancomycin + SER-401 and anti-PD-1 are safe in melanoma patients.","Although limited by poor accrual during the pandemic, important insights were gained via translational analyses, suggesting that antibiotic preconditioning and interventional drug dosing regimens should be carefully considered when designing such trials."],"Aspect":"a","Summary":"The study aims to investigate the safety and efficacy of SER-401, an orally delivered Fimicutesenriched spore formulation, in combination with nivolumab in patients with ICB-na\u00efve metastatic melanoma through a multicenter, randomized, placebo-controlled, biomarker-stratified phase I trial. ","Indexes":[1,2],"Sentences":["We performed a multicenter, randomized placebo-controlled, biomarker-stratified phase I trial in patients with ICB-na\u00efve metastatic melanoma using SER-401, an orally delivered Firmicutesenriched spore formulation.","Fecal microbiota signatures were characterized at baseline; patients were stratified by high versus low Ruminococcaceae abundance prior to randomization to the SER-401 arm (oral vancomycin-preconditioning\/SER-401 alone\/nivolumab + SER-401), versus the placebo arm [placebo antibiotic\/placebo microbiome modulation (PMM)\/nivolumab + PMM (NCT03817125)]."],"Revise":true}
{"PMID":"38048850","Document":["BACKGROUND: Tebentafusp demonstrated a superior overall survival (OS) benefit [hazard ratio (HR) 0.51] compared to investigator's choice (82% pembrolizumab) in a randomized, phase III trial (IMCgp100-202; N\u00a0= 378) in untreated metastatic uveal melanoma (mUM).","The 1-year OS rates for tebentafusp and pembrolizumab were 73% and 59%, respectively.","In the single-arm GEM1402 (N\u00a0= 52), the 1-year OS rate for nivolumab plus ipilimumab (N+I) in mUM was 52%.","Due to limitations in conducting randomized trials in mUM, we compared OS on tebentafusp or pembrolizumab (IMCgp100-202) to N+I (GEM1402) in untreated mUM using propensity scoring methods.","PATIENTS AND METHODS: Analyses were adjusted using propensity score-based inverse probability of treatment weighting (IPTW), balancing age, sex, baseline lactate dehydrogenase (LDH), baseline alkaline phosphatase, disease location, Eastern Cooperative Oncology Group status, and time from primary diagnosis to metastasis.","OS was assessed using IPT-weighted Kaplan-Meier and Cox proportional hazard models.","Sensitivity analyses using alternative missing data and weights methods were conducted.","RESULTS: The primary IPTW analysis included 240 of 252 patients randomized to tebentafusp from IMCgp100-202 and 45 of 52 N+I-treated patients from GEM-1402.","Key baseline covariates, including LDH, were generally well balanced before weighting.","The IPTW-adjusted OS favored tebentafusp, HR 0.52 [95% confidence interval (CI) 0.35-0.78]; 1-year OS was 73% for tebentafusp versus 50% for N+I.","Sensitivity analyses showed consistent superior OS for tebentafusp with all IPTW HRs \u22640.61.","IPTW analysis of pembrolizumab versus N+I showed no significant difference in OS (HR 0.72; 95% CI 0.50-1.06).","CONCLUSIONS: Tebentafusp was previously shown to provide an OS benefit compared to checkpoint inhibitors or chemotherapy in untreated mUM.","Propensity score analysis demonstrated a similar OS benefit for tebentafusp compared with N+I.","These data further support tebentafusp as the standard of care in previously untreated human leukocyte antigen (HLA)-A\u221702:01+ adult patients with mUM."],"Aspect":"o","Summary":"Tebentafusp showed a superior overall survival benefit compared to nivolumab plus ipilimumab (N+I) in untreated metastatic uveal melanoma (mUM), with a hazard ratio (HR) of 0.52 and a 1-year OS rate of 73% for tebentafusp versus 50% for N+I.","Indexes":[9,13],"Sentences":["The IPTW-adjusted OS favored tebentafusp, HR 0.52 [95% confidence interval (CI) 0.35-0.78]; 1-year OS was 73% for tebentafusp versus 50% for N+I.","Propensity score analysis demonstrated a similar OS benefit for tebentafusp compared with N+I."],"Revise":false}
{"PMID":"31653251","Document":["BACKGROUND: Amputation is the standard of care even for early-stage subungual melanomas (SUMs), known as nail apparatus melanoma, because the nail bed and nail matrix are close to the distal phalanx.","However, a recent study demonstrated that not all patients with SUMs had histologic invasion of the underlying distal phalanx.","As most SUMs occur in the thumb or big toe, amputation of either the thumb or big toe substantially interferes with activities of daily living, including poor cosmesis, loss of function, and phantom pain.","Non-amputative digit preservation surgery can thus be applied in such cases without compromising patient prognosis.","METHODS: We are conducting a multi-institutional single-arm trial to confirm the safety and efficacy of non-amputative digit preservation surgery.","We will compare our results with those reported in the Japanese Melanoma Study, in which patients underwent amputation for SUMs as a traditional standard of care.","Patients aged between 20 and 80\u2009years with stage I, II, or III without evidence of tumor invasion to the underlying distal phalanx on preoperative radiograph are included in the study.","The primary endpoint is major relapse-free survival (major RFS), which does not include local recurrence as an event; secondary endpoints include overall survival, digit-preservation survival, relapse-free survival, local relapse-free survival, partial relapse-free survival, and incidence of adverse events.","A total of 85 patients from 21 Japanese institutions will be recruited within 5.5\u2009years, and the follow-up period will last at least 5\u2009years.","The Japan Clinical Oncology Group Protocol Review Committee approved this study protocol in August 2017, and patient enrollment began in November 2017.","Ethical approval was obtained from each institution's Institutional Review Board prior to patient enrollment.","DISCUSSION: This is the first prospective trial to confirm the safety and efficacy of non-amputative digit preservation surgery for SUM without distant metastasis or bony invasion.","The results of this trial could provide evidence to support this less-invasive surgery as a new standard of care to preserve adequately functioning digits.","TRIAL REGISTRATION: Registry number: UMIN000029997 .","Date of Registration: 16\/Nov\/2017.","Date of First Participant Enrollment: 12\/Dec\/2017."],"Aspect":"i","Summary":"The study employs a multi-institutional, single-arm trial design to evaluate the safety and efficacy of non-amputative digit preservation surgery for SUM patients, comparing outcomes with historical data from traditional amputation-based care.","Indexes":[4,5],"Sentences":["METHODS: We are conducting a multi-institutional single-arm trial to confirm the safety and efficacy of non-amputative digit preservation surgery.","We will compare our results with those reported in the Japanese Melanoma Study, in which patients underwent amputation for SUMs as a traditional standard of care."],"Revise":true}
{"PMID":"31664428","Document":["IMPORTANCE: Obesity is a cancer risk factor, and bariatric surgery in patients with obesity is associated with reduced cancer risk.","However, evidence of an association among obesity, bariatric surgery, and skin cancer, including melanoma, is limited.","OBJECTIVE: To investigate the association of bariatric surgery with skin cancer (squamous cell carcinoma and melanoma) and melanoma incidence.","DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized controlled trial, the Swedish Obese Subjects (SOS) study, is ongoing at 25 surgical departments and 480 primary health care centers in Sweden and was designed to examine outcomes after bariatric surgery.","The study included 2007 patients with obesity who underwent bariatric surgery and 2040 contemporaneously matched controls who received conventional obesity treatment.","Patients were enrolled between September 1, 1987, and January 31, 2001.","Data analysis was performed from June 29, 2018, to November 22, 2018.","INTERVENTIONS: Patients in the surgery group underwent gastric bypass (n\u2009=\u2009266), banding (n\u2009=\u2009376), or vertical banded gastroplasty (n\u2009=\u20091365).","The control group (n\u2009=\u20092040) received the customary treatment for obesity at their primary health care centers.","MAIN OUTCOMES AND MEASURES: The SOS study was cross-linked to the Swedish National Cancer Registry, the Cause of Death Registry, and the Registry of the Total Population for data on cancer incidence, death, and emigration.","RESULTS: The study included 4047 participants (mean [SD] age, 47.9 [6.1] years; 2867 [70.8%] female).","Information on cancer events was available for 4042 patients.","The study found that bariatric surgery was associated with a markedly reduced risk of melanoma (adjusted subhazard ratio, 0.43; 95% CI, 0.21-0.87; P\u2009=\u2009.02; median follow-up, 18.1 years) and risk of skin cancer in general (adjusted subhazard ratio, 0.59; 95% CI, 0.35-0.99; P\u2009=\u2009.047).","The skin cancer risk reduction was not associated with baseline body mass index or weight; insulin, glucose, lipid, and creatinine levels; diabetes; blood pressure; alcohol intake; or smoking.","CONCLUSIONS AND RELEVANCE: The results of this study suggest that bariatric surgery in individuals with obesity is associated with a reduced risk of skin cancer, including melanoma.","TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01479452."],"Aspect":"o","Summary":"Bariatric surgery in individuals with obesity is associated with a reduced risk of skin cancer, including melanoma.","Indexes":[12,14],"Sentences":["The study found that bariatric surgery was associated with a markedly reduced risk of melanoma (adjusted subhazard ratio, 0.43; 95% CI, 0.21-0.87; P\u2009=\u2009.02; median follow-up, 18.1 years) and risk of skin cancer in general (adjusted subhazard ratio, 0.59; 95% CI, 0.35-0.99; P\u2009=\u2009.047).","CONCLUSIONS AND RELEVANCE: The results of this study suggest that bariatric surgery in individuals with obesity is associated with a reduced risk of skin cancer, including melanoma."],"Revise":false}
{"PMID":"32467299","Document":["BACKGROUND: A pilot study of stereotactic body radiation therapy (SBRT) followed by high-dose interleukin-2 (IL-2) showed a higher than anticipated objective response rate (ORR) among patients with metastatic melanoma (MM).","We performed a prospective randomized study to determine if the ORR of SBRT + IL-2 was greater than IL-2 monotherapy in patients with advanced melanoma.","METHODS: Patients with MM who had adequate physiological reserve for IL-2 and at least one site suitable for SBRT were eligible.","There was a 1:1 randomization to SBRT + IL-2 or IL-2 monotherapy.","Patients received one or two doses of SBRT (20\u2009Gy per fraction) with the last dose administered 3 days before starting the first cycle of IL-2.","IL-2 (600,000 IU per kg via intravenous bolus infusion) was given every 8\u2009hours for a maximum of 14 doses with a second cycle after a 2-week rest.","Responding patients received up to six IL-2 cycles.","Patients assigned to IL-2 monotherapy who exhibited progression of melanoma after cycle 2 were allowed to crossover and receive SBRT and additional IL-2.","Response Evaluation Criteria in Solid Tumors 1.1 criteria were applied to non-irradiated lesions for response assessment.","RESULTS: 44 patients were included in the analysis.","The ORR in the SBRT + IL-2 group was 54%: 21% complete response (CR), 33% partial response (PR), 21% stable disease (SD) and 25% progressive disease (PD).","The ORR in patients receiving IL-2 monotherapy was 35%: 15% CR, 20% PR, 25% SD and 40% PD.","Seven patients assigned to IL-2 subsequently received SBRT + IL-2.","One CR and two PRs were observed in the crossover group.","There was no difference in progression-free or overall survival (OS).","At 5 years the OS was 26% in the SBRT + IL-2 group and 25% in the IL-2 monotherapy group.","The disease control rate (DCR) was higher in the SBRT + IL-2 group (75% vs 60%, p=0.34).","CONCLUSIONS: SBRT + IL-2 induced more objective responses with a higher DCR compared to IL-2 monotherapy in MM.","IL-2 monotherapy resulted in a significantly higher ORR than anticipated.","Some patients in the crossover group also achieved objective responses.","TRIAL REGISTRATION NUMBER: NCT01416831."],"Aspect":"m","Summary":"The study used interleukin-2 (IL-2) at a dose of 600,000 IU per kg administered via intravenous bolus infusion every 8 hours for up to 14 doses, with stereotactic body radiation therapy (SBRT) at 20 Gy per fraction for one or two doses.","Indexes":[4,5],"Sentences":["Patients received one or two doses of SBRT (20\u2009Gy per fraction) with the last dose administered 3 days before starting the first cycle of IL-2.","IL-2 (600,000 IU per kg via intravenous bolus infusion) was given every 8\u2009hours for a maximum of 14 doses with a second cycle after a 2-week rest."],"Revise":false}
{"PMID":"35867951","Document":["PURPOSE: Effective treatments are needed for melanoma that progresses on inhibitors of programmed cell death protein-1 (PD-1) or its ligand (PD-L1).","We conducted the phase II LEAP-004 study to evaluate the combination of the multikinase inhibitor lenvatinib and the PD-1 inhibitor pembrolizumab in this population (ClinicalTrials.gov identifier: NCT03776136).","METHODS: Eligible patients with unresectable stage III-IV melanoma with confirmed progressive disease (PD) within 12 weeks of the last dose of a PD-1\/L1 inhibitor given alone or with other therapies, including cytotoxic T-cell lymphocyte-associated antigen 4 (CTLA-4) inhibitors, received lenvatinib 20 mg orally once daily plus \u2264 35 doses of pembrolizumab 200 mg intravenously once every 3 weeks until PD or unacceptable toxicity.","The primary end point was objective response rate (ORR) per RECIST, version 1.1, by independent central review.","RESULTS: A total of 103 patients were enrolled and treated.","The median study follow-up was 15.3 months.","ORR in the total population was 21.4% (95% CI, 13.9 to 30.5), with three (2.9%) complete responses and 19 (18.4%) partial responses.","The median duration of response was 8.3 months (range, 3.2-15.9+).","ORR was 33.3% in the 30 patients with PD on prior anti-PD-1 plus anti-CTLA-4 therapy.","The median progression-free survival and overall survival in the total population were 4.2 months (95% CI, 3.8 to 7.1) and 14.0 months (95% CI, 10.8 to not reached), respectively.","Grade 3-5 treatment-related adverse events occurred in 47 (45.6%) patients, most commonly hypertension (21.4%); one patient died from a treatment-related event (decreased platelet count).","CONCLUSION: Lenvatinib plus pembrolizumab provides clinically meaningful, durable responses in patients with advanced melanoma with confirmed PD on prior PD-1\/L1 inhibitor-based therapy, including those with PD on anti-PD-1 plus anti-CTLA-4 therapy.","The safety profile was as expected.","These data support lenvatinib plus pembrolizumab as a potential regimen for this population of high unmet need."],"Aspect":"a","Summary":"The study aims to evaluate the combination of lenvatinib and pembrolizumab in patients with advanced melanoma that progresses on PD-1 or PD-L1 inhibitors.","Indexes":[0,1],"Sentences":["PURPOSE: Effective treatments are needed for melanoma that progresses on inhibitors of programmed cell death protein-1 (PD-1) or its ligand (PD-L1).","We conducted the phase II LEAP-004 study to evaluate the combination of the multikinase inhibitor lenvatinib and the PD-1 inhibitor pembrolizumab in this population (ClinicalTrials.gov identifier: NCT03776136)."],"Revise":false}
{"PMID":"34255535","Document":["PURPOSE: Therapies that produce deep and durable responses in patients with metastatic melanoma are needed.","This phase II cohort from the international, single-arm PIVOT-02 study evaluated the CD122-preferential interleukin-2 pathway agonist bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in first-line metastatic melanoma.","METHODS: A total of 41 previously untreated patients with stage III\/IV melanoma received BEMPEG 0.006 mg\/kg plus NIVO 360 mg once every 3 weeks for \u2264 2 years; 38 were efficacy-evaluable (\u2265 1 postbaseline scan).","Primary end points were safety and objective response rate (blinded independent central review); other end points included progression-free survival, overall survival (OS), and exploratory biomarkers.","RESULTS: At 29.0 months' median follow-up, the objective response rate was 52.6% (20 of 38 patients), and the complete response rate was 34.2% (13 of 38 patients).","Median change in size of target lesions from baseline was -78.5% (response-evaluable population); 47.4% (18 of 38 patients) experienced complete clearance of target lesions.","Median progression-free survival was 30.9 months (95% CI, 5.3 to not estimable).","Median OS was not reached; the 24-month OS rate was 77.0% (95% CI, 60.4 to 87.3).","Grade 3 and 4 treatment-related and immune-mediated adverse events occurred in 17.1% (7 of 41) and 4.9% (2 of 41) of patients, respectively.","Increased polyfunctional responses in CD8+ and CD4+ T cells were seen in blood after treatment, driven by cytokines with effector functions.","Early on-treatment blood biomarkers (CD8+ polyfunctional strength difference and eosinophils) correlated with treatment response.","CONCLUSION: BEMPEG in combination with NIVO was tolerated, with relatively low rates of grade 3 and 4 treatment-related and immune-mediated adverse events.","The combination had encouraging antitumor activity in first-line metastatic melanoma, including an extended median progression-free survival.","Exploratory analyses associated noninvasive, on-treatment biomarkers with response, before radiologic evidence was observed."],"Aspect":"o","Summary":"In first-line metastatic melanoma, BEMPEG plus NIVO achieved an objective response rate of 52.6% (34.2% complete responses), a median progression-free survival of 30.9 months, and a 24-month overall survival rate of 77%, with low rates of grade 3-4 treatment-related adverse events (17.1%) and immune-mediated adverse events (4.9%).","Indexes":[4,6,7,8],"Sentences":["RESULTS: At 29.0 months' median follow-up, the objective response rate was 52.6% (20 of 38 patients), and the complete response rate was 34.2% (13 of 38 patients).","Median progression-free survival was 30.9 months (95% CI, 5.3 to not estimable).","Median OS was not reached; the 24-month OS rate was 77.0% (95% CI, 60.4 to 87.3).","Grade 3 and 4 treatment-related and immune-mediated adverse events occurred in 17.1% (7 of 41) and 4.9% (2 of 41) of patients, respectively."],"Revise":true}
{"PMID":"38029480","Document":["BACKGROUND: BRAF+MEK inhibitors extend life expectancy of patients with BRAFV600 mutant advanced melanoma.","Acquired resistance limits duration of benefit, but preclinical and case studies suggest intermittent dosing could overcome this limitation.","INTERIM was a phase 2 trial evaluating an intermittent dosing regimen.","METHODS: Patients with BRAFV600 mutant advanced melanoma due to start dabrafenib+trametinib were randomised to receive either continuous (CONT), or intermittent (INT; dabrafenib d1-21, trametinib d1-14 every 28 days) dosing.","A composite primary endpoint included progression-free survival (PFS) and quality of life (QoL).","Secondary endpoints included response rate (ORR), overall survival (OS) and adverse events (AEs).","Mutant BRAFV600E ctDNA was measured by droplet digital PCR (ddPCR), using mutant allele frequency of >\u00a01 % as the detection threshold.","RESULTS: 79 patients (39 INT, 40 CONT) were recruited; median age 67 years, 65 % AJCC (7th ed) stage IV M1c, 29 % had brain metastases.","With 19 months median follow-up, INT was inferior in all efficacy measures: median PFS 8.5 vs 10.7mo (HR 1.39, 95 %CI 0.79-2.45, p\u00a0=\u00a00.255); median OS 18.1mo vs not reached (HR 1.69, 95 %CI 0.87-3.28, p\u00a0=\u00a00.121), ORR 57 % vs 77 %.","INT patients experienced fewer treatment-related AEs (76 % vs 88 %), but more grade >\u00a03 AEs (53 % vs 42 %).","QoL favoured CONT.","Detection of BRAFV600E ctDNA prior to treatment correlated with worse OS (HR 2.55, 95 %CI 1.25-5.21, p\u00a0=\u00a00.01) in both arms.","A change to undetected during treatment did not significantly predict better OS.","CONCLUSION: INTERIM findings are consistent with other recent clinical trials reporting that intermittent dosing does not improve efficacy of BRAF+MEK inhibitors."],"Aspect":"o","Summary":"The INTERIM trial found that intermittent dosing of BRAF+MEK inhibitors was inferior to continuous dosing in all efficacy measures, including progression-free survival and overall survival.","Indexes":[8],"Sentences":["With 19 months median follow-up, INT was inferior in all efficacy measures: median PFS 8.5 vs 10.7mo (HR 1.39, 95 %CI 0.79-2.45, p\u00a0=\u00a00.255); median OS 18.1mo vs not reached (HR 1.69, 95 %CI 0.87-3.28, p\u00a0=\u00a00.121), ORR 57 % vs 77 %."],"Revise":false}
{"PMID":"32939750","Document":["INTRODUCTION: National Comprehensive Cancer Network guidelines recommend that sentinel lymph node biopsy (SLNB) be discussed with patients with thin melanoma at higher risk for lymph node metastasis (T1b or T1a with positive deep margins, lymphovascular invasion, or high mitotic index).","We examined the association between SLNB and resource utilization in this cohort.","METHODS: We conducted a retrospective cohort study of patients that underwent wide local excision for higher risk thin melanomas from 2009 to 2018 at a tertiary care center.","Patients who underwent SLNB were compared to those who did not undergo SLNB with regard to resource utilization, including total hospital cost.","RESULTS: A total of 70 patients were included in the analysis and 50 patients (71.4%) underwent SLNB.","SLNB was associated with increased hospital costs ($6700 vs. $3767;\u00a0p\u2009<\u2009.01) and increased operative time (68.5 vs. 36.0\u2009min; p\u2009<\u2009.01).","This cost difference persisted in multivariable regression (p\u2009<\u2009.01).","Of patients who underwent successful SLN mapping, 3 out of 49 patients had a positive SLN (6.1%).","The cost to identify a single positive sentinel lymph node (SLN) was $47,906.","CONCLUSION: In patients with a higher risk of thin melanoma, SLNB is associated with increased cost despite a low likelihood of SLN positivity.","These data better inform patient-provider discussions as the role of SLNB in thin melanoma evolves."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"35466524","Document":["Metastatic uveal melanoma (UM) is a devastating disease with few treatment options.","We evaluated the safety, tolerability and preliminary activity of arginine depletion using pegylated arginine deiminase (ADI-PEG20; pegargiminase) combined with pemetrexed (Pem) and cisplatin (Cis) chemotherapy in a phase 1 dose-expansion study of patients with argininosuccinate synthetase (ASS1)-deficient metastatic UM.","Eligible patients received up to six cycles of Pem (500\u2009mg\/m2 ) and Cis (75\u2009mg\/m2 ) every 3\u2009weeks plus weekly intramuscular ADI (36\u2009mg\/m2 ), followed by maintenance ADI until progression (NCT02029690).","Ten of fourteen ASS1-deficient patients with UM liver metastases and a median of one line of prior immunotherapy received ADIPemCis.","Only one \u2265 grade 3 adverse event of febrile neutropenia was reported.","Seven patients had stable disease with a median progression-free survival of 3.0\u00a0months (range, 1.3-8.1) and a median overall survival of 11.5\u00a0months (range, 3.2-36.9).","Despite anti-ADI-PEG20 antibody emergence, plasma arginine concentrations remained suppressed by 18\u2009weeks with a reciprocal increase in plasma citrulline.","Tumour rebiopsies at progression revealed ASS1 re-expression as an escape mechanism.","ADIPemCis was well tolerated with modest disease stabilisation in metastatic UM.","Further investigation of arginine deprivation is indicated in UM including combinations with immune checkpoint blockade and additional anti-metabolite strategies."],"Aspect":"o","Summary":"The study found that ADIPemCis was well tolerated and provided modest disease stabilization in metastatic uveal melanoma patients, with a median progression-free survival of 3.0 months and a median overall survival of 11.5 months.","Indexes":[5,8],"Sentences":["Seven patients had stable disease with a median progression-free survival of 3.0\u00a0months (range, 1.3-8.1) and a median overall survival of 11.5\u00a0months (range, 3.2-36.9).","ADIPemCis was well tolerated with modest disease stabilisation in metastatic UM."],"Revise":false}
{"PMID":"35398635","Document":["We conducted a retrospective tumor tissue analysis as part of the BRIM3 trial to evaluate the theragnostic significance of tumor-infiltrating lymphocytes (TILs) and melanoma cell proliferation.","Using manual semi-quantitative analyses, we assessed the density of TILs by pathology review of tissue sections stained with hematoxylin and eosin (H&E TIL score) and by immunohistochemistry (IHC) with an anti-CD8 antibody (CD8 TIL score); also, the melanoma cell proliferation by IHC with an anti-Ki67 antibody.","Three hundred and fifty-three, 280, and 172 patients' tumor tissue samples were available for H&E, CD8, and Ki67 IHC analysis, respectively.","There was no association between high (2+, 3+) peritumoral and intratumoral H&E and\/or TIL CD8 score or high Ki67 proliferation index (>15%) with serum LDH level and stage IV melanoma.","Neither high Ki67 proliferation, nor high peritumoral and\/or intratumoral TIL score was significantly associated with objective antitumor response in any treatment arm.","High intratumoral and high peritumoral CD8 TIL score was significantly associated with progression-free survival (PFS) only in DTIC-treated patients (P = 0.002 and 0.037, respectively); in vemurafenib-treated patients, high intratumoral and\/or peritumoral CD8 TIL score was not significant (log-rank P = 0.053 and 0.062, respectively).","Nevertheless, a high peritumoral CD8 TIL score was a significant predictor of PFS and overall survival after adjustment for age, sex, serum LDH, ECOG performance status, and treatment arm in a Cox regression model.","Vemurafenib does not only benefit patients bearing brisk TILs; even vemurafenib-treated patients with absent and\/or non-brisk TILs tend to have longer PFS compared to DTIC-treated patients with brisk TILs.","High peritumoral CD8 TIL score is a favorable prognostic factor independent of well-established AJCC staging factors."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"31270835","Document":["BACKGROUND: Melanoma is a globally significant and highly prevalent disease, with Breslow thickness widely recognized as the most important histologic indicator of prognosis.","In the newest edition of the AJCC Cancer Staging Manual, changes have been made to the definition of stages based on Breslow thickness.","It is therefore imperative we accurately measure the Breslow thickness in a standardized fashion.","METHODS: Our study aimed to identify the optimal number of levels required to measure Breslow thickness.","We reviewed archived cases of previously diagnosed invasive melanomas and assessed whether there was a change of T stage with the greater number of levels examined.","RESULTS: In our series of 54 cases, 10 (18.5%) cases were upgraded as additional levels were examined, statistically significant at the threshold of three levels.","CONCLUSIONS: Our data suggests the optimal number of levels to examine is 3, with no benefit seen in further levels up to 10."],"Aspect":"p","Summary":"The study reviewed 54 cases of previously diagnosed invasive melanomas.","Indexes":[4,5],"Sentences":["We reviewed archived cases of previously diagnosed invasive melanomas and assessed whether there was a change of T stage with the greater number of levels examined.","RESULTS: In our series of 54 cases, 10 (18.5%) cases were upgraded as additional levels were examined, statistically significant at the threshold of three levels."],"Revise":true}
{"PMID":"35074903","Document":["BACKGROUND: There are no validated biomarkers that can aid clinicians in selecting who would best benefit from anticytotoxic T lymphocyte-associated antigen 4 monotherapy versus combination checkpoint blockade in patients with advanced melanoma who have progressive disease after programmed death 1 (PD-1) blockade.","METHODS: We conducted a randomized multicenter phase II trial in patients with advanced melanoma.","Patients were randomly assigned to receive either 1\u2009mg\/kg of nivolumab plus 3\u2009mg\/kg of ipilimumab or 3\u2009mg\/kg of ipilimumab every 3 weeks for up to four doses.","Patients were stratified by histological subtype and prior response to PD-1 therapy.","The primary clinical objective was overall response rate by week 18.","Translational biomarker analyses were conducted in patients with blood and tissue samples.","RESULTS: Objective responses were seen in 5 of 9 patients in the ipilimumab arm and 2 of 10 patients in the ipilimumab+nivolumab\u2009arm; disease control rates (DCRs) (66.7% vs 60.0%) and rates of grade 3-4 adverse events (56% vs 50%) were comparable between arms.","In a pooled analysis, patients with clinical benefit (CB), defined as Response Evaluation Criteria in Solid Tumors response or progression-free for 6 months, showed increased circulating CD4+ T cells with higher polyfunctionality and interferon gamma production following treatment.","Tumor profiling revealed enrichment of NRAS mutations and activation of transcriptional programs associated with innate and adaptive immunity in patients with CB.","CONCLUSIONS: In patients with advanced melanoma that previously progressed on PD-1 blockade, objective responses were seen in both arms, with comparable DCRs.","Findings from biomarker analyses provided hypothesis-generating signals for validation in future studies of larger patient cohorts.","TRIAL REGISTRATION NUMBER: NCT02731729."],"Aspect":"o","Summary":"The study found objective responses and comparable disease control rates in both ipilimumab and ipilimumab+nivolumab arms for advanced melanoma patients who progressed on PD-1 blockade, with biomarker analyses suggesting immune-related features associated with clinical benefit for future validation.","Indexes":[6,9,10],"Sentences":["RESULTS: Objective responses were seen in 5 of 9 patients in the ipilimumab arm and 2 of 10 patients in the ipilimumab+nivolumab\u2009arm; disease control rates (DCRs) (66.7% vs 60.0%) and rates of grade 3-4 adverse events (56% vs 50%) were comparable between arms.","CONCLUSIONS: In patients with advanced melanoma that previously progressed on PD-1 blockade, objective responses were seen in both arms, with comparable DCRs.","Findings from biomarker analyses provided hypothesis-generating signals for validation in future studies of larger patient cohorts."],"Revise":true}
{"PMID":"34984539","Document":["Despite recent advance in immunotherapy agents, safe new therapies that enhance the effects of immune checkpoint inhibitors are still required to develop.","We previously demonstrated that hemagglutinating virus of Japan-envelope (HVJ-E) induced not only direct tumor cell death but also antitumor immunity through the activation of T and natural killer (NK) cells, thereafter, developed a manufacturing process of HVJ-E (GEN0101) for clinical use.","We here performed a phase Ia clinical trial of intratumoral GEN0101 administration in six patients with stage IIIC or IV malignant melanoma.","The primary aim was to evaluate the safety and tolerability of GEN0101, and the secondary aim was to examine the objective tumor response.","Patients were separated into two groups (n\u2009=\u20093 each) and received a low dose of 30,000 and high dose of 60,000 mNAU of GEN0101.","All patients completed a two-week follow-up evaluation without severe adverse events.","The overall response rate was 33% (2 of 6), with 2 partial responses in the high-dose group and 2 with stable disease, and 2 with progressive disease in the low-dose group.","Local complete or partial responses were observed in 11 of 18 (61%) target lesions.","One patient demonstrated shrinkage of lung metastases after the treatment.","The activity of NK cells and interferon-\u03b3 levels were increased in the circulation, indicating augmentation of antitumor immunity by GEN0101.","This trial showed not only the safety and tolerability but also the significant antitumor effect of GEN0101, suggesting that GEN0101 might be a promising new drug for patients with advanced melanoma."],"Aspect":"o","Summary":"The phase Ia clinical trial of GEN0101 demonstrated its safety, tolerability, and significant antitumor effect, with an overall response rate of 33% and local responses in 61% of target lesions.","Indexes":[5,6,7,10],"Sentences":["All patients completed a two-week follow-up evaluation without severe adverse events.","The overall response rate was 33% (2 of 6), with 2 partial responses in the high-dose group and 2 with stable disease, and 2 with progressive disease in the low-dose group.","Local complete or partial responses were observed in 11 of 18 (61%) target lesions.","This trial showed not only the safety and tolerability but also the significant antitumor effect of GEN0101, suggesting that GEN0101 might be a promising new drug for patients with advanced melanoma."],"Revise":false}
{"PMID":"32605909","Document":["PURPOSE: Combination therapy with reduced-dose programmed death 1 inhibitor plus standard-dose cytotoxic T-lymphocyte-associated antigen 4 inhibitor demonstrated efficacy, but substantial toxicity, in melanoma.","We present long-term results of part 1B of KEYNOTE-029, which assessed safety and efficacy of standard-dose pembrolizumab plus reduced-dose ipilimumab in advanced melanoma.","PATIENTS AND METHODS: Part 1B was an expansion cohort of the open-label, phase Ib portion of KEYNOTE-029.","Eligible patients had advanced melanoma and no previous immune checkpoint inhibitor therapy.","Patients received pembrolizumab 2 mg\/kg (amended to 200 mg) every 3 weeks plus ipilimumab 1 mg\/kg every 3 weeks (four cycles), then pembrolizumab alone for up to 2 years.","Primary end point was safety; secondary end points included objective response rate (ORR), progression-free survival (PFS), duration of response (DOR), and overall survival (OS).","RESULTS: A total of 153 patients received at least one dose of pembrolizumab plus ipilimumab.","At a median follow-up of 36.8 months, 71.9% had received four doses of ipilimumab and 30.7% had completed 2 years of pembrolizumab; 26.1% completed both treatments.","Treatment-related adverse events occurred in 96.1% (47.1% grade 3\/4; no deaths), leading to discontinuation of one or both study drugs in 35.9%.","ORR was 62.1% with 42 (27.5%) complete and 53 (34.6%) partial responses.","Median DOR was not reached; 36-month ongoing response rate was 84.2%.","Median PFS and OS were not reached; 36-month rates were 59.1% and 73.4%, respectively.","CONCLUSIONS: Standard-dose pembrolizumab plus reduced-dose ipilimumab demonstrated robust antitumor activity, durable response, and favorable long-term survival with manageable toxicity."],"Aspect":"d","Summary":"Patients received pembrolizumab 2 mg\/kg (amended to 200 mg) every 3 weeks plus ipilimumab 1 mg\/kg every 3 weeks (four cycles), then pembrolizumab alone for up to 2 years.","Indexes":[4],"Sentences":["Patients received pembrolizumab 2 mg\/kg (amended to 200 mg) every 3 weeks plus ipilimumab 1 mg\/kg every 3 weeks (four cycles), then pembrolizumab alone for up to 2 years."],"Revise":true}
{"PMID":"31358540","Document":["PURPOSE: Atezolizumab [anti-programmed death-ligand 1 (PD-L1)] selectively targets PD-L1 to block its interaction with receptors programmed death 1 and B7.1, thereby reinvigorating antitumor T-cell activity.","We evaluated the long-term safety and activity of atezolizumab, along with biological correlates of clinical activity endpoints, in a cohort of patients with melanoma in an ongoing phase Ia study (NCT01375842).","PATIENTS AND METHODS: Patients with unresectable or metastatic melanoma were enrolled to receive atezolizumab 0.1 to 20 mg\/kg or \u226510 mg\/kg every 3 weeks.","Primary study objectives were safety and tolerability.","Secondary objectives included investigator-assessed efficacy measures; pharmacodynamic and predictive biomarkers of antitumor activity were explored.","RESULTS: Forty-five patients were enrolled and were evaluable for safety.","Most treatment-related adverse events (AE) were grade 1\/2 (60%).","Fatigue (44%), pruritus (20%), pyrexia (18%), and rash (18%) were the most common treatment-related AEs of any grade.","No treatment-related deaths occurred.","Overall response rate was 30% among 43 efficacy- evaluable patients, with a median duration of response of 62 months [95% CI, 35-not estimable (NE)].","Clinically meaningful long-term survival was observed, with a median overall survival of 23 months (95% CI, 9-66).","Baseline biomarkers of tumor immunity [PD-L1 expression on immune cells, T effector (Teff), and antigen presentation gene signatures) and tumor mutational burden (TMB) were associated with improved response, progression-free survival, and overall survival.","CONCLUSIONS: Atezolizumab was well tolerated, with durable responses and survival in patients with melanoma.","PD-L1 expression, TMB, and Teff signatures may indicate improved benefit with atezolizumab in these patients."],"Aspect":"o","Summary":"Atezolizumab showed durable responses and survival in patients with melanoma, with an overall response rate of 30%,  a median duration of response of 62 months, and a median overall survival of 23 months.","Indexes":[9,10,12],"Sentences":["Overall response rate was 30% among 43 efficacy- evaluable patients, with a median duration of response of 62 months [95% CI, 35-not estimable (NE)].","Clinically meaningful long-term survival was observed, with a median overall survival of 23 months (95% CI, 9-66).","CONCLUSIONS: Atezolizumab was well tolerated, with durable responses and survival in patients with melanoma."],"Revise":true}
{"PMID":"31425480","Document":["Prognostic groups defined by lactate dehydrogenase concentration and number of organ sites containing metastases have been reported for patients treated with dabrafenib and trametinib for advanced melanoma.","We aimed to validate these prognostic groups for patients treated with vemurafenib and cobimetinib in the coBRIM and BRIM-3 clinical studies.","Eight hundred nine patients were included, 240 treated with vemurafenib plus cobimetinib and 569 with vemurafenib.","For patients treated with vemurafenib and cobimetinib, both overall survival (P < 0.001, c-statistic = 0.72) and progression-free survival (P < 0.001, c-statistic = 0.65) differed markedly between prognostic groups.","Two-year progression-free survival ranged from 3 (lactate dehydrogenase \u22652 times the upper limit of normal) to 50% (normal lactate dehydrogenase and \u22643 sites), and two-year overall survival ranged from 7 to 71%.","For patients treated with vemurafenib monotherapy, overall survival (P < 0.001, c-statistic = 0.66) and progression-free survival (P < 0.001, c-statistic = 0.62) also differed significantly between prognostic groups.","In conclusion, prognostic groups identified for patients treated with dabrafenib and trametinib are also applicable to patients treated with vemurafenib and cobimentinib."],"Aspect":"a","Summary":"The study aimed to validate prognostic groups for patients treated with vemurafenib and cobimetinib in the coBRIM and BRIM-3 clinical studies.","Indexes":[1],"Sentences":["We aimed to validate these prognostic groups for patients treated with vemurafenib and cobimetinib in the coBRIM and BRIM-3 clinical studies."],"Revise":false}
{"PMID":"32007138","Document":["BACKGROUND: Adjuvant dabrafenib plus trametinib reduced the risk of relapse versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma in the phase 3 COMBI-AD trial.","This prespecified exploratory biomarker analysis aimed to evaluate potential prognostic or predictive factors and mechanisms of resistance to adjuvant targeted therapy.","METHODS: COMBI-AD is a randomised, double-blind, placebo-controlled, phase 3 trial comparing dabrafenib 150 mg orally twice daily plus trametinib 2 mg orally once daily versus two matched placebos.","Study participants were at least 18 years of age and underwent complete resection of stage IIIA (lymph node metastases >1 mm), IIIB, or IIIC cutaneous melanoma, per American Joint Committee on Cancer 7th edition criteria, with a BRAFV600E or BRAFV600K mutation.","Patients were randomly assigned (1:1) to the two treatment groups by an interactive voice response system, stratified by mutation type and disease stage.","Patients, physicians, and the investigators who analysed data were masked to treatment allocation.","The primary outcome was relapse-free survival, defined as the time from randomisation to disease recurrence or death from any cause.","Biomarker assessment was a prespecified exploratory outcome of the trial.","We assessed intrinsic tumour genomic features by use of next-generation DNA sequencing and characteristics of the tumour microenvironment by use of a NanoString RNA assay, which might provide prognostic and predictive information.","This trial is registered with ClinicalTrials.gov, number NCT01682083, and is ongoing but no longer recruiting participants.","FINDINGS: Between Jan 31, 2013, and Dec 11, 2014, 870 patients were enrolled in the trial.","Median follow-up at data cutoff (April 30, 2018) was 44 months (IQR 38-49) in the dabrafenib plus trametinib group and 42 months (21-49) in the placebo group.","Intrinsic tumour genomic features were assessed in 368 patients (DNA sequencing set) and tumour microenvironment characteristics were assessed in 507 patients (NanoString biomarker set).","MAPK pathway genomic alterations at baseline did not affect treatment benefit or clinical outcome.","An IFN\u03b3 gene expression signature higher than the median was prognostic for prolonged relapse-free survival in both treatment groups.","Tumour mutational burden was independently prognostic for relapse-free survival in the placebo group (high TMB, top third; hazard ratio [HR] 0\u00b756, 95% CI 0\u00b737-0\u00b785, p=0\u00b70056), but not in the dabrafenib plus trametinib group (0\u00b783, 95% CI 0\u00b753-1\u00b732, p=0\u00b744).","Patients with tumour mutational burden in the lower two terciles seem to derive a substantial long-term relapse-free survival benefit from targeted therapy (HR [versus placebo] 0\u00b749, 95% CI 0\u00b735-0\u00b768, p<0\u00b70001).","However, patients with high tumour mutational burden seem to have a less pronounced benefit with targeted therapy (HR [versus placebo] 0\u00b775, 95% CI 0\u00b744-1\u00b726, p=0\u00b727), especially if they had an IFN\u03b3 signature lower than the median (HR 0\u00b788 [95% CI 0\u00b740-1\u00b793], p=0\u00b774).","INTERPRETATION: Tumour mutational burden alone or in combination with IFN\u03b3 gene expression signature or other markers for an adaptive immune response might be of relevance for identifying patients with stage III melanoma who might derive clinical benefit from targeted therapy.","Further validation in prospective clinical trials is warranted.","FUNDING: Novartis Pharmaceuticals."],"Aspect":"a","Summary":"The study aimed to evaluate potential prognostic or predictive factors and mechanisms of resistance to adjuvant targeted therapy in patients with resected, BRAFV600-mutant, stage III melanoma.","Indexes":[1],"Sentences":["This prespecified exploratory biomarker analysis aimed to evaluate potential prognostic or predictive factors and mechanisms of resistance to adjuvant targeted therapy."],"Revise":false}
{"PMID":"37261804","Document":["IMPORTANCE: Acral melanoma, known for low tumor mutation burden, responds poorly to immunotherapy.","A standard therapy is still lacking.","OBJECTIVE: To investigate the activity and safety of camrelizumab (an anti-programmed cell death-1 antibody) plus apatinib (a vascular endothelial growth factor receptor 2 inhibitor) and temozolomide as first-line treatment in patients with advanced acral melanoma.","DESIGN, SETTING, AND PARTICIPANTS: In this single-arm, single-center, phase 2 nonrandomized clinical trial, patients with treatment-naive unresectable stage III or IV acral melanoma were enrolled at Peking University Cancer Hospital and Institute between June 4, 2020, and August 24, 2021.","The data cutoff date was April 10, 2022.","INTERVENTIONS: Patients received 4-week cycles of intravenous camrelizumab, 200 mg, every 2 weeks; oral apatinib 250 mg, once daily; and intravenous temozolomide, 200 mg\/m2, once daily on days 1 to 5 until disease progression or unacceptable toxic effects.","MAIN OUTCOMES AND MEASURES: The primary end point was objective response rate as assessed by investigators according to the Response Evaluation Criteria In Solid Tumors (version 1.1).","Secondary end points included progression-free survival, time to response, duration of response, disease control rate, overall survival, and safety.","RESULTS: A total of 50 patients (32 men [64%]; median age, 57 years [IQR, 52-62 years]) were enrolled and received treatment.","The median follow-up duration was 13.4 months (IQR, 9.6-16.2 months).","The objective response rate was 64.0% (32 of 50; 95% CI, 49.2%-77.1%).","The median time to response and duration of response were 2.7 months (IQR, 0.9-2.9 months) and 17.5 months (95% CI, 12.0 to not reached), respectively.","The disease control rate was 88.0% (44 of 50; 95% CI, 75.7%-95.5%).","The estimated median progression-free survival was 18.4 months (95% CI, 10.6 to not reached).","The median overall survival was not reached.","The most common grade 3 or 4 treatment-related adverse events were increased gamma-glutamyltransferase levels (15 [30%]), decreased neutrophil count (11 [22%]), increased conjugated bilirubin levels (10 [20%]), and increased aspartate aminotransferase levels (10 [20%]).","No treatment-related deaths occurred.","CONCLUSIONS AND RELEVANCE: The findings of this nonrandomized clinical trial suggest that camrelizumab plus apatinib and temozolomide may be a potential first-line treatment option for patients with advanced acral melanoma, which warrants further validation in a randomized clinical trial.","TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04397770."],"Aspect":"d","Summary":"The treatment was administered until disease progression or unacceptable toxic effects.","Indexes":[5],"Sentences":["INTERVENTIONS: Patients received 4-week cycles of intravenous camrelizumab, 200 mg, every 2 weeks; oral apatinib 250 mg, once daily; and intravenous temozolomide, 200 mg\/m2, once daily on days 1 to 5 until disease progression or unacceptable toxic effects."],"Revise":false}
{"PMID":"38529706","Document":["Pembrolizumab demonstrated an acceptable safety profile and promising antitumor activity in Japanese patients with advanced melanoma in the phase 1b KEYNOTE-041 (Study of Pembrolizumab [MK-3475] in Participants With Advanced Melanoma) trial.","To evaluate the long-term efficacy and safety of pembrolizumab in Japanese patients with advanced melanoma in KEYNOTE-041.","The current analysis reports results of additional follow-up of approximately 12\u2009months since the initial analysis.","Eligible patients had locally advanced (unresectable stage III) or metastatic (stage IV) melanoma not amenable to local therapy and had received two or fewer prior systemic therapies.","Pembrolizumab 2\u2009mg\/kg was given every 3\u2009weeks for up to 2\u2009years or until confirmed progression or unacceptable toxicity.","Primary end points included safety, tolerability, and overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 by independent central review.","The data cutoff for this analysis was August 30, 2017.","Forty-two patients were followed up for a median of 22.3\u2009months (range, 2.63-30.82 months).","The ORR was 24.3% (nine of 37 evaluable patients [95% confidence interval (CI), 11.8%-41.2%]).","Two patients with partial response at the time of the initial analysis achieved complete response.","The median overall survival (OS) was 25.1\u2009months (95% CI, 13.1-not reached] and the 30-month OS rate was 46.3% (95% CI, 29.8%-61.3%).","The median duration of response was not reached.","Treatment-related adverse events (TRAEs) were reported in 78.6% of patients; the incidence of grade 3 to 5 TRAEs was 23.8%.","No additional treatment-related deaths occurred since the initial analysis.","Pembrolizumab provided durable antitumor activity and an acceptable safety profile in Japanese patients with advanced melanoma."],"Aspect":"i","Summary":"The study evaluated the long-term efficacy and safety of pembrolizumab in Japanese patients with advanced melanoma in the phase 1b KEYNOTE-041 trial, with pembrolizumab 2 mg\/kg given every 3 weeks for up to 2 years or until confirmed progression or unacceptable toxicity.","Indexes":[1,4],"Sentences":["To evaluate the long-term efficacy and safety of pembrolizumab in Japanese patients with advanced melanoma in KEYNOTE-041.","Pembrolizumab 2\u2009mg\/kg was given every 3\u2009weeks for up to 2\u2009years or until confirmed progression or unacceptable toxicity."],"Revise":false}
{"PMID":"33428772","Document":["This retrospective observational study aimed to determine the effectiveness, safety and patterns of the use of nivolumab in patients with advanced melanoma in real-world clinical practice in France using data from a Temporary Authorization for Use Program (ATU).","Data were collected from patients with unresectable or metastatic melanoma enrolled in a French national database (R\u00e9seau pour la Recherche et l'Investigation Clinique sur le M\u00e9lanome: Ric-Mel) and treated with nivolumab during the ATU program (12 September 2014 to 31 August 2015).","The primary objectives of the study were to evaluate the effect of patient characteristics on clinical response and overall survival (OS).","Among 400 included patients (median age 66\u2009years), the majority (83%) received nivolumab as second- or subsequent-line therapy.","The median durations of progression-free survival and OS were 3.3 and 14.1 months, respectively, and 31.6% of patients achieved an objective response with a median duration of 20.1 months (range: 0-34.7).","The safety profile of nivolumab was manageable and consistent with those of previous clinical trials, with an incidence of grade 3-5 adverse events of 13.8%.","The safety and effectiveness of nivolumab in patients with advanced melanoma in real-world clinical practice in France were in line with the data reported in the Phase 3 trials CheckMate 066 and 037 of nivolumab in this patient population."],"Aspect":"a","Summary":"The study aimed to determine the effectiveness, safety, and patterns of use of nivolumab in patients with advanced melanoma in real-world clinical practice in France.","Indexes":[0,2],"Sentences":["This retrospective observational study aimed to determine the effectiveness, safety and patterns of the use of nivolumab in patients with advanced melanoma in real-world clinical practice in France using data from a Temporary Authorization for Use Program (ATU).","The primary objectives of the study were to evaluate the effect of patient characteristics on clinical response and overall survival (OS)."],"Revise":false}
{"PMID":"31403867","Document":["PURPOSE: Metastatic mucosal melanoma responds poorly to anti-programmed cell death-1 (PD-1) monotherapy.","Vascular endothelial growth factor (VEGF) has been shown to play an important immunosuppressive role in the tumor microenvironment.","The combination of VEGF inhibition and PD-1 blockade provides therapeutic opportunities for patients refractory to either therapy alone.","PATIENTS AND METHODS: We conducted a single-center, phase IB trial evaluating the safety and preliminary efficacy of toripalimab, a humanized immunoglobulin G4 monoclonal antibody against PD-1 in combination with the VEGF receptor inhibitor axitinib in patients with advanced melanoma, including patients with chemotherapy-na\u00efve mucosal melanomas (88%).","Patients received toripalimab at 1 or 3 mg\/kg via intravenous infusion every 2 weeks, in combination with axitinib 5 mg orally twice a day, in a dose-escalation and cohort-expansion study until confirmed disease progression, unacceptable toxicity, or voluntary withdrawal.","The primary objective was safety.","Secondary objectives included efficacy, pharmacokinetics, pharmacodynamics, immunogenicity, and tumor tissue biomarkers.","RESULTS: Thirty-three patients were enrolled.","No dose-limiting toxicities were observed.","Ninety-seven percent of patients experienced treatment-related adverse events (TRAEs).","The most common TRAEs were mild (grade 1 or 2) and included diarrhea, proteinuria, hand and foot syndrome, fatigue, AST or ALT elevation, hypertension, hypo- or hyperthyroidism, and rash.","Grade 3 or greater TRAEs occurred in 39.4% of patients.","By the cutoff date, among 29 patients with chemotherapy-na\u00efve mucosal melanoma, 14 patients (48.3%; 95% CI, 29.4% to 67.5%) achieved objective response, and the median progression-free survival time was 7.5 months (95% CI, 3.7 months to not reached) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.","CONCLUSION: The combination of toripalimab plus axitinib was tolerable and showed promising antitumor activity in patients with treatment-na\u00efve metastatic mucosal melanoma.","Patients enrolled in this study were all Asian, and this combination therapy must be validated in a randomized phase III trial that includes a non-Asian population before it can become a standard of care."],"Aspect":"i","Summary":"The study was a single-center, phase IB trial assessing the safety and efficacy of toripalimab plus axitinib in patients with advanced melanoma, including chemotherapy-na\u00efve mucosal melanomas.","Indexes":[3,4,5,6],"Sentences":["PATIENTS AND METHODS: We conducted a single-center, phase IB trial evaluating the safety and preliminary efficacy of toripalimab, a humanized immunoglobulin G4 monoclonal antibody against PD-1 in combination with the VEGF receptor inhibitor axitinib in patients with advanced melanoma, including patients with chemotherapy-na\u00efve mucosal melanomas (88%).","Patients received toripalimab at 1 or 3 mg\/kg via intravenous infusion every 2 weeks, in combination with axitinib 5 mg orally twice a day, in a dose-escalation and cohort-expansion study until confirmed disease progression, unacceptable toxicity, or voluntary withdrawal.","The primary objective was safety.","Secondary objectives included efficacy, pharmacokinetics, pharmacodynamics, immunogenicity, and tumor tissue biomarkers."],"Revise":true}
{"PMID":"34021033","Document":["BACKGROUND: The adoptive transfer of tumor-infiltrating lymphocytes (TIL) has demonstrated robust efficacy in metastatic melanoma patients.","Tumor antigen-loaded dendritic cells (DCs) are believed to optimally activate antigen-specific T lymphocytes.","We hypothesized that the combined transfer of TIL, containing a melanoma antigen recognized by T cells 1 (MART-1) specific population, with MART-1-pulsed DC will result in enhanced proliferation and prolonged survival of transferred MART-1 specific T cells in vivo ultimately leading to improved clinical responses.","DESIGN: We tested the combination of TIL and DC in a phase II clinical trial of patients with advanced stage IV melanoma.","HLA-A0201 patients whose early TIL cultures demonstrated reactivity to MART-1 peptide were randomly assigned to receive TIL alone or TIL +DC pulsed with MART-1 peptide.","The primary endpoint was to evaluate the persistence of MART-1 TIL in the two arms.","Secondary endpoints were to evaluate clinical response and survival.","RESULTS: Ten patients were given TIL alone while eight patients received TIL+DC vaccine.","Infused MART-1 reactive CD8+ TIL were tracked in the blood over time by flow cytometry and results show good persistence in both arms, with no difference in the persistence of MART-1 between the two arms.","The objective response rate was 30% (3\/10) in the TIL arm and 50% (4\/8) in the TIL+DC arm.","All treatments were well tolerated.","CONCLUSIONS: The combination of TIL +DC showed no difference in the persistence of MART-1 TIL compared with TIL therapy alone.","Although more patients showed a clinical response to TIL+DC therapy, this study was not powered to resolve differences between groups.","TRIAL REGISTRATION NUMBER: NCT00338377."],"Aspect":"s","Summary":"All treatments were well tolerated.","Indexes":[10],"Sentences":["All treatments were well tolerated."],"Revise":false}
{"PMID":"32157728","Document":["BACKGROUND: Skin cancer is a well-recognized public health issue, and primary prevention is the most effective strategy for reducing skin cancer risk.","The current recommendations are that behavioral counseling for sun safety measures is most beneficial and effective for children and adolescents and that targeting this population at primary and middle schools is the ideal intervention strategy to increase sun-protective behaviors and reduce UV exposure, sunburn incidence, and formation of new moles.","Numerous studies on the effectiveness of school-based sun safety interventions among elementary and middle school students have shown an increase in sun safety knowledge, attitudes, and behaviors following the intervention.","OBJECTIVE: To conduct a pilot feasibility study of \"Live Sun Smart!,\" (LSS) a school-based, multicomponent, interactive sun safety presentation, at changing sun safety knowledge, attitudes, and behaviors among middle school students.","METHODS: A non-randomized, single-group pretest-posttest interventional pilot study of the LSS program among children enrolled in grade 6.","RESULTS: After exposure to LSS, participants were more likely to give correct answers to knowledge-based sun safety questions and to report negative attitudes toward tanning.","Minimal and not significant changes were found in self-reported sun safety behaviors, though students did report an intention to change behaviors following the intervention.","Participants were satisfied with the program and believed it increased their sun safety knowledge.","CONCLUSION: Live Sun Smart!","appears to be an effective school-based, multicomponent sun safety program for improving sun safety knowledge and attitudes toward tanning among middle school students in this initial test of it.","The strengths and weaknesses of this pilot study have implications for future research."],"Aspect":"m","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"36460017","Document":["BACKGROUND: Primary analysis of the phase 3 IMspire150 study showed improved investigator-assessed progression-free survival with first-line atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) versus placebo, vemurafenib, and cobimetinib (control group) in patients with BRAFV600 mutation-positive melanoma.","With a median follow-up of 18\u00b79 months (IQR 10\u00b74-23\u00b78) at the primary analysis, overall survival data were immature.","Here, we report the results from the second, prespecified, interim overall survival analysis.","METHODS: The multicentre, double-blind, placebo-controlled, randomised, phase 3 IMspire150 study was done at 108 academic and community hospitals in 20 countries.","Patients aged 18 years or older with previously untreated unresectable stage IIIc or stage IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion.","Patients were randomly assigned (1:1) to receive either atezolizumab (840 mg intravenously on day 1 and 15) or placebo plus vemurafenib (960 mg or 720 mg twice daily orally) and cobimetinib (60 mg once daily orally; 21 days on and 7 days off) in 28-day cycles.","Atezolizumab and placebo were added to treatment regimens from cycle two onwards.","Randomisation was done centrally (Durham, NC, USA) based on a permuted block randomisation scheme (block size of 4) using an interactive web-based response system and was stratified by geographical region and baseline lactate dehydrogenase concentration.","Overall survival was analysed in the intention-to-treat population and safety was analysed in all patients who received at least one dose of study drug according to actual treatment received.","The primary endpoint was investigator-assessed progression-free survival, which was previously reported.","Here, we report the second, prespecified, interim overall survival analysis, which was planned after about 270 overall survival events had occurred.","The trial is ongoing, but is no longer enrolling patients, and it is registered with ClinicalTrials.gov, NCT02908672.","FINDINGS: Between Jan 13, 2017, and April 26, 2018, 514 patients (median age 54 years [IQR 43-63]; 299 [58%] men and 215 [42%] women) were enrolled in the trial and randomly assigned to the atezolizumab group (256 [50%] patients) or the control group (258 [50%] patients).","At the data cutoff (Sept 8, 2021), 273 patients had died (126 in the atezolizumab group and 147 in the control group).","Median follow-up was 29\u00b71 months (IQR 10\u00b71-45\u00b74) for the atezolizumab group versus 22\u00b78 months (10\u00b76-44\u00b71) for the control group.","Median overall survival was 39\u00b70 months (95% CI 29\u00b79-not estimable) in the atezolizumab group versus 25\u00b78 months (22\u00b70-34\u00b76) in the control group (HR 0\u00b784 [95% CI 0\u00b766-1\u00b706]; p=0\u00b714).","The most common adverse events of any grade in the atezolizumab group were blood creatine phosphokinase increased (123 [53%] of 231 patients), diarrhoea (116 [50%]), and pyrexia (115 [50%]).","The most common adverse events of any grade in the control group were diarrhoea (157 [56%] of 280 patients), blood creatine phosphokinase increased (135 [48%]), and rash (119 [43%]).","The most common grade 3-4 adverse events were increased lipase (54 [23%] of 231 patients in the atezolizumab group vs 62 [22%] of 280 patients in the control group), increased blood creatine phosphokinase (51 [22%] vs 50 [18%]), and increased alanine aminotransferase (32 [14%] vs 26 [9%]).","Serious adverse events were reported in 112 (48%) patients in the atezolizumab group and 117 (42%) patients in the control group.","Grade 5 adverse events were reported in eight (3%) patients in the atezolizumab group versus six (2%) patients in the control group.","Two grade 5 adverse events (hepatitis fulminant and hepatic failure) in the atezolizumab group were considered to be associated with the triplet combination, and one event in the control group (pulmonary haemorrhage) was considered to be associated with cobimetinib.","INTERPRETATION: Additional follow-up of the IMspire150 trial showed that overall survival was not significantly improved with atezolizumab, vemurafenib, and cobimetinib compared with placebo, vemurafenib, and cobimetinib in patients with BRAFV600 mutation-positive advanced melanoma.","Results of the final analysis are awaited to establish whether a significant improvement in overall survival can be achieved with long-term treatment with this triplet combination versus vemurafenib plus cobimetinib.","FUNDING: F Hoffmann-La Roche."],"Aspect":"s","Summary":"The most common side effects in the atezolizumab group were increased blood creatine phosphokinase, diarrhoea, and pyrexia, while in the control group, they were diarrhoea, increased blood creatine phosphokinase, and rash.","Indexes":[16,17],"Sentences":["The most common adverse events of any grade in the atezolizumab group were blood creatine phosphokinase increased (123 [53%] of 231 patients), diarrhoea (116 [50%]), and pyrexia (115 [50%]).","The most common adverse events of any grade in the control group were diarrhoea (157 [56%] of 280 patients), blood creatine phosphokinase increased (135 [48%]), and rash (119 [43%])."],"Revise":true}
{"PMID":"34650833","Document":["Combination immunotherapy with sequential administration may enhance metastatic melanoma (MM) patients with long-term disease control.","High Dose Aldesleukin\/Recombinant Interleukin-2 (HD rIL-2) and ipilimumab (IPI) offer complementary mechanisms against MM.","This phase IV study assessed the sequenced use of HD rIL-2 and IPI in MM patients.","Eligible Stage IV MM patients were randomized to treatment with either two courses of HD rIL-2(600,000 IU\/kg) followed by four doses of IPI 3 mg\/kg or vice-versa.","The primary objective was to compare one-year overall survival (OS) with historical control (46%, Hodi et al., NEJM 2010).","Secondary objectives were 1-year progression-free survival (PFS), objective response rate (ORR), and adverse events (AEs) profile.","Evaluable Population (EP) included patients who received at least 50% of planned treatment with each drug.","Thirteen and 16 patients were randomized to receive HD rIL-2 first, and IPI first, respectively.","One-year OS rate was 75% for intention to treat population.","Eighteen patients were included in EP, 8 in HD rIL-2, 10 in IPI first arm.","In EP, 1-year OS, PFS and ORR rates were 87%, 68%, and 50%, respectively.","The frequency of AEs was similar in both arms with 13 patients experiencing Grade 3 or higher AEs, 3 resulting in the end of study participation.","There was one HD rIL-2-related death, from cerebral hemorrhage due to thrombocytopenia.","In this study with small sample size, HD rIL-2 and IPI were safe to administer sequentially in MM patients and showed more than additive effects.","1-year OS was superior to that of IPI alone from historical studies."],"Aspect":"i","Summary":"The study assessed the sequential use of High Dose Aldesleukin\/Recombinant Interleukin-2 (HD rIL-2) and ipilimumab (IPI) in metastatic melanoma (MM) patients, with eligible patients randomized to receive either two courses of HD rIL-2 followed by four doses of IPI or vice-versa.","Indexes":[2,3],"Sentences":["This phase IV study assessed the sequenced use of HD rIL-2 and IPI in MM patients.","Eligible Stage IV MM patients were randomized to treatment with either two courses of HD rIL-2(600,000 IU\/kg) followed by four doses of IPI 3 mg\/kg or vice-versa."],"Revise":false}
{"PMID":"38234043","Document":["BACKGROUND: Use of artificial intelligence (AI), or machine learning, to assess dermoscopic images of skin lesions to detect melanoma has, in several retrospective studies, shown high levels of diagnostic accuracy on par with - or even outperforming - experienced dermatologists.","However, the enthusiasm around these algorithms has not yet been matched by prospective clinical trials performed in authentic clinical settings.","In several European countries, including Sweden, the initial clinical assessment of suspected skin cancer is principally conducted in the primary healthcare setting by primary care physicians, with or without access to teledermoscopic support from dermatology clinics.","OBJECTIVES: To determine the diagnostic performance of an AI-based clinical decision support tool for cutaneous melanoma detection, operated by a smartphone application (app), when used prospectively by primary care physicians to assess skin lesions of concern due to some degree of melanoma suspicion.","METHODS: This prospective multicentre clinical trial was conducted at 36 primary care centres in Sweden.","Physicians used the smartphone app on skin lesions of concern by photographing them dermoscopically, which resulted in a dichotomous decision support text regarding evidence for melanoma.","Regardless of the app outcome, all lesions underwent standard diagnostic procedures (surgical excision or referral to a dermatologist).","After investigations were complete, lesion diagnoses were collected from the patients' medical records and compared with the app's outcome and other lesion data.","RESULTS: In total, 253 lesions of concern in 228 patients were included, of which 21 proved to be melanomas, with 11 thin invasive melanomas and 10 melanomas in situ.","The app's accuracy in identifying melanomas was reflected in an area under the receiver operating characteristic (AUROC) curve of 0.960 [95% confidence interval (CI) 0.928-0.980], corresponding to a maximum sensitivity and specificity of 95.2% and 84.5%, respectively.","For invasive melanomas alone, the AUROC was 0.988 (95% CI 0.965-0.997), corresponding to a maximum sensitivity and specificity of 100% and 92.6%, respectively.","CONCLUSIONS: The clinical decision support tool evaluated in this investigation showed high diagnostic accuracy when used prospectively in primary care patients, which could add significant clinical value for primary care physicians assessing skin lesions for melanoma."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"33444116","Document":["PURPOSE: Mucosal melanoma (MM) is a highly vascularized tumor with an extremely poor prognosis.","In this randomized, open-label, phase II study, we characterized the efficacy and safety of bevacizumab in combination with carboplatin plus paclitaxel (CPB) in patients with previously untreated advanced MM.","PATIENTS AND METHODS: Patients were randomly assigned in a 2:1 ratio to receive carboplatin (area under the curve, 5) plus paclitaxel (175 mg\/m2) once every 4 weeks in combination with (CPB arm, 5 mg\/kg) or without (CP arm) bevacizumab once every 2 weeks.","Progression-free survival (PFS) was the primary end point.","Secondary end points included overall survival (OS), objective response rate, and adverse events.","RESULTS: We recruited 114 patients to our study.","The median PFS was significantly longer in the CPB arm (4.8 months; 95% CI, 3.6 to 6.0 months) than in the CP arm (3.0 months; 95% CI, 1.7 to 4.3 months) (hazard ratio, 0.461; 95% CI, 0.306 to 0.695; P < .001).","Objective response rates were 19.7% and 13.2%, respectively (P = .384).","The median OS was also significantly longer in the CPB arm than in the CP arm (13.6 v 9.0 months; hazard ratio, 0.611; 95% CI, 0.407 to 0.917; P = .017).","No new safety signals were observed.","CONCLUSION: PFS and OS were significantly better in patients with metastatic MM who received bevacizumab in addition to CPB than in those who received CPB alone.","A phase III study should be performed to confirm these benefits (ClinicalTrials.gov identifier: NCT02023710)."],"Aspect":"i","Summary":"Patients were randomly assigned in a 2:1 ratio to receive carboplatin plus paclitaxel with or without bevacizumab, with progression-free survival as the primary end point and overall survival, objective response rate, and adverse events as secondary end points.","Indexes":[2,3,4],"Sentences":["PATIENTS AND METHODS: Patients were randomly assigned in a 2:1 ratio to receive carboplatin (area under the curve, 5) plus paclitaxel (175 mg\/m2) once every 4 weeks in combination with (CPB arm, 5 mg\/kg) or without (CP arm) bevacizumab once every 2 weeks.","Progression-free survival (PFS) was the primary end point.","Secondary end points included overall survival (OS), objective response rate, and adverse events."],"Revise":true}
{"PMID":"32376721","Document":["BACKGROUND: CTLA-4 blockade with ipilimumab is Food and Drug Administration-approved for melanoma as a monotherapy and has been shown to modulate the circulating T-cell repertoire.","We have previously reported clinical trials combining CTLA-4 blockade with granulocyte-macrophage colony-stimulating factor (GM-CSF) in metastatic melanoma patients and in metastatic castration resistant prostate cancer (mCRPC) patients.","Here, we investigate the effect that cancer type has on circulating T cells in metastatic melanoma and mCRPC patients, treated with ipilimumab and GM-CSF.","METHODS: We used next-generation sequencing of T-cell receptors (TCR) to compare the circulating T cells of melanoma and mCRPC patients receiving the same treatment with ipilimumab and GM-CSF by Wilcoxon rank sum test.","Flow cytometry was utilized to investigate specific T-cell populations.","TCR sequencing results were correlated with each T-cell subpopulation by Spearman's rank correlation coefficient.","Of note, 14 metastatic melanoma patients had samples available for TCR sequencing and 21 had samples available for flow cytometry analysis; 37 mCRPC patients had samples available for sequencing of whom 22 have TCR data available at both timepoints; 20 of these patients had samples available for flow cytometry analysis and 16 had data available at both timepoints.","RESULTS: While melanoma and mCRPC patients had similar pretreatment circulating T-cell counts, treatment induces greater expansion of circulating T cells in melanoma patients.","Metastatic melanoma patients have a higher proportion of clones that increased more than fourfold after the treatment compared with mCRPC patients (18.9% vs 11.0%, p=0.017).","Additionally, melanoma patients compared with mCRPC patients had a higher ratio of convergent frequency (1.22 vs 0.60, p=0.012).","Decreases in clonality induced by treatment are associated with baseline CD8+ T-cell counts in both patient groups, but are more pronounced in the melanoma patients (r=-0.81, p<0.001\u2009vs r=-0.59, p=0.02).","TRIAL REGISTRATION NUMBERS: NCT00064129; NCT01363206."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"31581055","Document":["BACKGROUND: Limited data are available on nivolumab in challenging subgroups with advanced melanoma.","We report outcomes of nivolumab after prior ipilimumab in patients who are typically excluded from clinical trials.","PATIENTS AND METHODS: In this phase II, single-arm, open-label, multicentre study (CheckMate 172), patients with advanced melanoma who progressed on or after ipilimumab received nivolumab 3\u00a0mg\/kg, every 2 weeks for up to 2 years.","The primary objective was incidence of grade \u22653, treatment-related select adverse events (AEs).","RESULTS: At a minimum follow-up of 18 months, grade \u22653 treatment-related select AEs with the most variation across subgroups were diarrhoea and colitis (1.1% [n\u00a0=\u00a011] and 0.3% [n\u00a0=\u00a03] for the total population [n\u00a0=\u00a01008]; 0.6% [n\u00a0=\u00a01] and 0.6% [n\u00a0=\u00a01] for patients with an asymptomatic central nervous system [CNS] metastasis [n\u00a0=\u00a0165; 16.4%]; 4.5% [n\u00a0=\u00a03] and 3.0% [n\u00a0=\u00a02] for patients with an Eastern Cooperative Oncology Group performance status [ECOG PS] of 2 [n\u00a0=\u00a066; 6.5%]; 2.4% [n\u00a0=\u00a02] and 0% for those who experienced a grade 3\/4 immune-related AE [irAE] with prior ipilimumab [n\u00a0=\u00a084; 8.3%]; and 0% and 0% for autoimmune disease [n\u00a0=\u00a025; 2.5%], respectively).","Median overall survival was 21.4 months in the total population and was 11.6, 2.4, 21.5, and 18.6 months in patients with a CNS metastasis, ECOG PS 2, a grade 3\/4 irAE with prior ipilimumab, and autoimmune disease, respectively.","CONCLUSIONS: In this large, phase II clinical trial of patients with advanced melanoma who progressed on or after ipilimumab, nivolumab demonstrated a safety profile consistent with that of prior clinical trials.","ClinicalTrials.gov ID: NCT02156804."],"Aspect":"o","Summary":"The study found that nivolumab demonstrated a consistent safety profile in advanced melanoma patients who progressed on or after ipilimumab, with median overall survival varying across different subgroups.","Indexes":[4,5,6],"Sentences":["RESULTS: At a minimum follow-up of 18 months, grade \u22653 treatment-related select AEs with the most variation across subgroups were diarrhoea and colitis (1.1% [n\u00a0=\u00a011] and 0.3% [n\u00a0=\u00a03] for the total population [n\u00a0=\u00a01008]; 0.6% [n\u00a0=\u00a01] and 0.6% [n\u00a0=\u00a01] for patients with an asymptomatic central nervous system [CNS] metastasis [n\u00a0=\u00a0165; 16.4%]; 4.5% [n\u00a0=\u00a03] and 3.0% [n\u00a0=\u00a02] for patients with an Eastern Cooperative Oncology Group performance status [ECOG PS] of 2 [n\u00a0=\u00a066; 6.5%]; 2.4% [n\u00a0=\u00a02] and 0% for those who experienced a grade 3\/4 immune-related AE [irAE] with prior ipilimumab [n\u00a0=\u00a084; 8.3%]; and 0% and 0% for autoimmune disease [n\u00a0=\u00a025; 2.5%], respectively).","Median overall survival was 21.4 months in the total population and was 11.6, 2.4, 21.5, and 18.6 months in patients with a CNS metastasis, ECOG PS 2, a grade 3\/4 irAE with prior ipilimumab, and autoimmune disease, respectively.","CONCLUSIONS: In this large, phase II clinical trial of patients with advanced melanoma who progressed on or after ipilimumab, nivolumab demonstrated a safety profile consistent with that of prior clinical trials."],"Revise":false}
{"PMID":"34825282","Document":["INTRODUCTION: The effect of neoadjuvant systemic therapies (NST) on technical aspects of operation for resectable stage III melanoma is unknown.","Prospective capture of the estimated and actual degree of difficulty of therapeutic lymphadenectomy at presentation and after NST may inform the relative merits of NST versus surgery followed by adjuvant therapy.","METHODS: We designed surgeon survey tools to capture key impressions at baseline prior to NST and postoperatively.","We conducted a sub-study within a multi-institutional clinical trial for high-risk operable stage III melanoma (NeoACTIVATE, NCT03554083) which enrolls clinically node-positive patients to 12 weeks of combinatorial NST determined by BRAF status.","Survey data were analyzed.","RESULTS: Surveys were completed for 24 of 25 patients (96%).","Affected nodal basins were cervical (3, 13%) axillary (9, 38%), inguinal \u00b1 pelvic (14, 58%); 2 (8%) involved \u2265 2 basins.","Baseline estimates included largest affected node size (median\/range 4\/1.4-11 cm), number of involved nodes (median\/range 3\/1-10) and tumor fixation (present in 12, 50%).","At operation, actual degree of difficulty increased from the baseline estimate in 4 (17%) and decreased in 6 (25%).","Surgery was less difficult, average, or more difficult versus usual operation in 4, 9, and 11 cases (17%, 38%, 46%), respectively.","CONCLUSIONS: Although many operations were judged to be more difficult than the usual therapeutic lymphadenectomy, operation following NST was more often perceived as easier than more difficult versus baseline impression.","Engaging surgical oncologists to perform similar structured assessments across clinical trials will permit cross-study analysis of the effect of NSTs on the technical conduct of lymphadenectomy."],"Aspect":"i","Summary":"The study involved a sub-study within a multi-institutional clinical trial for high-risk operable stage III melanoma, where patients were enrolled to receive 12 weeks of combinatorial neoadjuvant systemic therapies determined by BRAF status, and surgeon survey tools were used to capture key impressions at baseline and postoperatively.","Indexes":[2,3],"Sentences":["METHODS: We designed surgeon survey tools to capture key impressions at baseline prior to NST and postoperatively.","We conducted a sub-study within a multi-institutional clinical trial for high-risk operable stage III melanoma (NeoACTIVATE, NCT03554083) which enrolls clinically node-positive patients to 12 weeks of combinatorial NST determined by BRAF status."],"Revise":false}
{"PMID":"38246194","Document":["BACKGROUND: Checkpoint inhibitors are standard adjuvant treatment for stage IIB-IV resected melanoma, but many patients recur.","Our study aimed to evaluate whether mRNA-4157 (V940), a novel mRNA-based individualised neoantigen therapy, combined with pembrolizumab, improved recurrence-free survival and distant metastasis-free survival versus pembrolizumab monotherapy in resected high-risk melanoma.","METHODS: We did an open-label, randomised, phase 2b, adjuvant study of mRNA-4157 plus pembrolizumab versus pembrolizumab monotherapy in patients, enrolled from sites in the USA and Australia, with completely resected high-risk cutaneous melanoma.","Patients with completely resected melanoma (stage IIIB-IV) were assigned 2:1 to receive open-label mRNA-4157 plus pembrolizumab or pembrolizumab monotherapy.","mRNA-4157 was administered intramuscularly (maximum nine doses) and pembrolizumab intravenously (maximum 18 doses) in 3-week cycles.","The primary endpoint was recurrence-free survival in the intention-to-treat population.","This ongoing trial is registered at ClinicalTrials.gov, NCT03897881.","FINDINGS: From July 18, 2019, to Sept 30, 2021, 157 patients were assigned to mRNA-4157 plus pembrolizumab combination therapy (n=107) or pembrolizumab monotherapy (n=50); median follow-up was 23 months and 24 months, respectively.","Recurrence-free survival was longer with combination versus monotherapy (hazard ratio [HR] for recurrence or death, 0\u00b7561 [95% CI 0\u00b7309-1\u00b7017]; two-sided p=0\u00b7053), with lower recurrence or death event rate (24 [22%] of 107 vs 20 [40%] of 50); 18-month recurrence-free survival was 79% (95% CI 69\u00b70-85\u00b76) versus 62% (46\u00b79-74\u00b73).","Most treatment-related adverse events were grade 1-2.","Grade \u22653 treatment-related adverse events occurred in 25% of patients in the combination group and 18% of patients in the monotherapy group, with no mRNA-4157-related grade 4-5 events.","Immune-mediated adverse event frequency was similar for the combination (37 [36%]) and monotherapy (18 [36%]) groups.","INTERPRETATION: Adjuvant mRNA-4157 plus pembrolizumab prolonged recurrence-free survival versus pembrolizumab monotherapy in patients with resected high-risk melanoma and showed a manageable safety profile.","These results provide evidence that an mRNA-based individualised neoantigen therapy might be beneficial in the adjuvant setting.","FUNDING: Moderna in collaboration with Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway, NJ, USA."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"31721173","Document":["Lower clearance of immune checkpoint inhibitors is a predictor of improved overall survival (OS) in patients with advanced cancer.","We investigated a novel approach using machine learning to identify a baseline composite cytokine signature via clearance, which, in turn, could be associated with OS in advanced melanoma.","Peripheral nivolumab clearance and cytokine data from patients treated with nivolumab in two phase III studies (n\u00a0=\u00a0468 (pooled)) and another phase III study (n\u00a0=\u00a0158) were used for machine-learning model development and validation, respectively.","Random forest (Boruta) algorithm was used for feature selection and classification of nivolumab clearance.","The 16 top-ranking baseline inflammatory cytokines reflecting immune-cell modulation were selected as a composite signature to predict nivolumab clearance (area under the curve (AUC)\u00a0=\u00a00.75; accuracy\u00a0=\u00a00.7).","Predicted clearance (high vs. low) via the cytokine signature was significantly associated with OS across all three studies (P\u00a0<\u00a00.01), regardless of treatment (nivolumab vs. chemotherapy)."],"Aspect":"a","Summary":"The study aims to investigate a novel approach using machine learning to identify a baseline composite cytokine signature via clearance associated with overall survival (OS) in advanced melanoma.","Indexes":[1],"Sentences":["We investigated a novel approach using machine learning to identify a baseline composite cytokine signature via clearance, which, in turn, could be associated with OS in advanced melanoma."],"Revise":false}
{"PMID":"34464163","Document":["PURPOSE: We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma.","PATIENTS AND METHODS: In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 \u00d7 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL volume by intratumoral injection.","Ten sets of V937 injections were administered between days 1 and 127 (NCT01227551).","Patients who had stable disease or were responding could continue treatment in an extension study (NCT01636882).","Response and progression status were based on contrast-enhanced computed tomography, magnetic resonance imaging, or caliper measurement and were categorized using immune-related Response Evaluation Criteria in Solid Tumors (irRECIST).","Other evaluations included monitoring of adverse events and serum levels of V937 and anti-V937 antibody titers.","The primary efficacy end point was 6-month progression-free survival (PFS) rate per irRECIST.","RESULTS: The primary efficacy end point, 6-month PFS rate per irRECIST, was 38.6% (95% CI, 26.0 to 52.4).","Durable response rate (partial or complete response for \u2265 6 months) was 21.1% per irRECIST.","Best overall response rate (complete plus partial response) was 38.6% (unconfirmed) and 28.1% (confirmed) per irRECIST.","Regression of melanoma was observed in noninjected lesions.","Based on Kaplan-Meier estimation, 12-month PFS was 32.9% (95% CI, 19.5 to 46.9) per irRECIST and 12-month overall survival was 75.4% (95% CI, 62.1 to 84.7).","No treatment-related grade \u2265 3 adverse events occurred.","Viral RNA was detected in serum within 30 minutes of administration.","Neutralizing antibody titers increased to > 1:16 in all patients after day 22, without effect on clinical or immunologic response.","CONCLUSION: V937 was well tolerated and warrants further investigation for treatment of patients with unresectable melanoma.","Studies of combination approaches with V937 and immune checkpoint inhibitors are ongoing."],"Aspect":"o","Summary":"The primary efficacy endpoint, 6-month progression-free survival rate per irRECIST, was 38.6% (95% CI, 26.0 to 52.4). V937 was well tolerated and warrants further investigation for treatment of patients with unresectable melanoma.","Indexes":[7,8,9,10,15],"Sentences":["RESULTS: The primary efficacy end point, 6-month PFS rate per irRECIST, was 38.6% (95% CI, 26.0 to 52.4).","Durable response rate (partial or complete response for \u2265 6 months) was 21.1% per irRECIST.","Best overall response rate (complete plus partial response) was 38.6% (unconfirmed) and 28.1% (confirmed) per irRECIST.","Regression of melanoma was observed in noninjected lesions.","CONCLUSION: V937 was well tolerated and warrants further investigation for treatment of patients with unresectable melanoma."],"Revise":true}
{"PMID":"32816891","Document":["PURPOSE: Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain, which redirects T cells to kill gp100-expressing tumor cells.","Here, we report a multicenter phase I\/II trial of tebentafusp in metastatic melanoma (NCT01211262) focusing on the mechanism of action of tebentafusp.","PATIENTS AND METHODS: Eighty-four patients with advanced melanoma received tebentafusp.","Treatment efficacy, treatment-related adverse events, and biomarker assessments were performed for blood-derived and tumor biopsy samples obtained at baseline and on-treatment.","RESULTS: Tebentafusp was generally well-tolerated and active in both patients with metastatic uveal melanoma and patients with metastatic cutaneous melanoma.","A 1-year overall survival rate of 65% was achieved for both patient cohorts.","On-treatment cytokine measurements were consistent with the induction of IFN\u03b3 pathway-related markers in the periphery and tumor.","Notably, tebentafusp induced an increase in serum CXCL10 (a T-cell attractant) and a reduction in circulating CXCR3+ CD8+ T cells together with an increase in cytotoxic T cells in the tumor microenvironment.","Furthermore, increased serum CXCL10 or the appearance of rash (likely due to cytotoxic T cells targeting gp100-expressing skin melanocytes) showed a positive association with patient survival.","CONCLUSIONS: These data suggest that redirecting T cells using a gp100-targeting TCR\/anti-CD3 bispecific fusion protein may provide benefit to patients with metastatic melanoma.","Furthermore, the activity observed in these two molecularly disparate melanoma classes hints at the broad therapeutic potential of tebentafusp."],"Aspect":"s","Summary":"Tebentafusp induced a rash likely due to cytotoxic T cells targeting gp100-expressing skin melanocytes.","Indexes":[8],"Sentences":["Furthermore, increased serum CXCL10 or the appearance of rash (likely due to cytotoxic T cells targeting gp100-expressing skin melanocytes) showed a positive association with patient survival."],"Revise":false}
{"PMID":"37247116","Document":["BRAF\/MEK targeted therapies and immune checkpoint inhibition have dramatically improved disease control and survival of patients with advanced melanoma.","However, most patients do not have durable benefit from either of these therapies.","BRAF targeted therapy often has a limited duration of efficacy due to the development of resistance.","Pre-clinical data suggest that one possible way to overcome resistance to BRAF\/MEK targeted therapy may be the addition of CSF1R inhibition.","In this phase I\/II study we evaluated the safety and efficacy of LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody in combination with the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib in patients with BRAF V600E\/K mutant metastatic melanoma.","The trial was terminated early due to discontinuation of the development program for LY3022855 by the sponsor.","Between August 2017 and May 2018 five pts were enrolled.","Three patients experienced grade 3 events that were deemed possibly related to LY3022855.","There were no grade 4 or grade 5 events related to LY3022855.","One of the 5 patients had a complete response (CR), whereas the other 4 had progressive disease (PD).","Median progression free survival was 3.9 months (90% CI: 1.9-37.2 mos).","CSF1R inhibition with LY3022855 in combination with BRAF\/MEK inhibition with vemurafenib and cobimetinib was difficult to tolerate in a small melanoma population.","One response was observed in this small sample of patients suggesting this combination might be worthy of further exploration."],"Aspect":"m","Summary":"The study evaluated LY3022855, a CSF-1R inhibitor, combined with BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib.","Indexes":[4],"Sentences":["In this phase I\/II study we evaluated the safety and efficacy of LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody in combination with the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib in patients with BRAF V600E\/K mutant metastatic melanoma."],"Revise":false}
{"PMID":"37261804","Document":["IMPORTANCE: Acral melanoma, known for low tumor mutation burden, responds poorly to immunotherapy.","A standard therapy is still lacking.","OBJECTIVE: To investigate the activity and safety of camrelizumab (an anti-programmed cell death-1 antibody) plus apatinib (a vascular endothelial growth factor receptor 2 inhibitor) and temozolomide as first-line treatment in patients with advanced acral melanoma.","DESIGN, SETTING, AND PARTICIPANTS: In this single-arm, single-center, phase 2 nonrandomized clinical trial, patients with treatment-naive unresectable stage III or IV acral melanoma were enrolled at Peking University Cancer Hospital and Institute between June 4, 2020, and August 24, 2021.","The data cutoff date was April 10, 2022.","INTERVENTIONS: Patients received 4-week cycles of intravenous camrelizumab, 200 mg, every 2 weeks; oral apatinib 250 mg, once daily; and intravenous temozolomide, 200 mg\/m2, once daily on days 1 to 5 until disease progression or unacceptable toxic effects.","MAIN OUTCOMES AND MEASURES: The primary end point was objective response rate as assessed by investigators according to the Response Evaluation Criteria In Solid Tumors (version 1.1).","Secondary end points included progression-free survival, time to response, duration of response, disease control rate, overall survival, and safety.","RESULTS: A total of 50 patients (32 men [64%]; median age, 57 years [IQR, 52-62 years]) were enrolled and received treatment.","The median follow-up duration was 13.4 months (IQR, 9.6-16.2 months).","The objective response rate was 64.0% (32 of 50; 95% CI, 49.2%-77.1%).","The median time to response and duration of response were 2.7 months (IQR, 0.9-2.9 months) and 17.5 months (95% CI, 12.0 to not reached), respectively.","The disease control rate was 88.0% (44 of 50; 95% CI, 75.7%-95.5%).","The estimated median progression-free survival was 18.4 months (95% CI, 10.6 to not reached).","The median overall survival was not reached.","The most common grade 3 or 4 treatment-related adverse events were increased gamma-glutamyltransferase levels (15 [30%]), decreased neutrophil count (11 [22%]), increased conjugated bilirubin levels (10 [20%]), and increased aspartate aminotransferase levels (10 [20%]).","No treatment-related deaths occurred.","CONCLUSIONS AND RELEVANCE: The findings of this nonrandomized clinical trial suggest that camrelizumab plus apatinib and temozolomide may be a potential first-line treatment option for patients with advanced acral melanoma, which warrants further validation in a randomized clinical trial.","TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04397770."],"Aspect":"i","Summary":"The study investigated the activity and safety of camrelizumab plus apatinib and temozolomide as first-line treatment in patients with advanced acral melanoma, where patients received 4-week cycles of intravenous camrelizumab, oral apatinib, and intravenous temozolomide until disease progression or unacceptable toxic effects.","Indexes":[2,5],"Sentences":["OBJECTIVE: To investigate the activity and safety of camrelizumab (an anti-programmed cell death-1 antibody) plus apatinib (a vascular endothelial growth factor receptor 2 inhibitor) and temozolomide as first-line treatment in patients with advanced acral melanoma.","INTERVENTIONS: Patients received 4-week cycles of intravenous camrelizumab, 200 mg, every 2 weeks; oral apatinib 250 mg, once daily; and intravenous temozolomide, 200 mg\/m2, once daily on days 1 to 5 until disease progression or unacceptable toxic effects."],"Revise":false}
{"PMID":"32753545","Document":["UNLABELLED: Treatment of metastatic melanoma with autologous tumor infiltrating lymphocytes (TILs) is currently applied in several centers.","Robust and remarkably consistent overall response rates, of around 50% of treated patients, have been observed across hospitals, including a substantial fraction of durable, complete responses.","PURPOSE: Execute a phase I\/II feasibility study with TIL therapy in metastatic melanoma at the Netherlands Cancer Institute, with the goal to assess feasibility and potential value of a randomized phase III trial.","EXPERIMENTAL: Ten patients were treated with TIL therapy.","Infusion products and peripheral blood samples were phenotypically characterized and neoantigen reactivity was assessed.","Here, we present long-term clinical outcome and translational data on neoantigen reactivity of the T cell products.","RESULTS: Five out of 10 patients, who were all anti-PD-1 na\u00efve at time of treatment, showed an objective clinical response, including two patients with a complete response that are both ongoing for more than 7 years.","Immune monitoring demonstrated that neoantigen-specific T cells were detectable in TIL infusion products from three out of three patients analyzed.","For six out of the nine neoantigen-specific T cell responses detected in these TIL products, T cell response magnitude increased significantly in the peripheral blood compartment after therapy, and neoantigen-specific T cells were detectable for up to 3 years after TIL infusion.","CONCLUSION: The clinical results from this study confirm the robustness of TIL therapy in metastatic melanoma and the potential role of neoantigen-specific T cell reactivity.","In addition, the data from this study supported the rationale to initiate an ongoing multicenter phase III TIL trial."],"Aspect":"o","Summary":"The study found that five out of ten patients with metastatic melanoma, who were all anti-PD-1 na\u00efve, showed an objective clinical response to TIL therapy, including two patients with ongoing complete responses for over 7 years.","Indexes":[6],"Sentences":["RESULTS: Five out of 10 patients, who were all anti-PD-1 na\u00efve at time of treatment, showed an objective clinical response, including two patients with a complete response that are both ongoing for more than 7 years."],"Revise":true}
{"PMID":"32152202","Document":["PURPOSE: We analyzed whole transcriptome sequencing in tumors from 23 patients with stage III or IV melanoma from a pilot trial of the anti-GD2 immunocytokine, hu14.18-IL2, to identify predictive immune and\/or tumor biomarkers in patients with melanoma at high risk for recurrence.","EXPERIMENTAL DESIGN: Patients were randomly assigned to receive the first of three monthly courses of hu14.18-IL2 immunotherapy either before (Group A) or after (Group B) complete surgical resection of all known diseases.","Tumors were evaluated by histology and whole transcriptome sequencing.","RESULTS: Tumor-infiltrating lymphocyte (TIL) levels directly associated with relapse-free survival (RFS) and overall survival (OS) in resected tumors from Group A, where early responses to the immunotherapy agent could be assessed.","TIL levels directly associated with a previously reported immune signature, which associated with RFS and OS, particularly in Group A tumors.","In Group A tumors, there were decreased cell-cycling gene RNA transcripts, but increased RNA transcripts for repair and growth genes.","We found that outcome (RFS and OS) was directly associated with several immune signatures and immune-related RNA transcripts and inversely associated with several tumor growth-associated transcripts, particularly in Group A tumors.","Most of these associations were not seen in Group B tumors.","CONCLUSIONS: We interpret these data to signify that both immunologic and tumoral cell processes, as measured by RNA-sequencing analyses detected shortly after initiation of hu14.18-IL2 therapy, are associated with long-term survival and could potentially be used as prognostic biomarkers in tumor resection specimens obtained after initiating neoadjuvant immunotherapy."],"Aspect":"d","Summary":"The treatment duration involved three monthly courses of hu14.18-IL2 immunotherapy.","Indexes":[1],"Sentences":["EXPERIMENTAL DESIGN: Patients were randomly assigned to receive the first of three monthly courses of hu14.18-IL2 immunotherapy either before (Group A) or after (Group B) complete surgical resection of all known diseases."],"Revise":false}
{"PMID":"34046035","Document":["BACKGROUND: Ipilimumab improves survival for patients with metastatic malignant melanoma.","Combining a therapeutic cancer vaccine with ipilimumab may increase efficacy by providing enhanced anti-tumor immune responses.","UV1 consists of three synthetic long peptides from human telomerase reverse transcriptase (hTERT).","These peptides comprise epitopes recognized by T cells from cancer patients experiencing long-term survival following treatment with a first-generation hTERT vaccine, and generate long-lasting immune responses in cancer patients when used as monotherapy.","The objective of this trial was to investigate the safety and efficacy of combining UV1 with ipilimumab in metastatic melanoma.","PATIENTS AND METHODS: In this phase I\/IIa, single center trial [NCT02275416], patients with metastatic melanoma received repeated UV1 vaccinations, with GM-CSF as an adjuvant, in combination with ipilimumab.","Patients were evaluated for safety, efficacy and immune response.","Immune responses against vaccine peptides were monitored in peripheral blood by measuring antigen-specific proliferation and IFN-\u03b3 production.","RESULTS: Twelve patients were recruited.","Adverse events were mainly diarrhea, injection site reaction, pruritus, rash, nausea and fatigue.","Ten patients showed a Th1 immune response to UV1 peptides, occurring early and after few vaccinations.","Three patients obtained a partial response and one patient a complete response.","Overall survival was 50% at 5 years.","CONCLUSION: Treatment was well tolerated.","The rapid expansion of UV1-specific Th1 cells in the majority of patients indicates synergy between UV1 vaccine and CTLA-4 blockade.","This may have translated into clinical benefit, encouraging the combination of UV1 vaccination with standard of care treatment regimes containing ipilimumab\/CTLA-4 blocking antibodies."],"Aspect":"o","Summary":"The study found that combining UV1 vaccine with ipilimumab resulted in a 50% overall survival rate at 5 years, with a majority of patients showing a Th1 immune response to UV1 peptides.","Indexes":[10,11,12],"Sentences":["Ten patients showed a Th1 immune response to UV1 peptides, occurring early and after few vaccinations.","Three patients obtained a partial response and one patient a complete response.","Overall survival was 50% at 5 years."],"Revise":false}
{"PMID":"33064988","Document":["Neoantigens arise from mutations in cancer cells and are important targets of T\u00a0cell-mediated anti-tumor immunity.","Here, we report the first open-label, phase Ib clinical trial of a personalized neoantigen-based vaccine, NEO-PV-01, in combination with PD-1 blockade in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer.","This analysis of 82 patients demonstrated that the regimen was safe, with no treatment-related serious adverse events observed.","De novo neoantigen-specific CD4+ and CD8+ T\u00a0cell responses were observed post-vaccination in all of the patients.","The vaccine-induced T cells had a cytotoxic phenotype and were capable of trafficking to the tumor and mediating cell killing.","In addition, epitope spread to neoantigens not included in the vaccine was detected post-vaccination.","These data support the safety and immunogenicity of this regimen in patients with advanced solid tumors (Clinicaltrials.gov: NCT02897765)."],"Aspect":"i","Summary":"This study conducted the first open-label, phase Ib clinical trial of a personalized neoantigen-based vaccine, NEO-PV-01, in combination with PD-1 blockade in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer.","Indexes":[1],"Sentences":["Here, we report the first open-label, phase Ib clinical trial of a personalized neoantigen-based vaccine, NEO-PV-01, in combination with PD-1 blockade in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer."],"Revise":false}
{"PMID":"35772575","Document":["BACKGROUND: The addition of stereotactic ablative radiotherapy (SABR) to immune checkpoint inhibitors (ICIs) has the potential to significantly improve outcomes in the treatment of metastatic melanoma.","We analysed peripheral blood immune cells of patients receiving combination SABR and ICI to detect the effect of treatment and identify potential biomarkers that predict outcome.","METHODS: 24 polymetastatic melanoma patients participated in the SABR IMPACT trial, receiving standard dose immunotherapy with anti-PD-1 and\/or anti-CTLA-4 and stereotactic ablative radiotherapy to one site.","Comprehensive immunophenotyping of T-cells was performed with flow cytometry on blood samples from 13 patients at baseline and following the first 4 cycles of treatment.","RESULTS: Following four cycles of immunotherapy and SABR, the proportion of na\u00efve subsets were reduced within both the CD4 and CD8 T-cell lineages.","Independently, SABR resulted in increased expression of PD-1 (p\u00a0=\u00a00.019) and ICOS (p\u00a0=\u00a00.046) on the CD8+ T-cells, accompanied by a reduction in regulatory T-cell frequencies (p\u00a0=\u00a00.048).","A multivariate discriminant analysis revealed a baseline signature of lower levels of CD8+ naive T-cells and higher expression of TIM-3 on regulatory T-cells and memory T-cells better predicted response.","CONCLUSION: The combination of immunotherapy and SABR changed the immunophenotype of blood T cells, with some shifts attributable to SABR.","Importantly, we identified a T-cell signature at baseline that best predicted response.","Validation of these findings in an independent cohort could confirm these as biomarkers at baseline or early during treatment, and whether these can be utilised to stratify patients for high or low intensity treatment to reduce toxicity."],"Aspect":"o","Summary":"The combination of immunotherapy and SABR altered the immunophenotype of blood T cells, with SABR specifically increasing PD-1 and ICOS expression on CD8+ T-cells and reducing regulatory T-cell frequencies, and a baseline T-cell signature was identified to predict response.","Indexes":[4,5,6,7,8],"Sentences":["RESULTS: Following four cycles of immunotherapy and SABR, the proportion of na\u00efve subsets were reduced within both the CD4 and CD8 T-cell lineages.","Independently, SABR resulted in increased expression of PD-1 (p\u00a0=\u00a00.019) and ICOS (p\u00a0=\u00a00.046) on the CD8+ T-cells, accompanied by a reduction in regulatory T-cell frequencies (p\u00a0=\u00a00.048).","A multivariate discriminant analysis revealed a baseline signature of lower levels of CD8+ naive T-cells and higher expression of TIM-3 on regulatory T-cells and memory T-cells better predicted response.","CONCLUSION: The combination of immunotherapy and SABR changed the immunophenotype of blood T cells, with some shifts attributable to SABR.","Importantly, we identified a T-cell signature at baseline that best predicted response."],"Revise":false}
{"PMID":"38506710","Document":["PURPOSE: Personalized vaccines targeting multiple neoantigens (nAgs) are a promising strategy for eliciting a diversified antitumor T-cell response to overcome tumor heterogeneity.","NOUS-PEV is a vector-based personalized vaccine, expressing 60 nAgs and consists of priming with a nonhuman Great Ape Adenoviral vector (GAd20) followed by boosts with Modified Vaccinia Ankara.","Here, we report data of a phase Ib trial of NOUS-PEV in combination with pembrolizumab in treatment-na\u00efve patients with metastatic melanoma (NCT04990479).","PATIENTS AND METHODS: The feasibility of this approach was demonstrated by producing, releasing, and administering to 6 patients 11 of 12 vaccines within 8 weeks from biopsy collection to GAd20 administration.","RESULTS: The regimen was safe, with no treatment-related serious adverse events observed and mild vaccine-related reactions.","Vaccine immunogenicity was demonstrated in all evaluable patients receiving the prime\/boost regimen, with detection of robust neoantigen-specific immune responses to multiple neoantigens comprising both CD4 and CD8 T cells.","Expansion and diversification of vaccine-induced T-cell receptor (TCR) clonotypes was observed in the posttreatment biopsies of patients with clinical response, providing evidence of tumor infiltration by vaccine-induced neoantigen-specific T cells.","CONCLUSIONS: These findings indicate the ability of NOUS-PEV to amplify and broaden the repertoire of tumor-reactive T cells to empower a diverse, potent, and durable antitumor immune response.","Finally, a gene signature indicative of the reduced presence of activated T cells together with very poor expression of the antigen-processing machinery genes has been identified in pretreatment biopsies as a potential biomarker of resistance to the treatment."],"Aspect":"p","Summary":"The phase Ib trial involved 6 treatment-na\u00efve patients with metastatic melanoma.","Indexes":[2,3],"Sentences":["Here, we report data of a phase Ib trial of NOUS-PEV in combination with pembrolizumab in treatment-na\u00efve patients with metastatic melanoma (NCT04990479).","PATIENTS AND METHODS: The feasibility of this approach was demonstrated by producing, releasing, and administering to 6 patients 11 of 12 vaccines within 8 weeks from biopsy collection to GAd20 administration."],"Revise":false}
{"PMID":"36564918","Document":["Talimogene Laherparepvec (T-VEC) is a first-in-class oncolytic virotherapy approved for the treatment of unresectable melanoma recurrent after initial surgery.","Biodistribution data from a phase II study was used to develop a viral kinetic mechanistic model describing the interaction between cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF), the immune system, and T-VEC treatment.","Our analysis found that (1) the viral infection rate has a great influence on T-VEC treatment efficacy; (2) an increase in T-VEC dose of 102 plaque-forming units\/ml 21\u2009days and beyond after the initial dose of T-VEC resulted in an ~12% increase in response; and (3) at the systemic level, the ratio of resting innate immune cells to the death rate of innate immune impact T-VEC treatment efficacy.","This analysis clarifies under which condition the immune system either assists in eliminating tumor cells or inhibits T-VEC treatment efficacy, which is critical to both efficiently design future oncolytic agents and understand cancer development."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"39386211","Document":["INTRODUCTION: Point-of-care (POC) manufacturing of chimeric antigen receptor (CAR) modified T cell has expanded rapidly over the last decade.","In addition to the use of CD19 CAR T cells for hematological diseases, there is a growing interest in targeting a variety of tumor-associated epitopes.","METHODS: Here, we report the manufacturing and characterization of autologous anti-CD20 CAR T cells from melanoma patients within phase I clinical trial (NCT03893019).","Using a second-generation lentiviral vector for the production of the CD20 CAR T cells on the CliniMACS Prodigy\u00ae.","RESULTS: We demonstrated consistency in cell composition and functionality of the products manufactured at two different production sites.","The T cell purity was >98.5%, a CD4\/CD8 ratio between 2.5 and 5.5 and transduction rate between 34% and 61% on day 12 (harvest).","Median expansion rate was 53-fold (range, 42-65-fold) with 1.7-3.8\u00d7109 CAR T cells at harvest, a sufficient number for the planned dose escalation steps (1\u00d7105\/kg, 1\u00d7106\/kg, 1\u00d7107\/kg BW).","Complementary research of some of the products pointed out that the CAR+ cells expressed mainly central memory T-cell phenotype.","All tested CAR T cell products were capable to translate into T cell activation upon engagement of CAR target cells, indicated by the increase in pro-inflammatory cytokine release and by the increase in CAR T cell amplification.","Notably, there were some interindividual, cell-intrinsic differences at the level of cytokine release and amplification.","CAR-mediated T cell activation depended on the level of CAR cognate antigen.","DISCUSSION: In conclusion, the CliniMACS Prodigy\u00ae platform is well suited for decentralized POC manufacturing of anti-CD20 CAR T cells and may be likewise applicable for the rapid and automated manufacturing of CAR T cells directed against other targets.","CLINICAL TRIAL REGISTRATION: https:\/\/clinicaltrials.gov\/study\/NCT03893019?cond=Melanoma&term=NCT03893019&rank=1, identifier NCT03893019."],"Aspect":"p","Summary":"The study involves melanoma patients participating in a phase I clinical trial (NCT03893019).","Indexes":[2],"Sentences":["METHODS: Here, we report the manufacturing and characterization of autologous anti-CD20 CAR T cells from melanoma patients within phase I clinical trial (NCT03893019)."],"Revise":false}
{"PMID":"34817543","Document":["IMPORTANCE: Patient-led surveillance is a promising new model of follow-up care following excision of localized melanoma.","OBJECTIVE: To determine whether patient-led surveillance in patients with prior localized primary cutaneous melanoma is as safe, feasible, and acceptable as clinician-led surveillance.","DESIGN, SETTING, AND PARTICIPANTS: This was a pilot for a randomized clinical trial at 2 specialist-led clinics in metropolitan Sydney, Australia, and a primary care skin cancer clinic managed by general practitioners in metropolitan Newcastle, Australia.","The participants were 100 patients who had been treated for localized melanoma, owned a smartphone, had a partner to assist with skin self-examination (SSE), and had been routinely attending scheduled follow-up visits.","The study was conducted from November 1, 2018, to January 17, 2020, with analysis performed from September 1, 2020, to November 15, 2020.","INTERVENTION: Participants were randomized (1:1) to 6 months of patient-led surveillance (the intervention comprised usual care plus reminders to perform SSE, patient-performed dermoscopy, teledermatologist assessment, and fast-tracked unscheduled clinic visits) or clinician-led surveillance (the control was usual care).","MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of eligible and contacted patients who were randomized.","Secondary outcomes included patient-reported outcomes (eg, SSE knowledge, attitudes, and practices, psychological outcomes, other health care use) and clinical outcomes (eg, clinic visits, skin surgeries, subsequent new primary or recurrent melanoma).","RESULTS: Of 326 patients who were eligible and contacted, 100 (31%) patients (mean [SD] age, 58.7 [12.0] years; 53 [53%] men) were randomized to patient-led (n\u2009=\u200949) or clinician-led (n\u2009=\u200951) surveillance.","Data were available on patient-reported outcomes for 66 participants and on clinical outcomes for 100 participants.","Compared with clinician-led surveillance, patient-led surveillance was associated with increased SSE frequency (odds ratio [OR], 3.5; 95% CI, 0.9 to 14.0) and thoroughness (OR, 2.2; 95% CI, 0.8 to 5.7), had no detectable adverse effect on psychological outcomes (fear of cancer recurrence subscale score; mean difference, -1.3; 95% CI, -3.1 to 0.5), and increased clinic visits (risk ratio [RR], 1.5; 95% CI, 1.1 to 2.1), skin lesion excisions (RR, 1.1; 95% CI, 0.6 to 2.0), and subsequent melanoma diagnoses and subsequent melanoma diagnoses (risk difference, 10%; 95% CI, -2% to 23%).","New primary melanomas and 1 local recurrence were diagnosed in 8 (16%) of the participants in the intervention group, including 5 (10%) ahead of routinely scheduled visits; and in 3 (6%) of the participants in the control group, with none (0%) ahead of routinely scheduled visits (risk difference, 10%; 95% CI, 2% to 19%).","CONCLUSIONS AND RELEVANCE: This pilot of a randomized clinical trial found that patient-led surveillance after treatment of localized melanoma appears to be safe, feasible, and acceptable.","Experiences from this pilot study have prompted improvements to the trial processes for the larger trial of the same intervention.","TRIAL REGISTRATION: http:\/\/anzctr.org.au Identifier: ACTRN12616001716459."],"Aspect":"i","Summary":"This pilot study of a randomized clinical trial compared patient-led surveillance with physician-led surveillance in the follow-up of localized melanoma and evaluated patient-reported outcomes, clinic visits, skin surgery, and melanoma recurrence rates to determine the safety, feasibility, and acceptability of patient-led surveillance.","Indexes":[1,5,6,7],"Sentences":["OBJECTIVE: To determine whether patient-led surveillance in patients with prior localized primary cutaneous melanoma is as safe, feasible, and acceptable as clinician-led surveillance.","INTERVENTION: Participants were randomized (1:1) to 6 months of patient-led surveillance (the intervention comprised usual care plus reminders to perform SSE, patient-performed dermoscopy, teledermatologist assessment, and fast-tracked unscheduled clinic visits) or clinician-led surveillance (the control was usual care).","MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of eligible and contacted patients who were randomized.","Secondary outcomes included patient-reported outcomes (eg, SSE knowledge, attitudes, and practices, psychological outcomes, other health care use) and clinical outcomes (eg, clinic visits, skin surgeries, subsequent new primary or recurrent melanoma)."],"Revise":true}
{"PMID":"38048850","Document":["BACKGROUND: Tebentafusp demonstrated a superior overall survival (OS) benefit [hazard ratio (HR) 0.51] compared to investigator's choice (82% pembrolizumab) in a randomized, phase III trial (IMCgp100-202; N\u00a0= 378) in untreated metastatic uveal melanoma (mUM).","The 1-year OS rates for tebentafusp and pembrolizumab were 73% and 59%, respectively.","In the single-arm GEM1402 (N\u00a0= 52), the 1-year OS rate for nivolumab plus ipilimumab (N+I) in mUM was 52%.","Due to limitations in conducting randomized trials in mUM, we compared OS on tebentafusp or pembrolizumab (IMCgp100-202) to N+I (GEM1402) in untreated mUM using propensity scoring methods.","PATIENTS AND METHODS: Analyses were adjusted using propensity score-based inverse probability of treatment weighting (IPTW), balancing age, sex, baseline lactate dehydrogenase (LDH), baseline alkaline phosphatase, disease location, Eastern Cooperative Oncology Group status, and time from primary diagnosis to metastasis.","OS was assessed using IPT-weighted Kaplan-Meier and Cox proportional hazard models.","Sensitivity analyses using alternative missing data and weights methods were conducted.","RESULTS: The primary IPTW analysis included 240 of 252 patients randomized to tebentafusp from IMCgp100-202 and 45 of 52 N+I-treated patients from GEM-1402.","Key baseline covariates, including LDH, were generally well balanced before weighting.","The IPTW-adjusted OS favored tebentafusp, HR 0.52 [95% confidence interval (CI) 0.35-0.78]; 1-year OS was 73% for tebentafusp versus 50% for N+I.","Sensitivity analyses showed consistent superior OS for tebentafusp with all IPTW HRs \u22640.61.","IPTW analysis of pembrolizumab versus N+I showed no significant difference in OS (HR 0.72; 95% CI 0.50-1.06).","CONCLUSIONS: Tebentafusp was previously shown to provide an OS benefit compared to checkpoint inhibitors or chemotherapy in untreated mUM.","Propensity score analysis demonstrated a similar OS benefit for tebentafusp compared with N+I.","These data further support tebentafusp as the standard of care in previously untreated human leukocyte antigen (HLA)-A\u221702:01+ adult patients with mUM."],"Aspect":"i","Summary":"The study compared overall survival (OS) between tebentafusp, pembrolizumab, and nivolumab plus ipilimumab (N+I) in untreated metastatic uveal melanoma (mUM) using propensity score-based inverse probability of treatment weighting (IPTW), adjusting for various baseline covariates.","Indexes":[3,4,5],"Sentences":["Due to limitations in conducting randomized trials in mUM, we compared OS on tebentafusp or pembrolizumab (IMCgp100-202) to N+I (GEM1402) in untreated mUM using propensity scoring methods.","PATIENTS AND METHODS: Analyses were adjusted using propensity score-based inverse probability of treatment weighting (IPTW), balancing age, sex, baseline lactate dehydrogenase (LDH), baseline alkaline phosphatase, disease location, Eastern Cooperative Oncology Group status, and time from primary diagnosis to metastasis.","OS was assessed using IPT-weighted Kaplan-Meier and Cox proportional hazard models."],"Revise":false}
{"PMID":"37907221","Document":["BACKGROUND: Preclinically, interleukin-15 (IL-15) monotherapy promotes antitumor immune responses, which are enhanced when IL-15 is used in combination with immune checkpoint inhibitors (ICIs).","This first-in-human study investigated NIZ985, a recombinant heterodimer comprising physiologically active IL-15 and IL-15 receptor \u03b1, as monotherapy and in combination with spartalizumab, an anti-programmed cell death protein-1 (anti-PD-1) monoclonal antibody, in patients with advanced solid tumors.","METHODS: This phase I\/Ib study had two dose-escalation arms: single-agent NIZ985 administered subcutaneously thrice weekly (TIW, 2 weeks on\/2 weeks off) or once weekly (QW, 3 weeks on\/1 week off), and NIZ985 TIW or QW administered subcutaneously plus spartalizumab (400\u2009mg intravenously every 4 weeks (Q4W)).","The dose-expansion phase investigated NIZ985 1\u2009\u00b5g\/kg TIW\/spartalizumab 400\u2009mg Q4W in patients with anti-PD-1-sensitive or anti-PD-1-resistant tumor types stratified according to approved indications.","The primary objectives were the safety, tolerability, and the maximum tolerated doses (MTDs) and\/or recommended dose for expansion (RDE) of NIZ985 for the dose-expansion phase.","RESULTS: As of February 17, 2020, 83 patients (median age: 63 years; range: 28-85) were treated in dose escalation (N=47; single-agent NIZ985: n=27; NIZ985\/spartalizumab n=20) and dose expansion (N=36).","No dose-limiting toxicities occurred nor was the MTD identified.","The most common treatment-related adverse event (TRAE) was injection site reaction (primarily grades 1-2; single-agent NIZ985: 85% (23\/27)); NIZ985\/spartalizumab: 89% [50\/56]).","The most common grade 3-4 TRAE was decreased lymphocyte count (single-agent NIZ985: 7% [2\/27]; NIZ985\/spartalizumab: 5% [3\/56]).","The best overall response was stable disease in the single-agent arm (30% (8\/27)) and partial response in the NIZ985\/spartalizumab arm (5% [3\/56]; melanoma, pancreatic cancer, gastric cancer).","In dose expansion, the disease control rate was 45% (5\/11) in the anti-PD-1-sensitive and 20% (5\/25) in the anti-PD-1-resistant tumor type cohorts.","Pharmacokinetic parameters were similar across arms.","The transient increase in CD8+ T\u2009cell and natural killer cell proliferation and induction of several cytokines occurred in response to the single-agent and combination treatments.","CONCLUSIONS: NIZ985 was well tolerated in the single-agent and NIZ985\/spartalizumab regimens.","The RDE was established at 1\u2009\u00b5g\/kg TIW.","Antitumor activity of the combination was observed against tumor types known to have a poor response to ICIs.","TRIAL REGISTRATION NUMBER: NCT02452268."],"Aspect":"m","Summary":"The study involved NIZ985 administered alone subcutaneously at doses of 1 \u00b5g\/kg thrice weekly (TIW, 2 weeks on\/2 weeks off) or once weekly (QW, 3 weeks on\/1 week off), and combination of NIZ985 (TIW or QW) plus spartalizumab at 400 mg intravenously every 4 weeks (Q4W).","Indexes":[2,3],"Sentences":["METHODS: This phase I\/Ib study had two dose-escalation arms: single-agent NIZ985 administered subcutaneously thrice weekly (TIW, 2 weeks on\/2 weeks off) or once weekly (QW, 3 weeks on\/1 week off), and NIZ985 TIW or QW administered subcutaneously plus spartalizumab (400\u2009mg intravenously every 4 weeks (Q4W)).","The dose-expansion phase investigated NIZ985 1\u2009\u00b5g\/kg TIW\/spartalizumab 400\u2009mg Q4W in patients with anti-PD-1-sensitive or anti-PD-1-resistant tumor types stratified according to approved indications."],"Revise":true}
{"PMID":"38547774","Document":["AIMS: The MAPK pathway is constitutively activated in uveal melanoma (UM).","Selumetinib (AZD6244, ARRY-142886), a MEK inhibitor, has shown limited activity as monotherapy in metastatic UM.","Pre-clinical studies support synergistic cytotoxic activity for MEK inhibitors combined with taxanes, and here we sought to assess the clinical efficacy of combining selumetinib and paclitaxel.","PATIENTS AND METHODS: Seventy-seven patients with metastatic UM who had not received prior chemotherapy were randomised to selumetinib alone, or combined with paclitaxel with or without interruption in selumetinib two days before paclitaxel.","The primary endpoint was progression free survival (PFS).","After amendment, the combination arms were combined for analysis and the sample size adjusted to detect a hazard ratio (HR): 0.55, 80% power at 1-sided 5% significance level.","RESULTS: The median PFS in the combination arms was 4.8 months (95% CI: 3.8 - 5.6) compared with 3.4 months (2.0 - 3.9) in the selumetinib arm (HR 0.62 [90% CI 0.41 - 0.92], 1-sided p-value = 0.022).","ORR was 14% and 4% in the combination and monotherapy arms respectively.","Median OS was 9 months for the combination and was not significantly different from selumetinib alone (10 months) with HR of 0.98 [90% CI 0.58 - 1.66], 1-sided p-value =\u00a00.469.","Toxicity was in keeping with the known profiles of the agents involved.","CONCLUSIONS: SelPac met its primary endpoint, demonstrating an improvement in PFS for combination selumetinib and paclitaxel.","No improvement in OS was observed, and the modest improvement in PFS is not practice changing."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"38704501","Document":["BACKGROUND: Uveal melanoma (UM) has a poor prognosis once liver metastases occur.","The melphalan\/Hepatic Delivery System (melphalan\/HDS) is a drug\/device combination used for liver-directed treatment of metastatic UM (mUM) patients.","The purpose of the FOCUS study was to assess the efficacy and safety of melphalan\/HDS in patients with unresectable mUM.","METHODS: Eligible patients with mUM received treatment with melphalan (3.0 mg\/kg ideal body weight) once every 6 to 8 weeks for a maximum of six cycles.","The primary end point was the objective response rate (ORR).","The secondary end points included duration of response (DOR), overall survival (OS), and progression-free survival (PFS).","RESULTS: The study enrolled 102 patients with mUM.","Treatment was attempted in 95 patients, and 91 patients received treatment.","In the treated population (n = 91), the ORR was 36.3 % (95 % confidence interval [CI], 26.44-47.01), including 7.7 % of patients with a complete response.","Thus, the study met its primary end point because the lower bound of the 95 % CI for ORR exceeded the upper bound (8.3 %) from the benchmark meta-analysis.","The median DOR was 14 months, and the median OS was 20.5 months, with an OS of 80 % at 1 year.","The median PFS was 9 months, with a PFS of 65 % at 6 months.","The most common serious treatment-emergent adverse events were thrombocytopenia (15.8 %) and neutropenia (10.5 %), treated\u00a0mostly on an outpatient basis with observation.","No treatment-related deaths were observed.","CONCLUSION: Treatment with melphalan\/HDS provides a clinically meaningful response rate and demonstrates a favorable benefit-risk profile in patients with unresectable mUM (study funded by Delcath; ClinicalTrials.gov identifier: NCT02678572; EudraCT no.","2015-000417-44)."],"Aspect":"a","Summary":"The purpose of the FOCUS study was to assess the efficacy and safety of melphalan\/HDS in patients with unresectable mUM.","Indexes":[2],"Sentences":["The purpose of the FOCUS study was to assess the efficacy and safety of melphalan\/HDS in patients with unresectable mUM."],"Revise":false}
{"PMID":"37738028","Document":["The treatment of metastatic uveal melanoma remains a major clinical challenge.","Procaspase-3, a proapoptotic protein and precursor to the key apoptotic executioner caspase-3, is overexpressed in a wide range of malignancies, and the drug PAC-1 leverages this overexpression to selectively kill cancer cells.","Herein, we investigate the efficacy of PAC-1 against uveal melanoma cell lines and report the synergistic combination of PAC-1 and entrectinib.","This preclinical activity, tolerability data in mice, and the known clinical effectiveness of these drugs in human cancer patients led to a small Phase 1b study in patients with metastatic uveal melanoma.","The combination of PAC-1 and entrectinib was tolerated with no treatment-related grade \u22653 toxicities in these patients.","The pharmacokinetics of entrectinib were not affected by PAC-1 treatment.","In this small and heavily pretreated initial cohort, stable disease was observed in four out of six patients, with a median progression-free survival of 3.38 months (95% CI 1.6-6.5 months).","This study is an initial demonstration that the combination of PAC-1 and entrectinib may warrant further clinical investigation.","Clinical trial registration: Clinical Trials.gov: NCT04589832."],"Aspect":"s","Summary":"The combination of PAC-1 and entrectinib was tolerated with no treatment-related grade \u22653 toxicities in these patients.","Indexes":[4],"Sentences":["The combination of PAC-1 and entrectinib was tolerated with no treatment-related grade \u22653 toxicities in these patients."],"Revise":false}
{"PMID":"36947734","Document":["PURPOSE: No approved targeted therapy for the treatment of patients with neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS)-mutant melanoma is currently available.","PATIENTS AND METHODS: In this phase Ib escalation\/expansion study (ClinicalTrials.gov identifier: NCT02974725), the safety, tolerability, and preliminary antitumor activity of naporafenib (LXH254), a BRAF\/CRAF protein kinases inhibitor, were explored in combination with trametinib in patients with advanced\/metastatic KRAS- or BRAF-mutant non-small-cell lung cancer (escalation arm) or NRAS-mutant melanoma (escalation and expansion arms).","RESULTS: Thirty-six and 30 patients were enrolled in escalation and expansion, respectively.","During escalation, six patients reported grade \u22653 dose-limiting toxicities, including dermatitis acneiform (n = 2), maculopapular rash (n = 2), increased lipase (n = 1), and Stevens-Johnson syndrome (n = 1).","The recommended doses for expansion were naporafenib 200 mg twice a day plus trametinib 1 mg once daily and naporafenib 400 mg twice a day plus trametinib 0.5 mg once daily.","During expansion, all 30 patients experienced a treatment-related adverse event, the most common being rash (80%, n = 24), blood creatine phosphokinase increased, diarrhea, and nausea (30%, n = 9 each).","In expansion, the objective response rate, median duration of response, and median progression-free survival were 46.7% (95% CI, 21.3 to 73.4; 7 of 15 patients), 3.75 (95% CI, 1.97 to not estimable [NE]) months, and 5.52 months, respectively, in patients treated with naporafenib 200 mg twice a day plus trametinib 1 mg once daily, and 13.3% (95% CI, 1.7 to 40.5; 2 of 15 patients), 3.75 (95% CI, 2.04 to NE) months, and 4.21 months, respectively, in patients treated with naporafenib 400 mg twice a day plus trametinib 0.5 mg once daily.","CONCLUSION: Naporafenib plus trametinib showed promising preliminary antitumor activity in patients with NRAS-mutant melanoma.","Prophylactic strategies aimed to lower the incidence of skin-related events are under investigation."],"Aspect":"o","Summary":"Naporafenib plus trametinib showed promising preliminary antitumor activity in patients with NRAS-mutant melanoma.","Indexes":[7],"Sentences":["CONCLUSION: Naporafenib plus trametinib showed promising preliminary antitumor activity in patients with NRAS-mutant melanoma."],"Revise":false}
{"PMID":"33361337","Document":["BACKGROUND: In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib (triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and trametinib (doublet) without reaching statistical significance.","Mature results on PFS, duration of response (DOR), and overall survival (OS) are reported.","METHODS: The double-blind, phase 2 part of KEYNOTE-022 enrolled patients with previously untreated BRAFV600E\/K-mutated advanced melanoma from 22 sites in seven countries.","Patients were randomly assigned 1:1 to intravenous pembrolizumab (200 mg every 3 weeks) or placebo plus dabrafenib (150 mg orally two times per day) and trametinib (2 mg orally one time a day).","Primary endpoint was PFS.","Secondary endpoints were objective response rate, DOR, and OS.","Efficacy was assessed in the intention-to-treat population, and safety was assessed in all patients who received at least one dose of study drug.","This analysis was not specified in the protocol.","RESULTS: Between November 30, 2015 and April 24, 2017, 120 patients were randomly assigned to triplet (n=60) or doublet (n=60) therapy.","With 36.6 months of follow-up, median PFS was 16.9 months (95% CI 11.3 to 27.9) with triplet and 10.7 months (95% CI 7.2 to 16.8) with doublet (HR 0.53; 95% CI 0.34 to 0.83).","With triplet and doublet, respectively, PFS at 24 months was 41.0% (95% CI 27.4% to 54.2%) and 16.3% (95% CI 8.1% to 27.1%); median DOR was 25.1 months (95% CI 14.1 to not reached) and 12.1 months (95% CI 6.0 to 15.7), respectively.","Median OS was not reached with triplet and was 26.3 months with doublet (HR 0.64; 95% CI 0.38 to 1.06).","With triplet and doublet, respectively, OS at 24 months was 63.0% (95% CI 49.4% to 73.9%) and 51.7% (95% CI 38.4% to 63.4%).","Grade 3-5 treatment-related adverse events (TRAEs) occurred in 35 patients (58%, including one death) receiving triplet and 15 patients (25%) receiving doublet.","CONCLUSION: In BRAFV600E\/K-mutant advanced melanoma, pembrolizumab plus dabrafenib and trametinib substantially improved PFS, DOR, and OS with a higher incidence of TRAEs.","Interpretation of these results is limited by the post hoc nature of the analysis."],"Aspect":"i","Summary":"Patients with previously untreated BRAFV600E\/K-mutated advanced melanoma were randomly assigned to receive pembrolizumab plus dabrafenib and trametinib or placebo plus dabrafenib and trametinib.","Indexes":[2,3],"Sentences":["METHODS: The double-blind, phase 2 part of KEYNOTE-022 enrolled patients with previously untreated BRAFV600E\/K-mutated advanced melanoma from 22 sites in seven countries.","Patients were randomly assigned 1:1 to intravenous pembrolizumab (200 mg every 3 weeks) or placebo plus dabrafenib (150 mg orally two times per day) and trametinib (2 mg orally one time a day)."],"Revise":false}
{"PMID":"37377890","Document":["PURPOSE: Treatments are limited for metastatic melanoma and metastatic triple-negative breast cancer (mTNBC).","This pilot phase I trial (NCT03060356) examined the safety and feasibility of intravenous RNA-electroporated chimeric antigen receptor (CAR) T cells targeting the cell-surface antigen cMET.","EXPERIMENTAL DESIGN: Metastatic melanoma or mTNBC subjects had at least 30% tumor expression of cMET, measurable disease and progression on prior therapy.","Patients received up to six infusions (1 \u00d7 10e8 T cells\/dose) of CAR T cells without lymphodepleting chemotherapy.","Forty-eight percent of prescreened subjects met the cMET expression threshold.","Seven (3 metastatic melanoma, 4 mTNBC) were treated.","RESULTS: Mean age was 50 years (35-64); median Eastern Cooperative Oncology Group 0 (0-1); median prior lines of chemotherapy\/immunotherapy were 4\/0 for TNBC and 1\/3 for melanoma subjects.","Six patients experienced grade 1 or 2 toxicity.","Toxicities in at least 1 patient included anemia, fatigue, and malaise.","One subject had grade 1 cytokine release syndrome.","No grade 3 or higher toxicity, neurotoxicity, or treatment discontinuation occurred.","Best response was stable disease in 4 and disease progression in 3 subjects.","mRNA signals corresponding to CAR T cells were detected by RT-PCR in all patients' blood including in 3 subjects on day +1 (no infusion administered on this day).","Five subjects underwent postinfusion biopsy with no CAR T-cell signals seen in tumor.","Three subjects had paired tumor tissue; IHC showed increases in CD8 and CD3 and decreases in pS6 and Ki67.","CONCLUSIONS: Intravenous administration of RNA-electroporated cMET-directed CAR T cells is safe and feasible.","SIGNIFICANCE: Data evaluating CAR T therapy in patients with solid tumors are limited.","This pilot clinical trial demonstrates that intravenous cMET-directed CAR T-cell therapy is safe and feasible in patients with metastatic melanoma and metastatic breast cancer, supporting the continued evaluation of cellular therapy for patients with these malignancies."],"Aspect":"i","Summary":"This pilot phase I trial examined the safety and feasibility of intravenous RNA-electroporated chimeric antigen receptor (CAR) T cells targeting the cell-surface antigen cMET in patients with metastatic melanoma or mTNBC, with patients receiving up to six infusions of CAR T cells without lymphodepleting chemotherapy.","Indexes":[1,3],"Sentences":["This pilot phase I trial (NCT03060356) examined the safety and feasibility of intravenous RNA-electroporated chimeric antigen receptor (CAR) T cells targeting the cell-surface antigen cMET.","Patients received up to six infusions (1 \u00d7 10e8 T cells\/dose) of CAR T cells without lymphodepleting chemotherapy."],"Revise":false}
{"PMID":"31880964","Document":["PURPOSE: Phase III adjuvant trials have reported significant benefits in both relapse-free survival (RFS) and overall survival (OS) for high-dose interferon alfa (HDI) and ipilimumab at 10 mg\/kg (ipi10).","E1609 evaluated the safety and efficacy of ipilimumab at 3 mg\/kg (ipi3) and ipi10 versus HDI.","PATIENTS AND METHODS: E1609 was a phase III trial in patients with resected cutaneous melanoma (American Joint Committee on Cancer 7th edition stage IIIB, IIIC, M1a, or M1b).","It had 2 coprimary end points: OS and RFS.","A 2-step hierarchic approach first evaluated ipi3 versus HDI followed by ipi10 versus HDI.","RESULTS: Between May 2011 and August 2014, 1,670 adult patients were centrally randomly assigned (1:1:1) to ipi3 (n = 523), HDI (n = 636), or ipi10 (n = 511).","Treatment-related adverse events grade \u2265 3 occurred in 37% of patients receiving ipi3, 79% receiving HDI, and 58% receiving ipi10, with adverse events leading to treatment discontinuation in 35%, 20%, and 54%, respectively.","Comparison of ipi3 versus HDI used an intent-to-treat analysis of concurrently randomly assigned patient cases (n = 1,051) and showed significant OS difference in favor of ipi3 (hazard ratio [HR], 0.78; 95.6% repeated CI, 0.61 to 0.99; P = .044; RFS: HR, 0.85; 99.4% CI, 0.66 to 1.09; P = .065).","In the second step, for ipi10 versus HDI (n = 989), trends in favor of ipi10 did not achieve statistical significance.","Salvage patterns after melanoma relapse showed significantly higher rates of ipilimumab and ipilimumab\/anti-programmed death 1 use in the HDI arm versus ipi3 and ipi10 (P \u2264 .001).","CONCLUSION: Adjuvant therapy with ipi3 benefits survival versus HDI; for the first time to our knowledge in melanoma adjuvant therapy, E1609 has demonstrated a significant improvement in OS against an active control regimen.","The currently approved adjuvant ipilimumab dose (ipi10) was more toxic and not superior in efficacy to HDI."],"Aspect":"o","Summary":"The study found that adjuvant therapy with ipilimumab at 3 mg\/kg (ipi3) significantly improves overall survival compared to high-dose interferon alfa (HDI) in patients with resected cutaneous melanoma.","Indexes":[7,10],"Sentences":["Comparison of ipi3 versus HDI used an intent-to-treat analysis of concurrently randomly assigned patient cases (n = 1,051) and showed significant OS difference in favor of ipi3 (hazard ratio [HR], 0.78; 95.6% repeated CI, 0.61 to 0.99; P = .044; RFS: HR, 0.85; 99.4% CI, 0.66 to 1.09; P = .065).","CONCLUSION: Adjuvant therapy with ipi3 benefits survival versus HDI; for the first time to our knowledge in melanoma adjuvant therapy, E1609 has demonstrated a significant improvement in OS against an active control regimen."],"Revise":false}
{"PMID":"31562797","Document":["BACKGROUND: Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma.","We now report 5-year outcomes in the trial.","METHODS: We randomly assigned patients with previously untreated advanced melanoma to receive one of the following regimens: nivolumab (at a dose of 1 mg per kilogram of body weight) plus ipilimumab (3 mg per kilogram) every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram every 2 weeks); nivolumab (3 mg per kilogram every 2 weeks) plus ipilimumab-matched placebo; or ipilimumab (3 mg per kilogram every 3 weeks for four doses) plus nivolumab-matched placebo.","The two primary end points were progression-free survival and overall survival in the nivolumab-plus-ipilimumab group and in the nivolumab group, as compared with the ipilimumab group.","RESULTS: At a minimum follow-up of 60 months, the median overall survival was more than 60.0 months (median not reached) in the nivolumab-plus-ipilimumab group and 36.9 months in the nivolumab group, as compared with 19.9 months in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.52; hazard ratio for death with nivolumab vs. ipilimumab, 0.63).","Overall survival at 5 years was 52% in the nivolumab-plus-ipilimumab group and 44% in the nivolumab group, as compared with 26% in the ipilimumab group.","No sustained deterioration of health-related quality of life was observed during or after treatment with nivolumab plus ipilimumab or with nivolumab alone.","No new late toxic effects were noted.","CONCLUSIONS: Among patients with advanced melanoma, sustained long-term overall survival at 5 years was observed in a greater percentage of patients who received nivolumab plus ipilimumab or nivolumab alone than in those who received ipilimumab alone, with no apparent loss of quality of life in the patients who received regimens containing nivolumab.","(Funded by Bristol-Myers Squibb and others; CheckMate 067 ClinicalTrials.gov number, NCT01844505.",")."],"Aspect":"s","Summary":"No new late toxic effects were noted.","Indexes":[7],"Sentences":["No new late toxic effects were noted."],"Revise":true}
{"PMID":"35254331","Document":["Heat shock proteins (hsp) are intracellular chaperones that possess extracellular immunostimulatory properties when complexed with antigens.","A recombinant Hsp110-gp100 chaperone complex vaccine showed an antitumor response and prolonged survival in murine melanoma.","A phase Ib dose-escalation study of a recombinant human Hsp110-gp100 vaccine in advanced-stage melanoma patients was performed to evaluate toxicity, immunostimulatory potential and clinical response.","Patients with pretreated, unresectable stage IIIB\/C\/IV melanoma received the chaperone complex vaccine in a dose-escalation protocol; three vaccinations over a 43-day-period.","Tumor response, clinical toxicity and immune response were measured.","Ten patients (eight female, median age 70\u2009years) were enrolled and two patients had grade 1 adverse events; minor skin rash, hyperhidrosis and fever (no grade 2 or higher adverse events).","Median progression-free survival was longer for lower vaccine doses as compared to the maximum dose of 180\u2009mcg (4.5 vs. 2.9\u2009months; P\u2009=\u20090.018).","The lowest dose patients (30 and 60\u2009mcg) had clinical tumor responses (one partial response, one stable disease).","CD8+ T cell interferon-\u03b3 responses to gp100 were greater in the clinically responding patients.","A pattern of B cell responses to vaccination was not observed.","Regulatory T cell populations and co-stimulatory molecules including cytotoxic T-lymphocyte-associated protein 4 and PD-1 appeared to differ in responders versus nonresponders.","A fully recombinant human Hsp110-gp100 chaperone complex vaccine had minimal toxicity, measurable tumor responses at lower doses and produced peripheral CD8+ T cell activation in patients with advanced, pretreated melanoma.","Combination with currently available immunotherapies may augment clinical responses."],"Aspect":"s","Summary":"Two patients had grade 1 adverse events including minor skin rash, hyperhidrosis, and fever, with no grade 2 or higher adverse events.","Indexes":[5],"Sentences":["Ten patients (eight female, median age 70\u2009years) were enrolled and two patients had grade 1 adverse events; minor skin rash, hyperhidrosis and fever (no grade 2 or higher adverse events)."],"Revise":false}
{"PMID":"39288737","Document":["UNLABELLED: In the previously reported primary analyses of this phase 3 trial, 12 months of adjuvant pembrolizumab resulted in significantly longer recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) than placebo in patients with resected high risk stage III melanoma.","Stability of these benefits when the median follow-up was 3.5 and 5 years was published.","Here we report results with a longer follow-up.","METHODS: We randomized 1019 patients to receive pembrolizumab 200\u00a0mg or placebo, intravenously every 3 weeks for a total of 18 doses.","RFS in the overall population and in the subgroup of patients with melanoma positive for the PD-1 ligand (PD-L1) were co-primary endpoints.","DMFS in these two populations was a secondary and progression\/recurrence-free survival 2 (PRFS2) an exploratory endpoint.","RESULTS: The median follow-up was 6.9 years.","In the overall intention-to-treat population, RFS was longer in the pembrolizumab group than in the placebo group (HR 0.63, 95\u00a0% CI 0.53 to 0.74).","RFS at 7 years was 50\u00a0% (95\u00a0% CI 46\u00a0% to 55\u00a0%) in the pembrolizumab and 36\u00a0% (95\u00a0% CI 32\u00a0% to 41\u00a0%) in the placebo group.","Positive effects were present both for loco-regional recurrences and distant metastases, and across substages IIIA-IIIB-IIIC, and PD-L1 positive and PD-L1 negative as well as for BRAF mutant and BRAF wild type populations.","DMFS was longer in the pembrolizumab group than in the placebo group (HR 0.64, 95\u00a0% CI 0.54 to 0.76).","DMFS at 7 years was 54\u00a0% (95\u00a0% CI 50\u00a0% to 59\u00a0%) in the pembrolizumab and 42\u00a0% (95\u00a0% CI 37\u00a0% to 46\u00a0%) in the placebo group.","PRFS2 was longer in the pembrolizumab group than in the placebo group (HR 0.69, 95\u00a0% CI 0.57 to 0.84).","PRFS2 at 7 years was 61\u00a0% (95\u00a0% CI 57\u00a0% to 66\u00a0%) in the pembrolizumab and 53\u00a0% (95\u00a0% CI 49\u00a0% to 57\u00a0%) in the placebo group.","CONCLUSIONS: The 7-year analysis of adjuvant therapy with pembrolizumab demonstrated a sustained improvement in the long-term RFS, DMFS and PRFS2 compared with placebo in patients with resected stage III melanoma."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"32602215","Document":["The effects of itraconazole, a strong CYP3A4 inhibitor, on the steady-state pharmacokinetics of vemurafenib were evaluated in a phase 1, multicenter, open-label, fixed-sequence study.","Patients with BRAFV600 mutation-positive metastatic malignancies received oral vemurafenib 960 mg twice daily on days 1 to 20 (period A) and oral vemurafenib 960 mg twice daily with oral itraconazole 200 mg once daily on days 21 to 40 (period B).","A mixed-effects analysis of variance model was used to compare log-transformed area under the concentration-time curve during the dosing interval and maximum plasma concentration values for vemurafenib in 8 patients between period B (vemurafenib plus itraconazole) and period A (vemurafenib alone).","Multiple doses of itraconazole increased steady-state exposure of vemurafenib by approximately 40%, with geometric least squares mean ratios (period B\/period A) of 140% (90% confidence interval, 121-161) for both maximum plasma concentration and area under the concentration-time curve during the dosing interval.","There was no apparent increase in incidence or severity of adverse events during coadministration of vemurafenib with itraconazole.","In conclusion, coadministration of itraconazole with vemurafenib resulted in a modest increase in exposure of vemurafenib at steady state and was generally well tolerated."],"Aspect":"o","Summary":"Coadministration of itraconazole with vemurafenib resulted in a 40% increase in the steady-state exposure of vemurafenib and was generally well tolerated.","Indexes":[3,5],"Sentences":["Multiple doses of itraconazole increased steady-state exposure of vemurafenib by approximately 40%, with geometric least squares mean ratios (period B\/period A) of 140% (90% confidence interval, 121-161) for both maximum plasma concentration and area under the concentration-time curve during the dosing interval.","In conclusion, coadministration of itraconazole with vemurafenib resulted in a modest increase in exposure of vemurafenib at steady state and was generally well tolerated."],"Revise":false}
{"PMID":"37167764","Document":["BACKGROUND: In the phase II\/III RELATIVITY-047 trial, a novel fixed-dose combination (FDC) of nivolumab plus relatlimab (NIVO\u202f+\u202fRELA; a programmed death-1 and a lymphocyte-activation gene 3 inhibitor, respectively) significantly improved progression-free survival (PFS) versus NIVO in patients with previously untreated unresectable or metastatic melanoma (median follow-up, 13.2 months) with stable health-related quality of life (HRQoL), although grade three or four treatment-related adverse events (TRAEs) were more frequent with the combination.","Updated HRQoL results (median follow-up, 19.3 months) are presented.","METHODS: Patients were randomised to receive intravenous NIVO\u202f+\u202fRELA (480\u202fmg and 160\u202fmg, respectively) or NIVO (480\u202fmg) every 4 weeks.","HRQoL was assessed using the Functional Assessment of Cancer Treatment-Melanoma (FACT-M) and EQ-5D-3L questionnaires at baseline, before dosing at each treatment cycle, and at follow-up (posttreatment) visits.","RESULTS: Consistent with the initial analysis, HRQoL remained stable with NIVO\u202f+\u202fRELA on treatment and was similar to that with NIVO.","Mean changes from baseline did not exceed clinically meaningful thresholds.","HRQoL results were consistent across instruments and scales\/subscales.","Despite an increased rate of grade three or four TRAEs with NIVO\u202f+\u202fRELA versus NIVO, the proportion of patients reporting that they were bothered 'quite a bit' or 'very much' by TRAEs was low and comparable between treatments.","CONCLUSION: Results from the RELATIVITY-047 trial show that the PFS benefit with NIVO\u202f+\u202fRELA FDC over NIVO was obtained with stable patient-reported HRQoL, supporting NIVO\u202f+\u202fRELA as a first-line treatment option for patients with advanced melanoma."],"Aspect":"i","Summary":"Patients were randomized to receive intravenous NIVO+RELA (480mg and 160mg, respectively) or NIVO (480mg) every 4 weeks.","Indexes":[2],"Sentences":["METHODS: Patients were randomised to receive intravenous NIVO\u202f+\u202fRELA (480\u202fmg and 160\u202fmg, respectively) or NIVO (480\u202fmg) every 4 weeks."],"Revise":false}
{"PMID":"38657233","Document":["IFx-Hu2.0 was designed to encode part of the Emm55 protein contained within a plasmid in a formulation intended for transfection into mammalian cells.","IFx-Hu2.0 promotes both adaptive and innate immune responses in animal studies.","Furthermore, previous studies have demonstrated safety\/efficacy in equine, canine, and murine species.","We present the first-in-human study of IFx-Hu2.0, administered by intralesional injection into melanoma tumors of seven patients with stage III\/IV unresectable melanoma.","No dose-limiting toxicities attributable to IFx-Hu2.0 were observed.","Grade 1\/2 injection site reactions were observed in five of seven patients.","IgG and IgM responses to Emm55 peptides and known melanoma antigens were seen in the peripheral blood, suggesting that IFx-Hu2.0 acts as an individualized \"in situ vaccine.\"","Three of four patients previously refractory to anti-PD1 experienced clinical benefit upon subsequent anti-PD1-based treatment.","Therefore, this approach is feasible, and clinical\/correlative outcomes warrant further investigation for treating patients with metastatic melanoma with an immune priming agent."],"Aspect":"i","Summary":"IFx-Hu2.0 was administered by intralesional injection into melanoma tumors of seven patients with stage III\/IV unresectable melanoma.","Indexes":[3],"Sentences":["We present the first-in-human study of IFx-Hu2.0, administered by intralesional injection into melanoma tumors of seven patients with stage III\/IV unresectable melanoma."],"Revise":false}
{"PMID":"36738540","Document":["Survival of macroscopic stage III melanoma is poor.","Five-year overall survival and relapse-free survival rates for surgery alone range from 40 to 59% and 30 to-39%, respectively.","The current standard of care is therapeutic lymph node dissection (TLND) followed by a year of adjuvant systemic therapy.","Multiple phase 2 trials have shown that neo-adjuvant immunotherapy induces major pathologic response (MPR) rates (pathologic complete response (pCR): pCR, 0% viable tumour cells; near-pCR, <10% viable tumour cells), which translate into durable relapse free survival rates.","Single agent anti-PD-1 achieves 20-30% MPR, the combination of ipilimumab and nivolumab doubles the MPR rates to 50-60%.","The OpACIN trial demonstrated that neoadjuvant immunotherapy induced both higher numbers and a broader repertoire of tumour-resident T-cells in peripheral blood compared with adjuvant immunotherapy.","Very recently, the randomised phase 2 trial S1801\u00a0reported its first interim results.","S1801 compared TLND, followed by 18 courses of adjuvant pembrolizumab, to three courses of neoadjuvant pembrolizumab, followed by surgery and 15 adjuvant doses.","With a median follow-up of 14 months, a 23% EFS rate benefit was observed.","The ongoing phase 3 NADINA trial randomises patients between TLND\u00a0+\u00a0one year of adjuvant nivolumab (control arm) or 2 courses of neoadjuvant therapy with ipilimumab\u00a0+\u00a0nivolumab, followed by adjuvant therapy only for non-MPR patients.","There is rapid, consistent, and accumulating evidence generated from all phase 1 and phase 2 trials, indicating clinical superiority of neoadjuvant immunotherapy over adjuvant systemic therapy for macroscopic stage III melanoma.","Therefore, payers should consider neoadjuvant immunotherapy for reimbursement\u00a0as this approach is the best option for our patients, and classify it as the best medical practice."],"Aspect":"o","Summary":"Neoadjuvant immunotherapy demonstrates clinical superiority over adjuvant systemic therapy for macroscopic stage III melanoma.","Indexes":[10],"Sentences":["There is rapid, consistent, and accumulating evidence generated from all phase 1 and phase 2 trials, indicating clinical superiority of neoadjuvant immunotherapy over adjuvant systemic therapy for macroscopic stage III melanoma."],"Revise":false}
{"PMID":"31901705","Document":["BACKGROUND: BRAF\/MEK inhibitor combinations are established treatments for BRAF V600-mutant melanoma based on demonstrated benefits on progression-free survival (PFS) and overall survival (OS).","Here, we report an updated analysis of the COLUMBUS\u00a0(COmbined LGX818 [encorafenib] Used with MEK162 [binimetinib] in\u00a0BRAF\u00a0mutant Unresectable Skin cancer) trial with long-term follow-up.","METHODS: In part 1 of the COLUMBUS trial, 577 patients with advanced\/metastatic BRAF V600-mutant melanoma, untreated or progressed after first-line immunotherapy, were randomised 1:1:1 to 450\u00a0mg of encorafenib QD\u00a0+\u00a045\u00a0mg of binimetinib BID (COMBO450) vs 960\u00a0mg of vemurafenib BID (VEM) or 300\u00a0mg of encorafenib ENCO QD (ENCO300).","An updated analysis was conducted that included PFS, OS, objective response rate, safety and tolerability\u00a0and analyses of results by prognostic subgroups.","RESULTS: At data cutoff, there were 116, 113\u00a0and 138 deaths in the COMBO450, ENCO300\u00a0and VEM treatment arms, respectively.","The median OS was 33.6 months (95% confidence interval [CI], 24.4-39.2) for COMBO450, 23.5 months (95% CI, 19.6-33.6) for ENCO300\u00a0and 16.9 months (95% CI, 14.0-24.5) for VEM.","Compared with VEM, COMBO450 decreased the risk of death by 39% (hazard ratio [HR], 0.61; 95% CI, 0.48-0.79).","The updated median PFS for COMBO450 was 14.9 months (95% CI, 11.0-20.2), ENCO300 was 9.6 months (95% CI, 7.4-14.8)\u00a0and VEM was 7.3 months (95% CI, 5.6-7.9).","PFS was longer for COMBO450 vs VEM (HR, 0.51; 95% CI, 0.39-0.67).","Landmark OS and PFS results show consistent results for each year analysed.","Subgroups all favoured COMBO450 vs VEM.","CONCLUSIONS: Updated PFS and OS results for COMBO450 from the COLUMBUS trial demonstrate a long-term benefit in patients with advanced BRAF V600-mutated melanoma."],"Aspect":"o","Summary":"The updated analysis of the COLUMBUS trial shows that the combination of encorafenib and binimetinib (COMBO450) provides a long-term benefit in patients with advanced BRAF V600-mutated melanoma, with a median overall survival of 33.6 months and a progression-free survival of 14.9 months.","Indexes":[5,7,11],"Sentences":["The median OS was 33.6 months (95% confidence interval [CI], 24.4-39.2) for COMBO450, 23.5 months (95% CI, 19.6-33.6) for ENCO300\u00a0and 16.9 months (95% CI, 14.0-24.5) for VEM.","The updated median PFS for COMBO450 was 14.9 months (95% CI, 11.0-20.2), ENCO300 was 9.6 months (95% CI, 7.4-14.8)\u00a0and VEM was 7.3 months (95% CI, 5.6-7.9).","CONCLUSIONS: Updated PFS and OS results for COMBO450 from the COLUMBUS trial demonstrate a long-term benefit in patients with advanced BRAF V600-mutated melanoma."],"Revise":false}
{"PMID":"33735809","Document":["BACKGROUND: Patients with synchronous clinical stage III melanoma can present with primary melanoma lesions, locally recurrent melanoma or in-transit metastases.","Neoadjuvant ipilimumab plus nivolumab induces high pathologic response rates and an impressive relapse-free survival in patients with nodal macroscopic stage III melanoma.","Whether primary site melanoma and in-transit metastases respond similarly to lymph node metastases with neoadjuvant immunotherapy is largely unknown.","Such data would clarify whether surgical excision of these melanoma lesions should be performed before neoadjuvant therapy or whether it could be deferred and performed in conjunction with lymphadenectomy following neoadjuvant immunotherapy.","PATIENTS: Patients with synchronous clinical stage III melanoma were identified from the OpACIN, OpACIN-neo and PRADO neoadjuvant trials, where all patients were treated with ipilimumab plus nivolumab.","An additional case treated outside those clinical trials was included.","RESULTS: Seven patients were identified; six patients had a concordant response in primary site melanoma lesions or in-transit metastasis and the lymph node metastases.","One patient had concordant progression in both the primary and nodal tumour lesions and developed stage IV disease during neoadjuvant treatment, and thus, no resection was performed.","CONCLUSION: Pathologic response following neoadjuvant ipilimumab plus nivolumab in primary site melanoma lesions or in-transit metastasis is concordant with a response in the lymph node metastases, indicating that there may be no need to perform upfront surgery to these melanoma lesions prior to neoadjuvant treatment."],"Aspect":"m","Summary":"The treatment involved ipilimumab plus nivolumab.","Indexes":[1,4],"Sentences":["Neoadjuvant ipilimumab plus nivolumab induces high pathologic response rates and an impressive relapse-free survival in patients with nodal macroscopic stage III melanoma.","PATIENTS: Patients with synchronous clinical stage III melanoma were identified from the OpACIN, OpACIN-neo and PRADO neoadjuvant trials, where all patients were treated with ipilimumab plus nivolumab."],"Revise":false}
{"PMID":"34772758","Document":["BACKGROUND: Angiogenic factors promote the growth of tumor vasculature, modulate lymphocyte trafficking into tumors, and inhibit maturation of dendritic cells.","We hypothesized that MEDI3617, a human IgG1 kappa monoclonal antibody directed against human angiopoietin-2, in combination with tremelimumab (treme), an IgG2 monoclonal antibody blocking cytotoxic T-lymphocyte-associated protein- (CTLA-4), is safe in patients with advanced melanoma.","METHODS: In a phase I, 3+3 dose escalation trial, patients with metastatic or unresectable melanoma received treme in combination with MEDI3617.","The primary objectives of the study were safety and determination of recommended phase II dose (RP2D).","The secondary objectives included determination of 6-month and 1-year overall survival and best overall response rate.","Immune cell populations and soluble factors were assessed in peripheral blood and metastatic tumors using Fluorescence activated cell sorting (FACS), Luminex, and multiplexed immunofluorescence.","RESULTS: Fifteen patients (median age: 62) were enrolled in the study (3 patients in cohort 1: treme at 10 mg\/kg and MEDI3617 at 200 mg; and 12 patients in cohort 2: treme at 10 mg\/kg and MEDI3617 at 600 mg).","The most common all-grade treatment-related adverse events were rash, pruritus, fatigue, and extremity edema.","No dose-limiting toxicities were observed.","Cohort 2 was determined to be the RP2D.","There were no patients with confirmed immune-related complete response or immune-related partial response.","Six of 15 patients had immune-related stable disease, resulting in a disease control rate of 0.40 (95% CI 0.16 to 0.68).","An increase in frequencies of circulating inducible T-cell costimulator (ICOS)+ and human leukocyte antigen (HLA)-DR+ CD4+ and CD8+ T cells and production of Interleukin-2 and Interleukin-10 was observed post therapy.","CONCLUSIONS: Tremelimumab in combination with MEDI3617 is safe in patients with advanced melanoma.","Angiopoietin-2 inhibition in combination with immune checkpoint inhibition warrants further exploration.","TRIAL REGISTRATION NUMBER: NCT02141542."],"Aspect":"o","Summary":"The study found that the combination of tremelimumab and MEDI3617 is safe in patients with advanced melanoma, with a disease control rate of 0.40, but no confirmed immune-related complete or partial responses were observed.","Indexes":[10,11,13],"Sentences":["There were no patients with confirmed immune-related complete response or immune-related partial response.","Six of 15 patients had immune-related stable disease, resulting in a disease control rate of 0.40 (95% CI 0.16 to 0.68).","CONCLUSIONS: Tremelimumab in combination with MEDI3617 is safe in patients with advanced melanoma."],"Revise":true}
{"PMID":"32448802","Document":["BACKGROUND: With immunotherapy gaining increasing approval for treatment of different tumor types, scientists rely on cutting edge methods for the monitoring of immune responses and biomarker development in patients.","Due to the lack of tools to efficiently detect rare circulating human tumor-specific CD4 T cells, their characterization in patients still remains very limited.","METHODS: We have used combinatorial staining strategies with peptide major histocompatibility complex class II (pMHCII) multimer constructs of different alleles to establish an optimized staining procedure for in vitro and direct ex-vivo visualization of tumor-specific CD4 T cells, in patient samples.","Furthermore, we have generated reversible multimers to achieve optimal cell staining and yet disassemble prior to in vitro cell expansion, thus preventing activation induced cell death.","RESULTS: We observed a vastly improved detection of tumor-specific, viral-specific and bacterial-specific cells with our optimization methods compared with the non-optimized staining procedure.","By increasing the variety of fluorochromes used to label the pMHCII multimers, we were also able to increase the parallel detection of different specificities within one sample, including antigen-specific CD8 T cells.","A decrease in cell viability was observed when using the full optimization method, but this was mitigated by the removal of neuraminidase and the use of reversible multimers.","CONCLUSION: This new optimized staining procedure represents an advance toward better detection and analysis of antigen-specific CD4 T cells.","It should facilitate state-of-the art precision monitoring of tumor-specific CD4 T cells and contribute to accelerate the use and the targeting of these cells in cancer immunotherapy."],"Aspect":"o","Summary":"The study found a vastly improved detection of tumor-specific, viral-specific, and bacterial-specific cells with optimized staining procedures compared to non-optimized methods.","Indexes":[4],"Sentences":["RESULTS: We observed a vastly improved detection of tumor-specific, viral-specific and bacterial-specific cells with our optimization methods compared with the non-optimized staining procedure."],"Revise":false}
{"PMID":"31809326","Document":["OBJECTIVES: With the introduction of novel immune therapeutics for the treatment of disseminated malignancies, we sought to evaluate whether deliberate sequencing of immunotherapy before\/after conventional cytotoxic chemotherapy would have an impact on clinical outcomes in patients with previously treated metastatic melanoma.","We sought to evaluate whether or not ipilimumab immunotherapy administered before or after cytotoxic chemotherapy (nab-paclitaxel+bevacizumab, AB) would impact clinical outcomes.","METHODS: We conducted a randomized phase 2 clinical trial of patients with BRAF wild-type metastatic melanoma (up to 2 prior therapies) who received either: (A) AB followed by ipilimumab therapy at progression; or (B) ipilimumab followed by AB treatment at progression.","The primary goal of the study was a comparison of AB versus ipilimumab progression-free survival, with secondary clinical and laboratory endpoints.","RESULTS: This study did not reach full accrual due to concurrent Food and Drug Administration approval of anti-programmed cell death 1 agents.","Nevertheless, the available data suggests a cumulative therapeutic advantage to the sequential use of ipilimumab followed by AB.","Correlative laboratory data revealed a favorable effect on systemic immune homeostasis in patients receiving AB therapy, of potential interest in further investigations, especially in the context of chemotherapy\/immunotherapy combinations.","CONCLUSION: Albeit limited in scope, our data suggest that cytotoxic therapy with nab-paclitaxel and bevacizumab appear to favorably alter systemic parameters of immune function of potential benefit in combination T-cell directed immune checkpoint inhibitor therapy."],"Aspect":"p","Summary":"The study involved patients with BRAF wild-type metastatic melanoma who had up to 2 prior therapies.","Indexes":[2],"Sentences":["METHODS: We conducted a randomized phase 2 clinical trial of patients with BRAF wild-type metastatic melanoma (up to 2 prior therapies) who received either: (A) AB followed by ipilimumab therapy at progression; or (B) ipilimumab followed by AB treatment at progression."],"Revise":false}
{"PMID":"36307938","Document":["BACKGROUND: Detectable circulating tumor DNA (ctDNA) has been associated with worse prognosis in melanoma patients.","MATERIAL AND METHODS: We studied plasma ctDNA as a prognostic biomarker in 19 patients with metastatic melanoma and a detectable tumor mutation (13 BRAF, 5 NRAS, and 1 KRAS).","Patients had received chemotherapy, interferon-alpha, and vemurafenib in a prospective clinical trial.","Mutant allele frequency (MAF %) was determined with droplet digital PCR from pretreatment and sequential plasma samples.","RESULTS: Higher pretreatment plasma ctDNA levels (MAF \u22653%) and detectable plasma ctDNA levels (MAF >0%) at the time of radiologically confirmed best objective response were associated with poor prognosis even when accounting for other relevant prognostic factors including performance status, tumor mutation, metastasis stage, and lactate dehydrogenase levels in multivariable analysis.","CONCLUSION: Higher pretreatment plasma ctDNA levels and sustained detectable plasma ctDNA levels during treatment indicated poor prognosis in metastatic melanoma patients."],"Aspect":"m","Summary":"The document mentions chemotherapy, interferon-alpha, and vemurafenib as treatments for metastatic melanoma patients.","Indexes":[2],"Sentences":["Patients had received chemotherapy, interferon-alpha, and vemurafenib in a prospective clinical trial."],"Revise":false}
{"PMID":"33982452","Document":["BACKGROUND: Checkpoint inhibitors (CPI) in combination with cell-based vaccines may produce synergistic antitumor immunity.","The primary analysis of the randomized and blinded phase IIb trial in resected stage III\/IV melanoma demonstrated TLPLDC is safe and improved 24-month disease-free survival (DFS) in the per treatment (PT) analysis.","Here, we examine efficacy within pre-specified and exploratory subgroups.","METHODS: Stage III\/IV patients rendered disease-free by surgery were randomized 2:1 to TLPLDC vaccine versus placebo.","The pre-specified PT analysis included only patients completing the primary vaccine\/placebo series at 6\u00a0months.","Kaplan-Meier analysis was used to compare 24-month DFS among subgroups.","RESULTS: There were no clinicopathologic differences between subgroups except stage IV patients were more likely to receive CPI.","In stage IV patients, 24-month DFS was 43% for vaccine versus 0% for placebo (p\u00a0=\u00a00.098) in the ITT analysis and 73% versus 0% (p\u00a0=\u00a00.002) in the PT analysis.","There was no significant difference in 24-month DFS when stratified by use of immunotherapy or CPI.","For patients with resected recurrent disease, 24-month DFS was 88.9% versus 33.3% (p\u00a0=\u00a00.013) in the PT analysis.","All benefit from vaccination was in the PT analysis; no benefit was found in patients receiving up to three doses.","CONCLUSION: The TLPLDC vaccine improved DFS in patients completing the primary vaccine series, particularly in the resected stage IV patients.","The efficacy of the TLPLDC vaccine will be confirmed in a phase III study evaluating adjuvant TLPLDC + CPI versus Placebo + CPI in resected stage IV melanoma patients."],"Aspect":"a","Summary":"The study aims to examine the efficacy of the TLPLDC vaccine within pre-specified and exploratory subgroups in resected stage III\/IV melanoma patients.","Indexes":[1,2],"Sentences":["The primary analysis of the randomized and blinded phase IIb trial in resected stage III\/IV melanoma demonstrated TLPLDC is safe and improved 24-month disease-free survival (DFS) in the per treatment (PT) analysis.","Here, we examine efficacy within pre-specified and exploratory subgroups."],"Revise":true}
{"PMID":"33558721","Document":["Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in patients with macroscopic stage III melanoma in the phase 1b OpACIN ( NCT02437279 ) and phase 2 OpACIN-neo ( NCT02977052 ) studies1,2.","While the results are promising, data on the durability of these pathologic responses and baseline biomarkers for response and survival were lacking.","After a median follow-up of 4 years, none of the patients with a pathologic response (n\u2009=\u20097\/9 patients) in the OpACIN study had relapsed.","In OpACIN-neo (n\u2009=\u200986), the 2-year estimated relapse-free survival was 84% for all patients, 97% for patients achieving a pathologic response and 36% for nonresponders (P\u2009<\u20090.001).","High tumor mutational burden (TMB) and high interferon-gamma-related gene expression signature score (IFN-\u03b3 score) were associated with pathologic response and low risk of relapse; pRR was 100% in patients with high IFN-\u03b3 score\/high TMB; patients with high IFN-\u03b3 score\/low TMB or low IFN-\u03b3 score\/high TMB had pRRs of 91% and 88%; while patients with low IFN-\u03b3 score\/low TMB had a pRR of only 39%.","These data demonstrate long-term benefit in patients with a pathologic response and show the predictive potential of TMB and IFN-\u03b3 score.","Our findings provide a strong rationale for a randomized phase 3 study comparing neoadjuvant ipilimumab plus nivolumab versus standard adjuvant therapy with antibodies against the programmed cell death protein-1 (anti-PD-1) in macroscopic stage III melanoma."],"Aspect":"m","Summary":"The article discusses the use of neoadjuvant ipilimumab plus nivolumab for the treatment of macroscopic stage III melanoma.","Indexes":[0,6],"Sentences":["Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in patients with macroscopic stage III melanoma in the phase 1b OpACIN ( NCT02437279 ) and phase 2 OpACIN-neo ( NCT02977052 ) studies1,2.","Our findings provide a strong rationale for a randomized phase 3 study comparing neoadjuvant ipilimumab plus nivolumab versus standard adjuvant therapy with antibodies against the programmed cell death protein-1 (anti-PD-1) in macroscopic stage III melanoma."],"Revise":false}
{"PMID":"32147213","Document":["BACKGROUND: Interleukin 12 (IL-12) is a pivotal regulator of innate and adaptive immunity.","We conducted a prospective open-label, phase II clinical trial of electroporated plasmid IL-12 in advanced melanoma patients (NCT01502293).","PATIENTS AND METHODS: Patients with stage III\/IV melanoma were treated intratumorally with plasmid encoding IL-12 (tavokinogene telseplasmid; tavo), 0.5 mg\/ml followed by electroporation (six pulses, 1500 V\/cm) on days 1, 5, and 8 every 90 days in the main study and additional patients were treated in two alternative schedule exploration cohorts.","Correlative analyses for programmed death-ligand 1 (PD-L1), flow cytometry to assess changes in immune cell subsets, and analysis of immune-related gene expression were carried out on pre- and post-treatment samples from study patients, as well as from additional patients treated during exploration of additional dosing schedules beyond the pre-specified protocol dosing schedule.","Response was measured by study-specific criteria to maximize detection of latent and potentially transient immune responses in patients with multiple skin lesions and toxicities were graded by the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0).","RESULTS: The objective overall response rate was 35.7% in the main study (29.8% in all cohorts), with a complete response rate of 17.9% (10.6% in all cohorts).","The median progression-free survival in the main study was 3.7 months while the median overall survival was not reached at a median follow up of 29.7 months.","A total of 46% of patients in all cohorts with uninjected lesions experienced regression of at least one of these lesions and 25% had a net regression of all untreated lesions.","Transcriptomic and immunohistochemistry analysis showed that immune activation and co-stimulatory transcripts were up-regulated but there was also increased adaptive immune resistance.","CONCLUSIONS: Intratumoral Tavo was well tolerated and led to systemic immune responses in advanced melanoma patients.","While tumor regression and increased immune infiltration were observed in treated as well as untreated\/distal lesions, adaptive immune resistance limited the response."],"Aspect":"o","Summary":"The research results show that intratumoral electroporated plasmid IL-12 (Tavo) treatment in advanced melanoma patients induced systemic immune responses, with a 35.7% overall response rate and regression in untreated lesions, but adaptive immune resistance limited the overall response","Indexes":[5,9,10],"Sentences":["RESULTS: The objective overall response rate was 35.7% in the main study (29.8% in all cohorts), with a complete response rate of 17.9% (10.6% in all cohorts).","CONCLUSIONS: Intratumoral Tavo was well tolerated and led to systemic immune responses in advanced melanoma patients.","While tumor regression and increased immune infiltration were observed in treated as well as untreated\/distal lesions, adaptive immune resistance limited the response."],"Revise":true}
{"PMID":"31732522","Document":["PURPOSE: Immune components of the tumor microenvironment (TME) have been associated with disease outcome.","We prospectively evaluated the association of an immune-related gene signature (GS) with clinical outcome in melanoma and non-small cell lung cancer (NSCLC) tumor samples from two phase III studies.","EXPERIMENTAL DESIGN: The GS was prospectively validated using an adaptive signature design to optimize it for the sample type and technology used in phase III studies.","One-third of the samples were used as \"training set\"; the remaining two thirds, constituting the \"test set,\" were used for the prospective validation of the GS.","RESULTS: In the melanoma training set, the expression level of eight Th1\/IFN\u03b3-related genes in tumor-positive lymph node tissue predicted the duration of disease-free survival (DFS) and overall survival (OS) in the placebo arm.","This GS was prospectively and independently validated as prognostic in the test set.","Building a multivariate Cox model in the test set placebo patients from clinical covariates and the GS score, an increased number of melanoma-involved lymph nodes and the GS were associated with DFS and OS.","This GS was not associated with DFS in NSCLC, although expression of the Th1\/IFN\u03b3-related genes was associated with the presence of lymphocytes in tumor samples in both indications.","CONCLUSIONS: These findings provide evidence that expression of Th1\/IFN\u03b3 genes in the TME, as measured by this GS, is associated with clinical outcome in melanoma.","This suggests that, using this GS, patients with stage IIIB\/C melanoma can be classified into different risk groups."],"Aspect":"a","Summary":"The study aims to prospectively evaluate the association of an immune-related gene signature with clinical outcomes in melanoma and non-small cell lung cancer (NSCLC) tumor samples from two phase III studies.","Indexes":[1],"Sentences":["We prospectively evaluated the association of an immune-related gene signature (GS) with clinical outcome in melanoma and non-small cell lung cancer (NSCLC) tumor samples from two phase III studies."],"Revise":false}
{"PMID":"38362837","Document":["SAR439459, a 'second-generation' human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody, inhibits all TGF\u03b2 isoforms and improves the antitumor activity of anti-programmed cell death protein-1 therapeutics.","This study reports the pharmacodynamics (PD) and biomarker results from phase I\/Ib first-in-human study of SAR439459\u2009\u00b1\u2009cemiplimab in patients with advanced solid tumors (NCT03192345).","In dose-escalation phase (Part 1), SAR439459 was administered intravenously at increasing doses either every 2\u2009weeks (Q2W) or every 3\u2009weeks (Q3W) with cemiplimab IV at 3\u2009mg\/kg Q2W or 350\u2009mg Q3W, respectively, in patients with advanced solid tumors.","In dose-expansion phase (Part 2), patients with melanoma received SAR439459 IV Q3W at preliminary recommended phase II dose (pRP2D) of 22.5\/7.5\u2009mg\/kg or at 22.5\u2009mg\/kg with cemiplimab 350\u2009mg IV Q3W.","Tumor biopsy and peripheral blood samples were collected for exploratory biomarker analyses to assess target engagement and PD, and results were correlated with patients' clinical parameters.","SAR439459\u2009\u00b1\u2009cemiplimab showed decreased plasma and tissue TGF\u03b2, downregulation of TGF\u03b2-pathway activation signature, modulation of peripheral natural killer (NK) and T cell expansion, proliferation, and increased secretion of CXCL10.","Conversion of tumor tissue samples from 'immune-excluded' to 'immune-infiltrated' phenotype in a representative patient with melanoma SAR439459 22.5\u2009mg\/kg with cemiplimab was observed.","In paired tumor and plasma, active and total TGF\u03b21 was more consistently elevated followed by TGF\u03b22, whereas TGF\u03b23 was only measurable (lower limit of quantitation \u22652.68\u2009pg\/mg) in tumors.","SAR439459\u2009\u00b1\u2009cemiplimab showed expected peripheral PD effects and TGF\u03b2 alteration.","However, further studies are needed to identify biomarkers of response."],"Aspect":"m","Summary":"The study involves SAR439459 administered intravenously at doses ranging from 22.5 mg\/kg to 22.5\/7.5 mg\/kg, either every 2 or 3 weeks, combined with cemiplimab at doses of 3 mg\/kg every 2 weeks or 350 mg every 3 weeks.","Indexes":[2,3],"Sentences":["In dose-escalation phase (Part 1), SAR439459 was administered intravenously at increasing doses either every 2\u2009weeks (Q2W) or every 3\u2009weeks (Q3W) with cemiplimab IV at 3\u2009mg\/kg Q2W or 350\u2009mg Q3W, respectively, in patients with advanced solid tumors.","In dose-expansion phase (Part 2), patients with melanoma received SAR439459 IV Q3W at preliminary recommended phase II dose (pRP2D) of 22.5\/7.5\u2009mg\/kg or at 22.5\u2009mg\/kg with cemiplimab 350\u2009mg IV Q3W."],"Revise":false}
{"PMID":"38039779","Document":["BACKGROUND: We investigated naporafenib (LXH254), a pan-RAF kinase inhibitor, with or without spartalizumab, in patients with advanced solid tumors harboring MAPK pathway alterations.","METHODS: This first-in-human phase 1 study had two dose-escalation arms: single-agent naporafenib (starting at 100\u00a0mg once-daily [QD]) and naporafenib (starting at the recommended dose\/regimen)\/spartalizumab (400\u00a0mg every 4 weeks).","The naporafenib\/spartalizumab dose-expansion part enrolled patients with KRAS-mutated non-small cell lung cancer (NSCLC) and NRAS-mutated melanoma.","The primary objectives were to establish the maximum tolerated doses (MTD)\/recommended doses for expansion (RDE) and evaluate tolerability and safety.","RESULTS: A total of 142 patients were included in the naporafenib dose-escalation (n\u00a0=\u00a087), naporafenib\/spartalizumab dose-escalation (n\u00a0=\u00a012) and naporafenib\/spartalizumab dose-expansion (n\u00a0=\u00a043) arms.","The MTD\/RDE of naporafenib was 600\u00a0mg twice-daily (BID).","In naporafenib escalation, five patients experienced 7 dose-limiting toxicities: decreased platelet count (1200\u00a0mg QD); neuralgia, maculopapular rash, pruritus (600\u00a0mg BID); increased blood bilirubin, hyponatremia, peripheral sensory neuropathy (800\u00a0mg BID).","No DLTs occurred in the naporafenib\/spartalizumab arm: the RDE was established at 400\u00a0mg BID.","The most common treatment-related adverse events were rash and dermatitis acneiform (each 24.1%; naporafenib), nausea and pruritus (each 33.3%; naporafenib\/spartalizumab; escalation) and rash (39.5%; naporafenib\/spartalizumab; expansion).","Naporafenib reduced DUSP6 expression in tumors.","Two partial responses (PRs) occurred in naporafenib escalation, and 1 complete response and 3 PRs in the naporafenib\/spartalizumab NRAS-mutated melanoma and KRAS-mutated NSCLC arms, respectively.","CONCLUSIONS: Naporafenib, with or without spartalizumab, showed an acceptable safety profile, pharmacodynamic activity and limited antitumor activity.","Additional naporafenib combination therapies are currently under investigation."],"Aspect":"m","Summary":"The study investigated naporafenib, a pan-RAF kinase inhibitor, starting at 100 mg once-daily, with or without spartalizumab at 400 mg every 4 weeks, with the maximum tolerated dose (MTD)\/recommended dose for expansion (RDE) of naporafenib being 600 mg twice-daily and an RDE of 400mg for the naporafenib\/spartalizumab arm.","Indexes":[0,1,5,7],"Sentences":["BACKGROUND: We investigated naporafenib (LXH254), a pan-RAF kinase inhibitor, with or without spartalizumab, in patients with advanced solid tumors harboring MAPK pathway alterations.","METHODS: This first-in-human phase 1 study had two dose-escalation arms: single-agent naporafenib (starting at 100\u00a0mg once-daily [QD]) and naporafenib (starting at the recommended dose\/regimen)\/spartalizumab (400\u00a0mg every 4 weeks).","The MTD\/RDE of naporafenib was 600\u00a0mg twice-daily (BID).","No DLTs occurred in the naporafenib\/spartalizumab arm: the RDE was established at 400\u00a0mg BID."],"Revise":true}
{"PMID":"32450331","Document":["PURPOSE: To determine the maximum tolerated dose (MTD) of stereotactic ablative radiation therapy (SABR) in combination with immunotherapy for the treatment of patients with metastatic melanoma.","The study also investigates the effects of timing and dosing of SABR on clinical efficacy.","METHODS: Metastatic melanoma patients with at least 2 metastases received SABR to a single metastatic site.","All patients had standard dose immunotherapy with anti-PD1 or anti-CTLA4 at the discretion of their treating clinician.","Following a standard 3 + 3 design, patients were escalated through 3 SABR doses (10 Gy, 15 Gy, and 20 Gy) delivered at 3 different time points (with cycle 1, 2, or 3 of immunotherapy).","Dose-limiting toxicities (DLT) were defined as grade 3 or higher toxicity within 3 months of first treatment and assessed by an independent data safety monitoring committee (IDSMC).","Logistic or Cox regressions were used to assess the impact of SABR dose and timing on the progression free (PFS) and overall survival (OS) of this cohort.","RESULTS: Twenty-four patients were enrolled with a median clinical follow-up of 28 months.","Four patients (16.7%) developed DLTs; 1 DLT occurred at a SABR-treated site, and all patients received 15 Gy.","On this basis the IDSMC recommended stopping the trial and the MTD was defined at 10 Gy.","The 2-year PFS was 21.9% (95% CI, 7.1%-41.8%) and 2-year OS was 49.6% (95% CI, 28.7%-67.6%).","The median PFS for those receiving 10 Gy was numerically higher than for those receiving 15 Gy, 8.3 months versus 2.1 months (P = .38).","The only treatment-related factor associated with both improved PFS (HR 0.08, P < .01) and OS (HR 0.008, P \u2264 .01) was receiving SABR with cycle 3.","SABR dose (PFS P = .17, OS P = .50) was not significant.","CONCLUSIONS: SABR at 10 Gy can be safely combined with immunotherapy.","SABR timing appears to influence efficacy more than dose and warrants consideration in research attempting to optimize synergism."],"Aspect":"a","Summary":"The study aims to determine the maximum tolerated dose (MTD) of stereotactic ablative radiation therapy (SABR) in combination with immunotherapy for the treatment of patients with metastatic melanoma and investigate the effects of timing and dosing of SABR on clinical efficacy.","Indexes":[0,1],"Sentences":["PURPOSE: To determine the maximum tolerated dose (MTD) of stereotactic ablative radiation therapy (SABR) in combination with immunotherapy for the treatment of patients with metastatic melanoma.","The study also investigates the effects of timing and dosing of SABR on clinical efficacy."],"Revise":false}
{"PMID":"31562797","Document":["BACKGROUND: Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma.","We now report 5-year outcomes in the trial.","METHODS: We randomly assigned patients with previously untreated advanced melanoma to receive one of the following regimens: nivolumab (at a dose of 1 mg per kilogram of body weight) plus ipilimumab (3 mg per kilogram) every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram every 2 weeks); nivolumab (3 mg per kilogram every 2 weeks) plus ipilimumab-matched placebo; or ipilimumab (3 mg per kilogram every 3 weeks for four doses) plus nivolumab-matched placebo.","The two primary end points were progression-free survival and overall survival in the nivolumab-plus-ipilimumab group and in the nivolumab group, as compared with the ipilimumab group.","RESULTS: At a minimum follow-up of 60 months, the median overall survival was more than 60.0 months (median not reached) in the nivolumab-plus-ipilimumab group and 36.9 months in the nivolumab group, as compared with 19.9 months in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.52; hazard ratio for death with nivolumab vs. ipilimumab, 0.63).","Overall survival at 5 years was 52% in the nivolumab-plus-ipilimumab group and 44% in the nivolumab group, as compared with 26% in the ipilimumab group.","No sustained deterioration of health-related quality of life was observed during or after treatment with nivolumab plus ipilimumab or with nivolumab alone.","No new late toxic effects were noted.","CONCLUSIONS: Among patients with advanced melanoma, sustained long-term overall survival at 5 years was observed in a greater percentage of patients who received nivolumab plus ipilimumab or nivolumab alone than in those who received ipilimumab alone, with no apparent loss of quality of life in the patients who received regimens containing nivolumab.","(Funded by Bristol-Myers Squibb and others; CheckMate 067 ClinicalTrials.gov number, NCT01844505.",")."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"31403867","Document":["PURPOSE: Metastatic mucosal melanoma responds poorly to anti-programmed cell death-1 (PD-1) monotherapy.","Vascular endothelial growth factor (VEGF) has been shown to play an important immunosuppressive role in the tumor microenvironment.","The combination of VEGF inhibition and PD-1 blockade provides therapeutic opportunities for patients refractory to either therapy alone.","PATIENTS AND METHODS: We conducted a single-center, phase IB trial evaluating the safety and preliminary efficacy of toripalimab, a humanized immunoglobulin G4 monoclonal antibody against PD-1 in combination with the VEGF receptor inhibitor axitinib in patients with advanced melanoma, including patients with chemotherapy-na\u00efve mucosal melanomas (88%).","Patients received toripalimab at 1 or 3 mg\/kg via intravenous infusion every 2 weeks, in combination with axitinib 5 mg orally twice a day, in a dose-escalation and cohort-expansion study until confirmed disease progression, unacceptable toxicity, or voluntary withdrawal.","The primary objective was safety.","Secondary objectives included efficacy, pharmacokinetics, pharmacodynamics, immunogenicity, and tumor tissue biomarkers.","RESULTS: Thirty-three patients were enrolled.","No dose-limiting toxicities were observed.","Ninety-seven percent of patients experienced treatment-related adverse events (TRAEs).","The most common TRAEs were mild (grade 1 or 2) and included diarrhea, proteinuria, hand and foot syndrome, fatigue, AST or ALT elevation, hypertension, hypo- or hyperthyroidism, and rash.","Grade 3 or greater TRAEs occurred in 39.4% of patients.","By the cutoff date, among 29 patients with chemotherapy-na\u00efve mucosal melanoma, 14 patients (48.3%; 95% CI, 29.4% to 67.5%) achieved objective response, and the median progression-free survival time was 7.5 months (95% CI, 3.7 months to not reached) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.","CONCLUSION: The combination of toripalimab plus axitinib was tolerable and showed promising antitumor activity in patients with treatment-na\u00efve metastatic mucosal melanoma.","Patients enrolled in this study were all Asian, and this combination therapy must be validated in a randomized phase III trial that includes a non-Asian population before it can become a standard of care."],"Aspect":"m","Summary":"The trial involved toripalimab administered at doses of 1 or 3 mg\/kg every 2 weeks, combined with axitinib at 5 mg orally twice a day.","Indexes":[3,4],"Sentences":["PATIENTS AND METHODS: We conducted a single-center, phase IB trial evaluating the safety and preliminary efficacy of toripalimab, a humanized immunoglobulin G4 monoclonal antibody against PD-1 in combination with the VEGF receptor inhibitor axitinib in patients with advanced melanoma, including patients with chemotherapy-na\u00efve mucosal melanomas (88%).","Patients received toripalimab at 1 or 3 mg\/kg via intravenous infusion every 2 weeks, in combination with axitinib 5 mg orally twice a day, in a dose-escalation and cohort-expansion study until confirmed disease progression, unacceptable toxicity, or voluntary withdrawal."],"Revise":false}
{"PMID":"32313721","Document":["The efficacy of immune checkpoint inhibitors has been shown to depend on preexisting antitumor immunity; thus, their combination with cancer vaccines is an attractive therapeutic approach.","Plasmacytoid dendritic cells (PDC) are strong inducers of antitumor responses and represent promising vaccine candidates.","We developed a cancer vaccine approach based on an allogeneic PDC line that functioned as a very potent antigen-presenting cell in pre-clinical studies.","In this phase Ib clinical trial, nine patients with metastatic stage IV melanoma received up to 60 million irradiated PDC line cells loaded with 4 melanoma antigens, injected subcutaneously at weekly intervals.","The primary endpoints were safety and tolerability.","The vaccine was well\u00a0tolerated and no serious vaccine-induced side effects were recorded.","Strikingly, there was no allogeneic response toward the vaccine, but a significant increase in the frequency of circulating anti-tumor specific T lymphocytes was observed in two patients, accompanied by a switch from a na\u00efve to memory phenotype, thus demonstrating priming of antigen-specific T-cells.","Signs of clinical activity were observed, including four stable diseases according to IrRC and vitiligo\u00efd lesions.","Four patients were still alive at week 48.","We also demonstrate the in vitro enhancement of specific T cell expansion induced by the synergistic combination of peptide-loaded PDC line with anti-PD-1, as compared to peptide-loaded PDC line alone.","Taken together, these clinical observations demonstrate the ability of the PDC line based-vaccine to prime and expand antitumor CD8+\u00a0responses in cancer patients.","Further trials should test the combination of this vaccine with immune checkpoint inhibitors."],"Aspect":"i","Summary":"In this phase Ib clinical trial, nine patients with metastatic stage IV melanoma received up to 60 million irradiated PDC line cells loaded with 4 melanoma antigens, injected subcutaneously at weekly intervals.","Indexes":[3],"Sentences":["In this phase Ib clinical trial, nine patients with metastatic stage IV melanoma received up to 60 million irradiated PDC line cells loaded with 4 melanoma antigens, injected subcutaneously at weekly intervals."],"Revise":false}
{"PMID":"33668679","Document":["Urine autofluorescence at 295 nm is significantly higher in patients with malignant melanoma at each clinical stage compared to the healthy group.","The largest difference is in the early-stages and without metastases.","With increasing stage, the autofluorescence at 295 nm decreases.","There is also a significant negative correlation between autofluorescence and Clark classification.","Based on our results, it is assumed that the way malignant melanoma grows also affects urinary autofluorescence."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"33125309","Document":["PURPOSE: Metastatic uveal melanoma has poor overall survival (OS) and no approved systemic therapy options.","Studies of single-agent immunotherapy regimens have shown minimal benefit.","There is the potential for improved responses with the use of combination immunotherapy.","PATIENTS AND METHODS: We conducted a phase II study of nivolumab with ipilimumab in patients with metastatic uveal melanoma.","Any number of prior treatments was permitted.","Patients received nivolumab 1 mg\/kg and ipilimumab 3 mg\/kg for four cycles, followed by nivolumab maintenance therapy for up to 2 years.","The primary outcome of the study was overall response rate (ORR) as determined by RECIST 1.1 criteria.","Progression-free survival (PFS), OS, and adverse events were also assessed.","RESULTS: Thirty-five patients were enrolled, and 33 patients were evaluable for efficacy.","The ORR was 18%, including one confirmed complete response and five confirmed partial responses.","The median PFS was 5.5 months (95% CI, 3.4 to 9.5 months), and the median OS was 19.1 months (95% CI, 9.6 months to NR).","Forty percent of patients experienced a grade 3-4 treatment-related adverse event.","CONCLUSION: The combination regimen of nivolumab plus ipilimumab demonstrates activity in metastatic uveal melanoma, with deep and sustained confirmed responses."],"Aspect":"d","Summary":"The duration of treatment in the trial was up to 2 years.","Indexes":[5],"Sentences":["Patients received nivolumab 1 mg\/kg and ipilimumab 3 mg\/kg for four cycles, followed by nivolumab maintenance therapy for up to 2 years."],"Revise":false}
{"PMID":"35466524","Document":["Metastatic uveal melanoma (UM) is a devastating disease with few treatment options.","We evaluated the safety, tolerability and preliminary activity of arginine depletion using pegylated arginine deiminase (ADI-PEG20; pegargiminase) combined with pemetrexed (Pem) and cisplatin (Cis) chemotherapy in a phase 1 dose-expansion study of patients with argininosuccinate synthetase (ASS1)-deficient metastatic UM.","Eligible patients received up to six cycles of Pem (500\u2009mg\/m2 ) and Cis (75\u2009mg\/m2 ) every 3\u2009weeks plus weekly intramuscular ADI (36\u2009mg\/m2 ), followed by maintenance ADI until progression (NCT02029690).","Ten of fourteen ASS1-deficient patients with UM liver metastases and a median of one line of prior immunotherapy received ADIPemCis.","Only one \u2265 grade 3 adverse event of febrile neutropenia was reported.","Seven patients had stable disease with a median progression-free survival of 3.0\u00a0months (range, 1.3-8.1) and a median overall survival of 11.5\u00a0months (range, 3.2-36.9).","Despite anti-ADI-PEG20 antibody emergence, plasma arginine concentrations remained suppressed by 18\u2009weeks with a reciprocal increase in plasma citrulline.","Tumour rebiopsies at progression revealed ASS1 re-expression as an escape mechanism.","ADIPemCis was well tolerated with modest disease stabilisation in metastatic UM.","Further investigation of arginine deprivation is indicated in UM including combinations with immune checkpoint blockade and additional anti-metabolite strategies."],"Aspect":"p","Summary":"The study included 14  ASS1-deficient patients with metastatic uveal melanoma and UM liver metastases and also had a median of one line of prior immunotherapy.","Indexes":[0,3],"Sentences":["Metastatic uveal melanoma (UM) is a devastating disease with few treatment options.","Ten of fourteen ASS1-deficient patients with UM liver metastases and a median of one line of prior immunotherapy received ADIPemCis."],"Revise":true}
{"PMID":"32369447","Document":["BACKGROUNDThe reshaping of the immune landscape by nivolumab (NIVO) and ipilimumab (IPI) and its relation to patient outcomes is not well described.METHODSWe used high-parameter flow cytometry and a computational platform, CytoBrute, to define immunophenotypes of up to 15 markers to assess peripheral blood samples from metastatic melanoma patients receiving sequential NIVO > IPI or IPI > NIVO (Checkmate-064).RESULTSThe 2 treatments were associated with distinct immunophenotypic changes and had differing profiles associated with response.","Only 2 immunophenotypes were shared but had opposing relationships to response\/survival.","To understand the impact of sequential treatment on response\/survival, phenotypes that changed after the initial treatment and differentiated response in the other cohort were identified.","Immunophenotypic changes occurring after NIVO were predominately associated with response to IPI > NIVO, but changes occurring after IPI were predominately associated with progression after NIVO > IPI.","Among these changes, CD4+CD38+CD39+CD127-GARP- T cell subsets were increased after IPI treatment and were negatively associated with response\/survival for the NIVO > IPI cohort.CONCLUSIONCollectively, these data suggest that the impact of IPI and NIVO on the immunophenotypic landscape of patients is distinct and that the impact of IPI may be associated with resistance to subsequent NIVO therapy, consistent with poor outcomes in the IPI > NIVO cohort of Checkmate-064."],"Aspect":"p","Summary":"The study involved metastatic melanoma patients receiving sequential NIVO > IPI or IPI > NIVO treatments.","Indexes":[0],"Sentences":["BACKGROUNDThe reshaping of the immune landscape by nivolumab (NIVO) and ipilimumab (IPI) and its relation to patient outcomes is not well described.METHODSWe used high-parameter flow cytometry and a computational platform, CytoBrute, to define immunophenotypes of up to 15 markers to assess peripheral blood samples from metastatic melanoma patients receiving sequential NIVO > IPI or IPI > NIVO (Checkmate-064).RESULTSThe 2 treatments were associated with distinct immunophenotypic changes and had differing profiles associated with response."],"Revise":false}
{"PMID":"38319852","Document":["BACKGROUND: In the previously reported primary analyses of this phase 3 trial, 12 months of adjuvant pembrolizumab resulted in significantly longer recurrence- and distant metastasis-free survival than placebo in patients with resected high-risk stage III melanoma.","To confirm the stability of these benefits, longer-term data were needed.","METHODS: We randomly assigned 1019 patients to receive 200 mg of pembrolizumab or placebo intravenously every 3 weeks for a total of 18 doses (approximately 1 year) and had previously reported data with a 15-, 36-, and 42-month median follow-up.","We now report data at a median follow-up of 4.9 years.","We report a number of outcomes, including recurrence-free survival in the overall population and in the subgroup of patients with cancer who were positive for the programmed death-ligand 1 (PD-L1).","Distant metastasis-free survival was a secondary end point.","RESULTS: In the overall intention-to-treat population, pembrolizumab was still associated with longer recurrence-free survival than placebo (5-year rate of recurrence-free survival, 55.4% [95% confidence interval (CI), 50.8 to 59.8] vs. 38.3% [95% CI, 33.9 to 42.7]; hazard ratio for recurrence or death, 0.61 [95% CI, 0.51 to 0.72]) and a longer distant metastasis-free survival (5-year rate of distant metastasis-free survival, 60.6% [95% CI, 56.0 to 64.9] vs. 44.5% [95% CI, 39.9 to 48.9]; hazard ratio for distant metastasis or death, 0.62 [95% CI, 0.52 to 0.75]).","Similar findings were obtained in the subgroup of 853 patients with PD-L1\u2013positive tumors.","CONCLUSIONS: The 5-year analysis of adjuvant therapy with pembrolizumab resulted in a sustained improvement in the long-term recurrence- and distant metastasis-free survival compared with placebo in patients with resected stage III melanoma.","(Funded by Merck & Co., Inc.; ClinicalTrials.gov number, NCT02362594, and EudraCT number, 2014-004944-37.)"],"Aspect":"m","Summary":"The trial involved pembrolizumab administered at a dose of 200 mg intravenously every 3 weeks for a total of 18 doses (approximately 1 year).","Indexes":[2],"Sentences":["METHODS: We randomly assigned 1019 patients to receive 200 mg of pembrolizumab or placebo intravenously every 3 weeks for a total of 18 doses (approximately 1 year) and had previously reported data with a 15-, 36-, and 42-month median follow-up."],"Revise":false}
{"PMID":"32428937","Document":["The pomegranate phenolics are reported to have cutaneous benefits and to be effective in treating skin disorders, including hyperpigmentation.","In this context, a preparation method was developed by which to obtain phenolic-rich pomegranate peel extract.","Sinapic acid was presented as the major pomegranate peel phenolics, followed by gallic and ellagic acids, and 4 additional phenolics.","The extract exhibited strong antioxidant activity with an in vitro tyrosinase inhibitory effect.","The skin hyperpigmentation treating potency was confirmed by the suppression of cellular melanogenesis through tyrosinase and TRP-2 inhibitions as examined in the B16F10 melanoma cells.","Cellular antioxidant and proliferative activities of the extract toward human dermal fibroblasts were evidenced, as well as an inhibitory effect against MMP-2.","The extract was developed into the stable serum and mask.","The products were proved to be non-irritated in 30 Thai volunteers participating in a single application closed patch test.","A split-face, randomized, double-blind, placebo-controlled test of the skin lightening effect was evaluated in the 30 volunteers over 28 consecutive daily treatments and monitored by the Mexameter MX 18.","The active serum and mask were better in facial skin lightening efficacy than the placebo (p\u2009<\u20090.005).","That was in accordance with the sensory evaluation scored by the volunteers.","Phenolic-rich pomegranate peel extract is evidenced as a safe herbal derived material promising for skin hyperpigmentation treatment.","Supportive information regarding chemical and biological profiles is presented with the confirmed safety and cutaneous benefits in volunteers."],"Aspect":"o","Summary":"The study found that phenolic-rich pomegranate peel extract is effective in treating skin hyperpigmentation, showing significant skin lightening effects in clinical trials.","Indexes":[4,9,11],"Sentences":["The skin hyperpigmentation treating potency was confirmed by the suppression of cellular melanogenesis through tyrosinase and TRP-2 inhibitions as examined in the B16F10 melanoma cells.","The active serum and mask were better in facial skin lightening efficacy than the placebo (p\u2009<\u20090.005).","Phenolic-rich pomegranate peel extract is evidenced as a safe herbal derived material promising for skin hyperpigmentation treatment."],"Revise":false}
{"PMID":"36842739","Document":["In recent years, the unprecedented increase in various cancers such as melanoma has caused researchers to focus more on the formulation of newer drugs with less side effects.","In this study, we herein indicate the biogenic nanoarchitechtonics of Ag NPs template over chitosan\/starch mixed hydrogel having notable reducing potential and anti-malignant melanoma effects.","The two biopolymers also could stabilize as-synthesized Ag NPs.","Physicochemical features of the material were further characterized over a range of advanced methods like X-ray diffraction (XRD), elemental mapping, dynamic light scattering (DLS), energy-dispersive X-ray spectroscopy (EDS), transmission electron microscopy (TEM), field emission scanning electron microscopy (FESEM), and Fourier transformed infrared spectroscopy (FT-IR).","TEM analysis showed the spherical-shaped nanocomposite with the mean diameter in the range of 5-15\u00a0nm.","Thereafter, the nanocomposite was exploited in the anti-malignant melanoma and cytotoxicity effects studies against various human malignant melanoma cell lines (HT144, RPMI7951, SKMEL2, UACC3074, WM266-4 and MUM2C) in situ.","The bio-composite corresponding IC50 values were 193, 102, 227, 250, 301, and 203\u00a0\u03bcg\/mL against MUM2C, WM266-4, UACC3074, SKMEL2, RPMI7951, and HT144 cell lines, respectively.","A significantly high IC50 value offered an excellent antioxidant capacity of bio-composite.","According to the above results, Ag NPs\/CS-Starch nanomaterial can be utilized as an efficient drug to treat malignant melanoma in humans after doing clinical trial studies."],"Aspect":"i","Summary":"Advanced physicochemical characterization techniques and in situ cytotoxicity studies were employed, including XRD, elemental mapping, DLS, EDS, TEM, FESEM, FT-IR, and testing against human malignant melanoma cell lines.","Indexes":[3,4,5],"Sentences":["Physicochemical features of the material were further characterized over a range of advanced methods like X-ray diffraction (XRD), elemental mapping, dynamic light scattering (DLS), energy-dispersive X-ray spectroscopy (EDS), transmission electron microscopy (TEM), field emission scanning electron microscopy (FESEM), and Fourier transformed infrared spectroscopy (FT-IR).","TEM analysis showed the spherical-shaped nanocomposite with the mean diameter in the range of 5-15\u00a0nm.","Thereafter, the nanocomposite was exploited in the anti-malignant melanoma and cytotoxicity effects studies against various human malignant melanoma cell lines (HT144, RPMI7951, SKMEL2, UACC3074, WM266-4 and MUM2C) in situ."],"Revise":true}
{"PMID":"34413169","Document":["BACKGROUND: We performed a clinical trial to evaluate safety and immunogenicity of a novel long peptide vaccine administered in combinations of incomplete Freund's adjuvant (IFA) and agonists for TLR3 (polyICLC) and TLR7\/8 (resiquimod).","We hypothesized that T cell responses to minimal epitope peptides (MEPs) within the long peptides would be enhanced compared with prior vaccines with MEP themselves and that T cell responses would be enhanced with TLR agonists, compared with IFA alone.","METHODS: Participants with resected stage IIB-IV melanoma were vaccinated with seven long melanoma peptides (LPV7) from tyrosinase, gp100, MAGE-A1, MAGE-A10, and NY-ESO-1, each containing a known MEP for CD8+ T cells, plus a tetanus helper peptide (Tet) restricted by Class II MHC.","Enrollment was guided by an adaptive design to one of seven adjuvant combinations.","Vaccines were administered at weeks 1, 2, 3, 6, 9, 12 at rotating injection sites.","T cell and IgG antibody (Ab) responses were measured with IFN-gamma ELIspot assay ex vivo and ELISA, respectively.","RESULTS: Fifty eligible participants were assigned to seven study groups, with highest enrollment on arm E (LPV7+Tet+IFA+polyICLC).","There was one dose-limiting toxicity (DLT) in Group E (grade 3 injection site reaction, 6% DLT rate).","All other treatment-related adverse events were grades 1-2.","The CD8+ T cell immune response rate (IRR) to MEPs was 18%, less than in prior studies using MEP vaccines in IFA.","The CD8+ T cell IRR trended higher for IFA-containing adjuvants (24%) than adjuvants containing only TLR agonists (6%).","Overall T cell IRR to full-length LPV7 was 30%; CD4+ T cell IRR to Tet was 40%, and serum Ab IRR to LPV7 was 84%.","These IRRs also trended higher for IFA-containing adjuvants (36% vs 18%, 48% vs 24%, and 97% vs 60%, respectively).","CONCLUSIONS: The LPV7 vaccine is safe with each of seven adjuvant strategies and induced T cell responses to CD8 MEPs ex vivo in a subset of patients but did not enhance IRRs compared with prior vaccines using short peptides.","Immunogenicity was supported more by IFA than by TLR agonists alone and may be enhanced by polyICLC plus IFA.","TRIAL REGISTRATION NUMBER: NCT02126579."],"Aspect":"d","Summary":"The treatment was administered over a period of 12 weeks.","Indexes":[4],"Sentences":["Vaccines were administered at weeks 1, 2, 3, 6, 9, 12 at rotating injection sites."],"Revise":false}
{"PMID":"32939750","Document":["INTRODUCTION: National Comprehensive Cancer Network guidelines recommend that sentinel lymph node biopsy (SLNB) be discussed with patients with thin melanoma at higher risk for lymph node metastasis (T1b or T1a with positive deep margins, lymphovascular invasion, or high mitotic index).","We examined the association between SLNB and resource utilization in this cohort.","METHODS: We conducted a retrospective cohort study of patients that underwent wide local excision for higher risk thin melanomas from 2009 to 2018 at a tertiary care center.","Patients who underwent SLNB were compared to those who did not undergo SLNB with regard to resource utilization, including total hospital cost.","RESULTS: A total of 70 patients were included in the analysis and 50 patients (71.4%) underwent SLNB.","SLNB was associated with increased hospital costs ($6700 vs. $3767;\u00a0p\u2009<\u2009.01) and increased operative time (68.5 vs. 36.0\u2009min; p\u2009<\u2009.01).","This cost difference persisted in multivariable regression (p\u2009<\u2009.01).","Of patients who underwent successful SLN mapping, 3 out of 49 patients had a positive SLN (6.1%).","The cost to identify a single positive sentinel lymph node (SLN) was $47,906.","CONCLUSION: In patients with a higher risk of thin melanoma, SLNB is associated with increased cost despite a low likelihood of SLN positivity.","These data better inform patient-provider discussions as the role of SLNB in thin melanoma evolves."],"Aspect":"p","Summary":"The study included 70 patients with higher-risk thin melanomas who underwent wide local excision, with 50 patients (71.4%) undergoing SLNB.","Indexes":[2,4],"Sentences":["METHODS: We conducted a retrospective cohort study of patients that underwent wide local excision for higher risk thin melanomas from 2009 to 2018 at a tertiary care center.","RESULTS: A total of 70 patients were included in the analysis and 50 patients (71.4%) underwent SLNB."],"Revise":false}
{"PMID":"37114291","Document":["BACKGROUND: Lentigo maligna (LM) is a melanocytic proliferation occurring on photo-exposed skin that may progress to LM melanoma.","Surgery is recommended as first-line treatment.","Excision margins of 5-10\u2009mm remain, without international consensus.","Several studies have shown that imiquimod, an immunomodulator, induces LM regression.","This study investigated the effect of imiquimod versus placebo in neoadjuvant settings.","PATIENTS AND METHODS: We performed a prospective, randomized, multicentre, phase III clinical study.","Patients were randomly assigned in 1:1 ratio to receive imiquimod or placebo for 4\u2009weeks, followed by LM excision 4\u2009weeks after the last application of imiquimod or placebo.","The primary endpoint was extra-lesional excision, with a 5\u2009mm margin from the residual pigmentation after imiquimod or vehicle.","Secondary endpoints included the gain on the surface removed between the two groups; number of revision surgeries to obtain extra-lesional excisions; relapse-free time; and number of complete remissions after treatment.","RESULTS: A total of 283 patients participated in this study; 247 patients, 121 patients in the placebo group and 126 in the imiquimod group, accounted for the modified ITT population.","The first extralesional extirpation was performed in 116 (92%) imiquimod patients and in 102 (84%) placebo patients; the difference was not significant (p\u2009=\u20090.0743).","Regarding the surface of LM, imiquimod reduced the LM surface (4.6-3.1\u2009cm2 ) significantly (p\u2009<\u20090.001) more compared to the placebo (3.9-4.1\u2009cm2 ).","CONCLUSION: Imiquimod reduces the lentigo maligna surface after 1\u2009month of treatment, without a higher risk of intralesional excision and with a positive aesthetic outcome."],"Aspect":"o","Summary":"Imiquimod reduces the lentigo maligna surface after 1 month of treatment, without a higher risk of intralesional excision and with a positive aesthetic outcome.","Indexes":[11,12],"Sentences":["Regarding the surface of LM, imiquimod reduced the LM surface (4.6-3.1\u2009cm2 ) significantly (p\u2009<\u20090.001) more compared to the placebo (3.9-4.1\u2009cm2 ).","CONCLUSION: Imiquimod reduces the lentigo maligna surface after 1\u2009month of treatment, without a higher risk of intralesional excision and with a positive aesthetic outcome."],"Revise":false}
{"PMID":"38704501","Document":["BACKGROUND: Uveal melanoma (UM) has a poor prognosis once liver metastases occur.","The melphalan\/Hepatic Delivery System (melphalan\/HDS) is a drug\/device combination used for liver-directed treatment of metastatic UM (mUM) patients.","The purpose of the FOCUS study was to assess the efficacy and safety of melphalan\/HDS in patients with unresectable mUM.","METHODS: Eligible patients with mUM received treatment with melphalan (3.0 mg\/kg ideal body weight) once every 6 to 8 weeks for a maximum of six cycles.","The primary end point was the objective response rate (ORR).","The secondary end points included duration of response (DOR), overall survival (OS), and progression-free survival (PFS).","RESULTS: The study enrolled 102 patients with mUM.","Treatment was attempted in 95 patients, and 91 patients received treatment.","In the treated population (n = 91), the ORR was 36.3 % (95 % confidence interval [CI], 26.44-47.01), including 7.7 % of patients with a complete response.","Thus, the study met its primary end point because the lower bound of the 95 % CI for ORR exceeded the upper bound (8.3 %) from the benchmark meta-analysis.","The median DOR was 14 months, and the median OS was 20.5 months, with an OS of 80 % at 1 year.","The median PFS was 9 months, with a PFS of 65 % at 6 months.","The most common serious treatment-emergent adverse events were thrombocytopenia (15.8 %) and neutropenia (10.5 %), treated\u00a0mostly on an outpatient basis with observation.","No treatment-related deaths were observed.","CONCLUSION: Treatment with melphalan\/HDS provides a clinically meaningful response rate and demonstrates a favorable benefit-risk profile in patients with unresectable mUM (study funded by Delcath; ClinicalTrials.gov identifier: NCT02678572; EudraCT no.","2015-000417-44)."],"Aspect":"o","Summary":"The study found that treatment with melphalan\/HDS had a clinically meaningful response rate and a favorable benefit-risk profile with an objective response rate (ORR) of 36.3%, a median overall survival (OS) of 20.5 months and a median PFS of 9 months in patients with unresectable metastatic uveal melanoma (mUM)","Indexes":[3,8,10,11,14],"Sentences":["METHODS: Eligible patients with mUM received treatment with melphalan (3.0 mg\/kg ideal body weight) once every 6 to 8 weeks for a maximum of six cycles.","In the treated population (n = 91), the ORR was 36.3 % (95 % confidence interval [CI], 26.44-47.01), including 7.7 % of patients with a complete response.","The median DOR was 14 months, and the median OS was 20.5 months, with an OS of 80 % at 1 year.","The median PFS was 9 months, with a PFS of 65 % at 6 months.","CONCLUSION: Treatment with melphalan\/HDS provides a clinically meaningful response rate and demonstrates a favorable benefit-risk profile in patients with unresectable mUM (study funded by Delcath; ClinicalTrials.gov identifier: NCT02678572; EudraCT no."],"Revise":true}
{"PMID":"33641012","Document":["BACKGROUND: Melanoma therapy has changed dramatically over the last decade with improvements in immunotherapy, yet many patients do not respond to current therapies.","This novel vaccine strategy may prime a patient's immune system against their tumor and work synergistically with immunotherapy against advanced-stage melanoma.","METHODS: This was a prospective, randomized, double-blind, placebo-controlled, phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine administered to prevent recurrence in patients with resected stage III\/IV melanoma.","Patients were enrolled and randomized 2:1 to the TLPLDC vaccine or placebo (empty yeast cell wall particles and autologous dendritic cells).","Both intention-to-treat (ITT) and per treatment (PT) analyses were predefined, with PT analysis including patients who remained disease-free through the primary vaccine\/placebo series (6 months).","RESULTS: A total of 144 patients were randomized (103 vaccine, 41 control).","Therapy was well-tolerated with similar toxicity between treatment arms; one patient in each group experienced related serious adverse events.","While disease-free survival (DFS) was not different between groups in ITT analysis, in PT analysis the vaccine group showed improved 24-month DFS (62.9% vs. 34.8%, p = 0.041).","CONCLUSIONS: This phase IIb trial of TLPLDC vaccine administered to patients with resected stage III\/IV melanoma shows TLPLDC is well-tolerated and improves DFS in patients who complete the primary vaccine series.","This suggests patients who do not recur early benefit from TLPLDC in preventing future recurrence from melanoma.","A phase III trial of TLPLDC + checkpoint inhibitor versus checkpoint inhibitor alone in patients with advanced, surgically resected melanoma is under development.","TRIAL REGISTRATION: NCT02301611."],"Aspect":"p","Summary":"The study involved 144 patients with resected stage III\/IV melanoma, randomized into two groups: 103 received the TLPLDC vaccine and 41 received a placebo.","Indexes":[3,5],"Sentences":["Patients were enrolled and randomized 2:1 to the TLPLDC vaccine or placebo (empty yeast cell wall particles and autologous dendritic cells).","RESULTS: A total of 144 patients were randomized (103 vaccine, 41 control)."],"Revise":false}
{"PMID":"32450331","Document":["PURPOSE: To determine the maximum tolerated dose (MTD) of stereotactic ablative radiation therapy (SABR) in combination with immunotherapy for the treatment of patients with metastatic melanoma.","The study also investigates the effects of timing and dosing of SABR on clinical efficacy.","METHODS: Metastatic melanoma patients with at least 2 metastases received SABR to a single metastatic site.","All patients had standard dose immunotherapy with anti-PD1 or anti-CTLA4 at the discretion of their treating clinician.","Following a standard 3 + 3 design, patients were escalated through 3 SABR doses (10 Gy, 15 Gy, and 20 Gy) delivered at 3 different time points (with cycle 1, 2, or 3 of immunotherapy).","Dose-limiting toxicities (DLT) were defined as grade 3 or higher toxicity within 3 months of first treatment and assessed by an independent data safety monitoring committee (IDSMC).","Logistic or Cox regressions were used to assess the impact of SABR dose and timing on the progression free (PFS) and overall survival (OS) of this cohort.","RESULTS: Twenty-four patients were enrolled with a median clinical follow-up of 28 months.","Four patients (16.7%) developed DLTs; 1 DLT occurred at a SABR-treated site, and all patients received 15 Gy.","On this basis the IDSMC recommended stopping the trial and the MTD was defined at 10 Gy.","The 2-year PFS was 21.9% (95% CI, 7.1%-41.8%) and 2-year OS was 49.6% (95% CI, 28.7%-67.6%).","The median PFS for those receiving 10 Gy was numerically higher than for those receiving 15 Gy, 8.3 months versus 2.1 months (P = .38).","The only treatment-related factor associated with both improved PFS (HR 0.08, P < .01) and OS (HR 0.008, P \u2264 .01) was receiving SABR with cycle 3.","SABR dose (PFS P = .17, OS P = .50) was not significant.","CONCLUSIONS: SABR at 10 Gy can be safely combined with immunotherapy.","SABR timing appears to influence efficacy more than dose and warrants consideration in research attempting to optimize synergism."],"Aspect":"m","Summary":"The study involved standard dose immunotherapy with anti-PD1 or anti-CTLA4, and stereotactic ablative radiation therapy (SABR) at doses of 10 Gy, 15 Gy, and 20 Gy.","Indexes":[3,4],"Sentences":["All patients had standard dose immunotherapy with anti-PD1 or anti-CTLA4 at the discretion of their treating clinician.","Following a standard 3 + 3 design, patients were escalated through 3 SABR doses (10 Gy, 15 Gy, and 20 Gy) delivered at 3 different time points (with cycle 1, 2, or 3 of immunotherapy)."],"Revise":false}
{"PMID":"32995974","Document":["OBJECTIVES: To compare tumor best overall response (BOR) by RECIST 1.1 and iRECIST, to explore the incidence of pseudoprogression in melanoma treated with pembrolizumab, and to assess the impact of pseudoprogression on overall survival (OS).","METHODS: A total of 221 patients with locally advanced\/unresectable melanoma who received pembrolizumab as part of KEYNOTE-002 trial were included in this study.","Radiological assessment of imaging was centrally reviewed to assess tumor response.","Incidence of discordance in BOR between RECIST 1.1 and iRECIST as well as rate of pseudoprogression were measured.","OS of patients with pseudoprogression was compared with that of those with uncontrolled disease.","RESULTS: Of the 221 patients in this cohort, 136 patients developed PD as per RECIST v1.1 and 78 patients with PD continued treatment and imaging beyond initial RECIST 1.1-defined PD.","Among the 78 patients who continued therapy and imaging post-progression, RECIST 1.1 and iRECIST were discordant in 10 patients (12.8%) and pseudoprogression was encountered in 14 patients (17.9%).","OS of patients with pseudoprogression was longer than that of patients with uncontrolled disease\/true progression (29.9\u00a0months versus 8.0\u00a0months, p value <\u20090.001).","CONCLUSIONS: Effectiveness of immunotherapy in clinical trials depends on the criterion used to assess tumor response (RECIST 1.1 vs iRECIST) with iRECIST being more appropriate to detect pseudoprogression and potentially prevent premature termination of effective therapy.","Pseudoprogression was associated with improved OS in comparison with that of patients with uncontrolled disease.","KEY POINTS: \u2022 Discordance between iRECIST and RECIST 1.1 was found in 12.8% of unresectable melanoma patients on pembrolizumab who continued therapy beyond initial RECIST 1.1-defined progression.","\u2022 Pseudoprogression, captured with iRECIST, occurred in 17.9% and was significantly associated with improved overall survival in comparison with uncontrolled disease."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"35348754","Document":["BACKGROUND: The prognosis of patients with metastatic malignant melanoma is very poor and partly due to resistance to conventional chemotherapies.","The study's objectives were to assess the activity and tolerability of apatinib, an oral small molecule anti-angiogenesis inhibitor, in patients with recurrent advanced melanoma.","METHODS: This was a single-arm, single-center phase II trial.","The primary endpoint was progression-free survival (PFS) and the secondary endpoints were objective response rate (ORR), disease control rate (DCR), and overall survival (OS).","Eligible patients had received at least one first-line therapy for advanced melanoma and experienced recurrence.","Apatinib (500\u00a0mg) was orally administered daily.","RESULTS: Fifteen patients (V660E BRAF status: 2 mutation, 2 unknown, 11 wild type) were included in the analysis.","The median PFS was 4.0 months.","There were two major objective responses, for a 13.3% response rate.","Eleven patients had stable disease, with a DCR of 86.7%.","The median OS was 12.0 months.","The most common treatment-related adverse events of any grade were hypertension (80.0%), mucositis oral (33.3%), hand-foot skin reaction (26.7%), and liver function abnormalities, hemorrhage, diarrhea (each 20%).","The only grade \u22653 treatment-related adverse effects that occurred in 2 patients was hypertension (6.7%) and mucositis (6.7%).","No treatment-related deaths occurred.","CONCLUSION: Apatinib showed antitumor activity as a second- or above-line therapy in patients with malignant melanoma.","The toxicity was manageable.","CLINICALTRIALS.GOV IDENTIFIER: NCT03383237."],"Aspect":"a","Summary":"The study aims to assess the activity and tolerability of apatinib in patients with recurrent advanced melanoma.","Indexes":[1],"Sentences":["The study's objectives were to assess the activity and tolerability of apatinib, an oral small molecule anti-angiogenesis inhibitor, in patients with recurrent advanced melanoma."],"Revise":false}
{"PMID":"34608333","Document":["Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-based intralesional oncolytic immunotherapy approved for the treatment of unresectable melanoma.","The present, ongoing study aimed to estimate the treatment effect of neoadjuvant T-VEC on recurrence-free survival (RFS) of patients with advanced resectable melanoma.","An open-label, phase 2 trial (NCT02211131) was conducted in 150 patients with resectable stage IIIB-IVM1a melanoma who were randomized to receive T-VEC followed by surgery (arm 1, n\u2009=\u200976) or surgery alone (arm 2, n\u2009=\u200974).","The primary endpoint was a 2-year RFS in the intention-to-treat population.","Secondary and exploratory endpoints included overall survival (OS), pathological complete response (pCR), safety and biomarker analyses.","The 2-year RFS was 29.5% in arm 1 and 16.5% in arm 2 (overall hazard ratio (HR)\u2009=\u20090.75, 80% confidence interval (CI)\u2009=\u20090.58-0.96).","The 2-year OS was 88.9% for arm 1 and 77.4% for arm 2 (overall HR\u2009=\u20090.49, 80% CI\u2009=\u20090.30-0.79).","The RFS and OS differences between arms persisted at 3\u2009years.","In arm 1, 17.1% achieved a pCR.","Increased CD8+ density correlated with clinical outcomes in an exploratory analysis.","Arm 1 adverse events were consistent with previous reports for T-VEC.","The present study met its primary endpoint and estimated a 25% reduction in the risk of disease recurrence for neoadjuvant T-VEC plus surgery versus upfront surgery for patients with resectable stage IIIB-IVM1a melanoma."],"Aspect":"p","Summary":"The study involved 150 patients with resectable stage IIIB-IVM1a melanoma, randomly assigned to two groups: 76 to T-VEC followed by surgery (arm 1) and 74 to surgery alone (arm 2).","Indexes":[2],"Sentences":["An open-label, phase 2 trial (NCT02211131) was conducted in 150 patients with resectable stage IIIB-IVM1a melanoma who were randomized to receive T-VEC followed by surgery (arm 1, n\u2009=\u200976) or surgery alone (arm 2, n\u2009=\u200974)."],"Revise":false}
{"PMID":"32609563","Document":["We sought to investigate the effect of extracts from Rosa gallica petals (RPE) on skin whitening and anti-wrinkle activity.","Tyrosinase activity was attenuated by RPE treatment, concomitant with the reduction of melanin accumulation in human B16F10 melanoma.","Treatment of the facial skin of volunteers in a clinical trial with an RPE-containing formulation enhanced skin brightness (L* value) significantly.","The underlying mechanism responsible was determined to be associated with mitogen-activated protein kinase (MAPK) activation.","In addition, RPE exhibited anti-wrinkle formation activity of human dermal fibroblasts by suppressing matrix metalloproteinase (MMP)-1 level.","In vivo study, RPE also inhibited solar ultraviolet-stimulated MMP-1 level by c-Jun regulation.","Overall, our findings indicate that RPE evokes skin whitening and anti-wrinkle formation activity by regulating intracellular signaling, supporting its utility as an ingredient for skin whitening and anti-wrinkle cosmetic products."],"Aspect":"p","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"31425480","Document":["Prognostic groups defined by lactate dehydrogenase concentration and number of organ sites containing metastases have been reported for patients treated with dabrafenib and trametinib for advanced melanoma.","We aimed to validate these prognostic groups for patients treated with vemurafenib and cobimetinib in the coBRIM and BRIM-3 clinical studies.","Eight hundred nine patients were included, 240 treated with vemurafenib plus cobimetinib and 569 with vemurafenib.","For patients treated with vemurafenib and cobimetinib, both overall survival (P < 0.001, c-statistic = 0.72) and progression-free survival (P < 0.001, c-statistic = 0.65) differed markedly between prognostic groups.","Two-year progression-free survival ranged from 3 (lactate dehydrogenase \u22652 times the upper limit of normal) to 50% (normal lactate dehydrogenase and \u22643 sites), and two-year overall survival ranged from 7 to 71%.","For patients treated with vemurafenib monotherapy, overall survival (P < 0.001, c-statistic = 0.66) and progression-free survival (P < 0.001, c-statistic = 0.62) also differed significantly between prognostic groups.","In conclusion, prognostic groups identified for patients treated with dabrafenib and trametinib are also applicable to patients treated with vemurafenib and cobimentinib."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"35131452","Document":["BACKGROUND: The phase III IMspire150 study (NCT02908672) demonstrated significantly improved progression-free survival (PFS) with atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) versus placebo, vemurafenib, and cobimetinib (control group) in patients with BRAFV600-mutated advanced melanoma.","We report exploratory biomarker analyses to optimize targeting of patients who are more likely to benefit from triplet combination therapy.","PATIENTS AND METHODS: Five hundred fourteen patients were randomized to atezolizumab (n\u00a0= 256) or control (n\u00a0= 258).","Outcomes were evaluated in subgroups defined by key biomarkers, including programmed death-ligand 1 (PD-L1) expression, lactate dehydrogenase (LDH) level, tumor mutational burden (TMB), and interferon-\u03b3 (IFN-\u03b3) gene signature.","Exploratory recursive partitioning analysis was then used to model associations between PFS and baseline covariates, including key biomarkers.","RESULTS: PFS benefit for atezolizumab versus control was greater in patients with high TMB [\u226510 mutations\/Mb; hazard ratio (HR) 0.73; 95% confidence interval (CI) 0.52-1.02; P\u00a0= 0.067] versus low TMB (<10 mutations\/Mb; HR 0.92; 95% CI 0.65-1.30; P\u00a0= 0.64) and similar between patients with strong IFN-\u03b3 (\u2265median; HR 0.76; 95% CI 0.54-1.06) versus weak IFN-\u03b3 (<median; HR 0.79; 95% CI 0.58-1.08).","In patients with elevated LDH, PFS benefit for atezolizumab versus control was greater in the PD-L1- subgroup (HR 0.53; 95% CI 0.29-0.95; P\u00a0= 0.032) than in the PD-L1+ subgroup (HR 1.16; 95% CI 0.75-1.80; P\u00a0= 0.51).","Recursive partitioning analysis showed that IFN-\u03b3 discriminated PFS outcomes in patients with normal LDH, whereas TMB discriminated outcomes in patients with elevated LDH in the atezolizumab group.","Neither IFN-\u03b3 nor TMB discriminated PFS outcomes in the control group.","CONCLUSIONS: Treatment benefits in the atezolizumab group seemed to be most evident in patients with elevated LDH and PD-L1- tumors.","LDH remains the primary predictor of outcomes regardless of treatment.","IFN-\u03b3 and TMB further differentiate outcomes for patients treated with atezolizumab, vemurafenib, and cobimetinib."],"Aspect":"p","Summary":"The study involved 514 patients with BRAFV600-mutated advanced melanoma, randomized into two groups: 256 to the atezolizumab group and 258 to the control group.","Indexes":[2],"Sentences":["PATIENTS AND METHODS: Five hundred fourteen patients were randomized to atezolizumab (n\u00a0= 256) or control (n\u00a0= 258)."],"Revise":false}
{"PMID":"31732523","Document":["PURPOSE: To report the 5-year overall survival (OS) landmark and the long-term safety profile of vemurafenib plus cobimetinib (BRAF plus MEK inhibition, respectively) in the BRIM7 study.","PATIENTS AND METHODS: This phase Ib, dose-finding, and expansion study evaluated combination treatment with vemurafenib and cobimetinib in two cohorts of patients with advanced BRAF V600-mutated melanoma: patients who were BRAF inhibitor (BRAFi)-na\u00efve (n = 63) or patients who had progressed on prior treatment with BRAFi monotherapy [vemurafenib monotherapy-progressive disease (PD); n = 66].","Patients in the dose-escalation phase received vemurafenib at 720 or 960 mg twice daily in combination with cobimetinib at 60, 80, or 100 mg\/d for 14 days on\/14 days off, 21 days on\/7 days off, or continuously.","Two regimens were selected for expansion: vemurafenib (720 and 960 mg twice daily) and cobimetinib (60 mg\/d 21\/7).","RESULTS: Median OS was 31.8 months [95% confidence interval (CI), 24.5-not estimable] in the BRAFi-na\u00efve cohort.","The landmark OS rate plateaued at 39.2% at years 4 and 5 of follow-up.","In the vemurafenib monotherapy-PD cohort, the median OS was 8.5 months (95% CI, 6.7-11.1), and the landmark OS rate plateaued at 14.0% from 3 years of follow-up.","No increase was observed in the frequency and severity of adverse events with long-term follow-up.","No new toxicities were detected, and there was no increase in the frequency of symptomatic MEK inhibitor class-effect adverse events.","CONCLUSIONS: A subset of patients with advanced BRAF V600-mutated melanoma treated with a combination regimen of vemurafenib and cobimetinib achieve favorable long-term outcomes."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"30998526","Document":["This study describes a randomised control trial investigating whether printed leaflets or social media are more effective in increasing knowledge of the risks of sun exposure and melanoma in people aged 18-29.","The study participants were 18-29-year-old university students or graduates, recruited in London.","A baseline level of knowledge was measured using the Skin Cancer and Sun Knowledge questionnaire.","Study participants were then randomised into either a leaflet arm or Facebook arm.","Identical information was delivered through a SunSafe campaign via either posted leaflets or Facebook during a 10-day exposure window.","Following this, participants repeated the Skin Cancer and Sun Knowledge questionnaire.","Following the SunSafe intervention, the mean knowledge score improved in both groups to a statistically significant degree (Facebook\u2009=\u20091.82, leaflets\u2009=\u20093.04, P\u2009<\u20090.001).","Moreover, the improvement in knowledge score of the leaflet arm was statistically significantly greater than in the Facebook arm (95% confidence interval: 0.35-2.09, P\u2009=\u20090.0059).","Participants of lighter skin colour demonstrated greater levels of knowledge about skin cancer and sun exposure at baseline (P\u2009=\u20090.005; P\u2009<\u20090.05).","There was no correlation between sex and baseline knowledge (P\u2009=\u20090.7725).","There was no significant effect of skin tone or sex on the knowledge change (P\u2009=\u20090.139 and 0.643).","The findings suggest that printed information in the form of leaflets is more impactful in increasing knowledge than online platforms such as Facebook among a young adult demographic in the UK.","These findings should be considered when designing public health campaigns, acting as a reminder to not neglect traditional media in health promotion."],"Aspect":"m","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"37776537","Document":["BACKGROUND: Resistance to BRAF and MEK inhibitors in BRAF V600-mutant melanoma is common.","Multiple resistance mechanisms involve heat-shock protein 90 (HSP90) clients, and a phase 1 study of vemurafenib with the HSP90 inhibitor XL888 in patients with advanced melanoma showed activity equivalent to that of BRAF and MEK inhibitors.","METHODS: Vemurafenib (960\u00a0mg orally twice daily) and cobimetinib (60\u00a0mg orally once daily for 21 of 28\u00a0days) with escalating dose cohorts of XL888 (30, 45, 60, or 90\u00a0mg orally twice weekly) was investigated in a phase 1 trial of advanced melanoma, with a modified Ji dose-escalation design.","RESULTS: Twenty-five patients were enrolled.","After two dose-limiting toxicities (DLTs) (rash and acute kidney injury) in the first cohort, lower doses of vemurafenib (720\u00a0mg) and cobimetinib (40\u00a0mg) were investigated with the same XL888 doses.","Three DLTs (rash) were observed in 12 patients in the XL888 60-mg cohort, and this was determined as the maximum tolerated dose.","Objective responses were observed in 19 patients (76%), and the median progression-free survival was 7.6\u00a0months, with a 5-year progression-free survival rate of 20%.","The median overall survival was 41.7\u00a0months, with a 5-year overall survival rate of 37%.","Single-cell RNA sequencing was performed on baseline and on-treatment biopsies; treatment was associated with increased immune cell influx (CD4-positive and CD8-positive T cells) and decreased melanoma cells.","CONCLUSIONS: Combined vemurafenib and cobimetinib plus XL888 had significant toxicity, requiring frequent dose reductions, which may have contributed to the relatively low progression-free survival despite a high tumor response rate.","Given overlapping toxicities, caution must be used when combining HSP90 inhibitors with BRAF and MEK inhibitors."],"Aspect":"a","Summary":"The study aims to investigate the efficacy and safety of combined vemurafenib and cobimetinib with escalating doses of XL888 in patients with advanced melanoma.","Indexes":[2],"Sentences":["METHODS: Vemurafenib (960\u00a0mg orally twice daily) and cobimetinib (60\u00a0mg orally once daily for 21 of 28\u00a0days) with escalating dose cohorts of XL888 (30, 45, 60, or 90\u00a0mg orally twice weekly) was investigated in a phase 1 trial of advanced melanoma, with a modified Ji dose-escalation design."],"Revise":false}
{"PMID":"35552458","Document":["Few studies have examined cognitive responses to mailed precision prevention materials.","MC1R is a robust, well-described melanoma susceptibility marker.","The purpose was to assess cognitive responses to generic or precision prevention materials incorporating MC1R genetic risk.","Non-Hispanic White participants (n = 1134) enrolled in a randomized controlled trial received either precision prevention materials incorporating MC1R genetic risk (higher\/average) or generic prevention (standard) materials.","Six months after baseline, 808 (71.3%) participants reported on the amount of prevention materials read (5-point scale); believability and clarity of materials; intention to change preventive behaviors (7-point Likert scale); and recall of their MC1R genetic risk.","Comparisons were conducted using Kruskal-Wallis and chi-squared tests.","Overall, participants read most to all (Mdn = 4, IQR = 2) of the prevention materials, reported high believability (Mdn = 7, IQR = 1) and clarity (Mdn = 7, IQR = 1), and moderate intention to change preventive behaviors (Mdn = 5, IQR = 2).","Higher-risk participants reported slightly less clarity (Mdn = 6, IQR = 2) than either average-risk (Mdn = 6, IQR = 1, p = 2.50 \u00d7 10-3) or standard participants (Mdn = 7, IQR = 1, p = 2.30 \u00d7 10-5); and slightly less believability (Mdn = 6, IQR = 1) than standard participants (Mdn = 7, IQR = 1, p = .005).","Higher-risk participants were 2.21 times as likely (95% CI = 1.43-3.43) to misremember or forget their risk compared to average-risk participants; misremembering was observed only among higher-risk participants (14%).","Mailed precision prevention information were mostly read, highly believable and clear, and resulted in moderate levels of intention to change sun protection behaviors, bolstering the feasibility of population-level precision prevention.","Defensive reactions may explain lower clarity, believability, and higher incorrect risk recall among higher-risk participants.","Precision prevention uses an individual\u2019s genetics, environment, and\/or lifestyle to promote prevention behaviors.","However, if materials incorporating precision prevention information are not easily accessible, individuals may misinterpret or distrust findings.","Few studies have examined participant-reported believability and clarity of mailed precision prevention materials, how much they read, and whether they intend to change preventive behaviors.","We assessed genetic risk for melanoma by determining DNA variation at the MC1R gene, a known melanoma risk marker.","Participants were mailed either precision prevention materials conveying their MC1R genetic risk or generic (without genetic risk information) prevention materials.","Overall, participants read most of the materials, gave high believability and clarity scores, and reported moderate levels of intention to change preventive behavior.","However, participants at higher genetic risk had slightly lower believability and clarity scores than the generic group and were more likely to forget or misremember their genetic risk than participants at average genetic risk.","Among participants who correctly recalled their genetic risk, differences in believability diminished, while differences in clarity remained.","We conclude that precision prevention materials are highly believable and clear, but additional strategies may be necessary to maximize believability, clarity, and risk recall for individuals at a higher genetic risk."],"Aspect":"a","Summary":"The purpose of the study was to assess cognitive responses to generic or precision prevention materials incorporating MC1R genetic risk.","Indexes":[2],"Sentences":["The purpose was to assess cognitive responses to generic or precision prevention materials incorporating MC1R genetic risk."],"Revise":false}
{"PMID":"36229663","Document":["In patients with previously treated metastatic uveal melanoma, the historical 1\u2009year overall survival rate is 37% with a median overall survival of 7.8\u2009months.","We conducted a multicenter, single-arm, open-label phase 2 study of tebentafusp, a soluble T cell receptor bispecific (gp100\u00d7CD3), in 127 patients with treatment-refractory metastatic uveal melanoma (NCT02570308).","The primary endpoint was the estimation of objective response rate based on RECIST (Response Evaluation Criteria in Solid Tumours) v1.1.","Secondary objectives included safety, overall survival, progression-free survival and disease control rate.","All patients had at least one treatment-related adverse event, with rash (87%), pyrexia (80%) and pruritus (67%) being the most common.","Toxicity was mostly mild to moderate in severity but was greatly reduced in incidence and intensity after the initial three doses.","Despite a low overall response rate of 5% (95% CI: 2-10%), the 1\u2009year overall survival rate was 62% (95% CI: 53-70%) with a median overall survival of 16.8\u2009months (95% CI: 12.9-21.3), suggesting benefit beyond traditional radiographic-based response criteria.","In an exploratory analysis, early on-treatment reduction in circulating tumour DNA was strongly associated with overall survival, even in patients with radiographic progression.","Our findings indicate that tebentafusp has promising clinical activity with an acceptable safety profile in patients with previously treated metastatic uveal melanoma, and data suggesting ctDNA as an early indicator of clinical benefit from tebentafusp need confirmation in a randomized trial."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"38657233","Document":["IFx-Hu2.0 was designed to encode part of the Emm55 protein contained within a plasmid in a formulation intended for transfection into mammalian cells.","IFx-Hu2.0 promotes both adaptive and innate immune responses in animal studies.","Furthermore, previous studies have demonstrated safety\/efficacy in equine, canine, and murine species.","We present the first-in-human study of IFx-Hu2.0, administered by intralesional injection into melanoma tumors of seven patients with stage III\/IV unresectable melanoma.","No dose-limiting toxicities attributable to IFx-Hu2.0 were observed.","Grade 1\/2 injection site reactions were observed in five of seven patients.","IgG and IgM responses to Emm55 peptides and known melanoma antigens were seen in the peripheral blood, suggesting that IFx-Hu2.0 acts as an individualized \"in situ vaccine.\"","Three of four patients previously refractory to anti-PD1 experienced clinical benefit upon subsequent anti-PD1-based treatment.","Therefore, this approach is feasible, and clinical\/correlative outcomes warrant further investigation for treating patients with metastatic melanoma with an immune priming agent."],"Aspect":"o","Summary":"The first-in-human study of IFx-Hu2.0 demonstrated no dose-limiting toxicities, induced IgG and IgM responses, and showed clinical benefit in patients with metastatic melanoma.","Indexes":[4,6,7],"Sentences":["No dose-limiting toxicities attributable to IFx-Hu2.0 were observed.","IgG and IgM responses to Emm55 peptides and known melanoma antigens were seen in the peripheral blood, suggesting that IFx-Hu2.0 acts as an individualized \"in situ vaccine.\"","Three of four patients previously refractory to anti-PD1 experienced clinical benefit upon subsequent anti-PD1-based treatment."],"Revise":false}
{"PMID":"38362837","Document":["SAR439459, a 'second-generation' human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody, inhibits all TGF\u03b2 isoforms and improves the antitumor activity of anti-programmed cell death protein-1 therapeutics.","This study reports the pharmacodynamics (PD) and biomarker results from phase I\/Ib first-in-human study of SAR439459\u2009\u00b1\u2009cemiplimab in patients with advanced solid tumors (NCT03192345).","In dose-escalation phase (Part 1), SAR439459 was administered intravenously at increasing doses either every 2\u2009weeks (Q2W) or every 3\u2009weeks (Q3W) with cemiplimab IV at 3\u2009mg\/kg Q2W or 350\u2009mg Q3W, respectively, in patients with advanced solid tumors.","In dose-expansion phase (Part 2), patients with melanoma received SAR439459 IV Q3W at preliminary recommended phase II dose (pRP2D) of 22.5\/7.5\u2009mg\/kg or at 22.5\u2009mg\/kg with cemiplimab 350\u2009mg IV Q3W.","Tumor biopsy and peripheral blood samples were collected for exploratory biomarker analyses to assess target engagement and PD, and results were correlated with patients' clinical parameters.","SAR439459\u2009\u00b1\u2009cemiplimab showed decreased plasma and tissue TGF\u03b2, downregulation of TGF\u03b2-pathway activation signature, modulation of peripheral natural killer (NK) and T cell expansion, proliferation, and increased secretion of CXCL10.","Conversion of tumor tissue samples from 'immune-excluded' to 'immune-infiltrated' phenotype in a representative patient with melanoma SAR439459 22.5\u2009mg\/kg with cemiplimab was observed.","In paired tumor and plasma, active and total TGF\u03b21 was more consistently elevated followed by TGF\u03b22, whereas TGF\u03b23 was only measurable (lower limit of quantitation \u22652.68\u2009pg\/mg) in tumors.","SAR439459\u2009\u00b1\u2009cemiplimab showed expected peripheral PD effects and TGF\u03b2 alteration.","However, further studies are needed to identify biomarkers of response."],"Aspect":"o","Summary":"SAR439459 \u00b1 cemiplimab showed TGF\u03b2 alteration, modulation of peripheral NK and T cell expansion and proliferation, and increased CXCL10 secretion, as well as a conversion of tumor tissue samples from 'immune-excluded' to 'immune-infiltrated' phenotype. ","Indexes":[5,6,8],"Sentences":["SAR439459\u2009\u00b1\u2009cemiplimab showed decreased plasma and tissue TGF\u03b2, downregulation of TGF\u03b2-pathway activation signature, modulation of peripheral natural killer (NK) and T cell expansion, proliferation, and increased secretion of CXCL10.","Conversion of tumor tissue samples from 'immune-excluded' to 'immune-infiltrated' phenotype in a representative patient with melanoma SAR439459 22.5\u2009mg\/kg with cemiplimab was observed.","SAR439459\u2009\u00b1\u2009cemiplimab showed expected peripheral PD effects and TGF\u03b2 alteration."],"Revise":true}
{"PMID":"32447657","Document":["Skin cancers remain the most common group of cancers globally, and the incidence continues to rise.","Although localized skin cancers tend to have excellent outcomes following surgical excisions, the less common cases that become surgically unresectable or metastatic have been associated with poor prognosis and suboptimal treatment responses to cytotoxic chemotherapy.","Development of monoclonal antibodies to programmed cell death-1 receptor and its ligand (PD-1\/PD-L1) have transformed the management of metastatic melanoma, squamous cell carcinoma, and Merkel cell carcinoma.","These agents, as monotherapies, are associated with response rates of approximately 40-60%, many of which persist durably.","Further efficacy is observed with combination immunotherapy in advanced melanoma.","Early reports suggest similar activity in locally advanced or metastatic basal cell carcinoma.","In this review, we describe common molecular features of skin cancers that may render them particularly susceptible to anti-PD-1\/PD-L1 and detail results from key clinical trials of these agents across skin cancers.","Overall, the superior response rates of skin cancer to anti-PD-1\/PD-L1 compared with other solid tumor types are likely due, at least in part, to a high mutational burden and, in Merkel cell carcinoma, viral etiology.","Although melanoma has been rigorously studied in the setting of anti-PD-1\/PD-L1 treatment, more research is needed for the other skin cancer types to establish toxicity profiles, responses, and quality-of-life outcomes."],"Aspect":"s","Summary":"More research is needed for the other skin cancer types to establish toxicity profiles.","Indexes":[8],"Sentences":["Although melanoma has been rigorously studied in the setting of anti-PD-1\/PD-L1 treatment, more research is needed for the other skin cancer types to establish toxicity profiles, responses, and quality-of-life outcomes."],"Revise":false}
{"PMID":"32133394","Document":["Monitoring targeted therapy in real time for cancer patients could provide vital information about the development of drug resistance and improve therapeutic outcomes.","Extracellular vesicles (EVs) have recently emerged as a promising cancer biomarker, and EV phenotyping shows high potential for monitoring treatment responses.","Here, we demonstrate the feasibility of monitoring patient treatment responses based on the plasma EV phenotypic evolution using a multiplex EV phenotype analyzer chip (EPAC).","EPAC incorporates the nanomixing-enhanced microchip and the multiplex surface-enhanced Raman scattering (SERS) nanotag system for direct EV phenotyping without EV enrichment.","In a preclinical model, we observe the EV phenotypic heterogeneity and different phenotypic responses to the treatment.","Furthermore, we successfully detect cancer-specific EV phenotypes from melanoma patient plasma.","We longitudinally monitor the EV phenotypic evolution of eight melanoma patients receiving targeted therapy and find specific EV profiles involved in the development of drug resistance, reflecting the potential of EV phenotyping for monitoring treatment responses."],"Aspect":"m","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"33734415","Document":["IMPORTANCE: Sentinel lymph node (SLN) mapping agents approved for current surgical practice lack sufficient brightness and target specificity for high-contrast, sensitive nodal visualization.","OBJECTIVE: To evaluate whether an ultrasmall, molecularly targeted core-shell silica nanoparticle (Cornell prime dots) can safely and reliably identify optically avid SLNs in head and neck melanoma during fluorescence-guided biopsy.","DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized clinical trial enrolled patients aged 18 years or older with histologically confirmed melanoma in whom SLN mapping was indicated.","Exclusion criteria included known pregnancy, breast-feeding, or medical illness unrelated to the tumor.","The trial was conducted between February 2015 and March 2018 at Memorial Sloan Kettering Cancer Center, with postoperative follow-up of 2 years.","Data analysis was conducted from February 2015 to March 2018.","INTERVENTIONS: Patients received standard-of-care technetium Tc 99m sulfur colloid followed by a microdose administration of integrin-targeting, dye-encapsulated nanoparticles, surface modified with polyethylene glycol chains and cyclic arginine-glycine-aspartic acid-tyrosine peptides (cRGDY-PEG-Cy5.5-nanoparticles) intradermally.","MAIN OUTCOMES AND MEASURES: The primary end points were safety, procedural feasibility, lowest particle dose and volume for maximizing nodal fluorescence signal, and proportion of nodes identified by technetium Tc 99m sulfur colloid that were optically visualized by cRGDY-PEG-Cy5.5-nanoparticles.","Secondary end points included proportion of patients in whom the surgical approach or extent of dissection was altered because of nodal visualization.","RESULTS: Of 24 consecutive patients enrolled (median [interquartile range] age, 64 [51-71] years), 18 (75%) were men.","In 24 surgical procedures, 40 SLNs were excised.","Preoperative localization of SLNs with technetium Tc 99m sulfur colloid was followed by particle dose-escalation studies, yielding optimized doses and volumes of 2 nmol and 0.4 mL, respectively, and maximum SLN signal-to-background ratios of 40.","No adverse events were observed.","The concordance rate of evaluable SLNs by technetium Tc 99m sulfur colloid and cRGDY-PEG-Cy5.5-nanoparticles was 90% (95% CI, 74%-98%), 5 of which were metastatic.","Ultrabright nanoparticle fluorescence enabled high-sensitivity SLN visualization (including difficult-to-access anatomic sites), deep tissue imaging, and, in some instances, detection through intact skin, thereby facilitating intraoperative identification without extensive dissection of adjacent normal tissue or nerves.","CONCLUSIONS AND RELEVANCE: This study found that nanoparticle-based fluorescence-guided SLN biopsy in head and neck melanoma was feasible and safe.","This technology holds promise for improving lymphatic mapping and SLN biopsy procedures, while potentially mitigating procedural risks.","This study serves as a first step toward developing new multimodal approaches for perioperative care.","TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02106598."],"Aspect":"i","Summary":"This nonrandomized clinical trial enrolled patients with head and neck melanoma for sentinel lymph node mapping using standard technetium Tc 99m sulfur colloid and intradermally injected cRGDY-PEG-Cy5.5-nanoparticles, evaluating safety, procedural feasibility, optimal dose and volume, and nodal fluorescence signal concordance.","Indexes":[1,2,6,7],"Sentences":["OBJECTIVE: To evaluate whether an ultrasmall, molecularly targeted core-shell silica nanoparticle (Cornell prime dots) can safely and reliably identify optically avid SLNs in head and neck melanoma during fluorescence-guided biopsy.","DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized clinical trial enrolled patients aged 18 years or older with histologically confirmed melanoma in whom SLN mapping was indicated.","INTERVENTIONS: Patients received standard-of-care technetium Tc 99m sulfur colloid followed by a microdose administration of integrin-targeting, dye-encapsulated nanoparticles, surface modified with polyethylene glycol chains and cyclic arginine-glycine-aspartic acid-tyrosine peptides (cRGDY-PEG-Cy5.5-nanoparticles) intradermally.","MAIN OUTCOMES AND MEASURES: The primary end points were safety, procedural feasibility, lowest particle dose and volume for maximizing nodal fluorescence signal, and proportion of nodes identified by technetium Tc 99m sulfur colloid that were optically visualized by cRGDY-PEG-Cy5.5-nanoparticles."],"Revise":true}
{"PMID":"37930123","Document":["PURPOSE: Preclinical studies show that activation of AMP kinase by phenformin can augment the cytotoxic effect and RAF inhibitors in BRAF V600-mutated melanoma.","We conducted a phase Ib dose-escalation trial of phenformin with standard dose dabrafenib\/trametinib in patients with metastatic BRAF V600-mutated melanoma.","EXPERIMENTAL DESIGN: We used a 3+3 dose-escalation design which explored phenformin doses between 50 and 200 mg twice daily.","Patients also received standard dose dabrafenib\/trametinib.","We measured phenformin pharmacokinetics and assessed the effect of treatment on circulating myeloid-derived suppressor cells (MDSC).","RESULTS: A total of 18 patients were treated at dose levels ranging from 50 to 200 mg twice daily.","The planned dose-escalation phase had to be cancelled because of the COVID 19 pandemic.","The most common toxicities were nausea\/vomiting; there were two cases of reversible lactic acidosis.","Responses were seen in 10 of 18 patients overall (56%) and in 2 of 8 patients who had received prior therapy with RAF inhibitor.","Pharmacokinetic data confirmed drug bioavailability.","MDSCs were measured in 7 patients treated at the highest dose levels and showed MDSC levels declined on study drug in 6 of 7 patients.","CONCLUSIONS: We identified the recommended phase II dose of phenformin as 50 mg twice daily when administered with dabrafenib\/trametinib, although some patients will require short drug holidays.","We observed a decrease in MDSCs, as predicted by preclinical studies, and may enhance immune recognition of melanoma cells.","SIGNIFICANCE: This is the first trial using phenformin in combination with RAF\/MEK inhibition in patients with BRAF V600-mutated melanoma.","This is a novel strategy, based on preclinical data, to increase pAMPK while blocking the MAPK pathway in melanoma.","Our data provide justification and a recommended dose for a phase II trial."],"Aspect":"p","Summary":"A total of 18 patients with metastatic BRAF V600-mutated melanoma were treated in a phase Ib dose-escalation trial.","Indexes":[5],"Sentences":["RESULTS: A total of 18 patients were treated at dose levels ranging from 50 to 200 mg twice daily."],"Revise":false}
{"PMID":"35552458","Document":["Few studies have examined cognitive responses to mailed precision prevention materials.","MC1R is a robust, well-described melanoma susceptibility marker.","The purpose was to assess cognitive responses to generic or precision prevention materials incorporating MC1R genetic risk.","Non-Hispanic White participants (n = 1134) enrolled in a randomized controlled trial received either precision prevention materials incorporating MC1R genetic risk (higher\/average) or generic prevention (standard) materials.","Six months after baseline, 808 (71.3%) participants reported on the amount of prevention materials read (5-point scale); believability and clarity of materials; intention to change preventive behaviors (7-point Likert scale); and recall of their MC1R genetic risk.","Comparisons were conducted using Kruskal-Wallis and chi-squared tests.","Overall, participants read most to all (Mdn = 4, IQR = 2) of the prevention materials, reported high believability (Mdn = 7, IQR = 1) and clarity (Mdn = 7, IQR = 1), and moderate intention to change preventive behaviors (Mdn = 5, IQR = 2).","Higher-risk participants reported slightly less clarity (Mdn = 6, IQR = 2) than either average-risk (Mdn = 6, IQR = 1, p = 2.50 \u00d7 10-3) or standard participants (Mdn = 7, IQR = 1, p = 2.30 \u00d7 10-5); and slightly less believability (Mdn = 6, IQR = 1) than standard participants (Mdn = 7, IQR = 1, p = .005).","Higher-risk participants were 2.21 times as likely (95% CI = 1.43-3.43) to misremember or forget their risk compared to average-risk participants; misremembering was observed only among higher-risk participants (14%).","Mailed precision prevention information were mostly read, highly believable and clear, and resulted in moderate levels of intention to change sun protection behaviors, bolstering the feasibility of population-level precision prevention.","Defensive reactions may explain lower clarity, believability, and higher incorrect risk recall among higher-risk participants.","Precision prevention uses an individual\u2019s genetics, environment, and\/or lifestyle to promote prevention behaviors.","However, if materials incorporating precision prevention information are not easily accessible, individuals may misinterpret or distrust findings.","Few studies have examined participant-reported believability and clarity of mailed precision prevention materials, how much they read, and whether they intend to change preventive behaviors.","We assessed genetic risk for melanoma by determining DNA variation at the MC1R gene, a known melanoma risk marker.","Participants were mailed either precision prevention materials conveying their MC1R genetic risk or generic (without genetic risk information) prevention materials.","Overall, participants read most of the materials, gave high believability and clarity scores, and reported moderate levels of intention to change preventive behavior.","However, participants at higher genetic risk had slightly lower believability and clarity scores than the generic group and were more likely to forget or misremember their genetic risk than participants at average genetic risk.","Among participants who correctly recalled their genetic risk, differences in believability diminished, while differences in clarity remained.","We conclude that precision prevention materials are highly believable and clear, but additional strategies may be necessary to maximize believability, clarity, and risk recall for individuals at a higher genetic risk."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"34360781","Document":["To identify potential early biomarkers of treatment response and immune-related adverse events (irAE), a pilot immune monitoring study was performed in stage IV melanoma patients by flow cytometric analysis of peripheral blood mononuclear cells (PBMC).","Overall, 17 patients were treated with either nivolumab or pembrolizumab alone, or with a combination of nivolumab and ipilimumab every three weeks.","Of 15 patients for which complete response assessment was available, treatment responders (n = 10) as compared to non-responders (n = 5) were characterized by enhanced PD-1 expression on CD8+ T cells immediately before treatment (median \u00b1 median absolute deviation\/MAD 26.7 \u00b1 10.4% vs. 17.2 \u00b1 5.3%).","Responders showed a higher T cell responsiveness after T cell receptor ex vivo stimulation as determined by measurement of programmed cell death 1 (PD-1) expression on CD3+ T cells before the second cycle of treatment.","The percentage of CD8+ effector memory (CD8+CD45RA-CD45RO+CCR7-) T cells was higher in responders compared to non-responders before and immediately after the first cycle of treatment (median \u00b1 MAD 39.2 \u00b1 7.3% vs. 30.5 \u00b1 4.1% and 37.7 \u00b1 4.6 vs. 24.0 \u00b1 6.4).","Immune-related adverse events (irAE) were accompanied by a higher percentage of activated CD4+ (CD4+CD38+HLADR+) T cells before the second treatment cycle (median \u00b1 MAD 14.9 \u00b1 3.9% vs. 5.3 \u00b1 0.4%).","In summary, PBMC immune monitoring of immune-checkpoint inhibition (ICI) treatment in melanoma appears to be a promising approach to identify early markers of treatment response and irAEs."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"36600247","Document":["BACKGROUND: HL-085 is a selective, orally administered MEK1\/2 inhibitor.","We aimed to evaluate the safety and efficacy of HL-085 in patients with advanced melanoma harboring NRAS mutations.","METHODS: This was a multicenter phase 1 study.","HL-085 was administered twice daily in a standard 3\u2009+\u20093 dose-escalation design (10 dose cohorts; 0.5-18\u00a0mg twice daily), followed by dose expansion at the recommended phase II dose (RP2D).","The primary endpoints included tolerability, dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and RP2D.","RESULTS: Between September 13, 2017, and January 18, 2021, 42 patients were enrolled (dose escalation phase: n\u2009=\u200930; dose expansion phase: n\u2009=\u200912).","No DLT was reported during dose escalation and MTD was not reached with HL-085 doses up to 18\u00a0mg twice daily.","The RP2D was 12\u00a0mg twice daily.","The most common all-grade drug-related adverse events (AEs) across all dose levels were rash (61.9%), increased creatine phosphokinase (CK, 59.5%), face edema (50.0%), increased aspartate aminotransferase (47.6%), peripheral edema (40.5%), diarrhea (33.3%), alanine aminotransferase (33.3%), and paronychia (19.0%), most of which were grade 1 and 2.","Most frequency of grade\u2009\u2265\u20093 AEs were CK (14.2%), asthenia (7.1%), peripheral edema (4.8%), and acneiform dermatitis (4.8%).","In the cohort of 12\u00a0mg twice daily dose (15 patients), confirmed objective response rate was 26.7%; disease control rate was 86.7%; median duration of response was 2.9\u00a0months; median progression-free survival was 3.6\u00a0months.","CONCLUSIONS: The HL-085 showed acceptable tolerability and substantial clinical activity in patients with advanced melanoma harboring NRAS mutations.","TRIAL REGISTRATION: Trial registration ClinicalTrials.gov number: NCT03973151."],"Aspect":"a","Summary":"The study aimed to evaluate the safety and efficacy of HL-085 in patients with advanced melanoma harboring NRAS mutations.","Indexes":[1],"Sentences":["We aimed to evaluate the safety and efficacy of HL-085 in patients with advanced melanoma harboring NRAS mutations."],"Revise":false}
{"PMID":"36947734","Document":["PURPOSE: No approved targeted therapy for the treatment of patients with neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS)-mutant melanoma is currently available.","PATIENTS AND METHODS: In this phase Ib escalation\/expansion study (ClinicalTrials.gov identifier: NCT02974725), the safety, tolerability, and preliminary antitumor activity of naporafenib (LXH254), a BRAF\/CRAF protein kinases inhibitor, were explored in combination with trametinib in patients with advanced\/metastatic KRAS- or BRAF-mutant non-small-cell lung cancer (escalation arm) or NRAS-mutant melanoma (escalation and expansion arms).","RESULTS: Thirty-six and 30 patients were enrolled in escalation and expansion, respectively.","During escalation, six patients reported grade \u22653 dose-limiting toxicities, including dermatitis acneiform (n = 2), maculopapular rash (n = 2), increased lipase (n = 1), and Stevens-Johnson syndrome (n = 1).","The recommended doses for expansion were naporafenib 200 mg twice a day plus trametinib 1 mg once daily and naporafenib 400 mg twice a day plus trametinib 0.5 mg once daily.","During expansion, all 30 patients experienced a treatment-related adverse event, the most common being rash (80%, n = 24), blood creatine phosphokinase increased, diarrhea, and nausea (30%, n = 9 each).","In expansion, the objective response rate, median duration of response, and median progression-free survival were 46.7% (95% CI, 21.3 to 73.4; 7 of 15 patients), 3.75 (95% CI, 1.97 to not estimable [NE]) months, and 5.52 months, respectively, in patients treated with naporafenib 200 mg twice a day plus trametinib 1 mg once daily, and 13.3% (95% CI, 1.7 to 40.5; 2 of 15 patients), 3.75 (95% CI, 2.04 to NE) months, and 4.21 months, respectively, in patients treated with naporafenib 400 mg twice a day plus trametinib 0.5 mg once daily.","CONCLUSION: Naporafenib plus trametinib showed promising preliminary antitumor activity in patients with NRAS-mutant melanoma.","Prophylactic strategies aimed to lower the incidence of skin-related events are under investigation."],"Aspect":"s","Summary":"Treatment side effects included grade \u22653 dose-limiting toxicities such as dermatitis acneiform, maculopapular rash, increased lipase, and Stevens-Johnson syndrome during escalation, and rash, increased blood creatine phosphokinase, diarrhea, and nausea during expansion.","Indexes":[3,5],"Sentences":["During escalation, six patients reported grade \u22653 dose-limiting toxicities, including dermatitis acneiform (n = 2), maculopapular rash (n = 2), increased lipase (n = 1), and Stevens-Johnson syndrome (n = 1).","During expansion, all 30 patients experienced a treatment-related adverse event, the most common being rash (80%, n = 24), blood creatine phosphokinase increased, diarrhea, and nausea (30%, n = 9 each)."],"Revise":true}
{"PMID":"36162037","Document":["PURPOSE: Ipilimumab and nivolumab have each shown treatment benefit for high-risk resected melanoma.","The phase III CheckMate 915 trial evaluated adjuvant nivolumab plus ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or IV melanoma.","PATIENTS AND METHODS: In this randomized, double-blind, phase III trial, 1,833 patients received nivolumab 240 mg once every 2 weeks plus ipilimumab 1 mg\/kg once every 6 weeks (916 patients) or nivolumab 480 mg once every 4 weeks (917 patients) for \u2264 1 year.","After random assignment, patients were stratified by tumor programmed death ligand 1 (PD-L1) expression and stage.","Dual primary end points were recurrence-free survival (RFS) in randomly assigned patients and in the tumor PD-L1 expression-level < 1% subgroup.","RESULTS: At a minimum follow-up of approximately 23.7 months, there was no significant difference between treatment groups for RFS in the all-randomly assigned patient population (hazard ratio, 0.92; 95% CI, 0.77 to 1.09; P = .269) or in patients with PD-L1 expression < 1% (hazard ratio, 0.91; 95% CI, 0.73 to 1.14).","In all patients, 24-month RFS rates were 64.6% (combination) and 63.2% (nivolumab).","Treatment-related grade 3 or 4 adverse events were reported in 32.6% of patients in the combination group and 12.8% in the nivolumab group.","Treatment-related deaths were reported in 0.4% of patients in the combination group and in no nivolumab-treated patients.","CONCLUSION: Nivolumab 240 mg once every 2 weeks plus ipilimumab 1 mg\/kg once every 6 weeks did not improve RFS versus nivolumab 480 mg once every 4 weeks in patients with stage IIIB-D or stage IV melanoma.","Nivolumab showed efficacy consistent with previous adjuvant studies in a population resembling current practice using American Joint Committee on Cancer eighth edition, reaffirming nivolumab as a standard of care for melanoma adjuvant treatment."],"Aspect":"o","Summary":"The CheckMate 915 trial found that the combination of nivolumab and ipilimumab did not improve recurrence-free survival compared to nivolumab alone in patients with stage IIIB-D or IV melanoma.","Indexes":[5,9],"Sentences":["RESULTS: At a minimum follow-up of approximately 23.7 months, there was no significant difference between treatment groups for RFS in the all-randomly assigned patient population (hazard ratio, 0.92; 95% CI, 0.77 to 1.09; P = .269) or in patients with PD-L1 expression < 1% (hazard ratio, 0.91; 95% CI, 0.73 to 1.14).","CONCLUSION: Nivolumab 240 mg once every 2 weeks plus ipilimumab 1 mg\/kg once every 6 weeks did not improve RFS versus nivolumab 480 mg once every 4 weeks in patients with stage IIIB-D or stage IV melanoma."],"Revise":false}
{"PMID":"33219094","Document":["BACKGROUND: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, in combination with the programmed cell death-1 (PD-1) antagonist pembrolizumab.","METHODS: The study was divided into two parts; parts A and B, where part A was the dose escalation part and part B was an extension part of the study.","Patients with metastatic melanoma were treated with efti plus the standard dose of pembrolizumab.","Blood samples were assayed to determine plasma pharmacokinetic parameters, detect efti antibody formation and determine long-lived CD8 T cell responses and associated pharmacodynamic parameters.","RESULTS: Twenty-four patients with melanoma received pembrolizumab and bi-weekly subcutaneous (s.c.) injections of efti at doses 1 mg, 6 mg or 30 mg\/injection for up to 6 months (part A) or 30 mg\/injection for up 12 months (part B).","No dose-limiting toxicities were reported and the main adverse event for efti was injection site reactions.","Sustained systemic exposure to the product was obtained in all patients following s.c. injections of 30 mg dose.","Treatment induced an increase in activated CD8 and CD4 T cell counts, and in some of the soluble biomarkers, particularly interferon (IFN)-\u03b3, a Th1 signature cytokine.","An overall response rate (ORR) of 33% was observed in patients partly with pembrolizumab-refractory of part A and ORR of 50% was observed in patients with PD-1 na\u00efve of part B.","CONCLUSIONS: Efti was well tolerated in combination with pembrolizumab with encouraging antitumor activity.","This warrants further clinical studies of this new combination therapy combining an antigen-presenting cell activator with an immune checkpoint inhibitor."],"Aspect":"m","Summary":"The study involved eftilagimod alpha (efti) administered at doses of 1 mg, 6 mg, or 30 mg\/injection bi-weekly via subcutaneous injections, combined with the standard dose of pembrolizumab.","Indexes":[0,4],"Sentences":["BACKGROUND: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, in combination with the programmed cell death-1 (PD-1) antagonist pembrolizumab.","RESULTS: Twenty-four patients with melanoma received pembrolizumab and bi-weekly subcutaneous (s.c.) injections of efti at doses 1 mg, 6 mg or 30 mg\/injection for up to 6 months (part A) or 30 mg\/injection for up 12 months (part B)."],"Revise":false}
{"PMID":"34158360","Document":["PURPOSE: The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall survival (OS) with addition of cobimetinib to vemurafenib compared with vemurafenib in patients with previously untreated BRAFV600 mutation-positive advanced melanoma.","We report long-term follow-up of coBRIM, with at least 5 years since the last patient was randomized.","PATIENTS AND METHODS: Eligible patients were randomized 1:1 to receive either oral cobimetinib (60 mg once daily on days 1-21 in each 28-day cycle) or placebo in combination with oral vemurafenib (960 mg twice daily).","RESULTS: 495 patients were randomized to cobimetinib plus vemurafenib (n = 247) or placebo plus vemurafenib (n = 248).","Median follow-up was 21.2 months for cobimetinib plus vemurafenib and 16.6 months for placebo plus vemurafenib.","Median OS was 22.5 months (95% CI, 20.3-28.8) with cobimetinib plus vemurafenib and 17.4 months (95% CI, 15.0-19.8) with placebo plus vemurafenib; 5-year OS rates were 31% and 26%, respectively.","Median PFS was 12.6 months (95% CI, 9.5-14.8) with cobimetinib plus vemurafenib and 7.2 months (95% CI, 5.6-7.5) with placebo plus vemurafenib; 5-year PFS rates were 14% and 10%, respectively.","OS and PFS were longest in patients with normal baseline lactate dehydrogenase levels and low tumor burden, and in those achieving complete response.","The safety profile remained consistent with previously published reports.","CONCLUSIONS: Extended follow-up of coBRIM confirms the long-term clinical benefit and safety profile of cobimetinib plus vemurafenib compared with vemurafenib monotherapy in patients with BRAFV600 mutation-positive advanced melanoma."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"32056395","Document":["BRAF and MEKis have revolutionized the management of BRAFV600 -mutated melanoma patients.","Left ventricular ejection fraction decrease (LVEF-D) related to these treatments has not been thoroughly evaluated to date.","The main objective of this study was to describe characteristics of LVEF-D in melanoma patients treated with BRAF and\/or MEKis.","Metastatic melanoma patients treated with BRAF and\/or MEKis between March 1, 2012 and May 18, 2018 were included retrospectively (Lyon Sud University Hospital, Hospices Civils de Lyon).","LVEF-D was defined as a reduction in LVEF \u226510% from baseline to a value <55%; normalization was defined as a value \u226555%.","Among the 88 patients included, 12 (13.6%) experienced a LVEF-D, including 10 grade 2 and 2 grade 3.","The median onset of which was 11\u00a0months (IQR [3-21]).","No patient previously treated with beta-blockers (n\u00a0=\u00a012) experienced a LVEF-D.","Analysis of laboratory parameters, electrocardiogram, and transthoracic echocardiography during the follow-up did not find any predictive marker of LVEF-D. All patients who benefited from a specific treatment of LVEF-D had a normalization of LVEF at the end of follow-up.","LVEF recovery was significantly better for patients treated with angiotensin converting enzyme inhibitors and beta-blockers than those who did not (P\u00a0=\u00a0.019).","Ophthalmological adverse events were significantly more frequent in patients who experienced a LVEF-D (P\u00a0=\u00a0.006) and the latter did not influence overall-survival (P\u00a0=\u00a0.117) or progression-free-survival (P\u00a0=\u00a0.297).","LVEF-D is a common and easily manageable adverse event due to BRAF and MEKis.","Its association with ocular toxicity suggests a close ophthalmological monitoring when LVEF-D occurs."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"31704549","Document":["AIM OF STUDY: The aim of the study was to assess the impact of treatment with adjuvant vemurafenib monotherapy on health-related quality of life (HRQOL) in patients with resected stage IIC-IIIC melanoma.","METHODS: The phase 3 BRIM8 study (NCT01667419) randomised patients with BRAFV600 mutation-positive resected stage IIC-IIIC melanoma to 960\u00a0mg of vemurafenib twice daily or matching placebo for 52 weeks (13\u00a0\u00d7\u00a028-day cycles).","Patients completed the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) version 3\u00a0at baseline, cycle 1 (days 1, 15 and 22), cycle 2 (days 1 and 15), day 1 of every subsequent 4-week cycle, the end-of-treatment visit and each visit during the follow-up period.","RESULTS: Completion rates for the EORTC QLQ-C30 questionnaire were high (>80%).","There was a mean decline in the global health status (GHS)\/quality of life (QOL) score of 17.4 (\u00b122.9) and 17.3 (\u00b124.1) points at days 15 and 22 of cycle 1, respectively, among vemurafenib-treated patients who recovered to approximately 10 points below baseline for the remainder of the treatment period.","A similar trend was observed in all functional scales except for cognitive function (<10-point change from baseline at all visits) and in the symptom scores for appetite loss, fatigue and pain.","As observed for the GHS\/QOL score, all scores rapidly returned to baseline after completion of planned vemurafenib treatment or treatment discontinuation.","CONCLUSIONS: The schedule of HRQOL assessments allowed for an accurate and complete evaluation of the impact of acute treatment-related symptoms.","Vemurafenib-treated patients experience clinically meaningful moderate worsening in some treatment- or disease-related symptoms and GHS\/QOL that resolve over time."],"Aspect":"m","Summary":"The study involved vemurafenib monotherapy administered at a dose of 960 mg twice daily for 52 weeks.","Indexes":[1],"Sentences":["METHODS: The phase 3 BRIM8 study (NCT01667419) randomised patients with BRAFV600 mutation-positive resected stage IIC-IIIC melanoma to 960\u00a0mg of vemurafenib twice daily or matching placebo for 52 weeks (13\u00a0\u00d7\u00a028-day cycles)."],"Revise":false}
{"PMID":"36197494","Document":["BACKGROUND: Recurrence-free survival (RFS) and overall survival (OS) data for adjuvant nivolumab versus placebo (proxy for routine surveillance) in patients with high-risk, resected melanoma are lacking.","This post hoc, indirect treatment comparison (ITC) used pooled data from the phase 3 EORTC 18,071 (ipilimumab vs. placebo) and CheckMate 238 (nivolumab vs. ipilimumab) trials to assess RFS and OS with nivolumab versus placebo and the numbers needed to treat (NNT) over 4\u00a0years.","METHODS: Patients with resected stage IIIB-C cutaneous melanoma (American Joint Committee on Cancer seventh edition) were included.","Inverse probability treatment weighting (IPTW) was used to balance baseline characteristics.","RFS NNTs were calculated for nivolumab versus ipilimumab and placebo.","OS NNTs were calculated for nivolumab versus placebo.","To adjust for different post-recurrence treatments, the difference in post-recurrence survival between the two ipilimumab arms was added to OS of the placebo arm.","RESULTS: This ITC included 278, 643, and 365 patients treated with nivolumab, ipilimumab, and placebo, respectively.","Following IPTW, nivolumab was associated with improved RFS versus placebo (hazard ratio [HR]: 0.49; 95% confidence interval [CI] 0.39-0.61) and ipilimumab (HR: 0.69; 95% CI 0.56-0.85).","RFS NNT was 4.2 for nivolumab versus placebo and 8.9 for nivolumab versus ipilimumab.","After post-recurrence survival adjustment, weighted 4-year OS rates were 75.8% for nivolumab and 64.1% for placebo; OS NNT for nivolumab versus placebo was 8.5.","CONCLUSIONS: In patients with resected stage IIIB-C cutaneous melanoma in this ITC, nivolumab improved RFS versus placebo and ipilimumab, and OS versus placebo after post-recurrence survival adjustment."],"Aspect":"p","Summary":"The study included 278, 643, and 365 patients with resected stage IIIB-C cutaneous melanoma treated with nivolumab, ipilimumab, and placebo, respectively.","Indexes":[7],"Sentences":["RESULTS: This ITC included 278, 643, and 365 patients treated with nivolumab, ipilimumab, and placebo, respectively."],"Revise":false}
{"PMID":"35593340","Document":["BACKGROUND: SV-BR-1-GM, derived from a patient with grade 2 (moderately differentiated) breast cancer, is a GM-CSF-secreting breast cancer cell line with properties of antigen-presenting cells.","SV-BR-1-GM and next-generation versions are covered by several pending and granted patents.","METHODS: We report findings from an open-label phase I, single-arm pilot study with irradiated SV-BR-1-GM cells in 3 breast and 1 ovarian cancer subjects.","Inoculations were preceded by lowdose intravenous cyclophosphamide and followed by interferon-alpha2b injections into the SVBR- 1-GM inoculation sites.","We assessed both cellular and humoral immune responses, and measured expression levels of SV-BR-1-GM HLA alleles.","RESULTS: Treatment was generally safe and well tolerated.","Immune responses were elicited universally.","Overall survival was more than 33 months for three of the four patients.","As previously reported, one patient had prompt regression of metastases in lung, breast, and soft tissue.","Following cessation of treatment, the patient relapsed widely, including in the brain.","Upon retreatment, rapid tumor response was again seen, including complete regression of brain metastases.","Consistent with a role of Class II HLA in contributing to SV-BR-1-GM's mechanism of action, this patient allele-matched SV-BR-1-GM at the HLA-DRB1 and HLA-DRB3 loci.","We are in the process of developing next-generation SV-BR-1-GM, expressing patient-specific HLAs.","Patent applications were filed in various jurisdictions.","Thus far, one is granted, in Japan.","CONCLUSION: A whole-cell immunotherapy regimen with SV-BR-1-GM cells induced regression of metastatic breast cancer.","We develop intellectual property based on SV-BR-1-GM's predicted mechanism of action to develop additional whole-cell immunotherapies for cancer patients."],"Aspect":"o","Summary":"The study found that a whole-cell immunotherapy regimen with SV-BR-1-GM cells induced regression of metastatic breast cancer.","Indexes":[15],"Sentences":["CONCLUSION: A whole-cell immunotherapy regimen with SV-BR-1-GM cells induced regression of metastatic breast cancer."],"Revise":false}
{"PMID":"33125309","Document":["PURPOSE: Metastatic uveal melanoma has poor overall survival (OS) and no approved systemic therapy options.","Studies of single-agent immunotherapy regimens have shown minimal benefit.","There is the potential for improved responses with the use of combination immunotherapy.","PATIENTS AND METHODS: We conducted a phase II study of nivolumab with ipilimumab in patients with metastatic uveal melanoma.","Any number of prior treatments was permitted.","Patients received nivolumab 1 mg\/kg and ipilimumab 3 mg\/kg for four cycles, followed by nivolumab maintenance therapy for up to 2 years.","The primary outcome of the study was overall response rate (ORR) as determined by RECIST 1.1 criteria.","Progression-free survival (PFS), OS, and adverse events were also assessed.","RESULTS: Thirty-five patients were enrolled, and 33 patients were evaluable for efficacy.","The ORR was 18%, including one confirmed complete response and five confirmed partial responses.","The median PFS was 5.5 months (95% CI, 3.4 to 9.5 months), and the median OS was 19.1 months (95% CI, 9.6 months to NR).","Forty percent of patients experienced a grade 3-4 treatment-related adverse event.","CONCLUSION: The combination regimen of nivolumab plus ipilimumab demonstrates activity in metastatic uveal melanoma, with deep and sustained confirmed responses."],"Aspect":"i","Summary":"The study conducted a phase II trial of nivolumab with ipilimumab in patients with metastatic uveal melanoma, using a dosing regimen of nivolumab 1 mg\/kg and ipilimumab 3 mg\/kg for four cycles, followed by nivolumab maintenance therapy for up to 2 years.","Indexes":[3,5],"Sentences":["PATIENTS AND METHODS: We conducted a phase II study of nivolumab with ipilimumab in patients with metastatic uveal melanoma.","Patients received nivolumab 1 mg\/kg and ipilimumab 3 mg\/kg for four cycles, followed by nivolumab maintenance therapy for up to 2 years."],"Revise":false}
{"PMID":"37307514","Document":["PURPOSE: To address the paucity of data in patients with historically poor outcomes, we conducted the single-arm phase IIIb CheckMate 401 study to evaluate the safety and efficacy of nivolumab plus ipilimumab followed by nivolumab monotherapy in clinically diverse patient populations with advanced melanoma.","METHODS: Treatment-naive patients with unresectable stage III-IV melanoma received nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg once every 3 weeks (four doses) followed by nivolumab 3 mg\/kg (240 mg following a protocol amendment) once every 2 weeks for \u226424 months.","The primary end point was the incidence of grade 3-5 select treatment-related adverse events (TRAEs).","Overall survival (OS) was a secondary end point.","Outcomes were evaluated in subgroups defined by Eastern Cooperative Oncology Group performance status (ECOG PS), brain metastasis status, and melanoma subtype.","RESULTS: In total, 533 patients received at least one dose of study drug.","Grade 3-5 select TRAEs affecting the GI (16%), hepatic (15%), endocrine (11%), skin (7%), renal (2%), and pulmonary (1%) systems occurred in the all-treated population; similar incidence rates were observed across all subgroups.","At 21.6 months' median follow-up, 24-month OS rates were 63% in the all-treated population, 44% in the ECOG PS 2 subgroup (including patients with cutaneous melanoma only), 71% in the brain metastasis subgroup, 36% in the ocular\/uveal melanoma subgroup, and 38% in the mucosal melanoma subgroup.","CONCLUSION: Nivolumab plus ipilimumab followed by nivolumab monotherapy was tolerable in patients with advanced melanoma and poor prognostic characteristics.","Efficacy was similar between the all-treated population and patients with brain metastases.","Reduced efficacy was observed in patients with ECOG PS 2, ocular\/uveal melanoma, and\/or mucosal melanoma, highlighting the continued need for novel treatment options for these difficult-to-treat patients."],"Aspect":"i","Summary":"Treatment-naive patients with unresectable stage III-IV melanoma received nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg every 3 weeks (four doses) followed by nivolumab 3 mg\/kg every 2 weeks for up to 24 months.","Indexes":[1],"Sentences":["METHODS: Treatment-naive patients with unresectable stage III-IV melanoma received nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg once every 3 weeks (four doses) followed by nivolumab 3 mg\/kg (240 mg following a protocol amendment) once every 2 weeks for \u226424 months."],"Revise":true}
{"PMID":"33593880","Document":["PURPOSE: Triple-negative breast cancer (TNBC) is an aggressive disease with limited therapeutic options.","Antibodies targeting programmed cell death protein 1 (PD-1)\/PD-1 ligand 1 (PD-L1) have entered the therapeutic landscape in TNBC, but only a minority of patients benefit.","A way to reliably enhance immunogenicity, T-cell infiltration, and predict responsiveness is critically needed.","PATIENTS AND METHODS: Using mouse models of TNBC, we evaluate immune activation and tumor targeting of intratumoral IL12 plasmid followed by electroporation (tavokinogene telseplasmid; Tavo).","We further present a single-arm, prospective clinical trial of Tavo monotherapy in patients with treatment refractory, advanced TNBC (OMS-I140).","Finally, we expand these findings using publicly available breast cancer and melanoma datasets.","RESULTS: Single-cell RNA sequencing of murine tumors identified a CXCR3 gene signature (CXCR3-GS) following Tavo treatment associated with enhanced antigen presentation, T-cell infiltration and expansion, and PD-1\/PD-L1 expression.","Assessment of pretreatment and posttreatment tissue from patients confirms enrichment of this CXCR3-GS in tumors from patients that exhibited an enhancement of CD8+ T-cell infiltration following treatment.","One patient, previously unresponsive to anti-PD-L1 therapy, but who exhibited an increased CXCR3-GS after Tavo treatment, went on to receive additional anti-PD-1 therapy as their immediate next treatment after OMS-I140, and demonstrated a significant clinical response.","CONCLUSIONS: These data show a safe, effective intratumoral therapy that can enhance antigen presentation and recruit CD8 T cells, which are required for the antitumor efficacy.","We identify a Tavo treatment-related gene signature associated with improved outcomes and conversion of nonresponsive tumors, potentially even beyond TNBC."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"31699709","Document":["Given its ability to induce both humoral and cellular immune responses, NY-ESO-1 has been considered a suitable antigen for a cancer vaccine.","Despite promising results from early-phase clinical studies in patients with melanoma, NY-ESO-1 vaccine immunotherapy has not been widely investigated in larger trials; consequently, many questions remain as to the optimal vaccine formulation, predictive biomarkers, and sequencing and timing of vaccines in melanoma treatment.","We conducted an adjuvant phase I\/II clinical trial in high-risk resected melanoma to optimize the delivery of poly-ICLC, a TLR-3\/MDA-5 agonist, as a component of vaccine formulation.","A phase I dose-escalation part was undertaken to identify the MTD of poly-ICLC administered in combination with NY-ESO-1 and montanide.","This was followed by a randomized phase II part investigating the MTD of poly-ICLC with NY-ESO-1 with or without montanide.","The vaccine regimens were generally well tolerated, with no treatment-related grade 3\/4 adverse events.","Both regimens induced integrated NY-ESO-1-specific CD4+ T-cell and humoral responses.","CD8+ T-cell responses were mainly detected in patients receiving montanide.","T-cell avidity toward NY-ESO-1 peptides was higher in patients vaccinated with montanide.","In conclusion, NY-ESO-1 protein in combination with poly-ICLC is safe, well tolerated, and capable of inducing integrated antibody and CD4+ T-cell responses in most patients.","Combination with montanide enhances antigen-specific T-cell avidity and CD8+ T-cell cross-priming in a fraction of patients, indicating that montanide contributes to the induction of specific CD8+ T-cell responses to NY-ESO-1."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"34984539","Document":["Despite recent advance in immunotherapy agents, safe new therapies that enhance the effects of immune checkpoint inhibitors are still required to develop.","We previously demonstrated that hemagglutinating virus of Japan-envelope (HVJ-E) induced not only direct tumor cell death but also antitumor immunity through the activation of T and natural killer (NK) cells, thereafter, developed a manufacturing process of HVJ-E (GEN0101) for clinical use.","We here performed a phase Ia clinical trial of intratumoral GEN0101 administration in six patients with stage IIIC or IV malignant melanoma.","The primary aim was to evaluate the safety and tolerability of GEN0101, and the secondary aim was to examine the objective tumor response.","Patients were separated into two groups (n\u2009=\u20093 each) and received a low dose of 30,000 and high dose of 60,000 mNAU of GEN0101.","All patients completed a two-week follow-up evaluation without severe adverse events.","The overall response rate was 33% (2 of 6), with 2 partial responses in the high-dose group and 2 with stable disease, and 2 with progressive disease in the low-dose group.","Local complete or partial responses were observed in 11 of 18 (61%) target lesions.","One patient demonstrated shrinkage of lung metastases after the treatment.","The activity of NK cells and interferon-\u03b3 levels were increased in the circulation, indicating augmentation of antitumor immunity by GEN0101.","This trial showed not only the safety and tolerability but also the significant antitumor effect of GEN0101, suggesting that GEN0101 might be a promising new drug for patients with advanced melanoma."],"Aspect":"s","Summary":"All patients completed a two-week follow-up evaluation without severe adverse events.","Indexes":[5],"Sentences":["All patients completed a two-week follow-up evaluation without severe adverse events."],"Revise":false}
{"PMID":"31358540","Document":["PURPOSE: Atezolizumab [anti-programmed death-ligand 1 (PD-L1)] selectively targets PD-L1 to block its interaction with receptors programmed death 1 and B7.1, thereby reinvigorating antitumor T-cell activity.","We evaluated the long-term safety and activity of atezolizumab, along with biological correlates of clinical activity endpoints, in a cohort of patients with melanoma in an ongoing phase Ia study (NCT01375842).","PATIENTS AND METHODS: Patients with unresectable or metastatic melanoma were enrolled to receive atezolizumab 0.1 to 20 mg\/kg or \u226510 mg\/kg every 3 weeks.","Primary study objectives were safety and tolerability.","Secondary objectives included investigator-assessed efficacy measures; pharmacodynamic and predictive biomarkers of antitumor activity were explored.","RESULTS: Forty-five patients were enrolled and were evaluable for safety.","Most treatment-related adverse events (AE) were grade 1\/2 (60%).","Fatigue (44%), pruritus (20%), pyrexia (18%), and rash (18%) were the most common treatment-related AEs of any grade.","No treatment-related deaths occurred.","Overall response rate was 30% among 43 efficacy- evaluable patients, with a median duration of response of 62 months [95% CI, 35-not estimable (NE)].","Clinically meaningful long-term survival was observed, with a median overall survival of 23 months (95% CI, 9-66).","Baseline biomarkers of tumor immunity [PD-L1 expression on immune cells, T effector (Teff), and antigen presentation gene signatures) and tumor mutational burden (TMB) were associated with improved response, progression-free survival, and overall survival.","CONCLUSIONS: Atezolizumab was well tolerated, with durable responses and survival in patients with melanoma.","PD-L1 expression, TMB, and Teff signatures may indicate improved benefit with atezolizumab in these patients."],"Aspect":"i","Summary":"Patients with unresectable or metastatic melanoma were enrolled to receive atezolizumab at varying dosages every 3 weeks to evaluate its safety and tolerability.","Indexes":[2,3],"Sentences":["PATIENTS AND METHODS: Patients with unresectable or metastatic melanoma were enrolled to receive atezolizumab 0.1 to 20 mg\/kg or \u226510 mg\/kg every 3 weeks.","Primary study objectives were safety and tolerability."],"Revise":false}
{"PMID":"35021863","Document":["Background: Liver metastases from uveal melanoma carry a very poor prognosis.","Hepatic artery infusions with Yttrium-90 (90Y) resin microspheres have some activity in this disease, and radiation and immunotherapy may be synergistic.","The primary objective of this study was to determine the safety and tolerability of sequential 90Y resin microspheres and immunotherapy with ipilimumab and nivolumab in metastatic uveal melanoma.","Materials and Methods: Twenty-six patients with uveal melanoma with hepatic metastases were entered into a pilot study.","Treatment consisted of two infusions of 90Y resin microspheres, one to each lobe of the liver, followed in 2-4 weeks by immunotherapy with ipilimumab and nivolumab every 3 weeks for four doses, then maintenance immunotherapy with nivolumab alone.","Results: Initial dosing of both 90Y and immunotherapy resulted in excessive toxicity.","With decreasing the dosage of 90Y to limit the normal liver dose to 35Gy and lowering the ipilimumab dose to 1\u2009mg\/kg, the toxicity was tolerable, with no apparent change in efficacy.","There was one complete and four confirmed partial responses, for an objective response rate of 20% and a disease control rate of 68%.","The median progression-free survival was 5.5 months (95% confidence interval [CI]: 1.3-9.7 months), with a median overall survival of 15 months (95% CI: 9.7-20.1 months).","Conclusions: With dose reductions, sequential therapy with 90Y and immunotherapy with ipilimumab and nivolumab is safe and tolerable, and has activity in metastatic uveal melanoma.","These results justify a controlled trial to demonstrate whether 90Y resin microspheres add to the utility of combination immunotherapy in this disease.","Clinical Trial Registration number: NCT02913417."],"Aspect":"i","Summary":"The study involved treating patients with uveal melanoma with hepatic metastases using two infusions of 90Y resin microspheres followed by immunotherapy with ipilimumab and nivolumab.","Indexes":[4],"Sentences":["Treatment consisted of two infusions of 90Y resin microspheres, one to each lobe of the liver, followed in 2-4 weeks by immunotherapy with ipilimumab and nivolumab every 3 weeks for four doses, then maintenance immunotherapy with nivolumab alone."],"Revise":false}
{"PMID":"36800443","Document":["SGN-CD228A is an investigational antibody-drug conjugate (ADC) directed to melanotransferrin (CD228, MELTF, MFI2, p97), a cell-surface protein first identified in melanoma.","SGN-CD228A consists of a humanized antibody, hL49, with high specificity and affinity for CD228 that is stably conjugated to 8 molecules of the clinically validated microtubule-disrupting agent monomethyl auristatin E (MMAE) via a novel glucuronide linker.","We performed comprehensive IHC studies, which corroborated published RNA sequencing data and confirmed low CD228 expression in normal tissues and high expression in several cancers, including melanoma, squamous non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), colorectal cancer, and pancreatic cancer.","SGN-CD228A was efficiently internalized in various tumor cell types, and its cytotoxic activity was dependent on CD228 expression and internalization and intrinsic sensitivity to the MMAE payload.","Compared with the valine-citrulline dipeptide linker, the novel glucuronide linker increased the cellular retention of MMAE in vitro and conferred improved antitumor activity against melanoma cell lines in vitro and in vivo.","In addition, SGN-CD228A was active across melanoma, TNBC, and NSCLC cell line- and patient-derived xenograft models with heterogeneous antigen expression.","In vivo, CD228 expression was important for response to SGN-CD228A but was not well correlated across all tumor types, suggesting that other factors associated with ADC activity are important.","Overall, SGN-CD228A is a CD228-directed, investigational ADC that employs innovative technology and has compelling preclinical antitumor activity.","SGN-CD228A is investigated in a Phase I clinical trial (NCT04042480) in patients with advanced solid tumors."],"Aspect":"i","Summary":"The study investigated the efficacy of SGN-CD228A, an antibody-drug conjugate targeting CD228, in various cancer types using in vitro and in vivo models, including a Phase I clinical trial in patients with advanced solid tumors.","Indexes":[0,4,5,8],"Sentences":["SGN-CD228A is an investigational antibody-drug conjugate (ADC) directed to melanotransferrin (CD228, MELTF, MFI2, p97), a cell-surface protein first identified in melanoma.","Compared with the valine-citrulline dipeptide linker, the novel glucuronide linker increased the cellular retention of MMAE in vitro and conferred improved antitumor activity against melanoma cell lines in vitro and in vivo.","In addition, SGN-CD228A was active across melanoma, TNBC, and NSCLC cell line- and patient-derived xenograft models with heterogeneous antigen expression.","SGN-CD228A is investigated in a Phase I clinical trial (NCT04042480) in patients with advanced solid tumors."],"Revise":false}
{"PMID":"37738028","Document":["The treatment of metastatic uveal melanoma remains a major clinical challenge.","Procaspase-3, a proapoptotic protein and precursor to the key apoptotic executioner caspase-3, is overexpressed in a wide range of malignancies, and the drug PAC-1 leverages this overexpression to selectively kill cancer cells.","Herein, we investigate the efficacy of PAC-1 against uveal melanoma cell lines and report the synergistic combination of PAC-1 and entrectinib.","This preclinical activity, tolerability data in mice, and the known clinical effectiveness of these drugs in human cancer patients led to a small Phase 1b study in patients with metastatic uveal melanoma.","The combination of PAC-1 and entrectinib was tolerated with no treatment-related grade \u22653 toxicities in these patients.","The pharmacokinetics of entrectinib were not affected by PAC-1 treatment.","In this small and heavily pretreated initial cohort, stable disease was observed in four out of six patients, with a median progression-free survival of 3.38 months (95% CI 1.6-6.5 months).","This study is an initial demonstration that the combination of PAC-1 and entrectinib may warrant further clinical investigation.","Clinical trial registration: Clinical Trials.gov: NCT04589832."],"Aspect":"m","Summary":"The study investigated the drugs PAC-1 and entrectinib, used in combination for the treatment of metastatic uveal melanoma.","Indexes":[2,3,4],"Sentences":["Herein, we investigate the efficacy of PAC-1 against uveal melanoma cell lines and report the synergistic combination of PAC-1 and entrectinib.","This preclinical activity, tolerability data in mice, and the known clinical effectiveness of these drugs in human cancer patients led to a small Phase 1b study in patients with metastatic uveal melanoma.","The combination of PAC-1 and entrectinib was tolerated with no treatment-related grade \u22653 toxicities in these patients."],"Revise":false}
{"PMID":"32000743","Document":["BACKGROUND: People increase their risk of melanoma unless they are protected from the harmful effects of sun exposure during childhood and adolescence.","We aimed to assess the feasibility of a three-component sun protection intervention- presentation, action planning, and SMS messages - and trial parameters.","METHODS: This feasibility wait-list trial was conducted in the United Kingdom in 2018.","Students aged 13-15\u2009years were eligible.","Feasibility outcomes were collected for recruitment rates; data availability rates for objective measurements of melanin and erythema using a Mexameter and self-reported sunburn occurrences, severity and body location, tanning, sun protection behaviours and Skin Self-Examination (SSE) collected before (baseline) and after the school summer holidays (follow-up); intervention reach, adherence, perceived impact and acceptability.","Quantitative data were analysed using descriptive statistics; qualitative data were analysed thematically.","RESULTS: Five out of eight schools expressing an interest in participating with four allocated to act as intervention and one control.","Four parents\/carers opted their child out of the study.","Four hundred and eighty-seven out of 724 students on the school register consented to the study at baseline (67%).","Three hundred and eighty-five were in intervention group schools.","Objective skin measurements were available for 255 (66%) of the intervention group at baseline and 237 (61%) of the group at follow up.","Melanin increased; erythema decreased.","Complete self-report data were available for 247 (64%) students in the intervention group.","The number of students on the school register who attended the presentation and given the booklet was 379 (98%) and gave their mobile phone number was 155 (40%).","No intervention component was perceived as more impactful on sun protection behaviours.","Adolescents did not see the relevance of sun protection in the UK or for their age group.","CONCLUSIONS: This is the first study to use a Mexameter to measure skin colour in adolescents.","Erythema (visible redness) lasts no more than three days and its measurement before and after a six week summer holiday may not yield relevant or meaningful data.","A major challenge is that adolescents do not see the relevance of sun protection and SSE.","TRIAL REGISTRATION: International Standard Randomised Controlled Trial Number ISRCTN11141528.","Date registered 0\/2\/03\/2018; last edited 31\/05\/2018.","Retrospectively registered."],"Aspect":"a","Summary":"The study aimed to assess the feasibility of a three-component sun protection intervention and trial parameters.","Indexes":[1],"Sentences":["We aimed to assess the feasibility of a three-component sun protection intervention- presentation, action planning, and SMS messages - and trial parameters."],"Revise":false}
{"PMID":"36763627","Document":["BACKGROUND: Melanoma survivors are at increased risk of developing a second primary melanoma; however, some report sub-optimal sun behaviors and sunburns.","We tested the effectiveness of a wearable device with ultraviolet radiation (UVR)-sensing technology to improve sun behaviors and reduce sunburns in cutaneous melanoma survivors.","MATERIALS AND METHODS: We conducted a randomized controlled trial using Shade 2, a commercially available wrist device that measures UVR.","The intervention group received the device and mobile application notifications about their exposure and prompts to use sunscreen.","The control group received the device and a separate research mobile application without information about their exposure or notifications.","Participants wore the device for 12 weeks and self-reported sun behaviors before, during, and after the intervention.","The primary outcome was a composite score of sun protection behaviors at week 12.","RESULTS: 386 participants were randomized (186 control, 182 intervention).","Most were female and 5+ years past their first melanoma diagnosis.","The average age was 56 years.","Most (93%) completed the study, though 40% experienced device issues.","No meaningful differences were observed in self-reported sun protection behaviors at week 12 (controls 3.0\u00b10.5 vs. intervention 2.9\u00b10.5, p = 0.06), any sunburn during the intervention period (controls 14.4% vs. intervention 12.7%, p = 0.75), or average daily objective UVR exposure (controls median 87 vs. intervention 83 J\/m2, p = 0.43).","CONCLUSION: Wearing a device that measured and alerted melanoma survivors to UVR exposure did not result in different sun behaviors, exposure, or sunburns relative to controls.","The technology needs refinement before further attempts to assess the effectiveness of self-monitoring UVR exposure.","CLINICAL TRIALS REGISTRATION: NCT03927742."],"Aspect":"m","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"33361337","Document":["BACKGROUND: In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib (triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and trametinib (doublet) without reaching statistical significance.","Mature results on PFS, duration of response (DOR), and overall survival (OS) are reported.","METHODS: The double-blind, phase 2 part of KEYNOTE-022 enrolled patients with previously untreated BRAFV600E\/K-mutated advanced melanoma from 22 sites in seven countries.","Patients were randomly assigned 1:1 to intravenous pembrolizumab (200 mg every 3 weeks) or placebo plus dabrafenib (150 mg orally two times per day) and trametinib (2 mg orally one time a day).","Primary endpoint was PFS.","Secondary endpoints were objective response rate, DOR, and OS.","Efficacy was assessed in the intention-to-treat population, and safety was assessed in all patients who received at least one dose of study drug.","This analysis was not specified in the protocol.","RESULTS: Between November 30, 2015 and April 24, 2017, 120 patients were randomly assigned to triplet (n=60) or doublet (n=60) therapy.","With 36.6 months of follow-up, median PFS was 16.9 months (95% CI 11.3 to 27.9) with triplet and 10.7 months (95% CI 7.2 to 16.8) with doublet (HR 0.53; 95% CI 0.34 to 0.83).","With triplet and doublet, respectively, PFS at 24 months was 41.0% (95% CI 27.4% to 54.2%) and 16.3% (95% CI 8.1% to 27.1%); median DOR was 25.1 months (95% CI 14.1 to not reached) and 12.1 months (95% CI 6.0 to 15.7), respectively.","Median OS was not reached with triplet and was 26.3 months with doublet (HR 0.64; 95% CI 0.38 to 1.06).","With triplet and doublet, respectively, OS at 24 months was 63.0% (95% CI 49.4% to 73.9%) and 51.7% (95% CI 38.4% to 63.4%).","Grade 3-5 treatment-related adverse events (TRAEs) occurred in 35 patients (58%, including one death) receiving triplet and 15 patients (25%) receiving doublet.","CONCLUSION: In BRAFV600E\/K-mutant advanced melanoma, pembrolizumab plus dabrafenib and trametinib substantially improved PFS, DOR, and OS with a higher incidence of TRAEs.","Interpretation of these results is limited by the post hoc nature of the analysis."],"Aspect":"p","Summary":"The study enrolled 120 patients with previously untreated BRAFV600E\/K-mutated advanced melanoma, randomly assigned to triplet (n=60) or doublet (n=60) therapy.","Indexes":[2,8],"Sentences":["METHODS: The double-blind, phase 2 part of KEYNOTE-022 enrolled patients with previously untreated BRAFV600E\/K-mutated advanced melanoma from 22 sites in seven countries.","RESULTS: Between November 30, 2015 and April 24, 2017, 120 patients were randomly assigned to triplet (n=60) or doublet (n=60) therapy."],"Revise":false}
{"PMID":"32946353","Document":["PURPOSE: We conducted the phase III double-blind European Organisation for Research and Treatment of Cancer (EORTC) 1325\/KEYNOTE-054 trial to evaluate pembrolizumab versus placebo in patients with resected high-risk stage III melanoma.","On the basis of 351 recurrence-free survival (RFS) events at a 1.25-year median follow-up, pembrolizumab prolonged RFS (hazard ratio [HR], 0.57; P < .0001) compared with placebo.","This led to the approval of pembrolizumab adjuvant treatment by the European Medicines Agency and US Food and Drug Administration.","Here, we report an updated RFS analysis at the 3.05-year median follow-up.","PATIENTS AND METHODS: A total of 1,019 patients with complete lymph node dissection of American Joint Committee on Cancer Staging Manual (seventh edition; AJCC-7), stage IIIA (at least one lymph node metastasis > 1 mm), IIIB, or IIIC (without in-transit metastasis) cutaneous melanoma were randomly assigned to receive pembrolizumab at a flat dose of 200 mg (n = 514) or placebo (n = 505) every 3 weeks for 1 year or until disease recurrence or unacceptable toxicity.","The two coprimary end points were RFS in the overall population and in those with programmed death-ligand 1 (PD-L1)-positive tumors.","RESULTS: Pembrolizumab (190 RFS events) compared with placebo (283 RFS events) resulted in prolonged RFS in the overall population (3-year RFS rate, 63.7% v 44.1% for pembrolizumab v placebo, respectively; HR, 0.56; 95% CI, 0.47 to 0.68) and in the PD-L1-positive tumor subgroup (HR, 0.57; 99% CI, 0.43 to 0.74).","The impact of pembrolizumab on RFS was similar in subgroups, in particular according to AJCC-7 and AJCC-8 staging, and BRAF mutation status (HR, 0.51 [99% CI, 0.36 to 0.73] v 0.66 [99% CI, 0.46 to 0.95] for V600E\/K v wild type).","CONCLUSION: In resected high-risk stage III melanoma, pembrolizumab adjuvant therapy provided a sustained and clinically meaningful improvement in RFS at 3-year median follow-up.","This improvement was consistent across subgroups."],"Aspect":"i","Summary":"The study conducted a phase III double-blind trial evaluating pembrolizumab versus placebo in patients with resected high-risk stage III melanoma, with patients randomly assigned to receive pembrolizumab or placebo every 3 weeks for 1 year or until disease recurrence or unacceptable toxicity.","Indexes":[0,4],"Sentences":["PURPOSE: We conducted the phase III double-blind European Organisation for Research and Treatment of Cancer (EORTC) 1325\/KEYNOTE-054 trial to evaluate pembrolizumab versus placebo in patients with resected high-risk stage III melanoma.","PATIENTS AND METHODS: A total of 1,019 patients with complete lymph node dissection of American Joint Committee on Cancer Staging Manual (seventh edition; AJCC-7), stage IIIA (at least one lymph node metastasis > 1 mm), IIIB, or IIIC (without in-transit metastasis) cutaneous melanoma were randomly assigned to receive pembrolizumab at a flat dose of 200 mg (n = 514) or placebo (n = 505) every 3 weeks for 1 year or until disease recurrence or unacceptable toxicity."],"Revise":false}
{"PMID":"34088741","Document":["BACKGROUND: Despite significant progress with antiprogrammed cell death protein 1 (PD-1) therapy, a substantial fraction of metastatic melanoma patients show upfront therapy resistance.","Biomarkers for outcome are missing and the association of baseline immune function and clinical outcome remains to be determined.","We assessed the in vitro nonspecific stimulation of immune response at baseline and during anti-PD-1 therapy for metastatic melanoma.","METHODS: Previously untreated metastatic melanoma patients received nivolumab and radiotherapy as part of the multicentric phase II trial NIRVANA (NCT02799901).","The levels of Th1, Th2 and Th17 cytokines on in vitro non-specific stimulation of innate and adaptive immune cells were measured in patient sera before treatment, and at week 2 and week 6 after the beginning of the treatment, and correlated with tumorous response, progression-free survival (PFS) and occurrence of immune-related adverse events (irAEs).","The results in melanoma patients were compared with those of a cohort of 9 sex and age-matched healthy donors.","RESULTS: Seventeen patients were enrolled in this ancillary study.","Median follow-up was 16 months (2.2-28.4).","The 12-month PFS rate was 67.7%.","The incidence of irAEs of any grade was 58.8%.","Without in vitro stimulation no differences in cytokines levels were observed between responders and non-responders.","On in vitro stimulation, metastatic patients had lower Th1 cytokine levels than healthy donors at baseline for tumor necrosis factor-\u03b1 and interferon-\u03b3 (IFN-\u03b3) (1136\u2009pg\/mL vs 5558\u2009pg\/mL, p<0.0001; and 3894\u2009pg\/mL vs 17\u2009129\u2009pg\/mL, p=0.02, respectively).","Responders exhibited increasing cytokine levels from baseline to week 6.","Non-responders had lower interleukin 17A (IL-17A) levels at baseline than responders (7\u2009pg\/mL vs 32\u2009pg\/mL, p=0.03), and lower IFN-\u03b3 levels at week 6 (3.3\u2009ng\/mL vs 14.5\u2009ng\/mL, p=0.03).","A lower level of IL-17A at week 2 and a lower level of IFN-\u03b3 at week 6 correlated with worse PFS (p=0.04\u2009and p=0.04 respectively).","At baseline, patients who developed irAEs had higher IL-6 levels (19.3\u2009ng\/mL vs 9.2\u2009ng\/mL, p=0.03) and higher IL-17A levels (52.5\u2009pg\/mL vs 2.5\u2009pg\/mL, p=0.009) than those without irAEs.","CONCLUSIONS: Our findings indicate that cytokine levels after in vitro non-specific stimulation could be a promising biomarker to predict the outcome of PD-1 inhibition therapy."],"Aspect":"o","Summary":"Cytokine levels after in vitro non-specific stimulation correlated with PD-1 therapy outcomes in metastatic melanoma, with responders showing increased cytokine levels, non-responders exhibiting lower IL-17A and IFN-\u03b3 levels, and baseline IL-6 and IL-17A levels predicting irAE development.","Indexes":[12,13,15,16],"Sentences":["Responders exhibited increasing cytokine levels from baseline to week 6.","Non-responders had lower interleukin 17A (IL-17A) levels at baseline than responders (7\u2009pg\/mL vs 32\u2009pg\/mL, p=0.03), and lower IFN-\u03b3 levels at week 6 (3.3\u2009ng\/mL vs 14.5\u2009ng\/mL, p=0.03).","At baseline, patients who developed irAEs had higher IL-6 levels (19.3\u2009ng\/mL vs 9.2\u2009ng\/mL, p=0.03) and higher IL-17A levels (52.5\u2009pg\/mL vs 2.5\u2009pg\/mL, p=0.009) than those without irAEs.","CONCLUSIONS: Our findings indicate that cytokine levels after in vitro non-specific stimulation could be a promising biomarker to predict the outcome of PD-1 inhibition therapy."],"Revise":true}
{"PMID":"36445410","Document":["BACKGROUND: CAPRA (NCT02565992) evaluated Coxsackievirus A21 (V937)\u2009+\u2009pembrolizumab for metastatic\/unresectable stage IIIB-IV melanoma.","METHODS: Patients received intratumoral V937 on days 1, 3, 5, and 8 (then every 3\u00a0weeks [Q3W]) and intravenous pembrolizumab 2\u00a0mg\/kg Q3W from day 8.","Primary endpoint was safety.","RESULTS: Median time from first dose to data cutoff was 32.0\u00a0months.","No dose-limiting toxicities occurred; 14% (5\/36) of patients experienced grade 3\u20125 treatment-related adverse events.","Objective response rate was 47% (complete response, 22%).","Among 17 responders, 14 (82%) had responses\u2009\u2265\u20096\u00a0months.","Among 8 patients previously treated with immunotherapy, 3 responded (1 complete, 2 partial).","Responses were associated with increased serum CXCL10 and CCL22, suggesting viral replication contributes to antitumor immunity.","For responders versus nonresponders, there was no difference in baseline tumor PD-L1 expression, ICAM1 expression, or CD3+ infiltrates.","Surprisingly, the baseline cell density of CD3+CD8- T cells in the tumor microenvironment was significantly lower in responders compared with nonresponders (P\u2009=\u20090.0179).","CONCLUSIONS: These findings suggest responses to this combination may be seen even in patients without a typical \"immune-active\" microenvironment.","TRIAL REGISTRATION NUMBER: NCT02565992."],"Aspect":"o","Summary":"The combination treatment demonstrated a 47% objective response rate (22% complete responses), with durable responses in 82% of responders lasting \u22656 months, including activity in patients previously treated with immunotherapy, and associated with increased serum CXCL10 and CCL22 levels.","Indexes":[5,6,7,8],"Sentences":["Objective response rate was 47% (complete response, 22%).","Among 17 responders, 14 (82%) had responses\u2009\u2265\u20096\u00a0months.","Among 8 patients previously treated with immunotherapy, 3 responded (1 complete, 2 partial).","Responses were associated with increased serum CXCL10 and CCL22, suggesting viral replication contributes to antitumor immunity."],"Revise":true}
{"PMID":"36516188","Document":["PURPOSE: Androgen deprivation regenerates the thymus in adults, expanding of T-cell receptor V \u03b2 repertoire in blood and lymphoid organs and tumor-infiltrating lymphocytes in human prostate tumors.","In melanoma murine models, androgen receptor promotes metastases and androgen blockade potentiates antitumor vaccine efficacy.","This phase I study evaluated the safety, efficacy, and pharmocodynamics of androgen deprivation with the gonadotropin releasing hormone (GnRH) agonist triptorelin combined with nivolumab in male patients with melanoma resistant to anti-PD-1.","PATIENTS AND METHODS: Adult male patients with advanced melanoma who progressed under anti-PD-1 containing regimens received triptorelin 3.75 mg every 4 weeks, nivolumab 3 mg\/kg every 2 weeks, and bicalutamide 50 mg once daily during the first 28 days.","Tumor response was first assessed after 3 months; adverse events (AE) were monitored throughout the study.","T-cell receptor excision circles (TREC), a biomarker of thymus activity, were explored throughout the study.","RESULTS: Of 14 patients, 4 were locally advanced and 10 had distant metastases.","There were no grade 4 or 5 AEs.","Five grade three AEs were reported in 4 patients.","According to RECIST v1.1, best overall response was partial response (PR) in one patient with a pancreas metastasis, stable disease (SD) in 5 patients, and progressive disease in 8 patients.","According to iRECIST, a second PR occurred after an initial pseudoprogression, TRECs increased in 2 patients, one with PR who also had an increase in TILs, and the second with SD.","CONCLUSIONS: This combination was well tolerated.","Disease control was obtained in 42.8% (RECIST) and 50% (iRECIST).","The evidence for thymus rejuvenation was limited."],"Aspect":"a","Summary":"The study aims to evaluate the safety, efficacy, and pharmacodynamics of androgen deprivation with the GnRH agonist triptorelin combined with nivolumab in male patients with melanoma resistant to anti-PD-1.","Indexes":[2],"Sentences":["This phase I study evaluated the safety, efficacy, and pharmocodynamics of androgen deprivation with the gonadotropin releasing hormone (GnRH) agonist triptorelin combined with nivolumab in male patients with melanoma resistant to anti-PD-1."],"Revise":false}
{"PMID":"34199802","Document":["Patients with newly resected stage II melanoma (n = 104) were randomized to receive adjuvant vitamin D3 (100,000 IU every 50 days) or placebo for 3 years to investigate vitamin D3 protective effects on developing a recurrent disease.","Median age at diagnosis was 50 years, and 43% of the patients were female.","Median serum 25-hydroxy vitamin D (25OHD) level at baseline was 18 ng\/mL, interquartile range (IQ) was 13-24 ng\/mL, and 80% of the patients had insufficient vitamin D levels.","We observed pronounced increases in 25OHD levels after 4 months in the active arm (median 32.9 ng\/mL; IQ range 25.9-38.4) against placebo (median 19.05 ng\/mL; IQ range 13.0-25.9), constantly rising during treatment.","Remarkably, patients with low Breslow score (<3 mm) had a double increase in 25OHD levels from baseline, whereas patients with Breslow score \u22653 mm had a significantly lower increase over time.","After 12 months, subjects with low 25OHD levels and Breslow score \u22653 mm had shorter disease-free survival (p = 0.02) compared to those with Breslow score <3 mm and\/or high levels of 25OHD.","Adjusting for age and treatment arm, the hazard ratio for relapse was 4.81 (95% CI: 1.44-16.09, p = 0.011).","Despite the evidence of a role of 25OHD in melanoma prognosis, larger trials with vitamin D supplementation involving subjects with melanoma are needed."],"Aspect":"d","Summary":"The treatment duration in the trial was 3 years.","Indexes":[0],"Sentences":["Patients with newly resected stage II melanoma (n = 104) were randomized to receive adjuvant vitamin D3 (100,000 IU every 50 days) or placebo for 3 years to investigate vitamin D3 protective effects on developing a recurrent disease."],"Revise":false}
{"PMID":"34650833","Document":["Combination immunotherapy with sequential administration may enhance metastatic melanoma (MM) patients with long-term disease control.","High Dose Aldesleukin\/Recombinant Interleukin-2 (HD rIL-2) and ipilimumab (IPI) offer complementary mechanisms against MM.","This phase IV study assessed the sequenced use of HD rIL-2 and IPI in MM patients.","Eligible Stage IV MM patients were randomized to treatment with either two courses of HD rIL-2(600,000 IU\/kg) followed by four doses of IPI 3 mg\/kg or vice-versa.","The primary objective was to compare one-year overall survival (OS) with historical control (46%, Hodi et al., NEJM 2010).","Secondary objectives were 1-year progression-free survival (PFS), objective response rate (ORR), and adverse events (AEs) profile.","Evaluable Population (EP) included patients who received at least 50% of planned treatment with each drug.","Thirteen and 16 patients were randomized to receive HD rIL-2 first, and IPI first, respectively.","One-year OS rate was 75% for intention to treat population.","Eighteen patients were included in EP, 8 in HD rIL-2, 10 in IPI first arm.","In EP, 1-year OS, PFS and ORR rates were 87%, 68%, and 50%, respectively.","The frequency of AEs was similar in both arms with 13 patients experiencing Grade 3 or higher AEs, 3 resulting in the end of study participation.","There was one HD rIL-2-related death, from cerebral hemorrhage due to thrombocytopenia.","In this study with small sample size, HD rIL-2 and IPI were safe to administer sequentially in MM patients and showed more than additive effects.","1-year OS was superior to that of IPI alone from historical studies."],"Aspect":"s","Summary":"The frequency of adverse events (AEs) was similar in both treatment arms, with 13 patients experiencing Grade 3 or higher AEs, leading to the end of study participation for 3 patients, and one HD rIL-2-related death from cerebral hemorrhage due to thrombocytopenia.","Indexes":[11,12],"Sentences":["The frequency of AEs was similar in both arms with 13 patients experiencing Grade 3 or higher AEs, 3 resulting in the end of study participation.","There was one HD rIL-2-related death, from cerebral hemorrhage due to thrombocytopenia."],"Revise":false}
{"PMID":"32605909","Document":["PURPOSE: Combination therapy with reduced-dose programmed death 1 inhibitor plus standard-dose cytotoxic T-lymphocyte-associated antigen 4 inhibitor demonstrated efficacy, but substantial toxicity, in melanoma.","We present long-term results of part 1B of KEYNOTE-029, which assessed safety and efficacy of standard-dose pembrolizumab plus reduced-dose ipilimumab in advanced melanoma.","PATIENTS AND METHODS: Part 1B was an expansion cohort of the open-label, phase Ib portion of KEYNOTE-029.","Eligible patients had advanced melanoma and no previous immune checkpoint inhibitor therapy.","Patients received pembrolizumab 2 mg\/kg (amended to 200 mg) every 3 weeks plus ipilimumab 1 mg\/kg every 3 weeks (four cycles), then pembrolizumab alone for up to 2 years.","Primary end point was safety; secondary end points included objective response rate (ORR), progression-free survival (PFS), duration of response (DOR), and overall survival (OS).","RESULTS: A total of 153 patients received at least one dose of pembrolizumab plus ipilimumab.","At a median follow-up of 36.8 months, 71.9% had received four doses of ipilimumab and 30.7% had completed 2 years of pembrolizumab; 26.1% completed both treatments.","Treatment-related adverse events occurred in 96.1% (47.1% grade 3\/4; no deaths), leading to discontinuation of one or both study drugs in 35.9%.","ORR was 62.1% with 42 (27.5%) complete and 53 (34.6%) partial responses.","Median DOR was not reached; 36-month ongoing response rate was 84.2%.","Median PFS and OS were not reached; 36-month rates were 59.1% and 73.4%, respectively.","CONCLUSIONS: Standard-dose pembrolizumab plus reduced-dose ipilimumab demonstrated robust antitumor activity, durable response, and favorable long-term survival with manageable toxicity."],"Aspect":"a","Summary":"The study aims to assess the safety and efficacy of standard-dose pembrolizumab plus reduced-dose ipilimumab in patients with advanced melanoma.","Indexes":[1],"Sentences":["We present long-term results of part 1B of KEYNOTE-029, which assessed safety and efficacy of standard-dose pembrolizumab plus reduced-dose ipilimumab in advanced melanoma."],"Revise":false}
{"PMID":"32240562","Document":["LESSONS LEARNED: This study showed that carefully selected patients with locally advanced and metastatic forms of malignant melanoma and renal cell carcinoma could potentially have long-term disease control with a tag-7 gene-modified tumor cells-based vaccine.","Randomized clinical trials in patients whose tumors produce low amounts of immunosuppressive factors are needed to confirm this hypothesis in both the adjuvant and metastatic settings.","BACKGROUND: Immunotherapy may produce long-lasting effects on survival and toxicity.","The magnitude of efficacy may be dependent on immune factors.","We analyzed the results of a phase I\/II study of a tag-7 gene-modified tumor cells-based vaccine (GMV) in patients with malignant melanoma (MM) or renal cell carcinoma (RCC) with biomarker analysis of immunosuppressive factors (ISFs) production by their tumor cells.","METHODS: From 2001 to 2014, 80 patients received GMV: 68 with MM and 12 with RCC.","Treatment in the metastatic setting included 61 patients (MM, 51; RCC, 10), and treatment in the adjuvant setting (after complete cytoreduction) included 19 patients (MM, 17; RCC, 2).","Twenty-six patients were stage III (33%), and 54 (67%) were stage IV.","The patients' tumor samples were transferred to culture, transfected with tag-7 gene, and inactivated by radiation.","The produced product was injected subcutaneously every 3\u2009weeks until progression or 2\u2009years of therapy.","ISFs were measured in the supernatants of the tumor cell cultures and used as predictive factors.","RESULTS: No major safety issues or grade 5 adverse events (AEs) were seen.","One grade 4 and two grade 3 AEs were registered.","No AEs were registered in 89.4% of treatment cycles.","No delayed AE was found.","The 5-year overall survival (OS) in the intention-to-treat population was 25.1%.","There were no differences between MM OS and RCC OS (log rank, p = .44).","Median OS in the metastatic setting was 0.7\u2009years and in the adjuvant setting was 3.1\u2009years.","Classification trees were built on the basis of ISF production (Fig.","1).","The median OS was 6.6\u2009years in the favorable prognosis (FP) group (major histocompatibility complex class I polypeptide-related sequence A [MICA] level \u2264582 pg\/mL, n =\u200915) and 4.6 months in the unfavorable (UF) group (MICA level >582 pg\/mL, n =\u200912; p < .0001).","No significant differences were found between classification trees based on ISFs (transforming growth factor \u03b21 [TGF-\u03b21], interleukin-10 [IL-10], and vascular endothelial growth factor [VEGF]).","In patients with stage III-IV MM with FP, median OS was 2.3\u2009years, with 31% patients alive at 10\u2009years (Fig.","2) in the UF group (0.4\u2009years; log rank, p =\u20091.94E-5).","No FP patients received modern immunotherapy.","CONCLUSION: GMV showed high results in carefully selected patients with low ISF (TGF-\u03b21, IL-10, and VEGF) production.","The method should be further investigated in patients with FP."],"Aspect":"d","Summary":"The treatment duration was up to 2 years.","Indexes":[9],"Sentences":["The produced product was injected subcutaneously every 3\u2009weeks until progression or 2\u2009years of therapy."],"Revise":false}
{"PMID":"33355238","Document":["PURPOSE: In this first-in-human phase I study (NCT02132754), we explored MK-4166 [humanized IgG1 agonist mAb targeting glucocorticoid-induced TNF receptor (GITR)] with and without pembrolizumab in advanced solid tumors.","PATIENTS AND METHODS: MK-4166 was tested alone (0.0015-900 mg i.v.","every 3 weeks for four doses) or with pembrolizumab (200 mg i.v.","every 3 weeks for \u226435 doses) in patients with metastatic solid tumors (dose escalation\/confirmation) and advanced melanoma (expansion).","Primary objectives were to evaluate the safety and tolerability and establish the MTD of MK-4166.","Exploratory endpoints were objective response rate (ORR) and T cell-inflamed gene expression profile (GEP) analysis using RNA from baseline tumor samples.","RESULTS: A total of 113 patients were enrolled [monotherapy, n = 48; combination therapy, n = 65 (20 in the expansion)].","Forty-six patients (40.7%) had grade \u22653 adverse events, 9 (8.0%) of which were treatment related.","No treatment-related deaths were observed.","One dose-limiting toxicity event with monotherapy (bladder perforation in patient with neobladder) was considered related to study drug.","MTD was not reached.","MK-4166 pharmacodynamics showed decreased GITR availability on circulating T cells with increasing doses.","One objective response (ORR, 2.2%) was achieved with combination therapy in the dose escalation\/confirmation (n = 45).","In the expansion, 8 of 13 patients with immune checkpoint inhibitor (ICI)-na\u00efve melanoma achieved a response (ORR, 62%; 95% confidence interval, 32-86; 5 complete responses and 3 partial responses).","None of the ICI-pretreated patients (n = 7) responded.","High response rates were observed in ICI-na\u00efve patients irrespective of GEP status.","CONCLUSIONS: MK-4166 900 mg i.v.","every 3 weeks as monotherapy and with pembrolizumab was tolerable.","Responses were observed with combination therapy, mostly in patients with ICI-na\u00efve melanoma."],"Aspect":"o","Summary":"MK-4166 was tolerable as monotherapy and in combination with pembrolizumab, achieving a 62% ORR in ICI-na\u00efve melanoma patients but showing no response in ICI-pretreated patients, with pharmacodynamics indicating decreased GITR availability on circulating T cells with increasing doses.","Indexes":[11,13,14,16,17],"Sentences":["MK-4166 pharmacodynamics showed decreased GITR availability on circulating T cells with increasing doses.","In the expansion, 8 of 13 patients with immune checkpoint inhibitor (ICI)-na\u00efve melanoma achieved a response (ORR, 62%; 95% confidence interval, 32-86; 5 complete responses and 3 partial responses).","None of the ICI-pretreated patients (n = 7) responded.","CONCLUSIONS: MK-4166 900 mg i.v.","every 3 weeks as monotherapy and with pembrolizumab was tolerable."],"Revise":true}
{"PMID":"34813506","Document":["BACKGROUNDNeoantigen-driven recognition and T cell-mediated killing contribute to tumor clearance following adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs).","Yet how diversity, frequency, and persistence of expanded neoepitope-specific CD8+ T cells derived from TIL infusion products affect patient outcome is not fully determined.METHODSUsing barcoded pMHC multimers, we provide a comprehensive mapping of CD8+ T cells recognizing neoepitopes in TIL infusion products and blood samples from 26 metastatic melanoma patients who received ACT.RESULTSWe identified 106 neoepitopes within TIL infusion products corresponding to 1.8% of all predicted neoepitopes.","We observed neoepitope-specific recognition to be virtually devoid in TIL infusion products given to patients with progressive disease outcome.","Moreover, we found that the frequency of neoepitope-specific CD8+ T cells in TIL infusion products correlated with increased survival and that neoepitope-specific CD8+ T cells shared with the infusion product in posttreatment blood samples were unique to responders of TIL-ACT.","Finally, we found that a transcriptional signature for lymphocyte activity within the tumor microenvironment was associated with a higher frequency of neoepitope-specific CD8+ T cells in the infusion product.CONCLUSIONSThese data support previous case studies of neoepitope-specific CD8+ T cells in melanoma and indicate that successful TIL-ACT is associated with an expansion of neoepitope-specific CD8+ T cells.FUNDINGNEYE Foundation; European Research Council; Lundbeck Foundation Fellowship; Carlsberg Foundation."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"38319852","Document":["BACKGROUND: In the previously reported primary analyses of this phase 3 trial, 12 months of adjuvant pembrolizumab resulted in significantly longer recurrence- and distant metastasis-free survival than placebo in patients with resected high-risk stage III melanoma.","To confirm the stability of these benefits, longer-term data were needed.","METHODS: We randomly assigned 1019 patients to receive 200 mg of pembrolizumab or placebo intravenously every 3 weeks for a total of 18 doses (approximately 1 year) and had previously reported data with a 15-, 36-, and 42-month median follow-up.","We now report data at a median follow-up of 4.9 years.","We report a number of outcomes, including recurrence-free survival in the overall population and in the subgroup of patients with cancer who were positive for the programmed death-ligand 1 (PD-L1).","Distant metastasis-free survival was a secondary end point.","RESULTS: In the overall intention-to-treat population, pembrolizumab was still associated with longer recurrence-free survival than placebo (5-year rate of recurrence-free survival, 55.4% [95% confidence interval (CI), 50.8 to 59.8] vs. 38.3% [95% CI, 33.9 to 42.7]; hazard ratio for recurrence or death, 0.61 [95% CI, 0.51 to 0.72]) and a longer distant metastasis-free survival (5-year rate of distant metastasis-free survival, 60.6% [95% CI, 56.0 to 64.9] vs. 44.5% [95% CI, 39.9 to 48.9]; hazard ratio for distant metastasis or death, 0.62 [95% CI, 0.52 to 0.75]).","Similar findings were obtained in the subgroup of 853 patients with PD-L1\u2013positive tumors.","CONCLUSIONS: The 5-year analysis of adjuvant therapy with pembrolizumab resulted in a sustained improvement in the long-term recurrence- and distant metastasis-free survival compared with placebo in patients with resected stage III melanoma.","(Funded by Merck & Co., Inc.; ClinicalTrials.gov number, NCT02362594, and EudraCT number, 2014-004944-37.)"],"Aspect":"a","Summary":"The study aims to confirm the stability of benefits of adjuvant pembrolizumab over placebo in patients with resected high-risk stage III melanoma by evaluating longer-term data.","Indexes":[1],"Sentences":["To confirm the stability of these benefits, longer-term data were needed."],"Revise":false}
{"PMID":"33185716","Document":["Despite knowledge of subsequent melanoma risk and the benefit of sun protection in risk reduction, melanoma survivors often do not engage in adequate sun protection and continue to sunburn at rates similar to individuals without a history of skin cancer.","This novel intensive intervention provided a wearable UV sensor delivering real-time UV exposure with a smartphone and daily text messages.","On days 1-10 (period 1), behavioral facilitation and outcome expectancies messages were provided.","On day 10, participants reviewed and reflected on their daily UV exposure on the previous 10\u00a0days and set goals for improving sun protection.","Then on days 11-21 (period 2) self-efficacy and self-regulation messages were provided.","Sixty melanoma survivors were randomized (1:1) to receive structured or unstructured goal setting queries on day 10.","Controlling for cloudy\/rain conditions with less UV due to weather, there was a time effect with a significant decrease in UV exposure from periods 1-2 [period 1-2, F (59)\u2009=\u200922.60, p\u2009<\u20090.0001].","In this short-term study, melanoma survivors managed their daily UV exposure to stay below their maximum tolerated UV dose.","ClinicalTrials.gov Protocol Record NCT0334796, date of registration Nov 15, 2017."],"Aspect":"o","Summary":"In this short-term study, melanoma survivors significantly decreased their UV exposure from period 1 to period 2, managing to stay below their maximum tolerated UV dose.","Indexes":[6,7],"Sentences":["Controlling for cloudy\/rain conditions with less UV due to weather, there was a time effect with a significant decrease in UV exposure from periods 1-2 [period 1-2, F (59)\u2009=\u200922.60, p\u2009<\u20090.0001].","In this short-term study, melanoma survivors managed their daily UV exposure to stay below their maximum tolerated UV dose."],"Revise":true}
{"PMID":"36668984","Document":["OBJECTIVE: The aim of this study was to develop a pretreatment magnetic resonance imaging (MRI)-based radiomics model for disease-free survival (DFS) prediction in patients with uveal melanoma (UM).","METHODS: We randomly assigned 85 patients with UM into 2 cohorts: training (n = 60) and validation (n = 25).","The radiomics model was built from significant features that were selected from the training cohort by applying a least absolute shrinkage and selection operator to pretreatment MRI scans.","Least absolute shrinkage and selection operator regression and the Cox proportional hazard model were used to construct a radiomics score (rad-score).","Patients were divided into a low- or a high-risk group based on the median of the rad-score.","The Kaplan-Meier analysis was used to evaluate the association between the rad-score and DFS.","A nomogram incorporating the rad-score and MRI features was plotted to individually estimate DFS.","The model's discrimination power was assessed using the concordance index.","RESULTS: The radiomics model with 15 optimal radiomics features based on MRI performed well in stratifying patients into the high- or a low-risk group of DFS in both the training and validation cohorts (log-rank test, P = 0.009 and P = 0.02, respectively).","Age, basal diameter, and height were selected as significant clinical and MRI features.","The nomogram showed good predictive performance with concordance indices of 0.741 (95% confidence interval, 0.637-0.845) and 0.912 (95% confidence interval, 0.847-0.977) in the training and validation cohorts, respectively.","Calibration curves demonstrated good agreement.","CONCLUSION: The developed clinical-radiomics model may be a powerful predictor of the DFS of patients with UM, thereby providing evidence for preoperative risk stratification."],"Aspect":"m","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"32946353","Document":["PURPOSE: We conducted the phase III double-blind European Organisation for Research and Treatment of Cancer (EORTC) 1325\/KEYNOTE-054 trial to evaluate pembrolizumab versus placebo in patients with resected high-risk stage III melanoma.","On the basis of 351 recurrence-free survival (RFS) events at a 1.25-year median follow-up, pembrolizumab prolonged RFS (hazard ratio [HR], 0.57; P < .0001) compared with placebo.","This led to the approval of pembrolizumab adjuvant treatment by the European Medicines Agency and US Food and Drug Administration.","Here, we report an updated RFS analysis at the 3.05-year median follow-up.","PATIENTS AND METHODS: A total of 1,019 patients with complete lymph node dissection of American Joint Committee on Cancer Staging Manual (seventh edition; AJCC-7), stage IIIA (at least one lymph node metastasis > 1 mm), IIIB, or IIIC (without in-transit metastasis) cutaneous melanoma were randomly assigned to receive pembrolizumab at a flat dose of 200 mg (n = 514) or placebo (n = 505) every 3 weeks for 1 year or until disease recurrence or unacceptable toxicity.","The two coprimary end points were RFS in the overall population and in those with programmed death-ligand 1 (PD-L1)-positive tumors.","RESULTS: Pembrolizumab (190 RFS events) compared with placebo (283 RFS events) resulted in prolonged RFS in the overall population (3-year RFS rate, 63.7% v 44.1% for pembrolizumab v placebo, respectively; HR, 0.56; 95% CI, 0.47 to 0.68) and in the PD-L1-positive tumor subgroup (HR, 0.57; 99% CI, 0.43 to 0.74).","The impact of pembrolizumab on RFS was similar in subgroups, in particular according to AJCC-7 and AJCC-8 staging, and BRAF mutation status (HR, 0.51 [99% CI, 0.36 to 0.73] v 0.66 [99% CI, 0.46 to 0.95] for V600E\/K v wild type).","CONCLUSION: In resected high-risk stage III melanoma, pembrolizumab adjuvant therapy provided a sustained and clinically meaningful improvement in RFS at 3-year median follow-up.","This improvement was consistent across subgroups."],"Aspect":"a","Summary":"The study aims to evaluate pembrolizumab versus placebo in patients with resected high-risk stage III melanoma.","Indexes":[0],"Sentences":["PURPOSE: We conducted the phase III double-blind European Organisation for Research and Treatment of Cancer (EORTC) 1325\/KEYNOTE-054 trial to evaluate pembrolizumab versus placebo in patients with resected high-risk stage III melanoma."],"Revise":false}
{"PMID":"38657233","Document":["IFx-Hu2.0 was designed to encode part of the Emm55 protein contained within a plasmid in a formulation intended for transfection into mammalian cells.","IFx-Hu2.0 promotes both adaptive and innate immune responses in animal studies.","Furthermore, previous studies have demonstrated safety\/efficacy in equine, canine, and murine species.","We present the first-in-human study of IFx-Hu2.0, administered by intralesional injection into melanoma tumors of seven patients with stage III\/IV unresectable melanoma.","No dose-limiting toxicities attributable to IFx-Hu2.0 were observed.","Grade 1\/2 injection site reactions were observed in five of seven patients.","IgG and IgM responses to Emm55 peptides and known melanoma antigens were seen in the peripheral blood, suggesting that IFx-Hu2.0 acts as an individualized \"in situ vaccine.\"","Three of four patients previously refractory to anti-PD1 experienced clinical benefit upon subsequent anti-PD1-based treatment.","Therefore, this approach is feasible, and clinical\/correlative outcomes warrant further investigation for treating patients with metastatic melanoma with an immune priming agent."],"Aspect":"s","Summary":"While Grade 1\/2 injection site reactions were observed, there were no dose-limiting toxicities attributable to IFx-Hu2.0.","Indexes":[4,5],"Sentences":["No dose-limiting toxicities attributable to IFx-Hu2.0 were observed.","Grade 1\/2 injection site reactions were observed in five of seven patients."],"Revise":true}
{"PMID":"38939518","Document":["The need for reliable biomarkers to predict clinical benefit from anti-PD1 treatment in metastatic melanoma (MM) patients remains unmet.","Several parameters have been considered in the tumor environment or the blood, but none has yet achieved sufficient accuracy for routine clinical practice.","Whole blood samples from MM patients receiving second-line anti-PD1 treatment (NCT02626065), collected longitudinally, were analyzed by flow cytometry to assess the immune cell subsets absolute numbers, the expression of immune checkpoints or ligands on T cells and the functionality of innate immune cells and T cells.","Clinical response was assessed according to Progression-Free Survival (PFS) status at one-year following initiation of anti-PD1 (responders: PFS\u2009>\u20091\u2009year; non-responders: PFS\u2009\u2264\u20091\u2009year).","At baseline, several phenotypic and functional alterations in blood immune cells were observed in MM patients compared to healthy donors, but only the proportion of polyfunctional memory CD4+ T cells was associated with response to anti-PD1.","Under treatment, a decreased frequency of HVEM on CD4+ and CD8+ T cells after 3\u2009months of treatment identified responding patients, whereas its receptor BTLA was not modulated.","Both reduced proportion of CD69-expressing CD4+ and CD8+ T cells and increased number of polyfunctional blood memory T cells after 3\u2009months of treatment were associated with response to anti-PD1.","Of upmost importance, the combination of changes of all these markers accurately discriminated between responding and non-responding patients.","These results suggest that drugs targeting HVEM\/BTLA pathway may be of interest to improve anti-PD1 efficacy."],"Aspect":"p","Summary":"The study involved metastatic melanoma (MM) patients receiving second-line anti-PD1 treatment.","Indexes":[2],"Sentences":["Whole blood samples from MM patients receiving second-line anti-PD1 treatment (NCT02626065), collected longitudinally, were analyzed by flow cytometry to assess the immune cell subsets absolute numbers, the expression of immune checkpoints or ligands on T cells and the functionality of innate immune cells and T cells."],"Revise":false}
{"PMID":"33355238","Document":["PURPOSE: In this first-in-human phase I study (NCT02132754), we explored MK-4166 [humanized IgG1 agonist mAb targeting glucocorticoid-induced TNF receptor (GITR)] with and without pembrolizumab in advanced solid tumors.","PATIENTS AND METHODS: MK-4166 was tested alone (0.0015-900 mg i.v.","every 3 weeks for four doses) or with pembrolizumab (200 mg i.v.","every 3 weeks for \u226435 doses) in patients with metastatic solid tumors (dose escalation\/confirmation) and advanced melanoma (expansion).","Primary objectives were to evaluate the safety and tolerability and establish the MTD of MK-4166.","Exploratory endpoints were objective response rate (ORR) and T cell-inflamed gene expression profile (GEP) analysis using RNA from baseline tumor samples.","RESULTS: A total of 113 patients were enrolled [monotherapy, n = 48; combination therapy, n = 65 (20 in the expansion)].","Forty-six patients (40.7%) had grade \u22653 adverse events, 9 (8.0%) of which were treatment related.","No treatment-related deaths were observed.","One dose-limiting toxicity event with monotherapy (bladder perforation in patient with neobladder) was considered related to study drug.","MTD was not reached.","MK-4166 pharmacodynamics showed decreased GITR availability on circulating T cells with increasing doses.","One objective response (ORR, 2.2%) was achieved with combination therapy in the dose escalation\/confirmation (n = 45).","In the expansion, 8 of 13 patients with immune checkpoint inhibitor (ICI)-na\u00efve melanoma achieved a response (ORR, 62%; 95% confidence interval, 32-86; 5 complete responses and 3 partial responses).","None of the ICI-pretreated patients (n = 7) responded.","High response rates were observed in ICI-na\u00efve patients irrespective of GEP status.","CONCLUSIONS: MK-4166 900 mg i.v.","every 3 weeks as monotherapy and with pembrolizumab was tolerable.","Responses were observed with combination therapy, mostly in patients with ICI-na\u00efve melanoma."],"Aspect":"d","Summary":"The treatment duration was 12 weeks for MK-4166 alone and up to approximately 105 weeks for the combination with pembrolizumab.","Indexes":[2,3],"Sentences":["every 3 weeks for four doses) or with pembrolizumab (200 mg i.v.","every 3 weeks for \u226435 doses) in patients with metastatic solid tumors (dose escalation\/confirmation) and advanced melanoma (expansion)."],"Revise":false}
{"PMID":"31358540","Document":["PURPOSE: Atezolizumab [anti-programmed death-ligand 1 (PD-L1)] selectively targets PD-L1 to block its interaction with receptors programmed death 1 and B7.1, thereby reinvigorating antitumor T-cell activity.","We evaluated the long-term safety and activity of atezolizumab, along with biological correlates of clinical activity endpoints, in a cohort of patients with melanoma in an ongoing phase Ia study (NCT01375842).","PATIENTS AND METHODS: Patients with unresectable or metastatic melanoma were enrolled to receive atezolizumab 0.1 to 20 mg\/kg or \u226510 mg\/kg every 3 weeks.","Primary study objectives were safety and tolerability.","Secondary objectives included investigator-assessed efficacy measures; pharmacodynamic and predictive biomarkers of antitumor activity were explored.","RESULTS: Forty-five patients were enrolled and were evaluable for safety.","Most treatment-related adverse events (AE) were grade 1\/2 (60%).","Fatigue (44%), pruritus (20%), pyrexia (18%), and rash (18%) were the most common treatment-related AEs of any grade.","No treatment-related deaths occurred.","Overall response rate was 30% among 43 efficacy- evaluable patients, with a median duration of response of 62 months [95% CI, 35-not estimable (NE)].","Clinically meaningful long-term survival was observed, with a median overall survival of 23 months (95% CI, 9-66).","Baseline biomarkers of tumor immunity [PD-L1 expression on immune cells, T effector (Teff), and antigen presentation gene signatures) and tumor mutational burden (TMB) were associated with improved response, progression-free survival, and overall survival.","CONCLUSIONS: Atezolizumab was well tolerated, with durable responses and survival in patients with melanoma.","PD-L1 expression, TMB, and Teff signatures may indicate improved benefit with atezolizumab in these patients."],"Aspect":"p","Summary":"The study involved 45 patients with unresectable or metastatic melanoma enrolled to receive atezolizumab.","Indexes":[2,5],"Sentences":["PATIENTS AND METHODS: Patients with unresectable or metastatic melanoma were enrolled to receive atezolizumab 0.1 to 20 mg\/kg or \u226510 mg\/kg every 3 weeks.","RESULTS: Forty-five patients were enrolled and were evaluable for safety."],"Revise":false}
{"PMID":"31638282","Document":["The multinational phase 3 CheckMate 238 trial compared adjuvant therapy with nivolumab versus ipilimumab among patients with resected stage III or IV melanoma (N\u00a0=\u00a0906).","In this Japanese subgroup analysis of CheckMate 238 (n\u00a0=\u00a028; nivolumab, n\u00a0=\u00a018; ipilimumab, n\u00a0=\u00a010), both the 12- and 18-month recurrence-free survival rates were 56% for nivolumab and 30% for ipilimumab (hazard ratio, 0.66; 97.56% confidence interval, 0.19-2.24; P\u00a0=\u00a00.4390).","No new safety signals were reported for Japanese patients.","Results were consistent with those from the CheckMate 238 global population, indicating that nivolumab has the potential to be a treatment option for Japanese patients with resected melanoma who are at high risk of recurrence."],"Aspect":"p","Summary":"The multinational phase 3 CheckMate 238 trial involved 906 patients with resected stage III or IV melanoma, and the Japanese subgroup analysis included 28 patients (18 on nivolumab and 10 on ipilimumab).","Indexes":[0,1],"Sentences":["The multinational phase 3 CheckMate 238 trial compared adjuvant therapy with nivolumab versus ipilimumab among patients with resected stage III or IV melanoma (N\u00a0=\u00a0906).","In this Japanese subgroup analysis of CheckMate 238 (n\u00a0=\u00a028; nivolumab, n\u00a0=\u00a018; ipilimumab, n\u00a0=\u00a010), both the 12- and 18-month recurrence-free survival rates were 56% for nivolumab and 30% for ipilimumab (hazard ratio, 0.66; 97.56% confidence interval, 0.19-2.24; P\u00a0=\u00a00.4390)."],"Revise":false}
{"PMID":"34117113","Document":["BACKGROUND: The indoleamine 2,3-dioxygenase (IDO) pathway is a key counter-regulatory mechanism that, in cancer, is exploited by tumors to evade antitumor immunity.","Indoximod is a small-molecule IDO pathway inhibitor that reverses the immunosuppressive effects of low tryptophan (Trp) and high kynurenine (Kyn) that result from IDO activity.","In this study, indoximod was used in combination with a checkpoint inhibitor (CPI) pembrolizumab for the treatment for advanced melanoma.","METHODS: Patients with advanced melanoma were enrolled in a single-arm phase II clinical trial evaluating the addition of indoximod to standard of care CPI approved for melanoma.","Investigators administered their choice of CPI including pembrolizumab (P), nivolumab (N), or ipilimumab (I).","Indoximod was administered continuously (1200 mg orally two times per day), with concurrent CPI dosed per US Food and Drug Administration (FDA)-approved label.","RESULTS: Between July 2014 and July 2017, 131 patients were enrolled.","(P) was used more frequently (n=114, 87%) per investigator's choice.","The efficacy evaluable population consisted of 89 patients from the phase II cohort with non-ocular melanoma who received indoximod combined with (P).The objective response rate (ORR) for the evaluable population was 51% with confirmed complete response of 20% and disease control rate of 70%.","Median progression-free survival was 12.4 months (95% CI 6.4 to 24.9).","The ORR for Programmed Death-Ligand 1 (PD-L1)-positive patients was 70% compared with 46% for PD-L1-negative patients.","The combination was well tolerated, and side effects were similar to what was expected from single agent (P).","CONCLUSION: In this study, the combination of indoximod and (P) was well tolerated and showed antitumor efficacy that is worth further evaluation in selected patients with advanced melanoma."],"Aspect":"o","Summary":"The combination of indoximod and pembrolizumab in advanced melanoma demonstrated an objective response rate of 51%, a disease control rate of 70%, a median progression-free survival of 12.4 months, and was well tolerated, with higher efficacy observed in PD-L1-positive patients.","Indexes":[8,9,10,11],"Sentences":["The efficacy evaluable population consisted of 89 patients from the phase II cohort with non-ocular melanoma who received indoximod combined with (P).The objective response rate (ORR) for the evaluable population was 51% with confirmed complete response of 20% and disease control rate of 70%.","Median progression-free survival was 12.4 months (95% CI 6.4 to 24.9).","The ORR for Programmed Death-Ligand 1 (PD-L1)-positive patients was 70% compared with 46% for PD-L1-negative patients.","The combination was well tolerated, and side effects were similar to what was expected from single agent (P)."],"Revise":true}
{"PMID":"32885874","Document":["The educational effectiveness of dermoscopy image-based self-learning on a computer for medical students has not been well examined.","To assess the effect of an image-based self-learning session on the dermoscopic diagnostic performance for malignant melanoma (MM), basal cell carcinoma, melanocytic nevus and seborrheic keratosis (SK) on non-acral regions in comparison with a conventional classroom-style lecture, 114 fourth-year medical students (mean age, 23.7\u00a0years; male\u00a0:\u00a0female, 73:41) were enrolled.","The subjects were randomly assigned to either a self-learning to lecture (SL) or lecture to self-learning (LS) group to receive a 15-min image-based self-learning computer session and a 15-min video lecture session in different orders.","The user interface of the digital content was the same as that on a website (https:\/\/dz-image.casio.jp).","Diagnostic performance was determined using the total number of correct answers for the four diseases and by malignancy prediction in examination A (before training), B (after receiving one session) and C (after receiving both sessions).","The examinations were all unique and contained five dermoscopic images each of the four diseases.","The total number of correct answers and malignancy prediction results for examination B were significantly higher in the SL group than in LS (11.6 and 15.2 vs 10.1 and 13.4, respectively; both P\u00a0<\u00a00.01), with no remarkable differences for examination C (13.5 and 16.8 vs 13.3 and 16.4, respectively; P\u00a0=\u00a00.62 and P\u00a0=\u00a00.21).","In subanalyses, the number of correct answers for SK in examination B was significantly higher in the SL group (3.6 vs. 1.8, P\u00a0<\u00a00.01), while that for MM was significantly lower (2.2 vs 3.0, P\u00a0<\u00a00.01).","Diagnostic performance was comparable between sexes for examination B.","In conclusion, computer-assisted dermoscopy image-based self-learning may be a suitable and non-inferior alternative to classroom-style instruction for medical students within an ultra-short training period."],"Aspect":"p","Summary":"The study involved 114 fourth-year medical students (mean age, 23.7 years; male: female, 73:41) who were randomly assigned to either a self-learning to lecture (SL) or lecture to self-learning (LS) group.","Indexes":[1,2],"Sentences":["To assess the effect of an image-based self-learning session on the dermoscopic diagnostic performance for malignant melanoma (MM), basal cell carcinoma, melanocytic nevus and seborrheic keratosis (SK) on non-acral regions in comparison with a conventional classroom-style lecture, 114 fourth-year medical students (mean age, 23.7\u00a0years; male\u00a0:\u00a0female, 73:41) were enrolled.","The subjects were randomly assigned to either a self-learning to lecture (SL) or lecture to self-learning (LS) group to receive a 15-min image-based self-learning computer session and a 15-min video lecture session in different orders."],"Revise":false}
{"PMID":"33446823","Document":["There is a wide range of equivocal melanocytic lesions that can be clinically and dermoscopically indistinguishable from early melanoma.","In the present work, we assessed the possibilities of combined using of multiphoton microscopy (MPM) and optical coherence angiography (OCA) for differential diagnosis of the equivocal melanocytic lesions.","Clinical and dermoscopic examinations of 60 melanocytic lesions revealed 10 benign lesions and 32 melanomas, while 18 lesions remained difficult to diagnose.","Histopathological analysis of these lesions revealed 4 intradermal, 3 compound and 3 junctional nevi in the \"benign\" group, 7 superficial spreading, 14 lentigo maligna and 11 nodular melanomas in the \"melanoma\" group and 2 lentigo simplex, 4 dysplastic nevi, 6 melanomas in situ, 4 invasive lentigo melanomas and 2 invasive superficial spreading melanomas in the \"equivocal\" group.","On the basis of MPM, a multiphoton microscopy score (MPMS) has been developed for quantitative assessment of melanoma features at the cellular level, that showed lower score for benign lesions compare with malignant ones.","OCA revealed that the invasive melanoma has a higher vessel density and thicker blood vessels than melanoma in situ and benign lesions.","Discriminant functions analysis of MPM and OCA data allowed to differentiate correctly between all equivocal melanocytic lesions.","Therefore, we demonstrate, for the first time, that a combined use of MPM and OCA has the potential to improve early diagnosis of melanoma."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"34255535","Document":["PURPOSE: Therapies that produce deep and durable responses in patients with metastatic melanoma are needed.","This phase II cohort from the international, single-arm PIVOT-02 study evaluated the CD122-preferential interleukin-2 pathway agonist bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in first-line metastatic melanoma.","METHODS: A total of 41 previously untreated patients with stage III\/IV melanoma received BEMPEG 0.006 mg\/kg plus NIVO 360 mg once every 3 weeks for \u2264 2 years; 38 were efficacy-evaluable (\u2265 1 postbaseline scan).","Primary end points were safety and objective response rate (blinded independent central review); other end points included progression-free survival, overall survival (OS), and exploratory biomarkers.","RESULTS: At 29.0 months' median follow-up, the objective response rate was 52.6% (20 of 38 patients), and the complete response rate was 34.2% (13 of 38 patients).","Median change in size of target lesions from baseline was -78.5% (response-evaluable population); 47.4% (18 of 38 patients) experienced complete clearance of target lesions.","Median progression-free survival was 30.9 months (95% CI, 5.3 to not estimable).","Median OS was not reached; the 24-month OS rate was 77.0% (95% CI, 60.4 to 87.3).","Grade 3 and 4 treatment-related and immune-mediated adverse events occurred in 17.1% (7 of 41) and 4.9% (2 of 41) of patients, respectively.","Increased polyfunctional responses in CD8+ and CD4+ T cells were seen in blood after treatment, driven by cytokines with effector functions.","Early on-treatment blood biomarkers (CD8+ polyfunctional strength difference and eosinophils) correlated with treatment response.","CONCLUSION: BEMPEG in combination with NIVO was tolerated, with relatively low rates of grade 3 and 4 treatment-related and immune-mediated adverse events.","The combination had encouraging antitumor activity in first-line metastatic melanoma, including an extended median progression-free survival.","Exploratory analyses associated noninvasive, on-treatment biomarkers with response, before radiologic evidence was observed."],"Aspect":"p","Summary":"The study involved 41 previously untreated patients with stage III\/IV melanoma, with 38 being efficacy-evaluable.","Indexes":[2],"Sentences":["METHODS: A total of 41 previously untreated patients with stage III\/IV melanoma received BEMPEG 0.006 mg\/kg plus NIVO 360 mg once every 3 weeks for \u2264 2 years; 38 were efficacy-evaluable (\u2265 1 postbaseline scan)."],"Revise":false}
{"PMID":"34385669","Document":["PURPOSE: We evaluated the impact of personal melanoma genomic risk information on sun-related behaviors and psychological outcomes.","METHODS: In this parallel group, open, randomized controlled trial, 1,025 Australians of European ancestry without melanoma and aged 18-69 years were recruited via the Medicare database (3% consent).","Participants were randomized to the intervention (n\u2009=\u2009513; saliva sample for genetic testing, personalized melanoma risk booklet based on a 40-variant polygenic risk score, telephone-based genetic counseling, educational booklet) or control (n\u2009=\u2009512; educational booklet).","Wrist-worn ultraviolet (UV) radiation dosimeters (10-day wear) and questionnaires were administered at baseline, 1 month postintervention, and 12 months postbaseline.","RESULTS: At 12 months, 948 (92%) participants completed dosimetry and 973 (95%) the questionnaire.","For the primary outcome, there was no effect of the genomic risk intervention on objectively measured UV exposure at 12 months, irrespective of traditional risk factors.","For secondary outcomes at 12 months, the intervention reduced sunburns (risk ratio: 0.72, 95% confidence interval: 0.54-0.96), and increased skin examinations among women.","Melanoma-related worry was reduced.","There was no overall impact on general psychological distress.","CONCLUSION: Personalized genomic risk information did not influence sun exposure patterns but did improve some skin cancer prevention and early detection behaviors, suggesting it may be useful for precision prevention.","There was no evidence of psychological harm."],"Aspect":"o","Summary":"The study found that personalized genomic risk information did not affect sun exposure patterns but reduced sunburns, increased skin examinations among women, and reduced melanoma-related worry without impacting general psychological distress.","Indexes":[5,6,7,8],"Sentences":["For the primary outcome, there was no effect of the genomic risk intervention on objectively measured UV exposure at 12 months, irrespective of traditional risk factors.","For secondary outcomes at 12 months, the intervention reduced sunburns (risk ratio: 0.72, 95% confidence interval: 0.54-0.96), and increased skin examinations among women.","Melanoma-related worry was reduced.","There was no overall impact on general psychological distress."],"Revise":false}
{"PMID":"37482012","Document":["AIM: ImmunoCobiVem investigated whether a planned switch to atezolizumab after achieving tumour control during run-in with vemurafenib + cobimetinib improves progression-free survival (PFS) and overall survival (OS) compared to continuous targeted therapy (TT) in patients with previously untreated advanced BRAFV600-mutated melanoma.","METHODS: In this multicenter phase 2 study, patients received vemurafenib plus cobimetinib.","After 3months, patients without progressive disease (PD) were randomly assigned (1:1) to continue vemurafenib + cobimetinib (Arm A) or switch to atezolizumab (Arm B) until first documented PD (PD1).","Primary outcome was PFS1 (time from start of run-in until PD1 or death).","OS and safety were also assessed.","RESULTS: Of 185 patients enroled between November 2016 and December 2019, 135 were randomly assigned after the run-in period (Arm A, n\u00a0=\u00a069; Arm B, n\u00a0=\u00a066).","Median PFS1 was significantly longer in Arm A versus Arm B (13.9 versus 5.9months; hazard ratio [HR] 0.55; 95% confidence interval [CI], 0.37-0.84; PStratified=0.001).","Median OS was not reached in either arm (HR 1.22; 95%CI, 0.69-2.16; PStratified=0.389); 2-year OS was higher in Arm B versus Arm A (67%; 95%CI, 53-78 versus 58%; 95%CI, 45-70).","Grade 3\/4 AEs occurred in 55% of patients in Arm A and 64% in Arm B; treatment-related AEs led to discontinuation of any drug in 7% and 9% of patients, respectively.","CONCLUSION: In patients with BRAFV600-mutated advanced melanoma who achieve tumour control with TT, early switch at 3months to atezolizumab led to rapid loss of tumour control but provided a numerical OS benefit at 2years compared with continued TT."],"Aspect":"d","Summary":"The treatment duration involved a run-in period of 3 months, followed by treatment until the first documented progressive disease.","Indexes":[2],"Sentences":["After 3months, patients without progressive disease (PD) were randomly assigned (1:1) to continue vemurafenib + cobimetinib (Arm A) or switch to atezolizumab (Arm B) until first documented PD (PD1)."],"Revise":false}
{"PMID":"36100309","Document":["BACKGROUND: A vaccine containing 6 melanoma-associated peptides to stimulate helper T cells (6MHP) is safe, immunogenic, and clinically active.","A phase I\/II trial was designed to evaluate safety and immunogenicity of 6MHP vaccines plus programmed death 1 (PD-1) blockade.","PARTICIPANTS AND METHODS: Participants with advanced melanoma received 6MHP vaccines in an incomplete Freund's adjuvant (6 vaccines over 12 weeks).","Pembrolizumab was administered intravenously every 3 weeks.","Tumor biopsies at baseline and day 22 were analyzed by multiplex immunohistochemistry.","Primary end points were safety (Common Terminology Criteria for Adverse Events V.4.03) and immunogenicity (ex vivo interferon-\u03b3 ELISpot assay).","Additional end points included changes in the tumor microenvironment (TME) and clinical outcomes.","RESULTS: Twenty-two eligible participants were treated: 6 na\u00efve to PD-1 antibody (Ab) and 16 PD-1 Ab-experienced.","Median follow-up was 24.4 months.","Most common treatment-related adverse events (any grade) included injection site reactions, fatigue, anemia, lymphopenia, fever, elevated aspartate aminotransferase, pruritus, and rash.","Treatment-related dose-limiting toxicities were observed in 3 (14%) participants, which did not cross the study safety bound.","A high durable T cell response (Rsp) to 6MHP was detected in only one participant, but twofold T cell Rsps to 6MHP were detected in 7\/22 (32%; 90% CI (16% to 52%)) by week 13.","Objective clinical responses were observed in 23% (1 complete response, 4 partial responses), including 4\/6 PD-1 Ab-na\u00efve (67%) and 1\/16 PD-1 Ab-experienced (6%).","Overall survival (OS) was longer for PD-1 Ab-na\u00efve than Ab-experienced participants (HR 6.3 (90% CI (2.1 to 28.7)).","In landmark analyses at 13 weeks, OS was also longer for those with T cell Rsps (HR 6.5 (90% CI (2.1 to 29.2)) and for those with objective clinical responses.","TME evaluation revealed increased densities of CD8+ T cells, CD20+ B cells, and Tbet+ cells by day 22.","CONCLUSIONS: Treatment with the 6MHP vaccine plus pembrolizumab was safe, increased intratumoral lymphocytes, and induced T cell Rsps associated with prolonged OS.","The low T cell Rsp rate in PD-1 Ab-experienced participants corroborates prior murine studies that caution against delaying cancer vaccines until after PD-1 blockade.","The promising objective response rate and OS in PD-1 Ab-na\u00efve participants support consideration of a larger study in that setting."],"Aspect":"m","Summary":"The treatment involved a vaccine containing 6 melanoma-associated peptides (6MHP) administered with incomplete Freund's adjuvant over 12 weeks, and pembrolizumab administered intravenously every 3 weeks.","Indexes":[2,3],"Sentences":["PARTICIPANTS AND METHODS: Participants with advanced melanoma received 6MHP vaccines in an incomplete Freund's adjuvant (6 vaccines over 12 weeks).","Pembrolizumab was administered intravenously every 3 weeks."],"Revise":false}
{"PMID":"36682343","Document":["INTRODUCTION: Sentinel lymph node biopsy (SLNB) is a standard practice for staging cutaneous melanoma.","High false-negative rates have an increased interest in adjunctive techniques for localizing SLNs.","Mobile gamma cameras (MGCs) represent potential tools to enhance SLNB performance.","METHODS: An institutional review board approval was obtained for this study (ClinicalTrials.gov ID NCT01531608).","After obtaining informed consent, 20 eligible melanoma patients underwent 99mTc sulfur colloid injection and standard lymphoscintigraphy with a fixed gamma camera (FGC).","A survey using a 20\u00a0cm square MGC, performed immediately preoperatively by the study surgeon, was used to establish an operative plan while blinded to the FGC results.","Subsequently, SLNB was performed using a gamma probe and a novel 6\u00a0cm diameter handheld MGC.","RESULTS: A total of 24 SLN basins were detected by FGC.","Prior to unblinding, all 24 basins were identified with the preoperative MGC and the operative plan established by preoperative MGC imaging was confirmed accurate by review of the FGC images.","All individual sentinel lymph nodes were identified during intraoperative MGC imaging, and in 5\/24 (21%) cases, surgeon-reported additional clinically useful information was obtained from the MGC.","CONCLUSIONS: Preoperative MGC images provide information consistent with FGC images for planning SLNB and in some cases provide additional information that aided in surgical decision-making."],"Aspect":"a","Summary":"The study aims to evaluate the effectiveness of mobile gamma cameras (MGCs) for enhancing the performance of sentinel lymph node biopsy (SLNB) in melanoma patients.","Indexes":[2],"Sentences":["Mobile gamma cameras (MGCs) represent potential tools to enhance SLNB performance."],"Revise":false}
{"PMID":"38547774","Document":["AIMS: The MAPK pathway is constitutively activated in uveal melanoma (UM).","Selumetinib (AZD6244, ARRY-142886), a MEK inhibitor, has shown limited activity as monotherapy in metastatic UM.","Pre-clinical studies support synergistic cytotoxic activity for MEK inhibitors combined with taxanes, and here we sought to assess the clinical efficacy of combining selumetinib and paclitaxel.","PATIENTS AND METHODS: Seventy-seven patients with metastatic UM who had not received prior chemotherapy were randomised to selumetinib alone, or combined with paclitaxel with or without interruption in selumetinib two days before paclitaxel.","The primary endpoint was progression free survival (PFS).","After amendment, the combination arms were combined for analysis and the sample size adjusted to detect a hazard ratio (HR): 0.55, 80% power at 1-sided 5% significance level.","RESULTS: The median PFS in the combination arms was 4.8 months (95% CI: 3.8 - 5.6) compared with 3.4 months (2.0 - 3.9) in the selumetinib arm (HR 0.62 [90% CI 0.41 - 0.92], 1-sided p-value = 0.022).","ORR was 14% and 4% in the combination and monotherapy arms respectively.","Median OS was 9 months for the combination and was not significantly different from selumetinib alone (10 months) with HR of 0.98 [90% CI 0.58 - 1.66], 1-sided p-value =\u00a00.469.","Toxicity was in keeping with the known profiles of the agents involved.","CONCLUSIONS: SelPac met its primary endpoint, demonstrating an improvement in PFS for combination selumetinib and paclitaxel.","No improvement in OS was observed, and the modest improvement in PFS is not practice changing."],"Aspect":"p","Summary":"The study involved 77 patients with metastatic uveal melanoma who had not received prior chemotherapy, randomised to different treatment arms.","Indexes":[3],"Sentences":["PATIENTS AND METHODS: Seventy-seven patients with metastatic UM who had not received prior chemotherapy were randomised to selumetinib alone, or combined with paclitaxel with or without interruption in selumetinib two days before paclitaxel."],"Revise":false}
{"PMID":"33625104","Document":["Nearly 10% of patients with high-risk early-stage melanoma will develop satellite or in-transit metastases (ITM), classified as stage III disease similar to lymph node metastases.","The pivotal registration trials of the CTLA-4 antibody ipilimumab, and the PD-1 antibodies nivolumab and pembrolizumab, also included patients with unresectable stage III disease.","However, there has been no analysis of patients with ITM, and anecdotal retrospective small series have indicated a potential lesser effect.","This study aimed to identify patients with unresectable ITM within the randomized trials, and to determine response, progression-free survival and overall survival.","The pivotal phase III randomized intervention trials that included melanoma patients with ITM, with or without nodal metastasis, and were treated with ipilimumab, nivolumab or pembrolizumab was identified.","The datasets from each trial were then searched to identify the specific details of the investigated patient population for a pooled analysis.","The primary endpoint was complete response rate.","Seven trials that included stage III patients, and with accessible datasets, were identified.","There was a total of 4711 patients, however, no patients with ITM could be identified, as this data was not captured by the case report forms.","Evidence from prospective clinical trials on the use of immunotherapy in patients with ITM is lacking.","We recommend pooling data from multiple institutions to examine efficacy of available drug therapies in this patient population, but more importantly, prospective clinical trials of locoregional treatments with or without systemic drug therapies are required."],"Aspect":"p","Summary":"The study involved 4711 patients with stage III melanoma, including those with satellite or in-transit metastases (ITM).","Indexes":[0,7,8],"Sentences":["Nearly 10% of patients with high-risk early-stage melanoma will develop satellite or in-transit metastases (ITM), classified as stage III disease similar to lymph node metastases.","Seven trials that included stage III patients, and with accessible datasets, were identified.","There was a total of 4711 patients, however, no patients with ITM could be identified, as this data was not captured by the case report forms."],"Revise":false}
{"PMID":"35658604","Document":["Background: Oncogenic BRAF mutations are commonly found in advanced differentiated thyroid cancer (DTC), and reports have shown efficacy of BRAF inhibitors in these tumors.","We investigated the difference in response between dabrafenib monotherapy and dabrafenib + trametinib therapy in patients with BRAF-mutated radioactive iodine refractory DTC.","Methods: In this open-label randomized phase 2 multicenter trial, patients aged \u226518 years with BRAF-mutated radioactive iodine refractory DTC with progressive disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 within 13 months before enrollment were eligible.","Patients were randomly assigned to receive dabrafenib alone or dabrafenib + trametinib.","The primary endpoint was objective response rate by modified RECIST (minor response of -20% to -29%, partial and complete response) within the first 24 weeks of therapy.","Trial Registration Number: NCT01723202.","Results: A total of 53 patients were enrolled.","The objective response rate (modified RECIST) was 42% (11\/26 [95% confidence interval {CI} 23-63%]) with dabrafenib versus 48% (13\/27 [CI 29-68%]) with dabrafenib + trametinib (p\u2009=\u20090.67).","Objective response rate (RECIST 1.1) was 35% (9\/26 [CI 17-56%]) with dabrafenib and 30% (8\/27 [CI 14-51%]) with dabrafenib + trametinib.","Most common treatment-related adverse events included skin and subcutaneous tissue disorders (17\/26, 65%), fever (13\/26, 50%), hyperglycemia (12\/26, 46%) with dabrafenib alone and fever (16\/27, 59%), nausea, chills, fatigue (14\/27, 52% each) with dabrafenib + trametinib.","There were no treatment-related deaths.","Conclusions: Combination dabrafenib + trametinib was not superior in efficacy compared to dabrafenib monotherapy in patients with BRAF-mutated radioiodine refractory progressive DTC."],"Aspect":"s","Summary":"The most common treatment-related adverse events included skin and subcutaneous tissue disorders, fever, and hyperglycemia with dabrafenib alone, and fever, nausea, chills, and fatigue with dabrafenib + trametinib.","Indexes":[9],"Sentences":["Most common treatment-related adverse events included skin and subcutaneous tissue disorders (17\/26, 65%), fever (13\/26, 50%), hyperglycemia (12\/26, 46%) with dabrafenib alone and fever (16\/27, 59%), nausea, chills, fatigue (14\/27, 52% each) with dabrafenib + trametinib."],"Revise":false}
{"PMID":"39191779","Document":["Image-guided percutaneous cryoablation is an established minimally invasive oncologic treatment.","We hypothesized that cryoablation may modify the immune microenvironment through direct modulation of the tumor, thereby generating an anti-tumor response in tumors refractory to immune checkpoint inhibition (ICI).","In this non-randomized phase II single-center study (NCT03290677), subjects with unresectable melanoma progressing on ICI underwent cryoablation of an enlarging metastasis, and ICI was continued for a minimum of two additional cycles.","The primary endpoints were safety, feasibility and tumor response in non-ablated lesions.","From May 2018 through July 2020, 17 patients were treated on study.","The study met its primary endpoints with the combination strategy found to be safe and feasible with an objective response rate of 23.5% and disease control rate of 41% (4 partial response, 3 stable disease).","Our data support further study of this synergistic therapeutic approach."],"Aspect":"d","Summary":"In this study, subjects with unresectable melanoma progressing on ICI underwent cryoablation of an enlarging metastasis, and ICI was continued for a minimum of two additional cycles.","Indexes":[2],"Sentences":["In this non-randomized phase II single-center study (NCT03290677), subjects with unresectable melanoma progressing on ICI underwent cryoablation of an enlarging metastasis, and ICI was continued for a minimum of two additional cycles."],"Revise":true}
{"PMID":"36460017","Document":["BACKGROUND: Primary analysis of the phase 3 IMspire150 study showed improved investigator-assessed progression-free survival with first-line atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) versus placebo, vemurafenib, and cobimetinib (control group) in patients with BRAFV600 mutation-positive melanoma.","With a median follow-up of 18\u00b79 months (IQR 10\u00b74-23\u00b78) at the primary analysis, overall survival data were immature.","Here, we report the results from the second, prespecified, interim overall survival analysis.","METHODS: The multicentre, double-blind, placebo-controlled, randomised, phase 3 IMspire150 study was done at 108 academic and community hospitals in 20 countries.","Patients aged 18 years or older with previously untreated unresectable stage IIIc or stage IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible for inclusion.","Patients were randomly assigned (1:1) to receive either atezolizumab (840 mg intravenously on day 1 and 15) or placebo plus vemurafenib (960 mg or 720 mg twice daily orally) and cobimetinib (60 mg once daily orally; 21 days on and 7 days off) in 28-day cycles.","Atezolizumab and placebo were added to treatment regimens from cycle two onwards.","Randomisation was done centrally (Durham, NC, USA) based on a permuted block randomisation scheme (block size of 4) using an interactive web-based response system and was stratified by geographical region and baseline lactate dehydrogenase concentration.","Overall survival was analysed in the intention-to-treat population and safety was analysed in all patients who received at least one dose of study drug according to actual treatment received.","The primary endpoint was investigator-assessed progression-free survival, which was previously reported.","Here, we report the second, prespecified, interim overall survival analysis, which was planned after about 270 overall survival events had occurred.","The trial is ongoing, but is no longer enrolling patients, and it is registered with ClinicalTrials.gov, NCT02908672.","FINDINGS: Between Jan 13, 2017, and April 26, 2018, 514 patients (median age 54 years [IQR 43-63]; 299 [58%] men and 215 [42%] women) were enrolled in the trial and randomly assigned to the atezolizumab group (256 [50%] patients) or the control group (258 [50%] patients).","At the data cutoff (Sept 8, 2021), 273 patients had died (126 in the atezolizumab group and 147 in the control group).","Median follow-up was 29\u00b71 months (IQR 10\u00b71-45\u00b74) for the atezolizumab group versus 22\u00b78 months (10\u00b76-44\u00b71) for the control group.","Median overall survival was 39\u00b70 months (95% CI 29\u00b79-not estimable) in the atezolizumab group versus 25\u00b78 months (22\u00b70-34\u00b76) in the control group (HR 0\u00b784 [95% CI 0\u00b766-1\u00b706]; p=0\u00b714).","The most common adverse events of any grade in the atezolizumab group were blood creatine phosphokinase increased (123 [53%] of 231 patients), diarrhoea (116 [50%]), and pyrexia (115 [50%]).","The most common adverse events of any grade in the control group were diarrhoea (157 [56%] of 280 patients), blood creatine phosphokinase increased (135 [48%]), and rash (119 [43%]).","The most common grade 3-4 adverse events were increased lipase (54 [23%] of 231 patients in the atezolizumab group vs 62 [22%] of 280 patients in the control group), increased blood creatine phosphokinase (51 [22%] vs 50 [18%]), and increased alanine aminotransferase (32 [14%] vs 26 [9%]).","Serious adverse events were reported in 112 (48%) patients in the atezolizumab group and 117 (42%) patients in the control group.","Grade 5 adverse events were reported in eight (3%) patients in the atezolizumab group versus six (2%) patients in the control group.","Two grade 5 adverse events (hepatitis fulminant and hepatic failure) in the atezolizumab group were considered to be associated with the triplet combination, and one event in the control group (pulmonary haemorrhage) was considered to be associated with cobimetinib.","INTERPRETATION: Additional follow-up of the IMspire150 trial showed that overall survival was not significantly improved with atezolizumab, vemurafenib, and cobimetinib compared with placebo, vemurafenib, and cobimetinib in patients with BRAFV600 mutation-positive advanced melanoma.","Results of the final analysis are awaited to establish whether a significant improvement in overall survival can be achieved with long-term treatment with this triplet combination versus vemurafenib plus cobimetinib.","FUNDING: F Hoffmann-La Roche."],"Aspect":"a","Summary":"The study aims to investigate the overall survival outcomes of atezolizumab, vemurafenib, and cobimetinib compared to placebo, vemurafenib, and cobimetinib in patients with BRAFV600 mutation-positive advanced melanoma.","Indexes":[0,2,10],"Sentences":["BACKGROUND: Primary analysis of the phase 3 IMspire150 study showed improved investigator-assessed progression-free survival with first-line atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) versus placebo, vemurafenib, and cobimetinib (control group) in patients with BRAFV600 mutation-positive melanoma.","Here, we report the results from the second, prespecified, interim overall survival analysis.","Here, we report the second, prespecified, interim overall survival analysis, which was planned after about 270 overall survival events had occurred."],"Revise":false}
{"PMID":"34403293","Document":["BACKGROUND: With increased survival among patients with metastatic melanoma and limited time with health care providers, patients are expected to assume a more active role in managing their treatment and care.","Activated patients have the knowledge, skills, and confidence to make effective solutions to self-manage health.","The use of patient-reported outcomes (PRO) could have the potential to enhance patient activation.","However, PRO-based interventions that facilitate an activation in patients with metastatic melanoma are lacking and warranted.","MATERIAL AND METHODS: In this prospective non-randomized controlled, clinical trial, patients with metastatic melanoma were assigned to either the intervention (systematic feedback and discussion of PRO during consultation) given at one hospital or the control group (treatment as usual) if they received treatment from two other hospitals in Denmark.","The primary outcome was the patient activation measure (PAM), which reflects self-management.","Secondary outcomes were health-related quality of life (HRQoL), self-efficacy, and Patient-Physician interaction.","Outcomes were measured at baseline, and after 3, 6, and 12\u2009months.","The analysis of the effect from baseline to 12\u2009months employed mixed-effects modeling.","RESULTS: Between 2017 and 2019, patients were allocated to either the intervention group (n\u2009=\u2009137) or the control group (n\u2009=\u2009142).","We found no significant difference in the course of patient activation between the two groups over time.","The course of HRQoL was statistically significantly improved by the intervention compared to the control group.","Especially, females in the intervention group performed better than males.","The other secondary outcomes were not improved by the intervention.","CONCLUSION: The intervention did not improve knowledge, skills, and confidence for self-management for patients with metastatic melanoma.","Neither did it improve coping self-efficacy nor perceived efficacy in Patient-Physician interaction.","However, the results suggest that the intervention can have a significant impact on HRQoL and in particular social and emotional well-being among the females."],"Aspect":"o","Summary":"The intervention did not improve patient activation, coping self-efficacy, or Patient-Physician interaction but significantly improved health-related quality of life, particularly social and emotional well-being, especially among females.","Indexes":[14,15,16],"Sentences":["CONCLUSION: The intervention did not improve knowledge, skills, and confidence for self-management for patients with metastatic melanoma.","Neither did it improve coping self-efficacy nor perceived efficacy in Patient-Physician interaction.","However, the results suggest that the intervention can have a significant impact on HRQoL and in particular social and emotional well-being among the females."],"Revise":true}
{"PMID":"33826614","Document":["Although combination BRAF and MEK inhibitors are highly effective for the 40-50% of cutaneous metastatic melanomas harboring BRAFV600 mutations, targeted agents have been ineffective for BRAFV600wild-type (wt) metastatic melanomas.","The SU2C Genomics-Enabled Medicine for Melanoma Trial utilized a Simon two-stage optimal design to assess whether comprehensive genomic profiling improves selection of molecular-based therapies for BRAFV600wt metastatic melanoma patients who had progressed on standard-of-care therapy, which may include immunotherapy.","Of the response-evaluable patients, binimetinib was selected for 20 patients randomized to the genomics-enabled arm, and nine were treated on the alternate treatment arm.","Response rates for 27 patients treated with targeted recommendations included one (4%) partial response, 18 (67%) with stable disease, and eight (30%) with progressive disease.","Post-trial genomic and protein pathway activation mapping identified additional drug classes that may be considered for future studies.","Our results highlight the complexity and heterogeneity of metastatic melanomas, as well as how the lack of response in this trial may be associated with limitations including monotherapy drug selection and the dearth of available single and combination molecularly-driven therapies to treat BRAFV600wt metastatic melanomas."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"33668679","Document":["Urine autofluorescence at 295 nm is significantly higher in patients with malignant melanoma at each clinical stage compared to the healthy group.","The largest difference is in the early-stages and without metastases.","With increasing stage, the autofluorescence at 295 nm decreases.","There is also a significant negative correlation between autofluorescence and Clark classification.","Based on our results, it is assumed that the way malignant melanoma grows also affects urinary autofluorescence."],"Aspect":"a","Summary":"The study aims to investigate the correlation between urine autofluorescence and the stages and growth patterns of malignant melanoma.","Indexes":[0,4],"Sentences":["Urine autofluorescence at 295 nm is significantly higher in patients with malignant melanoma at each clinical stage compared to the healthy group.","Based on our results, it is assumed that the way malignant melanoma grows also affects urinary autofluorescence."],"Revise":false}
{"PMID":"33294862","Document":["T cells use highly diverse receptors (TCRs) to identify tumor cells presenting neoantigens arising from genetic mutations and establish anti-tumor activity.","Immunotherapy harnessing neoantigen-specific T\u00a0cells to target tumors has emerged as a promising clinical approach.","To assess whether a comprehensive peripheral mononuclear blood cell analysis predicts responses to a personalized neoantigen cancer vaccine combined with anti-PD-1 therapy, we characterize the TCR repertoires and T and B cell frequencies in 21 patients with metastatic melanoma who received this regimen.","TCR-\u03b1\/\u03b2-chain sequencing reveals that prolonged progression-free survival (PFS) is strongly associated with increased clonal baseline TCR repertoires and longitudinal repertoire stability.","Furthermore, the frequencies of antigen-experienced T and B cells in the peripheral blood correlate with repertoire characteristics.","Analysis of these baseline immune features enables prediction of PFS following treatment.","This method offers a pragmatic clinical approach to assess patients' immune state and to direct therapeutic decision making."],"Aspect":"m","Summary":"The treatment regimen includes a personalized neoantigen cancer vaccine combined with anti-PD-1 therapy.","Indexes":[2],"Sentences":["To assess whether a comprehensive peripheral mononuclear blood cell analysis predicts responses to a personalized neoantigen cancer vaccine combined with anti-PD-1 therapy, we characterize the TCR repertoires and T and B cell frequencies in 21 patients with metastatic melanoma who received this regimen."],"Revise":false}
{"PMID":"31704549","Document":["AIM OF STUDY: The aim of the study was to assess the impact of treatment with adjuvant vemurafenib monotherapy on health-related quality of life (HRQOL) in patients with resected stage IIC-IIIC melanoma.","METHODS: The phase 3 BRIM8 study (NCT01667419) randomised patients with BRAFV600 mutation-positive resected stage IIC-IIIC melanoma to 960\u00a0mg of vemurafenib twice daily or matching placebo for 52 weeks (13\u00a0\u00d7\u00a028-day cycles).","Patients completed the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) version 3\u00a0at baseline, cycle 1 (days 1, 15 and 22), cycle 2 (days 1 and 15), day 1 of every subsequent 4-week cycle, the end-of-treatment visit and each visit during the follow-up period.","RESULTS: Completion rates for the EORTC QLQ-C30 questionnaire were high (>80%).","There was a mean decline in the global health status (GHS)\/quality of life (QOL) score of 17.4 (\u00b122.9) and 17.3 (\u00b124.1) points at days 15 and 22 of cycle 1, respectively, among vemurafenib-treated patients who recovered to approximately 10 points below baseline for the remainder of the treatment period.","A similar trend was observed in all functional scales except for cognitive function (<10-point change from baseline at all visits) and in the symptom scores for appetite loss, fatigue and pain.","As observed for the GHS\/QOL score, all scores rapidly returned to baseline after completion of planned vemurafenib treatment or treatment discontinuation.","CONCLUSIONS: The schedule of HRQOL assessments allowed for an accurate and complete evaluation of the impact of acute treatment-related symptoms.","Vemurafenib-treated patients experience clinically meaningful moderate worsening in some treatment- or disease-related symptoms and GHS\/QOL that resolve over time."],"Aspect":"p","Summary":"The study involved patients with BRAFV600 mutation-positive resected stage IIC-IIIC melanoma who were randomized to receive vemurafenib or placebo.","Indexes":[0,1],"Sentences":["AIM OF STUDY: The aim of the study was to assess the impact of treatment with adjuvant vemurafenib monotherapy on health-related quality of life (HRQOL) in patients with resected stage IIC-IIIC melanoma.","METHODS: The phase 3 BRIM8 study (NCT01667419) randomised patients with BRAFV600 mutation-positive resected stage IIC-IIIC melanoma to 960\u00a0mg of vemurafenib twice daily or matching placebo for 52 weeks (13\u00a0\u00d7\u00a028-day cycles)."],"Revise":false}
{"PMID":"34453044","Document":["Preclinical studies have suggested that epigenetic therapy could enhance immunogenicity of cancer cells.","We report the results of the PEMDAC phase 2 clinical trial (n\u2009=\u200929; NCT02697630) where the HDAC inhibitor entinostat was combined with the PD-1 inhibitor pembrolizumab in patients with metastatic uveal melanoma (UM).","The primary endpoint was objective response rate (ORR), and was met with an ORR of 14%.","The clinical benefit rate at 18 weeks was 28%, median progression free survival was 2.1 months and the median overall survival was 13.4 months.","Toxicities were manageable, and there were no treatment-related deaths.","Objective responses and\/or prolonged survival were seen in patients with BAP1 wildtype tumors, and in one patient with an iris melanoma that exhibited a UV signature.","Longer survival also correlated with low baseline ctDNA levels or LDH.","In conclusion, HDAC inhibition and anti-PD1 immunotherapy results in durable responses in a subset of patients with metastatic UM.Trial registration ClinicalTrials.gov registration number: NCT02697630 (registered 3 March 2016).","EudraCT registration number: 2016-002114-50."],"Aspect":"o","Summary":"The PEMDAC phase 2 clinical trial showed that combining the HDAC inhibitor entinostat with the PD-1 inhibitor pembrolizumab resulted in an objective response rate of 14% and manageable toxicities in patients with metastatic uveal melanoma.","Indexes":[1,2,4],"Sentences":["We report the results of the PEMDAC phase 2 clinical trial (n\u2009=\u200929; NCT02697630) where the HDAC inhibitor entinostat was combined with the PD-1 inhibitor pembrolizumab in patients with metastatic uveal melanoma (UM).","The primary endpoint was objective response rate (ORR), and was met with an ORR of 14%.","Toxicities were manageable, and there were no treatment-related deaths."],"Revise":true}
{"PMID":"33971211","Document":["Children are a priority population for skin cancer prevention as excessive sun exposure in childhood increases the risk of melanoma in adulthood.","The complexity of sun protective behaviors has posed measurement challenges for trials testing intervention efficacy.","The current study evaluated a sun safety intervention for schoolchildren using latent transition analysis (LTA) to examine patterns of sun protection behaviors over time.","A three-armed randomized controlled trial was conducted between 2012 and 2016 with two intervention groups (N\u00a0=\u00a03368) and an observation-only control group (N\u00a0=\u00a0342) among 4th and 5th graders from 24 public schools in Los Angeles County.","Both interventions conditions were grouped and compared to controls.","Five self-reported sun protective behaviors were measured at baseline and three-month follow-up: use of sunscreen, long sleeves, long pants, hats, and shade seeking.","Participants comprised 3710 schoolchildren, mean age 9\u00a0years, 47% female and 69% Latino.","At baseline, four patterns of sun protection behaviors were found: children who engaged in 1) all sun protective behaviors; 2) few protective behaviors; 3) protective clothing and shade only; and 4) hats only.","Children in the control group were likely to remain in their baseline status or transition to a less protective status at three-month follow-up.","By contrast, 30% of children in the intervention group transitioned to a more protective status at follow-up.","In this RCT of a sun safety intervention, children in the intervention transitioned to more protective behaviors compared to controls.","Using LTA enriches understanding of intervention efficacy by modeling the complexity of sun protection behaviors over time.","TRIAL REGISTRATION: School-based Randomized Trial of SunSmart Interventions, ClinicalTrials.gov Identifier: NCT04176237 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04176237?cond=School-based+Randomized+Trial+of+SunSmart+Interventions&draw=2&rank=1."],"Aspect":"i","Summary":"This study employed a three-armed randomized controlled trial between 2012 and 2016 involving 4th and 5th graders from 24 Los Angeles County public schools, measuring five self-reported sun protective behaviors at baseline and three-month follow-up, using latent transition analysis to evaluate patterns of sun protection behaviors over time.","Indexes":[2,3,5],"Sentences":["The current study evaluated a sun safety intervention for schoolchildren using latent transition analysis (LTA) to examine patterns of sun protection behaviors over time.","A three-armed randomized controlled trial was conducted between 2012 and 2016 with two intervention groups (N\u00a0=\u00a03368) and an observation-only control group (N\u00a0=\u00a0342) among 4th and 5th graders from 24 public schools in Los Angeles County.","Five self-reported sun protective behaviors were measured at baseline and three-month follow-up: use of sunscreen, long sleeves, long pants, hats, and shade seeking."],"Revise":true}
{"PMID":"31901705","Document":["BACKGROUND: BRAF\/MEK inhibitor combinations are established treatments for BRAF V600-mutant melanoma based on demonstrated benefits on progression-free survival (PFS) and overall survival (OS).","Here, we report an updated analysis of the COLUMBUS\u00a0(COmbined LGX818 [encorafenib] Used with MEK162 [binimetinib] in\u00a0BRAF\u00a0mutant Unresectable Skin cancer) trial with long-term follow-up.","METHODS: In part 1 of the COLUMBUS trial, 577 patients with advanced\/metastatic BRAF V600-mutant melanoma, untreated or progressed after first-line immunotherapy, were randomised 1:1:1 to 450\u00a0mg of encorafenib QD\u00a0+\u00a045\u00a0mg of binimetinib BID (COMBO450) vs 960\u00a0mg of vemurafenib BID (VEM) or 300\u00a0mg of encorafenib ENCO QD (ENCO300).","An updated analysis was conducted that included PFS, OS, objective response rate, safety and tolerability\u00a0and analyses of results by prognostic subgroups.","RESULTS: At data cutoff, there were 116, 113\u00a0and 138 deaths in the COMBO450, ENCO300\u00a0and VEM treatment arms, respectively.","The median OS was 33.6 months (95% confidence interval [CI], 24.4-39.2) for COMBO450, 23.5 months (95% CI, 19.6-33.6) for ENCO300\u00a0and 16.9 months (95% CI, 14.0-24.5) for VEM.","Compared with VEM, COMBO450 decreased the risk of death by 39% (hazard ratio [HR], 0.61; 95% CI, 0.48-0.79).","The updated median PFS for COMBO450 was 14.9 months (95% CI, 11.0-20.2), ENCO300 was 9.6 months (95% CI, 7.4-14.8)\u00a0and VEM was 7.3 months (95% CI, 5.6-7.9).","PFS was longer for COMBO450 vs VEM (HR, 0.51; 95% CI, 0.39-0.67).","Landmark OS and PFS results show consistent results for each year analysed.","Subgroups all favoured COMBO450 vs VEM.","CONCLUSIONS: Updated PFS and OS results for COMBO450 from the COLUMBUS trial demonstrate a long-term benefit in patients with advanced BRAF V600-mutated melanoma."],"Aspect":"i","Summary":"Patients with advanced\/metastatic BRAF V600-mutant melanoma were randomized to receive encorafenib plus binimetinib, vemurafenib, or encorafenib alone to compare their efficacy and safety.","Indexes":[2],"Sentences":["METHODS: In part 1 of the COLUMBUS trial, 577 patients with advanced\/metastatic BRAF V600-mutant melanoma, untreated or progressed after first-line immunotherapy, were randomised 1:1:1 to 450\u00a0mg of encorafenib QD\u00a0+\u00a045\u00a0mg of binimetinib BID (COMBO450) vs 960\u00a0mg of vemurafenib BID (VEM) or 300\u00a0mg of encorafenib ENCO QD (ENCO300)."],"Revise":false}
{"PMID":"37270692","Document":["PURPOSE: The combination of encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor) has demonstrated clinical efficacy with an acceptable safety profile in patients with BRAFV600E\/K-mutant metastatic melanoma.","We evaluated the efficacy and safety of encorafenib plus binimetinib in patients with BRAFV600E-mutant metastatic non-small-cell lung cancer (NSCLC).","METHODS: In this ongoing, open-label, single-arm, phase II study, patients with BRAFV600E-mutant metastatic NSCLC received oral encorafenib 450 mg once daily plus binimetinib 45 mg twice daily in 28-day cycles.","The primary end point was confirmed objective response rate (ORR) by independent radiology review (IRR).","Secondary end points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival, time to response, and safety.","RESULTS: At data cutoff, 98 patients (59 treatment-na\u00efve and 39 previously treated) with BRAFV600E-mutant metastatic NSCLC received encorafenib plus binimetinib.","Median duration of treatment was 9.2 months with encorafenib and 8.4 months with binimetinib.","ORR by IRR was 75% (95% CI, 62 to 85) in treatment-na\u00efve and 46% (95% CI, 30 to 63) in previously treated patients; median DOR was not estimable (NE; 95% CI, 23.1 to NE) and 16.7 months (95% CI, 7.4 to NE), respectively.","DCR after 24 weeks was 64% in treatment-na\u00efve and 41% in previously treated patients.","Median PFS was NE (95% CI, 15.7 to NE) in treatment-na\u00efve and 9.3 months (95% CI, 6.2 to NE) in previously treated patients.","The most frequent treatment-related adverse events (TRAEs) were nausea (50%), diarrhea (43%), and fatigue (32%).","TRAEs led to dose reductions in 24 (24%) and permanent discontinuation of encorafenib plus binimetinib in 15 (15%) patients.","One grade 5 TRAE of intracranial hemorrhage was reported.","Interactive visualization of the data presented in this article is available at the PHAROS dashboard (https:\/\/clinical-trials.dimensions.ai\/pharos\/).","CONCLUSION: For patients with treatment-na\u00efve and previously treated BRAFV600E-mutant metastatic NSCLC, encorafenib plus binimetinib showed a meaningful clinical benefit with a safety profile consistent with that observed in the approved indication in melanoma."],"Aspect":"o","Summary":"Encorafenib plus binimetinib showed a meaningful clinical benefit for patients with BRAFV600E-mutant metastatic NSCLC, with an objective response rate (ORR) of 75% in treatment-na\u00efve and 46% in previously treated patients, and median progression-free survival (PFS) of NE and 9.3 months, respectively.","Indexes":[7,9,14],"Sentences":["ORR by IRR was 75% (95% CI, 62 to 85) in treatment-na\u00efve and 46% (95% CI, 30 to 63) in previously treated patients; median DOR was not estimable (NE; 95% CI, 23.1 to NE) and 16.7 months (95% CI, 7.4 to NE), respectively.","Median PFS was NE (95% CI, 15.7 to NE) in treatment-na\u00efve and 9.3 months (95% CI, 6.2 to NE) in previously treated patients.","CONCLUSION: For patients with treatment-na\u00efve and previously treated BRAFV600E-mutant metastatic NSCLC, encorafenib plus binimetinib showed a meaningful clinical benefit with a safety profile consistent with that observed in the approved indication in melanoma."],"Revise":true}
{"PMID":"37643378","Document":["PURPOSE: BRAF V600 mutation is detected in 5%-10% of pediatric high-grade gliomas (pHGGs), and effective treatments are limited.","In previous trials, dabrafenib as monotherapy or in combination with trametinib demonstrated activity in children and adults with relapsed\/refractory BRAF V600-mutant HGG.","METHODS: This phase II study evaluated dabrafenib plus trametinib in patients with relapsed\/refractory BRAF V600-mutant pHGG.","The primary objective was overall response rate (ORR) by independent review by Response Assessment in Neuro-Oncology criteria.","Secondary objectives included ORR by investigator determination, duration of response (DOR), progression-free survival, overall survival (OS), and safety.","RESULTS: A total of 41 pediatric patients with previously treated BRAF V600-mutant HGG were enrolled.","At primary analysis, median follow-up was 25.1 months, and 51% of patients remained on treatment.","Sixteen of 20 discontinuations were due to progressive disease in this relapsed\/refractory pHGG population.","Independently assessed ORR was 56% (95% CI, 40 to 72).","Median DOR was 22.2 months (95% CI, 7.6 months to not reached [NR]).","Fourteen deaths were reported.","Median OS was 32.8 months (95% CI, 19.2 months to NR).","The most common all-cause adverse events (AEs) were pyrexia (51%), headache (34%), and dry skin (32%).","Two patients (5%) had AEs (both rash) leading to discontinuation.","CONCLUSION: In relapsed\/refractory BRAF V600-mutant pHGG, dabrafenib plus trametinib improved ORR versus previous trials of chemotherapy in molecularly unselected patients with pHGG and was associated with durable responses and encouraging survival.","These findings suggest that dabrafenib plus trametinib is a promising targeted therapy option for children and adolescents with relapsed\/refractory BRAF V600-mutant HGG."],"Aspect":"a","Summary":"The study aims to evaluate the overall response rate (ORR) and other secondary objectives of dabrafenib plus trametinib in patients with relapsed\/refractory BRAF V600-mutant pediatric high-grade gliomas (pHGGs).","Indexes":[2,3,4],"Sentences":["METHODS: This phase II study evaluated dabrafenib plus trametinib in patients with relapsed\/refractory BRAF V600-mutant pHGG.","The primary objective was overall response rate (ORR) by independent review by Response Assessment in Neuro-Oncology criteria.","Secondary objectives included ORR by investigator determination, duration of response (DOR), progression-free survival, overall survival (OS), and safety."],"Revise":false}
{"PMID":"39077892","Document":["Mutant BRAFV600E is one of the most common oncogenic drivers in metastatic melanoma.","While first generation BRAFV600E inhibitors are capable of controlling tumors systemically, they are unable to adequately treat tumors that have metastasized to the brain due to insufficient penetration across the blood-brain barrier (BBB).","Through a combination of structure-based drug design (SBDD) and the optimization of physiochemical properties to enhance BBB penetration, we herein report the discovery of the brain-penetrant BRAFV600E inhibitor PF-07284890 (ARRY-461).","In mice studies, ARRY-461 proved to be highly brain-penetrant and was able to drive regressions of A375 BRAFV600E tumors implanted both subcutaneously and intracranially.","Based on compelling preclinical safety and efficacy studies, ARRY-461 was progressed into a Phase 1 A\/B clinical trial (NCT04543188)."],"Aspect":"m","Summary":"The article discusses the brain-penetrant BRAFV600E inhibitor PF-07284890 (ARRY-461), which was tested in mice studies and progressed to a Phase 1 A\/B clinical trial (NCT04543188).","Indexes":[2,4],"Sentences":["Through a combination of structure-based drug design (SBDD) and the optimization of physiochemical properties to enhance BBB penetration, we herein report the discovery of the brain-penetrant BRAFV600E inhibitor PF-07284890 (ARRY-461).","Based on compelling preclinical safety and efficacy studies, ARRY-461 was progressed into a Phase 1 A\/B clinical trial (NCT04543188)."],"Revise":false}
{"PMID":"38197138","Document":["Aim: Investigate TKI sitravatinib plus anti-PD-1 antibody tislelizumab in patients with unresectable\/advanced\/metastatic melanoma with disease progression on\/after prior first-line anti-PD-(L)1 monotherapy.","Methods: Open-label, multicenter, multicohort study (NCT03666143).","Patients in the melanoma cohort (N\u00a0=\u00a025) received sitravatinib once daily plus tislelizumab every 3\u00a0weeks.","The primary end point was safety and tolerability.","Results: Treatment-emergent adverse events (TEAEs) occurred in all patients, with \u2265grade 3 TEAEs in 52.0%.","Most TEAEs were mild-or-moderate in severity, none were fatal, and few patients discontinued treatment owing to TEAEs (12.0%).","Objective response rate was 36.0% (95% CI: 18.0-57.5).","Median progression-free survival was 6.7\u00a0months (95% CI: 4.1-not estimable).","Conclusion: Sitravatinib plus tislelizumab had manageable safety\/tolerability in patients with anti-PD-(L)1 refractory\/resistant unresectable\/advanced\/metastatic melanoma, with promising antitumor activity.","Clinical Trial Registration: NCT03666143 (ClinicalTrials.gov)."],"Aspect":"s","Summary":"Treatment-emergent adverse events (TEAEs) occurred in all patients, with \u2265grade 3 TEAEs in 52.0%, and 12.0% discontinued treatment due to TEAEs.","Indexes":[4,5],"Sentences":["Results: Treatment-emergent adverse events (TEAEs) occurred in all patients, with \u2265grade 3 TEAEs in 52.0%.","Most TEAEs were mild-or-moderate in severity, none were fatal, and few patients discontinued treatment owing to TEAEs (12.0%)."],"Revise":false}
{"PMID":"36445410","Document":["BACKGROUND: CAPRA (NCT02565992) evaluated Coxsackievirus A21 (V937)\u2009+\u2009pembrolizumab for metastatic\/unresectable stage IIIB-IV melanoma.","METHODS: Patients received intratumoral V937 on days 1, 3, 5, and 8 (then every 3\u00a0weeks [Q3W]) and intravenous pembrolizumab 2\u00a0mg\/kg Q3W from day 8.","Primary endpoint was safety.","RESULTS: Median time from first dose to data cutoff was 32.0\u00a0months.","No dose-limiting toxicities occurred; 14% (5\/36) of patients experienced grade 3\u20125 treatment-related adverse events.","Objective response rate was 47% (complete response, 22%).","Among 17 responders, 14 (82%) had responses\u2009\u2265\u20096\u00a0months.","Among 8 patients previously treated with immunotherapy, 3 responded (1 complete, 2 partial).","Responses were associated with increased serum CXCL10 and CCL22, suggesting viral replication contributes to antitumor immunity.","For responders versus nonresponders, there was no difference in baseline tumor PD-L1 expression, ICAM1 expression, or CD3+ infiltrates.","Surprisingly, the baseline cell density of CD3+CD8- T cells in the tumor microenvironment was significantly lower in responders compared with nonresponders (P\u2009=\u20090.0179).","CONCLUSIONS: These findings suggest responses to this combination may be seen even in patients without a typical \"immune-active\" microenvironment.","TRIAL REGISTRATION NUMBER: NCT02565992."],"Aspect":"s","Summary":"14% of patients experienced grade 3\u20125 treatment-related adverse events.","Indexes":[4],"Sentences":["No dose-limiting toxicities occurred; 14% (5\/36) of patients experienced grade 3\u20125 treatment-related adverse events."],"Revise":false}
{"PMID":"36202690","Document":["BACKGROUND: Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) versus placebo in resected stage IIB and IIC melanoma in the phase 3 KEYNOTE-716 study.","Health-related quality of life (HRQoL) results are reported.","METHODS: Patients were randomly assigned 1:1 to pembrolizumab 200\u00a0mg (2\u00a0mg\/kg, patients \u226512 to <18 years) Q3W or placebo for \u226417 cycles or until disease recurrence, unacceptable toxicity, or withdrawal.","Change from baseline in EORTC QLQ-C30 global health status (GHS)\/quality of life (QoL) was a prespecified exploratory end point.","Change in EORTC QLQ-C30 functioning, symptom, and single-item scales, and EQ-5D-5L visual analog scale (VAS) were also summarized.","Primary analyses were performed at week 48 to ensure adequate completion\/compliance.","The HRQoL population comprised patients who received \u22651 dose of treatment and completed \u22651 assessment.","RESULTS: The HRQoL population included 969 patients (pembrolizumab, n\u00a0=\u00a0483; placebo, n\u00a0=\u00a0486).","Compliance at week 48 was \u226580% for both instruments.","EORTC QLQ-C30 GHS\/QoL, physical functioning, role functioning, and EQ-5D-5L VAS scores were stable from baseline to week 48 in both arms, with no clinically meaningful decline observed.","Scores did not differ significantly between pembrolizumab and placebo.","EORTC QLQ-C30 GHS\/QoL, physical functioning, role functioning, and EQ-5D-5L VAS scores remained stable through week 96 in both arms.","CONCLUSIONS: HRQoL was stable with adjuvant pembrolizumab, with no clinically meaningful decline observed.","Change from baseline in HRQoL was similar between arms.","These results, in conjunction with the improved RFS and manageable safety previously reported, support the use of adjuvant pembrolizumab for high-risk stage II melanoma."],"Aspect":"a","Summary":"The study aims to evaluate the health-related quality of life (HRQoL) outcomes in patients with resected stage IIB and IIC melanoma who were treated with adjuvant pembrolizumab versus placebo.","Indexes":[1,3],"Sentences":["Health-related quality of life (HRQoL) results are reported.","Change from baseline in EORTC QLQ-C30 global health status (GHS)\/quality of life (QoL) was a prespecified exploratory end point."],"Revise":false}
{"PMID":"32157728","Document":["BACKGROUND: Skin cancer is a well-recognized public health issue, and primary prevention is the most effective strategy for reducing skin cancer risk.","The current recommendations are that behavioral counseling for sun safety measures is most beneficial and effective for children and adolescents and that targeting this population at primary and middle schools is the ideal intervention strategy to increase sun-protective behaviors and reduce UV exposure, sunburn incidence, and formation of new moles.","Numerous studies on the effectiveness of school-based sun safety interventions among elementary and middle school students have shown an increase in sun safety knowledge, attitudes, and behaviors following the intervention.","OBJECTIVE: To conduct a pilot feasibility study of \"Live Sun Smart!,\" (LSS) a school-based, multicomponent, interactive sun safety presentation, at changing sun safety knowledge, attitudes, and behaviors among middle school students.","METHODS: A non-randomized, single-group pretest-posttest interventional pilot study of the LSS program among children enrolled in grade 6.","RESULTS: After exposure to LSS, participants were more likely to give correct answers to knowledge-based sun safety questions and to report negative attitudes toward tanning.","Minimal and not significant changes were found in self-reported sun safety behaviors, though students did report an intention to change behaviors following the intervention.","Participants were satisfied with the program and believed it increased their sun safety knowledge.","CONCLUSION: Live Sun Smart!","appears to be an effective school-based, multicomponent sun safety program for improving sun safety knowledge and attitudes toward tanning among middle school students in this initial test of it.","The strengths and weaknesses of this pilot study have implications for future research."],"Aspect":"p","Summary":"The study involved middle school students enrolled in grade 6.","Indexes":[4],"Sentences":["METHODS: A non-randomized, single-group pretest-posttest interventional pilot study of the LSS program among children enrolled in grade 6."],"Revise":false}
{"PMID":"38362837","Document":["SAR439459, a 'second-generation' human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody, inhibits all TGF\u03b2 isoforms and improves the antitumor activity of anti-programmed cell death protein-1 therapeutics.","This study reports the pharmacodynamics (PD) and biomarker results from phase I\/Ib first-in-human study of SAR439459\u2009\u00b1\u2009cemiplimab in patients with advanced solid tumors (NCT03192345).","In dose-escalation phase (Part 1), SAR439459 was administered intravenously at increasing doses either every 2\u2009weeks (Q2W) or every 3\u2009weeks (Q3W) with cemiplimab IV at 3\u2009mg\/kg Q2W or 350\u2009mg Q3W, respectively, in patients with advanced solid tumors.","In dose-expansion phase (Part 2), patients with melanoma received SAR439459 IV Q3W at preliminary recommended phase II dose (pRP2D) of 22.5\/7.5\u2009mg\/kg or at 22.5\u2009mg\/kg with cemiplimab 350\u2009mg IV Q3W.","Tumor biopsy and peripheral blood samples were collected for exploratory biomarker analyses to assess target engagement and PD, and results were correlated with patients' clinical parameters.","SAR439459\u2009\u00b1\u2009cemiplimab showed decreased plasma and tissue TGF\u03b2, downregulation of TGF\u03b2-pathway activation signature, modulation of peripheral natural killer (NK) and T cell expansion, proliferation, and increased secretion of CXCL10.","Conversion of tumor tissue samples from 'immune-excluded' to 'immune-infiltrated' phenotype in a representative patient with melanoma SAR439459 22.5\u2009mg\/kg with cemiplimab was observed.","In paired tumor and plasma, active and total TGF\u03b21 was more consistently elevated followed by TGF\u03b22, whereas TGF\u03b23 was only measurable (lower limit of quantitation \u22652.68\u2009pg\/mg) in tumors.","SAR439459\u2009\u00b1\u2009cemiplimab showed expected peripheral PD effects and TGF\u03b2 alteration.","However, further studies are needed to identify biomarkers of response."],"Aspect":"p","Summary":"The study involved patients with advanced solid tumors, including a subset with melanoma, who were treated with SAR439459 \u00b1 cemiplimab in a phase I\/Ib first-in-human study.","Indexes":[1,3],"Sentences":["This study reports the pharmacodynamics (PD) and biomarker results from phase I\/Ib first-in-human study of SAR439459\u2009\u00b1\u2009cemiplimab in patients with advanced solid tumors (NCT03192345).","In dose-expansion phase (Part 2), patients with melanoma received SAR439459 IV Q3W at preliminary recommended phase II dose (pRP2D) of 22.5\/7.5\u2009mg\/kg or at 22.5\u2009mg\/kg with cemiplimab 350\u2009mg IV Q3W."],"Revise":false}
{"PMID":"38485189","Document":["BACKGROUND: Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) versus placebo in the phase 3 KEYNOTE-716 study of resected stage IIB or IIC melanoma.","At the prespecified third interim analysis (data cut-off, January 4, 2022), the HR for RFS in the overall population was 0.64 (95% CI, 0.50 to 0.84) and the HR for DMFS was 0.64 (95% CI, 0.47 to 0.88).","We present a post hoc analysis of efficacy by subtypes defined by histopathologic characteristics.","METHODS: Patients aged \u226512 years with newly diagnosed, resected stage IIB or IIC melanoma were randomly assigned (1:1) to pembrolizumab 200\u2009mg every 3 weeks (2\u2009mg\/kg up to 200\u2009mg for pediatric patients) or placebo.","The primary end point was RFS per investigator review; DMFS per investigator review was secondary.","Subgroups of interest were melanoma subtype (nodular vs non-nodular), tumor thickness (\u22644\u2009mm vs >4\u2009mm), presence of ulceration (yes vs no), mitotic rate (<5 per mm2 (median) vs \u22655 per mm2), and presence of tumor-infiltrating lymphocytes (TILs; absent vs present).","RESULTS: Between September 23, 2018, and November 4, 2020, 976 patients were assigned to pembrolizumab (n=487) or placebo (n=489).","Median follow-up was 27.4 months (range, 14.0-39.4).","The HR (95%\u2009CI) for RFS was 0.54 (0.37 to 0.79) for nodular and 0.77 (0.53 to 1.11) for non-nodular melanoma; 0.57 (0.37 to 0.89) for thickness \u22644\u2009mm and 0.69 (0.50 to 0.96) for >4\u2009mm; 0.66 (0.50 to 0.89) for ulceration and 0.57 (0.32 to 1.03) for no ulceration; 0.57 (0.35 to 0.92) for mitotic rate <5 per mm2 and 0.57 (0.40 to 0.80) for \u22655 per mm2; and 0.89 (0.52 to 1.54) for TILs absent and 0.51 (0.34 to 0.76) for TILs present.","DMFS results were similar.","In a Cox multivariate analysis, treatment arm, tumor thickness, and mitotic rate were significant independent factors for RFS, and treatment arm and mitotic rate were significant independent factors for DMFS.","CONCLUSIONS: In this post hoc analysis, the benefit of pembrolizumab was largely consistent with the overall study population regardless of histopathologic characteristics.","These results support the use of adjuvant pembrolizumab in patients with resected stage IIB or IIC melanoma.","TRIAL REGISTRATION NUMBER: ClinicalTrials.gov, NCT03553836."],"Aspect":"d","Summary":"Patients received pembrolizumab 200 mg every 3 weeks (or 2 mg\/kg up to 200 mg for pediatric patients).","Indexes":[3],"Sentences":["METHODS: Patients aged \u226512 years with newly diagnosed, resected stage IIB or IIC melanoma were randomly assigned (1:1) to pembrolizumab 200\u2009mg every 3 weeks (2\u2009mg\/kg up to 200\u2009mg for pediatric patients) or placebo."],"Revise":true}
{"PMID":"39191779","Document":["Image-guided percutaneous cryoablation is an established minimally invasive oncologic treatment.","We hypothesized that cryoablation may modify the immune microenvironment through direct modulation of the tumor, thereby generating an anti-tumor response in tumors refractory to immune checkpoint inhibition (ICI).","In this non-randomized phase II single-center study (NCT03290677), subjects with unresectable melanoma progressing on ICI underwent cryoablation of an enlarging metastasis, and ICI was continued for a minimum of two additional cycles.","The primary endpoints were safety, feasibility and tumor response in non-ablated lesions.","From May 2018 through July 2020, 17 patients were treated on study.","The study met its primary endpoints with the combination strategy found to be safe and feasible with an objective response rate of 23.5% and disease control rate of 41% (4 partial response, 3 stable disease).","Our data support further study of this synergistic therapeutic approach."],"Aspect":"o","Summary":"The study found that the combination of cryoablation and continued immune checkpoint inhibition was safe and feasible, with an objective response rate of 23.5% and a disease control rate of 41%.","Indexes":[5],"Sentences":["The study met its primary endpoints with the combination strategy found to be safe and feasible with an objective response rate of 23.5% and disease control rate of 41% (4 partial response, 3 stable disease)."],"Revise":false}
{"PMID":"39023605","Document":["INTRODUCTION: We conducted an open-label, single-arm, multi-center phase II trial to evaluate the efficacy and safety of imatinib chemotherapy-refractory or metastatic solid tumor patients with c-KIT mutations and\/or amplification.","METHODS: c-KIT mutations and amplification were detected using NGS.","Imatinib (400 mg daily) was administered continuously in 28-day cycles until disease progression, unacceptable adverse events, or death by any cause.","The primary endpoint was the objective response rate (ORR).","RESULT: In total, 18 patients were enrolled on this trial.","The most common tumor type was melanoma (n = 15, 83.3%), followed by ovarian cancer, breast cancer, and metastasis of unknown origin (MUO) (each n = 1, 5.5%).","The total number of evaluable patients was 17, of which one patient had a complete response, six patients had partial response, and two patients had stable disease.","The overall response rate (ORR) of 41.2% (95% CI 17.80-64.60) and a disease control rate of 52.9% (95% CI 29.17-76.63).","The median progression-free survival was 2.2 months (95% CI 1.29-3.20), and median overall survival was 9.1 months (95% CI 2.10-16.11).","The most common adverse events were edema (31.3%), anorexia (25.0%), nausea (18.8%), and skin rash (18.8%).","CONCLUSION: Imatinib demonstrated modest anti-tumor activity and a manageable safety profile in chemotherapy-refractory solid tumors with c-KIT mutation, especially in melanoma patients."],"Aspect":"p","Summary":"The study enrolled 18 patients with chemotherapy-refractory or metastatic solid tumors, the most common tumor type being melanoma (n = 15, 83.3%), followed by ovarian cancer, breast cancer, and metastasis of unknown origin (each n = 1, 5.5%).","Indexes":[4,5],"Sentences":["RESULT: In total, 18 patients were enrolled on this trial.","The most common tumor type was melanoma (n = 15, 83.3%), followed by ovarian cancer, breast cancer, and metastasis of unknown origin (MUO) (each n = 1, 5.5%)."],"Revise":false}
{"PMID":"33875611","Document":["BACKGROUND: While programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) antagonists have improved the prognosis for many patients with melanoma, around 60% fail therapy.","PVSRIPO is a non-neurovirulent rhinovirus:poliovirus chimera that facilitates an antitumor immune response following cell entry via the poliovirus receptor CD155, which is expressed on tumor and antigen-presenting cells.","Preclinical studies show that oncolytic virus plus anti-PD-1 therapy leads to a greater antitumor response than either agent alone, warranting clinical investigation.","METHODS: An open-label phase I trial of intratumoral PVSRIPO in patients with unresectable melanoma (American Joint Committee on Cancer V.7 stage IIIB, IIIC, or IV) was performed.","Eligible patients had disease progression on anti-PD-1 and V-raf murine sarcoma viral oncogene homolog B (BRAF)\/mitogen activated protein kinase kinase (MEK) inhibitors (if BRAF mutant).","The primary objective was to characterize the safety and tolerability of PVSRIPO.","Twelve patients in four cohorts received a total of 1, 2 or 3 injections of PVSRIPO monotherapy, with 21 days between injections.","RESULTS: PVSRIPO injections were well tolerated with no serious adverse events (SAEs) or dose-limiting toxicities (DLTs) reported.","All adverse events (AEs) were grade (G) 1 or G2 (G1 pruritus most common at 58%); all but two PVSRIPO-treatment related AEs were localized to the injected or adjacent lesions (n=1\u2009G1 hot flash, n=1\u2009G1 fatigue).","Four out of 12 patients (33%) achieved an objective response per immune-related response criteria (two observations, 4 weeks apart), including 4\/6 (67%) who received three injections.","In the four patients with in-transit disease, a pathological complete response (pCR) was observed in two (50%) patients.","Following study completion, 11\/12 patients (92%) reinitiated immune checkpoint inhibitor-based therapy, and 6\/12 patients (50%) remained without progression at a median follow-up time of 18 months.","CONCLUSION: Intratumoral PVSRIPO was well tolerated.","Despite the limited number of PVSRIPO treatments relative to the overall lesion burden (67% patients>5 lesions), intratumoral PVSRIPO showed promising antitumor activity, with pCR in injected as well as non-injected lesions in select patients.","TRIAL REGISTRATION NUMBER: NCT03712358."],"Aspect":"o","Summary":"Intratumoral PVSRIPO was well tolerated with no serious adverse events or dose-limiting toxicities, showing promising antitumor activity, including 33% objective response rate and 50% pathological complete response in in-transit disease.","Indexes":[7,9,10,13],"Sentences":["RESULTS: PVSRIPO injections were well tolerated with no serious adverse events (SAEs) or dose-limiting toxicities (DLTs) reported.","Four out of 12 patients (33%) achieved an objective response per immune-related response criteria (two observations, 4 weeks apart), including 4\/6 (67%) who received three injections.","In the four patients with in-transit disease, a pathological complete response (pCR) was observed in two (50%) patients.","Despite the limited number of PVSRIPO treatments relative to the overall lesion burden (67% patients>5 lesions), intratumoral PVSRIPO showed promising antitumor activity, with pCR in injected as well as non-injected lesions in select patients."],"Revise":true}
{"PMID":"37219686","Document":["PURPOSE: Genomic alterations of BRAF and NRAS are oncogenic drivers in malignant melanoma and other solid tumors.","Tovorafenib is an investigational, oral, selective, CNS-penetrant, small molecule, type II pan\u2011RAF inhibitor.","This first-in-human phase 1 study explored the safety and antitumor activity of tovorafenib.","METHODS: This two-part study in adult patients with relapsed or refractory advanced solid tumors included a dose escalation phase and a dose expansion phase including molecularly defined cohorts of patients with melanoma.","Primary objectives were to evaluate the safety of tovorafenib administered once every other day (Q2D) or once weekly (QW), and to determine the maximum-tolerated and recommended phase 2 dose (RP2D) on these schedules.","Secondary objectives included evaluation of antitumor activity and tovorafenib pharmacokinetics.","RESULTS: Tovorafenib was administered to 149 patients (Q2D n\u2009=\u2009110, QW n\u2009=\u200939).","The RP2D of tovorafenib was defined as 200\u00a0mg Q2D or 600\u00a0mg QW.","In the dose expansion phase, 58 (73%) of 80 patients in Q2D cohorts and 9 (47%) of 19 in the QW cohort had grade\u2009\u2265\u20093 adverse events.","The most common of these overall were anemia (14 patients, 14%) and maculo-papular rash (8 patients, 8%).","Responses were seen in 10 (15%) of 68 evaluable patients in the Q2D expansion phase, including in 8 of 16 (50%) patients with BRAF mutation-positive melanoma na\u00efve to RAF and MEK inhibitors.","In the QW dose expansion phase, there were no responses in 17 evaluable patients with NRAS mutation-positive melanoma na\u00efve to RAF and MEK inhibitors; 9 patients (53%) had a best response of stable disease.","QW dose administration was associated with minimal accumulation of tovorafenib in systemic circulation in the dose range of 400-800\u00a0mg.","CONCLUSIONS: The safety profile of both schedules was acceptable, with QW dosing at the RP2D of 600\u00a0mg QW preferred for future clinical studies.","Antitumor activity of tovorafenib in BRAF-mutated melanoma was promising and justifies continued clinical development across multiple settings.","GOV IDENTIFIER: NCT01425008."],"Aspect":"p","Summary":"The study involved 149 adult patients with relapsed or refractory advanced solid tumors, including those with melanoma.","Indexes":[3,6],"Sentences":["METHODS: This two-part study in adult patients with relapsed or refractory advanced solid tumors included a dose escalation phase and a dose expansion phase including molecularly defined cohorts of patients with melanoma.","RESULTS: Tovorafenib was administered to 149 patients (Q2D n\u2009=\u2009110, QW n\u2009=\u200939)."],"Revise":false}
{"PMID":"37378632","Document":["PURPOSE: Cancer vaccines represent a novel treatment modality with a complementary mode of action addressing a crucial bottleneck for checkpoint inhibitor (CPI) efficacy.","CPIs are expected to release brakes in T-cell responses elicited by vaccination, leading to more robust immune responses.","Increased antitumor T-cell responses may confer increased antitumor activity in patients with less immunogenic tumors, a subgroup expected to achieve reduced benefit from CPIs alone.","In this trial, a telomerase-based vaccine was combined with pembrolizumab to assess the safety and clinical activity in patients with melanoma.","PATIENTS AND METHODS: Thirty treatment-na\u00efve patients with advanced melanoma were enrolled.","Patients received intradermal injections of UV1 with adjuvant GM-CSF at two dose levels, and pembrolizumab according to the label.","Blood samples were assessed for vaccine-induced T-cell responses, and tumor tissues were collected for translational analyses.","The primary endpoint was safety, with secondary objectives including progression-free survival (PFS), overall survival (OS), and objective response rate (ORR).","RESULTS: The combination was considered safe and well-tolerated.","Grade 3 adverse events were observed in 20% of patients, with no grade 4 or 5 adverse events reported.","Vaccination-related adverse events were mostly mild injection site reactions.","The median PFS was 18.9 months, and the 1- and 2-year OS rates were 86.7% and 73.3%, respectively.","The ORR was 56.7%, with 33.3% achieving complete responses.","Vaccine-induced immune responses were observed in evaluable patients, and inflammatory changes were detected in posttreatment biopsies.","CONCLUSIONS: Encouraging safety and preliminary efficacy were observed.","Randomized phase II trials are currently ongoing."],"Aspect":"s","Summary":"Grade 3 adverse events were observed in 20% of patients, with vaccination-related adverse events being mostly mild injection site reactions.","Indexes":[9,10],"Sentences":["Grade 3 adverse events were observed in 20% of patients, with no grade 4 or 5 adverse events reported.","Vaccination-related adverse events were mostly mild injection site reactions."],"Revise":false}
{"PMID":"36524210","Document":["We evaluated the immunological responses of lymph-node involved (stage III) melanoma patients to adjuvant dendritic cell vaccination with subsets of naturally occurring dendritic cells (nDCs).","Fifteen patients with completely resected stage III melanoma were randomized to receive adjuvant dendritic cell vaccination with CD1c+ myeloid dendritic cells (cDC2s), plasmacytoid dendritic cells (pDCs) or the combination.","Immunological response was the primary endpoint and secondary endpoints included safety and survival.","In 80% of the patients, antigen-specific CD8+ T cells were detected in skin test-derived T cells and in 55% of patients, antigen-specific CD8+ T cells were detectable in peripheral blood.","Functional interferon-\u03b3-producing T cells were found in the skin test of 64% of the patients.","Production of nDC vaccines meeting release criteria was feasible for all patients.","Vaccination only induced grade 1-2 adverse events, mainly consisting of fatigue.","In conclusion, adjuvant dendritic cell vaccination with cDC2s and\/or pDCs is feasible, safe and induced immunological responses in the majority of stage III melanoma patients."],"Aspect":"s","Summary":"Vaccination only induced grade 1-2 adverse events, mainly consisting of fatigue.","Indexes":[6],"Sentences":["Vaccination only induced grade 1-2 adverse events, mainly consisting of fatigue."],"Revise":false}
{"PMID":"33861486","Document":["LESSONS LEARNED: This study suggests that trametinib has significant clinical activity in non-V600 BRAF mutation and BRAF fusion metastatic melanoma, albeit in a small cohort.","All patients with metastatic melanoma should undergo sequencing of the BRAF gene to identify noncanonical BRAF mutations that may indicate benefit from treatment with trametinib.","BACKGROUND: Non-V600 BRAF mutations and BRAF fusions in aggregate occur in approximately 5% of all melanomas.","Inhibition of the mitogen-activated protein kinase (MAPK) pathway has been implicated as a possible treatment strategy for these patients.","METHODS: In this open-label, multicenter, phase II study, patients with advanced melanoma harboring mutations in BRAF outside V600 (non-V600) or BRAF fusions received trametinib 2.0 mg daily.","Patients were divided into cohorts based on the intrinsic catalytic activity of BRAF mutation (high, cohort A; low\/unknown, cohort B).","The primary endpoint was objective response rate (ORR) for patients in cohort A; secondary endpoints included ORR in cohort B, safety, and survival in both treatment arms.","RESULTS: Among all patients, the ORR was 33% (three of nine patients), including 67% in cohort A and 17% in cohort B.","Two patients had stable disease as best response, and six patients had some degree of tumor shrinkage.","The median progression-free survival (PFS) was 7.3 months.","Treatment-related adverse events occurred in all patients (100%); most (89%) were grade 1-2.","CONCLUSION: In contrast to recently described tumor-agnostic studies in a genetically similar population, trametinib had considerable activity in a small population of patients with melanoma harboring BRAF non-V600 mutations and fusions, providing rationale for sequencing in search of these genomic alterations."],"Aspect":"s","Summary":"Treatment-related adverse events occurred in all patients (100%); most (89%) were grade 1-2.","Indexes":[10],"Sentences":["Treatment-related adverse events occurred in all patients (100%); most (89%) were grade 1-2."],"Revise":false}
{"PMID":"32997575","Document":["PURPOSE: The CheckMate 066 trial investigated nivolumab monotherapy as first-line treatment for patients with previously untreated BRAF wild-type advanced melanoma.","Five-year results are presented herein.","PATIENTS AND METHODS: In this multicenter, double-blind, phase III study, 418 patients with previously untreated, unresectable, stage III\/IV, wild-type BRAF melanoma were randomly assigned 1:1 to receive nivolumab 3 mg\/kg every 2 weeks or dacarbazine 1,000 mg\/m2 every 3 weeks.","The primary end point was overall survival (OS), and secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety.","RESULTS: Patients were followed for a minimum of 60 months from the last patient randomly assigned (median follow-up, 32.0 months for nivolumab and 10.9 months for dacarbazine).","Five-year OS rates were 39% with nivolumab and 17% with dacarbazine; PFS rates were 28% and 3%, respectively.","Five-year OS was 38% in patients randomly assigned to dacarbazine who had subsequent therapy, including nivolumab (n = 37).","ORR was 42% with nivolumab and 14% with dacarbazine; among patients alive at 5 years, ORR was 81% and 39%, respectively.","Of 42 patients treated with nivolumab who had a complete response (20%), 88% (37 of 42) were alive as of the 5-year analysis.","Among 75 nivolumab-treated patients alive and evaluable at the 5-year analysis, 83% had not received subsequent therapy; 23% were still on study treatment, and 60% were treatment free.","Safety analyses were similar to the 3-year report.","CONCLUSION: Results from this 5-year analysis confirm the significant benefit of nivolumab over dacarbazine for all end points and add to the growing body of evidence supporting long-term survival with nivolumab mono-therapy.","Survival is strongly associated with achieving a durable response, which can be maintained after treatment discontinuation, even without subsequent systemic therapies."],"Aspect":"s","Summary":"Safety analyses at the 5-year follow-up were consistent with those reported in the 3-year analysis.","Indexes":[10],"Sentences":["Safety analyses were similar to the 3-year report."],"Revise":true}
{"PMID":"31895407","Document":["IMPORTANCE: Whether immune-related adverse events (irAEs) indicate drug activity in patients treated with immune checkpoint inhibitors remains unknown.","OBJECTIVE: To investigate the association between irAEs and recurrence-free survival (RFS) in the double-blind EORTC 1325\/KEYNOTE-054 clinical trial comparing pembrolizumab therapy and placebo for the treatment of patients with high-risk stage III melanoma.","DESIGN, SETTING, AND PARTICIPANTS: A total of 1019 adults with stage III melanoma were randomly assigned on a 1:1 ratio to receive treatment with pembrolizumab therapy or placebo.","Eligible patients were adults 18 years and older with complete resection of cutaneous melanoma metastatic to lymph nodes, classified with stage IIIA (at least 1 micrometastasis measuring >1 mm in greatest diameter), IIIB, or IIIC (without in-transit metastasis) cancer.","Patients were randomized from August 26, 2015, to November 14, 2016.","The clinical cutoff for the data set was October 2, 2017.","Analyses were then performed on the database, which was locked on November 28, 2017.","INTERVENTIONS: Participants were scheduled to receive 200 mg of pembrolizumab or placebo every 3 weeks for a total of 18 doses for approximately\u20091 year or until disease recurrence, unacceptable toxic effects, major protocol violation, or withdrawal of consent.","MAIN OUTCOMES AND MEASURES: The association between irAEs and RFS was estimated using a Cox model adjusted for sex, age, and AJCC-7 stage, with a time-varying covariate that had a value of 0 before irAE onset and 1 after irAE onset.","RESULTS: Of 1011 patients who began treatment with pembrolizumab therapy or placebo, 622 (61.5%) were men and 389 (38.5%) were women; 386 patients (38.2%) were aged 50 to 64 years, 377 (37.3%) were younger than 50 years, and 248 (24.5%) were 65 years and older.","Consistent with the reported main analysis in the intent-to-treat population, RFS was longer in the pembrolizumab arm compared with the placebo arm (hazard ratio [HR], 0.56; 98.4% CI, 0.43-0.74) among patients who started treatment.","The incidence of irAEs was 190 (37.4%) in the pembrolizumab arm (n\u2009=\u2009509) and 45 (9.0%) in the placebo arm (n\u2009=\u2009502); in each treatment group, the incidence was similar for men and women.","The occurrence of an irAE was associated with a longer RFS in the pembrolizumab arm (HR, 0.61; 95% CI, 0.39-0.95; P\u2009=\u2009.03) in both men and women.","However, in the placebo arm, this association was not significant.","Compared with the placebo arm, the reduction in the hazard of recurrence or death in the pembrolizumab arm was greater after the onset of an irAE than without or before an irAE (HR, 0.37; 95% CI, 0.24-0.57 vs HR, 0.61; 95% CI, 0.49-0.77, respectively; P\u2009=\u2009.03).","CONCLUSIONS AND RELEVANCE: In this study, the occurrence of an irAE was associated with a longer RFS in the pembrolizumab arm.","TRIAL REGISTRATIONS: ClinicalTrials.gov identifier: NCT02362594; EudraCT identifier: 2014-004944-37."],"Aspect":"s","Summary":"The incidence of immune-related adverse events (irAEs) was 37.4% in the pembrolizumab arm and 9.0% in the placebo arm.","Indexes":[11],"Sentences":["The incidence of irAEs was 190 (37.4%) in the pembrolizumab arm (n\u2009=\u2009509) and 45 (9.0%) in the placebo arm (n\u2009=\u2009502); in each treatment group, the incidence was similar for men and women."],"Revise":true}
{"PMID":"33288749","Document":["Combining PD-L1 blockade with inhibition of oncogenic mitogen-activated protein kinase (MAPK) signaling may result in long-lasting responses in patients with advanced melanoma.","This phase 1, open-label, dose-escalation and -expansion study (NCT02027961) investigated safety, tolerability and preliminary efficacy of durvalumab (anti-PD-L1) combined with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) for patients with BRAF-mutated melanoma (cohort A, n\u2009=\u200926), or durvalumab and trametinib given concomitantly (cohort B, n\u2009=\u200920) or sequentially (cohort C, n\u2009=\u200922) for patients with BRAF-wild type melanoma.","Adverse events and treatment discontinuation rates were more common than previously reported for these agents given as monotherapy.","Objective responses were observed in 69.2% (cohort A), 20.0% (cohort B) and 31.8% (cohort C) of patients, with evidence of improved tumor immune infiltration and durable responses in a subset of patients with available biopsy samples.","In conclusion, combined MAPK inhibition and anti-PD-L1 therapy may provide treatment options for patients with advanced melanoma."],"Aspect":"p","Summary":"The study involved 68 patients with advanced melanoma, including 26 with BRAF-mutated melanoma and 42 with BRAF-wild type melanoma, divided into three cohorts (A, B, and C).","Indexes":[1],"Sentences":["This phase 1, open-label, dose-escalation and -expansion study (NCT02027961) investigated safety, tolerability and preliminary efficacy of durvalumab (anti-PD-L1) combined with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) for patients with BRAF-mutated melanoma (cohort A, n\u2009=\u200926), or durvalumab and trametinib given concomitantly (cohort B, n\u2009=\u200920) or sequentially (cohort C, n\u2009=\u200922) for patients with BRAF-wild type melanoma."],"Revise":false}
{"PMID":"37401516","Document":["BACKGROUND: Here we report clinical risk factors and event rates for the development of new non-melanoma skin cancer (NMSC) in a randomized, double-blind, placebo-controlled trial of the irreversible ornithine decarboxylase (ODC) inhibitor, difluromethylornithine (DFMO), over a 3-5-year follow-up.","METHODS: 147 placebo patients (white; mean age 60.2 years; 60% male) were evaluated for event rates and association of initial skin biomarkers and baseline patient characteristics with the development of squamous cell (SCC) and basal cell (BCC) carcinomas.","RESULTS: Post-study evaluation (median follow-up 4.4 years) indicates the measures of prior NMSCs ( P \u2005\u2264\u20050.001), prior BCCs ( P \u2005\u2264\u20050.001), prior SCCs ( P \u2005=\u20050.011), prior tumor rate ( P \u2005=\u20050.002), hemoglobin ( P \u2005=\u20050.022), and gender ( P \u2005=\u20050.045) as significant predictors for new NMSC development.","Similarly, all measures of prior BCCs and NMSCs ( P \u2005<\u20050.001), prior tumor rate ( P \u2005=\u20050.014), and SCCs in the prior 2 years ( P \u2005=\u20050.047) were statistically significant predictors for new BCC development.","Total prior NMSCs and those in the prior 5 years ( P \u2005<\u20050.001), total prior SCCs and those in the prior 5 years ( P \u2005<\u20050.001), total prior BCCs and those in the prior 5 years ( P \u2005\u2264\u20050.001), prior tumor rate ( P \u2005=\u20050.011) as well as age ( P \u2005=\u20050.008), hemoglobin ( P \u2005=\u20050.002), and gender ( P \u2005=\u20050.003) were statistically significant predictors of new SCC development.","TPA-induced ODC activity at baseline showed no statistically significant association with the development of new NMSC ( P \u2005=\u20050.35), new BCCs ( P \u2005=\u20050.62), or new SCCs ( P \u2005=\u20050.25).","CONCLUSION: In the studied population, the history of and rate at which prior NMSCs occur are predictive and should be controlled for in future NMSC prevention trials."],"Aspect":"o","Summary":"The study found that measures of prior NMSCs, BCCs, SCCs, prior tumor rate, hemoglobin, and gender were significant predictors for new NMSC development.","Indexes":[2],"Sentences":["RESULTS: Post-study evaluation (median follow-up 4.4 years) indicates the measures of prior NMSCs ( P \u2005\u2264\u20050.001), prior BCCs ( P \u2005\u2264\u20050.001), prior SCCs ( P \u2005=\u20050.011), prior tumor rate ( P \u2005=\u20050.002), hemoglobin ( P \u2005=\u20050.022), and gender ( P \u2005=\u20050.045) as significant predictors for new NMSC development."],"Revise":true}
{"PMID":"35156519","Document":["Macroautophagy\/autophagy is a resistance mechanism to targeted therapy in BRAF mutant cancers.","Preclinical evidence and clinical trial data demonstrate that hydroxychloroquine (HCQ) is an effective autophagy inhibitor at clinically achievable concentrations.","Here we highlight the results of a recently published single-arm phase I\/II multi-institution trial of dabrafenib, trametinib, and the autophagy inhibitor HCQ (the BAMM trial) that established the safety and activity of this regimen in BRAF V600-mutant melanoma patients.","Compared to the pivotal trials that led to FDA approval of dabrafenib and trametinib, the BAMM trial enrolled a high percentage of patients with elevated LDH and prior immunotherapy, reflecting the trend that poorer-prognosis patients are treated with targeted therapy in the modern era where multiple immunotherapy regimens are available for melanoma.","Dabrafenib, trametinib, and hydroxychloroquine are safe and produce a high response rate (85%).","Progression-free survival does not meet the pre-specified threshold for the entire cohort but looks especially promising in patients with elevated LDH and prior treatment.","A national randomized study has been launched to study this regimen further in poor-prognosis BRAF V600-mutant melanoma patients."],"Aspect":"p","Summary":"The BAMM trial enrolled patients with BRAF V600-mutant melanoma, including those with elevated LDH and prior immunotherapy.","Indexes":[2,3],"Sentences":["Here we highlight the results of a recently published single-arm phase I\/II multi-institution trial of dabrafenib, trametinib, and the autophagy inhibitor HCQ (the BAMM trial) that established the safety and activity of this regimen in BRAF V600-mutant melanoma patients.","Compared to the pivotal trials that led to FDA approval of dabrafenib and trametinib, the BAMM trial enrolled a high percentage of patients with elevated LDH and prior immunotherapy, reflecting the trend that poorer-prognosis patients are treated with targeted therapy in the modern era where multiple immunotherapy regimens are available for melanoma."],"Revise":false}
{"PMID":"38844408","Document":["BACKGROUND: Tebentafusp, a bispecific (gp100\u00d7CD3) ImmTAC, significantly improved overall survival (OS) outcomes for HLA-A*02:01+ adult patients with untreated metastatic uveal melanoma (mUM) and showed promising survival in previously treated mUM with 1-year OS of 62% in the primary analysis of study IMCgp100-102.","Here we report long-term outcomes from this phase 1\/2 study in pretreated mUM.","PATIENTS AND METHODS: Patients with previously treated mUM received tebentafusp weekly intravenous at 20 \u00b5g dose 1, 30 \u00b5g dose 2 and either 54, 64, 68, or 73\u2009\u00b5g (phase 1) or 68\u2009\u00b5g (phase 2) dose 3+.","The primary objective was overall response rate.","Secondary objectives included OS and safety.","OS was estimated by Kaplan-Meier methods.","Association between OS and baseline covariates, on-treatment Response Evaluation Criteria in Solid Tumors (RECIST) response, baseline tumor biopsy and circulating-tumor DNA (ctDNA) changes were assessed.","RESULTS: 146 patients were treated with tebentafusp: 19 in phase 1 and 127 in phase 2.","With a median follow-up duration of 48.5 months, the median OS was 17.4 months (95%\u2009CI, 13.1 to 22.8), and the 1-year, 2-year, 3-year and 4-year OS rates were 62%, 40%, 23% and 14%, respectively.","Improved survival was associated with lower ctDNA baseline levels and greater ctDNA reductions by week 9 on-treatment, with 100% 1-year, 73% 2-year and 45% 3-year OS rates for patients with ctDNA clearance.","Baseline gp100 expression was not associated with survival, despite more RECIST responses among patients with higher expression.","No new safety signals were reported with long-term dosing.","CONCLUSIONS: This study represents the longest follow-up of a Tcell receptor bispecific to date and confirms the durable survival benefits achieved with tebentafusp in previously treated mUM with good tolerability long-term.","A role for ctDNA reduction as an early indicator of clinical benefit was again suggested for patients treated with tebentafusp."],"Aspect":"m","Summary":"The medicine tebentafusp was administered weekly intravenously with varying dosages: 20 \u00b5g for the first dose, 30 \u00b5g for the second dose, and either 54, 64, 68, or 73 \u00b5g (phase 1) or 68 \u00b5g (phase 2) for subsequent doses.","Indexes":[2],"Sentences":["PATIENTS AND METHODS: Patients with previously treated mUM received tebentafusp weekly intravenous at 20 \u00b5g dose 1, 30 \u00b5g dose 2 and either 54, 64, 68, or 73\u2009\u00b5g (phase 1) or 68\u2009\u00b5g (phase 2) dose 3+."],"Revise":false}
{"PMID":"33471137","Document":["BACKGROUND: Limited data are available on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with preexisting autoimmune diseases (PAD).","METHODS: Retrospective study of patients with PAD referred for rheumatologic evaluation prior to starting or during immunotherapy between January 2013 and July 2019 from 10 academic sites across Canada.","Data were extracted by chart review using a standardized form.","RESULTS: Twenty-seven patients with PAD on ICI therapy were identified.","The most common PADs were rheumatoid arthritis (30%), psoriasis\/psoriatic arthritis (30%), inflammatory bowel disease (IBD, 15%) and axial spondyloarthritis (11%), and the most frequently observed cancers were lung cancer and melanoma.","All patients received anti-PD-1 therapies, and 2 received additional sequential anti-CTLA-4 therapy.","PAD exacerbations occurred in 52% over a median (IQR) follow-up of 11.0 (6.0-17.5) months, with 14% being severe, 57% requiring corticosteroids, 50% requiring immunosuppression and 14% requiring ICI discontinuation.","Flares were generally more frequent and severe in patients who previously required more intensive immunosuppression (i.e., biologics).","Flares occurred despite background immunosuppression at the time of ICI initiation.","In patients with preexisting psoriasis, IBD and axial spondyloarthritis, rheumatic immune-related adverse events (irAEs), mostly polyarthritis and tenosynovitis, were frequently observed.","Tumor progression was not associated with exposure to immunosuppressive drugs before or after ICI initiation and was numerically less frequent in patients with irAEs.","CONCLUSION: PAD exacerbations in the context of ICI treatment are common, although generally mild, and occur despite background immunosuppression.","Exacerbations are more frequent and severe in patients on more intensive immunosuppressive therapies pre-immunotherapy."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"34780711","Document":["BACKGROUND: The dependence of the adaptive immune system on circadian rhythm is an emerging field of study with potential therapeutic implications.","We aimed to determine whether specific time-of-day patterns of immune checkpoint inhibitor infusions might alter melanoma treatment efficacy.","METHODS: Melanoma Outcomes Following Immunotherapy (MEMOIR) is a longitudinal study of all patients with melanoma who received ipilimumab, nivolumab, or pembrolizumab, or a combination of these at a single tertiary cancer centre (Winship Cancer Institute of Emory University, Atlanta, GA, USA).","For this analysis, we collected deidentified participant-level data from the MEMOIR database for adults (age \u226518 years) diagnosed with stage IV melanoma between 2012 and 2020.","Those who received fewer than four infusions were excluded.","Standard of care doses were used, with modifications at the treating physicians' discretion.","The primary outcome was overall survival, defined as death from any cause and indexed from date of first infusion of immune checkpoint inhibitor.","We calculated the association between overall survival and proportion of infusions of immune checkpoint inhibitors received after 1630 h (a composite time cutoff derived from seminal studies of the immune-circadian rhythm to represent onset of evening) using Cox regression and propensity score-matching on age, Eastern Cooperative Oncology Group performance status, serum lactate dehydrogenase concentration, and receipt of corticosteroids and radiotherapy.","Treatment-related adverse events that led to change or discontinuation of immune checkpoint inhibitors were also assessed.","FINDINGS: Between Jan 1, 2012, and Dec 31, 2020, 481 patients with melanoma received treatment with immune checkpoint inhibitors at the study centre, of whom 299 had stage IV disease and were included in this study; median follow-up was 27 months (IQR 14 to 47).","In the complete unmatched sample, 102 (34%) patients were female and 197 (66%) were male, with a median age of 61 years (IQR 51 to 72).","Every additional 20% of infusions of immune checkpoint inhibitors received after 1630 h (among all infusions received by a patient) conferred an overall survival hazard ratio (HR) of 1\u00b731 (95% CI 1\u00b700 to 1\u00b771; p=0\u00b7046).","A propensity score-matched analysis of patients who did (n=73) and did not (n=73) receive at least 20% of their infusions of immune checkpoint inhibitors after 1630 h (54 [37%] of 146 patients were women and 92 [63%] were men, with a median age of 58 years [IQR 48 to 68]) showed that having at least 20% of infusions in the evening was associated with shorter overall survival (median 4\u00b78 years [95% CI 3\u00b79 to not estimable] vs not reached; HR 2\u00b704 [1\u00b704 to 4\u00b700; p=0\u00b7038]).","This result remained robust to multivariable proportional hazards adjustment with (HR 1\u00b780 [1\u00b708 to 2\u00b798; p=0\u00b7023]) and without (2\u00b716 [1\u00b710 to 4\u00b725; p=0\u00b7025]) inclusion of the complete unmatched study sample.","The most common adverse events were colitis (54 [18%] of 299 patients), hepatitis (27 [9%]), and hypophysitis (15 [5%]), and there were no treatment-related deaths.","INTERPRETATION: Our findings are in line with an increasing body of evidence that adaptive immune responses are less robust when initially stimulated in the evening than if stimulated in the daytime.","Although prospective studies of the timing of immune checkpoint inhibitor infusions are warranted, efforts towards scheduling infusions before mid-afternoon could be considered in the multidisciplinary management of advanced melanoma.","FUNDING: National Institutes of Health, American Society for Radiation Oncology and Melanoma Research Alliance, and Winship Cancer Institute."],"Aspect":"i","Summary":"The study examined the association between the timing of immune checkpoint inhibitor infusions and overall survival in patients with stage IV melanoma using data from the MEMOIR database, with a focus on infusions received after 1630 h.","Indexes":[2,3,7],"Sentences":["METHODS: Melanoma Outcomes Following Immunotherapy (MEMOIR) is a longitudinal study of all patients with melanoma who received ipilimumab, nivolumab, or pembrolizumab, or a combination of these at a single tertiary cancer centre (Winship Cancer Institute of Emory University, Atlanta, GA, USA).","For this analysis, we collected deidentified participant-level data from the MEMOIR database for adults (age \u226518 years) diagnosed with stage IV melanoma between 2012 and 2020.","We calculated the association between overall survival and proportion of infusions of immune checkpoint inhibitors received after 1630 h (a composite time cutoff derived from seminal studies of the immune-circadian rhythm to represent onset of evening) using Cox regression and propensity score-matching on age, Eastern Cooperative Oncology Group performance status, serum lactate dehydrogenase concentration, and receipt of corticosteroids and radiotherapy."],"Revise":true}
{"PMID":"34813506","Document":["BACKGROUNDNeoantigen-driven recognition and T cell-mediated killing contribute to tumor clearance following adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs).","Yet how diversity, frequency, and persistence of expanded neoepitope-specific CD8+ T cells derived from TIL infusion products affect patient outcome is not fully determined.METHODSUsing barcoded pMHC multimers, we provide a comprehensive mapping of CD8+ T cells recognizing neoepitopes in TIL infusion products and blood samples from 26 metastatic melanoma patients who received ACT.RESULTSWe identified 106 neoepitopes within TIL infusion products corresponding to 1.8% of all predicted neoepitopes.","We observed neoepitope-specific recognition to be virtually devoid in TIL infusion products given to patients with progressive disease outcome.","Moreover, we found that the frequency of neoepitope-specific CD8+ T cells in TIL infusion products correlated with increased survival and that neoepitope-specific CD8+ T cells shared with the infusion product in posttreatment blood samples were unique to responders of TIL-ACT.","Finally, we found that a transcriptional signature for lymphocyte activity within the tumor microenvironment was associated with a higher frequency of neoepitope-specific CD8+ T cells in the infusion product.CONCLUSIONSThese data support previous case studies of neoepitope-specific CD8+ T cells in melanoma and indicate that successful TIL-ACT is associated with an expansion of neoepitope-specific CD8+ T cells.FUNDINGNEYE Foundation; European Research Council; Lundbeck Foundation Fellowship; Carlsberg Foundation."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"36375115","Document":["PURPOSE: BRAF V600 mutations occur in many childhood cancers, including approximately 20% of low-grade gliomas (LGGs).","Here, we describe a phase I\/II study establishing pediatric dosing and pharmacokinetics of trametinib with or without dabrafenib, as well as efficacy and safety in a disease-specific cohort with BRAF V600-mutant LGG; other cohorts will be reported elsewhere.","METHODS: This is a four-part, phase I\/II study (ClinicalTrials.gov identifier: NCT02124772) in patients age < 18 years with relapsed\/refractory malignancies: trametinib monotherapy dose finding (part A) and disease-specific expansion (part B), and dabrafenib + trametinib dose finding (part C) and disease-specific expansion (part D).","The primary objective assessed in all patients in parts A and C was to determine pediatric dosing on the basis of steady-state pharmacokinetics.","Disease-specific efficacy and safety (across parts A-D) were secondary objectives.","RESULTS: Overall, 139 patients received trametinib (n = 91) or dabrafenib + trametinib (n = 48).","Trametinib dose-limiting toxicities in > 1 patient (part A) included mucosal inflammation (n = 3) and hyponatremia (n = 2).","There were no dose-limiting toxicities with combination therapy (part C).","The recommended phase II dose of trametinib, with or without dabrafenib, was 0.032 mg\/kg once daily for patients age < 6 years and 0.025 mg\/kg once daily for patients age \u2265 6 years; dabrafenib dosing in the combination was as previously identified for monotherapy.","In 49 patients with BRAF V600-mutant glioma (LGG, n = 47) across all four study parts, independently assessed objective response rates were 15% (95% CI, 1.9 to 45.4) for monotherapy (n = 13) and 25% (95% CI, 12.1 to 42.2) for combination (n = 36).","Adverse event-related treatment discontinuations were more common with monotherapy (54% v 22%).","CONCLUSION: The trial design provided efficient evaluation of pediatric dosing, safety, and efficacy of single-agent and combination targeted therapy.","Age-based and weight-based dosing of trametinib with or without dabrafenib achieved target concentrations with manageable safety and demonstrated clinical efficacy and tolerability in BRAF V600-mutant LGG."],"Aspect":"o","Summary":"The study determined the recommended phase II dose of trametinib, with or without dabrafenib, and demonstrated clinical efficacy and tolerability in BRAF V600-mutant LGG.","Indexes":[8,9,12],"Sentences":["The recommended phase II dose of trametinib, with or without dabrafenib, was 0.032 mg\/kg once daily for patients age < 6 years and 0.025 mg\/kg once daily for patients age \u2265 6 years; dabrafenib dosing in the combination was as previously identified for monotherapy.","In 49 patients with BRAF V600-mutant glioma (LGG, n = 47) across all four study parts, independently assessed objective response rates were 15% (95% CI, 1.9 to 45.4) for monotherapy (n = 13) and 25% (95% CI, 12.1 to 42.2) for combination (n = 36).","Age-based and weight-based dosing of trametinib with or without dabrafenib achieved target concentrations with manageable safety and demonstrated clinical efficacy and tolerability in BRAF V600-mutant LGG."],"Revise":false}
{"PMID":"34360781","Document":["To identify potential early biomarkers of treatment response and immune-related adverse events (irAE), a pilot immune monitoring study was performed in stage IV melanoma patients by flow cytometric analysis of peripheral blood mononuclear cells (PBMC).","Overall, 17 patients were treated with either nivolumab or pembrolizumab alone, or with a combination of nivolumab and ipilimumab every three weeks.","Of 15 patients for which complete response assessment was available, treatment responders (n = 10) as compared to non-responders (n = 5) were characterized by enhanced PD-1 expression on CD8+ T cells immediately before treatment (median \u00b1 median absolute deviation\/MAD 26.7 \u00b1 10.4% vs. 17.2 \u00b1 5.3%).","Responders showed a higher T cell responsiveness after T cell receptor ex vivo stimulation as determined by measurement of programmed cell death 1 (PD-1) expression on CD3+ T cells before the second cycle of treatment.","The percentage of CD8+ effector memory (CD8+CD45RA-CD45RO+CCR7-) T cells was higher in responders compared to non-responders before and immediately after the first cycle of treatment (median \u00b1 MAD 39.2 \u00b1 7.3% vs. 30.5 \u00b1 4.1% and 37.7 \u00b1 4.6 vs. 24.0 \u00b1 6.4).","Immune-related adverse events (irAE) were accompanied by a higher percentage of activated CD4+ (CD4+CD38+HLADR+) T cells before the second treatment cycle (median \u00b1 MAD 14.9 \u00b1 3.9% vs. 5.3 \u00b1 0.4%).","In summary, PBMC immune monitoring of immune-checkpoint inhibition (ICI) treatment in melanoma appears to be a promising approach to identify early markers of treatment response and irAEs."],"Aspect":"p","Summary":"The study involved 17 stage IV melanoma patients treated with either nivolumab or pembrolizumab alone, or with a combination of nivolumab and ipilimumab every three weeks.","Indexes":[1],"Sentences":["Overall, 17 patients were treated with either nivolumab or pembrolizumab alone, or with a combination of nivolumab and ipilimumab every three weeks."],"Revise":false}
{"PMID":"33064988","Document":["Neoantigens arise from mutations in cancer cells and are important targets of T\u00a0cell-mediated anti-tumor immunity.","Here, we report the first open-label, phase Ib clinical trial of a personalized neoantigen-based vaccine, NEO-PV-01, in combination with PD-1 blockade in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer.","This analysis of 82 patients demonstrated that the regimen was safe, with no treatment-related serious adverse events observed.","De novo neoantigen-specific CD4+ and CD8+ T\u00a0cell responses were observed post-vaccination in all of the patients.","The vaccine-induced T cells had a cytotoxic phenotype and were capable of trafficking to the tumor and mediating cell killing.","In addition, epitope spread to neoantigens not included in the vaccine was detected post-vaccination.","These data support the safety and immunogenicity of this regimen in patients with advanced solid tumors (Clinicaltrials.gov: NCT02897765)."],"Aspect":"o","Summary":"The phase Ib clinical trial demonstrated the safety and immunogenicity of the personalized neoantigen-based vaccine, NEO-PV-01, in combination with PD-1 blockade in patients with advanced solid tumors, inducing de novo neoantigen-specific CD4+ and CD8+ T cell responses and epitope spread.","Indexes":[2,3,5,6],"Sentences":["This analysis of 82 patients demonstrated that the regimen was safe, with no treatment-related serious adverse events observed.","De novo neoantigen-specific CD4+ and CD8+ T\u00a0cell responses were observed post-vaccination in all of the patients.","In addition, epitope spread to neoantigens not included in the vaccine was detected post-vaccination.","These data support the safety and immunogenicity of this regimen in patients with advanced solid tumors (Clinicaltrials.gov: NCT02897765)."],"Revise":false}
{"PMID":"38754916","Document":["BACKGROUND: Chimeric antigen receptor (CAR) T cell therapies specific for the CD19 and B-cell maturation antigen have become an approved standard of care worldwide for relapsed and refractory B-cell malignancies.","If CAR-T cell therapy for non-hematological malignancies is to achieve the same stage of clinical development, then iterative early-phase clinical testing can add value to the clinical development process for evaluating CAR-T cell products containing different CAR designs and manufactured under differing conditions.","METHODS: We conducted a phase 1 trial of third-generation GD2-specific CAR-T cell therapy, which has previously been tested in neuroblastoma patients.","In this study, the GD2-CAR-T therapy was evaluated for the first time in metastatic melanoma patients in combination with BRAF\/MEK inhibitor therapy, and as a monotherapy in patients with colorectal cancer and a patient with fibromyxoid sarcoma.","Feasibility and safety were determined and persistence studies, multiplex cytokine arrays on sera and detailed immune phenotyping of the original CAR-T products, the circulating CAR-T cells, and, in select patients, the tumor-infiltrating CAR-T cells were performed.","RESULTS: We demonstrate the feasibility of manufacturing CAR-T products at point of care for patients with solid cancer and show that a single intravenous infusion was well tolerated with no dose-limiting toxicities or severe adverse events.","In addition, we note significant improvements in CAR-T cell immune phenotype, and expansion when a modified manufacturing procedure was adopted for the latter 6 patients recruited to this 12-patient trial.","We also show evidence of CAR-T cell-mediated immune activity and in some patients expanded subsets of circulating myeloid cells after CAR-T cell therapy.","CONCLUSIONS: This is the first report of third-generation GD2-targeting CAR-T cells in patients with metastatic melanoma and other solid cancers such as colorectal cancer, showing feasibility, safety and immune activity, but limited clinical effect.","TRIAL REGISTRATION NUMBER: ACTRN12613000198729."],"Aspect":"m","Summary":"The trial involved a GD2-specific CAR-T cell therapy in combination with BRAF\/MEK inhibitor therapy.","Indexes":[3],"Sentences":["In this study, the GD2-CAR-T therapy was evaluated for the first time in metastatic melanoma patients in combination with BRAF\/MEK inhibitor therapy, and as a monotherapy in patients with colorectal cancer and a patient with fibromyxoid sarcoma."],"Revise":false}
{"PMID":"33211315","Document":["BACKGROUND: Pimasertib is a selective, potent mitogen-activated protein kinase kinase (MEK) 1\/2 inhibitor.","OBJECTIVES: The aim of this study was to describe the efficacy, safety, and pharmacodynamics of pimasertib at pharmacologically active doses in a cohort of patients with locally advanced\/metastatic melanoma from a first-in-human study of pimasertib.","METHODS: This was a phase I, open-label, two-part, dose-escalation study.","Part 1 was conducted in patients with solid tumors and identified the maximum tolerated dose, while Part 2 was restricted to patients with advanced\/metastatic melanoma.","Endpoints included safety, pharmacodynamics, and antitumor activity.","We present data for patients with melanoma only from both parts of the study.","RESULTS: In total, 93 patients with melanoma received pimasertib, 89 of whom received pharmacologically active doses (28-255 mg\/day) across four dose regimens in the two parts of the study.","The objective response rate was 12.4% (11\/89): complete response (n\u00a0=\u00a01) and partial response (PR; n\u00a0=\u00a010).","Six patients responded for > 24 weeks.","Nine of the 11 responders had tumors with B-Raf Proto-Oncogene, Serine\/Threonine Kinase (BRAF; n\u00a0=\u00a06) and\/or NRAS Proto-Oncogene, GTPase (NRAS; n\u00a0=\u00a03) mutations.","Forty-six patients had stable disease (SD).","In patients with ocular melanoma (n\u00a0=\u00a013), best overall response was PR (n\u00a0=\u00a01), SD (n\u00a0=\u00a011), and disease progression (n\u00a0=\u00a01).","Phosphorylated extracellular signal-regulated kinase (pERK) levels were substantially reduced within 2\u00a0h of treatment and inhibition was sustained with continuous twice-daily dosing.","Treatment-related, recurrent, grade 3 or higher adverse events were reported in eight patients, including diarrhea, and skin and ocular events.","CONCLUSION: Results from this phase I study indicate that pimasertib has clinical activity in patients with locally advanced\/metastatic melanoma, particularly BRAF- and NRAS-mutated tumors, at clinically relevant doses associated with pERK inhibition in peripheral blood mononuclear cells.","TRIAL REGISTRATION: ClinicalTrials.gov, NCT00982865."],"Aspect":"p","Summary":"The study involved 93 patients with locally advanced\/metastatic melanoma, 89 of whom received pharmacologically active doses.","Indexes":[6],"Sentences":["RESULTS: In total, 93 patients with melanoma received pimasertib, 89 of whom received pharmacologically active doses (28-255 mg\/day) across four dose regimens in the two parts of the study."],"Revise":false}
{"PMID":"34774225","Document":["BACKGROUND: Combination nivolumab plus ipilimumab was efficacious in patients with asymptomatic melanoma brain metastases (MBM) in CheckMate 204, but showed low efficacy in patients with symptomatic MBM.","Here, we provide final 3-year follow-up data from the trial.","METHODS: This open-label, multicentre, phase 2 study (CheckMate 204) included adults (aged \u226518 years) with measurable MBM (0\u00b75-3\u00b70 cm in diameter).","Asymptomatic patients (cohort A) had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and no neurological symptoms or baseline corticosteroid use; symptomatic patients (cohort B) had an ECOG performance status of 0-2 with stable neurological symptoms and could be receiving low-dose dexamethasone.","Nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg was given intravenously every 3 weeks for four doses, followed by nivolumab 3 mg\/kg every 2 weeks for up to 2 years, until disease progression or unacceptable toxicity.","The primary endpoint was intracranial clinical benefit rate (complete responses, partial responses, or stable disease lasting \u22656 months) assessed in all treated patients.","Intracranial progression-free survival and overall survival were key secondary endpoints.","This study is registered with ClinicalTrials.gov, NCT02320058.","FINDINGS: Between Feb 19, 2015, and Nov 1, 2017, 119 (72%) of 165 screened patients were enrolled and treated: 101 patients were asymptomatic (cohort A; median follow-up 34\u00b73 months [IQR 14\u00b77-36\u00b74]) and 18 were symptomatic (cohort B; median follow-up 7\u00b75 months [1\u00b72-35\u00b72]).","Investigator-assessed intracranial clinical benefit was observed in 58 (57\u00b74% [95% CI 47\u00b72-67\u00b72]) of 101 patients in cohort A and three (16\u00b77% [3\u00b76-41\u00b74]) of 18 patients in cohort B; investigator-assessed objective response was observed in 54 (53\u00b75% [43\u00b73-63\u00b75]) patients in cohort A and three (16\u00b77% [3\u00b76-41\u00b74]) patients in cohort B.","33 (33%) patients in cohort A and three (17%) patients in cohort B had an investigator-assessed intracranial complete response.","For patients in cohort A, 36-month intracranial progression-free survival was 54\u00b71% (95% CI 42\u00b77-64\u00b71) and overall survival was 71\u00b79% (61\u00b78-79\u00b78).","For patients in cohort B, 36-month intracranial progression-free survival was 18\u00b79% (95% CI 4\u00b76-40\u00b75) and overall survival was 36\u00b76% (14\u00b70-59\u00b78).","The most common grade 3-4 treatment-related adverse events (TRAEs) were increased alanine aminotransferase and aspartate aminotransferase (15 [15%] of 101 patients each) in cohort A; no grade 3 TRAEs occurred in more than one patient each in cohort B, and no grade 4 events occurred.","The most common serious TRAEs were colitis, diarrhoea, hypophysitis, and increased alanine aminotransferase (five [5%] of each among the 101 patients in cohort A); no serious TRAE occurred in more than one patient each in cohort B.","There was one treatment-related death (myocarditis in cohort A).","INTERPRETATION: The durable 3-year response, overall survival, and progression-free survival rates for asymptomatic patients support first-line use of nivolumab plus ipilimumab.","Symptomatic disease in patients with MBM remains difficult to treat, but some patients achieve a long-term response with the combination.","FUNDING: Bristol Myers Squibb."],"Aspect":"d","Summary":"Nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg was administered every 3 weeks for four doses, followed by nivolumab 3 mg\/kg every 2 weeks for up to 2 years.","Indexes":[4],"Sentences":["Nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg was given intravenously every 3 weeks for four doses, followed by nivolumab 3 mg\/kg every 2 weeks for up to 2 years, until disease progression or unacceptable toxicity."],"Revise":true}
{"PMID":"33982452","Document":["BACKGROUND: Checkpoint inhibitors (CPI) in combination with cell-based vaccines may produce synergistic antitumor immunity.","The primary analysis of the randomized and blinded phase IIb trial in resected stage III\/IV melanoma demonstrated TLPLDC is safe and improved 24-month disease-free survival (DFS) in the per treatment (PT) analysis.","Here, we examine efficacy within pre-specified and exploratory subgroups.","METHODS: Stage III\/IV patients rendered disease-free by surgery were randomized 2:1 to TLPLDC vaccine versus placebo.","The pre-specified PT analysis included only patients completing the primary vaccine\/placebo series at 6\u00a0months.","Kaplan-Meier analysis was used to compare 24-month DFS among subgroups.","RESULTS: There were no clinicopathologic differences between subgroups except stage IV patients were more likely to receive CPI.","In stage IV patients, 24-month DFS was 43% for vaccine versus 0% for placebo (p\u00a0=\u00a00.098) in the ITT analysis and 73% versus 0% (p\u00a0=\u00a00.002) in the PT analysis.","There was no significant difference in 24-month DFS when stratified by use of immunotherapy or CPI.","For patients with resected recurrent disease, 24-month DFS was 88.9% versus 33.3% (p\u00a0=\u00a00.013) in the PT analysis.","All benefit from vaccination was in the PT analysis; no benefit was found in patients receiving up to three doses.","CONCLUSION: The TLPLDC vaccine improved DFS in patients completing the primary vaccine series, particularly in the resected stage IV patients.","The efficacy of the TLPLDC vaccine will be confirmed in a phase III study evaluating adjuvant TLPLDC + CPI versus Placebo + CPI in resected stage IV melanoma patients."],"Aspect":"o","Summary":"The TLPLDC vaccine improved disease-free survival (DFS) in patients completing the primary vaccine series, particularly in resected stage IV melanoma patients.","Indexes":[1,7,11],"Sentences":["The primary analysis of the randomized and blinded phase IIb trial in resected stage III\/IV melanoma demonstrated TLPLDC is safe and improved 24-month disease-free survival (DFS) in the per treatment (PT) analysis.","In stage IV patients, 24-month DFS was 43% for vaccine versus 0% for placebo (p\u00a0=\u00a00.098) in the ITT analysis and 73% versus 0% (p\u00a0=\u00a00.002) in the PT analysis.","CONCLUSION: The TLPLDC vaccine improved DFS in patients completing the primary vaccine series, particularly in the resected stage IV patients."],"Revise":false}
{"PMID":"34818112","Document":["PURPOSE: In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab.","Here, we report 6.5-year efficacy and safety outcomes.","PATIENTS AND METHODS: Patients with previously untreated unresectable stage III or stage IV melanoma were randomly assigned 1:1:1 to receive nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg once every 3 weeks (four doses) followed by nivolumab 3 mg\/kg once every 2 weeks (n = 314), nivolumab 3 mg\/kg once every 2 weeks (n = 316), or ipilimumab 3 mg\/kg once every 3 weeks (four doses; n = 315).","Coprimary end points were progression-free survival and overall survival (OS) with nivolumab plus ipilimumab or nivolumab versus ipilimumab.","Secondary end points included objective response rate, descriptive efficacy assessments of nivolumab plus ipilimumab versus nivolumab alone, and safety.","Melanoma-specific survival (MSS; descriptive analysis), which excludes deaths unrelated to melanoma, was also evaluated.","RESULTS: Median OS (minimum follow-up, 6.5 years) was 72.1, 36.9, and 19.9 months in the combination, nivolumab, and ipilimumab groups, respectively.","Median MSS was not reached, 58.7, and 21.9 months, respectively; 6.5-year OS rates were 57%, 43%, and 25% in patients with BRAF-mutant tumors and 46%, 42%, and 22% in those with BRAF-wild-type tumors, respectively.","In patients who discontinued treatment, the median treatment-free interval was 27.6, 2.3, and 1.9 months, respectively.","Since the 5-year analysis, no new safety signals were observed.","CONCLUSION: These 6.5-year CheckMate 067 results, which include the longest median OS in a phase III melanoma trial reported to date and the first report of MSS, showed durable, improved clinical outcomes with nivolumab plus ipilimumab or nivolumab versus ipilimumab in patients with advanced melanoma and, in descriptive analyses, with the combination over nivolumab monotherapy."],"Aspect":"a","Summary":"The study aims to evaluate the 6.5-year efficacy and safety outcomes of nivolumab plus ipilimumab and nivolumab alone compared to ipilimumab in patients with advanced melanoma.","Indexes":[0,3,4],"Sentences":["PURPOSE: In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab.","Coprimary end points were progression-free survival and overall survival (OS) with nivolumab plus ipilimumab or nivolumab versus ipilimumab.","Secondary end points included objective response rate, descriptive efficacy assessments of nivolumab plus ipilimumab versus nivolumab alone, and safety."],"Revise":false}
{"PMID":"31479702","Document":["PURPOSE: An increasing number of clinical trials are studying immunotherapy for the treatment of brain metastases.","The role of local therapy in this setting has not been well described.","METHODS AND MATERIALS: Twenty-three melanoma patients with brain metastases were treated with pembrolizumab in a prospective phase 2 trial, NCT02085070, and included in this secondary analysis.","Patients had at least 1 untreated or progressive brain metastasis, 5 to 20 mm in size, without any associated neurologic symptoms.","Local therapy (stereotactic radiosurgery, surgery, or laser interstitial thermal therapy) was used to treat concerning lesions immediately before trial enrollment and was also allowed on trial in patients whose brain metastases were progressing, but who were otherwise deriving benefit.","RESULTS: In total, 13 out of 23 patients (57%) received local therapy immediately before or during the trial-4 patients received local therapy before the trial owing to lesion size or location in sensitive areas; 6 during the trial because of tumor growth, hemorrhage, or radiation necrosis\/cystic changes; and 3 both before and during the trial.","Of the 10 patients who did not receive local therapy immediately before or during the trial, 8 patients (35%) did not later receive local therapy owing to rapid disease progression, and only 2 patients (9%) lived for 2 years without requiring any local therapy.","CONCLUSIONS: Local therapy continues to play an important role in the management of melanoma patients with brain metastases being treated with immunotherapy.","These patients should be closely monitored via serial brain imaging, with a multidisciplinary team involved in clinical decision making to ensure each patient's neurologic safety."],"Aspect":"m","Summary":"The medicine used was pembrolizumab.","Indexes":[2],"Sentences":["METHODS AND MATERIALS: Twenty-three melanoma patients with brain metastases were treated with pembrolizumab in a prospective phase 2 trial, NCT02085070, and included in this secondary analysis."],"Revise":false}
{"PMID":"32753545","Document":["UNLABELLED: Treatment of metastatic melanoma with autologous tumor infiltrating lymphocytes (TILs) is currently applied in several centers.","Robust and remarkably consistent overall response rates, of around 50% of treated patients, have been observed across hospitals, including a substantial fraction of durable, complete responses.","PURPOSE: Execute a phase I\/II feasibility study with TIL therapy in metastatic melanoma at the Netherlands Cancer Institute, with the goal to assess feasibility and potential value of a randomized phase III trial.","EXPERIMENTAL: Ten patients were treated with TIL therapy.","Infusion products and peripheral blood samples were phenotypically characterized and neoantigen reactivity was assessed.","Here, we present long-term clinical outcome and translational data on neoantigen reactivity of the T cell products.","RESULTS: Five out of 10 patients, who were all anti-PD-1 na\u00efve at time of treatment, showed an objective clinical response, including two patients with a complete response that are both ongoing for more than 7 years.","Immune monitoring demonstrated that neoantigen-specific T cells were detectable in TIL infusion products from three out of three patients analyzed.","For six out of the nine neoantigen-specific T cell responses detected in these TIL products, T cell response magnitude increased significantly in the peripheral blood compartment after therapy, and neoantigen-specific T cells were detectable for up to 3 years after TIL infusion.","CONCLUSION: The clinical results from this study confirm the robustness of TIL therapy in metastatic melanoma and the potential role of neoantigen-specific T cell reactivity.","In addition, the data from this study supported the rationale to initiate an ongoing multicenter phase III TIL trial."],"Aspect":"a","Summary":"The study aims to execute a phase I\/II feasibility study with TIL therapy in metastatic melanoma to assess the feasibility and potential value of a randomized phase III trial.","Indexes":[2],"Sentences":["PURPOSE: Execute a phase I\/II feasibility study with TIL therapy in metastatic melanoma at the Netherlands Cancer Institute, with the goal to assess feasibility and potential value of a randomized phase III trial."],"Revise":false}
{"PMID":"32385144","Document":["BACKGROUND: Phosphorylated peptides presented by MHC molecules represent a new class of neoantigens expressed on cancer cells and recognized by CD8 T-cells.","These peptides are promising targets for cancer immunotherapy.","Previous work identified an HLA-A*0201-restricted phosphopeptide from insulin receptor substrate 2 (pIRS2) as one such target.","The purpose of this study was to characterize a second phosphopeptide, from breast cancer antiestrogen resistance 3 (BCAR3), and to evaluate safety and immunogenicity of a novel immunotherapic vaccine comprising either or both of these phosphorylated peptides.","METHODS: Phosphorylated BCAR3 protein was evaluated in melanoma and breast cancer cell lines by Western blot, and recognition by T-cells specific for HLA-A*0201-restricted phosphorylated BCAR3 peptide (pBCAR3126-134) was determined by 51Cr release assay and intracellular cytokine staining.","Human tumor explants were also evaluated by mass spectrometry for presentation of pIRS2 and pBCAR3 peptides.","For the clinical trial, participants with resected stage IIA-IV melanoma were vaccinated 6 times over 12 weeks with one or both peptides in incomplete Freund's adjuvant and Hiltonol (poly-ICLC).","Adverse events (AEs) were coded based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) V.4.03, with provision for early study termination if dose-limiting toxicity (DLT) rates exceeded 33%.","The enrollment target was 12 participants evaluable for immune response to each peptide.","T-cell responses were assessed by interferon-\u03b3 ELISpot assay.","RESULTS: pBCAR3 peptides were immunogenic in vivo in mice, and in vitro in normal human donors, and T-cells specific for pBCAR3126-134 controlled outgrowth of a tumor xenograft.","The pIRS21097-1105 peptide was identified by mass spectrometry from human hepatocellular carcinoma tumors.","In the clinical trial, 15 participants were enrolled.","All had grade 1 or 2 treatment-related AEs, but there were no grade 3-4 AEs, DLTs or deaths on study.","T-cell responses were induced to the pIRS21097-1105 peptide in 5\/12 patients (42%, 90% CI 18% to 68%) and to the pBCAR3126-134 peptide in 2\/12 patients (17%, 90% CI 3% to 44%).","CONCLUSION: This study supports the safety and immunogenicity of vaccines containing the cancer-associated phosphopeptides pBCAR3126-134 and pIRS21097-1105, and the data support continued development of immune therapy targeting phosphopeptides.","Future studies will define ways to further enhance the magnitude and durability of phosphopeptide-specific immune responses.","TRIAL REGISTRATION NUMBER: NCT01846143."],"Aspect":"a","Summary":"The purpose of this study was to characterize a second phosphopeptide, from breast cancer antiestrogen resistance 3 (BCAR3), and to evaluate safety and immunogenicity of a novel immunotherapic vaccine comprising either or both of these phosphorylated peptides.","Indexes":[3],"Sentences":["The purpose of this study was to characterize a second phosphopeptide, from breast cancer antiestrogen resistance 3 (BCAR3), and to evaluate safety and immunogenicity of a novel immunotherapic vaccine comprising either or both of these phosphorylated peptides."],"Revise":false}
{"PMID":"31515719","Document":["PURPOSE: Prospective data are lacking on long-term morbidity of inguinal lymphadenectomy including the influence of extent of surgery, use of radiotherapy, and patient factors.","The aim of this study is to evaluate the effects of these factors on patient outcome, quality of life (QOL), regional symptoms, and limb volumes after inguinal or ilio-inguinal lymphadenectomy for melanoma.","METHODS: Analysis of the subgroup of patients with inguinal lymph node field relapse of melanoma, treated by inguinal or ilio-inguinal lymphadenectomy in the ANZMTG\/TROG randomized trial of adjuvant radiotherapy versus observation.","RESULTS: Sixty-nine patients, 46 having undergone inguinal and 23 ilio-inguinal lymphadenectomy, with median follow-up of 73\u00a0months were analyzed.","Mean limb volume increased rapidly after surgery (7% by 3\u00a0months) and continued to increase for at least another 18\u00a0months.","Patients with body mass index (BMI)\u2009\u2265\u200925\u00a0kg\/m2 had greater limb volume increase than normal-weight patients (13.3% versus 6.9%, P\u2009=\u20090.030).","QOL improved over the first 18\u00a0months, but despite initial improvement, regional symptoms persisted long term.","Type of surgery (inguinal or ilio-inguinal lymphadenectomy) had no demonstrably significant effect on limb volume (9.9% versus 13.4%, P\u2009=\u20090.35), QOL (P\u2009=\u20090.68), or regional symptoms (P\u2009=\u20090.65).","There was no difference in overall survival between inguinal and ilio-inguinal lymphadenectomy [hazard ratio (HR)\u20090.75, 95% confidence interval (CI) 0.40-1.40, P\u2009=\u20090.43].","CONCLUSIONS: Inguinal lymphadenectomy for melanoma is a potentially morbid procedure with significant increases in limb volume.","Patients report reasonable QOL but may have ongoing regional symptoms.","Overweight\/obesity is associated with poorer QOL, increased limb volume, and regional symptoms."],"Aspect":"i","Summary":"The study analyzed a subgroup of patients with inguinal lymph node field relapse of melanoma, who were treated by inguinal or ilio-inguinal lymphadenectomy in a randomized trial of adjuvant radiotherapy versus observation.","Indexes":[2],"Sentences":["METHODS: Analysis of the subgroup of patients with inguinal lymph node field relapse of melanoma, treated by inguinal or ilio-inguinal lymphadenectomy in the ANZMTG\/TROG randomized trial of adjuvant radiotherapy versus observation."],"Revise":false}
{"PMID":"33272982","Document":["PURPOSE: TNF blockers can be used to manage gastrointestinal inflammatory side effects following nivolumab and\/or ipilimumab treatment in patients with advanced melanoma.","Our preclinical data showed that anti-TNF could promote the efficacy of immune checkpoint inhibitors.","PATIENTS AND METHODS: TICIMEL (NTC03293784) is an open-label, two-arm phase Ib clinical trial.","Fourteen patients with advanced and\/or metastatic melanoma (stage IIIc\/IV) were enrolled.","Patients were treated with nivolumab (1 mg\/kg) and ipilimumab (3 mg\/kg) combined to infliximab (5 mg\/kg, N = 6) or certolizumab (400\/200 mg, N = 8).","The primary endpoint was safety and the secondary endpoint was antitumor activity.","Adverse events (AEs) were graded according to the NCI Common Terminology Criteria for Adverse Events and response was assessed following RECIST 1.1.","RESULTS: Only one dose-limiting toxicity was observed in the infliximab cohort.","The two different combinations were found to be safe.","We observed lower treatment-related AEs with infliximab as compared with certolizumab.","In the certolizumab cohort, one patient was not evaluable for response.","In this cohort, four of eight patients exhibited hepatobiliary disorders and seven of seven evaluable patients achieved objective response including four complete responses (CRs) and three partial responses (PRs).","In the infliximab cohort, we observed one CR, two PRs, and three progressive diseases.","Signs of activation and maturation of systemic T-cell responses were seen in patients from both cohorts.","CONCLUSIONS: Our results show that both combinations are safe in human and provide clinical and biological activities.","The high response rate in the certolizumab-treated patient cohort deserves further investigations."],"Aspect":"p","Summary":"The study involved 14 patients with advanced and\/or metastatic melanoma (stage IIIc\/IV), divided into two groups: 6 patients treated with nivolumab, ipilimumab, and infliximab, and 8 patients treated with nivolumab, ipilimumab, and certolizumab.","Indexes":[3,4],"Sentences":["Fourteen patients with advanced and\/or metastatic melanoma (stage IIIc\/IV) were enrolled.","Patients were treated with nivolumab (1 mg\/kg) and ipilimumab (3 mg\/kg) combined to infliximab (5 mg\/kg, N = 6) or certolizumab (400\/200 mg, N = 8)."],"Revise":false}
{"PMID":"37167764","Document":["BACKGROUND: In the phase II\/III RELATIVITY-047 trial, a novel fixed-dose combination (FDC) of nivolumab plus relatlimab (NIVO\u202f+\u202fRELA; a programmed death-1 and a lymphocyte-activation gene 3 inhibitor, respectively) significantly improved progression-free survival (PFS) versus NIVO in patients with previously untreated unresectable or metastatic melanoma (median follow-up, 13.2 months) with stable health-related quality of life (HRQoL), although grade three or four treatment-related adverse events (TRAEs) were more frequent with the combination.","Updated HRQoL results (median follow-up, 19.3 months) are presented.","METHODS: Patients were randomised to receive intravenous NIVO\u202f+\u202fRELA (480\u202fmg and 160\u202fmg, respectively) or NIVO (480\u202fmg) every 4 weeks.","HRQoL was assessed using the Functional Assessment of Cancer Treatment-Melanoma (FACT-M) and EQ-5D-3L questionnaires at baseline, before dosing at each treatment cycle, and at follow-up (posttreatment) visits.","RESULTS: Consistent with the initial analysis, HRQoL remained stable with NIVO\u202f+\u202fRELA on treatment and was similar to that with NIVO.","Mean changes from baseline did not exceed clinically meaningful thresholds.","HRQoL results were consistent across instruments and scales\/subscales.","Despite an increased rate of grade three or four TRAEs with NIVO\u202f+\u202fRELA versus NIVO, the proportion of patients reporting that they were bothered 'quite a bit' or 'very much' by TRAEs was low and comparable between treatments.","CONCLUSION: Results from the RELATIVITY-047 trial show that the PFS benefit with NIVO\u202f+\u202fRELA FDC over NIVO was obtained with stable patient-reported HRQoL, supporting NIVO\u202f+\u202fRELA as a first-line treatment option for patients with advanced melanoma."],"Aspect":"m","Summary":"The trial involved nivolumab administered at a dose of 480 mg and relatlimab at 160 mg, given every 4 weeks.","Indexes":[2],"Sentences":["METHODS: Patients were randomised to receive intravenous NIVO\u202f+\u202fRELA (480\u202fmg and 160\u202fmg, respectively) or NIVO (480\u202fmg) every 4 weeks."],"Revise":false}
{"PMID":"34772758","Document":["BACKGROUND: Angiogenic factors promote the growth of tumor vasculature, modulate lymphocyte trafficking into tumors, and inhibit maturation of dendritic cells.","We hypothesized that MEDI3617, a human IgG1 kappa monoclonal antibody directed against human angiopoietin-2, in combination with tremelimumab (treme), an IgG2 monoclonal antibody blocking cytotoxic T-lymphocyte-associated protein- (CTLA-4), is safe in patients with advanced melanoma.","METHODS: In a phase I, 3+3 dose escalation trial, patients with metastatic or unresectable melanoma received treme in combination with MEDI3617.","The primary objectives of the study were safety and determination of recommended phase II dose (RP2D).","The secondary objectives included determination of 6-month and 1-year overall survival and best overall response rate.","Immune cell populations and soluble factors were assessed in peripheral blood and metastatic tumors using Fluorescence activated cell sorting (FACS), Luminex, and multiplexed immunofluorescence.","RESULTS: Fifteen patients (median age: 62) were enrolled in the study (3 patients in cohort 1: treme at 10 mg\/kg and MEDI3617 at 200 mg; and 12 patients in cohort 2: treme at 10 mg\/kg and MEDI3617 at 600 mg).","The most common all-grade treatment-related adverse events were rash, pruritus, fatigue, and extremity edema.","No dose-limiting toxicities were observed.","Cohort 2 was determined to be the RP2D.","There were no patients with confirmed immune-related complete response or immune-related partial response.","Six of 15 patients had immune-related stable disease, resulting in a disease control rate of 0.40 (95% CI 0.16 to 0.68).","An increase in frequencies of circulating inducible T-cell costimulator (ICOS)+ and human leukocyte antigen (HLA)-DR+ CD4+ and CD8+ T cells and production of Interleukin-2 and Interleukin-10 was observed post therapy.","CONCLUSIONS: Tremelimumab in combination with MEDI3617 is safe in patients with advanced melanoma.","Angiopoietin-2 inhibition in combination with immune checkpoint inhibition warrants further exploration.","TRIAL REGISTRATION NUMBER: NCT02141542."],"Aspect":"s","Summary":"The most common all-grade treatment-related adverse events were rash, pruritus, fatigue, and extremity edema.  No dose-limiting toxicities were observed.","Indexes":[7,8],"Sentences":["The most common all-grade treatment-related adverse events were rash, pruritus, fatigue, and extremity edema.","No dose-limiting toxicities were observed."],"Revise":true}
{"PMID":"34650833","Document":["Combination immunotherapy with sequential administration may enhance metastatic melanoma (MM) patients with long-term disease control.","High Dose Aldesleukin\/Recombinant Interleukin-2 (HD rIL-2) and ipilimumab (IPI) offer complementary mechanisms against MM.","This phase IV study assessed the sequenced use of HD rIL-2 and IPI in MM patients.","Eligible Stage IV MM patients were randomized to treatment with either two courses of HD rIL-2(600,000 IU\/kg) followed by four doses of IPI 3 mg\/kg or vice-versa.","The primary objective was to compare one-year overall survival (OS) with historical control (46%, Hodi et al., NEJM 2010).","Secondary objectives were 1-year progression-free survival (PFS), objective response rate (ORR), and adverse events (AEs) profile.","Evaluable Population (EP) included patients who received at least 50% of planned treatment with each drug.","Thirteen and 16 patients were randomized to receive HD rIL-2 first, and IPI first, respectively.","One-year OS rate was 75% for intention to treat population.","Eighteen patients were included in EP, 8 in HD rIL-2, 10 in IPI first arm.","In EP, 1-year OS, PFS and ORR rates were 87%, 68%, and 50%, respectively.","The frequency of AEs was similar in both arms with 13 patients experiencing Grade 3 or higher AEs, 3 resulting in the end of study participation.","There was one HD rIL-2-related death, from cerebral hemorrhage due to thrombocytopenia.","In this study with small sample size, HD rIL-2 and IPI were safe to administer sequentially in MM patients and showed more than additive effects.","1-year OS was superior to that of IPI alone from historical studies."],"Aspect":"p","Summary":"The study included 29 patients with Stage IV metastatic melanoma (MM), with 13 randomized to receive HD rIL-2 first and 16 to receive IPI first.","Indexes":[7],"Sentences":["Thirteen and 16 patients were randomized to receive HD rIL-2 first, and IPI first, respectively."],"Revise":false}
{"PMID":"35264434","Document":["BACKGROUND: The combination of antiangiogenic agents with immune checkpoint inhibitors could potentially overcome immune suppression driven by tumor angiogenesis.","We report results from a phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors.","METHODS: This is a multicenter phase IB dose-escalation study of the combination of ziv-aflibercept (at 2-4\u2009mg\/kg) plus pembrolizumab (at 2\u2009mg\/kg) administered intravenously every 2 weeks with expansion cohorts in programmed cell death protein 1 (PD-1)\/programmed death-ligand 1(PD-L1)-na\u00efve melanoma, renal cell carcinoma (RCC), microsatellite stable colorectal cancer (CRC), and ovarian cancer.","The primary objective was to determine maximum tolerated dose (MTD) and recommended dose of the combination.","Secondary endpoints included overall response rate (ORR) and overall survival (OS).","Exploratory objectives included correlation of clinical efficacy with tumor and peripheral immune population densities.","RESULTS: Overall, 33 patients were enrolled during dose escalation (n=3) and dose expansion (n=30).","No dose-limiting toxicities were reported in the initial dose level.","Ziv-aflibercept 4\u2009mg\/kg plus pembrolizumab 2\u2009mg\/kg every 2 weeks was established as the MTD.","Grade \u22653 adverse events occurred in 19\/33 patients (58%), the most common being hypertension (36%) and proteinuria (18%).","ORR in the dose-expansion cohort was 16.7% (5\/30, 90%\u2009CI 7% to 32%).","Complete responses occurred in melanoma (n=2); partial responses occurred in RCC (n=1), mesothelioma (n=1), and melanoma (n=1).","Median OS was as follows: melanoma, not reached (NR); RCC, 15.7 months (90%\u2009CI 2.5 to 15.7); CRC, 3.3 months (90%\u2009CI 0.6 to 3.4); ovarian, 12.5 months (90%\u2009CI 3.8 to 13.6); other solid tumors, NR.","Activated tumor-infiltrating CD8 T cells at baseline (CD8+PD1+), high CD40L expression, and increased peripheral memory CD8 T cells correlated with clinical response.","CONCLUSION: The combination of ziv-aflibercept and pembrolizumab demonstrated an acceptable safety profile with antitumor activity in solid tumors.","The combination is currently being studied in sarcoma and anti-PD-1-resistant melanoma.","TRIAL REGISTRATION NUMBER: NCT02298959."],"Aspect":"a","Summary":"The study aims to determine the maximum tolerated dose and evaluate the efficacy of the combination of ziv-aflibercept and pembrolizumab in patients with advanced solid tumors.","Indexes":[0,3,4,5],"Sentences":["BACKGROUND: The combination of antiangiogenic agents with immune checkpoint inhibitors could potentially overcome immune suppression driven by tumor angiogenesis.","The primary objective was to determine maximum tolerated dose (MTD) and recommended dose of the combination.","Secondary endpoints included overall response rate (ORR) and overall survival (OS).","Exploratory objectives included correlation of clinical efficacy with tumor and peripheral immune population densities."],"Revise":true}
{"PMID":"32877599","Document":["BACKGROUND: In the previously reported primary analysis of this phase 3 trial, 12 months of adjuvant dabrafenib plus trametinib resulted in significantly longer relapse-free survival than placebo in patients with resected stage III melanoma with BRAF V600E or V600K mutations.","To confirm the stability of the relapse-free survival benefit, longer-term data were needed.","METHODS: We randomly assigned 870 patients who had resected stage III melanoma with BRAF V600E or V600K mutations to receive 12 months of oral dabrafenib (at a dose of 150 mg twice daily) plus trametinib (2 mg once daily) or two matched placebos.","The primary end point was relapse-free survival.","Here, we report 5-year results for relapse-free survival and survival without distant metastasis as the site of the first relapse.","Overall survival was not analyzed, since the required number of events to trigger the final overall survival analysis had not been reached.","RESULTS: The minimum duration of follow-up was 59 months (median patient follow-up, 60 months for dabrafenib plus trametinib and 58 months for placebo).","At 5 years, the percentage of patients who were alive without relapse was 52% (95% confidence interval [CI], 48 to 58) with dabrafenib plus trametinib and 36% (95% CI, 32 to 41) with placebo (hazard ratio for relapse or death, 0.51; 95% CI, 0.42 to 0.61).","The percentage of patients who were alive without distant metastasis was 65% (95% CI, 61 to 71) with dabrafenib plus trametinib and 54% (95% CI, 49 to 60) with placebo (hazard ratio for distant metastasis or death, 0.55; 95% CI, 0.44 to 0.70).","No clinically meaningful between-group difference in the incidence or severity of serious adverse events was reported during the follow-up period.","CONCLUSIONS: In the 5-year follow-up of a phase 3 trial involving patients who had resected stage III melanoma with BRAF V600E or V600K mutations, 12 months of adjuvant therapy with dabrafenib plus trametinib resulted in a longer duration of survival without relapse or distant metastasis than placebo with no apparent long-term toxic effects.","(Funded by GlaxoSmithKline and Novartis; COMBI-AD ClinicalTrials.gov number, NCT01682083; EudraCT number, 2012-001266-15.",")."],"Aspect":"a","Summary":"The study aims to confirm the stability of the relapse-free survival benefit of 12 months of adjuvant dabrafenib plus trametinib compared to placebo in patients with resected stage III melanoma with BRAF V600E or V600K mutations.","Indexes":[0,1,3],"Sentences":["BACKGROUND: In the previously reported primary analysis of this phase 3 trial, 12 months of adjuvant dabrafenib plus trametinib resulted in significantly longer relapse-free survival than placebo in patients with resected stage III melanoma with BRAF V600E or V600K mutations.","To confirm the stability of the relapse-free survival benefit, longer-term data were needed.","The primary end point was relapse-free survival."],"Revise":false}
{"PMID":"37930123","Document":["PURPOSE: Preclinical studies show that activation of AMP kinase by phenformin can augment the cytotoxic effect and RAF inhibitors in BRAF V600-mutated melanoma.","We conducted a phase Ib dose-escalation trial of phenformin with standard dose dabrafenib\/trametinib in patients with metastatic BRAF V600-mutated melanoma.","EXPERIMENTAL DESIGN: We used a 3+3 dose-escalation design which explored phenformin doses between 50 and 200 mg twice daily.","Patients also received standard dose dabrafenib\/trametinib.","We measured phenformin pharmacokinetics and assessed the effect of treatment on circulating myeloid-derived suppressor cells (MDSC).","RESULTS: A total of 18 patients were treated at dose levels ranging from 50 to 200 mg twice daily.","The planned dose-escalation phase had to be cancelled because of the COVID 19 pandemic.","The most common toxicities were nausea\/vomiting; there were two cases of reversible lactic acidosis.","Responses were seen in 10 of 18 patients overall (56%) and in 2 of 8 patients who had received prior therapy with RAF inhibitor.","Pharmacokinetic data confirmed drug bioavailability.","MDSCs were measured in 7 patients treated at the highest dose levels and showed MDSC levels declined on study drug in 6 of 7 patients.","CONCLUSIONS: We identified the recommended phase II dose of phenformin as 50 mg twice daily when administered with dabrafenib\/trametinib, although some patients will require short drug holidays.","We observed a decrease in MDSCs, as predicted by preclinical studies, and may enhance immune recognition of melanoma cells.","SIGNIFICANCE: This is the first trial using phenformin in combination with RAF\/MEK inhibition in patients with BRAF V600-mutated melanoma.","This is a novel strategy, based on preclinical data, to increase pAMPK while blocking the MAPK pathway in melanoma.","Our data provide justification and a recommended dose for a phase II trial."],"Aspect":"i","Summary":"A phase Ib dose-escalation trial of phenformin with standard dose dabrafenib\/trametinib was conducted in patients with metastatic BRAF V600-mutated melanoma using a 3+3 dose-escalation design.","Indexes":[1,2,3],"Sentences":["We conducted a phase Ib dose-escalation trial of phenformin with standard dose dabrafenib\/trametinib in patients with metastatic BRAF V600-mutated melanoma.","EXPERIMENTAL DESIGN: We used a 3+3 dose-escalation design which explored phenformin doses between 50 and 200 mg twice daily.","Patients also received standard dose dabrafenib\/trametinib."],"Revise":false}
{"PMID":"34370787","Document":["Torque Teno Virus (TTV) is a small, non-enveloped, single-stranded and circular DNA virus that infects the majority of the population worldwide.","Increased levels of plasma TTV viral load have been observed in various situations of immune deficiency or dysregulation, and several studies have suggested that TTV levels may be inversely correlated with immune competence.","The measurement of TTV viremia by qPCR has been proposed as a potential biomarker for the follow-up of functional immune competence in immunosuppressed individuals, particularly hematopoietic stem cell transplant recipients.","We hypothesized that TTV viral load could be used as a prognostic marker of immune checkpoint inhibitor (ICI) efficacy, and therefore investigated the TTV viral load in melanoma patients treated with nivolumab or pembrolizumab before and after 6 months of treatment.","In the present study, TTV viral load was not different in melanoma patients before anti-PD-1 introduction compared to healthy volunteers, was not modified by ICI treatment and did not allowed to distinguish patients with treatment-sensitive tumor from patients with treatment-resistant tumor."],"Aspect":"o","Summary":"The study found that TTV viral load was not different in melanoma patients before anti-PD-1 treatment compared to healthy volunteers, was not modified by ICI treatment, and did not distinguish patients with treatment-sensitive tumors from those with treatment-resistant tumors.","Indexes":[4],"Sentences":["In the present study, TTV viral load was not different in melanoma patients before anti-PD-1 introduction compared to healthy volunteers, was not modified by ICI treatment and did not allowed to distinguish patients with treatment-sensitive tumor from patients with treatment-resistant tumor."],"Revise":false}
{"PMID":"33843797","Document":["OBJECTIVE: To evaluate the potency of short-term neoadjuvant cytoreductive therapy with dabrafenib plus trametinib (BRAF and MEK inhibitor) to allow for radical surgical resection in patients with unresectable locally advanced melanoma.","SUMMARY BACKGROUND DATA: Approximately 5% of stage III melanoma patients presents with unresectable locally advanced disease, making standard of care with resection followed by adjuvant systemic therapy impossible.","Although neoadjuvant targeted therapy has shown promising results in resectable stage III melanoma, its potency to enable surgical resection in patients with primarily unresectable locally advanced stage III melanoma is still unclear.","METHODS: In this prospective, single-arm, phase II trial, patients with unresectable BRAF-mutated locally advanced stage IIIC or oligometastatic stage IV melanoma were included.","After 8\u200aweeks of treatment with dabrafenib and trametinib, evaluation by positron emission tomography\/computed tomography and physical examination were used to assess sufficient downsizing of the tumor to enable resection.","The primary objective was the percentage of patients who achieved a radical (R0) resection.","RESULTS: Between August 2014 and March 2019, 21 patients (20\/21 stage IIIC American Joint Committee on Cancer staging manual 7th edition) were included.","Planned inclusion of 25 patients was not reached due to slow accrual and changing treatment landscape.","Despite this, the predefined endpoint was successfully met.","In 18\/21 (86%) patients a resection was performed, of which 17 were R0 resections.","At a median follow-up of 50\u200amonths (interquartile range 37.7-57.1\u200amonths), median recurrence-free survival was 9.9\u200amonths (95% confidence interval 7.52-not reached) in patients undergoing surgery.","CONCLUSIONS: This prospective, single-arm, open-label phase II trial, shows neoadjuvant dabrafenib plus trametinib as a potent cytoreductive treatment, allowing radical resection of metastases in 17\/21 (81%) patients with prior unresectable locally advanced melanoma."],"Aspect":"a","Summary":"The study aims to evaluate the potency of short-term neoadjuvant cytoreductive therapy with dabrafenib plus trametinib to allow for radical surgical resection in patients with unresectable locally advanced melanoma.","Indexes":[0],"Sentences":["OBJECTIVE: To evaluate the potency of short-term neoadjuvant cytoreductive therapy with dabrafenib plus trametinib (BRAF and MEK inhibitor) to allow for radical surgical resection in patients with unresectable locally advanced melanoma."],"Revise":false}
{"PMID":"38402687","Document":["BACKGROUND: Pain is common in patients with cancer.","The World Health Organisation recommends paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) for mild pain and combined with other agents for moderate\/severe pain.","This study estimated associations of NSAIDs with recurrence-free survival (RFS), distant metastasis-free survival (DMFS) and the incidence of immune-related adverse events (irAEs) in high-risk patients with resected melanoma in the EORTC 1325\/KEYNOTE-054 phase III clinical trial.","PATIENTS AND METHODS: Patients with AJCC7 stage IIIA, IIIB or IIIC resected melanoma were randomized to receive 200\u00a0mg of adjuvant pembrolizumab (N\u00a0=\u00a0514) or placebo (N\u00a0=\u00a0505) 3-weekly for one year or until recurrence.","As previously reported, pembrolizumab prolonged RFS and DMFS.","NSAID use was defined as administration between 7 days pre-randomization and starting treatment.","Multivariable Cox and Fine and Gray models were used to estimate hazard ratios (HRs) for associations of NSAIDs with RFS, DMFS and irAEs.","RESULTS: Of 1019 patients randomized, 59 and 44 patients in the pembrolizumab and placebo arms, respectively, used NSAIDs.","NSAIDs were not associated with RFS (HR 0.91, 95% CI 0.58-1.43) or DMFS in the pembrolizumab (HR 1.03, 95% CI 0.65-1.66) or placebo arms (for RFS, HR 0.76, 95% CI 0.48-1.20; for DMFS, HR 0.80, 95% CI 0.49-1.31).","NSAIDs were associated with the incidence of irAEs in the placebo arm (HR 3.06, 95% CI 1.45-6.45) but not in the pembrolizumab arm (HR 0.94, 95% CI 0.58-1.53).","CONCLUSION: NSAIDs were not associated with efficacy outcomes nor the risk of irAEs in patients with resected high-risk stage III melanoma receiving adjuvant pembrolizumab."],"Aspect":"o","Summary":"NSAIDs were not associated with recurrence-free survival or distant metastasis-free survival in patients with resected high-risk stage III melanoma receiving adjuvant pembrolizumab, but were associated with the incidence of immune-related adverse events in the placebo arm.","Indexes":[8,9,10],"Sentences":["NSAIDs were not associated with RFS (HR 0.91, 95% CI 0.58-1.43) or DMFS in the pembrolizumab (HR 1.03, 95% CI 0.65-1.66) or placebo arms (for RFS, HR 0.76, 95% CI 0.48-1.20; for DMFS, HR 0.80, 95% CI 0.49-1.31).","NSAIDs were associated with the incidence of irAEs in the placebo arm (HR 3.06, 95% CI 1.45-6.45) but not in the pembrolizumab arm (HR 0.94, 95% CI 0.58-1.53).","CONCLUSION: NSAIDs were not associated with efficacy outcomes nor the risk of irAEs in patients with resected high-risk stage III melanoma receiving adjuvant pembrolizumab."],"Revise":false}
{"PMID":"34772758","Document":["BACKGROUND: Angiogenic factors promote the growth of tumor vasculature, modulate lymphocyte trafficking into tumors, and inhibit maturation of dendritic cells.","We hypothesized that MEDI3617, a human IgG1 kappa monoclonal antibody directed against human angiopoietin-2, in combination with tremelimumab (treme), an IgG2 monoclonal antibody blocking cytotoxic T-lymphocyte-associated protein- (CTLA-4), is safe in patients with advanced melanoma.","METHODS: In a phase I, 3+3 dose escalation trial, patients with metastatic or unresectable melanoma received treme in combination with MEDI3617.","The primary objectives of the study were safety and determination of recommended phase II dose (RP2D).","The secondary objectives included determination of 6-month and 1-year overall survival and best overall response rate.","Immune cell populations and soluble factors were assessed in peripheral blood and metastatic tumors using Fluorescence activated cell sorting (FACS), Luminex, and multiplexed immunofluorescence.","RESULTS: Fifteen patients (median age: 62) were enrolled in the study (3 patients in cohort 1: treme at 10 mg\/kg and MEDI3617 at 200 mg; and 12 patients in cohort 2: treme at 10 mg\/kg and MEDI3617 at 600 mg).","The most common all-grade treatment-related adverse events were rash, pruritus, fatigue, and extremity edema.","No dose-limiting toxicities were observed.","Cohort 2 was determined to be the RP2D.","There were no patients with confirmed immune-related complete response or immune-related partial response.","Six of 15 patients had immune-related stable disease, resulting in a disease control rate of 0.40 (95% CI 0.16 to 0.68).","An increase in frequencies of circulating inducible T-cell costimulator (ICOS)+ and human leukocyte antigen (HLA)-DR+ CD4+ and CD8+ T cells and production of Interleukin-2 and Interleukin-10 was observed post therapy.","CONCLUSIONS: Tremelimumab in combination with MEDI3617 is safe in patients with advanced melanoma.","Angiopoietin-2 inhibition in combination with immune checkpoint inhibition warrants further exploration.","TRIAL REGISTRATION NUMBER: NCT02141542."],"Aspect":"i","Summary":"In a phase I, 3+3 dose escalation trial, patients with metastatic or unresectable melanoma received tremelimumab combined with MEDI3617 to evaluate safety, determine the recommended phase II dose, and assess immune responses, overall survival, and response rates.","Indexes":[2,3,4,5],"Sentences":["METHODS: In a phase I, 3+3 dose escalation trial, patients with metastatic or unresectable melanoma received treme in combination with MEDI3617.","The primary objectives of the study were safety and determination of recommended phase II dose (RP2D).","The secondary objectives included determination of 6-month and 1-year overall survival and best overall response rate.","Immune cell populations and soluble factors were assessed in peripheral blood and metastatic tumors using Fluorescence activated cell sorting (FACS), Luminex, and multiplexed immunofluorescence."],"Revise":true}
{"PMID":"31912791","Document":["BACKGROUND: We conducted a retrospective exploratory analysis to evaluate the effects of baseline tumour immune infiltrate on disease-free survival (DFS) outcomes in patients with fully resected stage IIC-IIIC melanoma receiving adjuvant vemurafenib monotherapy or placebo in the BRIM8 study.","PATIENTS AND METHODS: BRIM8 was a phase III, international, double-blind, randomised, placebo-controlled study.","Eligible patients with BRAFV600 mutation-positive, completely resected melanoma were randomly assigned to oral vemurafenib (960 mg twice daily) or matching placebo for 52 weeks.","The primary end point was DFS.","The association of CD8+ T-cell infiltration and programmed death ligand 1 (PD-L1) expression with DFS, as measured by immunohistochemistry, was explored retrospectively.","RESULTS: Four hundred ninety-eight patients were randomly assigned to receive adjuvant vemurafenib (n\u00a0= 250) or placebo (n\u00a0= 248); tumour samples were available for biomarker analysis for approximately 60% of patients.","In the pooled biomarker population, placebo-treated patients with <1% CD8+ T cells in the tumour centre had shorter median DFS than those with \u22651% CD8+ T cells (7.7 versus 47.8 months).","DFS benefit from vemurafenib versus placebo was greater in patients with <1% CD8+ T cells [hazard ratio (HR) 0.56; 95% confidence interval (CI) 0.34-0.92) than in patients with \u22651% CD8+ T cells (HR 0.77; 95% CI 0.48-1.22).","Likewise, median DFS was shorter among placebo-treated patients with <5% versus \u22655% PD-L1+ immune cells (IC) in the tumour (7.2 versus 47.8 months).","A greater DFS benefit with vemurafenib versus placebo was observed in patients with <5% PD-L1+IC (HR 0.36; 95% CI 0.24-0.56) than in patients with \u22655% PD-L1+IC (HR 0.99; 95% CI 0.58-1.69).","CONCLUSIONS: The presence of CD8+ T cells and PD-L1+IC are favourable prognostic factors for DFS.","Treatment with adjuvant vemurafenib may overcome the poor DFS prognosis associated with low CD8+ T-cell count or PD-L1 expression.","CLINICALTRIALS.","GOV IDENTIFIER: NCT01667419."],"Aspect":"o","Summary":"The study found that the presence of CD8+ T cells and PD-L1+IC are favourable prognostic factors for disease-free survival (DFS), and adjuvant vemurafenib may overcome the poor DFS prognosis associated with low CD8+ T-cell count or PD-L1 expression.","Indexes":[10,11],"Sentences":["CONCLUSIONS: The presence of CD8+ T cells and PD-L1+IC are favourable prognostic factors for DFS.","Treatment with adjuvant vemurafenib may overcome the poor DFS prognosis associated with low CD8+ T-cell count or PD-L1 expression."],"Revise":false}
{"PMID":"32559817","Document":["The aim was to provide evidence on systemically treated patients with advanced melanoma not represented in phase III trials to support clinical decision-making.","Analysis were performed on advanced melanoma patients diagnosed between 2014 and 2017 in the Netherlands, treated with immune- or targeted therapy, who met \u22651 trial exclusion criteria.","These criteria were derived from the KEYNOTE-006 and CHECKMATE-067\/-066 phase III trials.","Prognostic importance of factors associated with overall survival (OS) was assessed with the Kaplan-Meier method, Cox models, predicted OS probabilities of prognostic subgroups and a conditional inference survival tree (CIST).","A nationwide population-based registry was used as data source.","Of 2536 systemically treated patients with advanced melanoma, 1004 (40%) patients were ineligible for phase IIII trials.","Ineligible patients had a poorer median OS (mOS) compared to eligible patients (8.8 vs 23\u2009months).","Eligibility criteria strongly associated with OS in systemically treated ineligible patients were Eastern Cooperative Oncology Group Performance Score (ECOG PS) \u22652, brain metastases (BM) and lactate dehydrogenase (LDH) of >500\u2009U\/L.","Patients with ECOG PS of \u22652 with or without symptomatic BM had a predicted mOS of 6.5 and 11.3 months and a 3-year survival probability of 9.3% and 23.6%, respectively.","The CIST showed the strongest prognostic covariate for survival was LDH, followed by ECOG PS.","The prognosis of patients with LDH of >500\u2009U\/L is poor, but long-term survival is possible.","The prognosis of ineligible patients with advanced melanoma in real-world was very heterogeneous and highly dependent on LDH value, ECOG PS and symptomatic BM."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"34385669","Document":["PURPOSE: We evaluated the impact of personal melanoma genomic risk information on sun-related behaviors and psychological outcomes.","METHODS: In this parallel group, open, randomized controlled trial, 1,025 Australians of European ancestry without melanoma and aged 18-69 years were recruited via the Medicare database (3% consent).","Participants were randomized to the intervention (n\u2009=\u2009513; saliva sample for genetic testing, personalized melanoma risk booklet based on a 40-variant polygenic risk score, telephone-based genetic counseling, educational booklet) or control (n\u2009=\u2009512; educational booklet).","Wrist-worn ultraviolet (UV) radiation dosimeters (10-day wear) and questionnaires were administered at baseline, 1 month postintervention, and 12 months postbaseline.","RESULTS: At 12 months, 948 (92%) participants completed dosimetry and 973 (95%) the questionnaire.","For the primary outcome, there was no effect of the genomic risk intervention on objectively measured UV exposure at 12 months, irrespective of traditional risk factors.","For secondary outcomes at 12 months, the intervention reduced sunburns (risk ratio: 0.72, 95% confidence interval: 0.54-0.96), and increased skin examinations among women.","Melanoma-related worry was reduced.","There was no overall impact on general psychological distress.","CONCLUSION: Personalized genomic risk information did not influence sun exposure patterns but did improve some skin cancer prevention and early detection behaviors, suggesting it may be useful for precision prevention.","There was no evidence of psychological harm."],"Aspect":"i","Summary":"Participants were randomized to an intervention group (genetic testing, personalized risk booklet, genetic counseling) or a control group (educational booklet) to evaluate the impact of personal melanoma genomic risk information on behaviors and psychological outcomes.","Indexes":[1,2],"Sentences":["METHODS: In this parallel group, open, randomized controlled trial, 1,025 Australians of European ancestry without melanoma and aged 18-69 years were recruited via the Medicare database (3% consent).","Participants were randomized to the intervention (n\u2009=\u2009513; saliva sample for genetic testing, personalized melanoma risk booklet based on a 40-variant polygenic risk score, telephone-based genetic counseling, educational booklet) or control (n\u2009=\u2009512; educational booklet)."],"Revise":false}
{"PMID":"37643378","Document":["PURPOSE: BRAF V600 mutation is detected in 5%-10% of pediatric high-grade gliomas (pHGGs), and effective treatments are limited.","In previous trials, dabrafenib as monotherapy or in combination with trametinib demonstrated activity in children and adults with relapsed\/refractory BRAF V600-mutant HGG.","METHODS: This phase II study evaluated dabrafenib plus trametinib in patients with relapsed\/refractory BRAF V600-mutant pHGG.","The primary objective was overall response rate (ORR) by independent review by Response Assessment in Neuro-Oncology criteria.","Secondary objectives included ORR by investigator determination, duration of response (DOR), progression-free survival, overall survival (OS), and safety.","RESULTS: A total of 41 pediatric patients with previously treated BRAF V600-mutant HGG were enrolled.","At primary analysis, median follow-up was 25.1 months, and 51% of patients remained on treatment.","Sixteen of 20 discontinuations were due to progressive disease in this relapsed\/refractory pHGG population.","Independently assessed ORR was 56% (95% CI, 40 to 72).","Median DOR was 22.2 months (95% CI, 7.6 months to not reached [NR]).","Fourteen deaths were reported.","Median OS was 32.8 months (95% CI, 19.2 months to NR).","The most common all-cause adverse events (AEs) were pyrexia (51%), headache (34%), and dry skin (32%).","Two patients (5%) had AEs (both rash) leading to discontinuation.","CONCLUSION: In relapsed\/refractory BRAF V600-mutant pHGG, dabrafenib plus trametinib improved ORR versus previous trials of chemotherapy in molecularly unselected patients with pHGG and was associated with durable responses and encouraging survival.","These findings suggest that dabrafenib plus trametinib is a promising targeted therapy option for children and adolescents with relapsed\/refractory BRAF V600-mutant HGG."],"Aspect":"p","Summary":"The study involved 41 pediatric patients with previously treated BRAF V600-mutant high-grade gliomas (pHGGs).","Indexes":[5],"Sentences":["RESULTS: A total of 41 pediatric patients with previously treated BRAF V600-mutant HGG were enrolled."],"Revise":false}
{"PMID":"33955714","Document":["Nivolumab monotherapy is approved as adjuvant treatment for melanoma based on results from the pivotal CheckMate 238 trial.","We present a model-based, benefit-risk assessment of nivolumab in adjuvant melanoma supporting a posology change from a weight-based to a less frequent, flat-dosing regimen.","The exposure-response (E-R) relationship for efficacy was evaluated using recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) end points from the CheckMate 238 trial.","The E-R for safety was evaluated using data from 14 studies across a broad range of doses in several tumor types using grade 3+ adverse event (AE) and grade 2+ immune-mediated AE (IMAE) end points.","Nivolumab trough exposures were not significant predictors of RFS or DMFS.","Covariates significantly associated with increased risk of disease recurrence or death were programmed death ligand 1 (PD-L1; less than 5% cutoff), lower baseline lactate dehydrogenase, and higher age.","Covariates associated with increased risk of distant metastasis or death were PD-L1 (less than 5% cutoff) and higher age.","Higher nivolumab maximum concentration after first dose (Cmax1) was significantly associated with grade 2+ IMAEs, but not grade 3+ AEs.","The risk of grade 3+ AEs was significantly lower in adjuvant versus advanced melanoma.","Eastern Cooperative Oncology Group Performance Status higher than zero was associated with higher incidences of grade 2+ IMAEs and grade 3+ AEs.","Female patients had significantly higher incidences of grade 2+ IMAEs than male patients.","Nivolumab monotherapy in adjuvant melanoma demonstrated a relatively flat E-R relationship over the range of exposures produced by 3\u00a0mg\/kg every 2\u00a0weeks and predicted a comparable benefit-risk profile to flat-dosing regimens."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"32820818","Document":["BACKGROUND: Two recent publications have reported that a shorter interval between preoperative lymphoscintigraphy and sentinel node biopsy (SNB) is associated with improved survival of patients with primary cutaneous melanoma.","The aims of this study were to analyse prospectively collected survival data for patients who had SNB on the same day as lymphoscintigraphy or the day after; and to assess tracer migration from sentinel nodes to second-tier nodes after lymphoscintigraphy on the previous day.","METHODS: Outcome data were obtained for patients who had lymphoscintigraphy and SNB on the same day (time interval less than 8\u2009h) or the next day (interval more than 16\u2009h).","In a separate prospective cohort, same-day and next-day lymphoscintigraphic images of sentinel nodes and second-tier nodes were compared.","RESULTS: Following lymphoscintigraphy, 2848 patients had same-day and 3328 had next-day SNB.","Survival outcomes did not differ between these groups.","In a prospectively studied cohort of 30 patients, none had significant tracer migration from sentinel nodes to second-tier nodes on imaging the following day.","CONCLUSION: No difference in survival after same- or next-day sentinel node biopsy is seen when 99m Tc-labelled antimony sulphide colloid is used.","This may be because of less tracer migration to second-tier nodes.","ANTECEDENTES: Dos publicaciones recientes han se\u00f1alado que reducir el intervalo entre la linfograf\u00eda isot\u00f3pica preoperatoria y la biopsia del ganglio centinela (sentinel node biopsy, SNB) se asocia con una mejor supervivencia en pacientes con melanoma maligno primario.","Los objetivos de este estudio fueron los siguientes: (1) analizar los datos de supervivencia recogidos prospectivamente en pacientes en los que se realiza la SNB el mismo d\u00eda o al d\u00eda siguiente de la linfograf\u00eda isot\u00f3pica, y (2) evaluar la migraci\u00f3n del marcador desde los ganglios centinela a los ganglios de segundo nivel a partir de la linfograf\u00eda del d\u00eda anterior.","M\u00c9TODOS: Se analizaron los resultados de los pacientes a los que se realiz\u00f3 una linfograf\u00eda isot\u00f3pica y la SNB el mismo d\u00eda (intervalo de tiempo < 8 h) o al d\u00eda siguiente (intervalo > 16 h).","En una cohorte prospectiva diferente, se compararon las im\u00e1genes de los ganglios centinela y de los ganglios de segundo nivel en linfograf\u00edas isot\u00f3picas realizadas el mismo d\u00eda o al d\u00eda siguiente.","RESULTADOS: Tras la linfograf\u00eda isot\u00f3pica, se realiz\u00f3 la SNB el mismo d\u00eda en 2.848 pacientes y al d\u00eda siguiente en 3.328 pacientes.","No hubo diferencias en la supervivencia entre ambos grupos.","En una cohorte de 30 pacientes estudiada de forma prospectiva, no hubo migraci\u00f3n significativa del trazador de los ganglios centinela a los ganglios de segundo nivel en las im\u00e1genes obtenidas al d\u00eda siguiente.","CONCLUSI\u00d3N: La mejor supervivencia que se obtiene cuando se realiza la SNB poco despu\u00e9s de la linfograf\u00eda isot\u00f3pica podr\u00eda explicarse por una diferencia en la migraci\u00f3n del trazador a los ganglios de segundo nivel entre los dos marcadores utilizados: nanocoloide de alb\u00famina humana o coloide de sulfuro de antimonio, ambos marcados con 99mTc.","En este estudio y con este \u00faltimo marcador, no se observ\u00f3 migraci\u00f3n a ganglios de segundo nivel durante la noche."],"Aspect":"a","Summary":"The study aims to analyze prospectively collected survival data for patients who had sentinel node biopsy (SNB) on the same day as lymphoscintigraphy or the day after, and to assess tracer migration from sentinel nodes to second-tier nodes after lymphoscintigraphy on the previous day.","Indexes":[1],"Sentences":["The aims of this study were to analyse prospectively collected survival data for patients who had SNB on the same day as lymphoscintigraphy or the day after; and to assess tracer migration from sentinel nodes to second-tier nodes after lymphoscintigraphy on the previous day."],"Revise":true}
{"PMID":"34855329","Document":["Patients with advanced melanoma treated with immune checkpoint inhibitors can experience ongoing disease control after treatment discontinuation without subsequent systemic anticancer therapy.","We previously defined a novel outcome, treatment-free survival (TFS), as the time between protocol therapy cessation and subsequent therapy initiation\/death.","We assessed the effect of established prognostic variables [lactate dehydrogenase (LDH), programmed death ligand 1 status, BRAF mutation status, performance status, and sex] on TFS in different treatment scenarios: treatment until toxicity\/progression with frequent early cessation (nivolumab plus ipilimumab), treatment until toxicity\/progression with a well-tolerated regimen (nivolumab), and treatment for a short fixed duration (ipilimumab).","Data were pooled from 1077 patients with advanced melanoma treated in the CheckMate 069 and 067 trials.","TFS was defined as the area between the Kaplan-Meier curves for time to therapy cessation and time to subsequent therapy initiation\/death.","TFS was estimated by restricted mean (r-mean) survival time at 36\u2009months since randomization.","Clinically meaningful TFS (r-mean TFS 3.7-12.7\u2009months) was observed across all patient subgroups.","TFS was longest in patients treated with nivolumab plus ipilimumab.","The largest differences in r-mean TFS were observed with LDH in the nivolumab plus ipilimumab and ipilimumab treatment groups (TFS difference 4.7 and 4.9\u2009months, respectively).","In the nivolumab group, there was little difference in TFS across subgroups (r-mean TFS 3.7-5.5\u2009months).","TFS was sensitive to prognostic subgroup differences; however, duration of treatment affected the sensitivity of TFS.","These results provide further support for TFS as a clinical outcome measure."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"33407577","Document":["BACKGROUND: Studies carried out in vitro and in a mouse model have shown that BRAF inhibitors enhance the effects of IFN-\u03b1 on BRAFV600E melanoma cells through the inhibition of ERK.","Therefore, the combination of vemurafenib and IFN-\u03b1 in patients with BRAFV600E melanoma may provide therapeutic benefits; MEK inhibition may prevent the reactivation of the MAPK pathway induced by BRAF inhibitor resistance.","PATIENTS AND METHODS: In a phase I study, adult patients with advanced BRAFV600-mutated melanoma were treated with vemurafenib\u2009+\u2009PEG-IFN-\u03b1-2b or vemurafenib\u2009+\u2009cobimetinib\u2009+\u2009PEG-IFN-\u03b1-2b, to assess the safety of the combination and the upregulation of IFN-\u03b1\/\u03b2 receptor-1 (IFNAR1).","RESULTS: Eight patients were treated; 59 adverse events with four serious ones (three related to study treatments) were reported.","Patients with a pre-treatment IFNAR1 expression on\u2009\u2264\u200935% melanoma cells had a median progression-free survival of 12.0\u00a0months (range: 5.6-18.4\u00a0months) and a median overall survival of 31.0\u00a0months (range: 19.8-42.2\u00a0months), while patients with a pre-treatment IFNAR1 expression on\u2009>\u200935% of melanoma cells had a median progression-free survival of 4.0\u00a0months (range: 0-8.8; p\u2009=\u20090.03), and a median overall survival of 5\u00a0months (p\u2009=\u20090.02).","Following treatment, responders had higher levels of growth-suppressor genes, including GAS1 and DUSP1, and genes involved in a metabolically robust immune response, including FAP.","CONCLUSION: Our study supports the overall safety of the vemurafenib\u2009+\u2009PEG-IFN-\u03b1-2b\u2009+\u2009cobimetinib combination.","IFNAR1 expression levels correlated with response to treatment, including survival.","Vemurafenib\u2009+\u2009PEG-IFN-\u03b1-2b\u2009+\u2009cobimetinib would have difficulty finding a niche in the current treatment scenario for advanced melanoma, but we speculate that our findings may contribute to identify subjects particularly responsive to treatment.","TRIAL REGISTRATION: The study was registered at clinicaltrials.gov (NCT01959633).","Registered 10 October 2013, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01959633."],"Aspect":"o","Summary":"The study found that patients with a pre-treatment IFNAR1 expression on \u226435% of melanoma cells had a median progression-free survival of 12.0 months and a median overall survival of 31.0 months, while those with >35% expression had a median progression-free survival of 4.0 months and a median overall survival of 5 months.","Indexes":[4],"Sentences":["Patients with a pre-treatment IFNAR1 expression on\u2009\u2264\u200935% melanoma cells had a median progression-free survival of 12.0\u00a0months (range: 5.6-18.4\u00a0months) and a median overall survival of 31.0\u00a0months (range: 19.8-42.2\u00a0months), while patients with a pre-treatment IFNAR1 expression on\u2009>\u200935% of melanoma cells had a median progression-free survival of 4.0\u00a0months (range: 0-8.8; p\u2009=\u20090.03), and a median overall survival of 5\u00a0months (p\u2009=\u20090.02)."],"Revise":false}
{"PMID":"31852717","Document":["Whereas systemic IL12 is associated with potentially life-threatening toxicity, intratumoral delivery of IL12 through tavokinogene telseplasmid electroporation (tavo) is safe and can induce tumor regression at distant sites.","The mechanism by which these responses are mediated is unknown but is presumed to result from a cellular immune response.","In a phase II clinical trial of tavo (NCT01502293), samples from 29 patients with cutaneous melanoma with in-transit disease were assessed for immune responses induced with this treatment.","Within the blood circulating immune cell population, we found that the frequencies of circulating PD-1+ CD4+ and CD8+ T cells declined with treatment.","Circulating immune responses to gp100 were also detected following treatment as measured by IFN\u03b3 ELISpot.","Patients with a greater antigen-specific circulating immune response also had higher numbers of CD8+ T cells within the tumor.","Clinical response was also associated with increased intratumoral CD3+ T cells.","Finally, intratumoral T-cell clonality and convergence were increased after treatment, indicating a focusing of the T-cell receptor repertoire.","These results indicated that local treatment with tavo can induce a systemic T-cell response and recruit T cells to the tumor microenvironment."],"Aspect":"p","Summary":"The study involved 29 patients with cutaneous melanoma with in-transit disease.","Indexes":[2],"Sentences":["In a phase II clinical trial of tavo (NCT01502293), samples from 29 patients with cutaneous melanoma with in-transit disease were assessed for immune responses induced with this treatment."],"Revise":false}
{"PMID":"31912791","Document":["BACKGROUND: We conducted a retrospective exploratory analysis to evaluate the effects of baseline tumour immune infiltrate on disease-free survival (DFS) outcomes in patients with fully resected stage IIC-IIIC melanoma receiving adjuvant vemurafenib monotherapy or placebo in the BRIM8 study.","PATIENTS AND METHODS: BRIM8 was a phase III, international, double-blind, randomised, placebo-controlled study.","Eligible patients with BRAFV600 mutation-positive, completely resected melanoma were randomly assigned to oral vemurafenib (960 mg twice daily) or matching placebo for 52 weeks.","The primary end point was DFS.","The association of CD8+ T-cell infiltration and programmed death ligand 1 (PD-L1) expression with DFS, as measured by immunohistochemistry, was explored retrospectively.","RESULTS: Four hundred ninety-eight patients were randomly assigned to receive adjuvant vemurafenib (n\u00a0= 250) or placebo (n\u00a0= 248); tumour samples were available for biomarker analysis for approximately 60% of patients.","In the pooled biomarker population, placebo-treated patients with <1% CD8+ T cells in the tumour centre had shorter median DFS than those with \u22651% CD8+ T cells (7.7 versus 47.8 months).","DFS benefit from vemurafenib versus placebo was greater in patients with <1% CD8+ T cells [hazard ratio (HR) 0.56; 95% confidence interval (CI) 0.34-0.92) than in patients with \u22651% CD8+ T cells (HR 0.77; 95% CI 0.48-1.22).","Likewise, median DFS was shorter among placebo-treated patients with <5% versus \u22655% PD-L1+ immune cells (IC) in the tumour (7.2 versus 47.8 months).","A greater DFS benefit with vemurafenib versus placebo was observed in patients with <5% PD-L1+IC (HR 0.36; 95% CI 0.24-0.56) than in patients with \u22655% PD-L1+IC (HR 0.99; 95% CI 0.58-1.69).","CONCLUSIONS: The presence of CD8+ T cells and PD-L1+IC are favourable prognostic factors for DFS.","Treatment with adjuvant vemurafenib may overcome the poor DFS prognosis associated with low CD8+ T-cell count or PD-L1 expression.","CLINICALTRIALS.","GOV IDENTIFIER: NCT01667419."],"Aspect":"p","Summary":"The study involved 498 patients with fully resected stage IIC-IIIC melanoma with BRAFV600 mutation, randomly assigned to receive adjuvant vemurafenib (n=250) or placebo (n=248).","Indexes":[2,5],"Sentences":["Eligible patients with BRAFV600 mutation-positive, completely resected melanoma were randomly assigned to oral vemurafenib (960 mg twice daily) or matching placebo for 52 weeks.","RESULTS: Four hundred ninety-eight patients were randomly assigned to receive adjuvant vemurafenib (n\u00a0= 250) or placebo (n\u00a0= 248); tumour samples were available for biomarker analysis for approximately 60% of patients."],"Revise":false}
{"PMID":"36940407","Document":["PURPOSE: About half of patients with metastatic uveal melanoma present with isolated liver metastasis, in whom the median survival is 6-12 months.","The few systemic treatment options available only moderately prolong survival.","Isolated hepatic perfusion (IHP) with melphalan is a regional treatment option, but prospective efficacy and safety data are lacking.","METHODS: In this multicenter, randomized, open-label, phase III trial, patients with previously untreated isolated liver metastases from uveal melanoma were randomly assigned to receive a one-time treatment with IHP with melphalan or best alternative care (control group).","The primary end point was overall survival at 24 months.","Here, we report the secondary outcomes of response according to RECIST 1.1 criteria, progression-free survival (PFS), hepatic PFS (hPFS), and safety.","RESULTS: Ninety-three patients were randomly assigned, and 87 patients were assigned to either IHP (n = 43) or a control group receiving the investigator's choice of treatment (n = 44).","In the control group, 49% received chemotherapy, 39% immune checkpoint inhibitors, and 9% locoregional treatment other than IHP.","In an intention-to-treat analysis, the overall response rates (ORRs) were 40% versus 4.5% in the IHP and control groups, respectively (P < .0001).","The median PFS was 7.4 months versus 3.3 months (P < .0001), with a hazard ratio of 0.21 (95% CI, 0.12 to 0.36), and the median hPFS was 9.1 months versus 3.3 months (P < .0001), both favoring the IHP arm.","There were 11 treatment-related serious adverse events in the IHP group compared with seven in the control group.","There was one treatment-related death in the IHP group.","CONCLUSION: IHP treatment resulted in superior ORR, hPFS, and PFS compared with best alternative care in previously untreated patients with isolated liver metastases from primary uveal melanoma."],"Aspect":"i","Summary":"Patients with previously untreated isolated liver metastases from uveal melanoma were randomly assigned to receive a one-time treatment with isolated hepatic perfusion (IHP) with melphalan or best alternative care.","Indexes":[3],"Sentences":["METHODS: In this multicenter, randomized, open-label, phase III trial, patients with previously untreated isolated liver metastases from uveal melanoma were randomly assigned to receive a one-time treatment with IHP with melphalan or best alternative care (control group)."],"Revise":false}
{"PMID":"38485189","Document":["BACKGROUND: Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) versus placebo in the phase 3 KEYNOTE-716 study of resected stage IIB or IIC melanoma.","At the prespecified third interim analysis (data cut-off, January 4, 2022), the HR for RFS in the overall population was 0.64 (95% CI, 0.50 to 0.84) and the HR for DMFS was 0.64 (95% CI, 0.47 to 0.88).","We present a post hoc analysis of efficacy by subtypes defined by histopathologic characteristics.","METHODS: Patients aged \u226512 years with newly diagnosed, resected stage IIB or IIC melanoma were randomly assigned (1:1) to pembrolizumab 200\u2009mg every 3 weeks (2\u2009mg\/kg up to 200\u2009mg for pediatric patients) or placebo.","The primary end point was RFS per investigator review; DMFS per investigator review was secondary.","Subgroups of interest were melanoma subtype (nodular vs non-nodular), tumor thickness (\u22644\u2009mm vs >4\u2009mm), presence of ulceration (yes vs no), mitotic rate (<5 per mm2 (median) vs \u22655 per mm2), and presence of tumor-infiltrating lymphocytes (TILs; absent vs present).","RESULTS: Between September 23, 2018, and November 4, 2020, 976 patients were assigned to pembrolizumab (n=487) or placebo (n=489).","Median follow-up was 27.4 months (range, 14.0-39.4).","The HR (95%\u2009CI) for RFS was 0.54 (0.37 to 0.79) for nodular and 0.77 (0.53 to 1.11) for non-nodular melanoma; 0.57 (0.37 to 0.89) for thickness \u22644\u2009mm and 0.69 (0.50 to 0.96) for >4\u2009mm; 0.66 (0.50 to 0.89) for ulceration and 0.57 (0.32 to 1.03) for no ulceration; 0.57 (0.35 to 0.92) for mitotic rate <5 per mm2 and 0.57 (0.40 to 0.80) for \u22655 per mm2; and 0.89 (0.52 to 1.54) for TILs absent and 0.51 (0.34 to 0.76) for TILs present.","DMFS results were similar.","In a Cox multivariate analysis, treatment arm, tumor thickness, and mitotic rate were significant independent factors for RFS, and treatment arm and mitotic rate were significant independent factors for DMFS.","CONCLUSIONS: In this post hoc analysis, the benefit of pembrolizumab was largely consistent with the overall study population regardless of histopathologic characteristics.","These results support the use of adjuvant pembrolizumab in patients with resected stage IIB or IIC melanoma.","TRIAL REGISTRATION NUMBER: ClinicalTrials.gov, NCT03553836."],"Aspect":"m","Summary":"The trial involved pembrolizumab administered at a dose of 200 mg every 3 weeks (2 mg\/kg up to 200 mg for pediatric patients).","Indexes":[3],"Sentences":["METHODS: Patients aged \u226512 years with newly diagnosed, resected stage IIB or IIC melanoma were randomly assigned (1:1) to pembrolizumab 200\u2009mg every 3 weeks (2\u2009mg\/kg up to 200\u2009mg for pediatric patients) or placebo."],"Revise":false}
{"PMID":"35947391","Document":["IMPORTANCE: Medical second opinions are common, although little is known about the best processes for obtaining them.","This study assesses whether knowledge of a prior physician's diagnosis influences consulting physicians' diagnoses.","OBJECTIVE: To measure the extent to which dermatopathologists' diagnoses are influenced by prior diagnostic information from another dermatopathologist.","DESIGN, SETTING, AND PARTICIPANTS: Dermatopathologists were randomly assigned to interpret 1 slide set of 18 melanocytic skin biopsy specimens in 2 phases (5 slide sets totaling 90 cases).","Phase 1 interpretations were conducted without prior diagnostic information.","After a washout period of 12 or more months, dermatopathologists' phase 2 interpretations were conducted with their identical slide set; for a random subset of cases in phase 2, participants were shown prior diagnoses by other dermatopathologists that were either more or less severe than their own phase 1 diagnosis of the case.","Using the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis tool, cases ranged from class I (benign) to class V (\u2265pT1b invasive melanoma).","Data collection took place from August 2018 to March 2021, and data analysis was performed from March to December 2021.","INTERVENTION: Prior diagnoses were actual diagnoses from board-certified and\/or fellowship-trained dermatopathologists.","A prior diagnosis was always in a more severe or less severe diagnostic class than the participant's phase 1 interpretation; more or less severe was determined by the randomization scheme.","In the control condition of no prior diagnostic information, the participants were told that a prior diagnosis was not available.","MAIN OUTCOMES AND MEASURES: When exposure was to a prior diagnosis in a higher diagnostic class, the primary study outcome was whether a participant's diagnosis in phase 2 was in a higher diagnostic class than the participant's diagnosis in phase 1.","When exposure was to a prior diagnosis in a lower diagnostic class, the primary study outcome was whether a participant's diagnosis in phase 2 was in a lower diagnostic class than the participant's diagnosis in phase 1.","The effect of prior diagnostic information was measured using the relative risk (RR) of each outcome relative to the control condition of no prior diagnostic information, adjusted for the diagnostic class of the phase 1 diagnosis.","Prior to data collection, it was hypothesized that participants would be swayed in the direction of prior diagnostic information.","RESULTS: A total of 149 dermatopathologists (median [range] age, 47 years [34-76] years; 101 [68%] were male) provided 5322 interpretations of study cases.","Participants were more likely to increase the severity of their diagnosis when the prior diagnosis was of greater severity compared with when no prior diagnosis was provided (RR, 1.52; 95% CI, 1.34-1.73); likewise, participants gave less severe diagnoses when prior diagnoses were of lesser severity (RR, 1.38; 95% CI, 1.19-1.59).","Trends were similar among dermatopathologists who had previously stated they were \"not at all influenced\" by prior diagnoses.","Prior diagnoses also swayed dermatopathologists away from correct diagnoses.","CONCLUSIONS AND RELEVANCE: In this randomized controlled trial, despite the preference of most dermatopathologists to receive prior diagnoses when providing second opinions, this information swayed them away from a correct diagnosis to an incorrect diagnosis."],"Aspect":"p","Summary":"The study involved 149 dermatopathologists with a median age of 47 years (range 34-76 years), 68% of whom were male.","Indexes":[15],"Sentences":["RESULTS: A total of 149 dermatopathologists (median [range] age, 47 years [34-76] years; 101 [68%] were male) provided 5322 interpretations of study cases."],"Revise":false}
{"PMID":"32819972","Document":["BACKGROUND: A synergy between radiotherapy and anti-cytotoxic-T-lymphocyte-associated antigen 4 (anti-CTLA-4) monoclonal antibody has been demonstrated preclinically.","The Mel-Ipi-Rx phase 1 study aimed to determine the maximum tolerated dose (MTD) and safety profile of radiotherapy combined with ipilimumab in patients with metastatic melanoma.","PATIENTS AND METHODS: A 3+3 dose escalation design was used with 9, 15, 18 and 24 Gy dose of radiotherapy at week 4 combined with 10 mg\/kg ipilimumab every 3 weeks for four doses.","Patients with evidence of clinical benefit at week 12 were eligible for maintenance with ipilimumab 10 mg\/kg every 12 weeks starting at week 24 until severe toxicity or disease progression.","The database lock occurred on April 30, 2019.","Tumor growth rate of irradiated lesions and non-irradiated lesions were analyzed to assess the systemic immunologic antitumor response.","Blood immune monitoring was performed before and during treatment to determine if radiotherapy could modify ipilimumab pharmacodynamics.","RESULTS: 19 patients received ipilimumab between August 2011 and July 2015.","Nine patients received the four doses of ipilimumab.","All patients received the combined radiotherapy.","Grade 3 adverse events occurred in nine patients, the most common being colitis and hepatitis.","No drug-related death occurred.","Dose limiting toxicity occurred in two of six patients in the cohort receiving 15 Gy.","The MTD was 9 Gy.","Two patients had complete response, three had partial response response and seven had stable disease, giving an objective response rate of 31% and a clinical benefit rate of 75% at week 24.","The median duration of follow-up was 5.8 years (Q1=4.5; Q3=6.8).","The median overall survival (95% CI) was estimated at 0.9 years (0.5-2).","The median progression-free survival (PFS) (95% CI) was 0.4 (0.2-1.4).","Radiotherapy combined with ipilimumab was associated with increased CD4+ and CD8+ICOS+ T cells.","Increased CD8+ was significantly associated with PFS.","CONCLUSION: When combined with ipilimumab at 10 mg\/kg, the MTD of radiotherapy was 9 Gy.","This combination of ipilimumab and radiotherapy appears to be associated with antitumor activity.","Increased CD8+ was significantly associated with PFS.","Thus, immune biomarkers may be useful for early response evaluation.","TRIAL REGISTRATION NUMBER: NCT01557114."],"Aspect":"m","Summary":"The study used ipilimumab at a dose of 10 mg\/kg every 3 weeks for four doses, with maintenance doses of 10 mg\/kg every 12 weeks starting at week 24, combined with radiotherapy doses of 9, 15, 18, or 24 Gy at week 4.","Indexes":[2,3],"Sentences":["PATIENTS AND METHODS: A 3+3 dose escalation design was used with 9, 15, 18 and 24 Gy dose of radiotherapy at week 4 combined with 10 mg\/kg ipilimumab every 3 weeks for four doses.","Patients with evidence of clinical benefit at week 12 were eligible for maintenance with ipilimumab 10 mg\/kg every 12 weeks starting at week 24 until severe toxicity or disease progression."],"Revise":false}
{"PMID":"36029412","Document":["PURPOSE: Trial E1609 demonstrated superior overall survival with ipilimumab 3\u00a0mg\/kg (ipi3) compared to high-dose interferon (HDI) for patients with resected high-risk melanoma.","To inform treatment tolerability, we compared health-related quality of life (HRQoL), gastrointestinal (GI), and treatment-specific physical and cognitive\/emotional symptoms.","We also compared treatment-specific concerns between all arms.","METHODS: We assessed HRQoL using the Functional Assessment of Cancer Therapy-General, physical and cognitive\/emotional concerns using the FACT-Biologic Response Modifier subscale, and GI symptoms with the Functional Assessment of Chronic Illness Therapy-Diarrhea subscale pre-treatment and every 3 months.","The primary outcome was the difference in HRQoL at 3 months between ipi3\/ipi10 vs. HDI.","RESULTS: 549 patients (n\u2009=\u2009158 ipi3; n\u2009=\u2009191 ipi10; n\u2009=\u2009200 HDI) were analyzed.","3-month completion was 58.7%.","Compared to HDI, ipilimumab patients reported better HRQoL (ipi3\u2009=\u200987.5\u2009\u00b1\u200914.6 vs. HDI\u2009=\u200974.7\u2009\u00b1\u200915.4, p\u2009<\u2009.001; ipi10\u2009=\u200984.9\u2009\u00b1\u200916.5 vs. HDI, p\u2009<\u2009.001) and fewer physical (ipi3\u2009=\u200922.3\u2009\u00b1\u20094.6 vs. HDI\u2009=\u200917.1\u2009\u00b1\u20095.4, p\u2009<\u2009.001; ipi10\u2009=\u200921.8\u2009\u00b1\u20095.0 vs. HDI p\u2009<\u2009.001) and cognitive\/emotional (ipi3\u2009=\u200918.6\u2009\u00b1\u20094.4 vs. HDI\u2009=\u200915.0\u2009\u00b1\u20095.3, p\u2009<\u2009.001; ipi10\u2009=\u200917.7\u2009\u00b1\u20094.8 vs. HDI p\u2009<\u2009.001) concerns, but worse GI symptoms (ipi3\u2009=\u200940.8\u2009\u00b1\u20095.0 vs. HDI\u2009=\u200942.2\u2009\u00b1\u20092.9, p\u2009=\u2009.011; ipi10\u2009=\u200939.5\u2009\u00b1\u20097.0 vs. HDI, p\u2009<\u2009.001).","Fewer ipilimumab patients reported worsening treatment-specific concerns (e.g., 52% of ipi3 and 58% of ipi10 reported worsening fatigue vs. 82% HDI, p's\u2009<\u2009.001).","CONCLUSION: PROs demonstrated less toxicity of ipi3 compared to HDI and ipi10.","Priorities for symptom management among patients receiving ipilimumab include GI toxicities, fatigue, weakness, appetite loss, arthralgia, and depression.","TRIAL REGISTRATION: NCT01274338, January 11, 2011 (first posted date) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01274338?term=NCT01274338&draw=2&rank=1 ."],"Aspect":"a","Summary":"The study aims to compare the health-related quality of life (HRQoL), gastrointestinal (GI) symptoms, and treatment-specific concerns between different treatment arms (ipilimumab 3mg\/kg, ipilimumab 10mg\/kg, and high-dose interferon) for patients with resected high-risk melanoma.","Indexes":[1,2],"Sentences":["To inform treatment tolerability, we compared health-related quality of life (HRQoL), gastrointestinal (GI), and treatment-specific physical and cognitive\/emotional symptoms.","We also compared treatment-specific concerns between all arms."],"Revise":false}
{"PMID":"31812554","Document":["BACKGROUND: Pembrolizumab is approved for the treatment of advanced cancer in adults; however, no information is available on safety and efficacy in paediatric patients.","We aimed to establish the recommended phase 2 dose of pembrolizumab and its safety and antitumour activity in advanced paediatric cancer.","METHODS: KEYNOTE-051 is an ongoing phase 1-2 open-label trial.","In this interim analysis, children aged 6 months to 17 years were recruited at 30 hospitals located in Australia, Brazil, Canada, France, Germany, Israel, Italy, South Korea, Sweden, the UK, and the USA.","Patients with melanoma or a centrally confirmed, PD-L1-positive, relapsed or refractory solid tumour or lymphoma, and a Lansky Play\/Karnofsky Performance status score of 50 or higher, received intravenous pembrolizumab at an initial dose of 2 mg\/kg every 3 weeks.","Pharmacokinetics and dose-limiting toxicities were used to establish the recommended phase 2 dose, and the safety and antitumour activity of this dose were assessed.","Primary endpoints were determination of dose-limiting toxicities at the maximum administered dose, safety and tolerability, and the proportion of patients with objective response to pembrolizumab for each tumour type according to the Response Evaluation Criteria in Solid Tumours version 1.1 or the International Neuroblastoma Response Criteria.","Safety and efficacy were assessed in all treated patients who received at least one dose of pembrolizumab.","Separate reporting of the cohort of patients with relapsed or refractory classical Hodgkin lymphoma was a post-hoc decision.","The data cutoff for this interim analysis was Sept 3, 2018.","This trial is still enrolling patients and is registered with ClinicalTrials.gov, number NCT02332668.","FINDINGS: Of 863 patients screened between March 23, 2015, and Sept 3, 2018, 796 had tumours that were evaluable for PD-L1 expression (278 [35%] were PD-L1-positive); 155 eligible patients were enrolled and 154 had at least one dose of pembrolizumab.","The median age of the enrolled patients was 13 years (IQR 8-15).","Median follow-up was 8\u00b76 months (IQR 2\u00b75-16\u00b74).","No dose-limiting toxicities were reported in phase 1, and pembrolizumab plasma concentrations were consistent with those previously reported in adults; the recommended phase 2 dose was therefore established as 2 mg\/kg every 3 weeks.","Of the 154 patients treated, 69 (45%) experienced grade 3-5 adverse events, most commonly anaemia in 14 (9%) patients and decreased lymphocyte count in nine (6%) patients.","13 (8%) of the 154 patients had grade 3-5 treatment-related adverse events, most commonly decreased lymphocyte count in three (2%) patients and anaemia in two (1%) patients.","14 (9%) patients had serious treatment-related adverse events, most commonly pyrexia (four [3%]), and hypertension and pleural effusion (two [1%] each).","Four patients (3%) discontinued treatment because of treatment-related adverse events, and two (1%) died (one due to pulmonary oedema and one due to pleural effusion and pneumonitis).","Of 15 patients with relapsed or refractory Hodgkin lymphoma, two had complete and seven had partial responses; thus, nine patients achieved an objective response (60\u00b70%; 95% CI 32\u00b73-83\u00b77).","Of 136 patients with solid tumours and other lymphomas, eight had partial responses (two patients each with adrenocortical carcinoma and mesothelioma, and one patient each with malignant ganglioglioma, epithelioid sarcoma, lymphoepithelial carcinoma, and malignant rhabdoid tumour); the proportion of patients with an objective response was 5\u00b79% (95% CI 2\u00b76-11\u00b73).","INTERPRETATION: Pembrolizumab was well tolerated and showed encouraging antitumour activity in paediatric patients with relapsed or refractory Hodgkin lymphoma, consistent with experience in adult patients.","Pembrolizumab had low antitumour activity in the majority of paediatric tumour types, and responses were observed in only a few rare PD-L1-positive tumour types, suggesting that PD-L1 expression alone is not sufficient as a biomarker for the selection of paediatric patients who are likely to respond to PD-1 checkpoint inhibitors.","Final results of KEYNOTE-051, expected by September, 2022, with the possibility for extension, will report further on the activity of pembrolizumab in Hodgkin lymphoma, microsatellite instability-high tumours, and melanoma.","FUNDING: Merck Sharp & Dohme, a subsidiary of Merck & Co."],"Aspect":"a","Summary":"The study aimed to establish the recommended phase 2 dose of pembrolizumab and its safety and antitumour activity in advanced paediatric cancer.","Indexes":[1],"Sentences":["We aimed to establish the recommended phase 2 dose of pembrolizumab and its safety and antitumour activity in advanced paediatric cancer."],"Revise":false}
{"PMID":"31912791","Document":["BACKGROUND: We conducted a retrospective exploratory analysis to evaluate the effects of baseline tumour immune infiltrate on disease-free survival (DFS) outcomes in patients with fully resected stage IIC-IIIC melanoma receiving adjuvant vemurafenib monotherapy or placebo in the BRIM8 study.","PATIENTS AND METHODS: BRIM8 was a phase III, international, double-blind, randomised, placebo-controlled study.","Eligible patients with BRAFV600 mutation-positive, completely resected melanoma were randomly assigned to oral vemurafenib (960 mg twice daily) or matching placebo for 52 weeks.","The primary end point was DFS.","The association of CD8+ T-cell infiltration and programmed death ligand 1 (PD-L1) expression with DFS, as measured by immunohistochemistry, was explored retrospectively.","RESULTS: Four hundred ninety-eight patients were randomly assigned to receive adjuvant vemurafenib (n\u00a0= 250) or placebo (n\u00a0= 248); tumour samples were available for biomarker analysis for approximately 60% of patients.","In the pooled biomarker population, placebo-treated patients with <1% CD8+ T cells in the tumour centre had shorter median DFS than those with \u22651% CD8+ T cells (7.7 versus 47.8 months).","DFS benefit from vemurafenib versus placebo was greater in patients with <1% CD8+ T cells [hazard ratio (HR) 0.56; 95% confidence interval (CI) 0.34-0.92) than in patients with \u22651% CD8+ T cells (HR 0.77; 95% CI 0.48-1.22).","Likewise, median DFS was shorter among placebo-treated patients with <5% versus \u22655% PD-L1+ immune cells (IC) in the tumour (7.2 versus 47.8 months).","A greater DFS benefit with vemurafenib versus placebo was observed in patients with <5% PD-L1+IC (HR 0.36; 95% CI 0.24-0.56) than in patients with \u22655% PD-L1+IC (HR 0.99; 95% CI 0.58-1.69).","CONCLUSIONS: The presence of CD8+ T cells and PD-L1+IC are favourable prognostic factors for DFS.","Treatment with adjuvant vemurafenib may overcome the poor DFS prognosis associated with low CD8+ T-cell count or PD-L1 expression.","CLINICALTRIALS.","GOV IDENTIFIER: NCT01667419."],"Aspect":"d","Summary":"Patients received oral vemurafenib or matching placebo for 52 weeks.","Indexes":[2],"Sentences":["Eligible patients with BRAFV600 mutation-positive, completely resected melanoma were randomly assigned to oral vemurafenib (960 mg twice daily) or matching placebo for 52 weeks."],"Revise":true}
{"PMID":"38767650","Document":["PURPOSE: The Adaptively Dosed ImmunoTherapy Trial (ADAPT-IT;NCT03122522) investigated adaptive ipilimumab discontinuation in melanoma based on early radiographic assessment.","Initial findings indicated similar effectiveness compared with conventional nivolumab-ipilimumab (nivo-ipi).","Exploratory biomarker analyses and final clinical results are now reported.","PATIENTS AND METHODS: Patients with unresectable melanoma received two doses of nivo-ipi.","Radiographic assessment at Week 6 informed continuation of ipilimumab before nivolumab maintenance.","The primary endpoint was overall response rate at Week 12.","Plasma was assayed for circulating tumor DNA and 10 cytokines using a multiplex immunoassay.","Flow cytometry of peripheral blood mononuclear cells was performed with an 11-color panel.","RESULTS: Among the treated patients, expansion of proliferating T-cell populations was observed in responders and nonresponders.","Baseline IL6 levels were low in patients achieving an objective radiographic response (median 1.30 vs. 2.86 pg\/mL; P = 0.025).","High baseline IL6 levels were associated with short progression-free survival [PFS; HR = 1.24, 95% confidence interval (CI), 1.01-1.52; P = 0.041].","At Week 6, patients with response had lower average tumor variant allele fractions than nonresponders (median 0.000 vs. 0.019; P = 0.014).","Greater increases in average variant allele fractions from baseline to Week 6 correlated with short PFS (HR = 1.11, 95% CI, 1.01-1.21; P = 0.023).","Week 12 overall response rate was 47% (95% CI, 35%-59%) with a median follow-up of 34 months among survivors.","Median PFS was 21 months (95% CI, 10-not reached); 76% of responses (95% CI, 64%-91%) persisted at 36 months.","CONCLUSIONS: Adaptively dosed nivo-ipi responses are durable and resemble historical data for conventional nivo-ipi.","Baseline IL6 and circulating tumor DNA changes during treatment warrant further study as biomarkers of nivo-ipi response."],"Aspect":"i","Summary":"The study investigated adaptive ipilimumab discontinuation in melanoma patients based on early radiographic assessment and through exploratory biomarker analyses utilising flow cytometry and plasma plasma multiplex cytokine immunoassays with a focus on overall response rate at Week 12. ","Indexes":[0,3,4,5,6,7],"Sentences":["PURPOSE: The Adaptively Dosed ImmunoTherapy Trial (ADAPT-IT;NCT03122522) investigated adaptive ipilimumab discontinuation in melanoma based on early radiographic assessment.","PATIENTS AND METHODS: Patients with unresectable melanoma received two doses of nivo-ipi.","Radiographic assessment at Week 6 informed continuation of ipilimumab before nivolumab maintenance.","The primary endpoint was overall response rate at Week 12.","Plasma was assayed for circulating tumor DNA and 10 cytokines using a multiplex immunoassay.","Flow cytometry of peripheral blood mononuclear cells was performed with an 11-color panel."],"Revise":true}
{"PMID":"32369107","Document":["Immune and molecular profiling of CD8 T cells of patients receiving DC vaccines expressing three full-length melanoma antigens (MAs) was performed.","Antigen expression levels in DCs had no significant impact on T cell or clinical responses.","Patients who received checkpoint blockade before DC vaccination had higher baseline MA-specific CD8 T cell responses but no evidence for improved functional responses to the vaccine.","Patients who showed the best clinical responses had low PD-1 expression on MA-specific T cells before and after DC vaccination; however, blockade of PD-1 during antigen presentation by DC had minimal functional impact on PD-1high MA-specific T cells.","Gene and protein expression analyses in lymphocytes and tumor samples identified critical immunoregulatory pathways, including CTLA-4 and PD-1.","High immune checkpoint gene expression networks correlated with inferior clinical outcomes.","Soluble serum PD-L2 showed suggestive positive association with improved outcome.","These findings show that checkpoint molecular pathways are critical for vaccine outcomes and suggest specific sequencing of vaccine combinations."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"32152202","Document":["PURPOSE: We analyzed whole transcriptome sequencing in tumors from 23 patients with stage III or IV melanoma from a pilot trial of the anti-GD2 immunocytokine, hu14.18-IL2, to identify predictive immune and\/or tumor biomarkers in patients with melanoma at high risk for recurrence.","EXPERIMENTAL DESIGN: Patients were randomly assigned to receive the first of three monthly courses of hu14.18-IL2 immunotherapy either before (Group A) or after (Group B) complete surgical resection of all known diseases.","Tumors were evaluated by histology and whole transcriptome sequencing.","RESULTS: Tumor-infiltrating lymphocyte (TIL) levels directly associated with relapse-free survival (RFS) and overall survival (OS) in resected tumors from Group A, where early responses to the immunotherapy agent could be assessed.","TIL levels directly associated with a previously reported immune signature, which associated with RFS and OS, particularly in Group A tumors.","In Group A tumors, there were decreased cell-cycling gene RNA transcripts, but increased RNA transcripts for repair and growth genes.","We found that outcome (RFS and OS) was directly associated with several immune signatures and immune-related RNA transcripts and inversely associated with several tumor growth-associated transcripts, particularly in Group A tumors.","Most of these associations were not seen in Group B tumors.","CONCLUSIONS: We interpret these data to signify that both immunologic and tumoral cell processes, as measured by RNA-sequencing analyses detected shortly after initiation of hu14.18-IL2 therapy, are associated with long-term survival and could potentially be used as prognostic biomarkers in tumor resection specimens obtained after initiating neoadjuvant immunotherapy."],"Aspect":"i","Summary":"Patients with stage III or IV melanoma were randomly assigned to receive the anti-GD2 immunocytokine, hu14.18-IL2, either before or after complete surgical resection of all known diseases.","Indexes":[1],"Sentences":["EXPERIMENTAL DESIGN: Patients were randomly assigned to receive the first of three monthly courses of hu14.18-IL2 immunotherapy either before (Group A) or after (Group B) complete surgical resection of all known diseases."],"Revise":false}
{"PMID":"33288749","Document":["Combining PD-L1 blockade with inhibition of oncogenic mitogen-activated protein kinase (MAPK) signaling may result in long-lasting responses in patients with advanced melanoma.","This phase 1, open-label, dose-escalation and -expansion study (NCT02027961) investigated safety, tolerability and preliminary efficacy of durvalumab (anti-PD-L1) combined with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) for patients with BRAF-mutated melanoma (cohort A, n\u2009=\u200926), or durvalumab and trametinib given concomitantly (cohort B, n\u2009=\u200920) or sequentially (cohort C, n\u2009=\u200922) for patients with BRAF-wild type melanoma.","Adverse events and treatment discontinuation rates were more common than previously reported for these agents given as monotherapy.","Objective responses were observed in 69.2% (cohort A), 20.0% (cohort B) and 31.8% (cohort C) of patients, with evidence of improved tumor immune infiltration and durable responses in a subset of patients with available biopsy samples.","In conclusion, combined MAPK inhibition and anti-PD-L1 therapy may provide treatment options for patients with advanced melanoma."],"Aspect":"m","Summary":"The study investigated durvalumab (anti-PD-L1) combined with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) for patients with BRAF-mutated melanoma, and durvalumab with trametinib for BRAF-wild type melanoma.","Indexes":[1],"Sentences":["This phase 1, open-label, dose-escalation and -expansion study (NCT02027961) investigated safety, tolerability and preliminary efficacy of durvalumab (anti-PD-L1) combined with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) for patients with BRAF-mutated melanoma (cohort A, n\u2009=\u200926), or durvalumab and trametinib given concomitantly (cohort B, n\u2009=\u200920) or sequentially (cohort C, n\u2009=\u200922) for patients with BRAF-wild type melanoma."],"Revise":false}
{"PMID":"31653251","Document":["BACKGROUND: Amputation is the standard of care even for early-stage subungual melanomas (SUMs), known as nail apparatus melanoma, because the nail bed and nail matrix are close to the distal phalanx.","However, a recent study demonstrated that not all patients with SUMs had histologic invasion of the underlying distal phalanx.","As most SUMs occur in the thumb or big toe, amputation of either the thumb or big toe substantially interferes with activities of daily living, including poor cosmesis, loss of function, and phantom pain.","Non-amputative digit preservation surgery can thus be applied in such cases without compromising patient prognosis.","METHODS: We are conducting a multi-institutional single-arm trial to confirm the safety and efficacy of non-amputative digit preservation surgery.","We will compare our results with those reported in the Japanese Melanoma Study, in which patients underwent amputation for SUMs as a traditional standard of care.","Patients aged between 20 and 80\u2009years with stage I, II, or III without evidence of tumor invasion to the underlying distal phalanx on preoperative radiograph are included in the study.","The primary endpoint is major relapse-free survival (major RFS), which does not include local recurrence as an event; secondary endpoints include overall survival, digit-preservation survival, relapse-free survival, local relapse-free survival, partial relapse-free survival, and incidence of adverse events.","A total of 85 patients from 21 Japanese institutions will be recruited within 5.5\u2009years, and the follow-up period will last at least 5\u2009years.","The Japan Clinical Oncology Group Protocol Review Committee approved this study protocol in August 2017, and patient enrollment began in November 2017.","Ethical approval was obtained from each institution's Institutional Review Board prior to patient enrollment.","DISCUSSION: This is the first prospective trial to confirm the safety and efficacy of non-amputative digit preservation surgery for SUM without distant metastasis or bony invasion.","The results of this trial could provide evidence to support this less-invasive surgery as a new standard of care to preserve adequately functioning digits.","TRIAL REGISTRATION: Registry number: UMIN000029997 .","Date of Registration: 16\/Nov\/2017.","Date of First Participant Enrollment: 12\/Dec\/2017."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"32000743","Document":["BACKGROUND: People increase their risk of melanoma unless they are protected from the harmful effects of sun exposure during childhood and adolescence.","We aimed to assess the feasibility of a three-component sun protection intervention- presentation, action planning, and SMS messages - and trial parameters.","METHODS: This feasibility wait-list trial was conducted in the United Kingdom in 2018.","Students aged 13-15\u2009years were eligible.","Feasibility outcomes were collected for recruitment rates; data availability rates for objective measurements of melanin and erythema using a Mexameter and self-reported sunburn occurrences, severity and body location, tanning, sun protection behaviours and Skin Self-Examination (SSE) collected before (baseline) and after the school summer holidays (follow-up); intervention reach, adherence, perceived impact and acceptability.","Quantitative data were analysed using descriptive statistics; qualitative data were analysed thematically.","RESULTS: Five out of eight schools expressing an interest in participating with four allocated to act as intervention and one control.","Four parents\/carers opted their child out of the study.","Four hundred and eighty-seven out of 724 students on the school register consented to the study at baseline (67%).","Three hundred and eighty-five were in intervention group schools.","Objective skin measurements were available for 255 (66%) of the intervention group at baseline and 237 (61%) of the group at follow up.","Melanin increased; erythema decreased.","Complete self-report data were available for 247 (64%) students in the intervention group.","The number of students on the school register who attended the presentation and given the booklet was 379 (98%) and gave their mobile phone number was 155 (40%).","No intervention component was perceived as more impactful on sun protection behaviours.","Adolescents did not see the relevance of sun protection in the UK or for their age group.","CONCLUSIONS: This is the first study to use a Mexameter to measure skin colour in adolescents.","Erythema (visible redness) lasts no more than three days and its measurement before and after a six week summer holiday may not yield relevant or meaningful data.","A major challenge is that adolescents do not see the relevance of sun protection and SSE.","TRIAL REGISTRATION: International Standard Randomised Controlled Trial Number ISRCTN11141528.","Date registered 0\/2\/03\/2018; last edited 31\/05\/2018.","Retrospectively registered."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"32200815","Document":["OBJECTIVE: To describe the frequency and predictors of local treatment failure and enucleation after iodine 125 (I125) brachytherapy in patients with choroidal melanoma treated and followed up in a large randomized clinical trial.","DESIGN: Prospective, noncomparative, interventional case series within a randomized, multicenter clinical trial.","PARTICIPANTS: Patients enrolled in the Collaborative Ocular Melanoma Study (COMS) trial of enucleation versus brachytherapy between February 1987 and July 1998; tumors measured 2.5 to 10.0 mm in apical height and no more than 16.0 mm in longest basal dimension.","METHODS: I125 brachytherapy was administered via episcleral plaque according to a standard protocol.","Follow-up ophthalmic evaluations, including ophthalmic ultrasound and fundus photography, were performed according to a standard protocol at baseline, every 6 months thereafter for 5 years, and subsequently at annual intervals.","Survival analysis methods were used to estimate the cumulative risk of postirradiation treatment failure and enucleation.","Factors associated with treatment failure and enucleation of plaqued eyes were evaluated using Cox proportional hazards analysis.","MAIN OUTCOME MEASURES: Reports of enucleation and of local treatment failure, defined as tumor growth, recurrence, or extrascleral extension, derived from clinical reports based on echographic and photographic documentation.","RESULTS: As of September 30, 2000, 638 of the 650 patients randomized to brachytherapy and so treated had been followed up for 1 year or longer, and 411 had been followed up for at least 5 years.","Sixty-nine eyes were enucleated during the first 5 years after brachytherapy, and treatment failure was reported for 57 eyes.","The Kaplan-Meier estimate of proportion of patients undergoing enucleation by 5 years was 12.5% (95% confidence interval [CI], 10.0%-15.6%); the risk of treatment failure was 10.3% (95% CI, 8.0%-13.2%).","Treatment failure was the most common reason for enucleation within 3 years of treatment; beyond 3 years, ocular pain was most common.","Risk factors for enucleation were greater tumor thickness, closer proximity of the posterior tumor border to the foveal avascular zone, and poorer baseline visual acuity in the affected eye.","Risk factors for treatment failure were older age, greater tumor thickness, and proximity of the tumor to the foveal avascular zone.","Local treatment failure was associated weakly with reduced survival after controlling for baseline tumor and personal characteristics (adjusted risk ratio, 1.5; P\u00a0= 0.08).","CONCLUSIONS: Local treatment failure and enucleation were relatively infrequent events after I125 brachytherapy within the COMS.","Treatment failure typically occurred early and was associated weakly with poorer survival.","The COMS randomized trial documented the absence of a clinically or statistically significant difference in survival for patients randomly assigned to enucleation versus brachytherapy.","This analysis documents the efficacy of brachytherapy to achieve sustained local tumor control and to conserve the globe."],"Aspect":"i","Summary":"The study involved administering I125 brachytherapy via episcleral plaque according to a standard protocol to patients with choroidal melanoma in a prospective, noncomparative, interventional case series within a randomized, multicenter clinical trial.","Indexes":[1,3],"Sentences":["DESIGN: Prospective, noncomparative, interventional case series within a randomized, multicenter clinical trial.","METHODS: I125 brachytherapy was administered via episcleral plaque according to a standard protocol."],"Revise":false}
{"PMID":"38395969","Document":["Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients.","In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB\/C melanoma were randomized to adjuvant treatment with nDCs (n\u2009=\u200999) or placebo (n\u2009=\u200949).","Active treatment consisted of intranodally injected autologous CD1c+ conventional and plasmacytoid DCs loaded with tumor antigens.","The primary endpoint was the 2-year recurrence-free survival (RFS) rate, whereas the secondary endpoints included median RFS, 2-year and median overall survival, adverse event profile, and immunological response The 2-year RFS rate was 36.8% in the nDC treatment group and 46.9% in the control group (p\u2009=\u20090.31).","Median RFS was 12.7 months vs 19.9 months, respectively (hazard ratio 1.25; 90% CI: 0.88-1.79; p\u2009=\u20090.29).","Median overall survival was not reached in both treatment groups (hazard ratio 1.32; 90% CI: 0.73-2.38; p\u2009=\u20090.44).","Grade 3-4 study-related adverse events occurred in 5% and 6% of patients.","Functional antigen-specific T cell responses could be detected in 67.1% of patients tested in the nDC treatment group vs 3.8% of patients tested in the control group (p\u2009<\u20090.001).","In conclusion, while adjuvant nDC treatment in stage IIIB\/C melanoma patients generated specific immune responses and was well tolerated, no benefit in RFS was observed."],"Aspect":"p","Summary":"The study involved 148 patients with resected stage IIIB\/C melanoma, with 99 patients in the nDC treatment group and 49 in the placebo group.","Indexes":[1],"Sentences":["In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB\/C melanoma were randomized to adjuvant treatment with nDCs (n\u2009=\u200999) or placebo (n\u2009=\u200949)."],"Revise":false}
{"PMID":"36625227","Document":["Skin cancer is the most common cancer in the United States, and early detection of melanoma may lead to diagnosis of thinner and more treatable cancers, resulting in improved survival rates.","This study examined the effects of message interactivity (high vs. low) and imagery (cartoon, real human character, or customized imagery preference) on accuracy of identifying abnormal skin lesions (ASL) and skin self-examination (SSE) intention.","This study employed a 3 (cartoon character vs. real person vs. customization) x 2 (high interactivity vs. low interactivity) between-subjects online experimental design.","Participants at risk for skin cancer were randomly assigned to one of the six conditions and completed a survey after reviewing the educational materials.","Univariate analyses were conducted to detect group differences on the accuracy of identifying ASL and intention to conduct SSE in the next 3\u00a0months.","Among 321 participants who completed the study, the mean age was 36.61\u00a0years, 56.7% were females, 76.1% had a college or higher degree, and over 60% self-identified as non-Hispanic White.","Individuals in the high interactivity and customization group (compared to the low interactivity and cartoon group) were more likely to accurately identify ASL.","Individuals in the high interactivity and customization or low interactivity and real person imagery groups (compared to the low interactivity and cartoon group) reported higher intention to conduct SSE in the next 3\u00a0months.","These results suggest that customization and interactivity may be beneficial for educational programs or intervention design to improve both melanoma identification and SSE intention."],"Aspect":"m","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"35050320","Document":["IMPORTANCE: Existing criteria to estimate the benefit of a therapy in patients with cancer rely almost exclusively on tumor size, an approach that was not designed to estimate survival benefit and is challenged by the unique properties of immunotherapy.","More accurate prediction of survival by treatment could enhance treatment decisions.","OBJECTIVE: To validate, using radiomics and machine learning, the performance of a signature of quantitative computed tomography (CT) imaging features for estimating overall survival (OS) in patients with advanced melanoma treated with immunotherapy.","DESIGN, SETTING, AND PARTICIPANTS: This prognostic study used radiomics and machine learning to retrospectively analyze CT images obtained at baseline and first follow-up and their associated clinical metadata.","Data were prospectively collected in the KEYNOTE-002 (Study of Pembrolizumab [MK-3475] Versus Chemotherapy in Participants With Advanced Melanoma; 2017 analysis) and KEYNOTE-006 (Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab [MK-3475] Compared to Ipilimumab in Participants With Advanced Melanoma; 2016 analysis) multicenter clinical trials.","Participants included 575 patients with a diagnosis of advanced melanoma who were randomly assigned to training and validation sets.","Data for the present study were collected from November 20, 2012, to June 3, 2019, and analyzed from July 1, 2019, to September 15, 2021.","INTERVENTIONS: KEYNOTE-002 featured trial groups testing intravenous pembrolizumab, 2 mg\/kg or 10 mg\/kg every 2 or every 3 weeks based on randomization, or investigator-choice chemotherapy; KEYNOTE-006 featured trial groups testing intravenous ipilimumab, 3 mg\/kg every 3 weeks and intravenous pembrolizumab, 10 mg\/kg every 2 or 3 weeks based on randomization.","MAIN OUTCOMES AND MEASURES: The performance of the signature CT imaging features for estimating OS at the month 6 posttreatment landmark in patients who received pembrolizumab was measured using an area under the time-dependent receiver operating characteristics curve (AUC).","RESULTS: A random forest model combined 25 imaging features extracted from tumors segmented on CT images to identify the combination (signature) that best estimated OS with pembrolizumab in 575 patients.","The signature combined 4 imaging features, 2 related to tumor size and 2 reflecting changes in tumor imaging phenotype.","In the validation set (287 patients treated with pembrolizumab), the signature reached an AUC for estimation of OS status of 0.92 (95% CI, 0.89-0.95).","The standard method, Response Evaluation Criteria in Solid Tumors 1.1, achieved an AUC of 0.80 (95% CI, 0.75-0.84) and classified tumor outcomes as partial or complete response (93 of 287 [32.4%]), stable disease (90 of 287 [31.3%]), or progressive disease (104 of 287 [36.2%]).","CONCLUSIONS AND RELEVANCE: The findings of this prognostic study suggest that the radiomic signature discerned from conventional CT images at baseline and on first follow-up may be used in clinical settings to provide an accurate early readout of future OS probability in patients with melanoma treated with single-agent programmed cell death 1 blockade."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"33734415","Document":["IMPORTANCE: Sentinel lymph node (SLN) mapping agents approved for current surgical practice lack sufficient brightness and target specificity for high-contrast, sensitive nodal visualization.","OBJECTIVE: To evaluate whether an ultrasmall, molecularly targeted core-shell silica nanoparticle (Cornell prime dots) can safely and reliably identify optically avid SLNs in head and neck melanoma during fluorescence-guided biopsy.","DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized clinical trial enrolled patients aged 18 years or older with histologically confirmed melanoma in whom SLN mapping was indicated.","Exclusion criteria included known pregnancy, breast-feeding, or medical illness unrelated to the tumor.","The trial was conducted between February 2015 and March 2018 at Memorial Sloan Kettering Cancer Center, with postoperative follow-up of 2 years.","Data analysis was conducted from February 2015 to March 2018.","INTERVENTIONS: Patients received standard-of-care technetium Tc 99m sulfur colloid followed by a microdose administration of integrin-targeting, dye-encapsulated nanoparticles, surface modified with polyethylene glycol chains and cyclic arginine-glycine-aspartic acid-tyrosine peptides (cRGDY-PEG-Cy5.5-nanoparticles) intradermally.","MAIN OUTCOMES AND MEASURES: The primary end points were safety, procedural feasibility, lowest particle dose and volume for maximizing nodal fluorescence signal, and proportion of nodes identified by technetium Tc 99m sulfur colloid that were optically visualized by cRGDY-PEG-Cy5.5-nanoparticles.","Secondary end points included proportion of patients in whom the surgical approach or extent of dissection was altered because of nodal visualization.","RESULTS: Of 24 consecutive patients enrolled (median [interquartile range] age, 64 [51-71] years), 18 (75%) were men.","In 24 surgical procedures, 40 SLNs were excised.","Preoperative localization of SLNs with technetium Tc 99m sulfur colloid was followed by particle dose-escalation studies, yielding optimized doses and volumes of 2 nmol and 0.4 mL, respectively, and maximum SLN signal-to-background ratios of 40.","No adverse events were observed.","The concordance rate of evaluable SLNs by technetium Tc 99m sulfur colloid and cRGDY-PEG-Cy5.5-nanoparticles was 90% (95% CI, 74%-98%), 5 of which were metastatic.","Ultrabright nanoparticle fluorescence enabled high-sensitivity SLN visualization (including difficult-to-access anatomic sites), deep tissue imaging, and, in some instances, detection through intact skin, thereby facilitating intraoperative identification without extensive dissection of adjacent normal tissue or nerves.","CONCLUSIONS AND RELEVANCE: This study found that nanoparticle-based fluorescence-guided SLN biopsy in head and neck melanoma was feasible and safe.","This technology holds promise for improving lymphatic mapping and SLN biopsy procedures, while potentially mitigating procedural risks.","This study serves as a first step toward developing new multimodal approaches for perioperative care.","TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02106598."],"Aspect":"o","Summary":"The study found that nanoparticle-based fluorescence-guided sentinel lymph node (SLN) biopsy in head and neck melanoma was feasible and safe, with a concordance rate of 90% between technetium Tc 99m sulfur colloid and cRGDY-PEG-Cy5.5-nanoparticles.","Indexes":[12,13,15],"Sentences":["No adverse events were observed.","The concordance rate of evaluable SLNs by technetium Tc 99m sulfur colloid and cRGDY-PEG-Cy5.5-nanoparticles was 90% (95% CI, 74%-98%), 5 of which were metastatic.","CONCLUSIONS AND RELEVANCE: This study found that nanoparticle-based fluorescence-guided SLN biopsy in head and neck melanoma was feasible and safe."],"Revise":false}
{"PMID":"34764195","Document":["UNLABELLED: We conducted a randomized phase III trial to evaluate whether adjuvant pembrolizumab for one year (647 patients) improved recurrence-free survival (RFS) or overall survival (OS) in comparison with high-dose IFN\u03b1-2b for one year or ipilimumab for up to three years (654 patients), the approved standard-of-care adjuvant immunotherapies at the time of enrollment for patients with high-risk resected melanoma.","At a median follow-up of 47.5 months, pembrolizumab was associated with significantly longer RFS than prior standard-of-care adjuvant immunotherapies [HR, 0.77; 99.62% confidence interval (CI), 0.59-0.99; P = 0.002].","There was no statistically significant association with OS among all patients (HR, 0.82; 96.3% CI, 0.61-1.09; P = 0.15).","Proportions of treatment-related adverse events of grades 3 to 5 were 19.5% with pembrolizumab, 71.2% with IFN\u03b1-2b, and 49.2% with ipilimumab.","Therefore, adjuvant pembrolizumab significantly improved RFS but not OS compared with the prior standard-of-care immunotherapies for patients with high-risk resected melanoma.","SIGNIFICANCE: Adjuvant PD-1 blockade therapy decreases the rates of recurrence, but not survival, in patients with surgically resectable melanoma, substituting the prior standard-of-care immunotherapies for this cancer.","See related commentary by Smithy and Shoushtari, p. 599.","This article is highlighted in the In This Issue feature, p. 587."],"Aspect":"s","Summary":"The proportions of treatment-related adverse events of grades 3 to 5 were 19.5% with pembrolizumab, 71.2% with IFN\u03b1-2b, and 49.2% with ipilimumab.","Indexes":[3],"Sentences":["Proportions of treatment-related adverse events of grades 3 to 5 were 19.5% with pembrolizumab, 71.2% with IFN\u03b1-2b, and 49.2% with ipilimumab."],"Revise":false}
{"PMID":"31530631","Document":["PURPOSE: The immunomodulatory activity of DNA hypomethylating agents (DHAs) suggests they may improve the effectiveness of cancer immunotherapies.","The phase Ib NIBIT-M4 trial tested this hypothesis using the next-generation DHA guadecitabine combined with ipilimumab.","PATIENTS AND METHODS: Patients with unresectable stage III\/IV melanoma received escalating doses of guadecitabine 30, 45, or 60 mg\/m2\/day subcutaneously on days 1 to 5 every 3 weeks, and ipilimumab 3 mg\/kg intravenously on day 1 every 3 weeks, starting 1 week after guadecitabine, for four cycles.","Primary endpoints were safety, tolerability, and MTD of treatment; secondary were immune-related (ir) disease control rate (DCR) and objective response rate (ORR); and exploratory were changes in methylome, transcriptome, and immune contextures in sequential tumor biopsies, and pharmacokinetics.","RESULTS: Nineteen patients were treated; 84% had grade 3\/4 adverse events, and neither dose-limiting toxicities per protocol nor overlapping toxicities were observed.","Ir-DCR and ir-ORR were 42% and 26%, respectively.","Median CpG site methylation of tumor samples (n = 8) at week 4 (74.5%) and week 12 (75.5%) was significantly (P < 0.05) lower than at baseline (80.3%), with a median of 2,454 (week 4) and 4,131 (week 12) differentially expressed genes.","Among the 136 pathways significantly (P < 0.05; Z score >2 or \u21902) modulated by treatment, the most frequently activated were immune-related.","Tumor immune contexture analysis (n = 11) demonstrated upregulation of HLA class I on melanoma cells, an increase in CD8+, PD-1+ T cells and in CD20+ B cells in posttreatment tumor cores.","CONCLUSIONS: Treatment of guadecitabine combined with ipilimumab is safe and tolerable in advanced melanoma and has promising immunomodulatory and antitumor activity."],"Aspect":"o","Summary":"The trial found that the combination of guadecitabine and ipilimumab had promising immunomodulatory and antitumor activity in advanced melanoma patients, with an immune-related disease control rate (ir-DCR) of 42% and an objective response rate (ir-ORR) of 26%.","Indexes":[5,9],"Sentences":["Ir-DCR and ir-ORR were 42% and 26%, respectively.","CONCLUSIONS: Treatment of guadecitabine combined with ipilimumab is safe and tolerable in advanced melanoma and has promising immunomodulatory and antitumor activity."],"Revise":false}
{"PMID":"38547052","Document":["BACKGROUND: To investigate the efficacy and toxicity after long-term follow-up of anti-PD-1 antibody in advanced melanoma with predominantly acral and mucosal subtypes.","METHODS AND PATIENTS: In the POLARIS-01 phase II trial, 128 Chinese patients with advanced melanoma refractory to standard therapy received toripalimab until disease progression or unacceptable toxicity for \u22642 years.","For those who progressed after discontinuation due to 2-year treatment completion, rechallenge was allowed.","The primary objectives were safety and overall response rate (ORR).","RESULTS: As of February 8, 2021, ORR was 17.3% (95% CI: 11.2-25.0) evaluated by the independent radiologic review committee.","The median overall survival (OS) for patients with known melanoma subtypes was 16.3 m for acral, 41.5 m for nonacral cutaneous, and 10.3 m for mucosal melanoma.","Thereafter, the evaluation was continued by investigators.","As of November 4, 2022, 5 years after the last enrollment, median duration of response was 15.6 months (range, 3.7-64.5+), median progression-free survival (PFS) was 3.5 months (95% CI, 2.2-5.3), and 60-month OS rate was 28.5% (95% CI: 20.2-37.2).","Thirteen patients completed a 2-year treatment of toripalimab, with the subtypes of acral (2\/13), non-acral cutaneous (4\/13), mucosal (3\/13) and unknown primary (4\/13).","Five patients were rechallenged.","Four of them, all of whom were non-mucosal, completed the rechallenge course of 2 years with PFS\u2005\u2265\u200524 months.","CONCLUSIONS: This is the largest prospective anti-PD-1 trial with mature data in advanced melanoma in China.","Toripalimab demonstrated a manageable safety profile and durable clinical response in Chinese patients with metastatic melanoma who had failed in standard therapy.","Immunotherapy seems less efficacious for long-term responders with mucosal primaries as rechallenge therapy."],"Aspect":"m","Summary":"The trial used toripalimab, an anti-PD-1 antibody, administered until disease progression or unacceptable toxicity for up to 2 years.","Indexes":[1],"Sentences":["METHODS AND PATIENTS: In the POLARIS-01 phase II trial, 128 Chinese patients with advanced melanoma refractory to standard therapy received toripalimab until disease progression or unacceptable toxicity for \u22642 years."],"Revise":false}
{"PMID":"31812554","Document":["BACKGROUND: Pembrolizumab is approved for the treatment of advanced cancer in adults; however, no information is available on safety and efficacy in paediatric patients.","We aimed to establish the recommended phase 2 dose of pembrolizumab and its safety and antitumour activity in advanced paediatric cancer.","METHODS: KEYNOTE-051 is an ongoing phase 1-2 open-label trial.","In this interim analysis, children aged 6 months to 17 years were recruited at 30 hospitals located in Australia, Brazil, Canada, France, Germany, Israel, Italy, South Korea, Sweden, the UK, and the USA.","Patients with melanoma or a centrally confirmed, PD-L1-positive, relapsed or refractory solid tumour or lymphoma, and a Lansky Play\/Karnofsky Performance status score of 50 or higher, received intravenous pembrolizumab at an initial dose of 2 mg\/kg every 3 weeks.","Pharmacokinetics and dose-limiting toxicities were used to establish the recommended phase 2 dose, and the safety and antitumour activity of this dose were assessed.","Primary endpoints were determination of dose-limiting toxicities at the maximum administered dose, safety and tolerability, and the proportion of patients with objective response to pembrolizumab for each tumour type according to the Response Evaluation Criteria in Solid Tumours version 1.1 or the International Neuroblastoma Response Criteria.","Safety and efficacy were assessed in all treated patients who received at least one dose of pembrolizumab.","Separate reporting of the cohort of patients with relapsed or refractory classical Hodgkin lymphoma was a post-hoc decision.","The data cutoff for this interim analysis was Sept 3, 2018.","This trial is still enrolling patients and is registered with ClinicalTrials.gov, number NCT02332668.","FINDINGS: Of 863 patients screened between March 23, 2015, and Sept 3, 2018, 796 had tumours that were evaluable for PD-L1 expression (278 [35%] were PD-L1-positive); 155 eligible patients were enrolled and 154 had at least one dose of pembrolizumab.","The median age of the enrolled patients was 13 years (IQR 8-15).","Median follow-up was 8\u00b76 months (IQR 2\u00b75-16\u00b74).","No dose-limiting toxicities were reported in phase 1, and pembrolizumab plasma concentrations were consistent with those previously reported in adults; the recommended phase 2 dose was therefore established as 2 mg\/kg every 3 weeks.","Of the 154 patients treated, 69 (45%) experienced grade 3-5 adverse events, most commonly anaemia in 14 (9%) patients and decreased lymphocyte count in nine (6%) patients.","13 (8%) of the 154 patients had grade 3-5 treatment-related adverse events, most commonly decreased lymphocyte count in three (2%) patients and anaemia in two (1%) patients.","14 (9%) patients had serious treatment-related adverse events, most commonly pyrexia (four [3%]), and hypertension and pleural effusion (two [1%] each).","Four patients (3%) discontinued treatment because of treatment-related adverse events, and two (1%) died (one due to pulmonary oedema and one due to pleural effusion and pneumonitis).","Of 15 patients with relapsed or refractory Hodgkin lymphoma, two had complete and seven had partial responses; thus, nine patients achieved an objective response (60\u00b70%; 95% CI 32\u00b73-83\u00b77).","Of 136 patients with solid tumours and other lymphomas, eight had partial responses (two patients each with adrenocortical carcinoma and mesothelioma, and one patient each with malignant ganglioglioma, epithelioid sarcoma, lymphoepithelial carcinoma, and malignant rhabdoid tumour); the proportion of patients with an objective response was 5\u00b79% (95% CI 2\u00b76-11\u00b73).","INTERPRETATION: Pembrolizumab was well tolerated and showed encouraging antitumour activity in paediatric patients with relapsed or refractory Hodgkin lymphoma, consistent with experience in adult patients.","Pembrolizumab had low antitumour activity in the majority of paediatric tumour types, and responses were observed in only a few rare PD-L1-positive tumour types, suggesting that PD-L1 expression alone is not sufficient as a biomarker for the selection of paediatric patients who are likely to respond to PD-1 checkpoint inhibitors.","Final results of KEYNOTE-051, expected by September, 2022, with the possibility for extension, will report further on the activity of pembrolizumab in Hodgkin lymphoma, microsatellite instability-high tumours, and melanoma.","FUNDING: Merck Sharp & Dohme, a subsidiary of Merck & Co."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"32672795","Document":["IMPORTANCE: The optimal sequencing of immune checkpoint inhibitors and targeted therapy for BRAF V600E\/K-mutant melanoma is not well established.","OBJECTIVE: To assess the association of BRAF wild-type (WT) or BRAF V600E\/K-mutant status and BRAF inhibitor (BRAFi) with or without MEK inhibitor (MEKi) therapy with response to pembrolizumab.","DESIGN, SETTING, AND PARTICIPANTS: This study is a post hoc subgroup analysis of pooled data from 3 multinational, multisite studies: KEYNOTE-001 (data cutoff September 1, 2017), KEYNOTE-002 (data cutoff May 30, 2018), and KEYNOTE-006 (data cutoff December 4, 2017).","Patients included in this analysis were adults with advanced melanoma and known BRAF V600E\/K tumor status who had received pembrolizumab.","INTERVENTIONS: Patients received pembrolizumab in dosages of 2 mg\/kg every 3 weeks, 10 mg\/kg every 2 weeks, or 10 mg\/kg every 3 weeks.","MAIN OUTCOMES AND MEASURES: End points were objective response rate (ORR) and progression-free survival (PFS) assessed by Response Evaluation Criteria in Solid Tumors, version 1.1, and overall survival (OS).","Objective response rates, 4-year PFS, and OS rates were compared in the following patient subgroups: BRAF WT vs BRAF V600E\/K-mutant melanoma and BRAF V600E\/K-mutant melanoma with vs without previous treatment with BRAFi with or without MEKi therapy.","RESULTS: The overall study population (N\u2009=\u20091558) included 944 men (60.6%) and 614 women (39.4%).","The mean (SD) age was 60.0 years (14.0).","The ORR was 38.3% (596\/1558), 4-year PFS rate was 22.0%, and 4-year OS rate was 36.9%.","For patients with BRAF WT (n\u2009=\u20091124) and BRAF V600E\/K-mutant melanoma (n\u2009=\u2009434), ORR was 39.8% (n\u2009=\u2009447) and 34.3% (n\u2009=\u2009149), 4-year PFS rate was 22.9% and 19.8%, and 4-year OS rate was 37.5% and 35.1%, respectively.","Patients with BRAF V600E\/K-mutant melanoma who had (n\u2009=\u2009271) vs had not (n\u2009=\u2009163) previously received BRAFi with or without MEKi therapy had baseline characteristics with worse prognosis; ORR was 28.4% (n\u2009=\u200977) and 44.2% (n\u2009=\u200972), 4-year PFS rate was 15.2% and 27.8%, and 4-year OS rate was 26.9% and 49.3%, respectively.","CONCLUSIONS AND RELEVANCE: Results of this subgroup analysis support the use of pembrolizumab for treatment of advanced melanoma regardless of BRAF V600E\/K mutation status or receipt of prior BRAFi with or without MEKi therapy."],"Aspect":"p","Summary":"The study included 1558 adult patients with advanced melanoma and known BRAF V600E\/K tumor status, consisting of 944 men (60.6%) and 614 women (39.4%) with a mean age of 60.0 years.","Indexes":[3,7,8],"Sentences":["Patients included in this analysis were adults with advanced melanoma and known BRAF V600E\/K tumor status who had received pembrolizumab.","RESULTS: The overall study population (N\u2009=\u20091558) included 944 men (60.6%) and 614 women (39.4%).","The mean (SD) age was 60.0 years (14.0)."],"Revise":false}
{"PMID":"32238469","Document":["BACKGROUND: Adoptive cell therapy (ACT) with tumor-reactive T cells has shown consistent clinical efficacy.","We evaluated the response to ACT in combination with interferon alpha (IFNa) preconditioning in patients with stage IV metastatic melanoma, most of which were progressive on cytotoxic T-lymphocyte-associated protein 4 and\/or programmed cell death protein 1 checkpoint blockade therapy.","METHODS: Thirty-four patients were treated with ex vivo expanded tumor reactive T cells, derived from mixed lymphocyte autologous tumor cultures, or with autologous tumor-infiltrating lymphocytes and evaluated for clinical response.","Clinical and immunological parameters associated with response were also evaluated.","RESULTS: Best overall response defined as clinical benefit, comprising either complete response, partial response or stable disease >6 months, was observed in 29% of the patients.","Forty-three per cent of the 14 immunotherapy-na\u00efve patients and 20% of the 20 patients progressive on prior immunotherapy benefited from ACT.","The overall survival (OS) was 90% versus 28.6% at 1\u2009year and 46.7% versus 0% at 3 years follow-up, of responder and non-responder patients, respectively.","Median OS was 36 versus 7 months, respectively.","IFNa pretreatment resulted in leukopenia, neutropenia and lymphopenia, which was sustained during the treatment in clinical responders and associated with response.","Differences in antigen specificity, but not in phenotype, cytokine profile or CD8+ T cell number of the ACT products correlated with clinical response.","Cross-reactivity of the ACT products to one or more allogeneic human leukocyte antigen-matched melanoma cell lines was associated with short OS after treatment while the ACT products of very long-term survivors showed no cross-reactivity but recognized patient-specific neoantigens.","CONCLUSION: This study demonstrates that ACT in combination with a mild IFNa preconditioning regimen can induce clinical benefit even in immunotherapy pretreated patients, although with lower success than in immunotherapy-na\u00efve patients.","ACT products comprising neoantigen reactivity may be more effective."],"Aspect":"i","Summary":"The research methods involved treating 34 patients with ex vivo expanded tumor-reactive T cells or autologous tumor-infiltrating lymphocytes, derived from mixed lymphocyte autologous tumor cultures, and evaluating their clinical response along with associated clinical and immunological parameters.","Indexes":[2,3],"Sentences":["METHODS: Thirty-four patients were treated with ex vivo expanded tumor reactive T cells, derived from mixed lymphocyte autologous tumor cultures, or with autologous tumor-infiltrating lymphocytes and evaluated for clinical response.","Clinical and immunological parameters associated with response were also evaluated."],"Revise":true}
{"PMID":"36041758","Document":["OBJECTIVES: To describe trajectories in melanoma survivors' adherence to monthly total skin self-examination (TSSE) over 12 months, and to investigate whether adherence trajectories can be predicted from demographic, cognitive or emotional factors at baseline.","DESIGN: A longitudinal observational study nested within the intervention arm of the ASICA (Achieving Self-Directed Integrated Cancer Aftercare) randomised controlled trial.","SETTING: Follow-up secondary care in Aberdeen and Cambridge UK.","PARTICIPANTS: n=104 adults (48 men\/56 women; mean age 58.83 years, SD 13.47, range 28-85 years; mean Scottish Index of Multiple Deprivation score 8.03, SD 1.73, range 2-10) who had been treated for stage 0-IIC primary cutaneous melanoma in the preceding 60 months and were actively participating in the intervention arm of the ASICA trial.","INTERVENTIONS: All participants were using the ASICA intervention-a tablet-based intervention designed to support monthly TSSE.","PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome was adherence to guideline recommended (monthly) TSSE over 12 months.","This was determined from time-stamped TSSE data recorded by the ASICA intervention app.","RESULTS: Latent growth mixture models identified three TSSE adherence trajectories (adherent -41%; drop-off -35%; non-adherent -24%).","People who were non-adherent were less likely to intend to perform TSSE as recommended, intending to do it more frequently (OR=0.21, 95% CI 0.06 to 0.81, p=0.023) and were more depressed (OR=1.31, 95% CI 1.06 to 1.61, p=0.011) than people who were adherent.","People whose adherence dropped off over time had less well-developed action plans (OR=0.78, 95% CI 0.63 to 0.96, p=0.016) and lower self-efficacy about TSSE (OR=0.92, 95% CI 0.86 to 0.99, p=0.028) than people who were adherent.","CONCLUSIONS: Adherence to monthly TSSE in people treated for melanoma can be differentiated into adherent, drop-off and non-adherent trajectories.","Collecting information about intentions to engage in TSSE, depression, self-efficacy and\/or action planning at outset may help to identify those who would benefit from additional intervention.","TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT03328247)."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"32775464","Document":["PURPOSE: To assess neurocognitive function (NCF), psychosocial outcome, health-related quality of life (HRQoL), and long-term effects of immune-related adverse events (irAE) on metastatic melanoma survivors treated with ipilimumab (IPI).","METHODS: Melanoma survivors were identified within two study populations (N = 104), at a single-center university hospital, and defined as patients who were disease-free for at least 2 years after initiating IPI.","Data were collected using 4 patient-reported outcome measures, computerized NCF testing, and a semistructured interview at the start and 1-year follow-up.","RESULTS: Out of 18 eligible survivors, 17 were recruited (5F\/12M); median age is 57 years (range 33-86); and median time since initiating IPI was 5.6 years (range 2.1-9.3).","The clinical interview revealed that survivors suffered from cancer-related emotional distress such as fear of recurrence (N = 8), existential problems (N = 2), survivor guilt (N = 2), and posttraumatic stress disorder (N = 6).","The mean EORTC QLQ-C30 Global Score was not significantly different from the European mean of the healthy population.","Nine survivors reported anxiety and\/or depression (Hospitalization Depression Scale) during the survey.","Seven survivors (41%) reported fatigue (Fatigue Severity Scale).","Seven patients (41%) had impairment in NCF; only three out of seven survivors had impairment in subjective cognition (Cognitive Failure Questionnaire).","Anxiety, depression, fatigue, and neurocognitive symptoms remained stable at the 1-year follow-up.","All cases of skin toxicity (N = 8), hepatitis (N = 1), colitis (N = 3), and sarcoidosis (N = 1) resolved without impact on HRQoL.","Three survivors experienced hypophysitis; all suffered from persistent fatigue and cognitive complaints 5 years after onset.","One survivor who experienced a Guillain-Barr\u00e9-like syndrome suffered from persisting depression, fatigue, and impairment in NCF.","CONCLUSION: A majority of melanoma survivors treated with IPI continue to suffer from emotional distress and impairment in NCF.","Timely detection in order to offer tailored care is imperative, with special attention for survivors with a history of neuroendocrine or neurological irAE.","The trial is registered with B.U.N.","143201421920."],"Aspect":"s","Summary":"Survivors experienced side effects such as skin toxicity, hepatitis, colitis, sarcoidosis, hypophysitis, and Guillain-Barr\u00e9-like syndrome, with some suffering from persistent fatigue, cognitive complaints, depression, and neurocognitive impairment.","Indexes":[10,11,12],"Sentences":["All cases of skin toxicity (N = 8), hepatitis (N = 1), colitis (N = 3), and sarcoidosis (N = 1) resolved without impact on HRQoL.","Three survivors experienced hypophysitis; all suffered from persistent fatigue and cognitive complaints 5 years after onset.","One survivor who experienced a Guillain-Barr\u00e9-like syndrome suffered from persisting depression, fatigue, and impairment in NCF."],"Revise":false}
{"PMID":"38362837","Document":["SAR439459, a 'second-generation' human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody, inhibits all TGF\u03b2 isoforms and improves the antitumor activity of anti-programmed cell death protein-1 therapeutics.","This study reports the pharmacodynamics (PD) and biomarker results from phase I\/Ib first-in-human study of SAR439459\u2009\u00b1\u2009cemiplimab in patients with advanced solid tumors (NCT03192345).","In dose-escalation phase (Part 1), SAR439459 was administered intravenously at increasing doses either every 2\u2009weeks (Q2W) or every 3\u2009weeks (Q3W) with cemiplimab IV at 3\u2009mg\/kg Q2W or 350\u2009mg Q3W, respectively, in patients with advanced solid tumors.","In dose-expansion phase (Part 2), patients with melanoma received SAR439459 IV Q3W at preliminary recommended phase II dose (pRP2D) of 22.5\/7.5\u2009mg\/kg or at 22.5\u2009mg\/kg with cemiplimab 350\u2009mg IV Q3W.","Tumor biopsy and peripheral blood samples were collected for exploratory biomarker analyses to assess target engagement and PD, and results were correlated with patients' clinical parameters.","SAR439459\u2009\u00b1\u2009cemiplimab showed decreased plasma and tissue TGF\u03b2, downregulation of TGF\u03b2-pathway activation signature, modulation of peripheral natural killer (NK) and T cell expansion, proliferation, and increased secretion of CXCL10.","Conversion of tumor tissue samples from 'immune-excluded' to 'immune-infiltrated' phenotype in a representative patient with melanoma SAR439459 22.5\u2009mg\/kg with cemiplimab was observed.","In paired tumor and plasma, active and total TGF\u03b21 was more consistently elevated followed by TGF\u03b22, whereas TGF\u03b23 was only measurable (lower limit of quantitation \u22652.68\u2009pg\/mg) in tumors.","SAR439459\u2009\u00b1\u2009cemiplimab showed expected peripheral PD effects and TGF\u03b2 alteration.","However, further studies are needed to identify biomarkers of response."],"Aspect":"a","Summary":"This study aims to report the pharmacodynamics and biomarker results from a phase I\/Ib first-in-human study of SAR439459 \u00b1 cemiplimab in patients with advanced solid tumors.","Indexes":[1],"Sentences":["This study reports the pharmacodynamics (PD) and biomarker results from phase I\/Ib first-in-human study of SAR439459\u2009\u00b1\u2009cemiplimab in patients with advanced solid tumors (NCT03192345)."],"Revise":false}
{"PMID":"37621406","Document":["PURPOSE: Neoadjuvant combination immune checkpoint blockade and intralesional oncolytic virotherapy have the potential to activate antitumor responses in patients with breast cancer.","EXPERIMENTAL DESIGN: Eligibility for this pilot phase I trial included patients with localized HER2-negative breast cancer who received systemic nivolumab and ipilimumab and intratumor talimogene laherparepvec (T-VEC; NCT04185311).","The primary objective was to evaluate the safety and adverse event profile of immunotherapy combined with T-VEC in patients with localized, HER2-negative breast cancer.","RESULTS: Six patients were enrolled, 4 having relapses after prior neoadjuvant chemotherapy and 2 who were previously untreated.","Toxicities included 1 patient having grade 3 hypotension and type 1 diabetes mellitus, 3 patients with hypothyroidism, and all patients having constitutional symptoms known to be associated with the administration of T-VEC.","One patient had a pathologic complete response, 3 patients had pathologic partial responses, 1 showed no significant response, and 1 had disease progression.","Biopsies demonstrated increased immune cell infiltration in samples from patients who responded to therapy.","CONCLUSIONS: This triple immunotherapy regimen provided responses in patients with advanced or relapsed HER2-negative breast cancer, at the expense of long-term toxicities.","SIGNIFICANCE: Systemic immune checkpoint blockade with a programmed death receptor 1 and a CTL antigen-4 blocking antibody, combined with intralesional oncolytic virotherapy, is a chemotherapy-free combination aimed at inducing an antitumor immune response locally and systemic immunity."],"Aspect":"m","Summary":"The pilot phase I trial used systemic nivolumab and ipilimumab along with intratumor talimogene laherparepvec (T-VEC).","Indexes":[1],"Sentences":["EXPERIMENTAL DESIGN: Eligibility for this pilot phase I trial included patients with localized HER2-negative breast cancer who received systemic nivolumab and ipilimumab and intratumor talimogene laherparepvec (T-VEC; NCT04185311)."],"Revise":false}
{"PMID":"32306076","Document":["BACKGROUND: Adoptive tumor-infiltrating lymphocytes (TIL) therapy and interleukin-2 (IL-2) have been investigated in melanoma.","AIM: To confirm previously observed preventive effects of TIL\u2009+\u2009IL2 in a subgroup of patients with relapsing metastatic stage III melanoma.","METHODOLOGY: Open-label, randomized two-group, multicenter five-year trial in adult stage III melanoma patients with only one invaded lymph node after complete resection.","Patients received TIL\u2009+\u2009IL2 or abstention.","TIL\u2009+\u2009IL2 was administered within 8\u00a0weeks after lymph node resection and 4\u00a0weeks after.","Disease-free survival was assessed every 2\u00a0months up to month 18, every 3\u00a0months up to month 36 and every 4\u00a0months up to 5\u00a0years.","A once-a-year follow-up was scheduled beyond the five-year follow-up.","Safety was assessed throughout the trial.","RESULTS: Overall, 49 patients accounted for the modified intent-to-treat and 47 for the PP.","Slightly more male than female patients participated; mean age was 57.7\u2009\u00b1\u200911.4\u00a0years in the TIL\u2009+\u2009IL2 group and 53.5\u2009\u00b1\u200913.0\u00a0years in the abstention group.","After 5\u00a0years of follow-up, 11\/26 patients in the TIL\u2009+\u2009IL2 group and 13\/23 in the abstention group had relapsed.","There was no statistical difference between the groups (HR: 0.63 CI 95% [0.28-1.41], p\u2009=\u20090.258), nine patients in the TIL\u2009+\u2009IL2 and 11 in the abstention group died with no significant difference between the two groups (HR: 0.65 CI95% [0.27\u2009-\u20091.59], p\u2009=\u20090.34).","Safety was good.","CONCLUSION: We did not confirm results of a previous trial.","However, ulceration of the primary melanoma may be considered predictive of the efficacy of TIL in melanoma in adjuvant setting, in a manner similar to interferon \u03b1."],"Aspect":"o","Summary":"The study found no statistical difference in relapse or death rates between the TIL+IL2 and abstention groups after 5 years of follow-up.","Indexes":[10,11],"Sentences":["After 5\u00a0years of follow-up, 11\/26 patients in the TIL\u2009+\u2009IL2 group and 13\/23 in the abstention group had relapsed.","There was no statistical difference between the groups (HR: 0.63 CI 95% [0.28-1.41], p\u2009=\u20090.258), nine patients in the TIL\u2009+\u2009IL2 and 11 in the abstention group died with no significant difference between the two groups (HR: 0.65 CI95% [0.27\u2009-\u20091.59], p\u2009=\u20090.34)."],"Revise":false}
{"PMID":"31385109","Document":["Background Endothelin B receptor (ETBR) is involved in melanoma pathogenesis and is overexpressed in metastatic melanoma.","The antibody-drug conjugate DEDN6526A targets ETBR and is comprised of the humanized anti-ETBR monoclonal antibody conjugated to the anti-mitotic agent monomethyl auristatin E (MMAE).","Methods This Phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DEDN6526A (0.3-2.8\u00a0mg\/kg) given every 3\u00a0weeks (q3w) in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma.","Results Fifty-three patients received a median of 6 doses of DEDN6526A (range 1-49).","The most common drug-related adverse events (>25% across dose levels) were fatigue, peripheral neuropathy, nausea, diarrhea, alopecia, and chills.","Three patients in dose-escalation experienced a dose-limiting toxicity (infusion-related reaction, increased ALT\/AST, and drug-induced liver injury).","Based on cumulative safety data across all dose levels, the recommended Phase II dose (RP2D) for DEDN6526A was 2.4\u00a0mg\/kg intravenous (IV) q3w.","The pharmacokinetics of antibody-conjugated MMAE and total antibody were dose-proportional at doses ranging from 1.8-2.8\u00a0mg\/kg.","A trend toward faster clearance was observed at doses of 0.3-1.2\u00a0mg\/kg.","There were 6 partial responses (11%) in patients with metastatic cutaneous or mucosal melanoma, and 17 patients (32%) had prolonged stable disease \u22656\u00a0months.","Responses were independent of BRAF mutation status but did correlate with ETBR expression.","Conclusion DEDN6526A administered at the RP2D of 2.4\u00a0mg\/kg q3w had an acceptable safety profile and showed evidence of anti-tumor activity in patients with cutaneous, mucosal, and uveal melanoma.","ClinicalTrials.gov identifier: NCT01522664."],"Aspect":"i","Summary":"This Phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DEDN6526A (0.3-2.8 mg\/kg) given every 3 weeks in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma.","Indexes":[2],"Sentences":["Methods This Phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DEDN6526A (0.3-2.8\u00a0mg\/kg) given every 3\u00a0weeks (q3w) in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma."],"Revise":false}
{"PMID":"32238469","Document":["BACKGROUND: Adoptive cell therapy (ACT) with tumor-reactive T cells has shown consistent clinical efficacy.","We evaluated the response to ACT in combination with interferon alpha (IFNa) preconditioning in patients with stage IV metastatic melanoma, most of which were progressive on cytotoxic T-lymphocyte-associated protein 4 and\/or programmed cell death protein 1 checkpoint blockade therapy.","METHODS: Thirty-four patients were treated with ex vivo expanded tumor reactive T cells, derived from mixed lymphocyte autologous tumor cultures, or with autologous tumor-infiltrating lymphocytes and evaluated for clinical response.","Clinical and immunological parameters associated with response were also evaluated.","RESULTS: Best overall response defined as clinical benefit, comprising either complete response, partial response or stable disease >6 months, was observed in 29% of the patients.","Forty-three per cent of the 14 immunotherapy-na\u00efve patients and 20% of the 20 patients progressive on prior immunotherapy benefited from ACT.","The overall survival (OS) was 90% versus 28.6% at 1\u2009year and 46.7% versus 0% at 3 years follow-up, of responder and non-responder patients, respectively.","Median OS was 36 versus 7 months, respectively.","IFNa pretreatment resulted in leukopenia, neutropenia and lymphopenia, which was sustained during the treatment in clinical responders and associated with response.","Differences in antigen specificity, but not in phenotype, cytokine profile or CD8+ T cell number of the ACT products correlated with clinical response.","Cross-reactivity of the ACT products to one or more allogeneic human leukocyte antigen-matched melanoma cell lines was associated with short OS after treatment while the ACT products of very long-term survivors showed no cross-reactivity but recognized patient-specific neoantigens.","CONCLUSION: This study demonstrates that ACT in combination with a mild IFNa preconditioning regimen can induce clinical benefit even in immunotherapy pretreated patients, although with lower success than in immunotherapy-na\u00efve patients.","ACT products comprising neoantigen reactivity may be more effective."],"Aspect":"s","Summary":"IFNa pretreatment resulted in leukopenia, neutropenia, and lymphopenia.","Indexes":[8],"Sentences":["IFNa pretreatment resulted in leukopenia, neutropenia and lymphopenia, which was sustained during the treatment in clinical responders and associated with response."],"Revise":false}
{"PMID":"35947391","Document":["IMPORTANCE: Medical second opinions are common, although little is known about the best processes for obtaining them.","This study assesses whether knowledge of a prior physician's diagnosis influences consulting physicians' diagnoses.","OBJECTIVE: To measure the extent to which dermatopathologists' diagnoses are influenced by prior diagnostic information from another dermatopathologist.","DESIGN, SETTING, AND PARTICIPANTS: Dermatopathologists were randomly assigned to interpret 1 slide set of 18 melanocytic skin biopsy specimens in 2 phases (5 slide sets totaling 90 cases).","Phase 1 interpretations were conducted without prior diagnostic information.","After a washout period of 12 or more months, dermatopathologists' phase 2 interpretations were conducted with their identical slide set; for a random subset of cases in phase 2, participants were shown prior diagnoses by other dermatopathologists that were either more or less severe than their own phase 1 diagnosis of the case.","Using the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis tool, cases ranged from class I (benign) to class V (\u2265pT1b invasive melanoma).","Data collection took place from August 2018 to March 2021, and data analysis was performed from March to December 2021.","INTERVENTION: Prior diagnoses were actual diagnoses from board-certified and\/or fellowship-trained dermatopathologists.","A prior diagnosis was always in a more severe or less severe diagnostic class than the participant's phase 1 interpretation; more or less severe was determined by the randomization scheme.","In the control condition of no prior diagnostic information, the participants were told that a prior diagnosis was not available.","MAIN OUTCOMES AND MEASURES: When exposure was to a prior diagnosis in a higher diagnostic class, the primary study outcome was whether a participant's diagnosis in phase 2 was in a higher diagnostic class than the participant's diagnosis in phase 1.","When exposure was to a prior diagnosis in a lower diagnostic class, the primary study outcome was whether a participant's diagnosis in phase 2 was in a lower diagnostic class than the participant's diagnosis in phase 1.","The effect of prior diagnostic information was measured using the relative risk (RR) of each outcome relative to the control condition of no prior diagnostic information, adjusted for the diagnostic class of the phase 1 diagnosis.","Prior to data collection, it was hypothesized that participants would be swayed in the direction of prior diagnostic information.","RESULTS: A total of 149 dermatopathologists (median [range] age, 47 years [34-76] years; 101 [68%] were male) provided 5322 interpretations of study cases.","Participants were more likely to increase the severity of their diagnosis when the prior diagnosis was of greater severity compared with when no prior diagnosis was provided (RR, 1.52; 95% CI, 1.34-1.73); likewise, participants gave less severe diagnoses when prior diagnoses were of lesser severity (RR, 1.38; 95% CI, 1.19-1.59).","Trends were similar among dermatopathologists who had previously stated they were \"not at all influenced\" by prior diagnoses.","Prior diagnoses also swayed dermatopathologists away from correct diagnoses.","CONCLUSIONS AND RELEVANCE: In this randomized controlled trial, despite the preference of most dermatopathologists to receive prior diagnoses when providing second opinions, this information swayed them away from a correct diagnosis to an incorrect diagnosis."],"Aspect":"o","Summary":"The study found that dermatopathologists were influenced by prior diagnostic information, leading them to change their diagnoses towards the severity of the prior diagnosis, which sometimes swayed them away from the correct diagnosis.","Indexes":[16,18,19],"Sentences":["Participants were more likely to increase the severity of their diagnosis when the prior diagnosis was of greater severity compared with when no prior diagnosis was provided (RR, 1.52; 95% CI, 1.34-1.73); likewise, participants gave less severe diagnoses when prior diagnoses were of lesser severity (RR, 1.38; 95% CI, 1.19-1.59).","Prior diagnoses also swayed dermatopathologists away from correct diagnoses.","CONCLUSIONS AND RELEVANCE: In this randomized controlled trial, despite the preference of most dermatopathologists to receive prior diagnoses when providing second opinions, this information swayed them away from a correct diagnosis to an incorrect diagnosis."],"Revise":false}
{"PMID":"37167764","Document":["BACKGROUND: In the phase II\/III RELATIVITY-047 trial, a novel fixed-dose combination (FDC) of nivolumab plus relatlimab (NIVO\u202f+\u202fRELA; a programmed death-1 and a lymphocyte-activation gene 3 inhibitor, respectively) significantly improved progression-free survival (PFS) versus NIVO in patients with previously untreated unresectable or metastatic melanoma (median follow-up, 13.2 months) with stable health-related quality of life (HRQoL), although grade three or four treatment-related adverse events (TRAEs) were more frequent with the combination.","Updated HRQoL results (median follow-up, 19.3 months) are presented.","METHODS: Patients were randomised to receive intravenous NIVO\u202f+\u202fRELA (480\u202fmg and 160\u202fmg, respectively) or NIVO (480\u202fmg) every 4 weeks.","HRQoL was assessed using the Functional Assessment of Cancer Treatment-Melanoma (FACT-M) and EQ-5D-3L questionnaires at baseline, before dosing at each treatment cycle, and at follow-up (posttreatment) visits.","RESULTS: Consistent with the initial analysis, HRQoL remained stable with NIVO\u202f+\u202fRELA on treatment and was similar to that with NIVO.","Mean changes from baseline did not exceed clinically meaningful thresholds.","HRQoL results were consistent across instruments and scales\/subscales.","Despite an increased rate of grade three or four TRAEs with NIVO\u202f+\u202fRELA versus NIVO, the proportion of patients reporting that they were bothered 'quite a bit' or 'very much' by TRAEs was low and comparable between treatments.","CONCLUSION: Results from the RELATIVITY-047 trial show that the PFS benefit with NIVO\u202f+\u202fRELA FDC over NIVO was obtained with stable patient-reported HRQoL, supporting NIVO\u202f+\u202fRELA as a first-line treatment option for patients with advanced melanoma."],"Aspect":"s","Summary":"The combination of nivolumab plus relatlimab resulted in more frequent grade three or four treatment-related adverse events compared to nivolumab alone.","Indexes":[0,7],"Sentences":["BACKGROUND: In the phase II\/III RELATIVITY-047 trial, a novel fixed-dose combination (FDC) of nivolumab plus relatlimab (NIVO\u202f+\u202fRELA; a programmed death-1 and a lymphocyte-activation gene 3 inhibitor, respectively) significantly improved progression-free survival (PFS) versus NIVO in patients with previously untreated unresectable or metastatic melanoma (median follow-up, 13.2 months) with stable health-related quality of life (HRQoL), although grade three or four treatment-related adverse events (TRAEs) were more frequent with the combination.","Despite an increased rate of grade three or four TRAEs with NIVO\u202f+\u202fRELA versus NIVO, the proportion of patients reporting that they were bothered 'quite a bit' or 'very much' by TRAEs was low and comparable between treatments."],"Revise":false}
{"PMID":"36881133","Document":["AIM: We have previously reported that polyfunctional T cell responses can be induced to the cancer testis antigen NY-ESO-1 in melanoma patients injected with mature autologous monocyte-derived dendritic cells (DCs) loaded with long NY-ESO-1-derived peptides together with \u03b1-galactosylceramide (\u03b1-GalCer), an agonist for type 1 Natural Killer T (NKT) cells.","OBJECTIVE: To assess whether inclusion of \u03b1-GalCer in autologous NY-ESO-1 long peptide-pulsed DC vaccines (DCV\u2009+\u2009\u03b1-GalCer) improves T cell responses when compared to peptide-pulsed DC vaccines without \u03b1-GalCer (DCV).","DESIGN, SETTING AND PARTICIPANTS: Single-centre blinded randomised controlled trial in patients\u2009\u2265\u200918\u00a0years old with histologically confirmed, fully resected stage II-IV malignant cutaneous melanoma, conducted between July 2015 and June 2018 at the Wellington Blood and Cancer Centre of the Capital and Coast District Health Board.","INTERVENTIONS: Stage I.","Patients were randomised to two cycles of DCV or DCV\u2009+\u2009\u03b1-GalCer (intravenous dose of 10\u2009\u00d7\u2009106 cells, interval of 28\u00a0days).","Stage II.","Patients assigned to DCV\u2009+\u2009\u03b1-GalCer were randomised to two further cycles of DCV\u2009+\u2009\u03b1-GalCer or observation, while patients initially assigned to DCV crossed over to two cycles of DCV\u2009+\u2009\u03b1-GalCer.","OUTCOME MEASURES: Primary: Area under the curve (AUC) of mean NY-ESO-1-specific T cell count detected by ex vivo IFN-\u03b3 ELISpot in pre- and post-treatment blood samples, compared between treatment arms at Stage I.","Secondary: Proportion of responders in each arm at Stage I; NKT cell count in each arm at Stage I; serum cytokine levels at Stage I; adverse events Stage I; T cell count for DCV\u2009+\u2009\u03b1-GalCer versus observation at Stage II, T cell count before versus after cross-over.","RESULTS: Thirty-eight patients gave written informed consent; 5 were excluded before randomisation due to progressive disease or incomplete leukapheresis, 17 were assigned to DCV, and 16 to DCV\u2009+\u2009\u03b1-GalCer.","The vaccines were well tolerated and associated with increases in mean total T cell count, predominantly CD4+ T cells, but the difference between the treatment arms was not statistically significant (difference\u2009-\u20096.85, 95% confidence interval,\u2009-\u200921.65 to 7.92; P\u2009=\u20090.36).","No significant improvements in T cell response were associated with DCV\u2009+\u2009\u03b1-GalCer with increased dosing, or in the cross-over.","However, the NKT cell response to \u03b1-GalCer-loaded vaccines was limited compared to previous studies, with mean circulating NKT cell levels not significantly increased in the DCV\u2009+\u2009\u03b1-GalCer arm and no significant differences in cytokine response between the treatment arms.","CONCLUSIONS: A high population coverage of NY-ESO-1-specific T cell responses was achieved with a good safety profile, but we failed to demonstrate that loading with \u03b1-GalCer provided an additional advantage to the T cell response with this cellular vaccine design.","CLINICAL TRIAL REGISTRATION: ACTRN12612001101875.","Funded by the Health Research Council of New Zealand."],"Aspect":"s","Summary":"The vaccines were well tolerated.","Indexes":[10],"Sentences":["The vaccines were well tolerated and associated with increases in mean total T cell count, predominantly CD4+ T cells, but the difference between the treatment arms was not statistically significant (difference\u2009-\u20096.85, 95% confidence interval,\u2009-\u200921.65 to 7.92; P\u2009=\u20090.36)."],"Revise":false}
{"PMID":"33211315","Document":["BACKGROUND: Pimasertib is a selective, potent mitogen-activated protein kinase kinase (MEK) 1\/2 inhibitor.","OBJECTIVES: The aim of this study was to describe the efficacy, safety, and pharmacodynamics of pimasertib at pharmacologically active doses in a cohort of patients with locally advanced\/metastatic melanoma from a first-in-human study of pimasertib.","METHODS: This was a phase I, open-label, two-part, dose-escalation study.","Part 1 was conducted in patients with solid tumors and identified the maximum tolerated dose, while Part 2 was restricted to patients with advanced\/metastatic melanoma.","Endpoints included safety, pharmacodynamics, and antitumor activity.","We present data for patients with melanoma only from both parts of the study.","RESULTS: In total, 93 patients with melanoma received pimasertib, 89 of whom received pharmacologically active doses (28-255 mg\/day) across four dose regimens in the two parts of the study.","The objective response rate was 12.4% (11\/89): complete response (n\u00a0=\u00a01) and partial response (PR; n\u00a0=\u00a010).","Six patients responded for > 24 weeks.","Nine of the 11 responders had tumors with B-Raf Proto-Oncogene, Serine\/Threonine Kinase (BRAF; n\u00a0=\u00a06) and\/or NRAS Proto-Oncogene, GTPase (NRAS; n\u00a0=\u00a03) mutations.","Forty-six patients had stable disease (SD).","In patients with ocular melanoma (n\u00a0=\u00a013), best overall response was PR (n\u00a0=\u00a01), SD (n\u00a0=\u00a011), and disease progression (n\u00a0=\u00a01).","Phosphorylated extracellular signal-regulated kinase (pERK) levels were substantially reduced within 2\u00a0h of treatment and inhibition was sustained with continuous twice-daily dosing.","Treatment-related, recurrent, grade 3 or higher adverse events were reported in eight patients, including diarrhea, and skin and ocular events.","CONCLUSION: Results from this phase I study indicate that pimasertib has clinical activity in patients with locally advanced\/metastatic melanoma, particularly BRAF- and NRAS-mutated tumors, at clinically relevant doses associated with pERK inhibition in peripheral blood mononuclear cells.","TRIAL REGISTRATION: ClinicalTrials.gov, NCT00982865."],"Aspect":"s","Summary":"Treatment-related, recurrent, grade 3 or higher adverse events were reported in eight patients, including diarrhea, and skin and ocular events.","Indexes":[13],"Sentences":["Treatment-related, recurrent, grade 3 or higher adverse events were reported in eight patients, including diarrhea, and skin and ocular events."],"Revise":false}
{"PMID":"32266730","Document":["Identification of melanoma or worrisome moles is often taught as an important part of routine skin checks.","We sought to evaluate the efficacy of gamified education vs. traditional ABCDEs education on melanoma identification and self-confidence in identifying worrisome moles.","We report that in our cohort (n\u00a0=\u00a0271), participants randomized to the gamified intervention were more likely to correctly identify melanoma and non-melanoma skin lesions than those randomized to the ABCDE control cohort (74.2% vs 63.5% correct, P\u00a0<\u00a0.0001) and perceived confidence in self-identifying worrisome lesions was slightly higher in the gamified group than the traditional group, though the trend was not significant.","These novel findings have significant implications on improved ways to educate young patients on the visual identification of melanoma and worrisome moles."],"Aspect":"i","Summary":"The study evaluated the efficacy of gamified education versus traditional ABCDEs education on melanoma identification and self-confidence in identifying worrisome moles by randomizing participants to either a gamified intervention or an ABCDE control cohort.","Indexes":[1,2],"Sentences":["We sought to evaluate the efficacy of gamified education vs. traditional ABCDEs education on melanoma identification and self-confidence in identifying worrisome moles.","We report that in our cohort (n\u00a0=\u00a0271), participants randomized to the gamified intervention were more likely to correctly identify melanoma and non-melanoma skin lesions than those randomized to the ABCDE control cohort (74.2% vs 63.5% correct, P\u00a0<\u00a0.0001) and perceived confidence in self-identifying worrisome lesions was slightly higher in the gamified group than the traditional group, though the trend was not significant."],"Revise":false}
{"PMID":"35028656","Document":["BACKGROUND: Identifying the characteristics of persons who benefit more from behavioral interventions can help health care providers decide which individuals should be offered particular interventions because this is the subgroup of persons who are more likely to derive greater benefit from the intervention and refine the underlying constructs of the model guiding the intervention.","PURPOSE: This study evaluated possible demographic, medical, knowledge and attitudinal, and psychosocial variables that may moderate the impact of an online intervention, called mySmartSkin (MSS), on engagement in skin self-examination (SSE) and sun protection behaviors among melanoma survivors.","METHODS: Participants completed a baseline survey and were then randomized to the MSS condition or usual care.","Follow-up surveys were completed by participants at 8-, 24-, and 48-week postrandomization.","RESULTS: A greater impact of MSS on SSE was illustrated among participants with more phenotypic skin cancer risk factors and participants reporting lower baseline self-efficacy in conducting SSE.","A more favorable response of MSS on sun protection behaviors was shown when initial knowledge about abnormal lesions and sun protection barriers were high.","Greater use of MSS and more favorable evaluations of it were also associated with higher intervention response.","CONCLUSIONS: Future studies seeking to improve SSE and sun protection among melanoma survivors might benefit from focusing on survivors who report more skin cancer risk factors, lower self-efficacy in conducting SSE, less knowledge about what abnormal skin lesions look like, more perceived barriers to sun protection behaviors, and less worry about recurrence and cancer-related distress."],"Aspect":"i","Summary":"Participants were randomized to either the mySmartSkin (MSS) online intervention or usual care to evaluate the impact on skin self-examination (SSE) and sun protection behaviors among melanoma survivors.","Indexes":[2],"Sentences":["METHODS: Participants completed a baseline survey and were then randomized to the MSS condition or usual care."],"Revise":true}
{"PMID":"32114500","Document":["BACKGROUND: We previously reported that dendritic cell-based mRNA vaccination plus ipilimumab (TriMixDC-MEL IPI) results in an encouraging rate of tumor responses in patients with pretreated advanced melanoma.","Here, we report the TriMixDC-MEL IPI-induced T-cell responses detected in the peripheral blood.","METHODS: Monocyte-derived dendritic cells electroporated with mRNA encoding CD70, CD40 ligand, and constitutively active TLR4 (TriMix) as well as the tumor-associated antigens tyrosinase, gp100, MAGE-A3, or MAGE-C2 were administered together with IPI for four cycles.","For 18\/39 patients, an additional vaccine was administered before the first IPI administration.","We evaluated tumor-associated antigen specific T-cell responses in previously collected peripheral blood mononuclear cells, available from 15 patients.","RESULTS: Vaccine-induced enzyme-linked immunospot assay responses detected after in vitro T-cell stimulation were shown in 12\/15 patients.","Immune responses detected in patients with a complete or partial response were significantly stronger and broader, and exhibited a higher degree of multifunctionality compared with responses in patients with stable or progressive disease.","CD8+ T-cell responses from patients with an ongoing clinical response, either elicited by TriMixDC-MEL IPI or on subsequent pembrolizumab treatment, exhibited the highest degree of multifunctionality.","CONCLUSIONS: TriMixDC-MEL IPI treatment results in robust CD8+ T-cell responses in a meaningful portion of stage III or IV melanoma patients, and obviously in patients with a clinical response.","The levels of polyfunctional and multiantigen T-cell responses measured in patients with a complete response, particularly in patients evidently cured after 5+ years of follow-up, may provide a benchmark for the level of immune stimulation needed to achieve a durable clinical remission.","TRIAL REGISTRATION NUMBER: NCT01302496."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"31414290","Document":["BACKGROUND: Talimogene laherparepvec (T-VEC) is the first injectable oncolytic viral therapy approved for in-transit melanoma metastasis, with a reported overall response rate (ORR) of 25% and complete response rate (CRR) of 10%.","To ascertain the role of patient selection on outcomes in routine practice, we evaluated the impact of patient, lesion, and treatment factors on clinical response.","METHODS: Medical records were extracted for patients with recurrent stage IIIB-IV melanoma completing T-VEC at Duke University Medical Center between 1 January 2016 and 1 September 2018.","Kaplan-Meier analysis assessed time to response and survival, while logistic regression measured associations of clinicopathologic status, lesion burden, T-VEC dosing, and use of prior and concurrent therapy with ORR and CRR.","RESULTS: Of 27 patients, an objective response was observed in 11 (40.7%), including one patient with partial response (3.7%) and 10 with complete response (37.0%).","Time to complete response and overall response was a median 22\u00a0weeks (95% confidence interval [CI] 2.0-41.9\u00a0weeks and 15.8-28.2\u00a0weeks, respectively), and median progression-free survival was 17\u00a0weeks (95% CI 0-36\u00a0weeks).","Logistic regression demonstrated each millimeter increase in maximum lesion diameter predicted decreased ORR (odds ratio [OR] 0.866, 95% CI 0.753-0.995; p\u2009=\u20090.04).","Stage IV disease (OR 0.04, 95% CI 0.00-0.74; p\u2009=\u20090.031) and programmed death-1 inhibitor treatment (OR 0.06, 95% CI 0.01-0.74; p\u2009=\u20090.028) also predicted reduced clinical response.","CONCLUSIONS: This study corroborates recent data suggesting response rates to T-VEC may be higher than reported in clinical trials, arising in part from patient selection.","T-VEC lesion diameter was persistently associated with clinical response and is a readily assessed predictor of successful T-VEC therapy."],"Aspect":"i","Summary":"Medical records of patients with recurrent stage IIIB-IV melanoma treated with T-VEC were evaluated to assess the impact of various factors on clinical response.","Indexes":[2,3],"Sentences":["METHODS: Medical records were extracted for patients with recurrent stage IIIB-IV melanoma completing T-VEC at Duke University Medical Center between 1 January 2016 and 1 September 2018.","Kaplan-Meier analysis assessed time to response and survival, while logistic regression measured associations of clinicopathologic status, lesion burden, T-VEC dosing, and use of prior and concurrent therapy with ORR and CRR."],"Revise":false}
{"PMID":"32366871","Document":["Advanced melanoma remains a disease with poor prognosis.","Several serologic markers have been investigated to help monitoring and prognostication, but to date only lactate dehydrogenase (LDH) has been validated as a standard prognostic factor biomarker for this disease by the American Joint Committee on Cancer.","In this work, we built a semi-mechanistic model to explore the relationship between the time course of several circulating biomarkers and overall or progression free survival in advanced melanoma patients treated with adjuvant high-dose interferon-[Formula: see text].","Additionally, due to the adverse interferon tolerability, a semi-mechanistic model describing the side effects of the treatment in the absolute neutrophil counts is proposed in order to simultaneously analyze the benefits and toxic effects of this treatment.","The results of our analysis suggest that the relative change from baseline of LDH was the most significant predictor of the overall survival of the patients.","Unfortunately, there was no significant difference in the proportion of patients with elevated serum biomarkers between the patients who recurred and those who remained free of disease.","Still, we believe that the modelling framework presented in this work of circulating biomarkers and adverse effects could constitute an additional strategy for disease monitoring in advance melanoma patients."],"Aspect":"i","Summary":"The study utilized a semi-mechanistic model to analyze the relationship between circulating biomarkers, overall or progression-free survival, and adverse effects in advanced melanoma patients treated with adjuvant high-dose interferon.","Indexes":[2,3],"Sentences":["In this work, we built a semi-mechanistic model to explore the relationship between the time course of several circulating biomarkers and overall or progression free survival in advanced melanoma patients treated with adjuvant high-dose interferon-[Formula: see text].","Additionally, due to the adverse interferon tolerability, a semi-mechanistic model describing the side effects of the treatment in the absolute neutrophil counts is proposed in order to simultaneously analyze the benefits and toxic effects of this treatment."],"Revise":false}
{"PMID":"38683104","Document":["PURPOSE: Uveal melanoma is a rare and aggressive subset of melanoma that is minimally responsive to traditional therapies.","Greater than 80% of uveal melanomas have a mutation in GNAQ or GNA11 which lead to downstream signaling through the MAPK pathway.","Ulixertinib (BVD-523) is a potent and reversible small-molecule ATP-competitive inhibitor of both ERK1 and ERK2 protein kinases.","MATERIALS AND METHODS: We performed a phase II study to determine the efficacy and safety of BVD-523 in patients with metastatic uveal melanoma.","This was conducted as a Simon two-stage design with a sample size of 25 patients and an initial evaluation of efficacy after 13 patients.","RESULTS: From April 2018 to April 2019, 13 patients were enrolled.","Patients were predominantly female (69%) with a median age of 64 years (34-76).","Sites of metastases included liver (84.6%) and lung (30.8%).","Grade 3 and 4 toxicities associated with therapy were consistent with ERK inhibitors and included liver function test (LFT) elevation, hyponatremia, pruritis, amylase elevation, anemia, and rash.","The best response, per RECIST 1.1, was stable disease in 4 patients, and disease progression in 7 patients.","Two patients were unevaluable for response due to withdrawal from study.","Median time to progression was 2.0 months.","There were eight deaths due to disease progression with a median overall survival of 6.9 months.","CONCLUSIONS: ERK inhibition with ulixertinib (BVD-523) did not demonstrate activity in patients with metastatic uveal melanoma.","The toxicities observed were consistent with what would be expected with MAPK pathway inhibition.","SIGNIFICANCE: Uveal melanoma is a difficult to treat disease with minimal therapy options.","The majority of uveal melanomas have mutations in GNAQ or GNA11 leading to activation of the MAPK pathway.","Efforts to target MEK in uveal melanoma has had mixed results.","This phase II trial of ERK inhibition with BVD-523 examined the potential role of this agent in uveal melanoma therapy."],"Aspect":"i","Summary":"A phase II study was conducted to determine the efficacy and safety of ulixertinib (BVD-523) in patients with metastatic uveal melanoma using a Simon two-stage design.","Indexes":[3,4],"Sentences":["MATERIALS AND METHODS: We performed a phase II study to determine the efficacy and safety of BVD-523 in patients with metastatic uveal melanoma.","This was conducted as a Simon two-stage design with a sample size of 25 patients and an initial evaluation of efficacy after 13 patients."],"Revise":false}
{"PMID":"33471137","Document":["BACKGROUND: Limited data are available on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with preexisting autoimmune diseases (PAD).","METHODS: Retrospective study of patients with PAD referred for rheumatologic evaluation prior to starting or during immunotherapy between January 2013 and July 2019 from 10 academic sites across Canada.","Data were extracted by chart review using a standardized form.","RESULTS: Twenty-seven patients with PAD on ICI therapy were identified.","The most common PADs were rheumatoid arthritis (30%), psoriasis\/psoriatic arthritis (30%), inflammatory bowel disease (IBD, 15%) and axial spondyloarthritis (11%), and the most frequently observed cancers were lung cancer and melanoma.","All patients received anti-PD-1 therapies, and 2 received additional sequential anti-CTLA-4 therapy.","PAD exacerbations occurred in 52% over a median (IQR) follow-up of 11.0 (6.0-17.5) months, with 14% being severe, 57% requiring corticosteroids, 50% requiring immunosuppression and 14% requiring ICI discontinuation.","Flares were generally more frequent and severe in patients who previously required more intensive immunosuppression (i.e., biologics).","Flares occurred despite background immunosuppression at the time of ICI initiation.","In patients with preexisting psoriasis, IBD and axial spondyloarthritis, rheumatic immune-related adverse events (irAEs), mostly polyarthritis and tenosynovitis, were frequently observed.","Tumor progression was not associated with exposure to immunosuppressive drugs before or after ICI initiation and was numerically less frequent in patients with irAEs.","CONCLUSION: PAD exacerbations in the context of ICI treatment are common, although generally mild, and occur despite background immunosuppression.","Exacerbations are more frequent and severe in patients on more intensive immunosuppressive therapies pre-immunotherapy."],"Aspect":"a","Summary":"The study aims to investigate the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with preexisting autoimmune diseases (PAD).","Indexes":[0],"Sentences":["BACKGROUND: Limited data are available on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with preexisting autoimmune diseases (PAD)."],"Revise":false}
{"PMID":"33072126","Document":["Despite the recent availability of several new drugs in hemato-oncology, T-cell lymphomas are still incurable and PD-1 blockade could represent a therapeutic chance for selected patients affected by these malignancies, although further studies are required to understand the biological effects of anti-PD-1 mAbs on neoplastic T-cells and to identify biomarkers for predicting and\/or monitoring patients' response to therapy.","Sezary Syndrome (SS) represents a rare and aggressive variant of cutaneous T cell lymphoma (CTCL) with a life expectancy of less than 5 years, characterized by the co-presence of neoplastic lymphocytes mainly in the blood, lymph nodes and skin.","In this study we analyzed longitudinal blood samples and lesional skin biopsies of a patient concurrently affected by SS and melanoma who underwent 22 nivolumab administrations.","In blood, we observed a progressive reduction of SS cell number and a raise in the percentage of normal CD4+ and CD8+ T cells and NK cells over total leukocytes.","Eight weeks from the start of nivolumab, these immune cell subsets showed an increase of Ki67 proliferation index that positively correlated with their PD-1 expression.","Conversely, SS cells displayed a strong reduction of Ki67 positivity despite their high PD-1 expression.","On skin biopsies we observed a marked reduction of SS cells which were no more detectable at the end of therapy.","We also found an increase in the percentage of normal CD4+ T cells with a concomitant decrease of that of CD8+ and CD4+ CD8+ T cells, two cell subsets that, however, acquired a cytotoxic phenotype.","In summary, our study demonstrated that nivolumab marked reduced SS tumor burden and invigorated immune responses in our patient.","Our data also suggest, for the first time, that Ki67 expression in circulating neoplastic and immune cell subsets, as well as an enrichment in T cells with a cytotoxic phenotype in lesional skin could be valuable markers to assess early on treatment SS patients' response to PD-1 blockade, a therapeutic strategy under clinical investigation in CTCL (ClinicalTrials.gov NCT03385226, NCT04118868)."],"Aspect":"i","Summary":"The study involved analyzing longitudinal blood samples and lesional skin biopsies of a patient with Sezary Syndrome (SS) and melanoma who underwent 22 administrations of nivolumab.","Indexes":[2],"Sentences":["In this study we analyzed longitudinal blood samples and lesional skin biopsies of a patient concurrently affected by SS and melanoma who underwent 22 nivolumab administrations."],"Revise":false}
{"PMID":"36651961","Document":["PURPOSE: No standard of care therapy exists for patients with metastatic uveal melanoma who are not HLA-A2:01 positive.","The phase 1b, open-label CLEVER study (NCT03408587) evaluated V937 in combination with ipilimumab in patients with uveal melanoma.","METHODS: Adults with advanced uveal melanoma and liver metastases received up to 8 cycles of intravenous V937 (1\u2009\u00d7\u2009109 TCID50 per infusion; infusions on days 1, 3, 5, and 8 [cycle 1], then every 3\u00a0weeks [Q3W] thereafter [cycles 2-8]) and 4 cycles of intravenous ipilimumab 3\u00a0mg\/kg Q3W (beginning at cycle 1\u00a0day 8).","The primary endpoint was safety.","Secondary endpoints included objective response rate and progression-free survival (PFS) per immune-related Response Evaluation Criteria in Solid Tumors (irRECIST).","RESULTS: Eleven patients were enrolled (median age, 65.0\u00a0years) and received a median of 6 injections of V937 and 3.5 infusions of ipilimumab.","The best overall response was stable disease in 3 patients and progressive disease in 8 patients.","All patients exhibited progression per irRECIST, with a 9% irPFS rate at week 26.","Ten patients had treatment-related AEs, the most frequent of which were diarrhea (55%), fatigue (45%), and myalgia (36%).","Two grade 3 AEs (diarrhea, n\u2009=\u20092) were considered related to ipilimumab; neither was related to V937.","CONCLUSION: Although the combination of V937 with ipilimumab had a manageable safety profile, meaningful clinical benefit was not observed in patients with uveal melanoma and liver metastases.","TRIAL REGISTRATION: ClinicalTrials.gov, NCT03408587 (January 24, 2018)."],"Aspect":"a","Summary":"The study aims to evaluate the safety and efficacy of V937 in combination with ipilimumab in patients with uveal melanoma.","Indexes":[1,3,4],"Sentences":["The phase 1b, open-label CLEVER study (NCT03408587) evaluated V937 in combination with ipilimumab in patients with uveal melanoma.","The primary endpoint was safety.","Secondary endpoints included objective response rate and progression-free survival (PFS) per immune-related Response Evaluation Criteria in Solid Tumors (irRECIST)."],"Revise":false}
{"PMID":"34385669","Document":["PURPOSE: We evaluated the impact of personal melanoma genomic risk information on sun-related behaviors and psychological outcomes.","METHODS: In this parallel group, open, randomized controlled trial, 1,025 Australians of European ancestry without melanoma and aged 18-69 years were recruited via the Medicare database (3% consent).","Participants were randomized to the intervention (n\u2009=\u2009513; saliva sample for genetic testing, personalized melanoma risk booklet based on a 40-variant polygenic risk score, telephone-based genetic counseling, educational booklet) or control (n\u2009=\u2009512; educational booklet).","Wrist-worn ultraviolet (UV) radiation dosimeters (10-day wear) and questionnaires were administered at baseline, 1 month postintervention, and 12 months postbaseline.","RESULTS: At 12 months, 948 (92%) participants completed dosimetry and 973 (95%) the questionnaire.","For the primary outcome, there was no effect of the genomic risk intervention on objectively measured UV exposure at 12 months, irrespective of traditional risk factors.","For secondary outcomes at 12 months, the intervention reduced sunburns (risk ratio: 0.72, 95% confidence interval: 0.54-0.96), and increased skin examinations among women.","Melanoma-related worry was reduced.","There was no overall impact on general psychological distress.","CONCLUSION: Personalized genomic risk information did not influence sun exposure patterns but did improve some skin cancer prevention and early detection behaviors, suggesting it may be useful for precision prevention.","There was no evidence of psychological harm."],"Aspect":"s","Summary":"There was no evidence of psychological harm.","Indexes":[10],"Sentences":["There was no evidence of psychological harm."],"Revise":false}
{"PMID":"33125309","Document":["PURPOSE: Metastatic uveal melanoma has poor overall survival (OS) and no approved systemic therapy options.","Studies of single-agent immunotherapy regimens have shown minimal benefit.","There is the potential for improved responses with the use of combination immunotherapy.","PATIENTS AND METHODS: We conducted a phase II study of nivolumab with ipilimumab in patients with metastatic uveal melanoma.","Any number of prior treatments was permitted.","Patients received nivolumab 1 mg\/kg and ipilimumab 3 mg\/kg for four cycles, followed by nivolumab maintenance therapy for up to 2 years.","The primary outcome of the study was overall response rate (ORR) as determined by RECIST 1.1 criteria.","Progression-free survival (PFS), OS, and adverse events were also assessed.","RESULTS: Thirty-five patients were enrolled, and 33 patients were evaluable for efficacy.","The ORR was 18%, including one confirmed complete response and five confirmed partial responses.","The median PFS was 5.5 months (95% CI, 3.4 to 9.5 months), and the median OS was 19.1 months (95% CI, 9.6 months to NR).","Forty percent of patients experienced a grade 3-4 treatment-related adverse event.","CONCLUSION: The combination regimen of nivolumab plus ipilimumab demonstrates activity in metastatic uveal melanoma, with deep and sustained confirmed responses."],"Aspect":"p","Summary":"The phase II study enrolled 35 patients with metastatic uveal melanoma.","Indexes":[8],"Sentences":["RESULTS: Thirty-five patients were enrolled, and 33 patients were evaluable for efficacy."],"Revise":false}
{"PMID":"36842739","Document":["In recent years, the unprecedented increase in various cancers such as melanoma has caused researchers to focus more on the formulation of newer drugs with less side effects.","In this study, we herein indicate the biogenic nanoarchitechtonics of Ag NPs template over chitosan\/starch mixed hydrogel having notable reducing potential and anti-malignant melanoma effects.","The two biopolymers also could stabilize as-synthesized Ag NPs.","Physicochemical features of the material were further characterized over a range of advanced methods like X-ray diffraction (XRD), elemental mapping, dynamic light scattering (DLS), energy-dispersive X-ray spectroscopy (EDS), transmission electron microscopy (TEM), field emission scanning electron microscopy (FESEM), and Fourier transformed infrared spectroscopy (FT-IR).","TEM analysis showed the spherical-shaped nanocomposite with the mean diameter in the range of 5-15\u00a0nm.","Thereafter, the nanocomposite was exploited in the anti-malignant melanoma and cytotoxicity effects studies against various human malignant melanoma cell lines (HT144, RPMI7951, SKMEL2, UACC3074, WM266-4 and MUM2C) in situ.","The bio-composite corresponding IC50 values were 193, 102, 227, 250, 301, and 203\u00a0\u03bcg\/mL against MUM2C, WM266-4, UACC3074, SKMEL2, RPMI7951, and HT144 cell lines, respectively.","A significantly high IC50 value offered an excellent antioxidant capacity of bio-composite.","According to the above results, Ag NPs\/CS-Starch nanomaterial can be utilized as an efficient drug to treat malignant melanoma in humans after doing clinical trial studies."],"Aspect":"a","Summary":"The study aims to investigate the anti-malignant melanoma effects of a biogenic nanoarchitectonic composite of Ag NPs with chitosan\/starch mixed hydrogel.","Indexes":[1,5],"Sentences":["In this study, we herein indicate the biogenic nanoarchitechtonics of Ag NPs template over chitosan\/starch mixed hydrogel having notable reducing potential and anti-malignant melanoma effects.","Thereafter, the nanocomposite was exploited in the anti-malignant melanoma and cytotoxicity effects studies against various human malignant melanoma cell lines (HT144, RPMI7951, SKMEL2, UACC3074, WM266-4 and MUM2C) in situ."],"Revise":false}
{"PMID":"38234043","Document":["BACKGROUND: Use of artificial intelligence (AI), or machine learning, to assess dermoscopic images of skin lesions to detect melanoma has, in several retrospective studies, shown high levels of diagnostic accuracy on par with - or even outperforming - experienced dermatologists.","However, the enthusiasm around these algorithms has not yet been matched by prospective clinical trials performed in authentic clinical settings.","In several European countries, including Sweden, the initial clinical assessment of suspected skin cancer is principally conducted in the primary healthcare setting by primary care physicians, with or without access to teledermoscopic support from dermatology clinics.","OBJECTIVES: To determine the diagnostic performance of an AI-based clinical decision support tool for cutaneous melanoma detection, operated by a smartphone application (app), when used prospectively by primary care physicians to assess skin lesions of concern due to some degree of melanoma suspicion.","METHODS: This prospective multicentre clinical trial was conducted at 36 primary care centres in Sweden.","Physicians used the smartphone app on skin lesions of concern by photographing them dermoscopically, which resulted in a dichotomous decision support text regarding evidence for melanoma.","Regardless of the app outcome, all lesions underwent standard diagnostic procedures (surgical excision or referral to a dermatologist).","After investigations were complete, lesion diagnoses were collected from the patients' medical records and compared with the app's outcome and other lesion data.","RESULTS: In total, 253 lesions of concern in 228 patients were included, of which 21 proved to be melanomas, with 11 thin invasive melanomas and 10 melanomas in situ.","The app's accuracy in identifying melanomas was reflected in an area under the receiver operating characteristic (AUROC) curve of 0.960 [95% confidence interval (CI) 0.928-0.980], corresponding to a maximum sensitivity and specificity of 95.2% and 84.5%, respectively.","For invasive melanomas alone, the AUROC was 0.988 (95% CI 0.965-0.997), corresponding to a maximum sensitivity and specificity of 100% and 92.6%, respectively.","CONCLUSIONS: The clinical decision support tool evaluated in this investigation showed high diagnostic accuracy when used prospectively in primary care patients, which could add significant clinical value for primary care physicians assessing skin lesions for melanoma."],"Aspect":"m","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"38395969","Document":["Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients.","In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB\/C melanoma were randomized to adjuvant treatment with nDCs (n\u2009=\u200999) or placebo (n\u2009=\u200949).","Active treatment consisted of intranodally injected autologous CD1c+ conventional and plasmacytoid DCs loaded with tumor antigens.","The primary endpoint was the 2-year recurrence-free survival (RFS) rate, whereas the secondary endpoints included median RFS, 2-year and median overall survival, adverse event profile, and immunological response The 2-year RFS rate was 36.8% in the nDC treatment group and 46.9% in the control group (p\u2009=\u20090.31).","Median RFS was 12.7 months vs 19.9 months, respectively (hazard ratio 1.25; 90% CI: 0.88-1.79; p\u2009=\u20090.29).","Median overall survival was not reached in both treatment groups (hazard ratio 1.32; 90% CI: 0.73-2.38; p\u2009=\u20090.44).","Grade 3-4 study-related adverse events occurred in 5% and 6% of patients.","Functional antigen-specific T cell responses could be detected in 67.1% of patients tested in the nDC treatment group vs 3.8% of patients tested in the control group (p\u2009<\u20090.001).","In conclusion, while adjuvant nDC treatment in stage IIIB\/C melanoma patients generated specific immune responses and was well tolerated, no benefit in RFS was observed."],"Aspect":"i","Summary":"The study involved a phase III clinical trial where 148 patients with resected stage IIIB\/C melanoma were randomized to receive adjuvant treatment with natural dendritic cells (nDCs) or placebo, with active treatment consisting of intranodally injected autologous CD1c+ conventional and plasmacytoid DCs loaded with tumor antigens.","Indexes":[1,2],"Sentences":["In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB\/C melanoma were randomized to adjuvant treatment with nDCs (n\u2009=\u200999) or placebo (n\u2009=\u200949).","Active treatment consisted of intranodally injected autologous CD1c+ conventional and plasmacytoid DCs loaded with tumor antigens."],"Revise":false}
{"PMID":"32723187","Document":["Nivolumab, a PD-1 inhibitor, has demonstrated prolonged survival benefit in patients with advanced melanoma.","Bempegaldesleukin (BEMPEG; NKTR-214), a first-in-class CD122-preferential IL-2 pathway agonist, provides sustained signaling through the IL-2\u03b2\u03b3 receptor, which activates effector T and natural killer cells.","In the Phase I\/II PIVOT-02 trial, the combination of bempegaldesleukin plus nivolumab was well-tolerated and demonstrated clinical activity as first-line therapy in metastatic melanoma.","Here, we describe the design of and rationale for the Phase III, global, randomized, open-label PIVOT IO 001 trial comparing bempegaldesleukin plus nivolumab with nivolumab alone in patients with previously untreated, unresectable or metastatic melanoma.","Primary end points include objective response rate, progression-free survival and overall survival.","Key secondary end points include further investigation of safety\/tolerability, previously assessed in the PIVOT-02 trial.","Clinical Trial Registration: NCT03635983 (ClinicalTrials.gov)."],"Aspect":"o","Summary":"The combination of bempegaldesleukin plus nivolumab demonstrated clinical activity as first-line therapy in metastatic melanoma.","Indexes":[2],"Sentences":["In the Phase I\/II PIVOT-02 trial, the combination of bempegaldesleukin plus nivolumab was well-tolerated and demonstrated clinical activity as first-line therapy in metastatic melanoma."],"Revise":false}
{"PMID":"36763627","Document":["BACKGROUND: Melanoma survivors are at increased risk of developing a second primary melanoma; however, some report sub-optimal sun behaviors and sunburns.","We tested the effectiveness of a wearable device with ultraviolet radiation (UVR)-sensing technology to improve sun behaviors and reduce sunburns in cutaneous melanoma survivors.","MATERIALS AND METHODS: We conducted a randomized controlled trial using Shade 2, a commercially available wrist device that measures UVR.","The intervention group received the device and mobile application notifications about their exposure and prompts to use sunscreen.","The control group received the device and a separate research mobile application without information about their exposure or notifications.","Participants wore the device for 12 weeks and self-reported sun behaviors before, during, and after the intervention.","The primary outcome was a composite score of sun protection behaviors at week 12.","RESULTS: 386 participants were randomized (186 control, 182 intervention).","Most were female and 5+ years past their first melanoma diagnosis.","The average age was 56 years.","Most (93%) completed the study, though 40% experienced device issues.","No meaningful differences were observed in self-reported sun protection behaviors at week 12 (controls 3.0\u00b10.5 vs. intervention 2.9\u00b10.5, p = 0.06), any sunburn during the intervention period (controls 14.4% vs. intervention 12.7%, p = 0.75), or average daily objective UVR exposure (controls median 87 vs. intervention 83 J\/m2, p = 0.43).","CONCLUSION: Wearing a device that measured and alerted melanoma survivors to UVR exposure did not result in different sun behaviors, exposure, or sunburns relative to controls.","The technology needs refinement before further attempts to assess the effectiveness of self-monitoring UVR exposure.","CLINICAL TRIALS REGISTRATION: NCT03927742."],"Aspect":"p","Summary":"The study involved 386 melanoma survivors, most of whom were female with an average age of 56 years and 5+ years past their first melanoma diagnosis, randomized into 186 control and 182 intervention groups.","Indexes":[7,8,9],"Sentences":["RESULTS: 386 participants were randomized (186 control, 182 intervention).","Most were female and 5+ years past their first melanoma diagnosis.","The average age was 56 years."],"Revise":true}
{"PMID":"32539663","Document":["INTRODUCTION: Cancer drug therapy costs continue to rise and threaten the sustainability of Canada's public healthcare system.","Previous studies have calculated potential savings utilizing different dosing regimens of cancer treatments.","Our objectives were to determine the financial impact of drug wastage and to explore cost-effective dosing regimens for pembrolizumab.","METHODS: This was a retrospective study reviewing data for non-small cell lung cancer and melanoma patients at all six BC Cancer Regional Centres during fiscal years 2017 and 2018.","Pembrolizumab waste amounts recorded in pharmacy wastage logs were totalled.","Estimates of the number of vials used were compared between vial sharing and non-vial sharing practices to determine the cost differences.","Costs for dosing regimens used during fiscal years 2017 and 2018 were compared to 2\u2009mg\/kg weight-based dosing (to a maximum of 200\u2009mg), 2\u2009mg\/kg dosing rounding down within 5% and 10%, and flat dosing of 200\u2009mg.","RESULTS: There were a total of 202 non-small cell lung cancer and 182 melanoma patients with 2948 doses dispensed.","Documented wastage was valued at $1,829,047.44 (8.65%) and across all six centres, vial sharing could reduce costs by $3,207,600.00 using the 100\u2009mg vials.","Compared to fiscal years 2017 and 2018, 2\u2009mg\/kg dosing (to a maximum of 200\u2009mg) was the most cost-effective, decreasing costs by $222,719.20; flat dosing of 200\u2009mg was the most expensive, increasing costs by $6,625,260.40.","CONCLUSIONS: Having smaller vial sizes, practicing vial sharing, and using weight-based dosing all improve cost savings.","Further investigations on the allocation of resources to optimize drug use and minimize wastage are needed."],"Aspect":"a","Summary":"The study aims to determine the financial impact of drug wastage and explore cost-effective dosing regimens for pembrolizumab.","Indexes":[2],"Sentences":["Our objectives were to determine the financial impact of drug wastage and to explore cost-effective dosing regimens for pembrolizumab."],"Revise":false}
{"PMID":"38614074","Document":["KEYNOTE-9421 is a randomized phase II adjuvant study in patients with resected stage III melanoma investigating a personalized neoantigen mRNA vaccine in combination with anti-PD-1.","The study gave a clear signal of superiority for the vaccine plus anti-PD-1 in relapse-free and distant-metastasis-free survival but is not yet conclusive, and important questions remain."],"Aspect":"o","Summary":"The study showed a clear signal of superiority for the personalized neoantigen mRNA vaccine plus anti-PD-1 in improving relapse-free and distant-metastasis-free survival in patients with resected stage III melanoma.","Indexes":[1],"Sentences":["The study gave a clear signal of superiority for the vaccine plus anti-PD-1 in relapse-free and distant-metastasis-free survival but is not yet conclusive, and important questions remain."],"Revise":false}
{"PMID":"35648432","Document":["IMPORTANCE: Previous systematic reviews and meta-analyses have concluded that given data paucity, a comparison of reflectance confocal microscopy (RCM) with dermoscopy is complex.","They recommend comparative prospective studies in a real-world setting of suspect lesions.","OBJECTIVE: To test the hypothesis that RCM reduces unnecessary lesion excision by more than 30% and identifies all melanoma lesions thicker than 0.5 mm at baseline.","DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial included 3165 patients enrolled from 3 dermatology referral centers in Italy between January 2017 and December 2019, with a mean (SD) follow-up of 9.6 (6.9) months (range, 1.9-37.0 months).","The consecutive sample of 3165 suspect lesions determined through dermoscopy were eligible for inclusion (10 patients refused).","Diagnostic analysis included 3078 patients (48 lost, 39 refused excision).","Data were analyzed between April and September 2021.","INTERVENTIONS: Patients were randomly assigned 1:1 to standard therapeutic care (clinical and dermoscopy evaluation) with or without adjunctive RCM.","Information available guided prospective clinical decision-making (excision or follow-up).","MAIN OUTCOMES AND MEASURES: Hypotheses were defined prior to study initiation.","All lesions excised (baseline and follow-up) were registered, including histopathological diagnoses\/no change at dermoscopy follow-up (with or without adjunctive RCM).","Number needed to excise (total number of excised lesions\/number of melanomas) and Breslow thickness of delayed diagnosed melanomas were calculated based on real-life, prospective, clinical decision-making.","RESULTS: Among the 3165 participants, 1608 (50.8%) were male, and mean (SD) age was 49.3 (14.9) years.","When compared with standard therapeutic care only, adjunctive RCM was associated with a higher positive predictive value (18.9 vs 33.3), lower benign to malignant ratio (3.7:1.0 vs 1.8:1.0), and a number needed to excise reduction of 43.4% (5.3 vs 3.0).","All lesions (n\u2009=\u200915) with delayed melanoma diagnoses were thinner than 0.5 mm.","CONCLUSIONS AND RELEVANCE: This randomized clinical trial shows that adjunctive use of RCM for suspect lesions reduces unnecessary excisions and assures the removal of aggressive melanomas at baseline in a real-life, clinical decision-making application for referral centers with RCM.","TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04789421."],"Aspect":"m","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"32317292","Document":["BACKGROUND: To compare the clinical efficacy of New York Esophageal squamous cell carcinoma-1 (NY-ESO-1) vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in a randomized, double-blind phase II study in participants with fully resected melanoma at high risk of recurrence.","METHODS: Participants with resected stage IIc, IIIb, IIIc and IV melanoma expressing NY-ESO-1 were randomized to treatment with three doses of NY-ESO-1\/ISCOMATRIX or ISCOMATRIX adjuvant administered intramuscularly at 4-week intervals, followed by a further dose at 6 months.","Primary endpoint was the proportion free of relapse at 18 months in the intention-to-treat (ITT) population and two per-protocol populations.","Secondary endpoints included relapse-free survival (RFS) and overall survival (OS), safety and NY-ESO-1 immunity.","RESULTS: The ITT population comprised 110 participants, with 56 randomized to NY-ESO-1\/ISCOMATRIX and 54 to ISCOMATRIX alone.","No significant toxicities were observed.","There were no differences between the study arms in relapses at 18 months or for median time to relapse; 139 vs 176 days (p=0.296), or relapse rate, 27 (48.2%) vs 26 (48.1%) (HR 0.913; 95% CI 0.402 to 2.231), respectively.","RFS and OS were similar between the study arms.","Vaccine recipients developed strong positive antibody responses to NY-ESO-1 (p\u22640.0001) and NY-ESO-1-specific CD4+ and CD8+ responses.","Biopsies following relapse did not demonstrate differences in NY-ESO-1 expression between the study populations although an exploratory study demonstrated reduced (NY-ESO-1)+\/Human Leukocyte Antigen (HLA) class I+ double-positive cells in biopsies from vaccine recipients performed on relapse in 19 participants.","CONCLUSIONS: The vaccine was well tolerated, however, despite inducing antigen-specific immunity, it did not affect survival endpoints.","Immune escape through the downregulation of NY-ESO-1 and\/or HLA class I molecules on tumor may have contributed to relapse."],"Aspect":"a","Summary":"The study aims to compare the clinical efficacy of the NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in a randomized, double-blind phase II study in participants with fully resected melanoma at high risk of recurrence.","Indexes":[0],"Sentences":["BACKGROUND: To compare the clinical efficacy of New York Esophageal squamous cell carcinoma-1 (NY-ESO-1) vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in a randomized, double-blind phase II study in participants with fully resected melanoma at high risk of recurrence."],"Revise":false}
{"PMID":"34101300","Document":["To evaluate the feasibility of adoptive cell therapy (ACT) using ex vivo-expanded tumor-infiltrating lymphocytes (TILs) in Japanese patients with melanoma who failed immune-checkpoint inhibitor therapy, an open-label, single-arm, pilot study was conducted.","We investigated the immunological and genetic factors of the pretreatment tumor and expanded TILs that may be associated with the clinical response.","The treatment protocol comprised preparation of TIL culture, lympho-depleting non-myeloablative preconditioning with cyclophosphamide and fludarabine, TIL infusion, and intravenous administration of low-dose IL-2.","Three patients of clinical subtypes mucosal, superficial spreading, and acral melanoma underwent TIL-ACT.","Most severe adverse events, including fever and leukopenia, were manageable with the supportive regimen specified in the protocol, suggesting that the TIL-ACT regimen is suitable for Japanese patients with melanoma.","One patient showed a short-term partial response, one relatively long-stable disease, and one experienced disease progression.","Whole-exome and transcriptional sequencing of isolated tumor cells and immunohistochemical analyses before TIL-ACT revealed various immunostimulatory factors, including a high tumor mutation burden and immune cell-recruiting chemokines, as well as various immunosuppressive factors including TGF-\u03b2, VEGF, Wnt\/\u03b2-catenin, and MAPK signaling and epithelial-to-mesenchymal transition, which might influence the efficacy of TIL-ACT.","Our results imply mechanisms for the antitumor effect of and resistance to TIL-ACT.","Further studies of immune-resistant mechanisms of TIL-ACT are warranted.","This study is registered with the UMIN Clinical Trial Registry (UMIN 000011431)."],"Aspect":"s","Summary":"Most severe adverse events, including fever and leukopenia, were manageable with the supportive regimen specified in the protocol.","Indexes":[4],"Sentences":["Most severe adverse events, including fever and leukopenia, were manageable with the supportive regimen specified in the protocol, suggesting that the TIL-ACT regimen is suitable for Japanese patients with melanoma."],"Revise":false}
{"PMID":"31699709","Document":["Given its ability to induce both humoral and cellular immune responses, NY-ESO-1 has been considered a suitable antigen for a cancer vaccine.","Despite promising results from early-phase clinical studies in patients with melanoma, NY-ESO-1 vaccine immunotherapy has not been widely investigated in larger trials; consequently, many questions remain as to the optimal vaccine formulation, predictive biomarkers, and sequencing and timing of vaccines in melanoma treatment.","We conducted an adjuvant phase I\/II clinical trial in high-risk resected melanoma to optimize the delivery of poly-ICLC, a TLR-3\/MDA-5 agonist, as a component of vaccine formulation.","A phase I dose-escalation part was undertaken to identify the MTD of poly-ICLC administered in combination with NY-ESO-1 and montanide.","This was followed by a randomized phase II part investigating the MTD of poly-ICLC with NY-ESO-1 with or without montanide.","The vaccine regimens were generally well tolerated, with no treatment-related grade 3\/4 adverse events.","Both regimens induced integrated NY-ESO-1-specific CD4+ T-cell and humoral responses.","CD8+ T-cell responses were mainly detected in patients receiving montanide.","T-cell avidity toward NY-ESO-1 peptides was higher in patients vaccinated with montanide.","In conclusion, NY-ESO-1 protein in combination with poly-ICLC is safe, well tolerated, and capable of inducing integrated antibody and CD4+ T-cell responses in most patients.","Combination with montanide enhances antigen-specific T-cell avidity and CD8+ T-cell cross-priming in a fraction of patients, indicating that montanide contributes to the induction of specific CD8+ T-cell responses to NY-ESO-1."],"Aspect":"s","Summary":"The vaccine regimens were generally well tolerated, with no treatment-related grade 3\/4 adverse events.","Indexes":[5],"Sentences":["The vaccine regimens were generally well tolerated, with no treatment-related grade 3\/4 adverse events."],"Revise":false}
{"PMID":"36657497","Document":["PURPOSE: We hypothesized that concurrent ipilimumab with chemoradiationtherapy (chemoRT) followed by maintenance nivolumab would be safe for patients with unresectable stage III non-small cell lung cancer (NSCLC).","We aimed to assess the safety (phase 1) and the 12-month progression-free survival (PFS) (phase 2) in a multi-institution prospective trial.","METHODS AND MATERIALS: Eligible patients had unresectable stage III NSCLC.","The treatment included platinum doublet chemotherapy with concurrent thoracic radiation therapy to 60 Gy in 30 fractions and ipilimumab (1 mg\/kg) delivered during weeks 1 and 4.","After chemoRT, maintenance nivolumab (480 mg) was given every 4 weeks for up to 12 cycles.","Adverse events (AEs) were assessed according to the Common Terminology Criteria for Adverse Events, version 5.0.","Survival analyses were performed with Kaplan Meier (KM) methods and log-rank tests.","RESULTS: The trial was discontinued early after enrolling 19 patients without proceeding to the phase 2 component because of unacceptable toxicity.","Sixteen patients (84%) had grade \u22653 (G3+) possible treatment-related toxicity, most commonly pulmonary AEs (n\u00a0=\u00a08, 42%).","Fourteen patients (74%) discontinued study therapy early because of AEs (n\u00a0=\u00a012, 63%) or patient choice (n\u00a0=\u00a02, 11%).","Eleven patients (58%) experienced G2+ pulmonary toxicity with median time to onset 4.1 months (95% CI 2.6-not reached [NR]), and 12-month freedom from G2+ pulmonary toxicity 37% (95% CI, 16-59).","Five patients had G5 AEs, including 3 with G5 pulmonary AEs (1 respiratory failure with pneumonitis and pulmonary embolism, 1 pneumonia\/chronic obstructive pulmonary disease exacerbation, 1 pulmonary fibrosis).","Despite toxicities, the median PFS was 19.2 months (95% CI 6.1-NR) and the median overall survival was NR (95% CI 6.1-NR) with median follow-up of 30.1 months by the reverse KM method.","CONCLUSIONS: Concurrent ipilimumab with chemoRT for unresectable stage III NSCLC is associated with pulmonary toxicity that may limit opportunities for improved outcomes.","Future studies aiming to incorporate ipilimumab or other anti-CTLA4 therapies into management of unresectable stage III NSCLC should consider careful measures to minimize toxicity risk."],"Aspect":"i","Summary":"Eligible patients received platinum doublet chemotherapy with concurrent thoracic radiation therapy (60 Gy in 30 fractions) and ipilimumab (1 mg\/kg) during weeks 1 and 4, followed by maintenance nivolumab (480 mg) every 4 weeks for up to 12 cycles.","Indexes":[3,4],"Sentences":["The treatment included platinum doublet chemotherapy with concurrent thoracic radiation therapy to 60 Gy in 30 fractions and ipilimumab (1 mg\/kg) delivered during weeks 1 and 4.","After chemoRT, maintenance nivolumab (480 mg) was given every 4 weeks for up to 12 cycles."],"Revise":true}
{"PMID":"37845511","Document":["Patients with resected stage IIB\/C melanoma have high recurrence risk, similar to those with resected stage IIIA\/B disease.","The phase 3, double-blind CheckMate 76K trial assessed 790 patients with resected stage IIB\/C melanoma randomized 2:1 (stratified by tumor category) to nivolumab 480\u2009mg or placebo every 4\u2009weeks for 12\u2009months.","The primary endpoint was investigator-assessed recurrence-free survival (RFS).","Secondary endpoints included distant metastasis-free survival (DMFS) and safety.","At 7.8\u2009months of minimum follow-up, nivolumab significantly improved RFS versus placebo (hazard ratio (HR)\u2009=\u20090.42; 95% confidence interval (CI): 0.30-0.59; P\u2009<\u20090.0001), with 12-month RFS of 89.0% versus 79.4% and benefit observed across subgroups; DMFS was also improved (HR\u2009=\u20090.47; 95% CI: 0.30-0.72).","Treatment-related grade 3\/4 adverse events occurred in 10.3% (nivolumab) and 2.3% (placebo) of patients.","One treatment-related death (0.2%) occurred with nivolumab.","Nivolumab is an effective and generally well-tolerated adjuvant treatment in patients with resected stage IIB\/C melanoma.","ClinicalTrials.gov identifier: NCT04099251 ."],"Aspect":"i","Summary":"The phase 3, double-blind CheckMate 76K trial assessed patients with resected stage IIB\/C melanoma randomized to nivolumab 480 mg or placebo every 4 weeks for 12 months to evaluate recurrence-free survival.","Indexes":[1],"Sentences":["The phase 3, double-blind CheckMate 76K trial assessed 790 patients with resected stage IIB\/C melanoma randomized 2:1 (stratified by tumor category) to nivolumab 480\u2009mg or placebo every 4\u2009weeks for 12\u2009months."],"Revise":false}
{"PMID":"33934532","Document":["The risk factors affecting acral melanoma metastasis and prognosis remain unclear.","The study included 168 patients with invasive acral melanoma who were followed for \u22653\u00a0years.","We evaluated patient demographics, stages, clinicopathological features, anatomic site of melanoma including nail versus volar surface, and degree of melanoma pigmentations, sentinel lymph node biopsy results, and the first metastasis sites.","Of the 168 patients (mean age 64.5\u00a0years; 52.4% male), 43 (25.6%) had invasive melanoma without metastasis, 113 (67.3%) had invasive melanoma with a first lymph node metastasis, and 12 (7.1%) had invasive melanoma with invasive melanoma with a first distant metastasis.","Advanced T stage, high mitotic rate, ulceration, and the degree of pigmentation were significant risk factors for metastasis.","Amelanotic and mild pigmentation of acral melanoma was associated with first distant metastasis, whereas heavy pigmentation was associated with first lymph node metastasis.","Advanced TNM stages, high mitotic rate, volar location (hazard ratio\u00a0=\u00a02.24, 95% confidence interval 1.18-4.26), and low-pigmentation (hazard ratio\u00a0=\u00a02.02, 95% confidence interval 1.17-3.49) were associated with melanoma-specific mortality."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"35661157","Document":["Neoadjuvant ipilimumab and nivolumab induces high pathologic response rates (pRRs) in clinical stage III nodal melanoma, and pathologic response is strongly associated with prolonged relapse-free survival (RFS).","The PRADO extension cohort of the OpACIN-neo trial ( NCT02977052 ) addressed the feasibility and effect on clinical outcome of using pathologic response after neoadjuvant ipilimumab and nivolumab as a criterion for further treatment personalization.","In total, 99 patients with clinical stage IIIb-d nodal melanoma were included and treated with 6\u2009weeks of neoadjuvant ipilimumab 1\u2009mg\u2009kg-1 and nivolumab 3\u2009mg\u2009kg-1.","In patients achieving major pathologic response (MPR, \u226410% viable tumor) in their index lymph node (ILN, the largest lymph node metastasis at baseline), therapeutic lymph node dissection (TLND) and adjuvant therapy were omitted.","Patients with pathologic partial response (pPR; >10 to \u226450% viable tumor) underwent TLND only, whereas patients with pathologic non-response (pNR; >50% viable tumor) underwent TLND and adjuvant systemic therapy \u00b1 synchronous radiotherapy.","Primary objectives were confirmation of pRR (ILN, at week 6) of the winner neoadjuvant combination scheme identified in OpACIN-neo; to investigate whether TLND can be safely omitted in patients achieving MPR; and to investigate whether RFS at 24\u2009months can be improved for patients achieving pNR.","ILN resection and ILN-response-tailored treatment were feasible.","The pRR was 72%, including 61% MPR.","Grade 3-4 toxicity within the first 12\u2009weeks was observed in 22 (22%) patients.","TLND was omitted in 59 of 60 patients with MPR, resulting in significantly lower surgical morbidity and better quality of life.","The 24-month relapse-free survival and distant metastasis-free survival rates were 93% and 98% in patients with MPR, 64% and 64% in patients with pPR, and 71% and 76% in patients with pNR, respectively.","These findings provide a strong rationale for randomized clinical trials testing response-directed treatment personalization after neoadjuvant ipilimumab and nivolumab."],"Aspect":"s","Summary":"Grade 3-4 toxicity was observed in 22% of patients within the first 12 weeks.","Indexes":[8],"Sentences":["Grade 3-4 toxicity within the first 12\u2009weeks was observed in 22 (22%) patients."],"Revise":false}
{"PMID":"33947696","Document":["PURPOSE: In BRAF V600MUT metastatic melanoma, cyclin D-CDK4\/6-INK4-Rb pathway alterations are involved in resistance to MAPK inhibitors, suggesting a clinical benefit of cyclin-dependent kinase 4 (CDK4) inhibitors.","In this phase I-II study, we aimed to establish the MTD of palbociclib when added to vemurafenib.","PATIENTS AND METHODS: Patients with BRAF V600E\/KMUT metastatic melanoma harboring CDKN2A loss and RB1 expression were included and stratified into two groups according to previous BRAF inhibitor treatment (no:strata 1; yes:strata 2).","Treatment comprised palbociclib once daily for 14 days followed by a 7-day break + continuous dosing of vemurafenib.","The primary endpoint was the occurrence of dose-limiting toxicity (DLT), and the secondary endpoints included the best response, survival, pharmacokinetics, and tumor molecular profiling.","RESULTS: Eighteen patients were enrolled, with 15 in strata 2.","Characteristics at inclusion were American Joint Committee on Cancer stage IVM1c (N = 16; 88.9%), high lactate dehydrogenase (N = 9; 50.0%), and median number of previous treatments of 2.","One and 5 patients experienced DLT in strata 1 and 2, respectively, defining the MTD at palbociclib 25 mg and vemurafenib 960 mg in strata 2.","No significant evidence for drug-drug interactions was highlighted.","The median progression-free survival was 2.8 months, and 5 (27.8%) patients showed a clinical response.","The baseline differential mRNA expression analysis and in vitro data revealed the role of CHEK2 in the response to palbociclib.","CONCLUSIONS: Although the combination of palbociclib + fixed-dose vemurafenib did not allow an increased palbociclib dosage above 25 mg, a significant clinical benefit was achieved in pretreated patients with melanoma.","An association between the transcriptomic data and clinical response was highlighted."],"Aspect":"i","Summary":"Patients with BRAF V600E\/KMUT metastatic melanoma were treated with palbociclib once daily for 14 days followed by a 7-day break plus continuous dosing of vemurafenib to establish the maximum tolerated dose (MTD) of palbociclib.","Indexes":[3,1],"Sentences":["Treatment comprised palbociclib once daily for 14 days followed by a 7-day break + continuous dosing of vemurafenib.","In this phase I-II study, we aimed to establish the MTD of palbociclib when added to vemurafenib."],"Revise":false}
{"PMID":"32147213","Document":["BACKGROUND: Interleukin 12 (IL-12) is a pivotal regulator of innate and adaptive immunity.","We conducted a prospective open-label, phase II clinical trial of electroporated plasmid IL-12 in advanced melanoma patients (NCT01502293).","PATIENTS AND METHODS: Patients with stage III\/IV melanoma were treated intratumorally with plasmid encoding IL-12 (tavokinogene telseplasmid; tavo), 0.5 mg\/ml followed by electroporation (six pulses, 1500 V\/cm) on days 1, 5, and 8 every 90 days in the main study and additional patients were treated in two alternative schedule exploration cohorts.","Correlative analyses for programmed death-ligand 1 (PD-L1), flow cytometry to assess changes in immune cell subsets, and analysis of immune-related gene expression were carried out on pre- and post-treatment samples from study patients, as well as from additional patients treated during exploration of additional dosing schedules beyond the pre-specified protocol dosing schedule.","Response was measured by study-specific criteria to maximize detection of latent and potentially transient immune responses in patients with multiple skin lesions and toxicities were graded by the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0).","RESULTS: The objective overall response rate was 35.7% in the main study (29.8% in all cohorts), with a complete response rate of 17.9% (10.6% in all cohorts).","The median progression-free survival in the main study was 3.7 months while the median overall survival was not reached at a median follow up of 29.7 months.","A total of 46% of patients in all cohorts with uninjected lesions experienced regression of at least one of these lesions and 25% had a net regression of all untreated lesions.","Transcriptomic and immunohistochemistry analysis showed that immune activation and co-stimulatory transcripts were up-regulated but there was also increased adaptive immune resistance.","CONCLUSIONS: Intratumoral Tavo was well tolerated and led to systemic immune responses in advanced melanoma patients.","While tumor regression and increased immune infiltration were observed in treated as well as untreated\/distal lesions, adaptive immune resistance limited the response."],"Aspect":"p","Summary":"The study involved patients with stage III\/IV melanoma who were treated with plasmid encoding IL-12.","Indexes":[1,2],"Sentences":["We conducted a prospective open-label, phase II clinical trial of electroporated plasmid IL-12 in advanced melanoma patients (NCT01502293).","PATIENTS AND METHODS: Patients with stage III\/IV melanoma were treated intratumorally with plasmid encoding IL-12 (tavokinogene telseplasmid; tavo), 0.5 mg\/ml followed by electroporation (six pulses, 1500 V\/cm) on days 1, 5, and 8 every 90 days in the main study and additional patients were treated in two alternative schedule exploration cohorts."],"Revise":false}
{"PMID":"31812554","Document":["BACKGROUND: Pembrolizumab is approved for the treatment of advanced cancer in adults; however, no information is available on safety and efficacy in paediatric patients.","We aimed to establish the recommended phase 2 dose of pembrolizumab and its safety and antitumour activity in advanced paediatric cancer.","METHODS: KEYNOTE-051 is an ongoing phase 1-2 open-label trial.","In this interim analysis, children aged 6 months to 17 years were recruited at 30 hospitals located in Australia, Brazil, Canada, France, Germany, Israel, Italy, South Korea, Sweden, the UK, and the USA.","Patients with melanoma or a centrally confirmed, PD-L1-positive, relapsed or refractory solid tumour or lymphoma, and a Lansky Play\/Karnofsky Performance status score of 50 or higher, received intravenous pembrolizumab at an initial dose of 2 mg\/kg every 3 weeks.","Pharmacokinetics and dose-limiting toxicities were used to establish the recommended phase 2 dose, and the safety and antitumour activity of this dose were assessed.","Primary endpoints were determination of dose-limiting toxicities at the maximum administered dose, safety and tolerability, and the proportion of patients with objective response to pembrolizumab for each tumour type according to the Response Evaluation Criteria in Solid Tumours version 1.1 or the International Neuroblastoma Response Criteria.","Safety and efficacy were assessed in all treated patients who received at least one dose of pembrolizumab.","Separate reporting of the cohort of patients with relapsed or refractory classical Hodgkin lymphoma was a post-hoc decision.","The data cutoff for this interim analysis was Sept 3, 2018.","This trial is still enrolling patients and is registered with ClinicalTrials.gov, number NCT02332668.","FINDINGS: Of 863 patients screened between March 23, 2015, and Sept 3, 2018, 796 had tumours that were evaluable for PD-L1 expression (278 [35%] were PD-L1-positive); 155 eligible patients were enrolled and 154 had at least one dose of pembrolizumab.","The median age of the enrolled patients was 13 years (IQR 8-15).","Median follow-up was 8\u00b76 months (IQR 2\u00b75-16\u00b74).","No dose-limiting toxicities were reported in phase 1, and pembrolizumab plasma concentrations were consistent with those previously reported in adults; the recommended phase 2 dose was therefore established as 2 mg\/kg every 3 weeks.","Of the 154 patients treated, 69 (45%) experienced grade 3-5 adverse events, most commonly anaemia in 14 (9%) patients and decreased lymphocyte count in nine (6%) patients.","13 (8%) of the 154 patients had grade 3-5 treatment-related adverse events, most commonly decreased lymphocyte count in three (2%) patients and anaemia in two (1%) patients.","14 (9%) patients had serious treatment-related adverse events, most commonly pyrexia (four [3%]), and hypertension and pleural effusion (two [1%] each).","Four patients (3%) discontinued treatment because of treatment-related adverse events, and two (1%) died (one due to pulmonary oedema and one due to pleural effusion and pneumonitis).","Of 15 patients with relapsed or refractory Hodgkin lymphoma, two had complete and seven had partial responses; thus, nine patients achieved an objective response (60\u00b70%; 95% CI 32\u00b73-83\u00b77).","Of 136 patients with solid tumours and other lymphomas, eight had partial responses (two patients each with adrenocortical carcinoma and mesothelioma, and one patient each with malignant ganglioglioma, epithelioid sarcoma, lymphoepithelial carcinoma, and malignant rhabdoid tumour); the proportion of patients with an objective response was 5\u00b79% (95% CI 2\u00b76-11\u00b73).","INTERPRETATION: Pembrolizumab was well tolerated and showed encouraging antitumour activity in paediatric patients with relapsed or refractory Hodgkin lymphoma, consistent with experience in adult patients.","Pembrolizumab had low antitumour activity in the majority of paediatric tumour types, and responses were observed in only a few rare PD-L1-positive tumour types, suggesting that PD-L1 expression alone is not sufficient as a biomarker for the selection of paediatric patients who are likely to respond to PD-1 checkpoint inhibitors.","Final results of KEYNOTE-051, expected by September, 2022, with the possibility for extension, will report further on the activity of pembrolizumab in Hodgkin lymphoma, microsatellite instability-high tumours, and melanoma.","FUNDING: Merck Sharp & Dohme, a subsidiary of Merck & Co."],"Aspect":"i","Summary":"The study used a phase 1-2 open-label trial (KEYNOTE-051) to establish the recommended phase 2 dose of pembrolizumab and assess its safety and antitumour activity in advanced paediatric cancer patients, who received intravenous pembrolizumab at an initial dose of 2 mg\/kg every 3 weeks.","Indexes":[2,4,5],"Sentences":["METHODS: KEYNOTE-051 is an ongoing phase 1-2 open-label trial.","Patients with melanoma or a centrally confirmed, PD-L1-positive, relapsed or refractory solid tumour or lymphoma, and a Lansky Play\/Karnofsky Performance status score of 50 or higher, received intravenous pembrolizumab at an initial dose of 2 mg\/kg every 3 weeks.","Pharmacokinetics and dose-limiting toxicities were used to establish the recommended phase 2 dose, and the safety and antitumour activity of this dose were assessed."],"Revise":true}
{"PMID":"35138335","Document":["IMPORTANCE: Neoadjuvant checkpoint inhibition in patients with high-risk stage III melanoma shows high pathologic response rates associated with a durable relapse-free survival.","Whether a therapeutic lymph node dissection (TLND) can be safely omitted when a major pathologic response in the largest lymph node metastasis at baseline (index lymph node; ILN) is obtained is currently being investigated.","A previous small pilot study (n\u2009=\u200912) showed that the response in the ILN may be representative of the pathologic response in the entire TLND specimen.","OBJECTIVE: To assess the concordance of response between the ILN and the total lymph node bed in a larger clinical trial population.","DESIGN, SETTING, AND PARTICIPANTS: Retrospective pathologic response analysis of a multicenter clinical trial population of patients from the randomized Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients (OpACIN) and Optimal Neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo) trials.","Included patients were treated with 6 weeks neoadjuvant ipilimumab plus nivolumab.","Patient inclusion into the trials was conducted from August 12, 2015, to October 24, 2016 (OpACIN), and November 24, 2016, and June 28, 2018 (OpACIN-neo).","Data were analyzed from April 1, 2020, to August 31, 2021.","MAIN OUTCOMES AND MEASURES: Concordance of the pathologic response between the ILN and the TLND tumor bed.","The pathologic response of the ILN was retrospectively assessed according to the International Neoadjuvant Melanoma Consortium criteria and compared with the pathologic response of the entire TLND specimen.","RESULTS: A total of 82 patients treated with neoadjuvant ipilimumab and nivolumab followed by TLND (48 [59%] were male; median age, 58.5 [range, 18-80] years) were included.","The pathologic response in the ILN was concordant with the entire TLND specimen response in 81 of 82 patients (99%) and in 79 of 82 patients (96%) concordant when comparing the ILN response with the response in every individual lymph node.","In the single patient with a discordant response, the ILN response (20% viable tumor, partial pathologic response) underestimated the entire TLND specimen response (5% viable, near-complete pathologic response).","Two other patients each had 1 small nonindex node that contained 80% viable tumor (pathologic nonresponse) whereas all other lymph nodes (including the ILN) showed a partial pathologic response.","In these 2 patients, the risk of regional relapse might potentially have been increased if TLND had been omitted.","CONCLUSIONS AND RELEVANCE: The results of this study suggest that the pathologic response of the ILN may be considered a reliable indicator of the entire TLND specimen response and may support the ILN response-directed omission of TLND in a prospective trial."],"Aspect":"d","Summary":"The treatment duration was 6 weeks of neoadjuvant ipilimumab plus nivolumab.","Indexes":[5],"Sentences":["Included patients were treated with 6 weeks neoadjuvant ipilimumab plus nivolumab."],"Revise":false}
{"PMID":"33105036","Document":["LESSONS LEARNED: The overall safety profiles of ipilimumab 3 mg\/kg and 10 mg\/kg administered every 3\u2009weeks, were consistent between Chinese patients with solid tumors in the current study and patients from previous U.S. ipilimumab monotherapy studies.","No new safety signals were identified.","The mean systemic exposures to ipilimumab (assessed by first dose area under the curve during the dosing interval and maximum serum concentration) were numerically lower in the Chinese patient population than in U.S. patients for both 3 mg\/kg and 10 mg\/kg doses; however, the range of serum concentrations in the Chinese and U.S. populations overlapped (3 mg\/kg and 10 mg\/kg), suggesting that ipilimumab pharmacokinetics was ethnically insensitive in this study.","BACKGROUND: This phase I, open-label study assessed ipilimumab safety, tolerability, pharmacokinetics (PK), immunogenicity, and antitumor activity in Chinese patients with unresectable, metastatic, recurrent malignant melanoma (MM) or nasopharyngeal carcinoma (NPC).","METHODS: Of 39 patients enrolled, 25 received ipilimumab (11 patients received 3 mg\/kg, and 14 patients received 10 mg\/kg).","Reasons for not receiving treatment were withdrawal of consent (3 patients), no longer meeting the criteria (10 patients), and one recorded as \"other.\"","During the induction phase, patients received ipilimumab (3 mg\/kg, i.v.","), on day 1 of a 3-week cycle, to a maximum of four doses or progressive disease (PD).","During the maintenance phase at week 24, patients received ipilimumab (3 mg\/kg, i.v.)","on day 1 of a 12-week cycle, to a maximum of 3\u2009years or PD.","Considering the co-primary safety and PK endpoints, the successive dosing required nine patients with two or fewer dose-limiting toxicities during the 42-day observation period to proceed with a new cohort of nine patients at 10 mg\/kg.","RESULTS: Ipilimumab safety and PK profiles were similar in Chinese and predominantly White populations.","Ipilimumab was well tolerated.","Most adverse events (AEs) were grades 1-2 and experienced by 11 patients treated with 3 mg\/kg and 14 patients treated with 10 mg\/kg.","There were no new safety concerns.","Incidence of anti-ipilimumab antibodies was low (1 of 10 in the 3 mg\/kg patients and 2 of 13 in the 10 mg\/kg patients) and without safety implications.","In the 3 mg\/kg group, 8 of 11 patients had PD.","In the 10 mg\/kg group (all NPC, 0\u2009MM patients), 11 of 14 patients had PD.","Three patients had stable disease (one at 3 mg\/kg and two at 10 mg\/kg).","CONCLUSION: Ipilimumab was well tolerated in Chinese patients, showing similar safety and PK to previous studies in predominantly White populations."],"Aspect":"o","Summary":"The study found that ipilimumab was well tolerated and had a similar safety and pharmacokinetic profile in Chinese patients as in predominantly White populations.","Indexes":[11,12,19],"Sentences":["RESULTS: Ipilimumab safety and PK profiles were similar in Chinese and predominantly White populations.","Ipilimumab was well tolerated.","CONCLUSION: Ipilimumab was well tolerated in Chinese patients, showing similar safety and PK to previous studies in predominantly White populations."],"Revise":false}
{"PMID":"32995974","Document":["OBJECTIVES: To compare tumor best overall response (BOR) by RECIST 1.1 and iRECIST, to explore the incidence of pseudoprogression in melanoma treated with pembrolizumab, and to assess the impact of pseudoprogression on overall survival (OS).","METHODS: A total of 221 patients with locally advanced\/unresectable melanoma who received pembrolizumab as part of KEYNOTE-002 trial were included in this study.","Radiological assessment of imaging was centrally reviewed to assess tumor response.","Incidence of discordance in BOR between RECIST 1.1 and iRECIST as well as rate of pseudoprogression were measured.","OS of patients with pseudoprogression was compared with that of those with uncontrolled disease.","RESULTS: Of the 221 patients in this cohort, 136 patients developed PD as per RECIST v1.1 and 78 patients with PD continued treatment and imaging beyond initial RECIST 1.1-defined PD.","Among the 78 patients who continued therapy and imaging post-progression, RECIST 1.1 and iRECIST were discordant in 10 patients (12.8%) and pseudoprogression was encountered in 14 patients (17.9%).","OS of patients with pseudoprogression was longer than that of patients with uncontrolled disease\/true progression (29.9\u00a0months versus 8.0\u00a0months, p value <\u20090.001).","CONCLUSIONS: Effectiveness of immunotherapy in clinical trials depends on the criterion used to assess tumor response (RECIST 1.1 vs iRECIST) with iRECIST being more appropriate to detect pseudoprogression and potentially prevent premature termination of effective therapy.","Pseudoprogression was associated with improved OS in comparison with that of patients with uncontrolled disease.","KEY POINTS: \u2022 Discordance between iRECIST and RECIST 1.1 was found in 12.8% of unresectable melanoma patients on pembrolizumab who continued therapy beyond initial RECIST 1.1-defined progression.","\u2022 Pseudoprogression, captured with iRECIST, occurred in 17.9% and was significantly associated with improved overall survival in comparison with uncontrolled disease."],"Aspect":"m","Summary":"The study involved the use of pembrolizumab in patients with locally advanced\/unresectable melanoma as part of the KEYNOTE-002 trial.","Indexes":[1],"Sentences":["METHODS: A total of 221 patients with locally advanced\/unresectable melanoma who received pembrolizumab as part of KEYNOTE-002 trial were included in this study."],"Revise":false}
{"PMID":"34035112","Document":["BACKGROUND: Experimental cancer vaccines are traditionally administered by injection in subcutaneous tissue or muscle, commonly with adjuvants that create chronic inflammatory depots.","Injection of melanoma-derived peptides induces T cell responses; however, the depots that form following injection may inhibit optimization of the immune response.","In skin, epidermal Langerhans cells (LC) are a dominant source of professional antigen presenting cells.","We hypothesized that: (1) applying melanoma-derived peptides topically, in proximity to LC, could be immunogenic and safe, with low vaccine-site toxicity and (2) topical toll-like receptor 7 (TLR7) agonist would increase immunogenicity of the peptide vaccine.","METHODS: Twelve melanoma peptides plus a tetanus helper peptide were combined with granulocyte macrophage colony stimulating factor (GM-CSF) and were administered topically on days 1, 8, and 15, to 28 patients randomized to one of four adjuvant preparations: (1) incomplete Freund's adjuvant (IFA); (2) IFA plus a TLR7 agonist (imiquimod) administered on days 0, 7, 14; (3) dimethyl sulfoxide (DMSO) or (4) DMSO+ imiquimod administered on day 0, 7, 14.","Every 3 weeks thereafter (x 6), the peptides were combined with GM-CSF and were injected into the dermis and subcutis in an emulsion with IFA.","Toxicities were recorded and immune responses assayed by ELIspot.","RESULTS: CD8+ T cell responses to transdermal vaccination in DMSO occurred in 83% of participants in group 3 and 86% in group 4, and responses to vaccination in IFA were observed in 29% of participants in group 1 and 14% in group 2.","Overall, 61% of participants had CD4+ T cell immune responses to the tetanus peptide, with large, durable responses in groups 3 and 4.","Five of seven participants in group 4 had a severe rash, one that was dose limiting.","Ten-year overall survival was 67% and disease-free survival was 44%.","CONCLUSIONS: These data provide proof of principle for immunogenicity in humans of transdermal immunization using peptides in DMSO.","Further study is warranted into the pharmacokinetics and immunobiology of TLR agonists as vaccine adjuvants during transcutaneous application.","Overall survival is high, supporting further investigation of this immunization approach."],"Aspect":"m","Summary":"The study used twelve melanoma peptides plus a tetanus helper peptide combined with granulocyte macrophage colony stimulating factor (GM-CSF) and various adjuvants including incomplete Freund's adjuvant (IFA), TLR7 agonist (imiquimod), and dimethyl sulfoxide (DMSO).","Indexes":[4,5],"Sentences":["METHODS: Twelve melanoma peptides plus a tetanus helper peptide were combined with granulocyte macrophage colony stimulating factor (GM-CSF) and were administered topically on days 1, 8, and 15, to 28 patients randomized to one of four adjuvant preparations: (1) incomplete Freund's adjuvant (IFA); (2) IFA plus a TLR7 agonist (imiquimod) administered on days 0, 7, 14; (3) dimethyl sulfoxide (DMSO) or (4) DMSO+ imiquimod administered on day 0, 7, 14.","Every 3 weeks thereafter (x 6), the peptides were combined with GM-CSF and were injected into the dermis and subcutis in an emulsion with IFA."],"Revise":false}
{"PMID":"32820818","Document":["BACKGROUND: Two recent publications have reported that a shorter interval between preoperative lymphoscintigraphy and sentinel node biopsy (SNB) is associated with improved survival of patients with primary cutaneous melanoma.","The aims of this study were to analyse prospectively collected survival data for patients who had SNB on the same day as lymphoscintigraphy or the day after; and to assess tracer migration from sentinel nodes to second-tier nodes after lymphoscintigraphy on the previous day.","METHODS: Outcome data were obtained for patients who had lymphoscintigraphy and SNB on the same day (time interval less than 8\u2009h) or the next day (interval more than 16\u2009h).","In a separate prospective cohort, same-day and next-day lymphoscintigraphic images of sentinel nodes and second-tier nodes were compared.","RESULTS: Following lymphoscintigraphy, 2848 patients had same-day and 3328 had next-day SNB.","Survival outcomes did not differ between these groups.","In a prospectively studied cohort of 30 patients, none had significant tracer migration from sentinel nodes to second-tier nodes on imaging the following day.","CONCLUSION: No difference in survival after same- or next-day sentinel node biopsy is seen when 99m Tc-labelled antimony sulphide colloid is used.","This may be because of less tracer migration to second-tier nodes.","ANTECEDENTES: Dos publicaciones recientes han se\u00f1alado que reducir el intervalo entre la linfograf\u00eda isot\u00f3pica preoperatoria y la biopsia del ganglio centinela (sentinel node biopsy, SNB) se asocia con una mejor supervivencia en pacientes con melanoma maligno primario.","Los objetivos de este estudio fueron los siguientes: (1) analizar los datos de supervivencia recogidos prospectivamente en pacientes en los que se realiza la SNB el mismo d\u00eda o al d\u00eda siguiente de la linfograf\u00eda isot\u00f3pica, y (2) evaluar la migraci\u00f3n del marcador desde los ganglios centinela a los ganglios de segundo nivel a partir de la linfograf\u00eda del d\u00eda anterior.","M\u00c9TODOS: Se analizaron los resultados de los pacientes a los que se realiz\u00f3 una linfograf\u00eda isot\u00f3pica y la SNB el mismo d\u00eda (intervalo de tiempo < 8 h) o al d\u00eda siguiente (intervalo > 16 h).","En una cohorte prospectiva diferente, se compararon las im\u00e1genes de los ganglios centinela y de los ganglios de segundo nivel en linfograf\u00edas isot\u00f3picas realizadas el mismo d\u00eda o al d\u00eda siguiente.","RESULTADOS: Tras la linfograf\u00eda isot\u00f3pica, se realiz\u00f3 la SNB el mismo d\u00eda en 2.848 pacientes y al d\u00eda siguiente en 3.328 pacientes.","No hubo diferencias en la supervivencia entre ambos grupos.","En una cohorte de 30 pacientes estudiada de forma prospectiva, no hubo migraci\u00f3n significativa del trazador de los ganglios centinela a los ganglios de segundo nivel en las im\u00e1genes obtenidas al d\u00eda siguiente.","CONCLUSI\u00d3N: La mejor supervivencia que se obtiene cuando se realiza la SNB poco despu\u00e9s de la linfograf\u00eda isot\u00f3pica podr\u00eda explicarse por una diferencia en la migraci\u00f3n del trazador a los ganglios de segundo nivel entre los dos marcadores utilizados: nanocoloide de alb\u00famina humana o coloide de sulfuro de antimonio, ambos marcados con 99mTc.","En este estudio y con este \u00faltimo marcador, no se observ\u00f3 migraci\u00f3n a ganglios de segundo nivel durante la noche."],"Aspect":"o","Summary":"No difference in survival outcomes was observed between same-day and next-day sentinel node biopsy, and no significant tracer migration to second-tier nodes was detected in next-day imaging.","Indexes":[4,5,6],"Sentences":["RESULTS: Following lymphoscintigraphy, 2848 patients had same-day and 3328 had next-day SNB.","Survival outcomes did not differ between these groups.","In a prospectively studied cohort of 30 patients, none had significant tracer migration from sentinel nodes to second-tier nodes on imaging the following day."],"Revise":true}
{"PMID":"38531663","Document":["INTRODUCTION: In a multicenter, open-label randomized phase 3 clinical trial conducted in the Netherlands and Denmark, treatment with ex vivo-expanded tumor-infiltrating lymphocytes (TIL-NKI\/CCIT) from autologous melanoma tumor compared with ipilimumab improved progression-free survival in patients with unresectable stage IIIC-IV melanoma after failure of first-line or second-line treatment.","Based on this trial, we conducted a cost-utility analysis.","METHODS: A Markov decision model was constructed to estimate expected costs (expressed in 2021\u20ac) and outcomes (quality-adjusted life years (QALYs)) of TIL-NKI\/CCIT versus ipilimumab in the Netherlands.","The Danish setting was assessed in a scenario analysis.","A modified societal perspective was applied over a lifetime horizon.","TIL-NKI\/CCIT production costs were estimated via activity-based costing.","Through sensitivity analyses, uncertainties and their impact on the incremental cost-effectiveness ratio (ICER) were assessed.","RESULTS: Mean total undiscounted lifetime benefits were 4.47 life years (LYs) and 3.52 QALYs for TIL-NKI\/CCIT and 3.33 LYs and 2.46 QALYs for ipilimumab.","Total lifetime undiscounted costs in the Netherlands were \u20ac347,168 for TIL-NKI\/CCIT (including \u20ac67,547 for production costs) compared with \u20ac433,634 for ipilimumab.","Undiscounted lifetime cost in the Danish scenario were \u20ac337,309 and \u20ac436,135, respectively.","This resulted in a dominant situation for TIL-NKI\/CCIT compared with ipilimumab in both countries, meaning incremental QALYs were gained at lower costs.","Survival probabilities, and utility in progressive disease affected the ICER most.","CONCLUSION: Based on the data of a randomized phase 3 trial, treatment with TIL-NKI\/CCIT in patients with unresectable stage IIIC-IV melanoma is cost-effective and cost-saving, both in the current Dutch and Danish setting.","These findings led to inclusion of TIL-NKI\/CCIT as insured care and treatment guidelines.","Publicly funded development of the TIL-NKI\/CCIT cell therapy shows realistic promise to further explore development of effective personalized treatment while warranting economic sustainability of healthcare systems."],"Aspect":"m","Summary":"The trial compared treatment with ex vivo-expanded tumor-infiltrating lymphocytes (TIL-NKI\/CCIT) from autologous melanoma tumor with ipilimumab in patients with unresectable stage IIIC-IV melanoma.","Indexes":[0],"Sentences":["INTRODUCTION: In a multicenter, open-label randomized phase 3 clinical trial conducted in the Netherlands and Denmark, treatment with ex vivo-expanded tumor-infiltrating lymphocytes (TIL-NKI\/CCIT) from autologous melanoma tumor compared with ipilimumab improved progression-free survival in patients with unresectable stage IIIC-IV melanoma after failure of first-line or second-line treatment."],"Revise":false}
{"PMID":"35466524","Document":["Metastatic uveal melanoma (UM) is a devastating disease with few treatment options.","We evaluated the safety, tolerability and preliminary activity of arginine depletion using pegylated arginine deiminase (ADI-PEG20; pegargiminase) combined with pemetrexed (Pem) and cisplatin (Cis) chemotherapy in a phase 1 dose-expansion study of patients with argininosuccinate synthetase (ASS1)-deficient metastatic UM.","Eligible patients received up to six cycles of Pem (500\u2009mg\/m2 ) and Cis (75\u2009mg\/m2 ) every 3\u2009weeks plus weekly intramuscular ADI (36\u2009mg\/m2 ), followed by maintenance ADI until progression (NCT02029690).","Ten of fourteen ASS1-deficient patients with UM liver metastases and a median of one line of prior immunotherapy received ADIPemCis.","Only one \u2265 grade 3 adverse event of febrile neutropenia was reported.","Seven patients had stable disease with a median progression-free survival of 3.0\u00a0months (range, 1.3-8.1) and a median overall survival of 11.5\u00a0months (range, 3.2-36.9).","Despite anti-ADI-PEG20 antibody emergence, plasma arginine concentrations remained suppressed by 18\u2009weeks with a reciprocal increase in plasma citrulline.","Tumour rebiopsies at progression revealed ASS1 re-expression as an escape mechanism.","ADIPemCis was well tolerated with modest disease stabilisation in metastatic UM.","Further investigation of arginine deprivation is indicated in UM including combinations with immune checkpoint blockade and additional anti-metabolite strategies."],"Aspect":"s","Summary":"Only one \u2265 grade 3 adverse event of febrile neutropenia was reported.","Indexes":[4],"Sentences":["Only one \u2265 grade 3 adverse event of febrile neutropenia was reported."],"Revise":false}
{"PMID":"35680383","Document":["PURPOSE: Although recombinant human interleukin-15 (rhIL-15) has generated much excitement as an immunotherapeutic agent for cancer, activity in human clinical trials has been modest to date, in part due to the risks of toxicity with significant dose escalation.","Since pulmonary metastases are a major site of distant failure in human and dog cancers, we sought to investigate inhaled rhIL-15 in dogs with naturally occurring lung metastases from osteosarcoma (OSA) or melanoma.","We hypothesized a favorable benefit\/risk profile given the concentrated delivery to the lungs with decreased systemic exposure.","EXPERIMENTAL DESIGN: We performed a phase I trial of inhaled rhIL-15 in dogs with gross pulmonary metastases using a traditional 3+3 cohort design.","A starting dose of 10 \u00b5g twice daily \u00d7 14 days was used based on human, non-human primate, and murine studies.","Safety, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) were the primary objectives, while response rates, progression-free and overall survival (OS), and pharmacokinetic and immune correlative analyses were secondary.","RESULTS: From October 2018 to December 2020, we enrolled 21 dogs with 18 dogs reaching the 28-day response assessment to be evaluable.","At dose level 5 (70 \u03bcg), we observed two DLTs, thereby establishing 50 \u00b5g twice daily \u00d7 14 days as the MTD and recommended phase 2 dose.","Among 18 evaluable dogs, we observed one complete response >1 year, one partial response with resolution of multiple target lesions, and five stable disease for an overall clinical benefit rate of 39%.","Plasma rhIL-15 quantitation revealed detectable and sustained rhIL-15 concentrations between 1-hour and 6 hour postnebulization.","Decreased pretreatment lymphocyte counts were significantly associated with clinical benefit.","Cytotoxicity assays of banked peripheral blood mononuclear cells revealed significant increases in peak cytotoxicity against canine melanoma and OSA targets that correlated with OS.","CONCLUSIONS: In this first-in-dog clinical trial of inhaled rhIL-15 in dogs with advanced metastatic disease, we observed promising clinical activity when administered as a monotherapy for only 14 days.","These data have significant clinical and biological implications for both dogs and humans with refractory lung metastases and support exploration of combinatorial therapies using inhaled rhIL-15."],"Aspect":"i","Summary":"The study conducted a phase I trial of inhaled recombinant human interleukin-15 (rhIL-15) in dogs with naturally occurring lung metastases from osteosarcoma or melanoma, using a traditional 3+3 cohort design with a starting dose of 10 \u00b5g twice daily for 14 days.","Indexes":[1,3,4],"Sentences":["Since pulmonary metastases are a major site of distant failure in human and dog cancers, we sought to investigate inhaled rhIL-15 in dogs with naturally occurring lung metastases from osteosarcoma (OSA) or melanoma.","EXPERIMENTAL DESIGN: We performed a phase I trial of inhaled rhIL-15 in dogs with gross pulmonary metastases using a traditional 3+3 cohort design.","A starting dose of 10 \u00b5g twice daily \u00d7 14 days was used based on human, non-human primate, and murine studies."],"Revise":false}
{"PMID":"32976223","Document":["Uveal melanoma is a rare and aggressive malignancy and up to half of all patients will develop metastatic disease despite the effective treatment of the primary tumor.","Insulin-like growth factors I\/II play a fundamental role in the cell migration, proliferation, and apoptosis.","IMC-A12, a mAb specifically targets insulin-like growth factor type I receptor, has shown promise in preclinical studies.","We performed a multicenter phase II study for patients with metastatic uveal melanoma administered IMC-A12 10\u2009mg\/kg IV every two weeks until disease progression or unacceptable toxicity.","The primary endpoint was objective response (proportion of patients with complete or partial response), and secondary endpoints were disease control rate, progression-free survival, and overall survival.","A total of 18 patients enrolled in this study (10 males and eight females) with a median age.","Ten patients (55%) had stable disease, seven patients (38%) had progression as best overall response.","No partial response or complete response was observed; however, the disease control rate, defined as complete response + partial response + stable disease \u22653 months, was 50%.","Median progression-free survival was 3.1 months, and median overall survival was 13.8 months.","Adverse events of any grade occurred in 13 patients (72.2%).","Treatment-related grade 3 adverse events were rare, and there were no grade 4 or 5 related adverse events.","IMC-A12 was very well tolerated, however, showed limited clinical activity in uveal melanoma as a single agent.","Due to its low toxicity profile it could be studied in combination with other pathway-specific agents."],"Aspect":"m","Summary":"The study administered IMC-A12 at a dose of 10 mg\/kg IV every two weeks until disease progression or unacceptable toxicity.","Indexes":[3],"Sentences":["We performed a multicenter phase II study for patients with metastatic uveal melanoma administered IMC-A12 10\u2009mg\/kg IV every two weeks until disease progression or unacceptable toxicity."],"Revise":false}
{"PMID":"31584722","Document":["BACKGROUND: Patients with metastatic melanoma have variable responses to combination ipilimumab and nivolumab.","The objectives of this study were to examine the patterns of response and survival in patients treated with combination ipilimumab and anti-PD-1 therapy (IPI\u00a0+\u00a0PD1) and to explore the nature of pseudoprogression and acquired resistance.","METHODS: Patients with metastatic melanoma who received treatment with first-line IPI\u00a0+\u00a0PD1 had all metastases \u22655\u00a0mm measured on computed tomography\/magnetic resonance imaging studies.","The lesional response rate (LRR) and the overall response rate (ORR) were determined according to Response Evaluation Criteria in Solid Tumors, version 1.1.","RESULTS: In total, 140 patients who had 833 metastases were studied.","The ORR and the overall complete response (CR) rate decreased as tumor burden or the number of metastases increased.","Metastases that had a CR (49%) were smaller than metastases without a CR (median, 13 vs 17\u00a0mm; P\u00a0<\u00a0.0001).","Soft-tissue and lung metastases had the highest LRR (79% and 77%, respectively), whereas liver metastases had the lowest (46%).","In multivariate analysis, patients with lung metastases had superior ORR (odds ratio [OR], 2.75; P\u00a0=\u00a0.02) and progression-free survival (hazard ratio [HR], 0.46; P\u00a0=\u00a0.02), whereas those with liver metastases had inferior ORR (OR, 0.33; P\u00a0=\u00a0.02), progression-free survival (HR, 4.03; P\u00a0<\u00a0.01), and overall survival (HR, 3.17; P\u00a0=\u00a0.01).","Pseudoprogression occurred in one-third of patients who had progressive disease as their best response, with an overall survival that was comparable to that of patients without disease progression.","Acquired resistance occurred in 12% of responders after a median of 9.6\u00a0months, with an overall survival rate of 83% at 1\u00a0year from progression.","CONCLUSIONS: Metastases in different anatomical locations display distinct response patterns and also are associated with overall response and survival with combination immunotherapy.","Specific sites of disease may hold unique mechanisms of resistance and should allow for more personalized treatment."],"Aspect":"p","Summary":"The study involved 140 patients with metastatic melanoma who had 833 metastases.","Indexes":[4],"Sentences":["RESULTS: In total, 140 patients who had 833 metastases were studied."],"Revise":false}
{"PMID":"33771853","Document":["PURPOSE: As hypoxia can mediate resistance to immunotherapy, we investigated the safety, tolerability, and efficacy of combining evofosfamide, a prodrug that alleviates hypoxia, with ipilimumab, an immune checkpoint inhibitor, in immunologically \"cold\" cancers, which are intrinsically insensitive to immunotherapy, as well as in \"hot\/warm\" metastatic cancers that are, atypical of such cancers, resistant to immunotherapy.","PATIENTS AND METHODS: In a phase I, 3+3 dose-escalation trial (NCT03098160), evofosfamide (400-640 mg\/m2) and ipilimumab (3 mg\/kg) were administered in four 3-week cycles.","The former was administered on days 1 and 8 of cycles 1-2, while the latter was administered on day 8 of cycles 1-4.","Response was assessed using immune-related RECIST and retreatment was allowed, if deemed beneficial, after completion of cycle 4 or at progression.","RESULTS: Twenty-two patients were enrolled, of whom 21 were evaluable, encompassing castration-resistant prostate cancer (n = 11), pancreatic cancer (n = 7), immunotherapy-resistant melanoma (n = 2), and human papillomavirus-negative head and neck cancer (n = 1).","Drug-related hematologic toxicities, rash, fever, nausea, vomiting, and elevation of liver enzymes were observed in > 10% of patients.","The most common drug-related grade 3 adverse event was alanine aminotransferase elevation (33.3%).","Two patients discontinued ipilimumab and 4 required evofosfamide deescalation due to toxicity.","Of 18 patients with measurable disease at baseline, 3 (16.7%) achieved partial response and 12 (66.7%) achieved stable disease.","The best responses were observed at 560 mg\/m2 evofosfamide.","Preexisting immune gene signatures predicted response to therapy, while hypermetabolic tumors predicted progression.","Responders also showed improved peripheral T-cell proliferation and increased intratumoral T-cell infiltration into hypoxia.","CONCLUSIONS: No new or unexpected safety signals were observed from combining evofosfamide and ipilimumab, and evidence of therapeutic activity was noted."],"Aspect":"o","Summary":"The combination of evofosfamide and ipilimumab demonstrated no new or unexpected safety signals, with 16.7% of patients achieving partial response, 66.7% achieving stable disease, and evidence of improved T-cell proliferation and intratumoral T-cell infiltration in responders.","Indexes":[8,11,12],"Sentences":["Of 18 patients with measurable disease at baseline, 3 (16.7%) achieved partial response and 12 (66.7%) achieved stable disease.","Responders also showed improved peripheral T-cell proliferation and increased intratumoral T-cell infiltration into hypoxia.","CONCLUSIONS: No new or unexpected safety signals were observed from combining evofosfamide and ipilimumab, and evidence of therapeutic activity was noted."],"Revise":true}
{"PMID":"33643689","Document":["We conducted a phase I dose-escalation trial of radiation with ipilimumab in patients with melanoma with \u22652 metastatic lesions.","Here, we report the final full clinical analysis.","Patients received RT (6 or 8\u00a0Gy x 2 or 3 doses) to a single lesion followed by 4 cycles of ipilimumab.","The primary endpoint was maximum tolerated dose of RT, and secondary endpoint was response at non-radiated sites.","Twenty-two patients with treatment-na\u00efve (n\u00a0=\u00a011) or treatment-refractory (n\u00a0=\u00a011) Stage IV melanoma were enrolled.","There were 31 treatment-related adverse events (AEs), of which 16 were deemed immune-related.","Eleven patients had grade 3 AEs (no grade 4\/5).","There were no dose-limiting toxicities related to the radiation\/ipilimumab combination.","Five of 22 patients (22.7%, 95% CI 7.8-45.4%) had partial response as best response and three (13.6%) had stable disease.","Median overall survival was 10.7\u00a0months (95% CI, 4.9\u00a0months to not-estimable) and median progression-free survival 3.6\u00a0months (95% CI, 2.9\u00a0months to 7.8\u00a0months).","Seven patients were still alive at the time of last follow-up (median follow-up 89.2\u00a0months), most of whom received pembrolizumab after progression.","Radiotherapy followed by ipilimumab was well tolerated and yielded a response rate that compares favorably to the objective response rate with ipilimumab alone.","Furthermore, 32% of patients are long-term survivors, most of whom received pembrolizumab.","Based on these results, the recommended dose that was used in subsequent Phase 2 trials was 8\u00a0Gy x 3 doses.","Clinical Trial Registration: NCT01497808 (www.clinicaltrials.gov)."],"Aspect":"i","Summary":"The study conducted a phase I dose-escalation trial where patients with melanoma received radiation therapy (6 or 8 Gy x 2 or 3 doses) to a single lesion followed by 4 cycles of ipilimumab.","Indexes":[0,2],"Sentences":["We conducted a phase I dose-escalation trial of radiation with ipilimumab in patients with melanoma with \u22652 metastatic lesions.","Patients received RT (6 or 8\u00a0Gy x 2 or 3 doses) to a single lesion followed by 4 cycles of ipilimumab."],"Revise":false}
{"PMID":"33361337","Document":["BACKGROUND: In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib (triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and trametinib (doublet) without reaching statistical significance.","Mature results on PFS, duration of response (DOR), and overall survival (OS) are reported.","METHODS: The double-blind, phase 2 part of KEYNOTE-022 enrolled patients with previously untreated BRAFV600E\/K-mutated advanced melanoma from 22 sites in seven countries.","Patients were randomly assigned 1:1 to intravenous pembrolizumab (200 mg every 3 weeks) or placebo plus dabrafenib (150 mg orally two times per day) and trametinib (2 mg orally one time a day).","Primary endpoint was PFS.","Secondary endpoints were objective response rate, DOR, and OS.","Efficacy was assessed in the intention-to-treat population, and safety was assessed in all patients who received at least one dose of study drug.","This analysis was not specified in the protocol.","RESULTS: Between November 30, 2015 and April 24, 2017, 120 patients were randomly assigned to triplet (n=60) or doublet (n=60) therapy.","With 36.6 months of follow-up, median PFS was 16.9 months (95% CI 11.3 to 27.9) with triplet and 10.7 months (95% CI 7.2 to 16.8) with doublet (HR 0.53; 95% CI 0.34 to 0.83).","With triplet and doublet, respectively, PFS at 24 months was 41.0% (95% CI 27.4% to 54.2%) and 16.3% (95% CI 8.1% to 27.1%); median DOR was 25.1 months (95% CI 14.1 to not reached) and 12.1 months (95% CI 6.0 to 15.7), respectively.","Median OS was not reached with triplet and was 26.3 months with doublet (HR 0.64; 95% CI 0.38 to 1.06).","With triplet and doublet, respectively, OS at 24 months was 63.0% (95% CI 49.4% to 73.9%) and 51.7% (95% CI 38.4% to 63.4%).","Grade 3-5 treatment-related adverse events (TRAEs) occurred in 35 patients (58%, including one death) receiving triplet and 15 patients (25%) receiving doublet.","CONCLUSION: In BRAFV600E\/K-mutant advanced melanoma, pembrolizumab plus dabrafenib and trametinib substantially improved PFS, DOR, and OS with a higher incidence of TRAEs.","Interpretation of these results is limited by the post hoc nature of the analysis."],"Aspect":"m","Summary":"The trial involved pembrolizumab (200 mg every 3 weeks) combined with dabrafenib (150 mg orally two times per day) and trametinib (2 mg orally one time a day).","Indexes":[3],"Sentences":["Patients were randomly assigned 1:1 to intravenous pembrolizumab (200 mg every 3 weeks) or placebo plus dabrafenib (150 mg orally two times per day) and trametinib (2 mg orally one time a day)."],"Revise":false}
{"PMID":"34551229","Document":["BACKGROUND: Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma.","Data showing a proven overall survival benefit with a systemic treatment are lacking.","Tebentafusp is a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells.","METHODS: In this open-label, phase 3 trial, we randomly assigned previously untreated HLA-A*02:01-positive patients with metastatic uveal melanoma in a 2:1 ratio to receive tebentafusp (tebentafusp group) or the investigator's choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine (control group), stratified according to the lactate dehydrogenase level.","The primary end point was overall survival.","RESULTS: A total of 378 patients were randomly assigned to either the tebentafusp group (252 patients) or the control group (126 patients).","Overall survival at 1 year was 73% in the tebentafusp group and 59% in the control group (hazard ratio for death, 0.51; 95% confidence interval [CI], 0.37 to 0.71; P<0.001) in the intention-to-treat population.","Progression-free survival was also significantly higher in the tebentafusp group than in the control group (31% vs. 19% at 6 months; hazard ratio for disease progression or death, 0.73; 95% CI, 0.58 to 0.94; P\u2009=\u20090.01).","The most common treatment-related adverse events in the tebentafusp group were cytokine-mediated events (due to T-cell activation) and skin-related events (due to glycoprotein 100-positive melanocytes), including rash (83%), pyrexia (76%), and pruritus (69%).","These adverse events decreased in incidence and severity after the first three or four doses and infrequently led to discontinuation of the trial treatment (2%).","No treatment-related deaths were reported.","CONCLUSIONS: Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma.","(Funded by Immunocore; ClinicalTrials.gov number, NCT03070392; EudraCT number, 2015-003153-18.",")."],"Aspect":"o","Summary":"Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma.","Indexes":[6,11],"Sentences":["Overall survival at 1 year was 73% in the tebentafusp group and 59% in the control group (hazard ratio for death, 0.51; 95% confidence interval [CI], 0.37 to 0.71; P<0.001) in the intention-to-treat population.","CONCLUSIONS: Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma."],"Revise":false}
{"PMID":"31852717","Document":["Whereas systemic IL12 is associated with potentially life-threatening toxicity, intratumoral delivery of IL12 through tavokinogene telseplasmid electroporation (tavo) is safe and can induce tumor regression at distant sites.","The mechanism by which these responses are mediated is unknown but is presumed to result from a cellular immune response.","In a phase II clinical trial of tavo (NCT01502293), samples from 29 patients with cutaneous melanoma with in-transit disease were assessed for immune responses induced with this treatment.","Within the blood circulating immune cell population, we found that the frequencies of circulating PD-1+ CD4+ and CD8+ T cells declined with treatment.","Circulating immune responses to gp100 were also detected following treatment as measured by IFN\u03b3 ELISpot.","Patients with a greater antigen-specific circulating immune response also had higher numbers of CD8+ T cells within the tumor.","Clinical response was also associated with increased intratumoral CD3+ T cells.","Finally, intratumoral T-cell clonality and convergence were increased after treatment, indicating a focusing of the T-cell receptor repertoire.","These results indicated that local treatment with tavo can induce a systemic T-cell response and recruit T cells to the tumor microenvironment."],"Aspect":"o","Summary":"Local treatment with tavo can induce a systemic T-cell response and recruit T cells to the tumor microenvironment.","Indexes":[8],"Sentences":["These results indicated that local treatment with tavo can induce a systemic T-cell response and recruit T cells to the tumor microenvironment."],"Revise":false}
{"PMID":"34245960","Document":["INTRODUCTION: The complication rate after axillary lymph node dissection (ALND) and inguinal lymph node dissection (ILND) in melanoma patients is high.","The aim of this randomized non-inferiority study was to evaluate the effect of postoperative wound drainage on early complications after ALND and ILND.","MATERIALS AND METHODS: Between 2018 and 2020, 104 stage III melanoma patients operated on with ALND or ILND were randomized to a study group with complete wound drain removal 3 wk after surgery or a control group with progressive drain removal.","The primary end point was overall early complications graded according to the modified Clavien-Dindo classification.","Secondary endpoints were length of hospital stay and prognostic factors for early complications.","RESULTS: Of the 99 patients analyzed, ALND was performed in 58 patients and ILND in 41 patients.","Overall, 62 patients (62.6%) developed early complications: 30 in the study group and 32 in the control group (P\u00a0=\u00a00.53).","The confidence interval for the difference in proportions of patients without early complications in the two groups was -0.27 to 0.11 (P\u00a0=\u00a00.42), hence non-inferiority could be claimed.","Length of hospital stay was 5 d in the study group compared to 6 in the control group (P < 0.01).","ILND was associated with increased risk of early complications compared to ALND (75.6% versus 53.4%, P\u00a0=\u00a00.04).","CONCLUSIONS: Complete drain removal 3 wk after ALN and ILND in stage III melanoma patients did not increase the risk of early complications compared to progressive drain removal."],"Aspect":"s","Summary":"The study observed early complications in 62.6% of patients, with ILND associated with an increased risk compared to ALND (75.6% versus 53.4%).","Indexes":[6,9],"Sentences":["Overall, 62 patients (62.6%) developed early complications: 30 in the study group and 32 in the control group (P\u00a0=\u00a00.53).","ILND was associated with increased risk of early complications compared to ALND (75.6% versus 53.4%, P\u00a0=\u00a00.04)."],"Revise":false}
{"PMID":"36759673","Document":["Talimogene laherparepvec (T-VEC) is an oncolytic virus hypothesized to enhance triple-negative breast cancer (TNBC) responses to neoadjuvant chemotherapy (NAC).","This article describes the phase 2 trial of T-VEC plus NAC (ClinicalTrials.gov ID: NCT02779855 ).","Patients with stage 2-3 TNBC received five intratumoral T-VEC injections with paclitaxel followed by doxorubicin and cyclophosphamide and surgery to assess residual cancer burden index (RCB).","The primary end point was RCB0 rate.","Secondary end points were RCB0-1 rate, recurrence rate, toxicity and immune correlates.","Thirty-seven patients were evaluated.","Common T-VEC toxicities were fevers, chills, headache, fatigue and injection site pain.","NAC toxicities were as expected.","Four thromboembolic events occurred.","The primary end point was met with an estimated RCB0 rate\u2009=\u200945.9% and RCB0-1 descriptive rate\u2009=\u200965%.","The 2-year disease-free rate is equal to 89% with no recurrences in RCB0-1 patients.","Immune activation during treatment correlated with response.","T-VEC plus NAC in TNBC may increase RCB0-1 rates.","These results support continued investigation of T-VEC plus NAC for TNBC."],"Aspect":"i","Summary":"The study involved a phase 2 trial where patients with stage 2-3 triple-negative breast cancer received five intratumoral T-VEC injections with paclitaxel followed by doxorubicin and cyclophosphamide and surgery to assess residual cancer burden index.","Indexes":[0,1,2],"Sentences":["Talimogene laherparepvec (T-VEC) is an oncolytic virus hypothesized to enhance triple-negative breast cancer (TNBC) responses to neoadjuvant chemotherapy (NAC).","This article describes the phase 2 trial of T-VEC plus NAC (ClinicalTrials.gov ID: NCT02779855 ).","Patients with stage 2-3 TNBC received five intratumoral T-VEC injections with paclitaxel followed by doxorubicin and cyclophosphamide and surgery to assess residual cancer burden index (RCB)."],"Revise":false}
{"PMID":"36049147","Document":["PURPOSE: Limited prospective data are available on sequential immunotherapy and BRAF\/MEK inhibition for BRAFV600-mutant metastatic melanoma.","METHODS: SECOMBIT is a randomized, three-arm, noncomparative phase II trial (ClinicalTrials.gov identifier: NCT02631447).","Patients with untreated, metastatic BRAFV600-mutant melanoma from 37 sites in nine countries were randomly assigned to arm A (encorafenib [450 mg orally once daily] plus binimetinib [45 mg orally twice daily] until progressive disease [PD] -> ipilimumab plus nivolumab [ipilimumab 3 mg\/kg once every 3 weeks and nivolumab 1 mg\/kg once every 3 weeks \u00d7 four cycles -> nivolumab 3 mg\/kg every 2 weeks]), arm B [ipilimumab plus nivolumab until PD -> encorafenib plus binimetinib], or arm C (encorafenib plus binimetinib for 8 weeks -> ipilimumab plus nivolumab until PD -> encorafenib plus binimetinib).","The primary end point was overall survival (OS) at 2 years.","Secondary end points included total progression-free survival, 3-year OS, best overall response rate, duration of response, and biomarkers in the intent-to-treat population.","Safety was analyzed throughout sequential treatment in all participants who received at least one dose of study medication.","RESULTS: A total of 209 patients were randomly assigned (69 in arm A, 71 in arm B, and 69 in arm C).","At a median follow-up of 32.2 (interquartile range, 27.9-41.6) months, median OS was not reached in any arm and more than 30 patients were alive in all arms.","Assuming a null hypothesis of median OS of \u2264 15 months, the OS end point was met for all arms.","The 2-year and 3-year OS rates were 65% (95% CI, 54 to 76) and 54% (95% CI, 41 to 67) in arm A, 73% (95% CI, 62 to 84) and 62% (95% CI, 48 to 76) in arm B, and 69% (95% CI, 59 to 80) and 60% (95% CI, 58 to 72) in arm C. No new safety signals emerged.","CONCLUSION: Sequential immunotherapy and targeted therapy provide clinically meaningful survival benefits for patients with BRAFV600-mutant melanoma."],"Aspect":"o","Summary":"Sequential treatment with immunotherapy and targeted therapy demonstrated clinically meaningful survival outcomes, with 2-year and 3-year OS rates exceeding 50% in all arms.","Indexes":[8,9,10],"Sentences":["Assuming a null hypothesis of median OS of \u2264 15 months, the OS end point was met for all arms.","The 2-year and 3-year OS rates were 65% (95% CI, 54 to 76) and 54% (95% CI, 41 to 67) in arm A, 73% (95% CI, 62 to 84) and 62% (95% CI, 48 to 76) in arm B, and 69% (95% CI, 59 to 80) and 60% (95% CI, 58 to 72) in arm C. No new safety signals emerged.","CONCLUSION: Sequential immunotherapy and targeted therapy provide clinically meaningful survival benefits for patients with BRAFV600-mutant melanoma."],"Revise":true}
{"PMID":"32293341","Document":["BACKGROUND: For novel cancer treatments, effectiveness in clinical practice is not always aligned with clinical efficacy results.","As such it is important to understand a treatment's real-world effectiveness.","We examined real-world population-based comparative effectiveness of second-line ipilimumab versus non-ipilimumab treatments (chemotherapy or targeted treatments).","METHODS: We used a cohort of melanoma patients receiving systemic treatment for advanced disease since April 2005 from Ontario, Canada.","Patients were identified from provincial drug databases and the Ontario Cancer Registry who received second-line ipilimumab from 2012 to 2015 (treated) or second-line non-ipilimumab treatment prior to 2012 (historical controls).","Historical controls were chosen, to permit the most direct comparison to pivotal trial findings.","The cohort was linked to administrative databases to identify baseline characteristics and outcomes.","Kaplan-Meier curves and multivariable Cox regression models were used to assess overall survival (OS).","Observed potential confounders were adjusted for using inverse probability of treatment weighting (IPTW).","RESULTS: We identified 329 patients with metastatic melanoma (MM) who had received second-line treatments (189 treated; 140 controls).","Patients receiving second-line ipilimumab were older (61.7\u2009years vs 55.2\u2009years) compared to historical controls.","Median OS were 6.9 (95% CI: 5.4-8.3) and 4.95 (4.3-6.0) months for ipilimumab and controls, respectively.","The crude 1-year, 2-year, and 3-year OS probabilities were 34.3% (27-41%), 20.6% (15-27%), and 15.2% (9.6-21%) for ipilimumab and 17.1% (11-23%), 7.1% (2.9-11%), and 4.7% (1.2-8.2%) for controls.","Ipilimumab was associated with improved OS (IPTW HR\u2009=\u20090.62; 95% CI: 0.49-0.78; p\u2009<\u20090.0001).","CONCLUSIONS: This real-world analysis suggests second-line ipilimumab is associated with an improvement in OS for MM patients in routine practice."],"Aspect":"p","Summary":"The study involved 329 patients with metastatic melanoma who had received second-line treatments, including 189 treated with ipilimumab and 140 controls treated with non-ipilimumab therapies.","Indexes":[9],"Sentences":["RESULTS: We identified 329 patients with metastatic melanoma (MM) who had received second-line treatments (189 treated; 140 controls)."],"Revise":false}
{"PMID":"36113242","Document":["BACKGROUND: A phase 1a first-in-human study evaluated the safety\/tolerability, preliminary antitumour activity and pharmacokinetics of the oral MEK1\/2 inhibitor FCN-159 in Chinese patients with advanced, NRAS-mutant melanoma.","PATIENTS AND METHODS: Patients received a single FCN-159 dose at assigned levels, proceeding to continuous dosing (once daily [QD] for 28-day cycles) if no dose-limiting toxicities (DLTs) occurred within the next 3 days.","Dose escalation was initiated after review of data for the previous dose level.","The primary end-point was incidence of DLTs after the first dose.","RESULTS: Thirty-three patients were enrolled across nine FCN-159 dose groups (0.2-15\u00a0mg QD).","One DLT occurred: grade 3 folliculitis in the 15-mg group.","There was one grade &gt;3 treatment-emergent adverse event (TEAE), death of unknown aetiology (not FCN-159 related).","The most common FCN-159-related TEAE was rash (36.4%), and the incidence of grade \u22653 FCN-159-related TEAEs was 15.2%.","Antitumour activity at QD doses &lt;6\u00a0mg was limited; therefore, efficacy data are presented only for doses \u22656\u00a0mg (n\u00a0=\u00a021).","The objective response and clinical benefit rates were 19.0% (four partial responses) and 52.4%, respectively.","Median (95% confidence interval) duration of response and progression-free survival were 4.8 months (2.8-not reached) and 3.8 months (1.8-5.6), respectively.","FCN-159 exposure increased dose-proportionately; geometric mean terminal half-life was 29.9-56.9\u00a0h. CONCLUSIONS: FCN-159 was well tolerated and demonstrated promising antitumour activity at doses \u22656\u00a0mg QD in patients with advanced, NRAS-mutant melanoma.","The recommended phase 2 dose was 12\u00a0mg QD.","GOV IDENTIFIER: NCT03932253.","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03932253."],"Aspect":"a","Summary":"The study aims to evaluate the safety, tolerability, preliminary antitumour activity, and pharmacokinetics of the oral MEK1\/2 inhibitor FCN-159 in Chinese patients with advanced, NRAS-mutant melanoma.","Indexes":[0],"Sentences":["BACKGROUND: A phase 1a first-in-human study evaluated the safety\/tolerability, preliminary antitumour activity and pharmacokinetics of the oral MEK1\/2 inhibitor FCN-159 in Chinese patients with advanced, NRAS-mutant melanoma."],"Revise":false}
{"PMID":"34360781","Document":["To identify potential early biomarkers of treatment response and immune-related adverse events (irAE), a pilot immune monitoring study was performed in stage IV melanoma patients by flow cytometric analysis of peripheral blood mononuclear cells (PBMC).","Overall, 17 patients were treated with either nivolumab or pembrolizumab alone, or with a combination of nivolumab and ipilimumab every three weeks.","Of 15 patients for which complete response assessment was available, treatment responders (n = 10) as compared to non-responders (n = 5) were characterized by enhanced PD-1 expression on CD8+ T cells immediately before treatment (median \u00b1 median absolute deviation\/MAD 26.7 \u00b1 10.4% vs. 17.2 \u00b1 5.3%).","Responders showed a higher T cell responsiveness after T cell receptor ex vivo stimulation as determined by measurement of programmed cell death 1 (PD-1) expression on CD3+ T cells before the second cycle of treatment.","The percentage of CD8+ effector memory (CD8+CD45RA-CD45RO+CCR7-) T cells was higher in responders compared to non-responders before and immediately after the first cycle of treatment (median \u00b1 MAD 39.2 \u00b1 7.3% vs. 30.5 \u00b1 4.1% and 37.7 \u00b1 4.6 vs. 24.0 \u00b1 6.4).","Immune-related adverse events (irAE) were accompanied by a higher percentage of activated CD4+ (CD4+CD38+HLADR+) T cells before the second treatment cycle (median \u00b1 MAD 14.9 \u00b1 3.9% vs. 5.3 \u00b1 0.4%).","In summary, PBMC immune monitoring of immune-checkpoint inhibition (ICI) treatment in melanoma appears to be a promising approach to identify early markers of treatment response and irAEs."],"Aspect":"i","Summary":"A pilot immune monitoring study was performed using flow cytometric analysis of peripheral blood mononuclear cells (PBMC) in stage IV melanoma patients treated with either nivolumab or pembrolizumab alone, or a combination of nivolumab and ipilimumab every three weeks.","Indexes":[0,1],"Sentences":["To identify potential early biomarkers of treatment response and immune-related adverse events (irAE), a pilot immune monitoring study was performed in stage IV melanoma patients by flow cytometric analysis of peripheral blood mononuclear cells (PBMC).","Overall, 17 patients were treated with either nivolumab or pembrolizumab alone, or with a combination of nivolumab and ipilimumab every three weeks."],"Revise":false}
{"PMID":"35857579","Document":["Preclinical studies show that locoregional CTLA-4 blockade is equally effective in inducing tumor eradication as systemic delivery, without the added risk of immune-related side effects.","This efficacy is related to access of the CTLA-4 blocking antibodies to tumor-draining lymph nodes (TDLNs).","Local delivery of anti-CTLA-4 after surgical removal of primary melanoma, before sentinel lymph node biopsy (SLNB), provides a unique setting to clinically assess the role of TDLN in the biological efficacy of locoregional CTLA-4 blockade.","Here, we have evaluated the safety, tolerability, and immunomodulatory effects in the SLN and peripheral blood of a single dose of tremelimumab [a fully human immunoglobulin gamma-2 (IgG2) mAb directed against CTLA-4] in a dose range of 2 to 20 mg, injected intradermally at the tumor excision site 1 week before SLNB in 13 patients with early-stage melanoma (phase 1 trial; NCT04274816).","Intradermal delivery was safe and well tolerated and induced activation of migratory dendritic cell (DC) subsets in the SLN.","It also induced profound and durable decreases in regulatory T cell (Treg) frequencies and activation of effector T cells in both SLN and peripheral blood.","Moreover, systemic T cell responses against NY-ESO-1 or MART-1 were primed or boosted (N = 7), in association with T cell activation and central memory T cell differentiation.","These findings indicate that local administration of anti-CTLA-4 may offer a safe and promising adjuvant treatment strategy for patients with early-stage melanoma.","Moreover, our data demonstrate a central role for TDLN in the biological efficacy of CTLA-4 blockade and support TDLN-targeted delivery methods."],"Aspect":"i","Summary":"The study evaluated the safety, tolerability, and immunomodulatory effects of a single dose( range of 2 to 20 mg) of tremelimumab, injected intradermally at the tumor excision site before sentinel lymph node biopsy in patients with early-stage melanoma.","Indexes":[3],"Sentences":["Here, we have evaluated the safety, tolerability, and immunomodulatory effects in the SLN and peripheral blood of a single dose of tremelimumab [a fully human immunoglobulin gamma-2 (IgG2) mAb directed against CTLA-4] in a dose range of 2 to 20 mg, injected intradermally at the tumor excision site 1 week before SLNB in 13 patients with early-stage melanoma (phase 1 trial; NCT04274816)."],"Revise":true}
{"PMID":"33715172","Document":["We report the 5-year follow-up results from a single-arm, open-label, multicenter phase II study (ONO-4538-08) conducted in Japan.","Twenty-four patients with treatment-na\u00efve, recurrent, or unresectable stage III\/IV malignant melanoma received 3\u00a0mg\/kg nivolumab every 2\u00a0weeks until progressive disease or unacceptable toxicity occurred.","The 5-year overall survival (OS) rate was 26.1%.","Five years after the start of nivolumab treatment, there were six survivors.","The 5-year OS rate was 66.7% for patients with a superficial spreading type, 14.3% for acral lentiginous type, and 16.7% for mucosal type.","The 5-year progression-free survival rate was 17.2%.","No new cases of partial response or complete response were observed after 3\u00a0years, and overall response and disease control rates were similar to those reported at 3\u00a0years.","The treatment-related adverse events reported between the 3- and 5-year follow-up periods were anemia (grade 2), white blood cell count decrease (grade 2), and psoriasiform dermatitis (grade 2) in one patient each.","No new grade 3 or higher treatment-related adverse events occurred in this period.","In conclusion, first-line treatment with nivolumab in Japanese patients with unresectable or metastatic melanoma resulted in confirmed long-term survival.","No new safety signals were reported in the studied population."],"Aspect":"o","Summary":"The 5-year overall survival rate was 26.1% for patients with stage III\/IV malignant melanoma treated with nivolumab.","Indexes":[2],"Sentences":["The 5-year overall survival (OS) rate was 26.1%."],"Revise":false}
{"PMID":"35156519","Document":["Macroautophagy\/autophagy is a resistance mechanism to targeted therapy in BRAF mutant cancers.","Preclinical evidence and clinical trial data demonstrate that hydroxychloroquine (HCQ) is an effective autophagy inhibitor at clinically achievable concentrations.","Here we highlight the results of a recently published single-arm phase I\/II multi-institution trial of dabrafenib, trametinib, and the autophagy inhibitor HCQ (the BAMM trial) that established the safety and activity of this regimen in BRAF V600-mutant melanoma patients.","Compared to the pivotal trials that led to FDA approval of dabrafenib and trametinib, the BAMM trial enrolled a high percentage of patients with elevated LDH and prior immunotherapy, reflecting the trend that poorer-prognosis patients are treated with targeted therapy in the modern era where multiple immunotherapy regimens are available for melanoma.","Dabrafenib, trametinib, and hydroxychloroquine are safe and produce a high response rate (85%).","Progression-free survival does not meet the pre-specified threshold for the entire cohort but looks especially promising in patients with elevated LDH and prior treatment.","A national randomized study has been launched to study this regimen further in poor-prognosis BRAF V600-mutant melanoma patients."],"Aspect":"m","Summary":"The trial involved dabrafenib, trametinib, and hydroxychloroquine (HCQ) administered together, with dabrafenib and trametinib previously approved by the FDA.","Indexes":[1,2,3,4],"Sentences":["Preclinical evidence and clinical trial data demonstrate that hydroxychloroquine (HCQ) is an effective autophagy inhibitor at clinically achievable concentrations.","Here we highlight the results of a recently published single-arm phase I\/II multi-institution trial of dabrafenib, trametinib, and the autophagy inhibitor HCQ (the BAMM trial) that established the safety and activity of this regimen in BRAF V600-mutant melanoma patients.","Compared to the pivotal trials that led to FDA approval of dabrafenib and trametinib, the BAMM trial enrolled a high percentage of patients with elevated LDH and prior immunotherapy, reflecting the trend that poorer-prognosis patients are treated with targeted therapy in the modern era where multiple immunotherapy regimens are available for melanoma.","Dabrafenib, trametinib, and hydroxychloroquine are safe and produce a high response rate (85%)."],"Revise":false}
{"PMID":"38271746","Document":["BACKGROUND: The primary analysis of the phase III NIBIT-M2 study showed a 41% 4-year overall survival (OS) of melanoma patients with asymptomatic brain metastases treated with ipilimumab plus nivolumab.","METHODS: Here, we report the 7-year efficacy outcomes and the Health-Related Quality of Life (HRQoL) analyses of the NIBIT-M2 study.","RESULTS: As of May 1, 2023, at a median follow-up of 67 months (mo), the median OS was 8.5 (95% CI: 6.6-10.3), 8.2 (95% CI: 2.1-14.3) and 29.2 (95% CI: 0-69.9) mo for the fotemustine (F) Arm A, ipilimumab plus fotemustine Arm B, and ipilimumab plus nivolumab Arm C, respectively.","The 7-year OS rate was 10.0% (95% CI: 0-22.5) in Arm A, 10.3% (95% CI: 0-22.6) in Arm B, and 42.8% (95% CI: 23.4-62.2) in Arm C. HRQoL was preserved in all treatment arms.","Most functional scales evaluated from baseline to W12 were preserved, with a lower mean score decrease for EORTC Quality of Life Questionnaire (QLQ)-C30 and an increase for EORTC QLQ-Brain neoplasm (BN20) in patients receiving ipilimumab plus nivolumab.","CONCLUSIONS: With the longest follow-up available to date in melanoma patients with asymptomatic brain metastases, the NIBIT-M2 study continues to show persistent therapeutic efficacy of I ipilimumab plus nivolumab while preserving HRQoL."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"31664428","Document":["IMPORTANCE: Obesity is a cancer risk factor, and bariatric surgery in patients with obesity is associated with reduced cancer risk.","However, evidence of an association among obesity, bariatric surgery, and skin cancer, including melanoma, is limited.","OBJECTIVE: To investigate the association of bariatric surgery with skin cancer (squamous cell carcinoma and melanoma) and melanoma incidence.","DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized controlled trial, the Swedish Obese Subjects (SOS) study, is ongoing at 25 surgical departments and 480 primary health care centers in Sweden and was designed to examine outcomes after bariatric surgery.","The study included 2007 patients with obesity who underwent bariatric surgery and 2040 contemporaneously matched controls who received conventional obesity treatment.","Patients were enrolled between September 1, 1987, and January 31, 2001.","Data analysis was performed from June 29, 2018, to November 22, 2018.","INTERVENTIONS: Patients in the surgery group underwent gastric bypass (n\u2009=\u2009266), banding (n\u2009=\u2009376), or vertical banded gastroplasty (n\u2009=\u20091365).","The control group (n\u2009=\u20092040) received the customary treatment for obesity at their primary health care centers.","MAIN OUTCOMES AND MEASURES: The SOS study was cross-linked to the Swedish National Cancer Registry, the Cause of Death Registry, and the Registry of the Total Population for data on cancer incidence, death, and emigration.","RESULTS: The study included 4047 participants (mean [SD] age, 47.9 [6.1] years; 2867 [70.8%] female).","Information on cancer events was available for 4042 patients.","The study found that bariatric surgery was associated with a markedly reduced risk of melanoma (adjusted subhazard ratio, 0.43; 95% CI, 0.21-0.87; P\u2009=\u2009.02; median follow-up, 18.1 years) and risk of skin cancer in general (adjusted subhazard ratio, 0.59; 95% CI, 0.35-0.99; P\u2009=\u2009.047).","The skin cancer risk reduction was not associated with baseline body mass index or weight; insulin, glucose, lipid, and creatinine levels; diabetes; blood pressure; alcohol intake; or smoking.","CONCLUSIONS AND RELEVANCE: The results of this study suggest that bariatric surgery in individuals with obesity is associated with a reduced risk of skin cancer, including melanoma.","TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01479452."],"Aspect":"m","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"34904258","Document":["BACKGROUND AND OBJECTIVES: Opioids are commonly prescribed following surgery and can lead to persistent opioid use.","We assessed changes in prescribing practices following an opioid education initiative for patients undergoing lymphadenectomy for cutaneous malignancy.","METHODS: A single-institution retrospective study of all eligible patients (3\/2016-3\/2020) was performed.","RESULTS: Indications for lymphadenectomy in 328 patients were metastatic melanoma (84%), squamous cell carcinoma (10%), and Merkel cell carcinoma (5%).","At discharge, non-opioid analgesics were increasingly utilized over the 4-year study period, with dramatic increases after education initiatives (32%, 42%, 59%, and 79% of pts, respectively each year; p\u2009<\u20090.001).","Median oral morphine equivalents (OMEs) prescribed also decreased dramatically starting in year 3 (250, 238, 150, and 100\u2009mg, respectively; p\u2009<\u20090.001).","Patients discharged with 200\u2009mg OMEs were less likely to also be discharged with non-opioid analgesics (40% vs. 64%.","respectively, p\u2009<\u20090.001).","CONCLUSIONS: Analgesic prescribing practices following lymphadenectomy for cutaneous malignancy improved significantly over a 4-year period, with use of non-opioids more than doubling and a 60% reduction in median OME.","Opportunities exist to further increase non-opioid use and decrease opioid dissemination after lymphadenectomy for cutaneous malignancy."],"Aspect":"i","Summary":"The study conducted a single-institution retrospective analysis of patients who underwent lymphadenectomy for cutaneous malignancy between March 2016 and March 2020, assessing changes in opioid prescribing practices following an education initiative.","Indexes":[1,2],"Sentences":["We assessed changes in prescribing practices following an opioid education initiative for patients undergoing lymphadenectomy for cutaneous malignancy.","METHODS: A single-institution retrospective study of all eligible patients (3\/2016-3\/2020) was performed."],"Revise":false}
{"PMID":"38870745","Document":["BACKGROUND: Treatment options for immunotherapy-refractory melanoma are an unmet need.","The MASTERKEY-115 phase II, open-label, multicenter trial evaluated talimogene laherparepvec (T-VEC) plus pembrolizumab in advanced melanoma that progressed on prior programmed cell death protein-1 (PD-1) inhibitors.","METHODS: Cohorts 1 and 2 comprised patients (unresectable\/metastatic melanoma) who had primary or acquired resistance, respectively, and disease progression within 12 weeks of their last anti-PD-1 dose.","Cohorts 3 and 4 comprised patients (resectable disease) who underwent complete surgery, received adjuvant anti-PD-1, and experienced recurrence.","Cohort 3 were disease-free for <\u00a06 months and cohort 4 for \u2265\u00a06 months after starting the adjuvant anti-PD-1 therapy and before confirmed recurrence.","The primary endpoint was objective response rate (ORR) per RECIST v1.1.","Secondary endpoints included complete response rate (CRR), disease control rate (DCR) and progression-free survival (PFS) per RECIST v1.1 and irRC-RECIST, and safety.","RESULTS: Of the 72 enrolled patients, 71 were treated.","The ORR (95% CI) was 0%, 6.7% (0.2-32.0), 40.0% (16.3-67.7), and 46.7% (21.3-73.4) in cohorts 1-4, respectively; iORR was 3.8% (0.1-19.6), 6.7% (0.2-32.0), 53.3% (26.6-78.7), and 46.7% (21.3-73.4).","iCRR was 0%, 0%, 13.3%, and 13.3%.","Median iPFS (months) was 5.5, 8.2, not estimable [NE], and NE for cohorts 1-4, respectively; iDCR was 50.0%, 40.0%, 73.3%, and 86.7%.","Treatment-related adverse events (TRAEs), grade \u2265\u00a03 TRAEs, serious AEs, and fatal AEs occurred in 54 (76.1%), 9 (12.7%), 24 (33.8%), and 10 (14.1%) patients, respectively.","CONCLUSION: T-VEC-pembrolizumab demonstrated antitumor activity and tolerability in PD-1-refractory melanoma, specifically in patients with disease recurrence on or after adjuvant anti-PD-1.","TRIAL REGISTRATION: ClinicalTrials.gov identifier - NCT04068181."],"Aspect":"p","Summary":"The study involved 72 enrolled patients (of which 71 were treated) with advanced melanoma that progressed on prior PD-1 inhibitors, divided into four cohorts based on recurrence status and previous treatment, with a focus on objective response rate (ORR).","Indexes":[2,3,4,5,7],"Sentences":["METHODS: Cohorts 1 and 2 comprised patients (unresectable\/metastatic melanoma) who had primary or acquired resistance, respectively, and disease progression within 12 weeks of their last anti-PD-1 dose.","Cohorts 3 and 4 comprised patients (resectable disease) who underwent complete surgery, received adjuvant anti-PD-1, and experienced recurrence.","Cohort 3 were disease-free for <\u00a06 months and cohort 4 for \u2265\u00a06 months after starting the adjuvant anti-PD-1 therapy and before confirmed recurrence.","The primary endpoint was objective response rate (ORR) per RECIST v1.1.","RESULTS: Of the 72 enrolled patients, 71 were treated."],"Revise":true}
{"PMID":"35367525","Document":["INTRODUCTION: Trametinib is a MEK inhibitor with intracranial activity indicated for BRAF-mutant metastatic malignancies.","Yet, the safety of trametinib concurrent with whole brain radiation therapy (WBRT) is unknown.","We performed a single-institution, prospective, 3\u00a0+\u00a03, phase I clinical trial to determine the maximum tolerated dose (MTD) of trametinib with WBRT.","METHODS AND MATERIALS: Patients with brain metastases (BM) received daily trametinib for 28\u00a0days, starting 7\u00a0days prior to and continuing through WBRT (37.5\u00a0Gy\/15 fractions).","Dose levels (DL)1-3 were 1.0, 1.5, and 2.0\u00a0mg.","The MTD of trametinib plus WBRT, the max dose where \u22641 of 6 patients experienced a dose limiting toxicity (DLT), was the primary endpoint.","RESULTS: 10 patients were enrolled (median age-59 [47-64], BM-5 [1-10], 50% melanoma).","Three and 7 patients were assigned to DL1 and 2.","One DL2 patient withdrew.","89% of remaining patients completed therapy per protocol, but 1 DL2 patient with systemic progression discontinued therapy at 30\u00a0Gy.","Thirteen grade (G)3-4 toxicities were observed, of which 12 occurred at DL2 (4\/6 of patients).","DLT was reached at DL2 (G4 thrombocytopenia and G3 diarrhea, 1 each).","There were no G5 toxicities.","Median overall survival was 2.2\u00a0months.","During the study period, changing practice patterns favored utilization of stereotactic radiosurgery (SRS).","Thus, the trial closed early prior to completion.","CONCLUSIONS: In a patient population representative of modern candidates for WBRT, trametinib plus WBRT is highly toxic with a MTD <1.5\u00a0mg.","The safety of trametinib with SRS remains an important question for future study."],"Aspect":"s","Summary":"Thirteen grade 3-4 toxicities were observed, with dose-limiting toxicities including G4 thrombocytopenia and G3 diarrhea at dose level 2.","Indexes":[10,11],"Sentences":["Thirteen grade (G)3-4 toxicities were observed, of which 12 occurred at DL2 (4\/6 of patients).","DLT was reached at DL2 (G4 thrombocytopenia and G3 diarrhea, 1 each)."],"Revise":false}
{"PMID":"35217280","Document":["Skin cancer is the most common cancer in the United States and among Caucasians worldwide, with more people diagnosed each year than all other cancers combined.","Basal cell cancer is the most common form with an estimated 4.3 million cases diagnosed annually, and treatment costs estimated at $4.8 billion.","The objective of this study was to compare efficacy of a topical solution consisting of 30% ascorbic acid in 95% dimethylsulfoxide with topical imiquimod in the treatment of basal cell carcinoma.","Twenty-five patients with 29 biopsy confirmed basal cell carcinomas were randomly assigned to receive either the topically applied ascorbic acid treatment twice daily for 8 weeks or topical imiquimod, a standard and well characterized topical treatment.","After 8 weeks, post-treatment biopsy of lesions showed complete resolution of 13\/15 (86.7%) in the ascorbic acid group, while 8\/14 (57.1%) lesions in the IMQ group were resolved (p\u00a0<\u00a00.05 Chi Square).","Topical ascorbic acid was superior at 8 weeks, and non-inferior at 12 weeks to topical imiquimod in the treatment of low risk nodular and superficial lesions.","In addition, ascorbic acid was associated with fewer adverse effects than imiquimod.","70% of patients in the imiquinod group showed residual hypopigmentation at 30mo follow up versus 0% in the ascorbate group."],"Aspect":"s","Summary":"Ascorbic acid was associated with fewer adverse effects than imiquimod, including a notable absence of residual hypopigmentation in the ascorbate group compared to 70% in the imiquimod group at 30-month follow-up.","Indexes":[6,7],"Sentences":["In addition, ascorbic acid was associated with fewer adverse effects than imiquimod.","70% of patients in the imiquinod group showed residual hypopigmentation at 30mo follow up versus 0% in the ascorbate group."],"Revise":false}
{"PMID":"37651676","Document":["PURPOSE: Despite marked advances in the treatment of unresectable or metastatic melanoma, the need for novel therapies remains.","Bempegaldesleukin (BEMPEG), a pegylated interleukin-2 (IL-2) cytokine prodrug, demonstrated efficacy in the phase II PIVOT-02 trial.","PIVOT IO 001 (ClinicalTrials.gov identifier: NCT03635983) is a phase III, randomized, open-label study that builds on the PIVOT-02 results in first-line melanoma.","METHODS: Patients with previously untreated, unresectable, or metastatic melanoma were randomly assigned 1:1 to receive BEMPEG plus nivolumab (NIVO) or NIVO monotherapy.","Primary end points were objective response rate (ORR) and progression-free survival (PFS) by blinded independent central review and overall survival (OS).","Secondary and exploratory end points included additional efficacy measures, safety, and pharmacokinetics (PKs) and pharmacodynamics analyses.","RESULTS: In 783 patients (n = 391, BEMPEG plus NIVO; n = 392, NIVO monotherapy), the median follow-up was 11.6 months in the intent-to-treat population.","The ORR with BEMPEG plus NIVO was 27.7% versus 36.0% with NIVO (two-sided P = .0311).","The median PFS with BEMPEG plus NIVO was 4.17 months (95% CI, 3.52 to 5.55) versus 4.99 months (95% CI, 4.14 to 7.82) with NIVO (hazard ratio [HR], 1.09; 97% CI, 0.88 to 1.35; P = .3988).","The median OS was 29.67 months (95% CI, 22.14 to not reached [NR]) with BEMPEG plus NIVO versus 28.88 months (95% CI, 21.32 to NR) with NIVO (HR, 0.94; 99.929% CI, 0.59 to 1.48; P = .6361).","Grade 3-4 treatment-related adverse events (AEs) and serious AE rates were higher with the combination (21.7% and 10.1%, respectively) versus NIVO (11.5% and 5.5%, respectively).","BEMPEG PK exposure and absolute lymphocyte count changes after BEMPEG plus NIVO were comparable between PIVOT IO 001 and PIVOT-02.","CONCLUSION: The PIVOT IO 001 study did not meet its primary end points of ORR, PFS, and OS.","Increased toxicity was observed with BEMPEG plus NIVO versus NIVO."],"Aspect":"a","Summary":"The study aims to investigate the efficacy and safety of Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to NIVO monotherapy in first-line treatment of patients with previously untreated, unresectable, or metastatic melanoma.","Indexes":[0,2,3,4],"Sentences":["PURPOSE: Despite marked advances in the treatment of unresectable or metastatic melanoma, the need for novel therapies remains.","PIVOT IO 001 (ClinicalTrials.gov identifier: NCT03635983) is a phase III, randomized, open-label study that builds on the PIVOT-02 results in first-line melanoma.","METHODS: Patients with previously untreated, unresectable, or metastatic melanoma were randomly assigned 1:1 to receive BEMPEG plus nivolumab (NIVO) or NIVO monotherapy.","Primary end points were objective response rate (ORR) and progression-free survival (PFS) by blinded independent central review and overall survival (OS)."],"Revise":false}
{"PMID":"33303685","Document":["The gut microbiome has been shown to influence the response of tumors to anti-PD-1 (programmed cell death-1) immunotherapy in preclinical mouse models and observational patient cohorts.","However, modulation of gut microbiota in cancer patients has not been investigated in clinical trials.","In this study, we performed a phase 1 clinical trial to assess the safety and feasibility of fecal microbiota transplantation (FMT) and reinduction of anti-PD-1 immunotherapy in 10 patients with anti-PD-1-refractory metastatic melanoma.","We observed clinical responses in three patients, including two partial responses and one complete response.","Notably, treatment with FMT was associated with favorable changes in immune cell infiltrates and gene expression profiles in both the gut lamina propria and the tumor microenvironment.","These early findings have implications for modulating the gut microbiota in cancer treatment."],"Aspect":"m","Summary":"The study mentioned the use of anti-PD-1 immunotherapy and fecal microbiota transplantation (FMT) in patients with metastatic melanoma.","Indexes":[0,2],"Sentences":["The gut microbiome has been shown to influence the response of tumors to anti-PD-1 (programmed cell death-1) immunotherapy in preclinical mouse models and observational patient cohorts.","In this study, we performed a phase 1 clinical trial to assess the safety and feasibility of fecal microbiota transplantation (FMT) and reinduction of anti-PD-1 immunotherapy in 10 patients with anti-PD-1-refractory metastatic melanoma."],"Revise":false}
{"PMID":"34419232","Document":["INTRODUCTION: Text messaging is an effective way to reach large populations with health promotion support.","This study aims to establish the optimal text messaging intervention to achieve behavior change in young adults at risk of skin cancer.","STUDY DESIGN: Latin square crossover RCT.","SETTING\/PARTICIPANTS: Participants were women and men aged 18-40 years living in Queensland, Australia who owned a smartphone and had \u22652 skin cancer risk factors.","INTERVENTION: Participants were enrolled from December 2018 to February 2019 and completed an eligibility survey.","Eligible participants were randomized to 4 different text message interventions using a Latin square design with varying personalization, interactivity, and message frequency (February 2019\u2012July 2019).","Each intervention lasted for 1 month; between interventions, participants had a 1-week washout period in which they completed an online questionnaire.","Participants completed a 6-month follow-up online survey in January 2020.","MAIN OUTCOME MEASURES: Measures included self-reported sun protection habits and sunburns.","RESULTS: A total of 277 (71.2% response rate) participants completed the 6-month follow-up.","The sun protection habits index was significantly higher in all the 4 text messaging interventions (p<0.01 for each intervention) than at baseline, with similar sun protection habits improvements among all interventions (p=0.27).","Sunburn rates decreased significantly over time (p<0.01 each intervention), with all the 4 interventions achieving reductions in sunburn rates during the intervention periods (p=0.78).","Overall, the sunburn rates decreased from 40.3% at baseline to 7.0% at the end of the intervention, and at 6-month follow-up, it remained significantly below baseline levels at 23.5% (p<0.01).","CONCLUSIONS: Regular text messaging interventions result in significantly increased sun protection and decreased sunburn in young adults.","TRIAL REGISTRATION: This study is registered at the Australian and New Zealand Clinical Trials Registry ACTRN12618001299291."],"Aspect":"m","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"34887574","Document":["Anti-programmed death (PD)-1 (aPD1) therapy is an effective treatment for metastatic melanoma (MM); however, over 50% of patients progress due to resistance.","We tested a first-in-class immune-modulatory vaccine (IO102\/IO103) against indoleamine 2,3-dioxygenase (IDO) and PD ligand 1 (PD-L1), targeting immunosuppressive cells and tumor cells expressing IDO and\/or PD-L1 (IDO\/PD-L1), combined with nivolumab.","Thirty aPD1 therapy-naive patients with MM were treated in a phase 1\/2 study ( https:\/\/clinicaltrials.gov\/ , NCT03047928).","The primary endpoint was feasibility and safety; the systemic toxicity profile was comparable to that of nivolumab monotherapy.","Secondary endpoints were efficacy and immunogenicity; an objective response rate (ORR) of 80% (confidence interval (CI), 62.7-90.5%) was reached, with 43% (CI, 27.4-60.8%) complete responses.","After a median follow-up of 22.9 months, the median progression-free survival (PFS) was 26 months (CI, 15.4-69 months).","Median overall survival (OS) was not reached.","Vaccine-specific responses assessed in vitro were detected in the blood of >93% of patients during vaccination.","Vaccine-reactive T cells comprised CD4+ and CD8+ T cells with activity against IDO- and PD-L1-expressing cancer and immune cells.","T cell influx of peripherally expanded T cells into tumor sites was observed in responding patients, and general enrichment of IDO- and PD-L1-specific clones after treatment was documented.","These clinical efficacy and favorable safety data support further validation in a larger randomized trial to confirm the clinical potential of this immunomodulating approach."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"33051240","Document":["Therapeutic cancer vaccines targeting melanoma-associated antigens are commonly immunogenic but are rarely effective in promoting objective clinical responses.","To identify critical molecules for activation of effective antitumor immunity, we have profiled autologous dendritic cell (DC) vaccines used to treat 35 patients with melanoma.","We showed that checkpoint molecules induced by ex vivo maturation correlated with in vivo DC vaccine activity.","Melanoma patient DCs had reduced expression of cell surface inducible T-cell costimulator ligand (ICOSL) and had defective intrinsic NF-\u03baB signaling.","Chromatin immunoprecipitation assays revealed NF-\u03baB-dependent transcriptional regulation of ICOSL expression by DCs.","Blockade of ICOSL on DCs reduced priming of antigen-specific CD8+ and CD4+ T cells from na\u00efve donors in vitro Concentration of extracellular\/soluble ICOSL released from vaccine DCs positively correlated with patient clinical outcomes, which we showed to be partially regulated by ADAM10\/17 sheddase activity.","These data point to the critical role of canonical NF-\u03baB signaling, the regulation of matrix metalloproteinases, and DC-derived ICOSL in the specific priming of cognate T-cell responses in the cancer setting.","This study supports the implementation of targeted strategies to augment these pathways for improved immunotherapeutic outcomes in patients with cancer."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"34035112","Document":["BACKGROUND: Experimental cancer vaccines are traditionally administered by injection in subcutaneous tissue or muscle, commonly with adjuvants that create chronic inflammatory depots.","Injection of melanoma-derived peptides induces T cell responses; however, the depots that form following injection may inhibit optimization of the immune response.","In skin, epidermal Langerhans cells (LC) are a dominant source of professional antigen presenting cells.","We hypothesized that: (1) applying melanoma-derived peptides topically, in proximity to LC, could be immunogenic and safe, with low vaccine-site toxicity and (2) topical toll-like receptor 7 (TLR7) agonist would increase immunogenicity of the peptide vaccine.","METHODS: Twelve melanoma peptides plus a tetanus helper peptide were combined with granulocyte macrophage colony stimulating factor (GM-CSF) and were administered topically on days 1, 8, and 15, to 28 patients randomized to one of four adjuvant preparations: (1) incomplete Freund's adjuvant (IFA); (2) IFA plus a TLR7 agonist (imiquimod) administered on days 0, 7, 14; (3) dimethyl sulfoxide (DMSO) or (4) DMSO+ imiquimod administered on day 0, 7, 14.","Every 3 weeks thereafter (x 6), the peptides were combined with GM-CSF and were injected into the dermis and subcutis in an emulsion with IFA.","Toxicities were recorded and immune responses assayed by ELIspot.","RESULTS: CD8+ T cell responses to transdermal vaccination in DMSO occurred in 83% of participants in group 3 and 86% in group 4, and responses to vaccination in IFA were observed in 29% of participants in group 1 and 14% in group 2.","Overall, 61% of participants had CD4+ T cell immune responses to the tetanus peptide, with large, durable responses in groups 3 and 4.","Five of seven participants in group 4 had a severe rash, one that was dose limiting.","Ten-year overall survival was 67% and disease-free survival was 44%.","CONCLUSIONS: These data provide proof of principle for immunogenicity in humans of transdermal immunization using peptides in DMSO.","Further study is warranted into the pharmacokinetics and immunobiology of TLR agonists as vaccine adjuvants during transcutaneous application.","Overall survival is high, supporting further investigation of this immunization approach."],"Aspect":"o","Summary":"The study found that transdermal vaccination using melanoma-derived peptides in DMSO resulted in CD8+ T cell responses in 83-86% of participants and CD4+ T cell responses in 61% of participants, with a 10-year overall survival rate of 67%.","Indexes":[7,8,10],"Sentences":["RESULTS: CD8+ T cell responses to transdermal vaccination in DMSO occurred in 83% of participants in group 3 and 86% in group 4, and responses to vaccination in IFA were observed in 29% of participants in group 1 and 14% in group 2.","Overall, 61% of participants had CD4+ T cell immune responses to the tetanus peptide, with large, durable responses in groups 3 and 4.","Ten-year overall survival was 67% and disease-free survival was 44%."],"Revise":false}
{"PMID":"32266730","Document":["Identification of melanoma or worrisome moles is often taught as an important part of routine skin checks.","We sought to evaluate the efficacy of gamified education vs. traditional ABCDEs education on melanoma identification and self-confidence in identifying worrisome moles.","We report that in our cohort (n\u00a0=\u00a0271), participants randomized to the gamified intervention were more likely to correctly identify melanoma and non-melanoma skin lesions than those randomized to the ABCDE control cohort (74.2% vs 63.5% correct, P\u00a0<\u00a0.0001) and perceived confidence in self-identifying worrisome lesions was slightly higher in the gamified group than the traditional group, though the trend was not significant.","These novel findings have significant implications on improved ways to educate young patients on the visual identification of melanoma and worrisome moles."],"Aspect":"m","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"30998526","Document":["This study describes a randomised control trial investigating whether printed leaflets or social media are more effective in increasing knowledge of the risks of sun exposure and melanoma in people aged 18-29.","The study participants were 18-29-year-old university students or graduates, recruited in London.","A baseline level of knowledge was measured using the Skin Cancer and Sun Knowledge questionnaire.","Study participants were then randomised into either a leaflet arm or Facebook arm.","Identical information was delivered through a SunSafe campaign via either posted leaflets or Facebook during a 10-day exposure window.","Following this, participants repeated the Skin Cancer and Sun Knowledge questionnaire.","Following the SunSafe intervention, the mean knowledge score improved in both groups to a statistically significant degree (Facebook\u2009=\u20091.82, leaflets\u2009=\u20093.04, P\u2009<\u20090.001).","Moreover, the improvement in knowledge score of the leaflet arm was statistically significantly greater than in the Facebook arm (95% confidence interval: 0.35-2.09, P\u2009=\u20090.0059).","Participants of lighter skin colour demonstrated greater levels of knowledge about skin cancer and sun exposure at baseline (P\u2009=\u20090.005; P\u2009<\u20090.05).","There was no correlation between sex and baseline knowledge (P\u2009=\u20090.7725).","There was no significant effect of skin tone or sex on the knowledge change (P\u2009=\u20090.139 and 0.643).","The findings suggest that printed information in the form of leaflets is more impactful in increasing knowledge than online platforms such as Facebook among a young adult demographic in the UK.","These findings should be considered when designing public health campaigns, acting as a reminder to not neglect traditional media in health promotion."],"Aspect":"a","Summary":"The study aims to investigate whether printed leaflets or social media are more effective in increasing knowledge of the risks of sun exposure and melanoma in people aged 18-29.","Indexes":[0],"Sentences":["This study describes a randomised control trial investigating whether printed leaflets or social media are more effective in increasing knowledge of the risks of sun exposure and melanoma in people aged 18-29."],"Revise":false}
{"PMID":"37956739","Document":["BACKGROUND: The outcome of patients with resectable mucosal melanoma is poor.","Toripalimab combined with axitinib has shown impressive results in metastatic mucosal melanoma with an objective response rate of 48.3% and a median progression-free survival of 7.5 months in a phase Ib trial.","It was hypothesized that this combination administered in the neoadjuvant setting might induce a pathologic response in resectable mucosal melanoma, so we conducted this trial.","PATIENTS AND METHODS: This single-arm phase II trial enrolled patients with resectable mucosal melanoma.","Patients received toripalimab 3 mg\/kg once every 2 weeks (Q2W) plus axitinib 5 mg two times a day (b.i.d.)","for 8 weeks as neoadjuvant therapy, then surgery and adjuvant toripalimab 3 mg\/kg Q2W starting 2 \u00b1 1weeks after surgery for 44 weeks.","The primary endpoint was the pathologic response rate according to the International Neoadjuvant Melanoma Consortium recommendations.","RESULTS: Between August 2019 and October 2021, 29 patients were enrolled and received treatment, of whom 24 underwent resection.","The median follow-up time was 34.2 months (95% confidence interval 20.4-48.0 months).","The pathologic response rate was 33.3% (8\/24; 4 pathological complete responses and 4 pathological partial responses).","The median event-free survival for all patients was 11.1 months (95% confidence interval 5.3-16.9 months).","The median overall survival was not reached.","Neoadjuvant therapy was tolerable with 8 (27.5%) grade 3-4 treatment-related adverse events and no treatment-related deaths.","Tissue samples of 17 patients at baseline and after surgery were collected (5 responders and 12 nonresponders).","Multiplex immunohistochemistry demonstrated a significant increase in CD3+ (P\u00a0= 0.0032) and CD3+CD8+ (P\u00a0= 0.0038) tumor-infiltrating lymphocytes after neoadjuvant therapy, particularly in pathological responders.","CONCLUSIONS: Neoadjuvant toripalimab combined with axitinib in resectable mucosal melanoma demonstrated a promising pathologic response rate with significantly increased infiltrating CD3+ and CD3+CD8+ T cells after therapy."],"Aspect":"i","Summary":"Patients with resectable mucosal melanoma received toripalimab 3 mg\/kg Q2W plus axitinib 5 mg b.i.d. for 8 weeks as neoadjuvant therapy, followed by surgery and adjuvant toripalimab 3 mg\/kg Q2W for 44 weeks.","Indexes":[4,5],"Sentences":["Patients received toripalimab 3 mg\/kg once every 2 weeks (Q2W) plus axitinib 5 mg two times a day (b.i.d.)","for 8 weeks as neoadjuvant therapy, then surgery and adjuvant toripalimab 3 mg\/kg Q2W starting 2 \u00b1 1weeks after surgery for 44 weeks."],"Revise":false}
{"PMID":"31653251","Document":["BACKGROUND: Amputation is the standard of care even for early-stage subungual melanomas (SUMs), known as nail apparatus melanoma, because the nail bed and nail matrix are close to the distal phalanx.","However, a recent study demonstrated that not all patients with SUMs had histologic invasion of the underlying distal phalanx.","As most SUMs occur in the thumb or big toe, amputation of either the thumb or big toe substantially interferes with activities of daily living, including poor cosmesis, loss of function, and phantom pain.","Non-amputative digit preservation surgery can thus be applied in such cases without compromising patient prognosis.","METHODS: We are conducting a multi-institutional single-arm trial to confirm the safety and efficacy of non-amputative digit preservation surgery.","We will compare our results with those reported in the Japanese Melanoma Study, in which patients underwent amputation for SUMs as a traditional standard of care.","Patients aged between 20 and 80\u2009years with stage I, II, or III without evidence of tumor invasion to the underlying distal phalanx on preoperative radiograph are included in the study.","The primary endpoint is major relapse-free survival (major RFS), which does not include local recurrence as an event; secondary endpoints include overall survival, digit-preservation survival, relapse-free survival, local relapse-free survival, partial relapse-free survival, and incidence of adverse events.","A total of 85 patients from 21 Japanese institutions will be recruited within 5.5\u2009years, and the follow-up period will last at least 5\u2009years.","The Japan Clinical Oncology Group Protocol Review Committee approved this study protocol in August 2017, and patient enrollment began in November 2017.","Ethical approval was obtained from each institution's Institutional Review Board prior to patient enrollment.","DISCUSSION: This is the first prospective trial to confirm the safety and efficacy of non-amputative digit preservation surgery for SUM without distant metastasis or bony invasion.","The results of this trial could provide evidence to support this less-invasive surgery as a new standard of care to preserve adequately functioning digits.","TRIAL REGISTRATION: Registry number: UMIN000029997 .","Date of Registration: 16\/Nov\/2017.","Date of First Participant Enrollment: 12\/Dec\/2017."],"Aspect":"p","Summary":"The study includes patients aged between 20 and 80 years with stage I, II, or III subungual melanomas (SUMs) without evidence of tumor invasion to the underlying distal phalanx on preoperative radiograph.","Indexes":[6],"Sentences":["Patients aged between 20 and 80\u2009years with stage I, II, or III without evidence of tumor invasion to the underlying distal phalanx on preoperative radiograph are included in the study."],"Revise":false}
{"PMID":"32812243","Document":["Nivolumab plus ipilimumab combination is currently one of the preferred regimens for advanced melanoma in recently updated clinical practice guidelines.","However, the evidence on the efficacy of the combination for acral or mucosal subtypes remains less robust.","This is the final analysis of a multicenter, open-label, uncontrolled phase II study that investigated the long-term efficacy and safety in treatment-naive Japanese patients with advanced melanoma, including acral or mucosal subtypes, and subsequent therapy after discontinuation of the investigational agents.","Patients received four doses of nivolumab (1\u00a0mg\/kg i.v.)","in combination with ipilimumab (3\u00a0mg\/kg i.v.)","at 3-week intervals, followed by doses of nivolumab (3\u00a0mg\/kg i.v.)","at 2-week intervals.","The median follow-up period was 20.8\u00a0months (range, 5.2-35.0).","The centrally and locally assessed objective response rates were both 43.3% (13\/30; 95% confidence interval [CI], 25.5-62.6).","Median progression-free survival was not reached (95% CI, 3.02-not reached), and median overall survival was also not reached (95% CI, 19.52-not reached).","The 30-month progression-free survival and overall survival rates were 50.3% and 54.2%, respectively.","No new safety concerns were detected.","After discontinuation of the investigational agents, 83.3% of patients received some form of subsequent therapy including 43.3% of patients who received nivolumab monotherapy and 26.7% of patients who received radiotherapy.","Of the four patients who discontinued the investigational agents because of immune-related adverse events, two received subsequent therapy (nivolumab and ipilimumab, respectively) and the other two showed long-term treatment-free survival (659 and 590\u00a0days, respectively).","Long-term survival with nivolumab plus ipilimumab was observed in Japanese patients with melanoma including acral and mucosal subtypes, which is consistent with the CheckMate 067 study.","Many patients continued to receive some form of treatment safely after stopping treatment with nivolumab plus ipilimumab."],"Aspect":"o","Summary":"The study demonstrated long-term survival with nivolumab plus ipilimumab in Japanese patients with melanoma, including acral and mucosal subtypes.","Indexes":[14],"Sentences":["Long-term survival with nivolumab plus ipilimumab was observed in Japanese patients with melanoma including acral and mucosal subtypes, which is consistent with the CheckMate 067 study."],"Revise":false}
{"PMID":"32011509","Document":["BACKGROUND: Plenty of evidence has suggested that long non-coding RNAs (lncRNAs) have played a vital part may act as prognostic biomarkers in a variety of cancers.","The aim of this study was to screen survival-related lncRNAs and to construct a lncRNA-based prognostic model in patients with cutaneous melanoma (CM).","METHODS: We obtained lncRNAs expression profiles and clinicopathological data from the Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) databases.","A lncRNA-based prognostic model was established in training set.","The established prognostic model was evaluated, and validated in the validation set.","Then, a prognostic nomogram combining the lncRNA-based risk score and clinicopathological characteristics was developed in training set, and assessed in the validation set.","The accuracy of the model was evaluated by the discrimination and calibration plots.","RESULTS: A total of 212 lncRNAs were identified to be differentially expressed in CM.","After univariate analysis, LASSO penalized regression analysis, and multivariate analysis, 3 lncRNAs were used to construct risk score model.","The proposed risk score model could divide patients into high-risk and low-risk groups with significantly different survival in both training set and validation set.","The ROC curve showed good performance in survival prediction in both sets.","Furthermore, the nomogram for predicting 3-, 5-, and 10-year OS was established based on lncRNA-based risk score and clinicopathologic factors.","The prognostic accuracy of the risk model was confirmed by the discrimination and calibration plots in both training set and validation set.","CONCLUSIONS: We established a novel three lncRNA-based risk score model and nomogram to predict overall survival of CM.","The proposed nomogram may provide information for individualized treatment in CM patients."],"Aspect":"i","Summary":"The study utilized lncRNA expression profiles and clinicopathological data from TCGA and GTEx databases to construct and validate a lncRNA-based prognostic model for cutaneous melanoma.","Indexes":[2,3,4],"Sentences":["METHODS: We obtained lncRNAs expression profiles and clinicopathological data from the Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) databases.","A lncRNA-based prognostic model was established in training set.","The established prognostic model was evaluated, and validated in the validation set."],"Revise":true}
{"PMID":"33303575","Document":["Antitumor immunity is impaired in obese mice.","Mechanistic insight into this observation remains sparse and whether it is recapitulated in patients with cancer is unclear because clinical studies have produced conflicting and controversial findings.","We addressed this by analyzing data from patients with a diverse array of cancer types.","We found that survival after immunotherapy was not accurately predicted by body mass index or serum leptin concentrations.","However, oxidized low-density lipoprotein (ox-LDL) in serum was identified as a suppressor of T-cell function and a driver of tumor cytoprotection mediated by heme oxygenase-1 (HO-1).","Analysis of a human melanoma gene expression database showed a clear association between higher HMOX1 (HO-1) expression and reduced progression-free survival.","Our in vivo experiments using mouse models of both melanoma and breast cancer revealed HO-1 as a mechanism of resistance to anti-PD1 immunotherapy but also exposed HO-1 as a vulnerability that could be exploited therapeutically using a small-molecule inhibitor.","In conclusion, our clinical data have implicated serum ox-LDL as a mediator of therapeutic resistance in patients with cancer, operating as a double-edged sword that both suppressed T-cell immunity and simultaneously induced HO-1-mediated tumor cell protection.","Our studies also highlight the therapeutic potential of targeting HO-1 during immunotherapy, encouraging further translational development of this combination approach.See article by Kuehm et al., p. 227."],"Aspect":"i","Summary":"The study analyzed data from patients with various cancer types and conducted in vivo experiments using mouse models of melanoma and breast cancer to investigate the role of ox-LDL and HO-1 in immunotherapy resistance.","Indexes":[2,6],"Sentences":["We addressed this by analyzing data from patients with a diverse array of cancer types.","Our in vivo experiments using mouse models of both melanoma and breast cancer revealed HO-1 as a mechanism of resistance to anti-PD1 immunotherapy but also exposed HO-1 as a vulnerability that could be exploited therapeutically using a small-molecule inhibitor."],"Revise":false}
{"PMID":"35348754","Document":["BACKGROUND: The prognosis of patients with metastatic malignant melanoma is very poor and partly due to resistance to conventional chemotherapies.","The study's objectives were to assess the activity and tolerability of apatinib, an oral small molecule anti-angiogenesis inhibitor, in patients with recurrent advanced melanoma.","METHODS: This was a single-arm, single-center phase II trial.","The primary endpoint was progression-free survival (PFS) and the secondary endpoints were objective response rate (ORR), disease control rate (DCR), and overall survival (OS).","Eligible patients had received at least one first-line therapy for advanced melanoma and experienced recurrence.","Apatinib (500\u00a0mg) was orally administered daily.","RESULTS: Fifteen patients (V660E BRAF status: 2 mutation, 2 unknown, 11 wild type) were included in the analysis.","The median PFS was 4.0 months.","There were two major objective responses, for a 13.3% response rate.","Eleven patients had stable disease, with a DCR of 86.7%.","The median OS was 12.0 months.","The most common treatment-related adverse events of any grade were hypertension (80.0%), mucositis oral (33.3%), hand-foot skin reaction (26.7%), and liver function abnormalities, hemorrhage, diarrhea (each 20%).","The only grade \u22653 treatment-related adverse effects that occurred in 2 patients was hypertension (6.7%) and mucositis (6.7%).","No treatment-related deaths occurred.","CONCLUSION: Apatinib showed antitumor activity as a second- or above-line therapy in patients with malignant melanoma.","The toxicity was manageable.","CLINICALTRIALS.GOV IDENTIFIER: NCT03383237."],"Aspect":"s","Summary":"The most common treatment-related adverse events were hypertension, mucositis oral, hand-foot skin reaction, liver function abnormalities, hemorrhage, and diarrhea, with hypertension and mucositis being the most severe (grade \u22653).","Indexes":[11,12],"Sentences":["The most common treatment-related adverse events of any grade were hypertension (80.0%), mucositis oral (33.3%), hand-foot skin reaction (26.7%), and liver function abnormalities, hemorrhage, diarrhea (each 20%).","The only grade \u22653 treatment-related adverse effects that occurred in 2 patients was hypertension (6.7%) and mucositis (6.7%)."],"Revise":false}
{"PMID":"39366752","Document":["BACKGROUND: HBM4003 is a novel anti-CTLA-4 heavy chain-only antibody, designed to enhance Treg ablation and antibody-dependent cell-mediated cytotoxicity while ensuring a manageable safety profile.","This phase I trial investigated the safety, pharmacokinetics, immunogenicity and preliminary efficacy of HBM4003 plus with anti-PD-1 antibody toripalimab in patients with advanced solid tumors, especially focusing on melanoma.","METHODS: The multicenter, open-label phase I trial was divided into two parts: dose-escalation phase (part 1) and dose-expansion phase (part 2).","In part 1, HBM4003 was administered at doses of 0.03, 0.1, 0.3\u2009mg\/kg in combination with toripalimab with fixed dosage of 240\u2009mg every 3 weeks.","The recommended phase II dose (RP2D) was used in the expansion phase.","Primary endpoints were safety and RP2D in part 1 and objective response rate (ORR) in part 2.","Biomarkers based on cytokines and multiplex immunofluorescence staining were explored.","RESULTS: A total of 40 patients received study treatment, including 36 patients treated with RP2D of HBM4003 0.3\u2009mg\/kg plus toripalimab 240\u2009mg every 3 week.","36 participants (90.0%) experienced at least one treatment-related adverse event (TRAE), of which 10 (25.0%) patients experienced grade \u22653 TRAEs and 5 (12.5%) experienced immune-mediated adverse events (irAEs) with maximum severity of grade 3.","No grade 4 or 5 irAEs occurred.","Efficacy analysis set included 32 melanoma patients treated with RP2D and with available post-baseline imaging data.","The ORRs of anti-PD-1\/PD-L1 treatment-na\u00efve subgroup and anti-PD-1\/PD-L1 treatment-failed subgroup were 33.3% and 5.9%, respectively.","In mucosal melanoma, the ORR of the two subgroups were 40.0% and 10.0%, respectively.","Baseline high Treg\/CD4+ratio in the tumor serves as an independent predictive factor for the efficacy of immunotherapy.","CONCLUSIONS: HBM4003 0.3\u2009mg\/kg plus toripalimab 240\u2009mg every 3 week demonstrated manageable safety in solid tumors and no new safety signal.","Limited data demonstrated promising antitumor activity, especially in PD-1 treatment-na\u00efve mucosal melanoma.","TRIAL REGISTRATION NUMBER: NCT04727164."],"Aspect":"a","Summary":"This study aims to investigate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of HBM4003 in combination with the anti-PD-1 antibody toripalimab in patients with advanced solid tumors, with a focus on melanoma.","Indexes":[1],"Sentences":["This phase I trial investigated the safety, pharmacokinetics, immunogenicity and preliminary efficacy of HBM4003 plus with anti-PD-1 antibody toripalimab in patients with advanced solid tumors, especially focusing on melanoma."],"Revise":false}
{"PMID":"33446823","Document":["There is a wide range of equivocal melanocytic lesions that can be clinically and dermoscopically indistinguishable from early melanoma.","In the present work, we assessed the possibilities of combined using of multiphoton microscopy (MPM) and optical coherence angiography (OCA) for differential diagnosis of the equivocal melanocytic lesions.","Clinical and dermoscopic examinations of 60 melanocytic lesions revealed 10 benign lesions and 32 melanomas, while 18 lesions remained difficult to diagnose.","Histopathological analysis of these lesions revealed 4 intradermal, 3 compound and 3 junctional nevi in the \"benign\" group, 7 superficial spreading, 14 lentigo maligna and 11 nodular melanomas in the \"melanoma\" group and 2 lentigo simplex, 4 dysplastic nevi, 6 melanomas in situ, 4 invasive lentigo melanomas and 2 invasive superficial spreading melanomas in the \"equivocal\" group.","On the basis of MPM, a multiphoton microscopy score (MPMS) has been developed for quantitative assessment of melanoma features at the cellular level, that showed lower score for benign lesions compare with malignant ones.","OCA revealed that the invasive melanoma has a higher vessel density and thicker blood vessels than melanoma in situ and benign lesions.","Discriminant functions analysis of MPM and OCA data allowed to differentiate correctly between all equivocal melanocytic lesions.","Therefore, we demonstrate, for the first time, that a combined use of MPM and OCA has the potential to improve early diagnosis of melanoma."],"Aspect":"o","Summary":"The study demonstrates that the combined use of multiphoton microscopy (MPM) and optical coherence angiography (OCA) has the potential to improve the early diagnosis of melanoma by differentiating equivocal melanocytic lesions.","Indexes":[6,7],"Sentences":["Discriminant functions analysis of MPM and OCA data allowed to differentiate correctly between all equivocal melanocytic lesions.","Therefore, we demonstrate, for the first time, that a combined use of MPM and OCA has the potential to improve early diagnosis of melanoma."],"Revise":false}
{"PMID":"35193932","Document":["BACKGROUND: Mucosal melanoma is an aggressive melanoma subtype with poor response to antiprogrammed cell death-1 (PD-1) monotherapy.","Axitinib in combination with toripalimab, a humanized IgG4 mAb against PD-1, showed a promising response rate in patients with metastatic mucosal melanoma (MM) in a phase Ib study.","Here, we report the updated overall survival (OS), duration of response (DoR), and biomarker analysis results.","METHODS: Patients with advanced MM received toripalimab 1 or 3\u2009mg\/kg intravenously every 2 weeks combined with axitinib 5\u2009mg orally two times per day until disease progression or unacceptable toxicity.","Tumor programmed cell death ligand-1 (PD-L1) expression, tumor mutational burden (TMB), and gene expression profile (GEP) by messenger RNA sequencing were evaluated for correlation with survival.","RESULTS: As of April 2, 2021, the median follow-up was 42.5 months.","Among 29 chemotherapy-na\u00efve patients with metastatic MM, the median OS was 20.7 months (95%\u2009CI 9.7 to 32.7 months); the median progression-free survival (PFS) was 7.5 months (95%\u2009CI 3.8 to 14.8 months); and the median DoR was 13.4 months (95%\u2009CI 5.5 to 20.6 months).","The OS rates of 1, 2, and 3\u2009years were 62.1%, 44.8%, and 31.0%, respectively.","Biomarker analysis found that PD-L1 expression and TMB level were not associated with survival benefits.","In contrast, a 12-GEP signature correlated with improved PFS (17.7 vs 5.7 months, p=0.0083) and OS (35.6 vs 17.6 months, p=0.039).","CONCLUSIONS: The 3-year survival update confirmed the antitumor activity and long-term survival benefit of the toripalimab plus axitinib combination in patients with advanced MM.","The 12-gene GEP is of value in predicting the outcomes of vascular endothelial growth factor receptor-tyrosine kinase inhibitor and PD-1 blockade combination therapy, but requires further validation.","TRIAL REGISTRATION NUMBERS: NCT03086174."],"Aspect":"o","Summary":"The combination of toripalimab and axitinib demonstrated a median overall survival of 20.7 months and a 3-year survival rate of 31.0% in patients with advanced mucosal melanoma. Biomarker analysis showed no survival benefit from PD-L1 expression or TMB, but a 12-GEP signature was linked to improved PFS and OS.","Indexes":[6,7,8,9],"Sentences":["Among 29 chemotherapy-na\u00efve patients with metastatic MM, the median OS was 20.7 months (95%\u2009CI 9.7 to 32.7 months); the median progression-free survival (PFS) was 7.5 months (95%\u2009CI 3.8 to 14.8 months); and the median DoR was 13.4 months (95%\u2009CI 5.5 to 20.6 months).","The OS rates of 1, 2, and 3\u2009years were 62.1%, 44.8%, and 31.0%, respectively.","Biomarker analysis found that PD-L1 expression and TMB level were not associated with survival benefits.","In contrast, a 12-GEP signature correlated with improved PFS (17.7 vs 5.7 months, p=0.0083) and OS (35.6 vs 17.6 months, p=0.039)."],"Revise":true}
{"PMID":"32112140","Document":["PURPOSE: To demonstrate superiority of intravitreal ranibizumab 0.5\u00a0mg compared to focal and peripheral laser treatment in patients with radiation retinopathy for choroidal melanoma.","METHODS: Inclusion criteria were as follows: patients with radiation retinopathy and visual acuity impairment due to radiation maculopathy accessible for laser therapy, age\u2009\u2265\u200918\u00a0years, and BCVA less than 20\/32.","The main objective was to study the change in best-corrected visual acuity (BCVA) over 6\u00a0months from ranibizumab 0.5\u00a0mg (experimental) compared to focal laser of the macula and panretinal laser treatment of the ischemic retina (control) in patients with radiation retinopathy in choroidal melanoma.","The secondary objectives of the radiation retinopathy study were to compare functional and anatomical results between ranibizumab and laser group over 12\u00a0months and to measure the frequency of vitreous hemorrhage and rubeosis iridis.","RESULTS: The intention-to-treat analysis included 31 patients assigned to ranibizumab (n\u2009=\u200915) or laser treatment (n\u2009=\u200916).","In terms of BCVA at month 6, ranibizumab was superior to laser treatment, with an advantage of 0.14 logMAR, 95% CI 0.01 to 0.25, p\u2009=\u20090.030.","The positive effect of ranibizumab disappeared after treatment was discontinued.","Similar results without statistically significant difference were found with respect to macular thickness.","In both groups, no change was observed at month 6 in the size of ischemia in the macula or periphery compared to baseline.","There was 1 case of vitreous hemorrhage in the laser group and no case of rubeosis iridis over time.","CONCLUSIONS: This study showed a statistically significant improvement in visual acuity and clear superiority of ranibizumab compared to laser treatment up to 26\u00a0weeks, but this effect disappeared at week 52 after completion of intravitreal treatment.","Ranibizumab and PRP are considered equivalent in terms of the non-appearance of proliferative radiation retinopathy during the study.","TRIAL REGISTRATION: EudraCT Number: 2011-004463-69."],"Aspect":"i","Summary":"The study compared the effect of intravitreal ranibizumab 0.5 mg to focal and peripheral laser treatment in patients with radiation retinopathy for choroidal melanoma over 6 months.","Indexes":[0,2],"Sentences":["PURPOSE: To demonstrate superiority of intravitreal ranibizumab 0.5\u00a0mg compared to focal and peripheral laser treatment in patients with radiation retinopathy for choroidal melanoma.","The main objective was to study the change in best-corrected visual acuity (BCVA) over 6\u00a0months from ranibizumab 0.5\u00a0mg (experimental) compared to focal laser of the macula and panretinal laser treatment of the ischemic retina (control) in patients with radiation retinopathy in choroidal melanoma."],"Revise":true}
{"PMID":"36162037","Document":["PURPOSE: Ipilimumab and nivolumab have each shown treatment benefit for high-risk resected melanoma.","The phase III CheckMate 915 trial evaluated adjuvant nivolumab plus ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or IV melanoma.","PATIENTS AND METHODS: In this randomized, double-blind, phase III trial, 1,833 patients received nivolumab 240 mg once every 2 weeks plus ipilimumab 1 mg\/kg once every 6 weeks (916 patients) or nivolumab 480 mg once every 4 weeks (917 patients) for \u2264 1 year.","After random assignment, patients were stratified by tumor programmed death ligand 1 (PD-L1) expression and stage.","Dual primary end points were recurrence-free survival (RFS) in randomly assigned patients and in the tumor PD-L1 expression-level < 1% subgroup.","RESULTS: At a minimum follow-up of approximately 23.7 months, there was no significant difference between treatment groups for RFS in the all-randomly assigned patient population (hazard ratio, 0.92; 95% CI, 0.77 to 1.09; P = .269) or in patients with PD-L1 expression < 1% (hazard ratio, 0.91; 95% CI, 0.73 to 1.14).","In all patients, 24-month RFS rates were 64.6% (combination) and 63.2% (nivolumab).","Treatment-related grade 3 or 4 adverse events were reported in 32.6% of patients in the combination group and 12.8% in the nivolumab group.","Treatment-related deaths were reported in 0.4% of patients in the combination group and in no nivolumab-treated patients.","CONCLUSION: Nivolumab 240 mg once every 2 weeks plus ipilimumab 1 mg\/kg once every 6 weeks did not improve RFS versus nivolumab 480 mg once every 4 weeks in patients with stage IIIB-D or stage IV melanoma.","Nivolumab showed efficacy consistent with previous adjuvant studies in a population resembling current practice using American Joint Committee on Cancer eighth edition, reaffirming nivolumab as a standard of care for melanoma adjuvant treatment."],"Aspect":"s","Summary":"Treatment-related grade 3 or 4 adverse events were reported in 32.6% of patients in the combination group and 12.8% in the nivolumab group, with treatment-related deaths reported in 0.4% of patients in the combination group and none in the nivolumab group.","Indexes":[7,8],"Sentences":["Treatment-related grade 3 or 4 adverse events were reported in 32.6% of patients in the combination group and 12.8% in the nivolumab group.","Treatment-related deaths were reported in 0.4% of patients in the combination group and in no nivolumab-treated patients."],"Revise":false}
{"PMID":"32161584","Document":["Phenotyping of immune cell subsets in clinical trials is limited to well-defined phenotypes, due to technological limitations of reporting flow cytometry multi-dimensional phenotyping data.","We developed a multi-dimensional phenotyping analysis tool and applied it to detect nitric oxide (NO) levels in peripheral blood immune cells before and after adjuvant ipilimumab co-administration with a peptide vaccine in melanoma patients.","We analyzed inhibitory and stimulatory markers for immune cell phenotypes that were felt to be important in the NO analysis.","The pipeline allows visualization of immune cell phenotypes without knowledge of clustering techniques and to categorize cells by association with relapse-free survival (RFS).","Using this analysis, we uncovered the potential for a dichotomous role of NO as a pro- and anti-melanoma factor.","NO was found in subsets of immune-suppressor cells associated with shorter-term (\u2264 1 year) RFS, whereas NO was also present in immune-stimulatory effector cells obtained from patients with significant longer-term (> 1 year) RFS.","These studies provide insights into the cell-specific immunomodulatory role of NO.","The methods presented herein can be applied to monitor the pro- and anti-tumor effects of a variety of immune-based therapeutics in cancer patients.","Clinical Trial Registration Number: NCT00084656 (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00084656)."],"Aspect":"o","Summary":"The study found that nitric oxide (NO) plays a dichotomous role in melanoma, with its presence in immune-suppressor cells associated with shorter relapse-free survival (RFS) and in immune-stimulatory effector cells associated with longer RFS.","Indexes":[4,5],"Sentences":["Using this analysis, we uncovered the potential for a dichotomous role of NO as a pro- and anti-melanoma factor.","NO was found in subsets of immune-suppressor cells associated with shorter-term (\u2264 1 year) RFS, whereas NO was also present in immune-stimulatory effector cells obtained from patients with significant longer-term (> 1 year) RFS."],"Revise":false}
{"PMID":"33963015","Document":["BACKGROUND: The impact of immune-related adverse events (irAEs) occurring from adjuvant use of immunotherapy and of their management on relapse-free survival (RFS) and overall survival (OS) outcomes is currently not well understood.","PATIENTS AND METHODS: E1609 enrolled 1673 patients with resected high-risk melanoma and evaluated adjuvant ipilimumab 3 mg\/kg (ipi3) and 10 mg\/kg (ipi10) versus interferon-\u03b1.","We investigated the association of irAEs and of use of immunosuppressants with RFS and OS for patients treated with ipilimumab (n=1034).","RESULTS: Occurrence of grades 1-2 irAEs was associated with RFS (5 years: 52% (95% CI 47% to 56%) vs 41% (95% CI 31% to 50%) with no AE; p=0.006) and a trend toward improved OS (5 years: 75% (95% CI 71% to 79%) compared with 67% (95% CI 56% to 75%) with no AE; p=0.064).","Among specific irAEs, grades 1-2 rash was most significantly associated with RFS (p=0.002) and OS (p=0.003).","In multivariate models adjusting for prognostic factors, the most significant associations were seen for grades 1-2 rash with RFS (p<0.001, HR=0.70) and OS (p=0.01, HR=0.71) and for grades 1-2 endocrine+rash with RFS (p<0.001, HR=0.66) and OS (p=0.008, HR=0.7).","Overall, grades 1-2 irAEs had the best prognosis in terms of RFS and OS and those with grades 3-4 had less RFS benefits and no OS advantage over no irAE.","Patients experiencing grades 3-4 irAE had significantly higher exposure to corticosteroids and immunosuppressants than those with grades 1-2 (92% vs 60%; p<0.001), but no significant associations were found between corticosteroid and immunosuppressant use and RFS or OS.","In investigating the impact of non-corticosteroid immunosuppressants, although there were trends toward better RFS and OS favoring cases who were not exposed, no significant associations were found.","CONCLUSIONS: Rash and endocrine irAEs were independent prognostic factors of RFS and OS in patients treated with adjuvant ipilimumab.","Patients experiencing lower grade irAEs derived the most benefit, but we found no significant evidence supporting a negative impact of high dose corticosteroids and immunosuppressants more commonly used to manage grades 3-4 irAEs."],"Aspect":"p","Summary":"The study involved 1673 patients with resected high-risk melanoma, with a subset of 1034 patients treated with ipilimumab.","Indexes":[1,2],"Sentences":["PATIENTS AND METHODS: E1609 enrolled 1673 patients with resected high-risk melanoma and evaluated adjuvant ipilimumab 3 mg\/kg (ipi3) and 10 mg\/kg (ipi10) versus interferon-\u03b1.","We investigated the association of irAEs and of use of immunosuppressants with RFS and OS for patients treated with ipilimumab (n=1034)."],"Revise":false}
{"PMID":"37625814","Document":["BACKGROUND: Acral melanoma, the most common subtype of melanoma in Asians, is often diagnosed at an advanced stage and responds poorly to current programmed cell death protein 1 (PD-1) inhibitors.","OBJECTIVES: To evaluate the safety and efficacy of TQB2450 and anlotinib in patients with advanced acral melanoma in a phase Ib study (NCT03991975).","METHODS: Patients received TQB2450 (1200\u2009mg every 3\u2009weeks) and anlotinib (10\u2009mg or 12\u2009mg once daily, 2-week on\/1-week off) in the dose-escalation and dose-expansion phases.","The primary endpoints were dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and objective response rate (ORR).","RESULTS: Nineteen patients were enrolled between June 2019 and June 2022.","The majority of patients (16 of 19 patients) received anlotinib and TQB2450 as first-line treatment.","No DLTs were observed, and MTD was not reached.","Eighteen (94.7%) out of 19 patients experienced treatment-related adverse events (TRAEs), but most were grade 1 or 2.","Grade 3 or greater TRAEs occurred in seven patients (36.8%).","The ORR was 26.3% (two complete responses and three partial responses).","The disease control rate was 73.7%.","The median duration of response was 30.3\u2009months [95% confidence interval (CI): 5.8-NA].","The median progression-free survival (PFS) was 5.5\u2009months (95% CI: 2.8-NA), and median overall survival was 20.3\u2009months (95% CI: 14.8-NA).","Whole-exome sequencing suggested that acquired drug resistance might be attributed to activation of the MAPK signalling pathway and transformation to an immunosuppressive tumour environment.","CONCLUSIONS: TQB2450 combined with anlotinib showed favourable tolerance and promising anti-tumour activity with a prolonged PFS compared with anti-PD1 monotherapy in patients with advanced acral melanoma."],"Aspect":"m","Summary":"The medicines used were TQB2450 at 1200 mg every 3 weeks and anlotinib at 10 mg or 12 mg once daily on a 2-week on\/1-week off schedule.","Indexes":[2],"Sentences":["METHODS: Patients received TQB2450 (1200\u2009mg every 3\u2009weeks) and anlotinib (10\u2009mg or 12\u2009mg once daily, 2-week on\/1-week off) in the dose-escalation and dose-expansion phases."],"Revise":false}
{"PMID":"34199802","Document":["Patients with newly resected stage II melanoma (n = 104) were randomized to receive adjuvant vitamin D3 (100,000 IU every 50 days) or placebo for 3 years to investigate vitamin D3 protective effects on developing a recurrent disease.","Median age at diagnosis was 50 years, and 43% of the patients were female.","Median serum 25-hydroxy vitamin D (25OHD) level at baseline was 18 ng\/mL, interquartile range (IQ) was 13-24 ng\/mL, and 80% of the patients had insufficient vitamin D levels.","We observed pronounced increases in 25OHD levels after 4 months in the active arm (median 32.9 ng\/mL; IQ range 25.9-38.4) against placebo (median 19.05 ng\/mL; IQ range 13.0-25.9), constantly rising during treatment.","Remarkably, patients with low Breslow score (<3 mm) had a double increase in 25OHD levels from baseline, whereas patients with Breslow score \u22653 mm had a significantly lower increase over time.","After 12 months, subjects with low 25OHD levels and Breslow score \u22653 mm had shorter disease-free survival (p = 0.02) compared to those with Breslow score <3 mm and\/or high levels of 25OHD.","Adjusting for age and treatment arm, the hazard ratio for relapse was 4.81 (95% CI: 1.44-16.09, p = 0.011).","Despite the evidence of a role of 25OHD in melanoma prognosis, larger trials with vitamin D supplementation involving subjects with melanoma are needed."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"33971211","Document":["Children are a priority population for skin cancer prevention as excessive sun exposure in childhood increases the risk of melanoma in adulthood.","The complexity of sun protective behaviors has posed measurement challenges for trials testing intervention efficacy.","The current study evaluated a sun safety intervention for schoolchildren using latent transition analysis (LTA) to examine patterns of sun protection behaviors over time.","A three-armed randomized controlled trial was conducted between 2012 and 2016 with two intervention groups (N\u00a0=\u00a03368) and an observation-only control group (N\u00a0=\u00a0342) among 4th and 5th graders from 24 public schools in Los Angeles County.","Both interventions conditions were grouped and compared to controls.","Five self-reported sun protective behaviors were measured at baseline and three-month follow-up: use of sunscreen, long sleeves, long pants, hats, and shade seeking.","Participants comprised 3710 schoolchildren, mean age 9\u00a0years, 47% female and 69% Latino.","At baseline, four patterns of sun protection behaviors were found: children who engaged in 1) all sun protective behaviors; 2) few protective behaviors; 3) protective clothing and shade only; and 4) hats only.","Children in the control group were likely to remain in their baseline status or transition to a less protective status at three-month follow-up.","By contrast, 30% of children in the intervention group transitioned to a more protective status at follow-up.","In this RCT of a sun safety intervention, children in the intervention transitioned to more protective behaviors compared to controls.","Using LTA enriches understanding of intervention efficacy by modeling the complexity of sun protection behaviors over time.","TRIAL REGISTRATION: School-based Randomized Trial of SunSmart Interventions, ClinicalTrials.gov Identifier: NCT04176237 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04176237?cond=School-based+Randomized+Trial+of+SunSmart+Interventions&draw=2&rank=1."],"Aspect":"o","Summary":"Children in the intervention group of the sun safety study were more likely to transition to more protective behaviors compared to the control group.","Indexes":[9,10],"Sentences":["By contrast, 30% of children in the intervention group transitioned to a more protective status at follow-up.","In this RCT of a sun safety intervention, children in the intervention transitioned to more protective behaviors compared to controls."],"Revise":false}
{"PMID":"32007138","Document":["BACKGROUND: Adjuvant dabrafenib plus trametinib reduced the risk of relapse versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma in the phase 3 COMBI-AD trial.","This prespecified exploratory biomarker analysis aimed to evaluate potential prognostic or predictive factors and mechanisms of resistance to adjuvant targeted therapy.","METHODS: COMBI-AD is a randomised, double-blind, placebo-controlled, phase 3 trial comparing dabrafenib 150 mg orally twice daily plus trametinib 2 mg orally once daily versus two matched placebos.","Study participants were at least 18 years of age and underwent complete resection of stage IIIA (lymph node metastases >1 mm), IIIB, or IIIC cutaneous melanoma, per American Joint Committee on Cancer 7th edition criteria, with a BRAFV600E or BRAFV600K mutation.","Patients were randomly assigned (1:1) to the two treatment groups by an interactive voice response system, stratified by mutation type and disease stage.","Patients, physicians, and the investigators who analysed data were masked to treatment allocation.","The primary outcome was relapse-free survival, defined as the time from randomisation to disease recurrence or death from any cause.","Biomarker assessment was a prespecified exploratory outcome of the trial.","We assessed intrinsic tumour genomic features by use of next-generation DNA sequencing and characteristics of the tumour microenvironment by use of a NanoString RNA assay, which might provide prognostic and predictive information.","This trial is registered with ClinicalTrials.gov, number NCT01682083, and is ongoing but no longer recruiting participants.","FINDINGS: Between Jan 31, 2013, and Dec 11, 2014, 870 patients were enrolled in the trial.","Median follow-up at data cutoff (April 30, 2018) was 44 months (IQR 38-49) in the dabrafenib plus trametinib group and 42 months (21-49) in the placebo group.","Intrinsic tumour genomic features were assessed in 368 patients (DNA sequencing set) and tumour microenvironment characteristics were assessed in 507 patients (NanoString biomarker set).","MAPK pathway genomic alterations at baseline did not affect treatment benefit or clinical outcome.","An IFN\u03b3 gene expression signature higher than the median was prognostic for prolonged relapse-free survival in both treatment groups.","Tumour mutational burden was independently prognostic for relapse-free survival in the placebo group (high TMB, top third; hazard ratio [HR] 0\u00b756, 95% CI 0\u00b737-0\u00b785, p=0\u00b70056), but not in the dabrafenib plus trametinib group (0\u00b783, 95% CI 0\u00b753-1\u00b732, p=0\u00b744).","Patients with tumour mutational burden in the lower two terciles seem to derive a substantial long-term relapse-free survival benefit from targeted therapy (HR [versus placebo] 0\u00b749, 95% CI 0\u00b735-0\u00b768, p<0\u00b70001).","However, patients with high tumour mutational burden seem to have a less pronounced benefit with targeted therapy (HR [versus placebo] 0\u00b775, 95% CI 0\u00b744-1\u00b726, p=0\u00b727), especially if they had an IFN\u03b3 signature lower than the median (HR 0\u00b788 [95% CI 0\u00b740-1\u00b793], p=0\u00b774).","INTERPRETATION: Tumour mutational burden alone or in combination with IFN\u03b3 gene expression signature or other markers for an adaptive immune response might be of relevance for identifying patients with stage III melanoma who might derive clinical benefit from targeted therapy.","Further validation in prospective clinical trials is warranted.","FUNDING: Novartis Pharmaceuticals."],"Aspect":"i","Summary":"COMBI-AD is a randomised, double-blind, placebo-controlled, phase 3 trial comparing dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma.","Indexes":[2],"Sentences":["METHODS: COMBI-AD is a randomised, double-blind, placebo-controlled, phase 3 trial comparing dabrafenib 150 mg orally twice daily plus trametinib 2 mg orally once daily versus two matched placebos."],"Revise":true}
{"PMID":"33125309","Document":["PURPOSE: Metastatic uveal melanoma has poor overall survival (OS) and no approved systemic therapy options.","Studies of single-agent immunotherapy regimens have shown minimal benefit.","There is the potential for improved responses with the use of combination immunotherapy.","PATIENTS AND METHODS: We conducted a phase II study of nivolumab with ipilimumab in patients with metastatic uveal melanoma.","Any number of prior treatments was permitted.","Patients received nivolumab 1 mg\/kg and ipilimumab 3 mg\/kg for four cycles, followed by nivolumab maintenance therapy for up to 2 years.","The primary outcome of the study was overall response rate (ORR) as determined by RECIST 1.1 criteria.","Progression-free survival (PFS), OS, and adverse events were also assessed.","RESULTS: Thirty-five patients were enrolled, and 33 patients were evaluable for efficacy.","The ORR was 18%, including one confirmed complete response and five confirmed partial responses.","The median PFS was 5.5 months (95% CI, 3.4 to 9.5 months), and the median OS was 19.1 months (95% CI, 9.6 months to NR).","Forty percent of patients experienced a grade 3-4 treatment-related adverse event.","CONCLUSION: The combination regimen of nivolumab plus ipilimumab demonstrates activity in metastatic uveal melanoma, with deep and sustained confirmed responses."],"Aspect":"m","Summary":"The treatment regimen consisted of nivolumab at 1 mg\/kg and ipilimumab at 3 mg\/kg for four cycles, followed by nivolumab maintenance therapy for up to 2 years.","Indexes":[5],"Sentences":["Patients received nivolumab 1 mg\/kg and ipilimumab 3 mg\/kg for four cycles, followed by nivolumab maintenance therapy for up to 2 years."],"Revise":false}
{"PMID":"35131452","Document":["BACKGROUND: The phase III IMspire150 study (NCT02908672) demonstrated significantly improved progression-free survival (PFS) with atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) versus placebo, vemurafenib, and cobimetinib (control group) in patients with BRAFV600-mutated advanced melanoma.","We report exploratory biomarker analyses to optimize targeting of patients who are more likely to benefit from triplet combination therapy.","PATIENTS AND METHODS: Five hundred fourteen patients were randomized to atezolizumab (n\u00a0= 256) or control (n\u00a0= 258).","Outcomes were evaluated in subgroups defined by key biomarkers, including programmed death-ligand 1 (PD-L1) expression, lactate dehydrogenase (LDH) level, tumor mutational burden (TMB), and interferon-\u03b3 (IFN-\u03b3) gene signature.","Exploratory recursive partitioning analysis was then used to model associations between PFS and baseline covariates, including key biomarkers.","RESULTS: PFS benefit for atezolizumab versus control was greater in patients with high TMB [\u226510 mutations\/Mb; hazard ratio (HR) 0.73; 95% confidence interval (CI) 0.52-1.02; P\u00a0= 0.067] versus low TMB (<10 mutations\/Mb; HR 0.92; 95% CI 0.65-1.30; P\u00a0= 0.64) and similar between patients with strong IFN-\u03b3 (\u2265median; HR 0.76; 95% CI 0.54-1.06) versus weak IFN-\u03b3 (<median; HR 0.79; 95% CI 0.58-1.08).","In patients with elevated LDH, PFS benefit for atezolizumab versus control was greater in the PD-L1- subgroup (HR 0.53; 95% CI 0.29-0.95; P\u00a0= 0.032) than in the PD-L1+ subgroup (HR 1.16; 95% CI 0.75-1.80; P\u00a0= 0.51).","Recursive partitioning analysis showed that IFN-\u03b3 discriminated PFS outcomes in patients with normal LDH, whereas TMB discriminated outcomes in patients with elevated LDH in the atezolizumab group.","Neither IFN-\u03b3 nor TMB discriminated PFS outcomes in the control group.","CONCLUSIONS: Treatment benefits in the atezolizumab group seemed to be most evident in patients with elevated LDH and PD-L1- tumors.","LDH remains the primary predictor of outcomes regardless of treatment.","IFN-\u03b3 and TMB further differentiate outcomes for patients treated with atezolizumab, vemurafenib, and cobimetinib."],"Aspect":"o","Summary":"The study found that the progression-free survival benefit of atezolizumab combination therapy was greater in patients with high tumor mutational burden (TMB) and in patients with elevated lactate dehydrogenase (LDH) and programmed death-ligand 1 negative (PD-L1-) tumors.","Indexes":[5,6,9],"Sentences":["RESULTS: PFS benefit for atezolizumab versus control was greater in patients with high TMB [\u226510 mutations\/Mb; hazard ratio (HR) 0.73; 95% confidence interval (CI) 0.52-1.02; P\u00a0= 0.067] versus low TMB (<10 mutations\/Mb; HR 0.92; 95% CI 0.65-1.30; P\u00a0= 0.64) and similar between patients with strong IFN-\u03b3 (\u2265median; HR 0.76; 95% CI 0.54-1.06) versus weak IFN-\u03b3 (<median; HR 0.79; 95% CI 0.58-1.08).","In patients with elevated LDH, PFS benefit for atezolizumab versus control was greater in the PD-L1- subgroup (HR 0.53; 95% CI 0.29-0.95; P\u00a0= 0.032) than in the PD-L1+ subgroup (HR 1.16; 95% CI 0.75-1.80; P\u00a0= 0.51).","CONCLUSIONS: Treatment benefits in the atezolizumab group seemed to be most evident in patients with elevated LDH and PD-L1- tumors."],"Revise":true}
{"PMID":"36455412","Document":["OBJECTIVE: To evaluate the efficacy and safety of cobimetinib plus atezolizumab in the treatment of patients with advanced BRAFV600 wild-type melanoma who had progressed on prior anti\u2012programmed death-1 (PD-1) therapy.","PATIENTS AND METHODS: This phase 1b, open-label, international multicentre study enrolled 3 cohorts.","Herein, we report on patients in cohorts A and B who had progressed on prior anti\u2012PD-1 therapy.","Patients in cohort A received cobimetinib 60\u00a0mg once daily for 21 days followed by a 7-day break and concurrent intravenous atezolizumab 840\u00a0mg every 2 weeks.","Patients in cohort B received the same dosing regimen as cohort A except for cycle 1 in which patients received cobimetinib only for the first 14 days prior to initiation of atezolizumab on cycle 1 day 15.","Coprimary end-points were objective response rate\u00a0and disease control rate.","Secondary end-points were duration of response, progression free survival\u00a0and overall survival.","RESULTS: Between 19th June\u00a02017\u00a0and 12th December\u00a02018, 103 patients were enrolled.","Median follow-up was 6.9 months (interquartile range, 4.8-10.1 months); objective response rate was 14.6% and disease control rate was 38.8% (95% confidence interval, 29.39-48.94).","The median duration of response, progression-free survival and overall survival was 12.7 months, 3.8 months\u00a0and 14.7 months, respectively.","The most common adverse events were diarrhoea (75\/103; 72.8%), dermatitis acneiform (57\/103; 55.3%)\u00a0and nausea (52\/103; 50.5%).","Thirty-four patients (33.0%) died: 33 (91.7%) due to progressive disease and one (1%) due to treatment-related oesophagitis.","CONCLUSIONS: Combination therapy with cobimetinib and atezolizumab in patients with advanced BRAFV600 wild-type melanoma with disease progression on or after prior anti\u2012PD-1 therapy demonstrated limited activity.","CLINICAL TRIAL REGISTRATION: This study is registered with ClinicalTrials.gov; NCT03178851."],"Aspect":"m","Summary":"The medicines used are cobimetinib 60 mg once daily for 21 days followed by a 7-day break, and intravenous atezolizumab 840 mg every 2 weeks, with the exception that patients in cohort B received cobimetinib for 14 days before starting atezolizumab on cycle 1 day 15.","Indexes":[3,4],"Sentences":["Patients in cohort A received cobimetinib 60\u00a0mg once daily for 21 days followed by a 7-day break and concurrent intravenous atezolizumab 840\u00a0mg every 2 weeks.","Patients in cohort B received the same dosing regimen as cohort A except for cycle 1 in which patients received cobimetinib only for the first 14 days prior to initiation of atezolizumab on cycle 1 day 15."],"Revise":true}
{"PMID":"31425478","Document":["Despite an established history of intraocular antivascular endothelial growth factor (anti-VEGF) agents therapy in a variety of ocular pathologies as well as other cancer forms, use in the primary treatment of uveal melanoma has not been well assessed.","This was a two-stage therapeutic and exploratory phase II, non-randomised, single centre trial involving intraocular treatment with 0.5 mg in 0.05 ml of ranibizumab via six intravitreous injections over 6 months in patients with primary ocular melanoma that otherwise required radical surgery because of tumour size.","Seven patients were recruited with a median age of 66 years.","At baseline, the longest basal diameter was 15.1 mm (mean, range 10-20.4 mm) with a height measured by ultrasonography of 9.2 mm (mean, range 6.6-12.7 mm).","No patients achieved complete or partial response at any visit.","All required enucleation.","Histopathological analysis revealed mixed cell melanoma in 5\/7 (71%) and spindle cell morphology in 2\/7 (29%) with ciliary body involvement in 4\/7 (57%) and the presence of closed loops also in 4\/7 (57%).","Genetic analysis demonstrated loss of chromosome 3 in 5\/7 (71%) but abnormalities in chromosome 1,6 or 8 in all cases.","Our study was terminated early as alternative treatments were clearly superior for local tumour control.","There continues to be a role of intravitreal anti-VEGF for the treatment of the sequelae of local radiotherapy in the form of radiation retinopathy and so these agents may be used as adjuncts in the treatment of uveal melanoma rather than as a primary treatment."],"Aspect":"a","Summary":"The study aims to assess the use of intraocular ranibizumab as a primary treatment for uveal melanoma.","Indexes":[0,1],"Sentences":["Despite an established history of intraocular antivascular endothelial growth factor (anti-VEGF) agents therapy in a variety of ocular pathologies as well as other cancer forms, use in the primary treatment of uveal melanoma has not been well assessed.","This was a two-stage therapeutic and exploratory phase II, non-randomised, single centre trial involving intraocular treatment with 0.5 mg in 0.05 ml of ranibizumab via six intravitreous injections over 6 months in patients with primary ocular melanoma that otherwise required radical surgery because of tumour size."],"Revise":false}
{"PMID":"31880964","Document":["PURPOSE: Phase III adjuvant trials have reported significant benefits in both relapse-free survival (RFS) and overall survival (OS) for high-dose interferon alfa (HDI) and ipilimumab at 10 mg\/kg (ipi10).","E1609 evaluated the safety and efficacy of ipilimumab at 3 mg\/kg (ipi3) and ipi10 versus HDI.","PATIENTS AND METHODS: E1609 was a phase III trial in patients with resected cutaneous melanoma (American Joint Committee on Cancer 7th edition stage IIIB, IIIC, M1a, or M1b).","It had 2 coprimary end points: OS and RFS.","A 2-step hierarchic approach first evaluated ipi3 versus HDI followed by ipi10 versus HDI.","RESULTS: Between May 2011 and August 2014, 1,670 adult patients were centrally randomly assigned (1:1:1) to ipi3 (n = 523), HDI (n = 636), or ipi10 (n = 511).","Treatment-related adverse events grade \u2265 3 occurred in 37% of patients receiving ipi3, 79% receiving HDI, and 58% receiving ipi10, with adverse events leading to treatment discontinuation in 35%, 20%, and 54%, respectively.","Comparison of ipi3 versus HDI used an intent-to-treat analysis of concurrently randomly assigned patient cases (n = 1,051) and showed significant OS difference in favor of ipi3 (hazard ratio [HR], 0.78; 95.6% repeated CI, 0.61 to 0.99; P = .044; RFS: HR, 0.85; 99.4% CI, 0.66 to 1.09; P = .065).","In the second step, for ipi10 versus HDI (n = 989), trends in favor of ipi10 did not achieve statistical significance.","Salvage patterns after melanoma relapse showed significantly higher rates of ipilimumab and ipilimumab\/anti-programmed death 1 use in the HDI arm versus ipi3 and ipi10 (P \u2264 .001).","CONCLUSION: Adjuvant therapy with ipi3 benefits survival versus HDI; for the first time to our knowledge in melanoma adjuvant therapy, E1609 has demonstrated a significant improvement in OS against an active control regimen.","The currently approved adjuvant ipilimumab dose (ipi10) was more toxic and not superior in efficacy to HDI."],"Aspect":"a","Summary":"The study aims to evaluate the safety and efficacy of ipilimumab at 3 mg\/kg (ipi3) and ipilimumab at 10 mg\/kg (ipi10) versus high-dose interferon alfa (HDI) in patients with resected cutaneous melanoma.","Indexes":[0,1],"Sentences":["PURPOSE: Phase III adjuvant trials have reported significant benefits in both relapse-free survival (RFS) and overall survival (OS) for high-dose interferon alfa (HDI) and ipilimumab at 10 mg\/kg (ipi10).","E1609 evaluated the safety and efficacy of ipilimumab at 3 mg\/kg (ipi3) and ipi10 versus HDI."],"Revise":false}
{"PMID":"35466524","Document":["Metastatic uveal melanoma (UM) is a devastating disease with few treatment options.","We evaluated the safety, tolerability and preliminary activity of arginine depletion using pegylated arginine deiminase (ADI-PEG20; pegargiminase) combined with pemetrexed (Pem) and cisplatin (Cis) chemotherapy in a phase 1 dose-expansion study of patients with argininosuccinate synthetase (ASS1)-deficient metastatic UM.","Eligible patients received up to six cycles of Pem (500\u2009mg\/m2 ) and Cis (75\u2009mg\/m2 ) every 3\u2009weeks plus weekly intramuscular ADI (36\u2009mg\/m2 ), followed by maintenance ADI until progression (NCT02029690).","Ten of fourteen ASS1-deficient patients with UM liver metastases and a median of one line of prior immunotherapy received ADIPemCis.","Only one \u2265 grade 3 adverse event of febrile neutropenia was reported.","Seven patients had stable disease with a median progression-free survival of 3.0\u00a0months (range, 1.3-8.1) and a median overall survival of 11.5\u00a0months (range, 3.2-36.9).","Despite anti-ADI-PEG20 antibody emergence, plasma arginine concentrations remained suppressed by 18\u2009weeks with a reciprocal increase in plasma citrulline.","Tumour rebiopsies at progression revealed ASS1 re-expression as an escape mechanism.","ADIPemCis was well tolerated with modest disease stabilisation in metastatic UM.","Further investigation of arginine deprivation is indicated in UM including combinations with immune checkpoint blockade and additional anti-metabolite strategies."],"Aspect":"a","Summary":"The study aims to evaluate the safety, tolerability, and preliminary activity of arginine depletion using pegylated arginine deiminase (ADI-PEG20) combined with pemetrexed (Pem) and cisplatin (Cis) chemotherapy in patients with argininosuccinate synthetase (ASS1)-deficient metastatic uveal melanoma (UM).","Indexes":[1],"Sentences":["We evaluated the safety, tolerability and preliminary activity of arginine depletion using pegylated arginine deiminase (ADI-PEG20; pegargiminase) combined with pemetrexed (Pem) and cisplatin (Cis) chemotherapy in a phase 1 dose-expansion study of patients with argininosuccinate synthetase (ASS1)-deficient metastatic UM."],"Revise":false}
{"PMID":"35552458","Document":["Few studies have examined cognitive responses to mailed precision prevention materials.","MC1R is a robust, well-described melanoma susceptibility marker.","The purpose was to assess cognitive responses to generic or precision prevention materials incorporating MC1R genetic risk.","Non-Hispanic White participants (n = 1134) enrolled in a randomized controlled trial received either precision prevention materials incorporating MC1R genetic risk (higher\/average) or generic prevention (standard) materials.","Six months after baseline, 808 (71.3%) participants reported on the amount of prevention materials read (5-point scale); believability and clarity of materials; intention to change preventive behaviors (7-point Likert scale); and recall of their MC1R genetic risk.","Comparisons were conducted using Kruskal-Wallis and chi-squared tests.","Overall, participants read most to all (Mdn = 4, IQR = 2) of the prevention materials, reported high believability (Mdn = 7, IQR = 1) and clarity (Mdn = 7, IQR = 1), and moderate intention to change preventive behaviors (Mdn = 5, IQR = 2).","Higher-risk participants reported slightly less clarity (Mdn = 6, IQR = 2) than either average-risk (Mdn = 6, IQR = 1, p = 2.50 \u00d7 10-3) or standard participants (Mdn = 7, IQR = 1, p = 2.30 \u00d7 10-5); and slightly less believability (Mdn = 6, IQR = 1) than standard participants (Mdn = 7, IQR = 1, p = .005).","Higher-risk participants were 2.21 times as likely (95% CI = 1.43-3.43) to misremember or forget their risk compared to average-risk participants; misremembering was observed only among higher-risk participants (14%).","Mailed precision prevention information were mostly read, highly believable and clear, and resulted in moderate levels of intention to change sun protection behaviors, bolstering the feasibility of population-level precision prevention.","Defensive reactions may explain lower clarity, believability, and higher incorrect risk recall among higher-risk participants.","Precision prevention uses an individual\u2019s genetics, environment, and\/or lifestyle to promote prevention behaviors.","However, if materials incorporating precision prevention information are not easily accessible, individuals may misinterpret or distrust findings.","Few studies have examined participant-reported believability and clarity of mailed precision prevention materials, how much they read, and whether they intend to change preventive behaviors.","We assessed genetic risk for melanoma by determining DNA variation at the MC1R gene, a known melanoma risk marker.","Participants were mailed either precision prevention materials conveying their MC1R genetic risk or generic (without genetic risk information) prevention materials.","Overall, participants read most of the materials, gave high believability and clarity scores, and reported moderate levels of intention to change preventive behavior.","However, participants at higher genetic risk had slightly lower believability and clarity scores than the generic group and were more likely to forget or misremember their genetic risk than participants at average genetic risk.","Among participants who correctly recalled their genetic risk, differences in believability diminished, while differences in clarity remained.","We conclude that precision prevention materials are highly believable and clear, but additional strategies may be necessary to maximize believability, clarity, and risk recall for individuals at a higher genetic risk."],"Aspect":"m","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"31621203","Document":["This study aimed to evaluate the efficacy of carbon-ion radiotherapy in combination with chemotherapy using dacarbazine, nimustine, and vincristine (DAV therapy) in mucosal melanoma.","Twenty-one patients with clinically localized mucosal melanoma of the head and neck were enrolled.","The primary endpoint was 3-year overall survival (OS).","Secondary endpoints included local control, progression-free survival (PFS), and adverse event occurrence.","Carbon-ion radiotherapy with a dose of 57.6-64.0 Gy (relative biological effectiveness) in 16 fractions was delivered concurrently with DAV therapy, and 2 cycles of adjuvant DAV therapy were administered every 6\u00a0weeks.","The median follow-up periods were 15.5\u00a0months for all patients, and 31.2\u00a0months for 12 surviving patients.","All patients had locally advanced T4a or T4b disease in the rhino-sinus area.","In 16 patients (76.2%), 3 cycles of planned DAV therapy were completed.","The 3-year OS and PFS rates were 49.2% and 37.0% respectively.","The 3-year local control rate was 92.3%.","Eleven patients (52%) developed distant metastasis, which was the most frequent pattern of the first failure.","Commonly presenting acute grade 2-3 toxicities associated with radiotherapy and chemotherapy were mucositis (11 patients [53%]) and leukopenia (9 patients [43%]), which improved with conservative therapy.","None of the patients developed grade 3 or greater late toxicities.","Carbon-ion radiotherapy in combination with DAV therapy led to excellent local control for advanced mucosal melanoma within acceptable toxicities.","The efficacy of additional DAV therapy in improving survival was weaker than expected as distant metastases still occurred frequently.","Trial registration no.","UMIN000007939."],"Aspect":"m","Summary":"The treatment involved dacarbazine, nimustine, and vincristine (DAV therapy) with carbon-ion radiotherapy at a dose of 57.6-64.0 Gy in 16 fractions.","Indexes":[0,4],"Sentences":["This study aimed to evaluate the efficacy of carbon-ion radiotherapy in combination with chemotherapy using dacarbazine, nimustine, and vincristine (DAV therapy) in mucosal melanoma.","Carbon-ion radiotherapy with a dose of 57.6-64.0 Gy (relative biological effectiveness) in 16 fractions was delivered concurrently with DAV therapy, and 2 cycles of adjuvant DAV therapy were administered every 6\u00a0weeks."],"Revise":false}
{"PMID":"32205463","Document":["PURPOSE: Preclinical data suggest that radiotherapy (RT) is beneficial in combination with immune checkpoint blockade.","Clinical trials have explored RT with single-agent immune checkpoint blockade, but no trials have reported RT with the combination of nivolumab and ipilimumab.","PATIENTS AND METHODS: We conducted a phase 1 study of patients with stage IV melanoma receiving nivolumab and ipilimumab with two different dose-fractionation schemes of RT.","Patients had at least one melanoma metastasis that would benefit from palliative RT and one metastasis that would not be irradiated.","Nivolumab 1 mg\/kg + ipilimumab 3 mg\/kg and extracranial RT with a dose of 30 Gy in 10 fractions was administered in Cohort A, and then 27 Gy in 3 fractions was administered in Cohort B.","The primary outcome was safety.","RESULTS: Twenty patients were treated (10 in each cohort).","The rates of treatment-related grade 3-4 adverse events in Cohort A and B were 40% and 30%, respectively.","There were no grade \u22653 adverse events attributed to RT.","Patients responded to treatment outside of the irradiated volume (Cohort A 5\/10; Cohort B 1\/9).","No evaluable patients had progression of irradiated metastases.","Immunologic changes were seen in the peripheral blood with increases in T-cell receptor diversity in some responding patients.","CONCLUSIONS: RT with nivolumab and ipilimumab was safe compared with historical data of nivolumab and ipilimumab alone.","Immunologic effects were observed in the peripheral blood.","Randomized studies are ongoing to assess whether RT increases the efficacy of nivolumab and ipilimumab."],"Aspect":"i","Summary":"The study conducted a phase 1 trial where patients with stage IV melanoma received nivolumab and ipilimumab combined with two different dose-fractionation schemes of radiotherapy.","Indexes":[2,4],"Sentences":["PATIENTS AND METHODS: We conducted a phase 1 study of patients with stage IV melanoma receiving nivolumab and ipilimumab with two different dose-fractionation schemes of RT.","Nivolumab 1 mg\/kg + ipilimumab 3 mg\/kg and extracranial RT with a dose of 30 Gy in 10 fractions was administered in Cohort A, and then 27 Gy in 3 fractions was administered in Cohort B."],"Revise":false}
{"PMID":"31414290","Document":["BACKGROUND: Talimogene laherparepvec (T-VEC) is the first injectable oncolytic viral therapy approved for in-transit melanoma metastasis, with a reported overall response rate (ORR) of 25% and complete response rate (CRR) of 10%.","To ascertain the role of patient selection on outcomes in routine practice, we evaluated the impact of patient, lesion, and treatment factors on clinical response.","METHODS: Medical records were extracted for patients with recurrent stage IIIB-IV melanoma completing T-VEC at Duke University Medical Center between 1 January 2016 and 1 September 2018.","Kaplan-Meier analysis assessed time to response and survival, while logistic regression measured associations of clinicopathologic status, lesion burden, T-VEC dosing, and use of prior and concurrent therapy with ORR and CRR.","RESULTS: Of 27 patients, an objective response was observed in 11 (40.7%), including one patient with partial response (3.7%) and 10 with complete response (37.0%).","Time to complete response and overall response was a median 22\u00a0weeks (95% confidence interval [CI] 2.0-41.9\u00a0weeks and 15.8-28.2\u00a0weeks, respectively), and median progression-free survival was 17\u00a0weeks (95% CI 0-36\u00a0weeks).","Logistic regression demonstrated each millimeter increase in maximum lesion diameter predicted decreased ORR (odds ratio [OR] 0.866, 95% CI 0.753-0.995; p\u2009=\u20090.04).","Stage IV disease (OR 0.04, 95% CI 0.00-0.74; p\u2009=\u20090.031) and programmed death-1 inhibitor treatment (OR 0.06, 95% CI 0.01-0.74; p\u2009=\u20090.028) also predicted reduced clinical response.","CONCLUSIONS: This study corroborates recent data suggesting response rates to T-VEC may be higher than reported in clinical trials, arising in part from patient selection.","T-VEC lesion diameter was persistently associated with clinical response and is a readily assessed predictor of successful T-VEC therapy."],"Aspect":"p","Summary":"The study involved 27 patients with recurrent stage IIIB-IV melanoma who completed T-VEC therapy.","Indexes":[2,4],"Sentences":["METHODS: Medical records were extracted for patients with recurrent stage IIIB-IV melanoma completing T-VEC at Duke University Medical Center between 1 January 2016 and 1 September 2018.","RESULTS: Of 27 patients, an objective response was observed in 11 (40.7%), including one patient with partial response (3.7%) and 10 with complete response (37.0%)."],"Revise":false}
{"PMID":"36477181","Document":["PURPOSE: This study aimed to identify baseline clinical features associated with the outcomes of patients enrolled in the COMBI-MB phase II study of dabrafenib and trametinib treatment in patients with V600 BRAF-mutant metastatic melanoma with melanoma brain metastases (MBM).","Exploratory biomarker analysis was also conducted as part of the synergistic COMBI-BRV trial (BRV116521), to identify molecular and immunologic changes associated with dabrafenib in MBMs and extracranial metastases (ECM).","PATIENTS AND METHODS: Post hoc analysis was performed for baseline features of patients (n = 125) enrolled in COMBI-MB.","Analyses were performed to identify baseline clinical features associated with intracranial response rate (ICRR), progression-free survival (PFS), and overall survival (OS).","UNLABELLED: Exploratory biomarker analysis was performed on biospecimen collected in the COMBI-BRV trial in which patients with BRAF-mutant, resectable MBM were treated with dabrafenib for 10 to 14 days prior to craniotomy.","Accessible ECM were resected or biopsied at the time of craniotomy.","Biospecimens underwent molecular and immunologic profiling for comparative analyses.","RESULTS: In COMBI-MB baseline treatment with corticosteroids was independently associated with lower ICRR [39% vs. 63%; OR, 0.323; 95 % confidence interval (CI), 0.105-0.996; P = 0.049] and shorter PFS (HR, 1.93; 95% CI, 1.06-3.51; P = 0.031).","Additional significant associations identified in the multivariate analysis were improved PFS in patients with a BRAFV600E genotype (HR, 0.565; 95% CI, 0.321-0.996; P = 0.048) and improved OS in patients with Eastern Cooperative Oncology Group 0 (HR, 0.44; 95% CI, 0.25-0.78; P = 0.005).","CONCLUSIONS: Corticosteroid treatment was associated with reduced ICRR and PFS in COMBI-MB, similar to results with immunotherapy for MBMs.","Baseline corticosteroid treatment is a key factor to consider in MBM patient management and clinical trial design\/interpretation."],"Aspect":"i","Summary":"Patients with V600 BRAF-mutant metastatic melanoma with melanoma brain metastases (MBM) were enrolled in the COMBI-MB phase II study and treated with dabrafenib and trametinib, with post hoc analysis performed to identify baseline clinical features associated with outcomes.","Indexes":[0,2,3],"Sentences":["PURPOSE: This study aimed to identify baseline clinical features associated with the outcomes of patients enrolled in the COMBI-MB phase II study of dabrafenib and trametinib treatment in patients with V600 BRAF-mutant metastatic melanoma with melanoma brain metastases (MBM).","PATIENTS AND METHODS: Post hoc analysis was performed for baseline features of patients (n = 125) enrolled in COMBI-MB.","Analyses were performed to identify baseline clinical features associated with intracranial response rate (ICRR), progression-free survival (PFS), and overall survival (OS)."],"Revise":true}
{"PMID":"35940183","Document":["BACKGROUND: Targeted therapy and immunotherapy have shown intracranial activity in melanoma with CNS metastases, but there remains an unmet need, particularly for patients with symptomatic CNS metastases.","We aimed to evaluate atezolizumab in combination with cobimetinib or vemurafenib plus cobimetinib in patients with melanoma with CNS metastases.","METHODS: TRICOTEL was a multicentre, open-label, single-arm, phase 2 study done in two cohorts: a BRAFV600 wild-type cohort and a BRAFV600 mutation-positive cohort, recruited at 21 hospitals and oncology centres in Brazil, France, Germany, Hungary, Italy, Spain, and Switzerland.","Eligible patients were aged 18 years or older with previously untreated metastatic melanoma, CNS metastases of 5 mm or larger in at least one dimension, and an Eastern Cooperative Oncology Group performance status of 2 or less.","Patients in the BRAFV600 wild-type cohort received intravenous atezolizumab (840 mg, days 1 and 15 of each 28-day cycle) plus oral cobimetinib (60 mg once daily, days 1-21).","Patients in the BRAFV600 mutation-positive cohort received intravenous atezolizumab (840 mg, days 1 and 15 of each 28-day cycle) plus oral vemurafenib (720 mg twice daily) plus oral cobimetinib (60 mg once daily, days 1-21); atezolizumab was withheld in cycle 1.","Treatment was continued until progression, toxicity, or death.","The primary outcome was intracranial objective response rate confirmed by assessments at least 4 weeks apart, as assessed by independent review committee (IRC) using modified Response Evaluation Criteria in Solid Tumours version 1.1.","Because of early closure of the BRAFV600 wild-type cohort, the primary endpoint of intracranial objective response rate by IRC assessment was not done in this cohort; intracranial objective response rate by investigator assessment was reported instead.","Efficacy and safety were analysed in all patients who received at least one dose of study medication.","This trial is closed to enrolment and is registered with ClinicalTrials.gov, NCT03625141.","FINDINGS: Between Dec 13, 2018, and Dec 7, 2020, 65 patients were enrolled in the BRAFV600 mutation-positive cohort; the BRAFV600 wild-type cohort was closed early after enrolment of 15 patients.","Median follow-up was 9\u00b77 months (IQR 6\u00b73-15\u00b70) for the BRAFV600 mutation-positive cohort and 6\u00b72 months (3\u00b75-23\u00b70) for the BRAFV600 wild-type cohort.","Intracranial objective response rate was 42% (95% CI 29-54) by IRC assessment in the BRAFV600 mutation-positive cohort and 27% (95% CI 8-55) by investigator assessment in the BRAFV600 wild-type cohort.","Treatment-related grade 3 or worse adverse events occurred in 41 (68%) of 60 patients who received atezolizumab plus vemurafenib plus cobimetinib in the BRAFV600 mutation-positive cohort, the most common of which were lipase increased (15 [25%] of 60 patients) and blood creatine phosphokinase increased (ten [17%]).","Eight (53%) of 15 patients treated with atezolizumab plus cobimetinib in the BRAFV600 wild-type cohort had treatment-related grade 3 or worse adverse events, most commonly anaemia (two [13%]) and dermatitis acneiform (two [13%]).","Treatment-related serious adverse events occurred in 14 (23%) of 60 patients in the BRAFV600 mutation-positive cohort and two (13%) of 15 in the BRAFV600 wild-type cohort.","One death in the BRAFV600 mutation-positive cohort (limbic encephalitis) was considered to be related to atezolizumab treatment.","INTERPRETATION: Adding atezolizumab to vemurafenib plus cobimetinib provided promising intracranial activity in patients with BRAFV600-mutated melanoma with CNS metastases.","FUNDING: F Hoffmann-La Roche."],"Aspect":"p","Summary":"The study involved 65 patients in the BRAFV600 mutation-positive cohort and 15 patients in the BRAFV600 wild-type cohort, all aged 18 years or older with previously untreated metastatic melanoma and CNS metastases.","Indexes":[3,11],"Sentences":["Eligible patients were aged 18 years or older with previously untreated metastatic melanoma, CNS metastases of 5 mm or larger in at least one dimension, and an Eastern Cooperative Oncology Group performance status of 2 or less.","FINDINGS: Between Dec 13, 2018, and Dec 7, 2020, 65 patients were enrolled in the BRAFV600 mutation-positive cohort; the BRAFV600 wild-type cohort was closed early after enrolment of 15 patients."],"Revise":false}
{"PMID":"31852717","Document":["Whereas systemic IL12 is associated with potentially life-threatening toxicity, intratumoral delivery of IL12 through tavokinogene telseplasmid electroporation (tavo) is safe and can induce tumor regression at distant sites.","The mechanism by which these responses are mediated is unknown but is presumed to result from a cellular immune response.","In a phase II clinical trial of tavo (NCT01502293), samples from 29 patients with cutaneous melanoma with in-transit disease were assessed for immune responses induced with this treatment.","Within the blood circulating immune cell population, we found that the frequencies of circulating PD-1+ CD4+ and CD8+ T cells declined with treatment.","Circulating immune responses to gp100 were also detected following treatment as measured by IFN\u03b3 ELISpot.","Patients with a greater antigen-specific circulating immune response also had higher numbers of CD8+ T cells within the tumor.","Clinical response was also associated with increased intratumoral CD3+ T cells.","Finally, intratumoral T-cell clonality and convergence were increased after treatment, indicating a focusing of the T-cell receptor repertoire.","These results indicated that local treatment with tavo can induce a systemic T-cell response and recruit T cells to the tumor microenvironment."],"Aspect":"i","Summary":"The study investigated the use of intratumoral delivery of IL12 through tavokinogene telseplasmid electroporation (tavo) in a phase II clinical trial involving patients with cutaneous melanoma with in-transit disease.","Indexes":[0,2],"Sentences":["Whereas systemic IL12 is associated with potentially life-threatening toxicity, intratumoral delivery of IL12 through tavokinogene telseplasmid electroporation (tavo) is safe and can induce tumor regression at distant sites.","In a phase II clinical trial of tavo (NCT01502293), samples from 29 patients with cutaneous melanoma with in-transit disease were assessed for immune responses induced with this treatment."],"Revise":false}
{"PMID":"36195819","Document":["AIMS: Human health is intrinsically linked with planetary health.","But planetary resources are currently being degraded and this poses an existential threat to human health and the sustainability of our healthcare systems.","The aims of this study were to (1) describe an approach to integrate environmental impacts in a cost analysis; and (2) demonstrate this approach by estimating select environmental impacts alongside traditional health system and other costs using the example of the pilot MEL-SELF randomised controlled trial of patient-led melanoma surveillance.","METHODS: Economic costs were calculated alongside a randomised trial using standard cost analysis methodology from a societal perspective.","Environmental impacts were calculated using a type of carbon footprinting methodology called process-based life cycle analysis.","This method considers three scopes of carbon emissions: Scope 1, which occur directly from the intervention; Scope 2, which occur indirectly from the intervention's energy use; and Scope 3, which occur indirectly because of the value chain of the intervention.","In this study we only included emissions from patient transport to attend their melanoma clinic over the study period of 6 months.","RESULTS: The environmental impact per participant across allocated groups for patient transport to their melanoma clinic was estimated to be 10 kg carbon dioxide equivalent.","Economic costs across the allocated groups indicated substantial health system costs, out-of-pocket costs, and productivity losses associated with melanoma surveillance.","The largest cost contributor was health system costs, and the most expensive category of health system cost was hospital admission.","CONCLUSION: Calculating environmental impacts is worthwhile and feasible within a cost analysis framework.","Further work is needed to address outstanding conceptual and practical issues so that a comprehensive assessment of environmental impacts can be considered alongside economic costs in health technology assessments."],"Aspect":"d","Summary":"The study period was 6 months.","Indexes":[6],"Sentences":["In this study we only included emissions from patient transport to attend their melanoma clinic over the study period of 6 months."],"Revise":false}
{"PMID":"37270692","Document":["PURPOSE: The combination of encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor) has demonstrated clinical efficacy with an acceptable safety profile in patients with BRAFV600E\/K-mutant metastatic melanoma.","We evaluated the efficacy and safety of encorafenib plus binimetinib in patients with BRAFV600E-mutant metastatic non-small-cell lung cancer (NSCLC).","METHODS: In this ongoing, open-label, single-arm, phase II study, patients with BRAFV600E-mutant metastatic NSCLC received oral encorafenib 450 mg once daily plus binimetinib 45 mg twice daily in 28-day cycles.","The primary end point was confirmed objective response rate (ORR) by independent radiology review (IRR).","Secondary end points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival, time to response, and safety.","RESULTS: At data cutoff, 98 patients (59 treatment-na\u00efve and 39 previously treated) with BRAFV600E-mutant metastatic NSCLC received encorafenib plus binimetinib.","Median duration of treatment was 9.2 months with encorafenib and 8.4 months with binimetinib.","ORR by IRR was 75% (95% CI, 62 to 85) in treatment-na\u00efve and 46% (95% CI, 30 to 63) in previously treated patients; median DOR was not estimable (NE; 95% CI, 23.1 to NE) and 16.7 months (95% CI, 7.4 to NE), respectively.","DCR after 24 weeks was 64% in treatment-na\u00efve and 41% in previously treated patients.","Median PFS was NE (95% CI, 15.7 to NE) in treatment-na\u00efve and 9.3 months (95% CI, 6.2 to NE) in previously treated patients.","The most frequent treatment-related adverse events (TRAEs) were nausea (50%), diarrhea (43%), and fatigue (32%).","TRAEs led to dose reductions in 24 (24%) and permanent discontinuation of encorafenib plus binimetinib in 15 (15%) patients.","One grade 5 TRAE of intracranial hemorrhage was reported.","Interactive visualization of the data presented in this article is available at the PHAROS dashboard (https:\/\/clinical-trials.dimensions.ai\/pharos\/).","CONCLUSION: For patients with treatment-na\u00efve and previously treated BRAFV600E-mutant metastatic NSCLC, encorafenib plus binimetinib showed a meaningful clinical benefit with a safety profile consistent with that observed in the approved indication in melanoma."],"Aspect":"d","Summary":"The median duration of treatment was 9.2 months with encorafenib and 8.4 months with binimetinib.","Indexes":[6],"Sentences":["Median duration of treatment was 9.2 months with encorafenib and 8.4 months with binimetinib."],"Revise":false}
{"PMID":"36265502","Document":["BACKGROUND: Patients with stage IIB or IIC melanoma who undergo surgery alone are at a substantial risk for disease recurrence.","Adjuvant pembrolizumab significantly improved recurrence-free survival versus placebo in stage IIB or IIC melanoma in the first interim analysis of the KEYNOTE-716 trial.","Here, we report results from the secondary endpoint of distant metastasis-free survival (prespecified third interim analysis), and recurrence-free survival with longer follow-up.","METHODS: KEYNOTE-716 is a multicentre, double-blind, placebo-controlled, crossover or rechallenge, randomised, phase 3 trial done at 160 academic medical centres and hospitals across 16 countries.","Eligible patients were aged 12 years and older with newly-diagnosed, completely resected, and histologically confirmed stage IIB (T3b or T4a) or IIC (T4b) cutaneous melanoma; negative sentinel lymph node biopsy; and an Eastern Cooperative Oncology Group performance status of 0-1.","Patients were randomly assigned (1:1) to receive either 200 mg of pembrolizumab (2 mg\/kg up to a maximum of 200 mg in paediatric patients) or placebo, both intravenously, every 3 weeks for 17 cycles (part 1) or until disease recurrence or unacceptable toxicity.","Eligible patients with disease recurrence could receive further treatment with pembrolizumab in the part 2 crossover or rechallenge phase.","Randomisation was done using an interactive response technology system and stratified by T category and paediatric status.","The primary endpoint was investigator-assessed recurrence-free survival (assessed here with longer follow-up), and we report the prespecified third interim analysis of distant metastasis-free survival (secondary endpoint).","Efficacy analyses were done in the intention-to-treat population (all patients who were randomly assigned, according to assigned group) and safety was assessed in all patients who were randomly assigned and received at least one dose of trial treatment, according to the treatment received.","KEYNOTE-716 is registered at ClinicalTrials.gov, NCT03553836, and has completed recruitment.","FINDINGS: Between Sept 23, 2018, and Nov 4, 2020, 976 patients were randomly assigned to receive pembrolizumab (n=487) or placebo (n=489).","At a median follow-up of 27\u00b74 months (IQR 23\u00b71-31\u00b77), median distant metastasis-free survival was not reached (95% CI not reached [NR]-NR) in either group.","Pembrolizumab significantly improved distant metastasis-free survival (hazard ratio [HR] 0\u00b764, 95% CI 0\u00b747-0\u00b788, p=0\u00b70029) versus placebo.","Median recurrence-free survival was 37\u00b72 months (95% CI NR-NR) in the pembrolizumab group and not reached in the placebo group (95% CI NR-NR).","The risk of recurrence remained lower with pembrolizumab versus placebo (HR 0\u00b764, 95% CI 0\u00b750-0\u00b784).","The most common grade 3 or worse adverse events were hypertension (16 [3%] of 483 patients in the pembrolizumab group vs 17 [4%] of 486 patients in the placebo group), diarrhoea (eight [2%] vs one [&lt;1%]), rash (seven [1%] vs two [&lt;1%]), autoimmune hepatitis (seven [1%] vs two [&lt;1%]), and increased lipase (six [1%] vs eight [2%]).","Treatment-related serious adverse events occurred in 49 (10%) patients in the pembrolizumab group and 11 (2%) patients in the placebo group.","No treatment-related deaths were reported.","INTERPRETATION: Adjuvant pembrolizumab is an efficacious treatment option for resected stage IIB and IIC melanoma, with significant improvement in distant-metastasis free survival versus placebo and continued reduction in the risk of recurrence with an adverse event profile consistent with previous studies of pembrolizumab.","The overall benefit-risk of pembrolizumab continues to be positive in the adjuvant setting.","FUNDING: Merck Sharp &amp; Dohme, a subsidiary of Merck &amp; Co."],"Aspect":"p","Summary":"The study involved 976 patients aged 12 years and older with newly-diagnosed, completely resected, and histologically confirmed stage IIB (T3b or T4a) or IIC (T4b) cutaneous melanoma, randomly assigned to receive pembrolizumab (n=487) or placebo (n=489).","Indexes":[4,11],"Sentences":["Eligible patients were aged 12 years and older with newly-diagnosed, completely resected, and histologically confirmed stage IIB (T3b or T4a) or IIC (T4b) cutaneous melanoma; negative sentinel lymph node biopsy; and an Eastern Cooperative Oncology Group performance status of 0-1.","FINDINGS: Between Sept 23, 2018, and Nov 4, 2020, 976 patients were randomly assigned to receive pembrolizumab (n=487) or placebo (n=489)."],"Revise":false}
{"PMID":"32161584","Document":["Phenotyping of immune cell subsets in clinical trials is limited to well-defined phenotypes, due to technological limitations of reporting flow cytometry multi-dimensional phenotyping data.","We developed a multi-dimensional phenotyping analysis tool and applied it to detect nitric oxide (NO) levels in peripheral blood immune cells before and after adjuvant ipilimumab co-administration with a peptide vaccine in melanoma patients.","We analyzed inhibitory and stimulatory markers for immune cell phenotypes that were felt to be important in the NO analysis.","The pipeline allows visualization of immune cell phenotypes without knowledge of clustering techniques and to categorize cells by association with relapse-free survival (RFS).","Using this analysis, we uncovered the potential for a dichotomous role of NO as a pro- and anti-melanoma factor.","NO was found in subsets of immune-suppressor cells associated with shorter-term (\u2264 1 year) RFS, whereas NO was also present in immune-stimulatory effector cells obtained from patients with significant longer-term (> 1 year) RFS.","These studies provide insights into the cell-specific immunomodulatory role of NO.","The methods presented herein can be applied to monitor the pro- and anti-tumor effects of a variety of immune-based therapeutics in cancer patients.","Clinical Trial Registration Number: NCT00084656 (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00084656)."],"Aspect":"p","Summary":"The study involved melanoma patients who received adjuvant ipilimumab co-administration with a peptide vaccine.","Indexes":[1],"Sentences":["We developed a multi-dimensional phenotyping analysis tool and applied it to detect nitric oxide (NO) levels in peripheral blood immune cells before and after adjuvant ipilimumab co-administration with a peptide vaccine in melanoma patients."],"Revise":false}
{"PMID":"31557067","Document":["PURPOSE: We have previously reported on the 3-year results of the phase III German Dermatologic Cooperative Oncology Group trial (DeCOG; ClinicalTrials.gov identifier: NCT02434107) comparing distant metastasis-free survival (DMFS), recurrence-free survival (RFS), and overall survival (OS) in patients with positive sentinel lymph-node biopsy who were randomly assigned to complete lymph node dissection (CLND) or observation.","Here, we report the final analysis with 72 months of median follow up.","PATIENTS AND METHODS: The multicenter randomized phase III trial included patients with cutaneous melanoma of the trunk and extremities who were randomly assigned (1:1) to undergo CLND or observation.","DMFS was analyzed as the primary end point, and RFS, OS, and recurrences in the regional lymph node basin were secondary end points.","The analysis was by intention to treat.","Disease and survival information were collected quarterly.","RESULTS: From January 2006 to December 2014, 5,547 patients were screened to identify 1,256 with metastases in the sentinel lymph node (SLN).","Of these, 483 (39%) were included: 241 in the observation arm and 242 in the CLND arm.","In the final analysis, median follow up was 72 months (interquartile range, 67-77 months).","No significant treatment-related difference was seen in the 5-year DMFS between the observation and CLND arms (67.6% v 64.9%, respectively; hazard ratio [HR], 1.08; P = .87).","The 5-year RFS and OS also showed no difference (HR, 1.01 and 0.99, respectively).","Grade 3 and 4 adverse effects occurred in 32 patients (13%) in the CLND arm; lymphedema (n = 20) and delayed wound healing (n = 5) were most common and no serious adverse events were reported.","CONCLUSION: The final results of the German Dermatologic Cooperative Oncology Group trial with a median follow up of 72 months showed higher event rates, but similar HRs compared with those at the 3-year analysis.","These results confirm that immediate CLND in SLN-positive patients is not superior to observation in terms of DMFS, RFS, or OS and support not recommending CLND in patients with SLN metastasis."],"Aspect":"p","Summary":"The study included 483 patients with cutaneous melanoma of the trunk and extremities who had positive sentinel lymph-node biopsy, with 241 assigned to the observation arm and 242 to the complete lymph node dissection (CLND) arm.","Indexes":[2,7],"Sentences":["PATIENTS AND METHODS: The multicenter randomized phase III trial included patients with cutaneous melanoma of the trunk and extremities who were randomly assigned (1:1) to undergo CLND or observation.","Of these, 483 (39%) were included: 241 in the observation arm and 242 in the CLND arm."],"Revise":false}
{"PMID":"33661190","Document":["BACKGROUND: IL-2 inducible kinase (ITK) is highly expressed in metastatic melanomas and its inhibition suppresses melanoma cell proliferation.","We hypothesize that ibrutinib has a direct antitumor effect in melanoma cell lines and that treatment of metastatic melanomas with ibrutinib induces antitumor responses.","METHODS: We assessed the ibrutinib effect on melanoma cell proliferation, apoptosis, and motility.","Patients with metastatic melanoma refractory to PD-1 and MAPK inhibitors (if BRAFV600-mutant) were treated with ibrutinib, 840\u2009mg PO QD, as part of a phase II clinical trial (clinicaltrials.gov NCT02581930).","RESULTS: Melanoma cell lines frequently express ITK, YES1, and EGFR.","Ibrutinib suppressed cell motility and proliferation in most cell lines.","Eighteen patients (13 male; median age 63.5 years, range 37-82; 12 with ipilimumab resistance) were enrolled.","The most frequent side effects were fatigue (61%), anorexia (50%), hyponatremia (28%), nausea, and vomiting (22% each).","No antitumor responses were seen.","At a median follow-up of 6\u2009months (0.3-35.8\u2009months), the median progression-free survival was 1.3\u2009months (range 0.2-5.5\u2009months).","Fifteen patients were discontinued from the study due to progression, and 14 patients had died from metastatic melanoma.","All archived tumors expressed ITK, 41% had no expression of p16 and PTEN, and 61% had absent tumor-infiltrating lymphocytes (TILs).","Ibrutinib significantly suppressed proliferating (Ki67+) CD19+ peripheral blood mononuclear cells and had no significant effect on other lymphocyte subsets.","CONCLUSION: Ibrutinib did not induce any meaningful clinical benefit.","ITK expression may not be clinically relevant.","Treatment-refractory metastatic melanomas have other fundamental defects (i.e.","absent PTEN and p16 expression, absent TILs) that may contribute to an adverse prognosis."],"Aspect":"m","Summary":"The trial used ibrutinib, 840 mg PO QD, for patients with metastatic melanoma.","Indexes":[3],"Sentences":["Patients with metastatic melanoma refractory to PD-1 and MAPK inhibitors (if BRAFV600-mutant) were treated with ibrutinib, 840\u2009mg PO QD, as part of a phase II clinical trial (clinicaltrials.gov NCT02581930)."],"Revise":false}
{"PMID":"33945288","Document":["PURPOSE: Combination of antiprogrammed cell death protein-1 (PD-1) plus anti-cytotoxic T-cell lymphocyte-4 (anti-CTLA-4) immunotherapy shows greater response rates (RRs) than anti-PD-1 antibody alone in melanoma, but RR after initial anti-PD-1 and programmed death ligand-1 (PD-L1) antibody progression awaits robust investigation.","Anti-CTLA-4 antibody alone after anti-PD-1\/L1 antibody progression has a historical RR of 13%.","We report the results of the first prospective clinical trial evaluating ipilimumab 1 mg\/kg plus pembrolizumab following progression on anti-PD-1 immunotherapy.","METHODS: Patients with advanced melanoma who had progressed on anti-PD-1\/L1 antibody as immediate prior therapy (including non-anti-CTLA-4 antibody combinations) were eligible.","Patients received pembrolizumab 200 mg plus ipilimumab 1 mg\/kg once every 3 weeks for four doses, followed by pembrolizumab monotherapy.","The primary end point was RR by irRECIST.","After 35 patients, the trial met the primary end point and was expanded to enroll a total of 70 patients to better estimate the RR.","RESULTS: Prior treatments included 60 on anti-PD-1 antibody alone and 10 on anti-PD-1\/L1 antibody-based combinations.","Thirteen patients had progressed in the adjuvant setting.","The median length of prior treatment with anti-PD-1\/L1 antibody was 4.8 months.","Response assessments included five complete and 15 partial responses, making the irRECIST RR 29% among the entire trial population.","The median progression-free survival was 5.0 months, and the median overall survival was 24.7 months.","The median duration of response was 16.6 months.","There was no difference in median time on prior anti-PD1\/L1 or time to PD1 + CTLA4 initiation between responders and nonresponders.","Grade 3-4 drug-related adverse events occurred in 27% of patients.","Responses occurred in PD-L1-negative, non-T-cell-inflamed, and intermediate tumor phenotypes.","CONCLUSION: To our knowledge, this is the first prospective study in melanoma of pembrolizumab plus low-dose ipilimumab after anti-PD-1\/L1 immunotherapy failure, demonstrating significant antitumor activity and tolerability."],"Aspect":"p","Summary":"The study involved 70 patients with advanced melanoma who had progressed on anti-PD-1\/L1 antibody as immediate prior therapy.","Indexes":[3,6],"Sentences":["METHODS: Patients with advanced melanoma who had progressed on anti-PD-1\/L1 antibody as immediate prior therapy (including non-anti-CTLA-4 antibody combinations) were eligible.","After 35 patients, the trial met the primary end point and was expanded to enroll a total of 70 patients to better estimate the RR."],"Revise":false}
{"PMID":"31864178","Document":["BACKGROUND: Previous analyses of BREAK-2 and BREAK-3 showed that durable outcomes lasting \u22653 years are achievable with dabrafenib in some patients with BRAF V600-mutant metastatic melanoma (MM); however, additional follow-up is needed to fully characterise the long-term impact of dabrafenib in these patients.","METHODS: BREAK-2 was a single-arm phase 2 study evaluating dabrafenib in treatment-naive or previously treated BRAF V600E\/K-mutant MM.","BREAK-3, a randomised (3:1) phase 3 study, assessed dabrafenib versus dacarbazine in previously untreated unresectable or metastatic BRAF V600E-mutant melanoma.","Five-year analyses were performed.","RESULTS: All BREAK-2 patients (N\u00a0=\u00a092 [V600E, n\u00a0=\u00a076; V600K, n\u00a0=\u00a016]) discontinued treatment by the data cutoff.","Median follow-up was 13.0 months.","In BRAF V600E patients, 5-year progression-free survival (PFS) and overall survival (OS) were 11% and 20%, respectively.","Subsequent immunotherapy was received by 22% of patients.","In BREAK-3, median follow-up was 17.0 and 12.0 months in the dabrafenib (n\u00a0=\u00a0187) and dacarbazine (n\u00a0=\u00a063) arms, respectively.","Thirty-seven patients (59%) receiving dacarbazine crossed over to dabrafenib following disease progression as per protocol.","Five-year PFS was 12% in the dabrafenib arm; all dacarbazine-arm patients progressed or were censored by 5 years.","Dabrafenib improved PFS versus dacarbazine, regardless of baseline lactate dehydrogenase levels.","Five-year OS rates were 24% and 22% in the dabrafenib and dacarbazine arms, respectively.","Subsequent therapy in each arm included anti-CTLA-4 (dabrafenib [24%] and dacarbazine [24%]) and\/or anti-PD-1 (8% and 2%) treatment.","No new safety signals were observed.","CONCLUSIONS AND RELEVANCE: These data, representing extended follow-up for dabrafenib monotherapy, demonstrate that durable benefit lasting \u22655 years is achievable in a subset of patients.","TRIAL REGISTRATION: ClinicalTrials.gov (BREAK-2, NCT01153763; BREAK-3, NCT01227889)."],"Aspect":"o","Summary":"The study found that dabrafenib monotherapy can achieve durable benefits lasting \u22655 years in a subset of patients with BRAF V600-mutant metastatic melanoma.","Indexes":[15],"Sentences":["CONCLUSIONS AND RELEVANCE: These data, representing extended follow-up for dabrafenib monotherapy, demonstrate that durable benefit lasting \u22655 years is achievable in a subset of patients."],"Revise":false}
{"PMID":"34571336","Document":["OBJECTIVE: Patients with melanoma and early stable disease (SD) with pembrolizumab have unclear prognosis.","We present post hoc analyses of long-term outcomes for patients with early SD, partial response (PR)\u00a0or complete response (CR) with pembrolizumab.","PATIENTS AND METHODS: Patients who received pembrolizumab in the KEYNOTE-001 and KEYNOTE-006 studies and had SD, PR\u00a0or CR at weeks 12 or 24 were included.","RESULTS: Of 294 patients in the week 12 analysis, 107 (36.4%) had SD at week 12, of whom 7 (6.5%) had a best overall response of CR, 43 (40.2%) had PR\u00a0and 57 (53.3%) had SD.","Forty-eight-month overall survival (OS) rates were 95.2%, 73.0%\u00a0and 47.7%, respectively, for patients with CR, PR\u00a0and SD at week 12.","Similar results were observed in the 241 patients in the week 24 analysis.","Forty-eight-month OS rates were 72.1% for patients with SD at week 12 followed by subsequent response\u00a0and 75.0% for patients with PR at week 12 followed by no change in response or progression.","Thirty-six-month and 48-month OS rates were 11.6% and not reached, respectively, for patients with SD at week 12 followed by progression before week 24.","CONCLUSIONS: A substantial proportion of patients (46.7%) with early (week 12) SD with pembrolizumab achieved subsequent PR or CR.","Patients with SD at week 12 and subsequent CR\/PR had similar survival to those who maintained PR.","In contrast, patients with SD at week 12 and subsequent progression had poor survival outcomes.","These findings may guide treatment decisions for patients achieving early SD.","TRIAL REGISTRATION: Clinicaltrials.gov: NCT01295827 (KEYNOTE-001); NCT01866319 (KEYNOTE-006)."],"Aspect":"m","Summary":"The medicine used in the treatment is pembrolizumab.","Indexes":[0,2],"Sentences":["OBJECTIVE: Patients with melanoma and early stable disease (SD) with pembrolizumab have unclear prognosis.","PATIENTS AND METHODS: Patients who received pembrolizumab in the KEYNOTE-001 and KEYNOTE-006 studies and had SD, PR\u00a0or CR at weeks 12 or 24 were included."],"Revise":false}
{"PMID":"33417511","Document":["PURPOSE: This study aimed to assess the efficacy of the combination of nivolumab (nivo) plus ipilimumab (ipi) as a first-line therapy with respect to the 12-month overall survival (OS) in patients with metastatic uveal melanoma (MUM) who are not eligible for liver resection.","METHODS: This was a single-arm, phase II trial led by the Spanish Multidisciplinary Melanoma Group (GEM) on nivo plus ipi for systemic treatment-na\u00efve patients of age > 18 years, with histologically confirmed MUM, Eastern Cooperative Oncology Group-PS 0\/1, and confirmed progressive metastatic disease (M1).","Nivo (1 mg\/kg once every 3 weeks) and ipi (3 mg\/kg once every 3 weeks) were administered during four inductions, followed by nivo (3 mg\/kg once every 2 weeks) until progressive disease, toxicity, or withdrawal.","The primary end point was 12-month OS.","OS, progression-free survival (PFS), and overall response rate were evaluated every 6 weeks using RECIST (v1.1).","Safety was also evaluated.","Logistic regression and Cox proportional hazard models comprising relevant clinical factors were used to evaluate the potential association with response to treatment and survival.","Cytokines were quantified in serum samples for their putative role in immune modulation\/angiogenesis and\/or earlier evidence of involvement in immunotherapy.","RESULTS: A total of 52 patients with a median age of 59 years (range, 26-84 years) were enrolled.","Overall, 78.8%, 56%, and 32% of patients had liver M1, extra-liver M1, and elevated lactate dehydrogenase.","Stable disease was the most common outcome (51.9%).","The primary end point was 12-month OS, which was 51.9% (95% CI, 38.3 to 65.5).","The median OS and PFS were 12.7 months and 3.0 months, respectively.","PFS was influenced by higher LDH values.","CONCLUSIONS: Nivo plus ipi in the first-line setting for MUM showed a modest improvement in OS over historical benchmarks of chemotherapy, with a manageable toxicity profile."],"Aspect":"s","Summary":"The treatment showed a manageable toxicity profile.","Indexes":[14],"Sentences":["CONCLUSIONS: Nivo plus ipi in the first-line setting for MUM showed a modest improvement in OS over historical benchmarks of chemotherapy, with a manageable toxicity profile."],"Revise":false}
{"PMID":"34787471","Document":["OBJECTIVE: A qualitative sub-study was carried out within a larger phase II feasibility trial, to identify and describe the burden experienced by advanced melanoma patients participating in a clinical trial and the factors affecting their capacity to cope with the burden.","METHODS: Semi-structured interviews were conducted with fourteen patients with advanced melanoma recruited from National Health Service hospitals in the United Kingdom.","Qualitative analysis was undertaken using a framework analysis approach.","Normalisation process theory was applied to the concept of research participation burden in order to interpret and categorise findings.","RESULTS: Burdens of participation were identified as arising from making sense of the trial and treatment; arranging transport, appointment and prescriptions; enacting management strategies and enduring side effects; reflecting on trial documents and treatment efficacy, and emotional and mental effects of randomisation and treatment side effects.","Factors reported as influencing capacity include personal attributes and skills, physical and cognitive abilities and support network.","DISCUSSION: This is the first study to highlight the substantial burden faced by patients with advanced melanoma in a clinical trial and factors that may lessen or worsen the burden.","Consideration of identified burdens during trial design and execution will reduce the burden experienced by research participants."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"36044526","Document":["PURPOSE: Anti-programmed cell death-1 monotherapy is part of standard therapy for cutaneous melanoma but has low efficacy in mucosal melanoma.","We evaluated the efficacy and safety of atezolizumab plus bevacizumab as first-line therapy for advanced mucosal melanoma.","PATIENTS AND METHODS: This multicenter, open-label, single-arm, phase II study used a Simon's two-stage design.","Atezolizumab (fixed-dose, 1,200 mg) and bevacizumab (7.5 mg\/kg) were administered by intravenous infusion every 3 weeks.","The primary endpoint was objective response rate (ORR), determined per RECIST v1.1.","Secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of response (DOR), and safety, with adverse events (AE) summarized using NCI-CTCAE v5.0.","RESULTS: Overall, 43 patients were enrolled, including 20 (46.5%) with unresectable and 23 (53.5%) with metastatic mucosal melanoma.","Median follow-up was 13.4 months at data cutoff (July 30, 2021).","Forty patients were evaluable for response: ORR was 45.0% [95% confidence interval (CI), 29.3%-61.5%; one complete response, 17 partial responses].","Median PFS was 8.2 months (95% CI, 2.7-9.6); 6- and 12-month PFS rates were 53.4% (95% CI, 36.6%-67.6%) and 28.1% (95% CI, 14.2%-43.9%), respectively.","Median OS was not reached (NR; 95% CI, 14.4-NR).","Six- and 12-month OS rates were 92.5% (95% CI, 78.5%-97.5%) and 76.0% (95% CI, 57.1%-87.5%), respectively.","Median DOR was 12.5 months (95% CI, 5.5-NR).","Overall, 90.7% (39\/43) of patients experienced treatment-related AEs; 25.6% (11\/43) experienced grade \u22653 events.","CONCLUSIONS: Atezolizumab in combination with bevacizumab showed promising efficacy and manageable safety in patients with advanced mucosal melanoma."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"37401516","Document":["BACKGROUND: Here we report clinical risk factors and event rates for the development of new non-melanoma skin cancer (NMSC) in a randomized, double-blind, placebo-controlled trial of the irreversible ornithine decarboxylase (ODC) inhibitor, difluromethylornithine (DFMO), over a 3-5-year follow-up.","METHODS: 147 placebo patients (white; mean age 60.2 years; 60% male) were evaluated for event rates and association of initial skin biomarkers and baseline patient characteristics with the development of squamous cell (SCC) and basal cell (BCC) carcinomas.","RESULTS: Post-study evaluation (median follow-up 4.4 years) indicates the measures of prior NMSCs ( P \u2005\u2264\u20050.001), prior BCCs ( P \u2005\u2264\u20050.001), prior SCCs ( P \u2005=\u20050.011), prior tumor rate ( P \u2005=\u20050.002), hemoglobin ( P \u2005=\u20050.022), and gender ( P \u2005=\u20050.045) as significant predictors for new NMSC development.","Similarly, all measures of prior BCCs and NMSCs ( P \u2005<\u20050.001), prior tumor rate ( P \u2005=\u20050.014), and SCCs in the prior 2 years ( P \u2005=\u20050.047) were statistically significant predictors for new BCC development.","Total prior NMSCs and those in the prior 5 years ( P \u2005<\u20050.001), total prior SCCs and those in the prior 5 years ( P \u2005<\u20050.001), total prior BCCs and those in the prior 5 years ( P \u2005\u2264\u20050.001), prior tumor rate ( P \u2005=\u20050.011) as well as age ( P \u2005=\u20050.008), hemoglobin ( P \u2005=\u20050.002), and gender ( P \u2005=\u20050.003) were statistically significant predictors of new SCC development.","TPA-induced ODC activity at baseline showed no statistically significant association with the development of new NMSC ( P \u2005=\u20050.35), new BCCs ( P \u2005=\u20050.62), or new SCCs ( P \u2005=\u20050.25).","CONCLUSION: In the studied population, the history of and rate at which prior NMSCs occur are predictive and should be controlled for in future NMSC prevention trials."],"Aspect":"i","Summary":"The study involved a randomized, double-blind, placebo-controlled trial of the ODC inhibitor, DFMO, over a 3-5-year follow-up, with 147 placebo patients evaluated for the development of squamous cell and basal cell carcinomas.","Indexes":[0,1],"Sentences":["BACKGROUND: Here we report clinical risk factors and event rates for the development of new non-melanoma skin cancer (NMSC) in a randomized, double-blind, placebo-controlled trial of the irreversible ornithine decarboxylase (ODC) inhibitor, difluromethylornithine (DFMO), over a 3-5-year follow-up.","METHODS: 147 placebo patients (white; mean age 60.2 years; 60% male) were evaluated for event rates and association of initial skin biomarkers and baseline patient characteristics with the development of squamous cell (SCC) and basal cell (BCC) carcinomas."],"Revise":false}
{"PMID":"32278771","Document":["PURPOSE: To assess efficacy of intravitreal ranibizumab injections and targeted panretinal photocoagulation (TRP) for radiation retinopathy-related macular edema.","DESIGN: Phase IIb, prospective, randomized clinical trial.","METHODS: Setting: Multicenter.","SUBJECTS: Forty eyes in 40 treatment-na\u00efve patients with radiation-induced macular edema and a resulting decrease in visual acuity ranging between 20\/25 and 20\/400 (Snellen equivalent).","INTERVENTION: Patients either received intravitreal 0.5\u00a0mg ranibizumab monthly, monthly ranibizumab with TRP, or 3\u00a0monthly ranibizumab (loading doses) followed by as-needed (PRN) injections and TRP.","After week 52, all subjects entered a treat-and-extend protocol for ranibizumab.","MainOutcomeMeasures: Mean Early Treatment Diabetic Maculopathy Study (ETDRS) BCVA change from baseline.","RESULTS: Mean patient age was 57 years (range, 22-80 years), ETDRS BCVA was 56.7 letters (20\/74 Snellen equivalent), and central macular thickness (CMT) was 423\u00a0\u03bcm (range, 183-826\u00a0\u03bcm).","Thirty-seven patients completed the month 12 visit (92.5%), at which time the change in mean BCVA was\u00a0+4.0 letters,\u00a0-1.9 letters, and\u00a0+0.9 letters in the monthly, monthly plus laser, and PRN plus laser cohorts, respectively.","There was a significant difference in mean BCVA at 1 year among all 3 cohorts (P < .001), as well as between cohorts in pairwise comparisons, with the most significant gains in the monthly group.","A total of 82.5% of the patients retained visual acuity of 20\/200 or better, and 20.0% improved 10 or more ETDRS letters.","CONCLUSIONS: Ranibizumab may improve vision and anatomy in patients with radiation retinopathy-related macular edema and prevent vision loss through 48\u00a0weeks of therapy.","Monthly injections were more effective than as-needed approach, and the addition of TRP yielded no therapeutic benefits."],"Aspect":"m","Summary":"The study involved intravitreal ranibizumab injections at a dose of 0.5 mg monthly, or with a loading dose of 3 monthly injections followed by as-needed (PRN) injections, with or without targeted panretinal photocoagulation (TRP).","Indexes":[4],"Sentences":["INTERVENTION: Patients either received intravitreal 0.5\u00a0mg ranibizumab monthly, monthly ranibizumab with TRP, or 3\u00a0monthly ranibizumab (loading doses) followed by as-needed (PRN) injections and TRP."],"Revise":false}
{"PMID":"34453044","Document":["Preclinical studies have suggested that epigenetic therapy could enhance immunogenicity of cancer cells.","We report the results of the PEMDAC phase 2 clinical trial (n\u2009=\u200929; NCT02697630) where the HDAC inhibitor entinostat was combined with the PD-1 inhibitor pembrolizumab in patients with metastatic uveal melanoma (UM).","The primary endpoint was objective response rate (ORR), and was met with an ORR of 14%.","The clinical benefit rate at 18 weeks was 28%, median progression free survival was 2.1 months and the median overall survival was 13.4 months.","Toxicities were manageable, and there were no treatment-related deaths.","Objective responses and\/or prolonged survival were seen in patients with BAP1 wildtype tumors, and in one patient with an iris melanoma that exhibited a UV signature.","Longer survival also correlated with low baseline ctDNA levels or LDH.","In conclusion, HDAC inhibition and anti-PD1 immunotherapy results in durable responses in a subset of patients with metastatic UM.Trial registration ClinicalTrials.gov registration number: NCT02697630 (registered 3 March 2016).","EudraCT registration number: 2016-002114-50."],"Aspect":"p","Summary":"The study involved 29 patients with metastatic uveal melanoma (UM) who were treated with a combination of the HDAC inhibitor entinostat and the PD-1 inhibitor pembrolizumab.","Indexes":[1],"Sentences":["We report the results of the PEMDAC phase 2 clinical trial (n\u2009=\u200929; NCT02697630) where the HDAC inhibitor entinostat was combined with the PD-1 inhibitor pembrolizumab in patients with metastatic uveal melanoma (UM)."],"Revise":false}
{"PMID":"32602215","Document":["The effects of itraconazole, a strong CYP3A4 inhibitor, on the steady-state pharmacokinetics of vemurafenib were evaluated in a phase 1, multicenter, open-label, fixed-sequence study.","Patients with BRAFV600 mutation-positive metastatic malignancies received oral vemurafenib 960 mg twice daily on days 1 to 20 (period A) and oral vemurafenib 960 mg twice daily with oral itraconazole 200 mg once daily on days 21 to 40 (period B).","A mixed-effects analysis of variance model was used to compare log-transformed area under the concentration-time curve during the dosing interval and maximum plasma concentration values for vemurafenib in 8 patients between period B (vemurafenib plus itraconazole) and period A (vemurafenib alone).","Multiple doses of itraconazole increased steady-state exposure of vemurafenib by approximately 40%, with geometric least squares mean ratios (period B\/period A) of 140% (90% confidence interval, 121-161) for both maximum plasma concentration and area under the concentration-time curve during the dosing interval.","There was no apparent increase in incidence or severity of adverse events during coadministration of vemurafenib with itraconazole.","In conclusion, coadministration of itraconazole with vemurafenib resulted in a modest increase in exposure of vemurafenib at steady state and was generally well tolerated."],"Aspect":"s","Summary":"There was no apparent increase in incidence or severity of adverse events during coadministration of vemurafenib with itraconazole.","Indexes":[4],"Sentences":["There was no apparent increase in incidence or severity of adverse events during coadministration of vemurafenib with itraconazole."],"Revise":false}
{"PMID":"36049147","Document":["PURPOSE: Limited prospective data are available on sequential immunotherapy and BRAF\/MEK inhibition for BRAFV600-mutant metastatic melanoma.","METHODS: SECOMBIT is a randomized, three-arm, noncomparative phase II trial (ClinicalTrials.gov identifier: NCT02631447).","Patients with untreated, metastatic BRAFV600-mutant melanoma from 37 sites in nine countries were randomly assigned to arm A (encorafenib [450 mg orally once daily] plus binimetinib [45 mg orally twice daily] until progressive disease [PD] -> ipilimumab plus nivolumab [ipilimumab 3 mg\/kg once every 3 weeks and nivolumab 1 mg\/kg once every 3 weeks \u00d7 four cycles -> nivolumab 3 mg\/kg every 2 weeks]), arm B [ipilimumab plus nivolumab until PD -> encorafenib plus binimetinib], or arm C (encorafenib plus binimetinib for 8 weeks -> ipilimumab plus nivolumab until PD -> encorafenib plus binimetinib).","The primary end point was overall survival (OS) at 2 years.","Secondary end points included total progression-free survival, 3-year OS, best overall response rate, duration of response, and biomarkers in the intent-to-treat population.","Safety was analyzed throughout sequential treatment in all participants who received at least one dose of study medication.","RESULTS: A total of 209 patients were randomly assigned (69 in arm A, 71 in arm B, and 69 in arm C).","At a median follow-up of 32.2 (interquartile range, 27.9-41.6) months, median OS was not reached in any arm and more than 30 patients were alive in all arms.","Assuming a null hypothesis of median OS of \u2264 15 months, the OS end point was met for all arms.","The 2-year and 3-year OS rates were 65% (95% CI, 54 to 76) and 54% (95% CI, 41 to 67) in arm A, 73% (95% CI, 62 to 84) and 62% (95% CI, 48 to 76) in arm B, and 69% (95% CI, 59 to 80) and 60% (95% CI, 58 to 72) in arm C. No new safety signals emerged.","CONCLUSION: Sequential immunotherapy and targeted therapy provide clinically meaningful survival benefits for patients with BRAFV600-mutant melanoma."],"Aspect":"m","Summary":"The trial used encorafenib at 450 mg orally once daily and binimetinib at 45 mg orally twice daily, along with ipilimumab at 3 mg\/kg once every 3 weeks and nivolumab at 1 mg\/kg once every 3 weeks for four cycles, followed by nivolumab at 3 mg\/kg every 2 weeks.","Indexes":[2],"Sentences":["Patients with untreated, metastatic BRAFV600-mutant melanoma from 37 sites in nine countries were randomly assigned to arm A (encorafenib [450 mg orally once daily] plus binimetinib [45 mg orally twice daily] until progressive disease [PD] -> ipilimumab plus nivolumab [ipilimumab 3 mg\/kg once every 3 weeks and nivolumab 1 mg\/kg once every 3 weeks \u00d7 four cycles -> nivolumab 3 mg\/kg every 2 weeks]), arm B [ipilimumab plus nivolumab until PD -> encorafenib plus binimetinib], or arm C (encorafenib plus binimetinib for 8 weeks -> ipilimumab plus nivolumab until PD -> encorafenib plus binimetinib)."],"Revise":false}
{"PMID":"31498030","Document":["PURPOSE: Outcome measures that comprehensively capture attributes of immuno-oncology agents, including prolonged treatment-free time and persistent treatment-related adverse events (TRAEs), are needed to complement conventional survival end points.","METHODS: We pooled data from the CheckMate 067 and 069 clinical trials of nivolumab and ipilimumab, as monotherapies or in combination, for patients with advanced melanoma.","Treatment-free survival (TFS) was defined as the area between Kaplan-Meier curves for two conventional time-to-event end points, each defined from random assignment: time to immune checkpoint inhibitor (ICI) protocol therapy cessation and time to subsequent systemic therapy initiation or death.","TFS was partitioned as time with and without toxicity by a third end point, time to cessation of both ICI therapy and toxicity.","Toxicity included persistent and late-onset grade 3 or higher TRAEs.","The area under each Kaplan-Meier curve was estimated by the 36-month restricted mean time.","RESULTS: At 36 months, many of the 1,077 patients who initiated ICI therapy were surviving free of subsequent therapy initiation (47% nivolumab plus ipilimumab, 37% nivolumab, 15% ipilimumab).","The restricted mean TFS was longer for nivolumab plus ipilimumab (11.1 months) compared with nivolumab (4.6 months; difference, 6.5 months; 95% CI, 5.0 to 8.0 months) or ipilimumab (8.7 months; difference, 2.4 months; 95% CI, 0.8 to 4.1 months); restricted mean TFS represented 31% (3% with and 28% without toxicity), 13% (1% and 11%), and 24% (less than 1% and 23%) of the 36-month period, respectively, in the three treatment groups.","TFS without toxicity was longer for nivolumab plus ipilimumab than nivolumab (difference, 6.0 months) or ipilimumab (difference, 1.7 months).","CONCLUSION: The analysis of TFS between ICI cessation and subsequent therapy initiation revealed longer TFS without toxicity for patients with advanced melanoma who received nivolumab plus ipilimumab compared with nivolumab or ipilimumab.","Regardless of treatment, a small proportion of the TFS involved grade 3 or higher TRAEs."],"Aspect":"o","Summary":"The study found that patients with advanced melanoma who received nivolumab plus ipilimumab had longer treatment-free survival without toxicity compared to those who received nivolumab or ipilimumab alone.","Indexes":[7,8,9],"Sentences":["The restricted mean TFS was longer for nivolumab plus ipilimumab (11.1 months) compared with nivolumab (4.6 months; difference, 6.5 months; 95% CI, 5.0 to 8.0 months) or ipilimumab (8.7 months; difference, 2.4 months; 95% CI, 0.8 to 4.1 months); restricted mean TFS represented 31% (3% with and 28% without toxicity), 13% (1% and 11%), and 24% (less than 1% and 23%) of the 36-month period, respectively, in the three treatment groups.","TFS without toxicity was longer for nivolumab plus ipilimumab than nivolumab (difference, 6.0 months) or ipilimumab (difference, 1.7 months).","CONCLUSION: The analysis of TFS between ICI cessation and subsequent therapy initiation revealed longer TFS without toxicity for patients with advanced melanoma who received nivolumab plus ipilimumab compared with nivolumab or ipilimumab."],"Revise":false}
{"PMID":"33428772","Document":["This retrospective observational study aimed to determine the effectiveness, safety and patterns of the use of nivolumab in patients with advanced melanoma in real-world clinical practice in France using data from a Temporary Authorization for Use Program (ATU).","Data were collected from patients with unresectable or metastatic melanoma enrolled in a French national database (R\u00e9seau pour la Recherche et l'Investigation Clinique sur le M\u00e9lanome: Ric-Mel) and treated with nivolumab during the ATU program (12 September 2014 to 31 August 2015).","The primary objectives of the study were to evaluate the effect of patient characteristics on clinical response and overall survival (OS).","Among 400 included patients (median age 66\u2009years), the majority (83%) received nivolumab as second- or subsequent-line therapy.","The median durations of progression-free survival and OS were 3.3 and 14.1 months, respectively, and 31.6% of patients achieved an objective response with a median duration of 20.1 months (range: 0-34.7).","The safety profile of nivolumab was manageable and consistent with those of previous clinical trials, with an incidence of grade 3-5 adverse events of 13.8%.","The safety and effectiveness of nivolumab in patients with advanced melanoma in real-world clinical practice in France were in line with the data reported in the Phase 3 trials CheckMate 066 and 037 of nivolumab in this patient population."],"Aspect":"m","Summary":"The study involved the use of nivolumab, with the majority of patients receiving it as second- or subsequent-line therapy.","Indexes":[1,3],"Sentences":["Data were collected from patients with unresectable or metastatic melanoma enrolled in a French national database (R\u00e9seau pour la Recherche et l'Investigation Clinique sur le M\u00e9lanome: Ric-Mel) and treated with nivolumab during the ATU program (12 September 2014 to 31 August 2015).","Among 400 included patients (median age 66\u2009years), the majority (83%) received nivolumab as second- or subsequent-line therapy."],"Revise":false}
{"PMID":"37738028","Document":["The treatment of metastatic uveal melanoma remains a major clinical challenge.","Procaspase-3, a proapoptotic protein and precursor to the key apoptotic executioner caspase-3, is overexpressed in a wide range of malignancies, and the drug PAC-1 leverages this overexpression to selectively kill cancer cells.","Herein, we investigate the efficacy of PAC-1 against uveal melanoma cell lines and report the synergistic combination of PAC-1 and entrectinib.","This preclinical activity, tolerability data in mice, and the known clinical effectiveness of these drugs in human cancer patients led to a small Phase 1b study in patients with metastatic uveal melanoma.","The combination of PAC-1 and entrectinib was tolerated with no treatment-related grade \u22653 toxicities in these patients.","The pharmacokinetics of entrectinib were not affected by PAC-1 treatment.","In this small and heavily pretreated initial cohort, stable disease was observed in four out of six patients, with a median progression-free survival of 3.38 months (95% CI 1.6-6.5 months).","This study is an initial demonstration that the combination of PAC-1 and entrectinib may warrant further clinical investigation.","Clinical trial registration: Clinical Trials.gov: NCT04589832."],"Aspect":"o","Summary":"The combination of PAC-1 and entrectinib demonstrated tolerability and stable disease in four out of six patients with metastatic uveal melanoma, with a median progression-free survival of 3.38 months.","Indexes":[4,6],"Sentences":["The combination of PAC-1 and entrectinib was tolerated with no treatment-related grade \u22653 toxicities in these patients.","In this small and heavily pretreated initial cohort, stable disease was observed in four out of six patients, with a median progression-free survival of 3.38 months (95% CI 1.6-6.5 months)."],"Revise":false}
{"PMID":"33723350","Document":["BRAF and NRAS are the most reported mutations associated to melanomagenesis.","The lack of accurate diagnostic markers in response to therapeutic treatment in BRAF\/NRAS-driven melanomagenesis is one of the main challenges in melanoma personalized therapy.","In order to assess the diagnostic value of phosphatidylserine-specific phospholipase A1-alpha (PLA1A), a potent lysophospholipid mediating the production of lysophosphatidylserine, PLA1A mRNA and serum levels were compared in subjects with malignant melanoma (n\u2009=\u200918), primary melanoma (n\u2009=\u200913), and healthy subjects (n\u2009=\u200910).","Additionally, the correlation between histopathological subtypes of BRAF\/NRAS-mutated melanoma and PLA1A was analyzed.","PLA1A expression was significantly increased during melanogenesis and positively correlated to disease severity and histopathological markers of metastatic melanoma.","PLA1A mRNA and serum levels were significantly higher in patients with BRAF-mutated melanoma compared to the patients with NRAS-mutated melanoma.","Notably, PLA1A can be used as a diagnostic marker for an efficient discrimination between na\u00efve melanoma samples and advanced melanoma samples (sensitivity 91%, specificity 57%, and AUC 0.99), as well as BRAF-mutated melanoma samples (sensitivity 62%, specificity 61%, and AUC 0.75).","Our findings suggest that PLA1A can be considered as a potential diagnostic marker for advanced and BRAF-mutated melanoma."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"37309702","Document":["WHAT IS THIS SUMMARY ABOUT?",": Here, we summarize the 5-year results from part 1 of the COLUMBUS clinical study, which looked at the combination treatment of encorafenib plus binimetinib in people with a specific type of skin cancer called melanoma.","Encorafenib (BRAFTOVI\u00ae) and binimetinib (MEKTOVI\u00ae) are medicines used to treat a type of melanoma that has a change in the BRAF gene, called advanced or metastatic BRAF V600-mutant melanoma.","Participants with advanced or metastatic BRAF V600-mutant melanoma took either encorafenib plus binimetinib together (COMBO group), compared with encorafenib alone (ENCO group) or vemurafenib (ZELBORAF\u00ae) alone (VEMU group).","WHAT WERE THE RESULTS?",": In this 5-year update, more participants in the COMBO group were alive for longer without their disease getting worse after 5\u00a0years than those in the VEMU and ENCO groups.","Patients in the COMBO group were alive for longer without their disease getting worse when they: Had less advanced cancer Were able to do more daily activities Had normal lactate dehydrogenase (LDH) levels Had fewer organs with tumors before treatment After treatment, fewer participants in the COMBO group received additional anticancer treatment than participants in the VEMU and ENCO groups.","The number of participants who reported severe side effects was similar for each treatment.","The side effects caused by the drugs in the COMBO group decreased over time.","WHAT DO THE RESULTS MEAN?",": Overall, this 5-year update confirmed that people with BRAF V600-mutant melanoma that has spread to other parts of the body and who took encorafenib plus binimetinib were alive for longer without their disease getting worse than those who took vemurafenib or encorafenib alone.","Clinical Trial Registration: NCT01909453 (ClinicalTrials.gov)."],"Aspect":"s","Summary":"The number of participants who reported severe side effects was similar for each treatment, and the side effects caused by the drugs in the COMBO group decreased over time.","Indexes":[7,8],"Sentences":["The number of participants who reported severe side effects was similar for each treatment.","The side effects caused by the drugs in the COMBO group decreased over time."],"Revise":false}
{"PMID":"36564126","Document":["BACKGROUND: Intratumoral administration of V937, a bioselected, genetically unmodified coxsackievirus A21, has previously demonstrated antitumor activity in patients with advanced melanoma as monotherapy and in combination with the programmed cell death 1 (PD-1) antibody pembrolizumab.","We report results from an open-label, single-arm, phase 1b study (NCT02307149) evaluating V937 plus the cytotoxic T-lymphocyte antigen 4 inhibitor ipilimumab in patients with advanced melanoma.","METHODS: Adult patients (aged \u226518 years) with histologically confirmed metastatic or unresectable stage IIIB\/C or IV melanoma received intratumoral V937 on days 1, 3, 5, 8, and 22 and every 3 weeks (Q3W) thereafter for up to 19 sets of injections plus intravenous ipilimumab 3\u2009mg\/kg Q3W administered for four doses starting on day 22.","Imaging was performed at screening, on days 43 and 106 and every 6 weeks thereafter; response was assessed by immune-related response criteria per investigator assessment.","Primary endpoints were safety in all treated patients and objective response rate (ORR) in all treated patients and in patients with disease that progressed on prior anti-PD-1 therapy.","RESULTS: Fifty patients were enrolled and treated.","ORR was 30% (95% CI 18% to 45%) among all treated patients, 47% (95% CI 23% to 72%) among patients who had not received prior anti-PD-1 therapy, and 21% (95% CI 9% to 39%) among patients who had experienced disease progression on prior anti-PD-1 therapy.","Tumor regression occurred in injected and non-injected lesions.","Median immune-related progression-free survival was 6.2 months (95%\u2009CI 3.5 to 9.0 months), and median overall survival was 45.1 months (95%\u2009CI 28.3 months to not reached).","The most common treatment-related adverse events (AEs) were pruritus (n=25, 50%), fatigue (n=22, 44%), and diarrhea (n=16, 32%).","There were no V937-related dose-limiting toxicities and no treatment-related grade 5 AEs.","Treatment-related grade 3 or 4 AEs, all of which were considered related to ipilimumab, occurred in 14% of patients (most commonly dehydration, diarrhea, and hepatotoxicity in 4% each).","CONCLUSIONS: Responses associated with intratumoral V937 plus ipilimumab were robust, including in the subgroup of patients who had experienced disease progression on prior anti-PD-1 therapy.","Toxicities were manageable and consistent with those of the individual monotherapies."],"Aspect":"m","Summary":"V937 was administered intratumorally on days 1, 3, 5, 8, and 22, and every 3 weeks thereafter, combined with ipilimumab 3 mg\/kg intravenously every 3 weeks for four doses starting on day 22.","Indexes":[2],"Sentences":["METHODS: Adult patients (aged \u226518 years) with histologically confirmed metastatic or unresectable stage IIIB\/C or IV melanoma received intratumoral V937 on days 1, 3, 5, 8, and 22 and every 3 weeks (Q3W) thereafter for up to 19 sets of injections plus intravenous ipilimumab 3\u2009mg\/kg Q3W administered for four doses starting on day 22."],"Revise":false}
{"PMID":"34825282","Document":["INTRODUCTION: The effect of neoadjuvant systemic therapies (NST) on technical aspects of operation for resectable stage III melanoma is unknown.","Prospective capture of the estimated and actual degree of difficulty of therapeutic lymphadenectomy at presentation and after NST may inform the relative merits of NST versus surgery followed by adjuvant therapy.","METHODS: We designed surgeon survey tools to capture key impressions at baseline prior to NST and postoperatively.","We conducted a sub-study within a multi-institutional clinical trial for high-risk operable stage III melanoma (NeoACTIVATE, NCT03554083) which enrolls clinically node-positive patients to 12 weeks of combinatorial NST determined by BRAF status.","Survey data were analyzed.","RESULTS: Surveys were completed for 24 of 25 patients (96%).","Affected nodal basins were cervical (3, 13%) axillary (9, 38%), inguinal \u00b1 pelvic (14, 58%); 2 (8%) involved \u2265 2 basins.","Baseline estimates included largest affected node size (median\/range 4\/1.4-11 cm), number of involved nodes (median\/range 3\/1-10) and tumor fixation (present in 12, 50%).","At operation, actual degree of difficulty increased from the baseline estimate in 4 (17%) and decreased in 6 (25%).","Surgery was less difficult, average, or more difficult versus usual operation in 4, 9, and 11 cases (17%, 38%, 46%), respectively.","CONCLUSIONS: Although many operations were judged to be more difficult than the usual therapeutic lymphadenectomy, operation following NST was more often perceived as easier than more difficult versus baseline impression.","Engaging surgical oncologists to perform similar structured assessments across clinical trials will permit cross-study analysis of the effect of NSTs on the technical conduct of lymphadenectomy."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"32989226","Document":["BACKGROUND: Bromodomain and extra-terminal domain (BET) proteins are reported to be epigenetic anti-cancer drug targets.","This first-in-human study evaluated the safety, pharmacokinetics and preliminary anti-tumour activity of the BET inhibitor ODM-207 in patients with selected solid tumours.","METHODS: This was an open-label Phase 1 study comprised of a dose escalation part, and evaluation of the effect of food on pharmacokinetics.","ODM-207 was administered orally once daily.","The dose escalation part was initiated with a dose titration in the initial cohort, followed by a 3\u2009+\u20093 design.","RESULTS: Thirty-five patients were treated with ODM-207, of whom 12 (34%) had castrate-resistant prostate cancer.","One dose-limiting toxicity of intolerable fatigue was observed.","The highest studied dose achieved was 2\u2009mg\/kg due to cumulative toxicity observed beyond the dose-limiting toxicity (DLT) treatment window.","Common AEs included thrombocytopenia, asthenia, nausea, anorexia, diarrhoea, fatigue, and vomiting.","Platelet count decreased proportionally to exposure with rapid recovery upon treatment discontinuation.","No partial or complete responses were observed.","CONCLUSIONS: ODM-207 shows increasing exposure in dose escalation and was safe at doses up to 2\u2009mg\/kg but had a narrow therapeutic window.","CLINICAL TRIAL REGISTRATION: The clinical trial registration number is NCT03035591."],"Aspect":"s","Summary":"Common side effects of ODM-207 include thrombocytopenia, asthenia, nausea, anorexia, diarrhoea, fatigue, and vomiting.","Indexes":[8],"Sentences":["Common AEs included thrombocytopenia, asthenia, nausea, anorexia, diarrhoea, fatigue, and vomiting."],"Revise":false}
{"PMID":"38519525","Document":["The critical roles of CD4+ T cells have been understudied for cancer vaccines.","Here we report long-term clinical outcomes of a randomized multicenter phase II clinical trial (NCT00118274), where patients with high-risk melanoma received a multipeptide vaccine targeting CD8+ T cells (12MP) and were randomized to receive either of two vaccines for CD4+ (helper) T cells: 6MHP (6 melanoma-specific helper peptides), or tet (a nonspecific helper peptide from tetanus toxoid).","Cyclophosphamide (Cy) pre-treatment was also assessed.","Primary outcomes for T cell responses to 12MP, 6MHP, and tet were previously reported, suggesting immunogenicity of both vaccines but that CD8 T cell responses to 12MP were lower when tet was replaced with 6MHP.","Here, in post-hoc analyses, we report durable prolongation of overall survival by adding 6MHP instead of tet.","That benefit was experienced only by male patients.","A favorable interaction of 6MHP and Cy is also suggested.","Multivariable Cox regression analysis of the intent-to-treat population identify vaccine arm (12MP\u2009+\u20096MHP+Cy) and patient sex (male) as the two significant predictors of enhanced survival.","These findings support the value of adding cognate T cell help to cancer vaccines and also suggest a need to assess the impact of patient sex on immune therapy outcomes."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"37776537","Document":["BACKGROUND: Resistance to BRAF and MEK inhibitors in BRAF V600-mutant melanoma is common.","Multiple resistance mechanisms involve heat-shock protein 90 (HSP90) clients, and a phase 1 study of vemurafenib with the HSP90 inhibitor XL888 in patients with advanced melanoma showed activity equivalent to that of BRAF and MEK inhibitors.","METHODS: Vemurafenib (960\u00a0mg orally twice daily) and cobimetinib (60\u00a0mg orally once daily for 21 of 28\u00a0days) with escalating dose cohorts of XL888 (30, 45, 60, or 90\u00a0mg orally twice weekly) was investigated in a phase 1 trial of advanced melanoma, with a modified Ji dose-escalation design.","RESULTS: Twenty-five patients were enrolled.","After two dose-limiting toxicities (DLTs) (rash and acute kidney injury) in the first cohort, lower doses of vemurafenib (720\u00a0mg) and cobimetinib (40\u00a0mg) were investigated with the same XL888 doses.","Three DLTs (rash) were observed in 12 patients in the XL888 60-mg cohort, and this was determined as the maximum tolerated dose.","Objective responses were observed in 19 patients (76%), and the median progression-free survival was 7.6\u00a0months, with a 5-year progression-free survival rate of 20%.","The median overall survival was 41.7\u00a0months, with a 5-year overall survival rate of 37%.","Single-cell RNA sequencing was performed on baseline and on-treatment biopsies; treatment was associated with increased immune cell influx (CD4-positive and CD8-positive T cells) and decreased melanoma cells.","CONCLUSIONS: Combined vemurafenib and cobimetinib plus XL888 had significant toxicity, requiring frequent dose reductions, which may have contributed to the relatively low progression-free survival despite a high tumor response rate.","Given overlapping toxicities, caution must be used when combining HSP90 inhibitors with BRAF and MEK inhibitors."],"Aspect":"p","Summary":"The study included 25 patients with advanced melanoma.","Indexes":[3],"Sentences":["RESULTS: Twenty-five patients were enrolled."],"Revise":false}
{"PMID":"38319852","Document":["BACKGROUND: In the previously reported primary analyses of this phase 3 trial, 12 months of adjuvant pembrolizumab resulted in significantly longer recurrence- and distant metastasis-free survival than placebo in patients with resected high-risk stage III melanoma.","To confirm the stability of these benefits, longer-term data were needed.","METHODS: We randomly assigned 1019 patients to receive 200 mg of pembrolizumab or placebo intravenously every 3 weeks for a total of 18 doses (approximately 1 year) and had previously reported data with a 15-, 36-, and 42-month median follow-up.","We now report data at a median follow-up of 4.9 years.","We report a number of outcomes, including recurrence-free survival in the overall population and in the subgroup of patients with cancer who were positive for the programmed death-ligand 1 (PD-L1).","Distant metastasis-free survival was a secondary end point.","RESULTS: In the overall intention-to-treat population, pembrolizumab was still associated with longer recurrence-free survival than placebo (5-year rate of recurrence-free survival, 55.4% [95% confidence interval (CI), 50.8 to 59.8] vs. 38.3% [95% CI, 33.9 to 42.7]; hazard ratio for recurrence or death, 0.61 [95% CI, 0.51 to 0.72]) and a longer distant metastasis-free survival (5-year rate of distant metastasis-free survival, 60.6% [95% CI, 56.0 to 64.9] vs. 44.5% [95% CI, 39.9 to 48.9]; hazard ratio for distant metastasis or death, 0.62 [95% CI, 0.52 to 0.75]).","Similar findings were obtained in the subgroup of 853 patients with PD-L1\u2013positive tumors.","CONCLUSIONS: The 5-year analysis of adjuvant therapy with pembrolizumab resulted in a sustained improvement in the long-term recurrence- and distant metastasis-free survival compared with placebo in patients with resected stage III melanoma.","(Funded by Merck & Co., Inc.; ClinicalTrials.gov number, NCT02362594, and EudraCT number, 2014-004944-37.)"],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"38261444","Document":["BACKGROUND: Aberrant PI3K\/AKT signaling in BRAF-mutant cancers contributes to resistance to BRAF inhibitors.","The authors examined dual MAPK and PI3K pathway inhibition in patients who had BRAF-mutated solid tumors (ClinicalTrials.gov identifier NCT01902173).","METHODS: Patients with BRAF V600E\/V600K-mutant solid tumors received oral dabrafenib at 150\u00a0mg twice daily with dose escalation of oral uprosertib starting at 50\u00a0mg daily, or, in the triplet cohorts, with dose escalation of both oral trametinib starting at 1.5\u00a0mg daily and oral uprosertib starting at 25\u00a0mg daily.","Dose-limiting toxicities (DLTs) were assessed within the first 56\u00a0days of treatment.","Radiographic responses were assessed at 8-week intervals.","RESULTS: Twenty-seven patients (22 evaluable) were enrolled in parallel doublet and triplet cohorts.","No DLTs were observed in the doublet cohorts (N\u00a0=\u00a07).","One patient had a DLT at the maximum administered dose of triplet therapy (dabrafenib 150\u00a0mg twice daily and trametinib 2\u00a0mg daily plus uprosertib 75\u00a0mg daily).","Three patients in the doublet cohorts had partial responses (including one who had BRAF inhibitor-resistant melanoma).","Two patients in the triplet cohorts had a partial response, and one patient had an unconfirmed partial response.","Pharmacokinetic data suggested reduced dabrafenib and dabrafenib metabolite exposure in patients who were also exposed to both trametinib and uprosertib, but not in whose who were exposed to uprosertib without trametinib.","CONCLUSIONS: Concomitant inhibition of both the MAPK and PI3K-AKT pathways for the treatment of BRAF-mutated cancers was well tolerated, leading to objective responses, but higher level drug-drug interactions affected exposure to dabrafenib and its metabolites."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"31557067","Document":["PURPOSE: We have previously reported on the 3-year results of the phase III German Dermatologic Cooperative Oncology Group trial (DeCOG; ClinicalTrials.gov identifier: NCT02434107) comparing distant metastasis-free survival (DMFS), recurrence-free survival (RFS), and overall survival (OS) in patients with positive sentinel lymph-node biopsy who were randomly assigned to complete lymph node dissection (CLND) or observation.","Here, we report the final analysis with 72 months of median follow up.","PATIENTS AND METHODS: The multicenter randomized phase III trial included patients with cutaneous melanoma of the trunk and extremities who were randomly assigned (1:1) to undergo CLND or observation.","DMFS was analyzed as the primary end point, and RFS, OS, and recurrences in the regional lymph node basin were secondary end points.","The analysis was by intention to treat.","Disease and survival information were collected quarterly.","RESULTS: From January 2006 to December 2014, 5,547 patients were screened to identify 1,256 with metastases in the sentinel lymph node (SLN).","Of these, 483 (39%) were included: 241 in the observation arm and 242 in the CLND arm.","In the final analysis, median follow up was 72 months (interquartile range, 67-77 months).","No significant treatment-related difference was seen in the 5-year DMFS between the observation and CLND arms (67.6% v 64.9%, respectively; hazard ratio [HR], 1.08; P = .87).","The 5-year RFS and OS also showed no difference (HR, 1.01 and 0.99, respectively).","Grade 3 and 4 adverse effects occurred in 32 patients (13%) in the CLND arm; lymphedema (n = 20) and delayed wound healing (n = 5) were most common and no serious adverse events were reported.","CONCLUSION: The final results of the German Dermatologic Cooperative Oncology Group trial with a median follow up of 72 months showed higher event rates, but similar HRs compared with those at the 3-year analysis.","These results confirm that immediate CLND in SLN-positive patients is not superior to observation in terms of DMFS, RFS, or OS and support not recommending CLND in patients with SLN metastasis."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"34129153","Document":["BACKGROUND: Adjuvant therapy for stage III melanoma improves several measures of patient survival.","However, decisions regarding inclusion of adjuvant therapies in the formularies of public payers necessarily consider the cost-effectiveness of those treatments.","The objective of this study is to evaluate the cost-effectiveness of four recently approved adjuvant therapies for BRAF-mutant stage III melanoma in the Medicare patient population.","METHODS: In this cost-effectiveness analysis, a Markov microsimulation model was used to simulate the healthcare trajectory of patients randomized to receive either first-line targeted therapy (dabrafenib-trametinib) or immunotherapy (ipilimumab, nivolumab, or pembrolizumab).","The base case was a 65-year-old Medicare patient with BRAF V600E-mutant resected stage III melanoma.","Possible health states included recurrence-free survival, adverse events, local recurrence, distant metastases, and death.","Transition probabilities were determined from published clinical trials.","Costs were estimated from reimbursement rates reported by CMS and the Red Book drug price database.","Primary outcomes were costs (US$), life years, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs).","Model robustness was evaluated using one-way and probabilistic sensitivity analyses.","RESULTS: Dabrafenib-trametinib provided 1.83 QALYs over no treatment and 0.23 QALYs over the most effective immunotherapy, pembrolizumab.","Dabrafenib-trametinib was associated with an ICER of $95,758\/QALY over no treatment and $285,863\/QALY over pembrolizumab.","Pembrolizumab yielded an ICER of $68,396\/QALY over no treatment and dominated other immunotherapies.","CONCLUSIONS: Pembrolizumab is cost-effective at a conventional willingness-to-pay (WTP) threshold, but dabrafenib-trametinib is not.","Though dabrafenib-trametinib offers incremental QALYs, optimization of drug pricing is necessary to ensure dabrafenib-trametinib is accessible at an acceptable WTP threshold."],"Aspect":"m","Summary":"The medicines involved in the treatment are dabrafenib-trametinib, ipilimumab, nivolumab, and pembrolizumab.","Indexes":[3,10,11,12],"Sentences":["METHODS: In this cost-effectiveness analysis, a Markov microsimulation model was used to simulate the healthcare trajectory of patients randomized to receive either first-line targeted therapy (dabrafenib-trametinib) or immunotherapy (ipilimumab, nivolumab, or pembrolizumab).","RESULTS: Dabrafenib-trametinib provided 1.83 QALYs over no treatment and 0.23 QALYs over the most effective immunotherapy, pembrolizumab.","Dabrafenib-trametinib was associated with an ICER of $95,758\/QALY over no treatment and $285,863\/QALY over pembrolizumab.","Pembrolizumab yielded an ICER of $68,396\/QALY over no treatment and dominated other immunotherapies."],"Revise":false}
{"PMID":"36307938","Document":["BACKGROUND: Detectable circulating tumor DNA (ctDNA) has been associated with worse prognosis in melanoma patients.","MATERIAL AND METHODS: We studied plasma ctDNA as a prognostic biomarker in 19 patients with metastatic melanoma and a detectable tumor mutation (13 BRAF, 5 NRAS, and 1 KRAS).","Patients had received chemotherapy, interferon-alpha, and vemurafenib in a prospective clinical trial.","Mutant allele frequency (MAF %) was determined with droplet digital PCR from pretreatment and sequential plasma samples.","RESULTS: Higher pretreatment plasma ctDNA levels (MAF \u22653%) and detectable plasma ctDNA levels (MAF >0%) at the time of radiologically confirmed best objective response were associated with poor prognosis even when accounting for other relevant prognostic factors including performance status, tumor mutation, metastasis stage, and lactate dehydrogenase levels in multivariable analysis.","CONCLUSION: Higher pretreatment plasma ctDNA levels and sustained detectable plasma ctDNA levels during treatment indicated poor prognosis in metastatic melanoma patients."],"Aspect":"o","Summary":"Higher pretreatment plasma ctDNA levels and sustained detectable plasma ctDNA levels during treatment were associated with poor prognosis in metastatic melanoma patients.","Indexes":[4,5],"Sentences":["RESULTS: Higher pretreatment plasma ctDNA levels (MAF \u22653%) and detectable plasma ctDNA levels (MAF >0%) at the time of radiologically confirmed best objective response were associated with poor prognosis even when accounting for other relevant prognostic factors including performance status, tumor mutation, metastasis stage, and lactate dehydrogenase levels in multivariable analysis.","CONCLUSION: Higher pretreatment plasma ctDNA levels and sustained detectable plasma ctDNA levels during treatment indicated poor prognosis in metastatic melanoma patients."],"Revise":false}
{"PMID":"36202690","Document":["BACKGROUND: Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) versus placebo in resected stage IIB and IIC melanoma in the phase 3 KEYNOTE-716 study.","Health-related quality of life (HRQoL) results are reported.","METHODS: Patients were randomly assigned 1:1 to pembrolizumab 200\u00a0mg (2\u00a0mg\/kg, patients \u226512 to <18 years) Q3W or placebo for \u226417 cycles or until disease recurrence, unacceptable toxicity, or withdrawal.","Change from baseline in EORTC QLQ-C30 global health status (GHS)\/quality of life (QoL) was a prespecified exploratory end point.","Change in EORTC QLQ-C30 functioning, symptom, and single-item scales, and EQ-5D-5L visual analog scale (VAS) were also summarized.","Primary analyses were performed at week 48 to ensure adequate completion\/compliance.","The HRQoL population comprised patients who received \u22651 dose of treatment and completed \u22651 assessment.","RESULTS: The HRQoL population included 969 patients (pembrolizumab, n\u00a0=\u00a0483; placebo, n\u00a0=\u00a0486).","Compliance at week 48 was \u226580% for both instruments.","EORTC QLQ-C30 GHS\/QoL, physical functioning, role functioning, and EQ-5D-5L VAS scores were stable from baseline to week 48 in both arms, with no clinically meaningful decline observed.","Scores did not differ significantly between pembrolizumab and placebo.","EORTC QLQ-C30 GHS\/QoL, physical functioning, role functioning, and EQ-5D-5L VAS scores remained stable through week 96 in both arms.","CONCLUSIONS: HRQoL was stable with adjuvant pembrolizumab, with no clinically meaningful decline observed.","Change from baseline in HRQoL was similar between arms.","These results, in conjunction with the improved RFS and manageable safety previously reported, support the use of adjuvant pembrolizumab for high-risk stage II melanoma."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"38417447","Document":["Mucosal (MM) and acral melanomas (AM) are rare melanoma subtypes of unmet clinical need; 15%-20% harbor KIT mutations potentially targeted by small-molecule inhibitors, but none yet approved in melanoma.","This multicenter, single-arm Phase II trial (NICAM) investigates nilotinib safety and activity in KIT mutated metastatic MM and AM.","KIT mutations are identified in 39\/219 screened patients (18%); of 29\/39 treated, 26 are evaluable for primary analysis.","Six patients were alive and progression free at 6\u00a0months (local radiology review, 25%); 5\/26 (19%) had objective response at 12\u00a0weeks; median OS was 7.7\u00a0months; ddPCR assay correctly identifies KIT alterations in circulating tumor DNA (ctDNA) in 16\/17 patients.","Nilotinib is active in KIT-mutant AM and MM, comparable to other KIT inhibitors, with demonstrable activity in nonhotspot KIT mutations, supporting broadening of KIT evaluation in AM and MM.","Our results endorse further investigations of nilotinib for the treatment of KIT-mutated melanoma.","This clinical trial was registered with ISRCTN (ISRCTN39058880) and EudraCT (2009-012945-49)."],"Aspect":"i","Summary":"This multicenter, single-arm Phase II trial (NICAM) investigates nilotinib safety and activity in KIT mutated metastatic mucosal (MM) and acral melanomas (AM).","Indexes":[1],"Sentences":["This multicenter, single-arm Phase II trial (NICAM) investigates nilotinib safety and activity in KIT mutated metastatic MM and AM."],"Revise":false}
{"PMID":"36113242","Document":["BACKGROUND: A phase 1a first-in-human study evaluated the safety\/tolerability, preliminary antitumour activity and pharmacokinetics of the oral MEK1\/2 inhibitor FCN-159 in Chinese patients with advanced, NRAS-mutant melanoma.","PATIENTS AND METHODS: Patients received a single FCN-159 dose at assigned levels, proceeding to continuous dosing (once daily [QD] for 28-day cycles) if no dose-limiting toxicities (DLTs) occurred within the next 3 days.","Dose escalation was initiated after review of data for the previous dose level.","The primary end-point was incidence of DLTs after the first dose.","RESULTS: Thirty-three patients were enrolled across nine FCN-159 dose groups (0.2-15\u00a0mg QD).","One DLT occurred: grade 3 folliculitis in the 15-mg group.","There was one grade &gt;3 treatment-emergent adverse event (TEAE), death of unknown aetiology (not FCN-159 related).","The most common FCN-159-related TEAE was rash (36.4%), and the incidence of grade \u22653 FCN-159-related TEAEs was 15.2%.","Antitumour activity at QD doses &lt;6\u00a0mg was limited; therefore, efficacy data are presented only for doses \u22656\u00a0mg (n\u00a0=\u00a021).","The objective response and clinical benefit rates were 19.0% (four partial responses) and 52.4%, respectively.","Median (95% confidence interval) duration of response and progression-free survival were 4.8 months (2.8-not reached) and 3.8 months (1.8-5.6), respectively.","FCN-159 exposure increased dose-proportionately; geometric mean terminal half-life was 29.9-56.9\u00a0h. CONCLUSIONS: FCN-159 was well tolerated and demonstrated promising antitumour activity at doses \u22656\u00a0mg QD in patients with advanced, NRAS-mutant melanoma.","The recommended phase 2 dose was 12\u00a0mg QD.","GOV IDENTIFIER: NCT03932253.","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03932253."],"Aspect":"d","Summary":"Patients received continuous dosing of FCN-159 once daily for 28-day cycles.","Indexes":[1],"Sentences":["PATIENTS AND METHODS: Patients received a single FCN-159 dose at assigned levels, proceeding to continuous dosing (once daily [QD] for 28-day cycles) if no dose-limiting toxicities (DLTs) occurred within the next 3 days."],"Revise":false}
{"PMID":"34780711","Document":["BACKGROUND: The dependence of the adaptive immune system on circadian rhythm is an emerging field of study with potential therapeutic implications.","We aimed to determine whether specific time-of-day patterns of immune checkpoint inhibitor infusions might alter melanoma treatment efficacy.","METHODS: Melanoma Outcomes Following Immunotherapy (MEMOIR) is a longitudinal study of all patients with melanoma who received ipilimumab, nivolumab, or pembrolizumab, or a combination of these at a single tertiary cancer centre (Winship Cancer Institute of Emory University, Atlanta, GA, USA).","For this analysis, we collected deidentified participant-level data from the MEMOIR database for adults (age \u226518 years) diagnosed with stage IV melanoma between 2012 and 2020.","Those who received fewer than four infusions were excluded.","Standard of care doses were used, with modifications at the treating physicians' discretion.","The primary outcome was overall survival, defined as death from any cause and indexed from date of first infusion of immune checkpoint inhibitor.","We calculated the association between overall survival and proportion of infusions of immune checkpoint inhibitors received after 1630 h (a composite time cutoff derived from seminal studies of the immune-circadian rhythm to represent onset of evening) using Cox regression and propensity score-matching on age, Eastern Cooperative Oncology Group performance status, serum lactate dehydrogenase concentration, and receipt of corticosteroids and radiotherapy.","Treatment-related adverse events that led to change or discontinuation of immune checkpoint inhibitors were also assessed.","FINDINGS: Between Jan 1, 2012, and Dec 31, 2020, 481 patients with melanoma received treatment with immune checkpoint inhibitors at the study centre, of whom 299 had stage IV disease and were included in this study; median follow-up was 27 months (IQR 14 to 47).","In the complete unmatched sample, 102 (34%) patients were female and 197 (66%) were male, with a median age of 61 years (IQR 51 to 72).","Every additional 20% of infusions of immune checkpoint inhibitors received after 1630 h (among all infusions received by a patient) conferred an overall survival hazard ratio (HR) of 1\u00b731 (95% CI 1\u00b700 to 1\u00b771; p=0\u00b7046).","A propensity score-matched analysis of patients who did (n=73) and did not (n=73) receive at least 20% of their infusions of immune checkpoint inhibitors after 1630 h (54 [37%] of 146 patients were women and 92 [63%] were men, with a median age of 58 years [IQR 48 to 68]) showed that having at least 20% of infusions in the evening was associated with shorter overall survival (median 4\u00b78 years [95% CI 3\u00b79 to not estimable] vs not reached; HR 2\u00b704 [1\u00b704 to 4\u00b700; p=0\u00b7038]).","This result remained robust to multivariable proportional hazards adjustment with (HR 1\u00b780 [1\u00b708 to 2\u00b798; p=0\u00b7023]) and without (2\u00b716 [1\u00b710 to 4\u00b725; p=0\u00b7025]) inclusion of the complete unmatched study sample.","The most common adverse events were colitis (54 [18%] of 299 patients), hepatitis (27 [9%]), and hypophysitis (15 [5%]), and there were no treatment-related deaths.","INTERPRETATION: Our findings are in line with an increasing body of evidence that adaptive immune responses are less robust when initially stimulated in the evening than if stimulated in the daytime.","Although prospective studies of the timing of immune checkpoint inhibitor infusions are warranted, efforts towards scheduling infusions before mid-afternoon could be considered in the multidisciplinary management of advanced melanoma.","FUNDING: National Institutes of Health, American Society for Radiation Oncology and Melanoma Research Alliance, and Winship Cancer Institute."],"Aspect":"p","Summary":"The study involved 481 patients with melanoma, of whom 299 had stage IV disease; 102 (34%) were female and 197 (66%) were male, with a median age of 61 years.","Indexes":[9,10],"Sentences":["FINDINGS: Between Jan 1, 2012, and Dec 31, 2020, 481 patients with melanoma received treatment with immune checkpoint inhibitors at the study centre, of whom 299 had stage IV disease and were included in this study; median follow-up was 27 months (IQR 14 to 47).","In the complete unmatched sample, 102 (34%) patients were female and 197 (66%) were male, with a median age of 61 years (IQR 51 to 72)."],"Revise":false}
{"PMID":"37286303","Document":["BACKGROUND: Immune checkpoint inhibitors have significantly improved outcomes in first line cutaneous melanoma.","However, there is a high unmet need for patients who progress on these therapies and combination therapies are being explored to improve outcomes.","Tebentafusp is a first-in-class gp100\u00d7CD3 ImmTAC bispecific that demonstrated overall survival (OS) benefit (HR 0.51) in metastatic uveal melanoma despite a modest overall response rate of 9%.","This phase 1b trial evaluated the safety and initial efficacy of tebentafusp in combination with durvalumab (anti-programmed death ligand 1 (PDL1)) and\/or tremelimumab (anti-cytotoxic T lymphocyte-associated antigen 4) in patients with metastatic cutaneous melanoma (mCM), the majority of whom progressed on prior checkpoint inhibitors.","METHODS: In this open-label, multicenter, phase 1b, dose-escalation trial, HLA-A*02:01-positive patients with mCM received weekly intravenous tebentafusp with increasing monthly doses of durvalumab and\/or tremelimumab starting day 15 of each cycle.","The primary objective was to identify the maximum tolerated dose (MTD) or recommended phase 2 dose for each combination.","Efficacy analyses were performed in all tebentafusp with durvalumab\u00b1tremelimumab treated patients with a sensitivity analysis in those who progressed on prior anti-PD(L)1 therapy.","RESULTS: 85 patients were assigned to receive tebentafusp in combination with durvalumab (n=43), tremelimumab (n=13), or durvalumab and tremelimumab (n=29).","Patients were heavily pretreated with a median of 3 prior lines of therapy, including 76 (89%) who received prior anti-PD(L)1.","Maximum target doses of tebentafusp (68 mcg) alone or in combination with durvalumab (20\u2009mg\/kg) and tremelimumab (1\u2009mg\/kg) were tolerated; MTD was not formally identified for any arm.","Adverse event profile was consistent with each individual therapy and there were no new safety signals nor treatment-related deaths.","In the efficacy subset (n=72), the response rate was 14%, tumor shrinkage rate was 41% and 1-year OS rate was 76% (95% CI: 70% to 81%).","The 1-year OS for triplet combination (79%; 95%\u2009CI: 71% to 86%) was similar to tebentafusp plus durvalumab (74%; 95%\u2009CI: 67% to 80%).","CONCLUSION: At maximum target doses, the safety of tebentafusp with checkpoint inhibitors was consistent with safety of each individual therapy.","Tebentafusp with durvalumab demonstrated promising efficacy in heavily pretreated patients with mCM, including those who progressed on prior anti-PD(L)1.","TRIAL REGISTRATION NUMBER: NCT02535078."],"Aspect":"m","Summary":"The trial involved tebentafusp at a maximum dose of 68 mcg weekly, durvalumab at 20 mg\/kg monthly, and tremelimumab at 1 mg\/kg monthly.","Indexes":[4,9],"Sentences":["METHODS: In this open-label, multicenter, phase 1b, dose-escalation trial, HLA-A*02:01-positive patients with mCM received weekly intravenous tebentafusp with increasing monthly doses of durvalumab and\/or tremelimumab starting day 15 of each cycle.","Maximum target doses of tebentafusp (68 mcg) alone or in combination with durvalumab (20\u2009mg\/kg) and tremelimumab (1\u2009mg\/kg) were tolerated; MTD was not formally identified for any arm."],"Revise":false}
{"PMID":"37587862","Document":["BACKGROUND: Non-immunosuppressed patients with a history of multiple non-melanoma skin cancers (NMSCs) taking oral nicotinamide supplementation experienced a 23% decrease in annual NMSC risk in a randomized clinical trial.","Patient preferences for risks and costs associated with nicotinamide are unknown.","OBJECTIVES: To understand how patients prioritize NMSC reduction, infection risk, and cost.","METHODS: A sample of adults with history of \u22652 NMSC within the past five\u2009years undergoing Mohs procedure completed a discrete-choice experiment comprising two hypothetical treatments-characterized by varying reductions in NMSC incidence, increased severe infection risk, and cost-and no treatment.","The data were analyzed with random-parameters logit models.","RESULTS: A total of 203 subjects (mean age 71.5\u2009years, 65.5% males) participated.","For a 23% annual reduction in NMSC incidence, a 26% [95% CI: 8%-45%] annual increase in severe infection risk and $8 [95% CI: $2-14] monthly cost was acceptable.","Outcomes across analyzed subgroups (before vs. during COVID pandemic, site of interview, less vs. more prior NMSCs) were similar.","CONCLUSIONS: Patients were unwilling to accept high severe infection risks to obtain the reduction in NMSC incidence observed in a nicotinamide trial, suggesting that routinely recommending nicotinamide may run counter to some patients' preferences."],"Aspect":"i","Summary":"Adults with a history of \u22652 NMSCs within the past five years underwent a discrete-choice experiment to evaluate preferences for varying reductions in NMSC incidence, increased severe infection risk, and cost.","Indexes":[3],"Sentences":["METHODS: A sample of adults with history of \u22652 NMSC within the past five\u2009years undergoing Mohs procedure completed a discrete-choice experiment comprising two hypothetical treatments-characterized by varying reductions in NMSC incidence, increased severe infection risk, and cost-and no treatment."],"Revise":false}
{"PMID":"31895753","Document":["Approximately, 50% of patients with uveal melanoma develop distant metastasis for which no standard therapy is established.","In contrast to cutaneous melanoma, the anti-CTLA-4 antibody ipilimumab showed no clinical activity in uveal melanoma.","Liver directed therapies improve local control, but fail to show overall survival (OS) benefit.","Preclinical experiments demonstrated that radiofrequency ablation (RFA) induced durable responses in combination with anti-CTLA-4.","The aim of this phase Ib\/II study was to assess safety and efficacy of RFA plus ipilimumab in uveal melanoma.","Patients underwent RFA of one liver lesion and subsequently received four courses ipilimumab 0.3, 3 or 10 mg\/kg every 3 weeks in a 3\u2009+\u20093 design.","Primary endpoints were safety in terms of dose limiting toxicities per cohort to define the recommended phase II dose (RP2D) in the phase Ib part and confirmed the objective response rate and disease control rate (DCR) of non-RFA lesions in the phase II part.","Secondary endpoints were progression-free survival (PFS) and OS.","Ipilimumab 10 mg\/kg + RFA was initially defined as the RP2D.","However, after 19 patients, the study was amended to adjust the RP2D to ipilimumab 3 mg\/kg + RFA, because 47% of patients treated with 10 mg\/kg had developed grade 3 colitis.","In the 3 mg\/kg cohort, also 19 patients have been treated.","Immunotherapy-related grade \u22653 adverse events were observed in 53% of patients in the 10 mg\/kg cohort versus 32% in the 3 mg\/kg cohort.","No confirmed objective responses were observed; the confirmed DCR was 5% in the 10 mg\/kg cohort and 11% in the 3 mg\/kg cohort.","Median PFS was 3 months and comparable for both cohorts, median OS was 14.2 months for the 10 mg\/kg cohort versus 9.7 months for the 3 mg\/kg cohort.","Combining RFA with ipilimumab 3 mg\/kg was well tolerated, but showed very limited clinical activity in uveal melanoma."],"Aspect":"m","Summary":"The study assessed ipilimumab at doses of 0.3 mg\/kg, 3 mg\/kg, and 10 mg\/kg given every 3 weeks for four courses, with the recommended phase II dose being 3 mg\/kg in combination with RFA.","Indexes":[5,8,9],"Sentences":["Patients underwent RFA of one liver lesion and subsequently received four courses ipilimumab 0.3, 3 or 10 mg\/kg every 3 weeks in a 3\u2009+\u20093 design.","Ipilimumab 10 mg\/kg + RFA was initially defined as the RP2D.","However, after 19 patients, the study was amended to adjust the RP2D to ipilimumab 3 mg\/kg + RFA, because 47% of patients treated with 10 mg\/kg had developed grade 3 colitis."],"Revise":false}
{"PMID":"33417511","Document":["PURPOSE: This study aimed to assess the efficacy of the combination of nivolumab (nivo) plus ipilimumab (ipi) as a first-line therapy with respect to the 12-month overall survival (OS) in patients with metastatic uveal melanoma (MUM) who are not eligible for liver resection.","METHODS: This was a single-arm, phase II trial led by the Spanish Multidisciplinary Melanoma Group (GEM) on nivo plus ipi for systemic treatment-na\u00efve patients of age > 18 years, with histologically confirmed MUM, Eastern Cooperative Oncology Group-PS 0\/1, and confirmed progressive metastatic disease (M1).","Nivo (1 mg\/kg once every 3 weeks) and ipi (3 mg\/kg once every 3 weeks) were administered during four inductions, followed by nivo (3 mg\/kg once every 2 weeks) until progressive disease, toxicity, or withdrawal.","The primary end point was 12-month OS.","OS, progression-free survival (PFS), and overall response rate were evaluated every 6 weeks using RECIST (v1.1).","Safety was also evaluated.","Logistic regression and Cox proportional hazard models comprising relevant clinical factors were used to evaluate the potential association with response to treatment and survival.","Cytokines were quantified in serum samples for their putative role in immune modulation\/angiogenesis and\/or earlier evidence of involvement in immunotherapy.","RESULTS: A total of 52 patients with a median age of 59 years (range, 26-84 years) were enrolled.","Overall, 78.8%, 56%, and 32% of patients had liver M1, extra-liver M1, and elevated lactate dehydrogenase.","Stable disease was the most common outcome (51.9%).","The primary end point was 12-month OS, which was 51.9% (95% CI, 38.3 to 65.5).","The median OS and PFS were 12.7 months and 3.0 months, respectively.","PFS was influenced by higher LDH values.","CONCLUSIONS: Nivo plus ipi in the first-line setting for MUM showed a modest improvement in OS over historical benchmarks of chemotherapy, with a manageable toxicity profile."],"Aspect":"m","Summary":"The study used nivolumab (nivo) at a dose of 1 mg\/kg every 3 weeks for induction and 3 mg\/kg every 2 weeks for maintenance, combined with ipilimumab (ipi) at 3 mg\/kg every 3 weeks for induction.","Indexes":[2],"Sentences":["Nivo (1 mg\/kg once every 3 weeks) and ipi (3 mg\/kg once every 3 weeks) were administered during four inductions, followed by nivo (3 mg\/kg once every 2 weeks) until progressive disease, toxicity, or withdrawal."],"Revise":false}
{"PMID":"31895407","Document":["IMPORTANCE: Whether immune-related adverse events (irAEs) indicate drug activity in patients treated with immune checkpoint inhibitors remains unknown.","OBJECTIVE: To investigate the association between irAEs and recurrence-free survival (RFS) in the double-blind EORTC 1325\/KEYNOTE-054 clinical trial comparing pembrolizumab therapy and placebo for the treatment of patients with high-risk stage III melanoma.","DESIGN, SETTING, AND PARTICIPANTS: A total of 1019 adults with stage III melanoma were randomly assigned on a 1:1 ratio to receive treatment with pembrolizumab therapy or placebo.","Eligible patients were adults 18 years and older with complete resection of cutaneous melanoma metastatic to lymph nodes, classified with stage IIIA (at least 1 micrometastasis measuring >1 mm in greatest diameter), IIIB, or IIIC (without in-transit metastasis) cancer.","Patients were randomized from August 26, 2015, to November 14, 2016.","The clinical cutoff for the data set was October 2, 2017.","Analyses were then performed on the database, which was locked on November 28, 2017.","INTERVENTIONS: Participants were scheduled to receive 200 mg of pembrolizumab or placebo every 3 weeks for a total of 18 doses for approximately\u20091 year or until disease recurrence, unacceptable toxic effects, major protocol violation, or withdrawal of consent.","MAIN OUTCOMES AND MEASURES: The association between irAEs and RFS was estimated using a Cox model adjusted for sex, age, and AJCC-7 stage, with a time-varying covariate that had a value of 0 before irAE onset and 1 after irAE onset.","RESULTS: Of 1011 patients who began treatment with pembrolizumab therapy or placebo, 622 (61.5%) were men and 389 (38.5%) were women; 386 patients (38.2%) were aged 50 to 64 years, 377 (37.3%) were younger than 50 years, and 248 (24.5%) were 65 years and older.","Consistent with the reported main analysis in the intent-to-treat population, RFS was longer in the pembrolizumab arm compared with the placebo arm (hazard ratio [HR], 0.56; 98.4% CI, 0.43-0.74) among patients who started treatment.","The incidence of irAEs was 190 (37.4%) in the pembrolizumab arm (n\u2009=\u2009509) and 45 (9.0%) in the placebo arm (n\u2009=\u2009502); in each treatment group, the incidence was similar for men and women.","The occurrence of an irAE was associated with a longer RFS in the pembrolizumab arm (HR, 0.61; 95% CI, 0.39-0.95; P\u2009=\u2009.03) in both men and women.","However, in the placebo arm, this association was not significant.","Compared with the placebo arm, the reduction in the hazard of recurrence or death in the pembrolizumab arm was greater after the onset of an irAE than without or before an irAE (HR, 0.37; 95% CI, 0.24-0.57 vs HR, 0.61; 95% CI, 0.49-0.77, respectively; P\u2009=\u2009.03).","CONCLUSIONS AND RELEVANCE: In this study, the occurrence of an irAE was associated with a longer RFS in the pembrolizumab arm.","TRIAL REGISTRATIONS: ClinicalTrials.gov identifier: NCT02362594; EudraCT identifier: 2014-004944-37."],"Aspect":"d","Summary":"Participants were scheduled to receive 200 mg of pembrolizumab or placebo every 3 weeks for a total of 18 doses for approximately 1 year or until disease recurrence, unacceptable toxic effects, major protocol violation, or withdrawal of consent.","Indexes":[7],"Sentences":["INTERVENTIONS: Participants were scheduled to receive 200 mg of pembrolizumab or placebo every 3 weeks for a total of 18 doses for approximately\u20091 year or until disease recurrence, unacceptable toxic effects, major protocol violation, or withdrawal of consent."],"Revise":true}
{"PMID":"38851639","Document":["BACKGROUND: Cutaneous neurotropic melanoma (NM) of the head and neck (H&N) is prone to local relapse, possibly due to difficulties widely excising the tumor.","This trial assessed radiation therapy (RT) to the primary site after local excision.","METHODS: Participants from 15 international centers were randomized to observation or RT.","The participants were required to have microscopically negative excision margins 5 mm wide or wider and no evidence of disease elsewhere.","The primary outcome was time to local relapse.","The secondary outcomes included time to any recurrence, overall survival (OS), and toxicity.","RESULTS: The trial ceased prematurely due to slow recruitment and the COVID-19 pandemic.","During 2009-2020, 50 participants were randomized: 23 to observation and 27 to RT.","The most common NM subsites were scalp (32%), midface (22%), and lip (20%).","The median depth of invasion was 5 mm, and desmoplasia observed in 69%.","The median duration from randomization to last contact was 4.8 years.","Four participants (8%) experienced local relapse as a first recurrence during the study period: 3 in the observation arm and 1 in the RT arm (hazard ratio [HR] 0.29; 95% confidence interval [CI] 0.03-2.76; p = 0.279).","No statistically significant difference in time to any relapse or OS was observed.","More than 6 months after randomization, grade 3 or greater toxicity was experienced by 10% of the participants in the observation arm and 12.5% of the participants in the RT arm of the study.","CONCLUSION: Due to low accrual, the role of adjuvant RT for cutaneous NM of the H&N excised with microscopically negative margins 5 mm wide or wider remains undefined.","Its routine use cannot be recommended.","Local relapse might be less common than previously anticipated based on retrospective reports."],"Aspect":"i","Summary":"This trial assessed the safety and efficacy of radiation therapy (RT) to the primary site after local excision of cutaneous neurotropic melanoma of the head and neck, with participants randomized to observation or RT and a focus on time to local relapse.","Indexes":[0,1,2,4],"Sentences":["BACKGROUND: Cutaneous neurotropic melanoma (NM) of the head and neck (H&N) is prone to local relapse, possibly due to difficulties widely excising the tumor.","This trial assessed radiation therapy (RT) to the primary site after local excision.","METHODS: Participants from 15 international centers were randomized to observation or RT.","The primary outcome was time to local relapse."],"Revise":true}
{"PMID":"32470710","Document":["BACKGROUND: Subgroup analyses of two large EORTC adjuvant interferon-alpha2b (IFN\u03b1-2b) vs observation randomised trials demonstrated that a treatment benefit was observed only in patients with an ulcerated melanoma without palpable nodes (hazard ratio [HR] for recurrence-free survival [RFS] was 0.69).","This was confirmed by a meta-analysis of 15 adjuvant IFN trials (HR: 0.79).","PATIENTS AND METHODS: In the EORTC 18081 trial, sentinel node-negative stage II patients with an ulcerated primary melanoma were 1:1 randomised between pegylated (PEG)-IFN\u03b1-2b at 3\u00a0\u03bcg\/kg\/week subcutaneously and observation, for 2 years, or until disease recurrence or unacceptable toxicity in spite of dose adjustments to maintain an Eastern Cooperative Oncology Group performance status of 0 or 1.","Main end-point was RFS.","Secondary end-points included distant metastasis-free survival (DMFS), overall survival, and safety (EudraCT Number: 2009-010273-20).","RESULTS: Between February 2013 and January 2017, only 112 patients were randomised, 56 in each arm.","The trial was stopped early for lack of recruitment.","At a 3.4-year median follow-up, the estimated HR for the PEG-IFN\u03b1-2b group compared with the observation group regarding RFS was 0.66 (95% confidence interval [CI]: 0.32-1.37), and the 3-year RFS rate was 80.0% (95% CI: 65.7-88.8%) and 72.9% (95% CI: 58.3-83.0%), respectively.","DMFS was prolonged: HR: 0.39 (95% CI: 0.15-0.97), and the 3-year DMFS rate was 90.6% (95% CI: 78.9-96.0%) vs 76.4% (95% CI: 62.1-85.9%).","One patient in the PEG-IFN\u03b1-2b group died compared with 4 in the observation group.","Fifty-four patients started PEG-IFN\u03b1-2b treatment, 16 (29%) completed 2 years of treatment, 2 (4%) stopped due to recurrence, 23 (43%) due to toxicity and 14 (25%) due to other reasons.","CONCLUSIONS: The EORTC 18081 PEG-IFN\u03b1-2b randomised trial, observed a similar HR (0.69) for RFS as the previous EORTC trials (0.69).","In countries without access to new drugs, adjuvant (PEG)-IFN\u03b1-2b treatment is an option for patients with ulcerated melanomas without palpable nodes."],"Aspect":"p","Summary":"The study involved 112 patients with sentinel node-negative stage II ulcerated primary melanoma, with 56 patients in each arm (PEG-IFN\u03b1-2b and observation).","Indexes":[2,5],"Sentences":["PATIENTS AND METHODS: In the EORTC 18081 trial, sentinel node-negative stage II patients with an ulcerated primary melanoma were 1:1 randomised between pegylated (PEG)-IFN\u03b1-2b at 3\u00a0\u03bcg\/kg\/week subcutaneously and observation, for 2 years, or until disease recurrence or unacceptable toxicity in spite of dose adjustments to maintain an Eastern Cooperative Oncology Group performance status of 0 or 1.","RESULTS: Between February 2013 and January 2017, only 112 patients were randomised, 56 in each arm."],"Revise":false}
{"PMID":"33715172","Document":["We report the 5-year follow-up results from a single-arm, open-label, multicenter phase II study (ONO-4538-08) conducted in Japan.","Twenty-four patients with treatment-na\u00efve, recurrent, or unresectable stage III\/IV malignant melanoma received 3\u00a0mg\/kg nivolumab every 2\u00a0weeks until progressive disease or unacceptable toxicity occurred.","The 5-year overall survival (OS) rate was 26.1%.","Five years after the start of nivolumab treatment, there were six survivors.","The 5-year OS rate was 66.7% for patients with a superficial spreading type, 14.3% for acral lentiginous type, and 16.7% for mucosal type.","The 5-year progression-free survival rate was 17.2%.","No new cases of partial response or complete response were observed after 3\u00a0years, and overall response and disease control rates were similar to those reported at 3\u00a0years.","The treatment-related adverse events reported between the 3- and 5-year follow-up periods were anemia (grade 2), white blood cell count decrease (grade 2), and psoriasiform dermatitis (grade 2) in one patient each.","No new grade 3 or higher treatment-related adverse events occurred in this period.","In conclusion, first-line treatment with nivolumab in Japanese patients with unresectable or metastatic melanoma resulted in confirmed long-term survival.","No new safety signals were reported in the studied population."],"Aspect":"m","Summary":"Patients received 3 mg\/kg nivolumab every 2 weeks until progressive disease or unacceptable toxicity occurred.","Indexes":[1],"Sentences":["Twenty-four patients with treatment-na\u00efve, recurrent, or unresectable stage III\/IV malignant melanoma received 3\u00a0mg\/kg nivolumab every 2\u00a0weeks until progressive disease or unacceptable toxicity occurred."],"Revise":false}
{"PMID":"31535302","Document":["BACKGROUND: This study compares well-being, recurrences, and deaths of early-stage cutaneous melanoma patients in follow-up, as recommended in the Dutch guideline, with that of patients in a stage-adjusted reduced follow-up schedule, 3\u00a0years after diagnosis, as well as costs.","METHODS: Overall, 180 eligible pathological American Joint Committee on Cancer (AJCC) stage IB-IIC, sentinel node staged, melanoma patients (response rate\u2009=\u200987%, 48% male, median age 57\u00a0years), randomized into a conventional (CSG, n\u2009=\u200993) or experimental (ESG, n\u2009=\u200987) follow-up schedule group, completed patient-reported outcome measures (PROMs) at diagnosis (T1): State-Trait Anxiety Inventory-State version (STAI-S), Cancer Worry Scale (CWS), Impact of Event Scale (IES), and RAND-36 (Mental and Physical Component scales [PCS\/MCS]).","Three years later (T3), 110 patients (CSG, n\u2009=\u200956; ESG, n\u2009=\u200954) completed PROMs, while 42 declined (23%).","RESULTS: Repeated measures analyses of variance (ANOVAs) showed a significant group effect on the IES (p\u2009=\u20090.001) in favor of the ESG, and on the RAND-36 PCS (p\u2009=\u20090.02) favoring the CSG.","Mean IES and CWS scores decreased significantly over time, while those on the RAND-36 MCS and PCS increased.","Effect sizes were small.","Twenty-five patients developed a recurrence or second primary melanoma, of whom 13 patients died within 3\u00a0years.","Cox proportional hazards models showed no differences between groups in recurrence-free survival (hazard ratio [HR] 0.71 [0.32-1.58]; p\u2009=\u20090.400) and disease-free survival (HR 1.24 [0.42-3.71]; p\u2009=\u20090.690).","Costs per patient after 3\u00a0years (computed for 77.3% of patients) were 39% lower in the ESG.","CONCLUSION: These results seemingly support the notion that a stage-adjusted reduced follow-up schedule forms an appropriate, safe, and cost-effective alternative for pathological AJCC stage IB-IIC melanoma patients to the follow-up regimen as advised in the current melanoma guideline."],"Aspect":"o","Summary":"The study found that a stage-adjusted reduced follow-up schedule for early-stage cutaneous melanoma patients resulted in lower impact of event scale (IES) scores and was more cost-effective, with no differences in recurrence-free survival or disease-free survival compared to the conventional schedule.","Indexes":[3,7,8],"Sentences":["RESULTS: Repeated measures analyses of variance (ANOVAs) showed a significant group effect on the IES (p\u2009=\u20090.001) in favor of the ESG, and on the RAND-36 PCS (p\u2009=\u20090.02) favoring the CSG.","Cox proportional hazards models showed no differences between groups in recurrence-free survival (hazard ratio [HR] 0.71 [0.32-1.58]; p\u2009=\u20090.400) and disease-free survival (HR 1.24 [0.42-3.71]; p\u2009=\u20090.690).","Costs per patient after 3\u00a0years (computed for 77.3% of patients) were 39% lower in the ESG."],"Revise":false}
{"PMID":"33476492","Document":["Anti-programmed death-1 agents are an established option for advanced melanoma, but the anti-programmed death-ligand 1 (anti-PD-L1) antibody atezolizumab, an agent approved for the treatment of multiple solid tumors, was not previously evaluated.","This phase 1b study cohort (NCT03178851; cohort C) evaluated first-line atezolizumab 1,200\u00a0mg every 3\u00a0weeks in adults with BRAFV600 wild-type, histologically confirmed, advanced or metastatic melanoma.","The co-primary end points were confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors v1.1 and disease control rate (DCR\u00a0=\u00a0complete response [CR] +partial response [PR] +stable disease [SD] at 16\u00a0weeks).","Of 52 enrolled patients, most had lactate dehydrogenase levels lower than the upper limit of normal (77%) and PD-L1-positive tumors (55%).","Investigator-assessed confirmed ORR was 35% (95% CI, 22%-49%) and included three CRs (6%) and 15 PRs (29%); DCR was 46%.","Median investigator-assessed progression-free survival was 3.7\u00a0months (95% CI, 2.1-7.3).","The most common any-grade adverse events were anemia (27%), headache (19%), hypertension (19%), constipation (17%), diarrhea (17%), hypothyroidism (17%), asthenia (15%), and pain in extremity (15%).","First-line atezolizumab monotherapy is safe and tolerable and has antitumor activity in patients with BRAFV600 wild-type advanced or metastatic melanoma."],"Aspect":"m","Summary":"The medicine used is atezolizumab, administered at a dose of 1,200 mg every 3 weeks.","Indexes":[1],"Sentences":["This phase 1b study cohort (NCT03178851; cohort C) evaluated first-line atezolizumab 1,200\u00a0mg every 3\u00a0weeks in adults with BRAFV600 wild-type, histologically confirmed, advanced or metastatic melanoma."],"Revise":false}
{"PMID":"36375115","Document":["PURPOSE: BRAF V600 mutations occur in many childhood cancers, including approximately 20% of low-grade gliomas (LGGs).","Here, we describe a phase I\/II study establishing pediatric dosing and pharmacokinetics of trametinib with or without dabrafenib, as well as efficacy and safety in a disease-specific cohort with BRAF V600-mutant LGG; other cohorts will be reported elsewhere.","METHODS: This is a four-part, phase I\/II study (ClinicalTrials.gov identifier: NCT02124772) in patients age < 18 years with relapsed\/refractory malignancies: trametinib monotherapy dose finding (part A) and disease-specific expansion (part B), and dabrafenib + trametinib dose finding (part C) and disease-specific expansion (part D).","The primary objective assessed in all patients in parts A and C was to determine pediatric dosing on the basis of steady-state pharmacokinetics.","Disease-specific efficacy and safety (across parts A-D) were secondary objectives.","RESULTS: Overall, 139 patients received trametinib (n = 91) or dabrafenib + trametinib (n = 48).","Trametinib dose-limiting toxicities in > 1 patient (part A) included mucosal inflammation (n = 3) and hyponatremia (n = 2).","There were no dose-limiting toxicities with combination therapy (part C).","The recommended phase II dose of trametinib, with or without dabrafenib, was 0.032 mg\/kg once daily for patients age < 6 years and 0.025 mg\/kg once daily for patients age \u2265 6 years; dabrafenib dosing in the combination was as previously identified for monotherapy.","In 49 patients with BRAF V600-mutant glioma (LGG, n = 47) across all four study parts, independently assessed objective response rates were 15% (95% CI, 1.9 to 45.4) for monotherapy (n = 13) and 25% (95% CI, 12.1 to 42.2) for combination (n = 36).","Adverse event-related treatment discontinuations were more common with monotherapy (54% v 22%).","CONCLUSION: The trial design provided efficient evaluation of pediatric dosing, safety, and efficacy of single-agent and combination targeted therapy.","Age-based and weight-based dosing of trametinib with or without dabrafenib achieved target concentrations with manageable safety and demonstrated clinical efficacy and tolerability in BRAF V600-mutant LGG."],"Aspect":"m","Summary":"The trial involved trametinib administered at doses of 0.032 mg\/kg for patients under 6 years and 0.025 mg\/kg for patients 6 years and older, with or without dabrafenib.","Indexes":[8],"Sentences":["The recommended phase II dose of trametinib, with or without dabrafenib, was 0.032 mg\/kg once daily for patients age < 6 years and 0.025 mg\/kg once daily for patients age \u2265 6 years; dabrafenib dosing in the combination was as previously identified for monotherapy."],"Revise":false}
{"PMID":"31584722","Document":["BACKGROUND: Patients with metastatic melanoma have variable responses to combination ipilimumab and nivolumab.","The objectives of this study were to examine the patterns of response and survival in patients treated with combination ipilimumab and anti-PD-1 therapy (IPI\u00a0+\u00a0PD1) and to explore the nature of pseudoprogression and acquired resistance.","METHODS: Patients with metastatic melanoma who received treatment with first-line IPI\u00a0+\u00a0PD1 had all metastases \u22655\u00a0mm measured on computed tomography\/magnetic resonance imaging studies.","The lesional response rate (LRR) and the overall response rate (ORR) were determined according to Response Evaluation Criteria in Solid Tumors, version 1.1.","RESULTS: In total, 140 patients who had 833 metastases were studied.","The ORR and the overall complete response (CR) rate decreased as tumor burden or the number of metastases increased.","Metastases that had a CR (49%) were smaller than metastases without a CR (median, 13 vs 17\u00a0mm; P\u00a0<\u00a0.0001).","Soft-tissue and lung metastases had the highest LRR (79% and 77%, respectively), whereas liver metastases had the lowest (46%).","In multivariate analysis, patients with lung metastases had superior ORR (odds ratio [OR], 2.75; P\u00a0=\u00a0.02) and progression-free survival (hazard ratio [HR], 0.46; P\u00a0=\u00a0.02), whereas those with liver metastases had inferior ORR (OR, 0.33; P\u00a0=\u00a0.02), progression-free survival (HR, 4.03; P\u00a0<\u00a0.01), and overall survival (HR, 3.17; P\u00a0=\u00a0.01).","Pseudoprogression occurred in one-third of patients who had progressive disease as their best response, with an overall survival that was comparable to that of patients without disease progression.","Acquired resistance occurred in 12% of responders after a median of 9.6\u00a0months, with an overall survival rate of 83% at 1\u00a0year from progression.","CONCLUSIONS: Metastases in different anatomical locations display distinct response patterns and also are associated with overall response and survival with combination immunotherapy.","Specific sites of disease may hold unique mechanisms of resistance and should allow for more personalized treatment."],"Aspect":"i","Summary":"The study analyzed lesional and overall response rates in 140 patients with metastatic melanoma treated with first-line combination ipilimumab and anti-PD-1 therapy, using imaging to measure metastases and RECIST v1.1 criteria for evaluation.","Indexes":[2,3,4],"Sentences":["METHODS: Patients with metastatic melanoma who received treatment with first-line IPI\u00a0+\u00a0PD1 had all metastases \u22655\u00a0mm measured on computed tomography\/magnetic resonance imaging studies.","The lesional response rate (LRR) and the overall response rate (ORR) were determined according to Response Evaluation Criteria in Solid Tumors, version 1.1.","RESULTS: In total, 140 patients who had 833 metastases were studied."],"Revise":true}
{"PMID":"31732523","Document":["PURPOSE: To report the 5-year overall survival (OS) landmark and the long-term safety profile of vemurafenib plus cobimetinib (BRAF plus MEK inhibition, respectively) in the BRIM7 study.","PATIENTS AND METHODS: This phase Ib, dose-finding, and expansion study evaluated combination treatment with vemurafenib and cobimetinib in two cohorts of patients with advanced BRAF V600-mutated melanoma: patients who were BRAF inhibitor (BRAFi)-na\u00efve (n = 63) or patients who had progressed on prior treatment with BRAFi monotherapy [vemurafenib monotherapy-progressive disease (PD); n = 66].","Patients in the dose-escalation phase received vemurafenib at 720 or 960 mg twice daily in combination with cobimetinib at 60, 80, or 100 mg\/d for 14 days on\/14 days off, 21 days on\/7 days off, or continuously.","Two regimens were selected for expansion: vemurafenib (720 and 960 mg twice daily) and cobimetinib (60 mg\/d 21\/7).","RESULTS: Median OS was 31.8 months [95% confidence interval (CI), 24.5-not estimable] in the BRAFi-na\u00efve cohort.","The landmark OS rate plateaued at 39.2% at years 4 and 5 of follow-up.","In the vemurafenib monotherapy-PD cohort, the median OS was 8.5 months (95% CI, 6.7-11.1), and the landmark OS rate plateaued at 14.0% from 3 years of follow-up.","No increase was observed in the frequency and severity of adverse events with long-term follow-up.","No new toxicities were detected, and there was no increase in the frequency of symptomatic MEK inhibitor class-effect adverse events.","CONCLUSIONS: A subset of patients with advanced BRAF V600-mutated melanoma treated with a combination regimen of vemurafenib and cobimetinib achieve favorable long-term outcomes."],"Aspect":"o","Summary":"The study found that the median overall survival (OS) was 31.8 months in the BRAFi-na\u00efve cohort and 8.5 months in the vemurafenib monotherapy-PD cohort, with a subset of patients achieving favorable long-term outcomes with vemurafenib plus cobimetinib combination therapy.","Indexes":[4,5,6,9],"Sentences":["RESULTS: Median OS was 31.8 months [95% confidence interval (CI), 24.5-not estimable] in the BRAFi-na\u00efve cohort.","The landmark OS rate plateaued at 39.2% at years 4 and 5 of follow-up.","In the vemurafenib monotherapy-PD cohort, the median OS was 8.5 months (95% CI, 6.7-11.1), and the landmark OS rate plateaued at 14.0% from 3 years of follow-up.","CONCLUSIONS: A subset of patients with advanced BRAF V600-mutated melanoma treated with a combination regimen of vemurafenib and cobimetinib achieve favorable long-term outcomes."],"Revise":false}
{"PMID":"32376655","Document":["PURPOSE: Tumors with low frequencies of checkpoint positive tumor-infiltrating lymphocytes (cpTIL) have a low likelihood of response to PD-1 blockade.","We conducted a prospective multicenter phase II trial of intratumoral plasmid IL-12 (tavokinogene telseplasmid; \"tavo\") electroporation combined with pembrolizumab in patients with advanced melanoma with low frequencies of checkpoint positive cytotoxic lymphocytes (cpCTL).","PATIENTS AND METHODS: Tavo was administered intratumorally days 1, 5, and 8 every 6 weeks while pembrolizumab (200 mg, i.v.)","was administered every 3 weeks.","The primary endpoint was objective response rate (ORR) by RECIST, secondary endpoints included duration of response, overall survival and progression-free survival.","Toxicity was evaluated by the CTCAE v4.","Extensive correlative analysis was done.","RESULTS: The combination of tavo and pembrolizumab was well tolerated with adverse events similar to those previously reported with pembrolizumab alone.","Patients had a 41% ORR (n = 22, RECIST 1.1) with 36% complete responses.","Correlative analysis showed that the combination enhanced immune infiltration and sustained the IL-12\/IFN\u03b3 feed-forward cycle, driving intratumoral cross-presenting dendritic cell subsets with increased TILs, emerging T cell receptor clones and, ultimately, systemic cellular immune responses.","CONCLUSIONS: The combination of tavo and pembrolizumab was associated with a higher than expected response rate in this poorly immunogenic population.","No new or unexpected toxicities were observed.","Correlative analysis showed T cell infiltration with enhanced immunity paralleling the clinical activity in low cpCTL tumors."],"Aspect":"p","Summary":"The trial included patients with advanced melanoma with low frequencies of checkpoint positive cytotoxic lymphocytes (cpCTL).","Indexes":[1],"Sentences":["We conducted a prospective multicenter phase II trial of intratumoral plasmid IL-12 (tavokinogene telseplasmid; \"tavo\") electroporation combined with pembrolizumab in patients with advanced melanoma with low frequencies of checkpoint positive cytotoxic lymphocytes (cpCTL)."],"Revise":false}
{"PMID":"33875611","Document":["BACKGROUND: While programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) antagonists have improved the prognosis for many patients with melanoma, around 60% fail therapy.","PVSRIPO is a non-neurovirulent rhinovirus:poliovirus chimera that facilitates an antitumor immune response following cell entry via the poliovirus receptor CD155, which is expressed on tumor and antigen-presenting cells.","Preclinical studies show that oncolytic virus plus anti-PD-1 therapy leads to a greater antitumor response than either agent alone, warranting clinical investigation.","METHODS: An open-label phase I trial of intratumoral PVSRIPO in patients with unresectable melanoma (American Joint Committee on Cancer V.7 stage IIIB, IIIC, or IV) was performed.","Eligible patients had disease progression on anti-PD-1 and V-raf murine sarcoma viral oncogene homolog B (BRAF)\/mitogen activated protein kinase kinase (MEK) inhibitors (if BRAF mutant).","The primary objective was to characterize the safety and tolerability of PVSRIPO.","Twelve patients in four cohorts received a total of 1, 2 or 3 injections of PVSRIPO monotherapy, with 21 days between injections.","RESULTS: PVSRIPO injections were well tolerated with no serious adverse events (SAEs) or dose-limiting toxicities (DLTs) reported.","All adverse events (AEs) were grade (G) 1 or G2 (G1 pruritus most common at 58%); all but two PVSRIPO-treatment related AEs were localized to the injected or adjacent lesions (n=1\u2009G1 hot flash, n=1\u2009G1 fatigue).","Four out of 12 patients (33%) achieved an objective response per immune-related response criteria (two observations, 4 weeks apart), including 4\/6 (67%) who received three injections.","In the four patients with in-transit disease, a pathological complete response (pCR) was observed in two (50%) patients.","Following study completion, 11\/12 patients (92%) reinitiated immune checkpoint inhibitor-based therapy, and 6\/12 patients (50%) remained without progression at a median follow-up time of 18 months.","CONCLUSION: Intratumoral PVSRIPO was well tolerated.","Despite the limited number of PVSRIPO treatments relative to the overall lesion burden (67% patients>5 lesions), intratumoral PVSRIPO showed promising antitumor activity, with pCR in injected as well as non-injected lesions in select patients.","TRIAL REGISTRATION NUMBER: NCT03712358."],"Aspect":"a","Summary":"The study aimed to evaluate the safety, tolerability, and antitumor activity of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma.","Indexes":[3,5,13],"Sentences":["METHODS: An open-label phase I trial of intratumoral PVSRIPO in patients with unresectable melanoma (American Joint Committee on Cancer V.7 stage IIIB, IIIC, or IV) was performed.","The primary objective was to characterize the safety and tolerability of PVSRIPO.","Despite the limited number of PVSRIPO treatments relative to the overall lesion burden (67% patients>5 lesions), intratumoral PVSRIPO showed promising antitumor activity, with pCR in injected as well as non-injected lesions in select patients."],"Revise":true}
{"PMID":"37479483","Document":["BACKGROUND: Continuous combination of MAPK pathway inhibition (MAPKi) and anti-programmed death-(ligand) 1 (PD-(L)1) showed high response rates, but only limited improvement in progression-free survival (PFS) at the cost of a high frequency of treatment-related adverse events (TRAE) in patients with BRAFV600-mutated melanoma.","Short-term MAPKi induces T-cell infiltration in patients and is synergistic with anti-programmed death-1 (PD-1) in a preclinical melanoma mouse model.","The aim of this phase 2b trial was to identify an optimal regimen of short-term MAPKi with dabrafenib plus trametinib in combination with pembrolizumab.","METHODS: Patients with treatment-na\u00efve BRAFV600E\/K-mutant advanced melanoma started pembrolizumab 200\u2009mg every 3 weeks.","In week 6, patients were randomized to continue pembrolizumab only (cohort 1), or to receive, in addition, intermittent dabrafenib 150\u2009mg two times per day plus trametinib 2\u2009mg one time per day for two cycles of 1\u2009week (cohort 2), two cycles of 2 weeks (cohort 3), or continuously for 6 weeks (cohort 4).","All cohorts continued pembrolizumab for up to 2 years.","Primary endpoints were safety and treatment-adherence.","Secondary endpoints were objective response rate (ORR) at week 6, 12, 18 and PFS.","RESULTS: Between June 2016 and August 2018, 33 patients with advanced melanoma have been included and 32 were randomized.","Grade 3-4 TRAE were observed in 12%, 12%, 50%, and 63% of patients in cohort 1, 2, 3, and 4, respectively.","All planned targeted therapy was given in 88%, 63%, and 38% of patients in cohort 2, 3, and 4.","ORR at week 6, 12, and 18 were 38%, 63%, and 63% in cohort 1; 25%, 63%, and 75% in cohort 2; 25%, 50%, and 75% in cohort 3; and 0%, 63%, and 50% in cohort 4.","After a median follow-up of 43.5 months, median PFS was 10.6 months for pembrolizumab monotherapy and not reached for patients treated with pembrolizumab and intermittent dabrafenib and trametinib (p=0.17).","The 2-year and 3-year landmark PFS were both 25% for cohort 1, both 63% for cohort 2, 50% and 38% for cohort 3 and 75%\u2009and 60% for cohort 4.","CONCLUSIONS: The combination of pembrolizumab plus intermittent dabrafenib and trametinib seems more feasible and tolerable than continuous triple therapy.","The efficacy is promising and appears to be favorable over pembrolizumab monotherapy.","TRIAL REGISTRATION NUMBER: NCT02625337."],"Aspect":"a","Summary":"The aim of this phase 2b trial was to identify an optimal regimen of short-term MAPKi with dabrafenib plus trametinib in combination with pembrolizumab.","Indexes":[2],"Sentences":["The aim of this phase 2b trial was to identify an optimal regimen of short-term MAPKi with dabrafenib plus trametinib in combination with pembrolizumab."],"Revise":false}
{"PMID":"34710571","Document":["BACKGROUND: Antitumor activity of ipilimumab or BRAF \u00b1 MEK inhibitors (BRAFi \u00b1 MEKi) following pembrolizumab administration in melanoma is poorly characterized.","PATIENTS AND METHODS: In the phase III KEYNOTE-006 study, patients with unresectable stage III\/IV melanoma received pembrolizumab (10 mg\/kg) once every 2 or 3 weeks (Q3W) or ipilimumab (3 mg\/kg) Q3W.","The current post hoc analysis evaluates outcomes with ipilimumab or BRAFi \u00b1 MEKi as first subsequent systemic therapy after pembrolizumab administration and includes patients who completed or discontinued pembrolizumab after one or more dose.","Pembrolizumab arms were pooled.","RESULTS: At data cut-off (4 December 2017), median follow-up was 46.9 months.","Of 555 pembrolizumab-treated patients, first subsequent therapy was ipilimumab for 103 (18.6%) and BRAFi \u00b1 MEKi for 59 (10.6%) [33 received BRAFi\u00a0+ MEKi, 26 BRAFi alone; 37 (62.7%) were BRAFi \u00b1 MEKi na\u00efve].","In the subsequent ipilimumab group, ORR with previous pembrolizumab was 17.5% [1 complete response (CR); 17 partial response (PR)]; 79.6% had discontinued pembrolizumab due to progressive disease (PD); median overall survival (OS) was 21.5 months.","ORR with subsequent ipilimumab was 15.5%; 11\/16 responses (8 CRs; 3 PRs) were ongoing.","ORR with subsequent ipilimumab was 9.7% for patients with PD as best response to pembrolizumab.","Median OS from ipilimumab initiation was 9.8 months.","In the subsequent BRAFi \u00b1 MEKi group, ORR with previous pembrolizumab was 13.5% (8\u00a0PR); 76.3% had discontinued pembrolizumab due to PD; median OS was 17.9 months.","ORR with subsequent BRAFi \u00b1 MEKi was 30.5%, 7\/18 responses (4 CR, 3 PR) were ongoing.","Median OS from BRAFi \u00b1 MEKi initiation was 12.9 months.","ORR for BRAFi \u00b1 MEKi-na\u00efve patients who received subsequent BRAFi \u00b1 MEKi was 43.2%; 6\/16 were ongoing (3 CR, 3 PR).","CONCLUSIONS: Ipilimumab and BRAFi \u00b1 MEKi have antitumor activity as first subsequent therapy after pembrolizumab in patients with advanced melanoma."],"Aspect":"m","Summary":"Pembrolizumab was administered at a dose of 10 mg\/kg every 2 or 3 weeks, ipilimumab at 3 mg\/kg every 3 weeks, and BRAF inhibitors (BRAFi) \u00b1 MEK inhibitors (MEKi).","Indexes":[1,5],"Sentences":["PATIENTS AND METHODS: In the phase III KEYNOTE-006 study, patients with unresectable stage III\/IV melanoma received pembrolizumab (10 mg\/kg) once every 2 or 3 weeks (Q3W) or ipilimumab (3 mg\/kg) Q3W.","Of 555 pembrolizumab-treated patients, first subsequent therapy was ipilimumab for 103 (18.6%) and BRAFi \u00b1 MEKi for 59 (10.6%) [33 received BRAFi\u00a0+ MEKi, 26 BRAFi alone; 37 (62.7%) were BRAFi \u00b1 MEKi na\u00efve]."],"Revise":false}
{"PMID":"38039779","Document":["BACKGROUND: We investigated naporafenib (LXH254), a pan-RAF kinase inhibitor, with or without spartalizumab, in patients with advanced solid tumors harboring MAPK pathway alterations.","METHODS: This first-in-human phase 1 study had two dose-escalation arms: single-agent naporafenib (starting at 100\u00a0mg once-daily [QD]) and naporafenib (starting at the recommended dose\/regimen)\/spartalizumab (400\u00a0mg every 4 weeks).","The naporafenib\/spartalizumab dose-expansion part enrolled patients with KRAS-mutated non-small cell lung cancer (NSCLC) and NRAS-mutated melanoma.","The primary objectives were to establish the maximum tolerated doses (MTD)\/recommended doses for expansion (RDE) and evaluate tolerability and safety.","RESULTS: A total of 142 patients were included in the naporafenib dose-escalation (n\u00a0=\u00a087), naporafenib\/spartalizumab dose-escalation (n\u00a0=\u00a012) and naporafenib\/spartalizumab dose-expansion (n\u00a0=\u00a043) arms.","The MTD\/RDE of naporafenib was 600\u00a0mg twice-daily (BID).","In naporafenib escalation, five patients experienced 7 dose-limiting toxicities: decreased platelet count (1200\u00a0mg QD); neuralgia, maculopapular rash, pruritus (600\u00a0mg BID); increased blood bilirubin, hyponatremia, peripheral sensory neuropathy (800\u00a0mg BID).","No DLTs occurred in the naporafenib\/spartalizumab arm: the RDE was established at 400\u00a0mg BID.","The most common treatment-related adverse events were rash and dermatitis acneiform (each 24.1%; naporafenib), nausea and pruritus (each 33.3%; naporafenib\/spartalizumab; escalation) and rash (39.5%; naporafenib\/spartalizumab; expansion).","Naporafenib reduced DUSP6 expression in tumors.","Two partial responses (PRs) occurred in naporafenib escalation, and 1 complete response and 3 PRs in the naporafenib\/spartalizumab NRAS-mutated melanoma and KRAS-mutated NSCLC arms, respectively.","CONCLUSIONS: Naporafenib, with or without spartalizumab, showed an acceptable safety profile, pharmacodynamic activity and limited antitumor activity.","Additional naporafenib combination therapies are currently under investigation."],"Aspect":"i","Summary":"The study investigated naporafenib, a pan-RAF kinase inhibitor, with or without spartalizumab, in a first-in-human phase 1 trial with two dose-escalation arms in patients with advanced solid tumors harboring MAPK pathway alterations. ","Indexes":[0,1],"Sentences":["BACKGROUND: We investigated naporafenib (LXH254), a pan-RAF kinase inhibitor, with or without spartalizumab, in patients with advanced solid tumors harboring MAPK pathway alterations.","METHODS: This first-in-human phase 1 study had two dose-escalation arms: single-agent naporafenib (starting at 100\u00a0mg once-daily [QD]) and naporafenib (starting at the recommended dose\/regimen)\/spartalizumab (400\u00a0mg every 4 weeks)."],"Revise":true}
{"PMID":"37921680","Document":["BACKGROUND: Immune checkpoint inhibitors control effector mechanisms and work to restore downregulated T-cells in patients with melanoma.","Examples of such include programmed death-1 inhibitors and lymphocyte-activating gene 3 inhibitors.","The combination of nivolumab, a programmed death-1 inhibitor, and relatlimab-rmbw, a lymphocyte-activating gene 3 inhibitor, has shown antitumor activity and improved progression-free survival in patients with unresectable or metastatic melanoma.","MECHANISM OF ACTION PHARMACOKINETICS\/PHARMACODYNAMICS: The fixed-dose combination of nivolumab and relatlimab immunotherapy is approved for adults and pediatrics 12 years of age or older with metastatic or unresectable melanoma.","Volume of distribution is 6.6 L for relatlimab and nivolumab, and half-life is 27 and 26 days, respectively.","Clearance at steady state is 7.6 mL\/h for nivolumab and 5.5 mL\/h for relatlimab.","Sex, age, race, and mild hepatic\/renal impairment had no clinical effect on clearance.","The exposure-response relationship and pharmacodynamic response for the safety and effectiveness of nivolumab\/relatlimab-rmbw have not been fully characterized.","Safety concerns include severe and fatal immune-mediated adverse reactions, infusion-related reactions, and complications of allogeneic hematopoietic stem cell transplantation, and fetal toxicity.","Dosing is determined by patient's age and weight.","Solution is infused over a 30-minute timeframe.","CLINICAL TRIALS: In the RELATIVITY-047 trial, patients received nivolumab or nivolumab\/relatlimab-rmbw.","Results showed superiority of dual therapy over monotherapy with a progression-free survival of 10.1 months (95% CI, 6.4-15.7) compared with 4.6 months (95% CI, 3.4-5.6) and hazard ratio of 0.75 (95% CI, 0.62-0.92); P = 0.006, respectively.","No safety concerns were observed compared with monotherapy with treatment-related adverse events occurring in 18.9% of patients on combination therapy compared with 9.7% on nivolumab alone.","THERAPEUTIC ADVANCE: The novel mechanism and improvement in progression-free survival compared with standard of care highlight the therapeutic advancement of nivolumab\/relatlimab-rmbw in the treatment of unresectable and metastatic melanoma."],"Aspect":"p","Summary":"The study included adults and pediatrics 12 years of age or older with metastatic or unresectable melanoma.","Indexes":[3],"Sentences":["MECHANISM OF ACTION PHARMACOKINETICS\/PHARMACODYNAMICS: The fixed-dose combination of nivolumab and relatlimab immunotherapy is approved for adults and pediatrics 12 years of age or older with metastatic or unresectable melanoma."],"Revise":true}
{"PMID":"32062691","Document":["PURPOSE: This study aimed to determine the safety, tolerability, and recommended phase II doses of trametinib plus uprosertib (GSK2141795) in patients with solid tumors likely to be sensitive to MEK and\/or AKT inhibition.","METHODS: This was a phase I, open-label, dose-escalation, and dose-expansion study in patients with triple-negative breast cancer or BRAF-wild type advanced melanoma.","The primary outcome of the expansion study was investigator-assessed response.","Among 126 enrolled patients, 63 received continuous oral daily dosing of trametinib and uprosertib, 29 received various alternative dosing schedules, and 34 were enrolled into expansion cohorts.","Doses tested in the expansion cohort were trametinib 1.5\u00a0mg once daily (QD)\u2009+\u2009uprosertib 50\u00a0mg QD.","RESULTS: Adverse events (AEs) were consistent with those reported in monotherapy studies but occurred at lower doses and with greater severity.","Diarrhea was the most common dose-limiting toxicity; diarrhea and rash were particularly difficult to tolerate.","Overall, 59% and 6% of patients reported AEs with a maximum severity of grade 3 and 4, respectively.","Poor tolerability prevented adequate delivery of uprosertib with trametinib at a concentration predicted to have clinical activity.","The study was terminated early based on futility in the continuous-dosing expansion cohorts and a lack of pharmacological or therapeutic advantage with intermittent dosing.","The objective response rate was\u2009<\u20095% (1 complete response, 5 partial responses).","CONCLUSIONS: Continuous and intermittent dosing of trametinib in combination with uprosertib was not tolerated, and minimal clinical activity was observed in all schedules tested."],"Aspect":"o","Summary":"The study found that the combination of trametinib and uprosertib was not well tolerated and showed minimal clinical activity, leading to early termination.","Indexes":[5,8,9,10,11],"Sentences":["RESULTS: Adverse events (AEs) were consistent with those reported in monotherapy studies but occurred at lower doses and with greater severity.","Poor tolerability prevented adequate delivery of uprosertib with trametinib at a concentration predicted to have clinical activity.","The study was terminated early based on futility in the continuous-dosing expansion cohorts and a lack of pharmacological or therapeutic advantage with intermittent dosing.","The objective response rate was\u2009<\u20095% (1 complete response, 5 partial responses).","CONCLUSIONS: Continuous and intermittent dosing of trametinib in combination with uprosertib was not tolerated, and minimal clinical activity was observed in all schedules tested."],"Revise":false}
{"PMID":"34853302","Document":["Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring activating BRAF mutations.","Previous preclinical studies suggested that an intermittent dosing of these drugs could delay the emergence of resistance.","Contrary to expectations, the first published phase 2 randomized study comparing continuous versus intermittent schedule of dabrafenib (BRAFi) plus trametinib (MEKi) demonstrated a detrimental effect of the \"on-off\" schedule.","Here we report confirmatory data from the Phase II randomized open-label clinical trial comparing the antitumoral activity of the standard schedule versus an intermittent combination of vemurafenib (BRAFi) plus cobimetinib (MEKi) in advanced BRAF mutant melanoma patients (NCT02583516).","The trial did not meet its primary endpoint of progression free survival (PFS) improvement.","Our results show that the antitumor activity of the experimental intermittent schedule of vemurafenib plus cobimetinib is not superior to the standard continuous schedule.","Detection of BRAF mutation in cell free tumor DNA has prognostic value for survival and its dynamics has an excellent correlation with clinical response, but not with progression.","NGS analysis demonstrated de novo mutations in resistant cases."],"Aspect":"i","Summary":"The study compared the antitumoral activity of a standard schedule versus an intermittent combination of vemurafenib (BRAFi) plus cobimetinib (MEKi) in advanced BRAF mutant melanoma patients through a Phase II randomized open-label clinical trial.","Indexes":[3],"Sentences":["Here we report confirmatory data from the Phase II randomized open-label clinical trial comparing the antitumoral activity of the standard schedule versus an intermittent combination of vemurafenib (BRAFi) plus cobimetinib (MEKi) in advanced BRAF mutant melanoma patients (NCT02583516)."],"Revise":false}
{"PMID":"36651961","Document":["PURPOSE: No standard of care therapy exists for patients with metastatic uveal melanoma who are not HLA-A2:01 positive.","The phase 1b, open-label CLEVER study (NCT03408587) evaluated V937 in combination with ipilimumab in patients with uveal melanoma.","METHODS: Adults with advanced uveal melanoma and liver metastases received up to 8 cycles of intravenous V937 (1\u2009\u00d7\u2009109 TCID50 per infusion; infusions on days 1, 3, 5, and 8 [cycle 1], then every 3\u00a0weeks [Q3W] thereafter [cycles 2-8]) and 4 cycles of intravenous ipilimumab 3\u00a0mg\/kg Q3W (beginning at cycle 1\u00a0day 8).","The primary endpoint was safety.","Secondary endpoints included objective response rate and progression-free survival (PFS) per immune-related Response Evaluation Criteria in Solid Tumors (irRECIST).","RESULTS: Eleven patients were enrolled (median age, 65.0\u00a0years) and received a median of 6 injections of V937 and 3.5 infusions of ipilimumab.","The best overall response was stable disease in 3 patients and progressive disease in 8 patients.","All patients exhibited progression per irRECIST, with a 9% irPFS rate at week 26.","Ten patients had treatment-related AEs, the most frequent of which were diarrhea (55%), fatigue (45%), and myalgia (36%).","Two grade 3 AEs (diarrhea, n\u2009=\u20092) were considered related to ipilimumab; neither was related to V937.","CONCLUSION: Although the combination of V937 with ipilimumab had a manageable safety profile, meaningful clinical benefit was not observed in patients with uveal melanoma and liver metastases.","TRIAL REGISTRATION: ClinicalTrials.gov, NCT03408587 (January 24, 2018)."],"Aspect":"d","Summary":"The treatment duration was up to 8 cycles of V937 and 4 cycles of ipilimumab.","Indexes":[2],"Sentences":["METHODS: Adults with advanced uveal melanoma and liver metastases received up to 8 cycles of intravenous V937 (1\u2009\u00d7\u2009109 TCID50 per infusion; infusions on days 1, 3, 5, and 8 [cycle 1], then every 3\u00a0weeks [Q3W] thereafter [cycles 2-8]) and 4 cycles of intravenous ipilimumab 3\u00a0mg\/kg Q3W (beginning at cycle 1\u00a0day 8)."],"Revise":true}
{"PMID":"32997575","Document":["PURPOSE: The CheckMate 066 trial investigated nivolumab monotherapy as first-line treatment for patients with previously untreated BRAF wild-type advanced melanoma.","Five-year results are presented herein.","PATIENTS AND METHODS: In this multicenter, double-blind, phase III study, 418 patients with previously untreated, unresectable, stage III\/IV, wild-type BRAF melanoma were randomly assigned 1:1 to receive nivolumab 3 mg\/kg every 2 weeks or dacarbazine 1,000 mg\/m2 every 3 weeks.","The primary end point was overall survival (OS), and secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety.","RESULTS: Patients were followed for a minimum of 60 months from the last patient randomly assigned (median follow-up, 32.0 months for nivolumab and 10.9 months for dacarbazine).","Five-year OS rates were 39% with nivolumab and 17% with dacarbazine; PFS rates were 28% and 3%, respectively.","Five-year OS was 38% in patients randomly assigned to dacarbazine who had subsequent therapy, including nivolumab (n = 37).","ORR was 42% with nivolumab and 14% with dacarbazine; among patients alive at 5 years, ORR was 81% and 39%, respectively.","Of 42 patients treated with nivolumab who had a complete response (20%), 88% (37 of 42) were alive as of the 5-year analysis.","Among 75 nivolumab-treated patients alive and evaluable at the 5-year analysis, 83% had not received subsequent therapy; 23% were still on study treatment, and 60% were treatment free.","Safety analyses were similar to the 3-year report.","CONCLUSION: Results from this 5-year analysis confirm the significant benefit of nivolumab over dacarbazine for all end points and add to the growing body of evidence supporting long-term survival with nivolumab mono-therapy.","Survival is strongly associated with achieving a durable response, which can be maintained after treatment discontinuation, even without subsequent systemic therapies."],"Aspect":"o","Summary":"The 5-year analysis showed that nivolumab significantly improved OS (39% vs. 17%), PFS (28% vs. 3%), and ORR (42% vs. 14%) compared to dacarbazine in BRAF wild-type advanced melanoma, with 88% of complete responders alive and 83% of evaluable patients treatment-free without subsequent therapies.","Indexes":[5,7,8,9],"Sentences":["Five-year OS rates were 39% with nivolumab and 17% with dacarbazine; PFS rates were 28% and 3%, respectively.","ORR was 42% with nivolumab and 14% with dacarbazine; among patients alive at 5 years, ORR was 81% and 39%, respectively.","Of 42 patients treated with nivolumab who had a complete response (20%), 88% (37 of 42) were alive as of the 5-year analysis.","Among 75 nivolumab-treated patients alive and evaluable at the 5-year analysis, 83% had not received subsequent therapy; 23% were still on study treatment, and 60% were treatment free."],"Revise":true}
{"PMID":"35998300","Document":["PURPOSE: The combination of talimogene laherparepvec (T-VEC) and pembrolizumab previously demonstrated an acceptable safety profile and an encouraging complete response rate (CRR) in patients with advanced melanoma in a phase Ib study.","We report the efficacy and safety from a phase III, randomized, double-blind, multicenter, international study of T-VEC plus pembrolizumab (T-VEC-pembrolizumab) versus placebo plus pembrolizumab (placebo-pembrolizumab) in patients with advanced melanoma.","METHODS: Patients with stage IIIB-IVM1c unresectable melanoma, na\u00efve to antiprogrammed cell death protein-1, were randomly assigned 1:1 to T-VEC-pembrolizumab or placebo-pembrolizumab.","T-VEC was administered at \u2264 4 \u00d7 106 plaque-forming unit (PFU) followed by \u2264 4 \u00d7 108 PFU 3 weeks later and once every 2 weeks until dose 5 and once every 3 weeks thereafter.","Pembrolizumab was administered intravenously 200 mg once every 3 weeks.","The dual primary end points were progression-free survival (PFS) per modified RECIST 1.1 by blinded independent central review and overall survival (OS).","Secondary end points included objective response rate per mRECIST, CRR, and safety.","Here, we report the primary analysis for PFS, the second preplanned interim analysis for OS, and the final analysis.","RESULTS: Overall, 692 patients were randomly assigned (346 T-VEC-pembrolizumab and 346 placebo-pembrolizumab).","T-VEC-pembrolizumab did not significantly improve PFS (hazard ratio, 0.86; 95% CI, 0.71 to 1.04; P = .13) or OS (hazard ratio, 0.96; 95% CI, 0.76 to 1.22; P = .74) compared with placebo-pembrolizumab.","The objective response rate was 48.6% for T-VEC-pembrolizumab (CRR 17.9%) and 41.3% for placebo-pembrolizumab (CRR 11.6%); the durable response rate was 42.2% and 34.1% for the arms, respectively.","Grade \u2265 3 treatment-related adverse events occurred in 20.7% of patients in the T-VEC-pembrolizumab arm and in 19.5% of patients in the placebo-pembrolizumab arm.","CONCLUSION: T-VEC-pembrolizumab did not significantly improve PFS or OS compared with placebo-pembrolizumab.","Safety results of the T-VEC-pembrolizumab combination were consistent with the safety profiles of each agent alone."],"Aspect":"i","Summary":"Patients with advanced melanoma were randomly assigned to receive either T-VEC plus pembrolizumab or placebo plus pembrolizumab, with T-VEC administered in escalating doses and pembrolizumab given intravenously.","Indexes":[1,2,3,4],"Sentences":["We report the efficacy and safety from a phase III, randomized, double-blind, multicenter, international study of T-VEC plus pembrolizumab (T-VEC-pembrolizumab) versus placebo plus pembrolizumab (placebo-pembrolizumab) in patients with advanced melanoma.","METHODS: Patients with stage IIIB-IVM1c unresectable melanoma, na\u00efve to antiprogrammed cell death protein-1, were randomly assigned 1:1 to T-VEC-pembrolizumab or placebo-pembrolizumab.","T-VEC was administered at \u2264 4 \u00d7 106 plaque-forming unit (PFU) followed by \u2264 4 \u00d7 108 PFU 3 weeks later and once every 2 weeks until dose 5 and once every 3 weeks thereafter.","Pembrolizumab was administered intravenously 200 mg once every 3 weeks."],"Revise":false}
{"PMID":"38614074","Document":["KEYNOTE-9421 is a randomized phase II adjuvant study in patients with resected stage III melanoma investigating a personalized neoantigen mRNA vaccine in combination with anti-PD-1.","The study gave a clear signal of superiority for the vaccine plus anti-PD-1 in relapse-free and distant-metastasis-free survival but is not yet conclusive, and important questions remain."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"38039779","Document":["BACKGROUND: We investigated naporafenib (LXH254), a pan-RAF kinase inhibitor, with or without spartalizumab, in patients with advanced solid tumors harboring MAPK pathway alterations.","METHODS: This first-in-human phase 1 study had two dose-escalation arms: single-agent naporafenib (starting at 100\u00a0mg once-daily [QD]) and naporafenib (starting at the recommended dose\/regimen)\/spartalizumab (400\u00a0mg every 4 weeks).","The naporafenib\/spartalizumab dose-expansion part enrolled patients with KRAS-mutated non-small cell lung cancer (NSCLC) and NRAS-mutated melanoma.","The primary objectives were to establish the maximum tolerated doses (MTD)\/recommended doses for expansion (RDE) and evaluate tolerability and safety.","RESULTS: A total of 142 patients were included in the naporafenib dose-escalation (n\u00a0=\u00a087), naporafenib\/spartalizumab dose-escalation (n\u00a0=\u00a012) and naporafenib\/spartalizumab dose-expansion (n\u00a0=\u00a043) arms.","The MTD\/RDE of naporafenib was 600\u00a0mg twice-daily (BID).","In naporafenib escalation, five patients experienced 7 dose-limiting toxicities: decreased platelet count (1200\u00a0mg QD); neuralgia, maculopapular rash, pruritus (600\u00a0mg BID); increased blood bilirubin, hyponatremia, peripheral sensory neuropathy (800\u00a0mg BID).","No DLTs occurred in the naporafenib\/spartalizumab arm: the RDE was established at 400\u00a0mg BID.","The most common treatment-related adverse events were rash and dermatitis acneiform (each 24.1%; naporafenib), nausea and pruritus (each 33.3%; naporafenib\/spartalizumab; escalation) and rash (39.5%; naporafenib\/spartalizumab; expansion).","Naporafenib reduced DUSP6 expression in tumors.","Two partial responses (PRs) occurred in naporafenib escalation, and 1 complete response and 3 PRs in the naporafenib\/spartalizumab NRAS-mutated melanoma and KRAS-mutated NSCLC arms, respectively.","CONCLUSIONS: Naporafenib, with or without spartalizumab, showed an acceptable safety profile, pharmacodynamic activity and limited antitumor activity.","Additional naporafenib combination therapies are currently under investigation."],"Aspect":"o","Summary":"The study found that naporafenib, alone or in combination with spartalizumab, showed acceptable safety, pharmacodynamic activity, and limited antitumor activity.","Indexes":[10,11],"Sentences":["Two partial responses (PRs) occurred in naporafenib escalation, and 1 complete response and 3 PRs in the naporafenib\/spartalizumab NRAS-mutated melanoma and KRAS-mutated NSCLC arms, respectively.","CONCLUSIONS: Naporafenib, with or without spartalizumab, showed an acceptable safety profile, pharmacodynamic activity and limited antitumor activity."],"Revise":false}
{"PMID":"33975862","Document":["PURPOSE: Ceralasertib is a potent and selective oral inhibitor of the serine\/threonine protein kinase ataxia telangiectasia and Rad3-related (ATR) protein.","PATIENTS AND METHODS: Eligible patients with solid tumors, enriched for melanoma, received ceralasertib in combination with a fixed dose of paclitaxel (80 mg\/m2 on D1, D8, D15) in 28-day cycles.","The dose of ceralasertib was escalated to reach an MTD in a rolling 6 design.","The starting dose of ceralasertib was 40 mg QD.","Fifty-seven patients (33 patients with melanoma who failed prior PD1\/L1 treatment) were enrolled in 7 dose cohorts ranging from 40 mg QD to 240 mg BD plus weekly paclitaxel.","RESULTS: The RP2D was established as ceralasertib 240 mg BD days 1-14 plus paclitaxel 80 mg\/m2 on D1, D8, D15 every 28 days.","The most common toxicities were neutropenia (n = 39, 68%), anemia (n = 25, 44%), and thrombocytopenia (n = 21, 37%).","In the full analysis set of 57 patients, the overall response rate (ORR) was 22.6% (95% CI, 12.5-35.3).","In 33 patients with melanoma, resistant to prior anti-PD1 therapy, the ORR was 33.3% (95% CI, 18.0-51.8).","In the melanoma subset, the mPFS was 3.6 months (95% CI, 2.0-5.8), the median duration of response was 9.9 months (95% CI, 3.7-23.2), and the mOS was 7.4 months (95% CI, 5.7-11.9).","CONCLUSIONS: Ceralasertib in combination with paclitaxel was well tolerated in patients with advanced malignancies and showed evidence of antitumor activity.","Durable responses were observed in patients with advanced cutaneous, acral, and mucosal melanoma resistant to anti-PD1\/L1 treatment.See related commentary by Ashworth, p. 4667."],"Aspect":"s","Summary":"The most common toxicities were neutropenia (68%), anemia (44%), and thrombocytopenia (37%).","Indexes":[6],"Sentences":["The most common toxicities were neutropenia (n = 39, 68%), anemia (n = 25, 44%), and thrombocytopenia (n = 21, 37%)."],"Revise":false}
{"PMID":"36445410","Document":["BACKGROUND: CAPRA (NCT02565992) evaluated Coxsackievirus A21 (V937)\u2009+\u2009pembrolizumab for metastatic\/unresectable stage IIIB-IV melanoma.","METHODS: Patients received intratumoral V937 on days 1, 3, 5, and 8 (then every 3\u00a0weeks [Q3W]) and intravenous pembrolizumab 2\u00a0mg\/kg Q3W from day 8.","Primary endpoint was safety.","RESULTS: Median time from first dose to data cutoff was 32.0\u00a0months.","No dose-limiting toxicities occurred; 14% (5\/36) of patients experienced grade 3\u20125 treatment-related adverse events.","Objective response rate was 47% (complete response, 22%).","Among 17 responders, 14 (82%) had responses\u2009\u2265\u20096\u00a0months.","Among 8 patients previously treated with immunotherapy, 3 responded (1 complete, 2 partial).","Responses were associated with increased serum CXCL10 and CCL22, suggesting viral replication contributes to antitumor immunity.","For responders versus nonresponders, there was no difference in baseline tumor PD-L1 expression, ICAM1 expression, or CD3+ infiltrates.","Surprisingly, the baseline cell density of CD3+CD8- T cells in the tumor microenvironment was significantly lower in responders compared with nonresponders (P\u2009=\u20090.0179).","CONCLUSIONS: These findings suggest responses to this combination may be seen even in patients without a typical \"immune-active\" microenvironment.","TRIAL REGISTRATION NUMBER: NCT02565992."],"Aspect":"i","Summary":"Patients received intratumoral Coxsackievirus A21 (V937) on days 1, 3, 5, and 8 (then every 3 weeks) and intravenous pembrolizumab 2 mg\/kg every 3 weeks from day 8 to evaluate the safety and efficacy of this combination therapy for metastatic\/unresectable stage IIIB-IV melanoma.","Indexes":[1],"Sentences":["METHODS: Patients received intratumoral V937 on days 1, 3, 5, and 8 (then every 3\u00a0weeks [Q3W]) and intravenous pembrolizumab 2\u00a0mg\/kg Q3W from day 8."],"Revise":false}
{"PMID":"35998300","Document":["PURPOSE: The combination of talimogene laherparepvec (T-VEC) and pembrolizumab previously demonstrated an acceptable safety profile and an encouraging complete response rate (CRR) in patients with advanced melanoma in a phase Ib study.","We report the efficacy and safety from a phase III, randomized, double-blind, multicenter, international study of T-VEC plus pembrolizumab (T-VEC-pembrolizumab) versus placebo plus pembrolizumab (placebo-pembrolizumab) in patients with advanced melanoma.","METHODS: Patients with stage IIIB-IVM1c unresectable melanoma, na\u00efve to antiprogrammed cell death protein-1, were randomly assigned 1:1 to T-VEC-pembrolizumab or placebo-pembrolizumab.","T-VEC was administered at \u2264 4 \u00d7 106 plaque-forming unit (PFU) followed by \u2264 4 \u00d7 108 PFU 3 weeks later and once every 2 weeks until dose 5 and once every 3 weeks thereafter.","Pembrolizumab was administered intravenously 200 mg once every 3 weeks.","The dual primary end points were progression-free survival (PFS) per modified RECIST 1.1 by blinded independent central review and overall survival (OS).","Secondary end points included objective response rate per mRECIST, CRR, and safety.","Here, we report the primary analysis for PFS, the second preplanned interim analysis for OS, and the final analysis.","RESULTS: Overall, 692 patients were randomly assigned (346 T-VEC-pembrolizumab and 346 placebo-pembrolizumab).","T-VEC-pembrolizumab did not significantly improve PFS (hazard ratio, 0.86; 95% CI, 0.71 to 1.04; P = .13) or OS (hazard ratio, 0.96; 95% CI, 0.76 to 1.22; P = .74) compared with placebo-pembrolizumab.","The objective response rate was 48.6% for T-VEC-pembrolizumab (CRR 17.9%) and 41.3% for placebo-pembrolizumab (CRR 11.6%); the durable response rate was 42.2% and 34.1% for the arms, respectively.","Grade \u2265 3 treatment-related adverse events occurred in 20.7% of patients in the T-VEC-pembrolizumab arm and in 19.5% of patients in the placebo-pembrolizumab arm.","CONCLUSION: T-VEC-pembrolizumab did not significantly improve PFS or OS compared with placebo-pembrolizumab.","Safety results of the T-VEC-pembrolizumab combination were consistent with the safety profiles of each agent alone."],"Aspect":"s","Summary":"Grade \u2265 3 treatment-related adverse events occurred in 20.7% of patients in the T-VEC-pembrolizumab arm and in 19.5% of patients in the placebo-pembrolizumab arm.","Indexes":[11],"Sentences":["Grade \u2265 3 treatment-related adverse events occurred in 20.7% of patients in the T-VEC-pembrolizumab arm and in 19.5% of patients in the placebo-pembrolizumab arm."],"Revise":false}
{"PMID":"32885874","Document":["The educational effectiveness of dermoscopy image-based self-learning on a computer for medical students has not been well examined.","To assess the effect of an image-based self-learning session on the dermoscopic diagnostic performance for malignant melanoma (MM), basal cell carcinoma, melanocytic nevus and seborrheic keratosis (SK) on non-acral regions in comparison with a conventional classroom-style lecture, 114 fourth-year medical students (mean age, 23.7\u00a0years; male\u00a0:\u00a0female, 73:41) were enrolled.","The subjects were randomly assigned to either a self-learning to lecture (SL) or lecture to self-learning (LS) group to receive a 15-min image-based self-learning computer session and a 15-min video lecture session in different orders.","The user interface of the digital content was the same as that on a website (https:\/\/dz-image.casio.jp).","Diagnostic performance was determined using the total number of correct answers for the four diseases and by malignancy prediction in examination A (before training), B (after receiving one session) and C (after receiving both sessions).","The examinations were all unique and contained five dermoscopic images each of the four diseases.","The total number of correct answers and malignancy prediction results for examination B were significantly higher in the SL group than in LS (11.6 and 15.2 vs 10.1 and 13.4, respectively; both P\u00a0<\u00a00.01), with no remarkable differences for examination C (13.5 and 16.8 vs 13.3 and 16.4, respectively; P\u00a0=\u00a00.62 and P\u00a0=\u00a00.21).","In subanalyses, the number of correct answers for SK in examination B was significantly higher in the SL group (3.6 vs. 1.8, P\u00a0<\u00a00.01), while that for MM was significantly lower (2.2 vs 3.0, P\u00a0<\u00a00.01).","Diagnostic performance was comparable between sexes for examination B.","In conclusion, computer-assisted dermoscopy image-based self-learning may be a suitable and non-inferior alternative to classroom-style instruction for medical students within an ultra-short training period."],"Aspect":"a","Summary":"The study aims to assess the effect of an image-based self-learning session on the dermoscopic diagnostic performance for various skin conditions among medical students compared to a conventional classroom-style lecture.","Indexes":[1],"Sentences":["To assess the effect of an image-based self-learning session on the dermoscopic diagnostic performance for malignant melanoma (MM), basal cell carcinoma, melanocytic nevus and seborrheic keratosis (SK) on non-acral regions in comparison with a conventional classroom-style lecture, 114 fourth-year medical students (mean age, 23.7\u00a0years; male\u00a0:\u00a0female, 73:41) were enrolled."],"Revise":false}
{"PMID":"31385109","Document":["Background Endothelin B receptor (ETBR) is involved in melanoma pathogenesis and is overexpressed in metastatic melanoma.","The antibody-drug conjugate DEDN6526A targets ETBR and is comprised of the humanized anti-ETBR monoclonal antibody conjugated to the anti-mitotic agent monomethyl auristatin E (MMAE).","Methods This Phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DEDN6526A (0.3-2.8\u00a0mg\/kg) given every 3\u00a0weeks (q3w) in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma.","Results Fifty-three patients received a median of 6 doses of DEDN6526A (range 1-49).","The most common drug-related adverse events (>25% across dose levels) were fatigue, peripheral neuropathy, nausea, diarrhea, alopecia, and chills.","Three patients in dose-escalation experienced a dose-limiting toxicity (infusion-related reaction, increased ALT\/AST, and drug-induced liver injury).","Based on cumulative safety data across all dose levels, the recommended Phase II dose (RP2D) for DEDN6526A was 2.4\u00a0mg\/kg intravenous (IV) q3w.","The pharmacokinetics of antibody-conjugated MMAE and total antibody were dose-proportional at doses ranging from 1.8-2.8\u00a0mg\/kg.","A trend toward faster clearance was observed at doses of 0.3-1.2\u00a0mg\/kg.","There were 6 partial responses (11%) in patients with metastatic cutaneous or mucosal melanoma, and 17 patients (32%) had prolonged stable disease \u22656\u00a0months.","Responses were independent of BRAF mutation status but did correlate with ETBR expression.","Conclusion DEDN6526A administered at the RP2D of 2.4\u00a0mg\/kg q3w had an acceptable safety profile and showed evidence of anti-tumor activity in patients with cutaneous, mucosal, and uveal melanoma.","ClinicalTrials.gov identifier: NCT01522664."],"Aspect":"m","Summary":"The Phase I study evaluated the antibody-drug conjugate DEDN6526A, targeting ETBR, with dosages ranging from 0.3-2.8 mg\/kg every 3 weeks, and the recommended Phase II dose was 2.4 mg\/kg IV q3w.","Indexes":[1,2,6],"Sentences":["The antibody-drug conjugate DEDN6526A targets ETBR and is comprised of the humanized anti-ETBR monoclonal antibody conjugated to the anti-mitotic agent monomethyl auristatin E (MMAE).","Methods This Phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DEDN6526A (0.3-2.8\u00a0mg\/kg) given every 3\u00a0weeks (q3w) in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma.","Based on cumulative safety data across all dose levels, the recommended Phase II dose (RP2D) for DEDN6526A was 2.4\u00a0mg\/kg intravenous (IV) q3w."],"Revise":true}
{"PMID":"38566437","Document":["BACKGROUND: Treatment decisions in metastatic melanoma (MM) are highly dependent on patient preferences and require the patients' involvement.","The complexity of treatment options with their individual advantages and disadvantages is often overwhelming.","We therefore developed an online patient decision aid (PtDA) to facilitate shared decision making (SDM).","METHODS: To evaluate the PtDA we conducted a two-armed, twocenter, prospective, open randomized controlled trial with MM patients who were facing a decision about first-line treatment.","The patients were allotted randomly in a 1:1 ratio to an intervention group (IG) with access to the PtDA before discussion with a physician or to a control group (CG) without access to the PtDA.","The primary endpoint was knowledge about the options for first-line treatment (multiple-choice test, 10 items, range 0-40 points).","The secondary endpoints were the SDM (third-party ratings of audio recordings of the treatment discussions) and satisfaction with the decision at the follow-up visit.","RESULTS: Of the 128 randomized patients, 120 completed the baseline questionnaire and were analyzed (59% male, median age 66 years).","The primary endpoint, i.e., the mean difference in knowledge after discussion with a physician, differed significantly between the IG and the CG (-3.22, 95% CI [-6.32; -0.12], p = 0.042).","No differences were found for the secondary endpoints, SDM and satisfaction with the decision.","The patients in the IG rated the PtDA as very useful.","CONCLUSION: The PtDA improved the knowledge of patients with MM about the options for treatment.","Both groups were highly satisfied with their treatment decisions.","However, additional physician training seems necessary to promote SDM."],"Aspect":"p","Summary":"The study involved 120 patients with metastatic melanoma (MM) who were facing a decision about first-line treatment, with 59% being male and a median age of 66 years.","Indexes":[7],"Sentences":["RESULTS: Of the 128 randomized patients, 120 completed the baseline questionnaire and were analyzed (59% male, median age 66 years)."],"Revise":false}
{"PMID":"36600247","Document":["BACKGROUND: HL-085 is a selective, orally administered MEK1\/2 inhibitor.","We aimed to evaluate the safety and efficacy of HL-085 in patients with advanced melanoma harboring NRAS mutations.","METHODS: This was a multicenter phase 1 study.","HL-085 was administered twice daily in a standard 3\u2009+\u20093 dose-escalation design (10 dose cohorts; 0.5-18\u00a0mg twice daily), followed by dose expansion at the recommended phase II dose (RP2D).","The primary endpoints included tolerability, dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and RP2D.","RESULTS: Between September 13, 2017, and January 18, 2021, 42 patients were enrolled (dose escalation phase: n\u2009=\u200930; dose expansion phase: n\u2009=\u200912).","No DLT was reported during dose escalation and MTD was not reached with HL-085 doses up to 18\u00a0mg twice daily.","The RP2D was 12\u00a0mg twice daily.","The most common all-grade drug-related adverse events (AEs) across all dose levels were rash (61.9%), increased creatine phosphokinase (CK, 59.5%), face edema (50.0%), increased aspartate aminotransferase (47.6%), peripheral edema (40.5%), diarrhea (33.3%), alanine aminotransferase (33.3%), and paronychia (19.0%), most of which were grade 1 and 2.","Most frequency of grade\u2009\u2265\u20093 AEs were CK (14.2%), asthenia (7.1%), peripheral edema (4.8%), and acneiform dermatitis (4.8%).","In the cohort of 12\u00a0mg twice daily dose (15 patients), confirmed objective response rate was 26.7%; disease control rate was 86.7%; median duration of response was 2.9\u00a0months; median progression-free survival was 3.6\u00a0months.","CONCLUSIONS: The HL-085 showed acceptable tolerability and substantial clinical activity in patients with advanced melanoma harboring NRAS mutations.","TRIAL REGISTRATION: Trial registration ClinicalTrials.gov number: NCT03973151."],"Aspect":"i","Summary":"The treatment method involved administering HL-085 twice daily in a standard 3\u2009+\u20093 dose-escalation design, followed by dose expansion at the recommended phase II dose (RP2D).","Indexes":[3,4],"Sentences":["HL-085 was administered twice daily in a standard 3\u2009+\u20093 dose-escalation design (10 dose cohorts; 0.5-18\u00a0mg twice daily), followed by dose expansion at the recommended phase II dose (RP2D).","The primary endpoints included tolerability, dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and RP2D."],"Revise":true}
{"PMID":"37307514","Document":["PURPOSE: To address the paucity of data in patients with historically poor outcomes, we conducted the single-arm phase IIIb CheckMate 401 study to evaluate the safety and efficacy of nivolumab plus ipilimumab followed by nivolumab monotherapy in clinically diverse patient populations with advanced melanoma.","METHODS: Treatment-naive patients with unresectable stage III-IV melanoma received nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg once every 3 weeks (four doses) followed by nivolumab 3 mg\/kg (240 mg following a protocol amendment) once every 2 weeks for \u226424 months.","The primary end point was the incidence of grade 3-5 select treatment-related adverse events (TRAEs).","Overall survival (OS) was a secondary end point.","Outcomes were evaluated in subgroups defined by Eastern Cooperative Oncology Group performance status (ECOG PS), brain metastasis status, and melanoma subtype.","RESULTS: In total, 533 patients received at least one dose of study drug.","Grade 3-5 select TRAEs affecting the GI (16%), hepatic (15%), endocrine (11%), skin (7%), renal (2%), and pulmonary (1%) systems occurred in the all-treated population; similar incidence rates were observed across all subgroups.","At 21.6 months' median follow-up, 24-month OS rates were 63% in the all-treated population, 44% in the ECOG PS 2 subgroup (including patients with cutaneous melanoma only), 71% in the brain metastasis subgroup, 36% in the ocular\/uveal melanoma subgroup, and 38% in the mucosal melanoma subgroup.","CONCLUSION: Nivolumab plus ipilimumab followed by nivolumab monotherapy was tolerable in patients with advanced melanoma and poor prognostic characteristics.","Efficacy was similar between the all-treated population and patients with brain metastases.","Reduced efficacy was observed in patients with ECOG PS 2, ocular\/uveal melanoma, and\/or mucosal melanoma, highlighting the continued need for novel treatment options for these difficult-to-treat patients."],"Aspect":"d","Summary":"The treatment duration in the trial was up to 24 months.","Indexes":[1],"Sentences":["METHODS: Treatment-naive patients with unresectable stage III-IV melanoma received nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg once every 3 weeks (four doses) followed by nivolumab 3 mg\/kg (240 mg following a protocol amendment) once every 2 weeks for \u226424 months."],"Revise":false}
{"PMID":"32200815","Document":["OBJECTIVE: To describe the frequency and predictors of local treatment failure and enucleation after iodine 125 (I125) brachytherapy in patients with choroidal melanoma treated and followed up in a large randomized clinical trial.","DESIGN: Prospective, noncomparative, interventional case series within a randomized, multicenter clinical trial.","PARTICIPANTS: Patients enrolled in the Collaborative Ocular Melanoma Study (COMS) trial of enucleation versus brachytherapy between February 1987 and July 1998; tumors measured 2.5 to 10.0 mm in apical height and no more than 16.0 mm in longest basal dimension.","METHODS: I125 brachytherapy was administered via episcleral plaque according to a standard protocol.","Follow-up ophthalmic evaluations, including ophthalmic ultrasound and fundus photography, were performed according to a standard protocol at baseline, every 6 months thereafter for 5 years, and subsequently at annual intervals.","Survival analysis methods were used to estimate the cumulative risk of postirradiation treatment failure and enucleation.","Factors associated with treatment failure and enucleation of plaqued eyes were evaluated using Cox proportional hazards analysis.","MAIN OUTCOME MEASURES: Reports of enucleation and of local treatment failure, defined as tumor growth, recurrence, or extrascleral extension, derived from clinical reports based on echographic and photographic documentation.","RESULTS: As of September 30, 2000, 638 of the 650 patients randomized to brachytherapy and so treated had been followed up for 1 year or longer, and 411 had been followed up for at least 5 years.","Sixty-nine eyes were enucleated during the first 5 years after brachytherapy, and treatment failure was reported for 57 eyes.","The Kaplan-Meier estimate of proportion of patients undergoing enucleation by 5 years was 12.5% (95% confidence interval [CI], 10.0%-15.6%); the risk of treatment failure was 10.3% (95% CI, 8.0%-13.2%).","Treatment failure was the most common reason for enucleation within 3 years of treatment; beyond 3 years, ocular pain was most common.","Risk factors for enucleation were greater tumor thickness, closer proximity of the posterior tumor border to the foveal avascular zone, and poorer baseline visual acuity in the affected eye.","Risk factors for treatment failure were older age, greater tumor thickness, and proximity of the tumor to the foveal avascular zone.","Local treatment failure was associated weakly with reduced survival after controlling for baseline tumor and personal characteristics (adjusted risk ratio, 1.5; P\u00a0= 0.08).","CONCLUSIONS: Local treatment failure and enucleation were relatively infrequent events after I125 brachytherapy within the COMS.","Treatment failure typically occurred early and was associated weakly with poorer survival.","The COMS randomized trial documented the absence of a clinically or statistically significant difference in survival for patients randomly assigned to enucleation versus brachytherapy.","This analysis documents the efficacy of brachytherapy to achieve sustained local tumor control and to conserve the globe."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"37587862","Document":["BACKGROUND: Non-immunosuppressed patients with a history of multiple non-melanoma skin cancers (NMSCs) taking oral nicotinamide supplementation experienced a 23% decrease in annual NMSC risk in a randomized clinical trial.","Patient preferences for risks and costs associated with nicotinamide are unknown.","OBJECTIVES: To understand how patients prioritize NMSC reduction, infection risk, and cost.","METHODS: A sample of adults with history of \u22652 NMSC within the past five\u2009years undergoing Mohs procedure completed a discrete-choice experiment comprising two hypothetical treatments-characterized by varying reductions in NMSC incidence, increased severe infection risk, and cost-and no treatment.","The data were analyzed with random-parameters logit models.","RESULTS: A total of 203 subjects (mean age 71.5\u2009years, 65.5% males) participated.","For a 23% annual reduction in NMSC incidence, a 26% [95% CI: 8%-45%] annual increase in severe infection risk and $8 [95% CI: $2-14] monthly cost was acceptable.","Outcomes across analyzed subgroups (before vs. during COVID pandemic, site of interview, less vs. more prior NMSCs) were similar.","CONCLUSIONS: Patients were unwilling to accept high severe infection risks to obtain the reduction in NMSC incidence observed in a nicotinamide trial, suggesting that routinely recommending nicotinamide may run counter to some patients' preferences."],"Aspect":"s","Summary":"In patients taking oral nicotinamide supplementation a 26% annual increase in severe infection risk as well as $8 monthly cost were observed. ","Indexes":[6],"Sentences":["For a 23% annual reduction in NMSC incidence, a 26% [95% CI: 8%-45%] annual increase in severe infection risk and $8 [95% CI: $2-14] monthly cost was acceptable."],"Revise":true}
{"PMID":"31792256","Document":["The purpose was to evaluate the potential of diffusion-weighted-magnetic resonance imaging (DW-MRI) and 18F-fludeoxy-glucose-positron emission tomography integrated with CT (FDG-PET\/CT) for prediction of overall survival (OS) following AdCD40L-immunotherapy in patients with metastatic malignant melanoma (MMM).","Twenty-four patients with refractory MMM were treated with immunostimulatory AdCD40L gene therapy in a phase I\/IIa study.","Pre-therapeutic DW-MRI and FDG-PET\/CT were performed and then repeated at 5 and 9 weeks post-treatment.","Evaluation was conducted according to RECIST 1.1 and EORTC criteria.","Apparent diffusion coefficient (ADC), true diffusion coefficient (D), maximum standardized uptake value (SUVmax) were measured in the injected lesions.","Fold changes (F) in ADC (F ADC), D (F D), SUVmax (F SUVmax) were statistically assessed.","F D\u2009\u2265\u20091 and F ADC\u2009\u2265\u20091 were associated with better OS in scans at week 5 and 9 respectively.","F SUVmax was not correlated to OS.","F ADC\u2009\u2265\u20091 in both post-treatment scans and F D\u2009\u2265\u20091 at week 5 were related to a significant decrease of size of the injected lesions.","These results suggest that in patients with MMM treated with AdCD40l, functional parameters of DW-MRI are better early predictors of OS than the established metabolic and morphologic criteria for FDG-PET\/CT and MRI, respectively."],"Aspect":"d","Summary":"The treatment duration involved assessments at 5 and 9 weeks post-treatment.","Indexes":[2],"Sentences":["Pre-therapeutic DW-MRI and FDG-PET\/CT were performed and then repeated at 5 and 9 weeks post-treatment."],"Revise":false}
{"PMID":"34553670","Document":["BACKGROUND: Post-operative lymphorrhea is a well-known complication of inguinal lymph node dissection.","However, the interventions to reduce the duration of drain in situ have not been sufficiently elaborated.","OBJECTIVES: We evaluated the potential role of intra-operative mapping of lymphatic leakage with peri-incisional methylene blue injection and clipping of lymphatics after inguinal block dissection in reducing postoperative lymphorrhea.","METHODS: We randomized 39 inguinal dissections done for various malignancies such as for carcinoma penis, urethra, malignant melanoma, rectum into 19 dissections (Interventional group) and 20 dissections (Control group).","In the interventional group, after the completion of inguinal dissection, two ml of methylene blue dye was injected 4-8cm from the incision to identify the leaking lymphatics and they were clipped.","RESULTS: The primary outcome was the decrease in duration of days of drain in situ and was found to have significant reduction of 3.07\u2009days in the interventional arm.","(p value-0.02).","The secondary outcome was the reduction of 21\u2009ml of mean drain output in the interventional group (p\u2009=\u20090.09).","The number of lymphatics clipped was not found to have statistical correlation with the duration of drain in situ and the mean drain output.","CONCLUSION: The intraoperative mapping of lymphatic channels using methylene blue after inguinal dissection reduces the number of days of drain in situ."],"Aspect":"o","Summary":"The study found that intraoperative mapping of lymphatic channels using methylene blue after inguinal dissection significantly reduces the duration of drain in situ by 3.07 days. The secondary outcome was the reduction of 21\u2009ml of mean drain output in the interventional group (p\u2009=\u20090.09). ","Indexes":[5,7],"Sentences":["RESULTS: The primary outcome was the decrease in duration of days of drain in situ and was found to have significant reduction of 3.07\u2009days in the interventional arm.","The secondary outcome was the reduction of 21\u2009ml of mean drain output in the interventional group (p\u2009=\u20090.09)."],"Revise":true}
{"PMID":"38870745","Document":["BACKGROUND: Treatment options for immunotherapy-refractory melanoma are an unmet need.","The MASTERKEY-115 phase II, open-label, multicenter trial evaluated talimogene laherparepvec (T-VEC) plus pembrolizumab in advanced melanoma that progressed on prior programmed cell death protein-1 (PD-1) inhibitors.","METHODS: Cohorts 1 and 2 comprised patients (unresectable\/metastatic melanoma) who had primary or acquired resistance, respectively, and disease progression within 12 weeks of their last anti-PD-1 dose.","Cohorts 3 and 4 comprised patients (resectable disease) who underwent complete surgery, received adjuvant anti-PD-1, and experienced recurrence.","Cohort 3 were disease-free for <\u00a06 months and cohort 4 for \u2265\u00a06 months after starting the adjuvant anti-PD-1 therapy and before confirmed recurrence.","The primary endpoint was objective response rate (ORR) per RECIST v1.1.","Secondary endpoints included complete response rate (CRR), disease control rate (DCR) and progression-free survival (PFS) per RECIST v1.1 and irRC-RECIST, and safety.","RESULTS: Of the 72 enrolled patients, 71 were treated.","The ORR (95% CI) was 0%, 6.7% (0.2-32.0), 40.0% (16.3-67.7), and 46.7% (21.3-73.4) in cohorts 1-4, respectively; iORR was 3.8% (0.1-19.6), 6.7% (0.2-32.0), 53.3% (26.6-78.7), and 46.7% (21.3-73.4).","iCRR was 0%, 0%, 13.3%, and 13.3%.","Median iPFS (months) was 5.5, 8.2, not estimable [NE], and NE for cohorts 1-4, respectively; iDCR was 50.0%, 40.0%, 73.3%, and 86.7%.","Treatment-related adverse events (TRAEs), grade \u2265\u00a03 TRAEs, serious AEs, and fatal AEs occurred in 54 (76.1%), 9 (12.7%), 24 (33.8%), and 10 (14.1%) patients, respectively.","CONCLUSION: T-VEC-pembrolizumab demonstrated antitumor activity and tolerability in PD-1-refractory melanoma, specifically in patients with disease recurrence on or after adjuvant anti-PD-1.","TRIAL REGISTRATION: ClinicalTrials.gov identifier - NCT04068181."],"Aspect":"i","Summary":"The MASTERKEY-115 phase II trial evaluated the effect of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with advanced melanoma who have either unresectable\/metastatic melanoma and have acquired resistance to anti-PD1 (Cohort 1 and 2), or who have underwent complete surgery and received adjuvant anti-PD1 and were desease-free for <6 months (Cohort 3) or \u2265 6 months (Cohort 4) after starting adjuvant anti-PD1. ","Indexes":[1,2,3,4],"Sentences":["The MASTERKEY-115 phase II, open-label, multicenter trial evaluated talimogene laherparepvec (T-VEC) plus pembrolizumab in advanced melanoma that progressed on prior programmed cell death protein-1 (PD-1) inhibitors.","METHODS: Cohorts 1 and 2 comprised patients (unresectable\/metastatic melanoma) who had primary or acquired resistance, respectively, and disease progression within 12 weeks of their last anti-PD-1 dose.","Cohorts 3 and 4 comprised patients (resectable disease) who underwent complete surgery, received adjuvant anti-PD-1, and experienced recurrence.","Cohort 3 were disease-free for <\u00a06 months and cohort 4 for \u2265\u00a06 months after starting the adjuvant anti-PD-1 therapy and before confirmed recurrence."],"Revise":true}
{"PMID":"34699278","Document":["OBJECTIVE: Primary site is considered an important prognostic factor for cutaneous malignant melanoma (CMM); however, opinions vary regarding its influence on survival.","This study compares overall survival between head and neck melanoma (HNM) and melanoma of other regions (MOR), as well as between melanoma of the scalp and neck (MSN) and melanoma of other head regions (MOHR).","STUDY DESIGN: Level III retrospective cohort study.","SETTING: Patients from Commission on Cancer-accredited cancer programs affiliated to the National Cancer Database (NCDB).","METHODS: Patients with HNM (MSN and MOHR included) and MOR, stages I to IV (n = 39,754), and their linked survival data using the NCDB were identified.","Survival was analyzed using propensity score matching methods.","RESULTS: After matching using propensity scores, allowing this observational study to mimic a randomized controlled trial, subjects with HNM showed a 22% increased mortality when compared to MOR (P < .01).","Among those with HNM, hazard was not proportional over time.","Overall, subjects with MSN in the first 3.5 years of follow-up (75% of subjects) showed a 15% increased mortality when compared to MOHR (P < .01); however, after 3.5 years, no difference in survival was noted (P = .5).","CONCLUSION: Patients with HNM showed a higher mortality when compared to MOR.","The risk of death of primary sites within the head and neck varies over time, showing a higher risk of mortality for scalp and neck during the first 3.5 years of follow-up.","This increased risk was not evident after the 3.5-year threshold.","Further research is needed to evaluate additional patient factors or differences in treatment approaches."],"Aspect":"o","Summary":"Patients with head and neck melanoma (HNM) showed a 22% increased mortality compared to melanoma of other regions (MOR), with a higher risk of mortality for scalp and neck during the first 3.5 years of follow-up. However, after 3.5 years, no difference in survival was noted. ","Indexes":[6,7,8,9],"Sentences":["RESULTS: After matching using propensity scores, allowing this observational study to mimic a randomized controlled trial, subjects with HNM showed a 22% increased mortality when compared to MOR (P < .01).","Among those with HNM, hazard was not proportional over time.","Overall, subjects with MSN in the first 3.5 years of follow-up (75% of subjects) showed a 15% increased mortality when compared to MOHR (P < .01); however, after 3.5 years, no difference in survival was noted (P = .5).","CONCLUSION: Patients with HNM showed a higher mortality when compared to MOR."],"Revise":true}
{"PMID":"36625227","Document":["Skin cancer is the most common cancer in the United States, and early detection of melanoma may lead to diagnosis of thinner and more treatable cancers, resulting in improved survival rates.","This study examined the effects of message interactivity (high vs. low) and imagery (cartoon, real human character, or customized imagery preference) on accuracy of identifying abnormal skin lesions (ASL) and skin self-examination (SSE) intention.","This study employed a 3 (cartoon character vs. real person vs. customization) x 2 (high interactivity vs. low interactivity) between-subjects online experimental design.","Participants at risk for skin cancer were randomly assigned to one of the six conditions and completed a survey after reviewing the educational materials.","Univariate analyses were conducted to detect group differences on the accuracy of identifying ASL and intention to conduct SSE in the next 3\u00a0months.","Among 321 participants who completed the study, the mean age was 36.61\u00a0years, 56.7% were females, 76.1% had a college or higher degree, and over 60% self-identified as non-Hispanic White.","Individuals in the high interactivity and customization group (compared to the low interactivity and cartoon group) were more likely to accurately identify ASL.","Individuals in the high interactivity and customization or low interactivity and real person imagery groups (compared to the low interactivity and cartoon group) reported higher intention to conduct SSE in the next 3\u00a0months.","These results suggest that customization and interactivity may be beneficial for educational programs or intervention design to improve both melanoma identification and SSE intention."],"Aspect":"i","Summary":"The study used a 3 (cartoon character vs. real person vs. customization) x 2 (high interactivity vs. low interactivity) between-subjects online experimental design with participants at risk for skin cancer, who completed a survey after reviewing educational materials to assess accuracy in identifying ASL and intention to conduct SSE.","Indexes":[2,3,4],"Sentences":["This study employed a 3 (cartoon character vs. real person vs. customization) x 2 (high interactivity vs. low interactivity) between-subjects online experimental design.","Participants at risk for skin cancer were randomly assigned to one of the six conditions and completed a survey after reviewing the educational materials.","Univariate analyses were conducted to detect group differences on the accuracy of identifying ASL and intention to conduct SSE in the next 3\u00a0months."],"Revise":true}
{"PMID":"37845511","Document":["Patients with resected stage IIB\/C melanoma have high recurrence risk, similar to those with resected stage IIIA\/B disease.","The phase 3, double-blind CheckMate 76K trial assessed 790 patients with resected stage IIB\/C melanoma randomized 2:1 (stratified by tumor category) to nivolumab 480\u2009mg or placebo every 4\u2009weeks for 12\u2009months.","The primary endpoint was investigator-assessed recurrence-free survival (RFS).","Secondary endpoints included distant metastasis-free survival (DMFS) and safety.","At 7.8\u2009months of minimum follow-up, nivolumab significantly improved RFS versus placebo (hazard ratio (HR)\u2009=\u20090.42; 95% confidence interval (CI): 0.30-0.59; P\u2009<\u20090.0001), with 12-month RFS of 89.0% versus 79.4% and benefit observed across subgroups; DMFS was also improved (HR\u2009=\u20090.47; 95% CI: 0.30-0.72).","Treatment-related grade 3\/4 adverse events occurred in 10.3% (nivolumab) and 2.3% (placebo) of patients.","One treatment-related death (0.2%) occurred with nivolumab.","Nivolumab is an effective and generally well-tolerated adjuvant treatment in patients with resected stage IIB\/C melanoma.","ClinicalTrials.gov identifier: NCT04099251 ."],"Aspect":"m","Summary":"The trial assessed nivolumab at a dosage of 480 mg every 4 weeks for 12 months.","Indexes":[1],"Sentences":["The phase 3, double-blind CheckMate 76K trial assessed 790 patients with resected stage IIB\/C melanoma randomized 2:1 (stratified by tumor category) to nivolumab 480\u2009mg or placebo every 4\u2009weeks for 12\u2009months."],"Revise":false}
{"PMID":"38754780","Document":["BACKGROUND: Neoadjuvant dabrafenib plus trametinib has a high pathological response rate and impressive short-term survival in patients with resectable stage III melanoma.","We report 5-year outcomes from the phase II NeoCombi trial.","PATIENTS AND METHODS: NeoCombi (NCT01972347) was a single-arm, open-label, single-centre, phase II trial.","Eligible patients were adults (aged \u226518 years) with histologically confirmed, resectable, RECIST-measurable, American Joint Committee on Cancer seventh edition clinical stage IIIB-C BRAF V600E\/K-mutant melanoma and Eastern Cooperative Oncology Group performance status \u22641.","Patients received 52 weeks of treatment with dabrafenib 150 mg (orally twice per day) plus trametinib 2 mg (orally once per day), with complete resection of the pre-therapy tumour bed at week 12.","RESULTS: Between 20 August 2014 and 19 April 2017, 35 patients were enrolled.","At data cut-off (17 August 2021), the median follow-up was 60 months [95% confidence interval (CI) 56-72 months].","Overall, 21 of 35 (60%) patients recurred, including 12 (57%) with first recurrence in locoregional sites (followed by later distant recurrence in 6) and 9 (43%) with first recurrence in distant sites, including 3 in the brain.","Most recurrences occurred within 2 years, with no recurrences beyond 3 years.","At 5 years, recurrence-free survival (RFS) was 40% (95% CI 27% to 60%), distant metastasis-free survival (DMFS) was 57% (95% CI 42% to 76%), and overall survival was 80% (95% CI 67% to 94%).","Five-year survival outcomes were stratified by pathological response: RFS was 53% with pathological complete response (pCR) versus 28% with non-pCR (P\u00a0= 0.087), DMFS was 59% versus 55% (P\u00a0= 0.647), and overall survival was 88% versus 71% (P\u00a0= 0.205), respectively.","CONCLUSIONS: Neoadjuvant dabrafenib plus trametinib has high pathological response rates in clinical stage III melanoma, but low rates of RFS, similar to those achieved with adjuvant targeted therapy alone.","Patients with a pCR to dabrafenib plus trametinib still had a high risk of recurrence, unlike that seen with immunotherapy where recurrences are rare."],"Aspect":"a","Summary":"The study aims to report the 5-year outcomes from the phase II NeoCombi trial, which investigates the effects of neoadjuvant dabrafenib plus trametinib in patients with resectable stage III melanoma.","Indexes":[0,1,2],"Sentences":["BACKGROUND: Neoadjuvant dabrafenib plus trametinib has a high pathological response rate and impressive short-term survival in patients with resectable stage III melanoma.","We report 5-year outcomes from the phase II NeoCombi trial.","PATIENTS AND METHODS: NeoCombi (NCT01972347) was a single-arm, open-label, single-centre, phase II trial."],"Revise":true}
{"PMID":"32011509","Document":["BACKGROUND: Plenty of evidence has suggested that long non-coding RNAs (lncRNAs) have played a vital part may act as prognostic biomarkers in a variety of cancers.","The aim of this study was to screen survival-related lncRNAs and to construct a lncRNA-based prognostic model in patients with cutaneous melanoma (CM).","METHODS: We obtained lncRNAs expression profiles and clinicopathological data from the Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) databases.","A lncRNA-based prognostic model was established in training set.","The established prognostic model was evaluated, and validated in the validation set.","Then, a prognostic nomogram combining the lncRNA-based risk score and clinicopathological characteristics was developed in training set, and assessed in the validation set.","The accuracy of the model was evaluated by the discrimination and calibration plots.","RESULTS: A total of 212 lncRNAs were identified to be differentially expressed in CM.","After univariate analysis, LASSO penalized regression analysis, and multivariate analysis, 3 lncRNAs were used to construct risk score model.","The proposed risk score model could divide patients into high-risk and low-risk groups with significantly different survival in both training set and validation set.","The ROC curve showed good performance in survival prediction in both sets.","Furthermore, the nomogram for predicting 3-, 5-, and 10-year OS was established based on lncRNA-based risk score and clinicopathologic factors.","The prognostic accuracy of the risk model was confirmed by the discrimination and calibration plots in both training set and validation set.","CONCLUSIONS: We established a novel three lncRNA-based risk score model and nomogram to predict overall survival of CM.","The proposed nomogram may provide information for individualized treatment in CM patients."],"Aspect":"m","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"31839677","Document":["BACKGROUND: Aiming to improve treatment options for BRAF wild-type melanoma, we previously conducted the DOC-MEK study of docetaxel with MEK inhibitor (MEKi) selumetinib or placebo, revealing trends to prolongation of progression-free survival (hazard ratio 0.75, P\u2009=\u20090.130), and improved response rates (32% vs 14%, P\u2009=\u20090.059) with docetaxel plus selumetinib.","NRAS status did not associate with outcome.","Here, the aim was to identify novel biomarkers of response to MEKi.","METHODS: A MEK 6 gene signature was quantified using NanoString and correlated with clinical outcomes.","Two components of the gene signature were investigated by gene silencing in BRAF\/NRAS wild-type melanoma cells.","RESULTS: In melanomas of patients on the selumetinib but not the placebo arm, two gene signature components, dual-specificity protein phosphatase 4 (DUSP4) and ETS translocation variant 4 (ETV4), were expressed more highly in responders than non-responders.","In vitro, ETV4 depletion inhibited cell survival but did not influence sensitivity to MEKi selumetinib or trametinib.","In contrast, DUSP4-depleted cells showed enhanced cell survival and increased resistance to both selumetinib and trametinib.","CONCLUSIONS: ETV4 and DUSP4 associated with clinical response to docetaxel plus selumetinib.","DUSP4 depletion induced MEKi resistance, suggesting that DUSP4 is not only a biomarker but also a mediator of MEKi sensitivity.","CLINICAL TRIAL REGISTRATION: DOC-MEK (EudraCT no: 2009-018153-23)."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"32047956","Document":["Hemagglutinating virus of Japan (HVJ; Sendai virus) is an RNA virus that has cell fusion activity.","HVJ-envelope (HVJ-E) is a UV-irradiated HVJ particle that loses viral replication and protein synthesis activity but retains cell fusion activity.","We recently reported that HVJ-E has antitumor effects on several types of tumors.","Here, we describe the results of a first-in-human phase I\/IIa study in patients with advanced melanoma, receiving intratumoral administration of HVJ-E.","The primary aim was to evaluate the safety and tolerability of HVJ-E, and the secondary aim was to examine the objective tumor response and antitumor immunity.","Six patients with stage IIIC or IV progressive malignant melanoma with skin or lymph metastasis were enrolled.","Patients were separated into two groups (n\u2009=\u20093 each) and received low and high doses of HVJ-E. Five of the six patients completed 4\u00a0weeks of follow-up evaluation; one patient discontinued treatment owing to progressive disease.","Complete or partial responses were observed in 3 of 6 (50%) injected target lesions, 7 of 15 (47%) noninjected target lesions, and 10 of 21 (48%) target lesions.","Induction of antitumor immunity was observed: activation of natural killer cells, a marked increase in interferon-\u03b3 levels in the peripheral blood, and infiltration of cytotoxic T cells into both injected and noninjected tumor lesions.","Thus, intratumoral injection of HVJ-E in advanced melanoma patients showed safety and tolerability with local regression of the tumor mediated by antitumor immunity.","The results suggest that HVJ-E might be a new treatment approach in patients with advanced melanoma."],"Aspect":"o","Summary":"The study found that intratumoral injection of HVJ-E in advanced melanoma patients was safe and tolerable, with local regression of the tumor observed in 50% of injected target lesions and 47% of noninjected target lesions, mediated by antitumor immunity.","Indexes":[7,8,9],"Sentences":["Complete or partial responses were observed in 3 of 6 (50%) injected target lesions, 7 of 15 (47%) noninjected target lesions, and 10 of 21 (48%) target lesions.","Induction of antitumor immunity was observed: activation of natural killer cells, a marked increase in interferon-\u03b3 levels in the peripheral blood, and infiltration of cytotoxic T cells into both injected and noninjected tumor lesions.","Thus, intratumoral injection of HVJ-E in advanced melanoma patients showed safety and tolerability with local regression of the tumor mediated by antitumor immunity."],"Revise":false}
{"PMID":"37184115","Document":["PURPOSE: To determine the feasibility, safety and preliminary efficacy of a telehealth supervised exercise programme in patients with advanced melanoma receiving checkpoint inhibitor therapy.","METHODS: A 8-week non-randomised feasibility pilot trial utilising a telehealth delivered multimodal exercise programme undertaken thrice weekly with assessments at baseline and post-intervention.","The study was considered feasible if there were no severe or life-threatening adverse events as a result of exercise, and three or more of the following criteria were met: the recruitment rate was >50%, completion rate was >80%, median programme attendance was >75%, median exercise compliance >75%, and average tolerance was >70%.","Preliminary efficacy was assessed for objective measures of physical function (2-min step test, repeated chair stand test, 30-s push-up test, and a modified static balance test) and quality of life (QoL), fatigue and other patient-reported outcomes were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30.","RESULTS: Eleven patients (32-80\u2009years) were included in the study (6 female, 5 male).","The recruitment rate was 48%, completion rate 91%, programme attendance 88%, median exercise compliance 82.1% and 84.9% for resistance and aerobic exercise, respectively, and tolerance 88%, with no severe or life-threatening adverse events as a result of exercise.","In terms of preliminary efficacy, physical function significantly improved while QoL was maintained following the intervention.","CONCLUSION: An 8-week telehealth exercise intervention is feasible and safe for patients with advanced melanoma and appears to improve physical function while preserving QoL during checkpoint inhibitor therapy."],"Aspect":"o","Summary":"The 8-week telehealth exercise intervention was found to be feasible and safe for patients with advanced melanoma, significantly improving physical function while maintaining quality of life.","Indexes":[5,6,7],"Sentences":["The recruitment rate was 48%, completion rate 91%, programme attendance 88%, median exercise compliance 82.1% and 84.9% for resistance and aerobic exercise, respectively, and tolerance 88%, with no severe or life-threatening adverse events as a result of exercise.","In terms of preliminary efficacy, physical function significantly improved while QoL was maintained following the intervention.","CONCLUSION: An 8-week telehealth exercise intervention is feasible and safe for patients with advanced melanoma and appears to improve physical function while preserving QoL during checkpoint inhibitor therapy."],"Revise":true}
{"PMID":"33127652","Document":["PURPOSE: Increased \u03b2-adrenergic receptor (\u03b2-AR) signaling has been shown to promote the creation of an immunosuppressive tumor microenvironment (TME).","Preclinical studies have shown that abrogation of this signaling pathway, particularly \u03b22-AR, provides a more favorable TME that enhances the activity of anti-PD-1 checkpoint inhibitors.","We hypothesize that blocking stress-related immunosuppressive pathways would improve tumor response to immune checkpoint inhibitors in patients.","Here, we report the results of dose escalation of a nonselective \u03b2-blocker (propranolol) with pembrolizumab in patients with metastatic melanoma.","PATIENTS AND METHODS: A 3 + 3 dose escalation study for propranolol twice a day with pembrolizumab (200 mg every 3 weeks) was completed.","The primary objective was to determine the recommended phase II dose (RP2D).","Additional objectives included safety, antitumor activity, and biomarker analyses.","Responders were defined as patients with complete or partial response per immune-modified RECIST at 6 months.","RESULTS: Nine patients with metastatic melanoma received increasing doses of propranolol in cohorts of 10, 20, and 30 mg twice a day.","No dose-limiting toxicities were observed.","Most common treatment-related adverse events (TRAEs) were rash, fatigue, and vitiligo, observed in 44% patients.","One patient developed two grade \u22653 TRAEs.","Objective response rate was 78%.","While no significant changes in treatment-associated biomarkers were observed, an increase in IFN\u03b3 and a decrease in IL6 was noted in responders.","CONCLUSIONS: Combination of propranolol with pembrolizumab in treatment-na\u00efve metastatic melanoma is safe and shows very promising activity.","Propranolol 30 mg twice a day was selected as RP2D in addition to pembrolizumab based on safety, tolerability, and preliminary antitumor activity."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"37309702","Document":["WHAT IS THIS SUMMARY ABOUT?",": Here, we summarize the 5-year results from part 1 of the COLUMBUS clinical study, which looked at the combination treatment of encorafenib plus binimetinib in people with a specific type of skin cancer called melanoma.","Encorafenib (BRAFTOVI\u00ae) and binimetinib (MEKTOVI\u00ae) are medicines used to treat a type of melanoma that has a change in the BRAF gene, called advanced or metastatic BRAF V600-mutant melanoma.","Participants with advanced or metastatic BRAF V600-mutant melanoma took either encorafenib plus binimetinib together (COMBO group), compared with encorafenib alone (ENCO group) or vemurafenib (ZELBORAF\u00ae) alone (VEMU group).","WHAT WERE THE RESULTS?",": In this 5-year update, more participants in the COMBO group were alive for longer without their disease getting worse after 5\u00a0years than those in the VEMU and ENCO groups.","Patients in the COMBO group were alive for longer without their disease getting worse when they: Had less advanced cancer Were able to do more daily activities Had normal lactate dehydrogenase (LDH) levels Had fewer organs with tumors before treatment After treatment, fewer participants in the COMBO group received additional anticancer treatment than participants in the VEMU and ENCO groups.","The number of participants who reported severe side effects was similar for each treatment.","The side effects caused by the drugs in the COMBO group decreased over time.","WHAT DO THE RESULTS MEAN?",": Overall, this 5-year update confirmed that people with BRAF V600-mutant melanoma that has spread to other parts of the body and who took encorafenib plus binimetinib were alive for longer without their disease getting worse than those who took vemurafenib or encorafenib alone.","Clinical Trial Registration: NCT01909453 (ClinicalTrials.gov)."],"Aspect":"a","Summary":"The study aimed to evaluate the 5-year results of the combination treatment of encorafenib plus binimetinib in patients with advanced or metastatic BRAF V600-mutant melanoma.","Indexes":[1,2,3],"Sentences":[": Here, we summarize the 5-year results from part 1 of the COLUMBUS clinical study, which looked at the combination treatment of encorafenib plus binimetinib in people with a specific type of skin cancer called melanoma.","Encorafenib (BRAFTOVI\u00ae) and binimetinib (MEKTOVI\u00ae) are medicines used to treat a type of melanoma that has a change in the BRAF gene, called advanced or metastatic BRAF V600-mutant melanoma.","Participants with advanced or metastatic BRAF V600-mutant melanoma took either encorafenib plus binimetinib together (COMBO group), compared with encorafenib alone (ENCO group) or vemurafenib (ZELBORAF\u00ae) alone (VEMU group)."],"Revise":false}
{"PMID":"33668679","Document":["Urine autofluorescence at 295 nm is significantly higher in patients with malignant melanoma at each clinical stage compared to the healthy group.","The largest difference is in the early-stages and without metastases.","With increasing stage, the autofluorescence at 295 nm decreases.","There is also a significant negative correlation between autofluorescence and Clark classification.","Based on our results, it is assumed that the way malignant melanoma grows also affects urinary autofluorescence."],"Aspect":"i","Summary":"The study measured urine autofluorescence at 295 nm in patients with malignant melanoma at various clinical stages and compared it to a healthy group.","Indexes":[0],"Sentences":["Urine autofluorescence at 295 nm is significantly higher in patients with malignant melanoma at each clinical stage compared to the healthy group."],"Revise":false}
{"PMID":"32591862","Document":["BACKGROUND: Autologous monocyte-derived mRNA co-electroporated dendritic cells with mRNA encoding CD40 ligand (CD40L), CD70 and a constitutively activated TLR4 (caTLR4) (referred to as TriMixDC-MEL) have anti-tumor activity in advanced melanoma patients.","We investigated the safety and activity of adjuvant TriMixDC-MEL in stage III\/IV melanoma patients.","MATERIALS AND METHODS: Forty-one patients were randomly assigned to treatment with TriMixDC-MEL (n\u2009=\u200921) and standard follow-up (n\u2009=\u200920).","\"Cross-over\" was allowed at the time of non-salvageable recurrence.","The primary endpoint was the percentage of patients alive and disease-free at 1-year.","For a subset of patients, (formalin-fixed paraffin-embedded), tumor tissue samples were available for mRNA expression profiling and PD-L1 immunohistochemical staining.","RESULTS: Baseline characteristics were well balanced.","One-year after randomization, 71% of patients in the study arm were alive and free of disease compared to 35% in the control arm.","After a median follow-up of 53\u00a0months (range 3-67), 23 patients experienced a non-salvageable melanoma recurrence (TriMixDC-Mel arm n\u2009=\u20099 and control arm n\u2009=\u200914).The median time to non-salvageable recurrence was superior in the TriMixDC-MEL arm (median 8\u00a0months (range 1-6) vs. not reached; log-rank p 0.044).","TriMixDC-MEL-related adverse events (AE) consisted of transient local skin reactions, flu-like symptoms and post-infusion chills.","No grade\u2009\u2265\u20093 AE's occurred.","The mRNA expression profiling revealed four genes (STAT2, TPSAB1, CD9 and CSF2) as potential predictive biomarkers.","CONCLUSION: TriMixDC-MEL id\/iv as adjuvant therapy is tolerable and may improve the 1-year disease-free survival rate.","Combination of optimized autologous monocyte-derived DC-formulations warrants further investigation in combination with currently approved adjuvant therapy options."],"Aspect":"p","Summary":"The study involved 41 patients with stage III\/IV melanoma, randomly assigned to two groups: 21 to treatment with TriMixDC-MEL and 20 to standard follow-up.","Indexes":[2],"Sentences":["MATERIALS AND METHODS: Forty-one patients were randomly assigned to treatment with TriMixDC-MEL (n\u2009=\u200921) and standard follow-up (n\u2009=\u200920)."],"Revise":false}
{"PMID":"37103470","Document":["In phase III trials, ipilimumab plus nivolumab combination therapy is highly efficacious for advanced melanoma, despite many treatment-related grades 3-4 adverse events.","Here, we report real-world safety and survival outcomes of ipilimumab plus nivolumab for advanced melanoma.","Patients with advanced melanoma who received first-line ipilimumab plus nivolumab between January 1, 2015 and June 30, 2021 were selected from the Dutch Melanoma Treatment Registry.","We evaluated response status at 3, 6, 12, 18, and 24 months.","OS and PFS were estimated with the Kaplan-Meier method.","Separate analyses were performed for patients with or without brain metastases and for patients who met the inclusion criteria of the Checkmate-067 trial.","In total, 709 patients received first-line ipilimumab plus nivolumab.","Three hundred sixty (50.7%) patients experienced grade 3-4 adverse events, with 211 of the (58.6%) patients requiring hospital admission.","The median treatment duration was 42 days (IQR = 31-139).","At 24 months, disease control was achieved in 37% of patients.","Median PFS since the start of treatment was 6.6 months (95% CI: 5.3-8.7), and median OS was 28.7 months (95% CI: 20.7-42.2).","CheckMate-067 trial-like patients had a 4-year OS of 50% (95% CI: 43-59).","Among patients with no asymptomatic or symptomatic brain metastases, the 4-year OS probabilities were 48% (95% CI: 41-55), 45% (95% CI: 35-57), and 32% (95% CI: 23-46).","Ipilimumab plus nivolumab can achieve long-term survival in advanced melanoma patients in a real-world setting, including patients not represented in the CheckMate-067 trial.","However, the proportion of patients with disease control in the real world is lower compared with clinical trials."],"Aspect":"a","Summary":"The study aims to evaluate real-world safety and survival outcomes of ipilimumab plus nivolumab for advanced melanoma.","Indexes":[1],"Sentences":["Here, we report real-world safety and survival outcomes of ipilimumab plus nivolumab for advanced melanoma."],"Revise":false}
{"PMID":"38167503","Document":["No prospective data were available prior to 2021 to inform selection between combination BRAF and MEK inhibition versus dual blockade of programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) as first-line treatment options for BRAFV600-mutant melanoma.","SECOMBIT (NCT02631447) was a randomized, three-arm, noncomparative phase II trial in which patients were randomized to one of two sequences with immunotherapy or targeted therapy first, with a third arm in which an 8-week induction course of targeted therapy followed by a planned switch to immunotherapy was the first treatment.","BRAF\/MEK inhibitors were encorafenib plus binimetinib and checkpoint inhibitors ipilimumab plus nivolumab.","Primary outcome of overall survival was previously reported, demonstrating improved survival with immunotherapy administered until progression and followed by BRAF\/MEK inhibition.","Here we report 4-year survival outcomes, confirming long-term benefit with first-line immunotherapy.","We also describe preliminary results of predefined biomarkers analyses that identify a trend toward improved 4-year overall survival and total progression-free survival in patients with loss-of-function mutations affecting JAK or low baseline levels of serum interferon gamma (IFNy).","These long-term survival outcomes confirm immunotherapy as the preferred first-line treatment approach for most patients with BRAFV600-mutant metastatic melanoma, and the biomarker analyses are hypothesis-generating for future investigations of predictors of durable benefit with dual checkpoint blockade and targeted therapy."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"34764195","Document":["UNLABELLED: We conducted a randomized phase III trial to evaluate whether adjuvant pembrolizumab for one year (647 patients) improved recurrence-free survival (RFS) or overall survival (OS) in comparison with high-dose IFN\u03b1-2b for one year or ipilimumab for up to three years (654 patients), the approved standard-of-care adjuvant immunotherapies at the time of enrollment for patients with high-risk resected melanoma.","At a median follow-up of 47.5 months, pembrolizumab was associated with significantly longer RFS than prior standard-of-care adjuvant immunotherapies [HR, 0.77; 99.62% confidence interval (CI), 0.59-0.99; P = 0.002].","There was no statistically significant association with OS among all patients (HR, 0.82; 96.3% CI, 0.61-1.09; P = 0.15).","Proportions of treatment-related adverse events of grades 3 to 5 were 19.5% with pembrolizumab, 71.2% with IFN\u03b1-2b, and 49.2% with ipilimumab.","Therefore, adjuvant pembrolizumab significantly improved RFS but not OS compared with the prior standard-of-care immunotherapies for patients with high-risk resected melanoma.","SIGNIFICANCE: Adjuvant PD-1 blockade therapy decreases the rates of recurrence, but not survival, in patients with surgically resectable melanoma, substituting the prior standard-of-care immunotherapies for this cancer.","See related commentary by Smithy and Shoushtari, p. 599.","This article is highlighted in the In This Issue feature, p. 587."],"Aspect":"o","Summary":"Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) but not overall survival (OS) compared with prior standard-of-care immunotherapies for patients with high-risk resected melanoma.","Indexes":[1,2,4],"Sentences":["At a median follow-up of 47.5 months, pembrolizumab was associated with significantly longer RFS than prior standard-of-care adjuvant immunotherapies [HR, 0.77; 99.62% confidence interval (CI), 0.59-0.99; P = 0.002].","There was no statistically significant association with OS among all patients (HR, 0.82; 96.3% CI, 0.61-1.09; P = 0.15).","Therefore, adjuvant pembrolizumab significantly improved RFS but not OS compared with the prior standard-of-care immunotherapies for patients with high-risk resected melanoma."],"Revise":false}
{"PMID":"34818112","Document":["PURPOSE: In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab.","Here, we report 6.5-year efficacy and safety outcomes.","PATIENTS AND METHODS: Patients with previously untreated unresectable stage III or stage IV melanoma were randomly assigned 1:1:1 to receive nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg once every 3 weeks (four doses) followed by nivolumab 3 mg\/kg once every 2 weeks (n = 314), nivolumab 3 mg\/kg once every 2 weeks (n = 316), or ipilimumab 3 mg\/kg once every 3 weeks (four doses; n = 315).","Coprimary end points were progression-free survival and overall survival (OS) with nivolumab plus ipilimumab or nivolumab versus ipilimumab.","Secondary end points included objective response rate, descriptive efficacy assessments of nivolumab plus ipilimumab versus nivolumab alone, and safety.","Melanoma-specific survival (MSS; descriptive analysis), which excludes deaths unrelated to melanoma, was also evaluated.","RESULTS: Median OS (minimum follow-up, 6.5 years) was 72.1, 36.9, and 19.9 months in the combination, nivolumab, and ipilimumab groups, respectively.","Median MSS was not reached, 58.7, and 21.9 months, respectively; 6.5-year OS rates were 57%, 43%, and 25% in patients with BRAF-mutant tumors and 46%, 42%, and 22% in those with BRAF-wild-type tumors, respectively.","In patients who discontinued treatment, the median treatment-free interval was 27.6, 2.3, and 1.9 months, respectively.","Since the 5-year analysis, no new safety signals were observed.","CONCLUSION: These 6.5-year CheckMate 067 results, which include the longest median OS in a phase III melanoma trial reported to date and the first report of MSS, showed durable, improved clinical outcomes with nivolumab plus ipilimumab or nivolumab versus ipilimumab in patients with advanced melanoma and, in descriptive analyses, with the combination over nivolumab monotherapy."],"Aspect":"i","Summary":"Patients with previously untreated unresectable stage III or stage IV melanoma were randomly assigned to receive nivolumab plus ipilimumab, nivolumab alone, or ipilimumab alone.","Indexes":[2],"Sentences":["PATIENTS AND METHODS: Patients with previously untreated unresectable stage III or stage IV melanoma were randomly assigned 1:1:1 to receive nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg once every 3 weeks (four doses) followed by nivolumab 3 mg\/kg once every 2 weeks (n = 314), nivolumab 3 mg\/kg once every 2 weeks (n = 316), or ipilimumab 3 mg\/kg once every 3 weeks (four doses; n = 315)."],"Revise":false}
{"PMID":"33715172","Document":["We report the 5-year follow-up results from a single-arm, open-label, multicenter phase II study (ONO-4538-08) conducted in Japan.","Twenty-four patients with treatment-na\u00efve, recurrent, or unresectable stage III\/IV malignant melanoma received 3\u00a0mg\/kg nivolumab every 2\u00a0weeks until progressive disease or unacceptable toxicity occurred.","The 5-year overall survival (OS) rate was 26.1%.","Five years after the start of nivolumab treatment, there were six survivors.","The 5-year OS rate was 66.7% for patients with a superficial spreading type, 14.3% for acral lentiginous type, and 16.7% for mucosal type.","The 5-year progression-free survival rate was 17.2%.","No new cases of partial response or complete response were observed after 3\u00a0years, and overall response and disease control rates were similar to those reported at 3\u00a0years.","The treatment-related adverse events reported between the 3- and 5-year follow-up periods were anemia (grade 2), white blood cell count decrease (grade 2), and psoriasiform dermatitis (grade 2) in one patient each.","No new grade 3 or higher treatment-related adverse events occurred in this period.","In conclusion, first-line treatment with nivolumab in Japanese patients with unresectable or metastatic melanoma resulted in confirmed long-term survival.","No new safety signals were reported in the studied population."],"Aspect":"i","Summary":"Twenty-four patients with treatment-na\u00efve, recurrent, or unresectable stage III\/IV malignant melanoma received 3 mg\/kg nivolumab every 2 weeks until progressive disease or unacceptable toxicity occurred in a single-arm, open-label, multicenter phase II study.","Indexes":[0,1],"Sentences":["We report the 5-year follow-up results from a single-arm, open-label, multicenter phase II study (ONO-4538-08) conducted in Japan.","Twenty-four patients with treatment-na\u00efve, recurrent, or unresectable stage III\/IV malignant melanoma received 3\u00a0mg\/kg nivolumab every 2\u00a0weeks until progressive disease or unacceptable toxicity occurred."],"Revise":false}
{"PMID":"36753834","Document":["BACKGROUND: At present, immune monotherapy and combination therapy has not shown satisfactory effects on acral melanoma, and still no standard treatment is available for advanced acral melanoma.","Here, a phase II trial was performed to explore the safety and efficacy of apatinib combined with camrelizumab in advanced acral melanoma patients as first-line therapy (NCT03955354).","METHODS: Patients with pathologically confirmed, locally unresectable or metastatic treatment native acral melanoma received 250\u00a0mg apatinib once daily and camrelizumab 200\u00a0mg once every two weeks intravenously every 28-day cycle.","The primary end-point was objective response rate and the secondary end-points were disease control rate, overall survival, progression-free survival\u00a0and safety.","RESULTS: Thirty patients were recruited between January 2015 and January 2022.","Among them, 21 (70.0%) had stage IV, and a median tumour burden was 50\u00a0mm (range: 11-187).","Objective response rate was 24.1%, and 7 of 29 patients had an anti-tumour response, including partial response (n\u00a0=\u00a05) and complete response (n\u00a0=\u00a02).","Disease control rate was 82.8%, median progression-free survival was 7.39 months (confidence interval: 3.65-9.92), and median overall survival was 13.4 months (confidence interval: 1.9-25.0).","Grade 3-4 treatment-related toxicity (grade 3 50.5%; grade 4 3.3%) included transaminase elevations, proteinuria, leukocytopenia, vomiting, diarrhea and drug-induced liver injury.","No treatment-related mortality occurred.","The mutations of TTN, MUC16, VPS13D, ALPK2 and SCUBE1 showed significant alterations with survival outcome.","CONCLUSIONS: Apatinib combined with camrelizumab showed manageable safety profile and reasonable anti-tumour activity in advanced acral melanoma patients as first-line therapy."],"Aspect":"s","Summary":"Grade 3-4 treatment-related toxicity included transaminase elevations, proteinuria, leukocytopenia, vomiting, diarrhea, and drug-induced liver injury.","Indexes":[8],"Sentences":["Grade 3-4 treatment-related toxicity (grade 3 50.5%; grade 4 3.3%) included transaminase elevations, proteinuria, leukocytopenia, vomiting, diarrhea and drug-induced liver injury."],"Revise":false}
{"PMID":"34400899","Document":["Plant tissue culture holds immense potential for the production of secondary metabolites with various physiological functions.","We recently established a plant tissue culture system capable of producing secondary metabolites from Aster yomena.","This study aimed to uncover the mechanisms underlying the potential therapeutic effects of Aster yomena callus pellet extract (AYC-P-E) on photoaging-induced skin pigmentation.","Excessive melanogenesis was induced in B16F10 melanoma cells using \u03b1-melanocyte stimulating hormone (\u03b1-MSH).","The effects of AYC-P-E treatment on melanin biosynthesis inducers and melanin synthesis inhibition were assessed.","Based on the results, a clinical study was conducted in subjects with skin pigmentation.","AYC-P-E inhibited melanogenesis in \u03b1-MSH-treated B16F10 cells, accompanied by decreased mRNA and protein expression of melanin biosynthesis inducers, including cyclic AMP response element-binding protein (CREB), tyrosinase, microphthalmia-associated transcription factor (MITF), tyrosinase related protein-1 (TRP-1), and TRP-2.","This anti-melanogenic effect was mediated by mitogen-activated protein kinase (MEK)\/extracellular signal-regulated kinase (ERK) and protein kinase B (AKT) phosphorylation.","Treatment of subjects with skin pigmentation with AYC-P-E-containing cream formulations resulted in 3.33%, 7.06%, and 8.68% improvement in the melanin levels at 2, 4, and 8 weeks, respectively.","Our findings suggest that AYC-P-E inhibits excessive melanogenesis by activating MEK\/ERK and AKT signaling, potentiating its cosmetic applications in hyperpigmentation treatment."],"Aspect":"i","Summary":"The study assessed the effects of Aster yomena callus pellet extract (AYC-P-E) on melanogenesis in \u03b1-MSH-treated B16F10 cells and conducted a clinical study on subjects with skin pigmentation using AYC-P-E-containing cream formulations.","Indexes":[3,4,5,8],"Sentences":["Excessive melanogenesis was induced in B16F10 melanoma cells using \u03b1-melanocyte stimulating hormone (\u03b1-MSH).","The effects of AYC-P-E treatment on melanin biosynthesis inducers and melanin synthesis inhibition were assessed.","Based on the results, a clinical study was conducted in subjects with skin pigmentation.","Treatment of subjects with skin pigmentation with AYC-P-E-containing cream formulations resulted in 3.33%, 7.06%, and 8.68% improvement in the melanin levels at 2, 4, and 8 weeks, respectively."],"Revise":false}
{"PMID":"33771853","Document":["PURPOSE: As hypoxia can mediate resistance to immunotherapy, we investigated the safety, tolerability, and efficacy of combining evofosfamide, a prodrug that alleviates hypoxia, with ipilimumab, an immune checkpoint inhibitor, in immunologically \"cold\" cancers, which are intrinsically insensitive to immunotherapy, as well as in \"hot\/warm\" metastatic cancers that are, atypical of such cancers, resistant to immunotherapy.","PATIENTS AND METHODS: In a phase I, 3+3 dose-escalation trial (NCT03098160), evofosfamide (400-640 mg\/m2) and ipilimumab (3 mg\/kg) were administered in four 3-week cycles.","The former was administered on days 1 and 8 of cycles 1-2, while the latter was administered on day 8 of cycles 1-4.","Response was assessed using immune-related RECIST and retreatment was allowed, if deemed beneficial, after completion of cycle 4 or at progression.","RESULTS: Twenty-two patients were enrolled, of whom 21 were evaluable, encompassing castration-resistant prostate cancer (n = 11), pancreatic cancer (n = 7), immunotherapy-resistant melanoma (n = 2), and human papillomavirus-negative head and neck cancer (n = 1).","Drug-related hematologic toxicities, rash, fever, nausea, vomiting, and elevation of liver enzymes were observed in > 10% of patients.","The most common drug-related grade 3 adverse event was alanine aminotransferase elevation (33.3%).","Two patients discontinued ipilimumab and 4 required evofosfamide deescalation due to toxicity.","Of 18 patients with measurable disease at baseline, 3 (16.7%) achieved partial response and 12 (66.7%) achieved stable disease.","The best responses were observed at 560 mg\/m2 evofosfamide.","Preexisting immune gene signatures predicted response to therapy, while hypermetabolic tumors predicted progression.","Responders also showed improved peripheral T-cell proliferation and increased intratumoral T-cell infiltration into hypoxia.","CONCLUSIONS: No new or unexpected safety signals were observed from combining evofosfamide and ipilimumab, and evidence of therapeutic activity was noted."],"Aspect":"p","Summary":"The study enrolled 22 patients with various cancers, including 11 with castration-resistant prostate cancer, 7 with pancreatic cancer, 2 with immunotherapy-resistant melanoma, and 1 with human papillomavirus-negative head and neck cancer.","Indexes":[4],"Sentences":["RESULTS: Twenty-two patients were enrolled, of whom 21 were evaluable, encompassing castration-resistant prostate cancer (n = 11), pancreatic cancer (n = 7), immunotherapy-resistant melanoma (n = 2), and human papillomavirus-negative head and neck cancer (n = 1)."],"Revise":false}
{"PMID":"36215121","Document":["PURPOSE: Metastatic melanoma is a tumor amenable to immunotherapy in part due to the presence of antigen-specific tumor-infiltrating lymphocytes (TIL).","These T cells can be activated and expanded for adoptive cell transfer (ACT), which has resulted in relatively high rates of clinical responses.","Similarly, immune checkpoint inhibitors, specifically programmed cell death protein 1 (PD-1) blocking antibodies, augment antitumor immunity and increase the influx of T cells into tumors.","Thus, we hypothesized that addition of PD-1 inhibition may improve the outcomes for patients undergoing ACT with TILs.","PATIENTS AND METHODS: Patients with stage III\/IV metastatic melanoma with unresectable disease who were anti-PD-1 treatment-na\u00efve were enrolled.","TILs were generated in the presence of anti-4-1BB antibody in vitro and expanded for ACT.","Patients in cohort 1 received TIL infusion followed by nivolumab.","Patients in cohort 2 also received nivolumab prior to surgical harvest and during TIL production.","RESULTS: A total of 11 patients were enrolled, all of whom were evaluated for response, and nine completed ACT.","Predominantly CD8+ TILs were successfully expanded from all ACT-treated patients and were tumor reactive in vitro.","The trial met its safety endpoint, as there were no protocol-defined dose-limiting toxicity events.","The objective response rate was 36%, and median progression-free survival was 5 months.","Two nonresponders who developed new metastatic lesions were analyzed to determine potential mechanisms of therapeutic resistance, which included clonal divergence and intrinsic TIL dysfunction.","CONCLUSIONS: Combination therapy with TILs and nivolumab was safe and feasible for patients with metastatic melanoma and provides important insights for future therapeutic developments in ACT with TILs."],"Aspect":"s","Summary":"The trial met its safety endpoint, as there were no protocol-defined dose-limiting toxicity events.","Indexes":[10],"Sentences":["The trial met its safety endpoint, as there were no protocol-defined dose-limiting toxicity events."],"Revise":false}
{"PMID":"32761987","Document":["BACKGROUND: Compared with other cancers, melanoma has the longest delays measured as the median time to patient presentation for care from symptom onset.","Time to presentation for care is a key determinant of outcomes, including disease stage, prognosis, and treatment.","METHODS: Melanoma survivors with localized disease and their skin check partners enrolled in two sequential randomized control trials of skin self-examination (SSE) training.","In Phase 1, the pair read a workbook in the office and had quarterly total body skin examinations with a study dermatologist.","In Phase 2, materials were mailed to pairs, whose surveillance was with a community physician.","SSE knowledge, performance (frequency and extent), and identification of concerning moles were compared between phases.","RESULTS: Among 341 patients, 197 received the workbook and the others were controls.","Knowledge in performing SSE was higher for the workbook relative to controls in both phases.","The SSE frequency ranged from 2.38 to 5.97 times in 9\u00a0months.","Patients randomized to the workbook in both phases performed significantly more SSE than controls at 9\u00a0months (P\u00a0<\u00a0.05).","In both phases, trained survivors performed significantly more SSEs on the scalp than controls at 9 and 18\u00a0months (P\u00a0<\u00a0.05).","Phase 1 survivors performed significantly more SSEs on the abdomen, buttocks, and soles of the feet than controls, but this did not occur in Phase 2.","Finally, in both phases, survivors trained with the workbook resulted in greater detection of suspicious lesions and melanomas.","CONCLUSIONS: These findings justify the benefits of remote SSE training for patients as an adjunct to provider-administered screening."],"Aspect":"p","Summary":"The study involved 341 melanoma survivors with localized disease, with 197 receiving a workbook and the others serving as controls.","Indexes":[6],"Sentences":["RESULTS: Among 341 patients, 197 received the workbook and the others were controls."],"Revise":false}
{"PMID":"32147213","Document":["BACKGROUND: Interleukin 12 (IL-12) is a pivotal regulator of innate and adaptive immunity.","We conducted a prospective open-label, phase II clinical trial of electroporated plasmid IL-12 in advanced melanoma patients (NCT01502293).","PATIENTS AND METHODS: Patients with stage III\/IV melanoma were treated intratumorally with plasmid encoding IL-12 (tavokinogene telseplasmid; tavo), 0.5 mg\/ml followed by electroporation (six pulses, 1500 V\/cm) on days 1, 5, and 8 every 90 days in the main study and additional patients were treated in two alternative schedule exploration cohorts.","Correlative analyses for programmed death-ligand 1 (PD-L1), flow cytometry to assess changes in immune cell subsets, and analysis of immune-related gene expression were carried out on pre- and post-treatment samples from study patients, as well as from additional patients treated during exploration of additional dosing schedules beyond the pre-specified protocol dosing schedule.","Response was measured by study-specific criteria to maximize detection of latent and potentially transient immune responses in patients with multiple skin lesions and toxicities were graded by the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0).","RESULTS: The objective overall response rate was 35.7% in the main study (29.8% in all cohorts), with a complete response rate of 17.9% (10.6% in all cohorts).","The median progression-free survival in the main study was 3.7 months while the median overall survival was not reached at a median follow up of 29.7 months.","A total of 46% of patients in all cohorts with uninjected lesions experienced regression of at least one of these lesions and 25% had a net regression of all untreated lesions.","Transcriptomic and immunohistochemistry analysis showed that immune activation and co-stimulatory transcripts were up-regulated but there was also increased adaptive immune resistance.","CONCLUSIONS: Intratumoral Tavo was well tolerated and led to systemic immune responses in advanced melanoma patients.","While tumor regression and increased immune infiltration were observed in treated as well as untreated\/distal lesions, adaptive immune resistance limited the response."],"Aspect":"i","Summary":"Patients with stage III\/IV melanoma were treated intratumorally with plasmid encoding IL-12 followed by electroporation on days 1, 5, and 8 every 90 days.","Indexes":[2],"Sentences":["PATIENTS AND METHODS: Patients with stage III\/IV melanoma were treated intratumorally with plasmid encoding IL-12 (tavokinogene telseplasmid; tavo), 0.5 mg\/ml followed by electroporation (six pulses, 1500 V\/cm) on days 1, 5, and 8 every 90 days in the main study and additional patients were treated in two alternative schedule exploration cohorts."],"Revise":true}
{"PMID":"33744385","Document":["BACKGROUND: Guidelines for pathological evaluation of neoadjuvant specimens and pathological response categories have been developed by the International Neoadjuvant Melanoma Consortium (INMC).","As part of the Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo) clinical trial of neoadjuvant combination anti-programmed cell death protein 1\/anti-cytotoxic T-lymphocyte-associated protein 4 immunotherapy for stage III melanoma, we sought to determine interobserver reproducibility of INMC histopathological assessment principles, identify specific tumour bed histopathological features of immunotherapeutic response that correlated with recurrence and relapse-free survival (RFS) and evaluate proposed INMC pathological response categories for predicting recurrence and RFS.","PATIENTS AND METHODS: Clinicopathological characteristics of lymph node dissection specimens of 83 patients enrolled in the OpACIN-neo clinical trial were evaluated.","Two methods of assessing histological features of immunotherapeutic response were evaluated: the previously described immune-related pathologic response (irPR) score and our novel immunotherapeutic response score (ITRS).","For a subset of cases (n\u00a0= 29), cellular composition of the tumour bed was analysed by flow cytometry.","RESULTS: There was strong interobserver reproducibility in assessment of pathological response (\u03ba\u00a0= 0.879) and percentage residual viable melanoma (intraclass correlation coefficient\u00a0= 0.965).","The immunotherapeutic response subtype with high fibrosis had the strongest association with lack of recurrence (P\u00a0= 0.008) and prolonged RFS (P\u00a0= 0.019).","Amongst patients with criteria for pathological non-response (pNR, >50% viable tumour), all who recurred had \u226570% viable melanoma.","Higher ITRS and irPR scores correlated with lack of recurrence in the entire cohort (P\u00a0= 0.002 and P \u2264 0.0001).","The number of B lymphocytes was significantly increased in patients with a high fibrosis subtype of treatment response (P\u00a0= 0.046).","CONCLUSIONS: There is strong reproducibility for assessment of pathological response using INMC criteria.","Immunotherapeutic response of fibrosis subtype correlated with improved RFS, and may represent a biomarker.","Potential B-cell contribution to fibrosis development warrants further study.","Reclassification of pNR to a threshold of \u226570% viable melanoma and incorporating additional criteria of <10% fibrosis subtype of response may identify those at highest risk of recurrence, but requires validation."],"Aspect":"p","Summary":"The study involved 83 patients with stage III melanoma enrolled in the OpACIN-neo clinical trial.","Indexes":[2],"Sentences":["PATIENTS AND METHODS: Clinicopathological characteristics of lymph node dissection specimens of 83 patients enrolled in the OpACIN-neo clinical trial were evaluated."],"Revise":false}
{"PMID":"36596029","Document":["Skin malignant melanoma is one of the most aggressive skin tumors.","Superficial spreading melanoma (SSM) is the most common histological type, which can originate from different body skin sites, and some patients can still accumulate regional lymph nodes and even have distant metastasis in some cases.","This study used the relevant data from the monitoring, epidemiology and results database of the National Cancer Institute database to study the overall survival (OS) and cancer-specific survival (CSS) of SSM patients and established an SSM nomogram to evaluate the prognosis of patients.","A total of 13,922 patients were collected from the monitoring, epidemiology and results database of the National Cancer Institute and randomly divided into a training cohort (8353 cases) and a validation cohort (5569 cases).","Univariate and multivariate Cox regression analysis were used to determine prognostic factors, and these factors were used to construct OS and CSS nomograms for patients with SSM.","Finally, the discrimination and consistency of the nomogram model were evaluated by the consistency index (C-index), area under the curve (AUC) and calibration curve.","Multivariate Cox regression analysis suggested that age, sex, tumor site, the American joint committee on cancer T stage and the first primary melanoma were independent predictors of OS and CSS in patients with SSM and that the American joint committee on cancer N stage was also an independent predictor of CSS in patients with SSM.","Based on the above prognostic factors, this study constructed a predictive model.","The C-index of the model OS and CSS for this training cohort was 0.805 [95% CI: 0.793-0.817] and 0.896 [95% CI: 0.878-0.913], respectively.","The AUC values for 1-, 3-, and 5-year OS were 0.822, 0.820, and 0.821, respectively, and the AUC values for CSS were 0.914, 0.922, and 0.893, respectively.","The data indicated that both nomograms showed better predictive accuracy.","The calibration curves of the training cohort and the validation cohort were in good agreement.","The nomogram has superior predictive performance in predicting 1-, 3-, and 5-year OS and CSS prognosis in patients with SSM and can provide a reference for individualized treatment and clinical counseling of SSM."],"Aspect":"m","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"34295326","Document":["There is limited experience of PD-1 antibody combined with other therapies in children.","We aimed to explore the antitumor activity and safety of PD-1 antibody monotherapy or combination with other regimens in relapsed or refractory pediatric cancer.","This is a retrospective-case study conducted in two Chinese expert centers.","The primary objective of this study was to describe the overall response rate (ORR) and disease control rate (DCR).","Secondary objectives included characterizing toxicities.","Of the 22 pediatric patients with cancer who received PD-1 inhibitors, the median follow-up for all patients after the commencement of PD-1 therapy with or without other regimens was 12.3 months (0 - 43 months).","PD-1 antibody monotherapy demonstrated antitumor activity in a population of pediatric patients with Hodgkin lymphoma (HL), with an objective response rate (ORR) and disease control rate (DCR) of 83.3% (3CR and 2PR) and 100%, respectively.","However, no objective response was observed in patients with melanoma or Burkitt lymphoma evaluated in this study.","We reviewed responses for patients with chemotherapy, decitabine or everolimus combination therapies with PD-1 antibodies, and found that PD-1 antibody combined with decitabine showed potential efficacy in pediatric patients with advanced embryonal rhabdomyosarcoma and lymphoepitheliomatoid-like carcinoma.","There were no severe treatment-related adverse events (TRAEs) directly attributed to PD-1 antibody monotherapy in Asian pediatric patients with lower incidence of hematologic toxicity and nonhematologic toxicity.","The Grade \u22653 TRAEs were attributed to the combination chemotherapy."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"35156519","Document":["Macroautophagy\/autophagy is a resistance mechanism to targeted therapy in BRAF mutant cancers.","Preclinical evidence and clinical trial data demonstrate that hydroxychloroquine (HCQ) is an effective autophagy inhibitor at clinically achievable concentrations.","Here we highlight the results of a recently published single-arm phase I\/II multi-institution trial of dabrafenib, trametinib, and the autophagy inhibitor HCQ (the BAMM trial) that established the safety and activity of this regimen in BRAF V600-mutant melanoma patients.","Compared to the pivotal trials that led to FDA approval of dabrafenib and trametinib, the BAMM trial enrolled a high percentage of patients with elevated LDH and prior immunotherapy, reflecting the trend that poorer-prognosis patients are treated with targeted therapy in the modern era where multiple immunotherapy regimens are available for melanoma.","Dabrafenib, trametinib, and hydroxychloroquine are safe and produce a high response rate (85%).","Progression-free survival does not meet the pre-specified threshold for the entire cohort but looks especially promising in patients with elevated LDH and prior treatment.","A national randomized study has been launched to study this regimen further in poor-prognosis BRAF V600-mutant melanoma patients."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"32995974","Document":["OBJECTIVES: To compare tumor best overall response (BOR) by RECIST 1.1 and iRECIST, to explore the incidence of pseudoprogression in melanoma treated with pembrolizumab, and to assess the impact of pseudoprogression on overall survival (OS).","METHODS: A total of 221 patients with locally advanced\/unresectable melanoma who received pembrolizumab as part of KEYNOTE-002 trial were included in this study.","Radiological assessment of imaging was centrally reviewed to assess tumor response.","Incidence of discordance in BOR between RECIST 1.1 and iRECIST as well as rate of pseudoprogression were measured.","OS of patients with pseudoprogression was compared with that of those with uncontrolled disease.","RESULTS: Of the 221 patients in this cohort, 136 patients developed PD as per RECIST v1.1 and 78 patients with PD continued treatment and imaging beyond initial RECIST 1.1-defined PD.","Among the 78 patients who continued therapy and imaging post-progression, RECIST 1.1 and iRECIST were discordant in 10 patients (12.8%) and pseudoprogression was encountered in 14 patients (17.9%).","OS of patients with pseudoprogression was longer than that of patients with uncontrolled disease\/true progression (29.9\u00a0months versus 8.0\u00a0months, p value <\u20090.001).","CONCLUSIONS: Effectiveness of immunotherapy in clinical trials depends on the criterion used to assess tumor response (RECIST 1.1 vs iRECIST) with iRECIST being more appropriate to detect pseudoprogression and potentially prevent premature termination of effective therapy.","Pseudoprogression was associated with improved OS in comparison with that of patients with uncontrolled disease.","KEY POINTS: \u2022 Discordance between iRECIST and RECIST 1.1 was found in 12.8% of unresectable melanoma patients on pembrolizumab who continued therapy beyond initial RECIST 1.1-defined progression.","\u2022 Pseudoprogression, captured with iRECIST, occurred in 17.9% and was significantly associated with improved overall survival in comparison with uncontrolled disease."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"34400899","Document":["Plant tissue culture holds immense potential for the production of secondary metabolites with various physiological functions.","We recently established a plant tissue culture system capable of producing secondary metabolites from Aster yomena.","This study aimed to uncover the mechanisms underlying the potential therapeutic effects of Aster yomena callus pellet extract (AYC-P-E) on photoaging-induced skin pigmentation.","Excessive melanogenesis was induced in B16F10 melanoma cells using \u03b1-melanocyte stimulating hormone (\u03b1-MSH).","The effects of AYC-P-E treatment on melanin biosynthesis inducers and melanin synthesis inhibition were assessed.","Based on the results, a clinical study was conducted in subjects with skin pigmentation.","AYC-P-E inhibited melanogenesis in \u03b1-MSH-treated B16F10 cells, accompanied by decreased mRNA and protein expression of melanin biosynthesis inducers, including cyclic AMP response element-binding protein (CREB), tyrosinase, microphthalmia-associated transcription factor (MITF), tyrosinase related protein-1 (TRP-1), and TRP-2.","This anti-melanogenic effect was mediated by mitogen-activated protein kinase (MEK)\/extracellular signal-regulated kinase (ERK) and protein kinase B (AKT) phosphorylation.","Treatment of subjects with skin pigmentation with AYC-P-E-containing cream formulations resulted in 3.33%, 7.06%, and 8.68% improvement in the melanin levels at 2, 4, and 8 weeks, respectively.","Our findings suggest that AYC-P-E inhibits excessive melanogenesis by activating MEK\/ERK and AKT signaling, potentiating its cosmetic applications in hyperpigmentation treatment."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"33771853","Document":["PURPOSE: As hypoxia can mediate resistance to immunotherapy, we investigated the safety, tolerability, and efficacy of combining evofosfamide, a prodrug that alleviates hypoxia, with ipilimumab, an immune checkpoint inhibitor, in immunologically \"cold\" cancers, which are intrinsically insensitive to immunotherapy, as well as in \"hot\/warm\" metastatic cancers that are, atypical of such cancers, resistant to immunotherapy.","PATIENTS AND METHODS: In a phase I, 3+3 dose-escalation trial (NCT03098160), evofosfamide (400-640 mg\/m2) and ipilimumab (3 mg\/kg) were administered in four 3-week cycles.","The former was administered on days 1 and 8 of cycles 1-2, while the latter was administered on day 8 of cycles 1-4.","Response was assessed using immune-related RECIST and retreatment was allowed, if deemed beneficial, after completion of cycle 4 or at progression.","RESULTS: Twenty-two patients were enrolled, of whom 21 were evaluable, encompassing castration-resistant prostate cancer (n = 11), pancreatic cancer (n = 7), immunotherapy-resistant melanoma (n = 2), and human papillomavirus-negative head and neck cancer (n = 1).","Drug-related hematologic toxicities, rash, fever, nausea, vomiting, and elevation of liver enzymes were observed in > 10% of patients.","The most common drug-related grade 3 adverse event was alanine aminotransferase elevation (33.3%).","Two patients discontinued ipilimumab and 4 required evofosfamide deescalation due to toxicity.","Of 18 patients with measurable disease at baseline, 3 (16.7%) achieved partial response and 12 (66.7%) achieved stable disease.","The best responses were observed at 560 mg\/m2 evofosfamide.","Preexisting immune gene signatures predicted response to therapy, while hypermetabolic tumors predicted progression.","Responders also showed improved peripheral T-cell proliferation and increased intratumoral T-cell infiltration into hypoxia.","CONCLUSIONS: No new or unexpected safety signals were observed from combining evofosfamide and ipilimumab, and evidence of therapeutic activity was noted."],"Aspect":"m","Summary":"The trial involved evofosfamide administered at doses of 400-640 mg\/m2 on days 1 and 8 of cycles 1-2, and ipilimumab at 3 mg\/kg on day 8 of cycles 1-4.","Indexes":[1,2],"Sentences":["PATIENTS AND METHODS: In a phase I, 3+3 dose-escalation trial (NCT03098160), evofosfamide (400-640 mg\/m2) and ipilimumab (3 mg\/kg) were administered in four 3-week cycles.","The former was administered on days 1 and 8 of cycles 1-2, while the latter was administered on day 8 of cycles 1-4."],"Revise":false}
{"PMID":"33674736","Document":["BACKGROUND: Arginine depletion interferes with pyrimidine metabolism and DNA damage-repair pathways, and pairing arginine deiminase pegylated with 20,000-molecular-weight polyethylene glycol (ADI-PEG20) with platinum enhances cytotoxicity in vitro and in vivo in arginine auxotrophs.","METHODS: This single-centre, Phase 1 trial was conducted using a 3\u2009+\u20093 dose escalation designed to assess safety, tolerability and determine the recommended Phase 2 dose (RP2D) of ADI-PEG20.","RESULTS: We enrolled 99 patients with metastatic argininosuccinate synthetase 1 (ASS1) deficient malignancies.","We observed no dose-limiting toxic effects or treatment-related mortality.","Three percent of patients discontinued treatment because of toxicity.","After treatment, 5% (5\/99) of patients had partial responses, and 41% had stable disease.","The median progression-free and overall survival durations were 3.62 and 8.06 months, respectively.","Substantial arginine depletion and citrulline escalation persisted in most patients through weeks 24 and 8, respectively.","Tumour responses were associated with anti-ADI-PEG20 antibody levels at weeks 8 and 16 (p\u2009=\u20090.031 and p\u2009=\u20090.0357, respectively).","CONCLUSION: Concurrently administered ADI-PEG20 and cisplatin had an acceptable safety profile and had shown antitumour activity against metastatic ASS1-deficient solid tumours.","Further evaluation of this treatment combination is warranted."],"Aspect":"a","Summary":"The study aims to assess the safety, tolerability, and determine the recommended Phase 2 dose (RP2D) of ADI-PEG20 in patients with metastatic argininosuccinate synthetase 1 (ASS1) deficient malignancies.","Indexes":[1],"Sentences":["METHODS: This single-centre, Phase 1 trial was conducted using a 3\u2009+\u20093 dose escalation designed to assess safety, tolerability and determine the recommended Phase 2 dose (RP2D) of ADI-PEG20."],"Revise":false}
{"PMID":"30908472","Document":["PURPOSE: To evaluate the safety and efficacy of primary photodynamic therapy (PDT) for posterior choroidal amelanotic melanomas.","METHODS: Patients with posterior choroidal amelanotic melanomas up to 6 mm in height were treated with PDT using verteporfin as the photosensitizing agent.","Treatment was repeated every 3 months until the tumor was flat up to a maximum of 6 treatments.","Tumor response and recurrence was assessed by clinical examination, photography, and ultrasonography.","Patients were monitored 3 monthly for a minimum of 3 years.","RESULTS: Thirty-six of 41 (88%) patients had complete regression after an initial course of PDT.","Of them, 20 (56%) had no recurrence, 3 (8%) had recurrences that were successfully treated with further PDT, and 13 (36%) had recurrences that failed or were not amenable to further PDT.","None of the measured baseline characteristics predicted treatment outcomes.","There was no reduction in visual acuity due to PDT.","The mean follow-up time was 3.5 years.","CONCLUSION: In this large series, primary PDT was highly effective in achieving initial regression of posterior choroidal amelanotic melanomas.","Photodynamic therapy is a vision-preserving treatment option for these tumors; however, patients need to be followed up closely because there is a significant rate of recurrence."],"Aspect":"a","Summary":"The study aims to evaluate the safety and efficacy of primary photodynamic therapy (PDT) for posterior choroidal amelanotic melanomas.","Indexes":[0],"Sentences":["PURPOSE: To evaluate the safety and efficacy of primary photodynamic therapy (PDT) for posterior choroidal amelanotic melanomas."],"Revise":false}
{"PMID":"34140403","Document":["PURPOSE: PD-1\/PD-L1 inhibitors are approved for multiple tumor types.","However, resistance poses substantial clinical challenges.","PATIENTS AND METHODS: We conducted a phase I trial of CD40 agonist APX005M (sotigalimab) and CSF1R inhibitor cabiralizumab with or without nivolumab using a 3+3 dose-escalation design (NCT03502330).","Patients were enrolled from June 2018 to April 2019.","Eligibility included patients with biopsy-proven advanced melanoma, non-small cell lung cancer (NSCLC), or renal cell carcinoma (RCC) who progressed on anti-PD-1\/PD-L1.","APX005M was dose escalated (0.03, 0.1, or 0.3 mg\/kg i.v.)","with a fixed dose of cabiralizumab with or without nivolumab every 2 weeks until disease progression or intolerable toxicity.","RESULTS: Twenty-six patients (12 melanoma, 1 NSCLC, and 13 RCC) were enrolled in six cohorts, 17 on nivolumab-containing regimens.","Median duration of follow-up was 21.3 months.","The most common treatment-related adverse events were asymptomatic elevations of lactate dehydrogenase (n = 26), creatine kinase (n = 25), aspartate aminotransferase (n = 25), and alanine aminotransferase (n = 19); periorbital edema (n = 17); and fatigue (n = 13).","One dose-limiting toxicity (acute respiratory distress syndrome) occurred in cohort 2.","The recommended phase 2 dose was APX005M 0.3 mg\/kg, cabiralizumab 4 mg\/kg, and nivolumab 240 mg every 2 weeks.","Median days on treatment were 66 (range, 23-443).","Median cycles were 4.5 (range, 2-21).","One patient had unconfirmed partial response (4%), 8 stable disease (31%), 16 disease progression (62%), and 1 unevaluable (4%).","Pro-inflammatory cytokines were upregulated 4 hours post-infusion.","CD40 and MCSF increased after therapy.","CONCLUSIONS: This first in-human study of patients with anti-PD-1\/PD-L1-resistant tumors treated with dual macrophage-polarizing therapy, with or without nivolumab demonstrated safety and pharmacodynamic activity.","Optimization of the dosing frequency and sequence of this combination is warranted."],"Aspect":"s","Summary":"The most common treatment-related adverse events were asymptomatic elevations of lactate dehydrogenase, creatine kinase, aspartate aminotransferase, and alanine aminotransferase; periorbital edema; and fatigue.","Indexes":[9],"Sentences":["The most common treatment-related adverse events were asymptomatic elevations of lactate dehydrogenase (n = 26), creatine kinase (n = 25), aspartate aminotransferase (n = 25), and alanine aminotransferase (n = 19); periorbital edema (n = 17); and fatigue (n = 13)."],"Revise":false}
{"PMID":"34088741","Document":["BACKGROUND: Despite significant progress with antiprogrammed cell death protein 1 (PD-1) therapy, a substantial fraction of metastatic melanoma patients show upfront therapy resistance.","Biomarkers for outcome are missing and the association of baseline immune function and clinical outcome remains to be determined.","We assessed the in vitro nonspecific stimulation of immune response at baseline and during anti-PD-1 therapy for metastatic melanoma.","METHODS: Previously untreated metastatic melanoma patients received nivolumab and radiotherapy as part of the multicentric phase II trial NIRVANA (NCT02799901).","The levels of Th1, Th2 and Th17 cytokines on in vitro non-specific stimulation of innate and adaptive immune cells were measured in patient sera before treatment, and at week 2 and week 6 after the beginning of the treatment, and correlated with tumorous response, progression-free survival (PFS) and occurrence of immune-related adverse events (irAEs).","The results in melanoma patients were compared with those of a cohort of 9 sex and age-matched healthy donors.","RESULTS: Seventeen patients were enrolled in this ancillary study.","Median follow-up was 16 months (2.2-28.4).","The 12-month PFS rate was 67.7%.","The incidence of irAEs of any grade was 58.8%.","Without in vitro stimulation no differences in cytokines levels were observed between responders and non-responders.","On in vitro stimulation, metastatic patients had lower Th1 cytokine levels than healthy donors at baseline for tumor necrosis factor-\u03b1 and interferon-\u03b3 (IFN-\u03b3) (1136\u2009pg\/mL vs 5558\u2009pg\/mL, p<0.0001; and 3894\u2009pg\/mL vs 17\u2009129\u2009pg\/mL, p=0.02, respectively).","Responders exhibited increasing cytokine levels from baseline to week 6.","Non-responders had lower interleukin 17A (IL-17A) levels at baseline than responders (7\u2009pg\/mL vs 32\u2009pg\/mL, p=0.03), and lower IFN-\u03b3 levels at week 6 (3.3\u2009ng\/mL vs 14.5\u2009ng\/mL, p=0.03).","A lower level of IL-17A at week 2 and a lower level of IFN-\u03b3 at week 6 correlated with worse PFS (p=0.04\u2009and p=0.04 respectively).","At baseline, patients who developed irAEs had higher IL-6 levels (19.3\u2009ng\/mL vs 9.2\u2009ng\/mL, p=0.03) and higher IL-17A levels (52.5\u2009pg\/mL vs 2.5\u2009pg\/mL, p=0.009) than those without irAEs.","CONCLUSIONS: Our findings indicate that cytokine levels after in vitro non-specific stimulation could be a promising biomarker to predict the outcome of PD-1 inhibition therapy."],"Aspect":"i","Summary":"Previously untreated metastatic melanoma patients received nivolumab and radiotherapy as part of the multicentric phase II trial NIRVANA, with cytokine levels measured at baseline, week 2, and week 6 to correlate with clinical outcomes.","Indexes":[3,4],"Sentences":["METHODS: Previously untreated metastatic melanoma patients received nivolumab and radiotherapy as part of the multicentric phase II trial NIRVANA (NCT02799901).","The levels of Th1, Th2 and Th17 cytokines on in vitro non-specific stimulation of innate and adaptive immune cells were measured in patient sera before treatment, and at week 2 and week 6 after the beginning of the treatment, and correlated with tumorous response, progression-free survival (PFS) and occurrence of immune-related adverse events (irAEs)."],"Revise":false}
{"PMID":"38783296","Document":["BACKGROUND: Difficulty obtaining a dermatological consultation is an obstacle to the early diagnosis of melanoma.","On the one hand, patients survival depends on the lesion thickness at the time of diagnosis.","On the other hand, dermatologists treat many patients with benign lesions.","Optimizing patient care pathways is a major concern.","The aim of the present study was to assess whether the e-mail transmission of photographs of suspected melanoma lesions between general practitioners (GPs) and dermatologists reduces the time to dermatological consultation for patients whose suspicious skin lesions ultimately require resection.","METHODS: We conducted a cluster-randomized controlled study in primary care involving 51 French GPs between April 2017 and August 2019.","A total of 250 patients referred to a dermatologist for a suspected melanoma lesion were included GPs were randomized to either the smartphone arm or the usual care arm.","In the smartphone arm, the GPs referred patients to the dermatologist by sending 2 photographs of the suspicious lesion using their smartphone.","The dermatologist then had to set up an appointment at an appropriate time.","In the usual care arm, GPs referred patients to a dermatologist according to their usual practice.","The primary outcome was the time to dermatological consultation for patients whose lesion ultimately required resection.","RESULTS: 57 GPs volunteered were randomized (27 to the smartphone arm, and 30 to the usual care arm).","A total of 125 patients were included in each arm (mean age: 49.8 years; 53% women) and followed 8 months.","Twenty-three dermatologists participated in the study.","The time to dermatological consultation for patients whose suspicious skin lesion required resection was 56.5 days in the smartphone arm and 63.7 days in the usual care arm (mean adjusted time reduction: -18.5 days, 95% CI [-74.1;23.5], p\u2009=\u2009.53).","CONCLUSIONS: The e-mail transmission of photographs from GPs to dermatologists did not improve the dermatological management of patients whose suspicious skin lesions ultimately required resection.","Further research is needed to validate quality criteria that might be useful for tele-expertise in dermatology.","TRIAL REGISTRATION: Registered on ClinicalTrials.gov under reference number NCT03137511 (May 2, 2017)."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"32385144","Document":["BACKGROUND: Phosphorylated peptides presented by MHC molecules represent a new class of neoantigens expressed on cancer cells and recognized by CD8 T-cells.","These peptides are promising targets for cancer immunotherapy.","Previous work identified an HLA-A*0201-restricted phosphopeptide from insulin receptor substrate 2 (pIRS2) as one such target.","The purpose of this study was to characterize a second phosphopeptide, from breast cancer antiestrogen resistance 3 (BCAR3), and to evaluate safety and immunogenicity of a novel immunotherapic vaccine comprising either or both of these phosphorylated peptides.","METHODS: Phosphorylated BCAR3 protein was evaluated in melanoma and breast cancer cell lines by Western blot, and recognition by T-cells specific for HLA-A*0201-restricted phosphorylated BCAR3 peptide (pBCAR3126-134) was determined by 51Cr release assay and intracellular cytokine staining.","Human tumor explants were also evaluated by mass spectrometry for presentation of pIRS2 and pBCAR3 peptides.","For the clinical trial, participants with resected stage IIA-IV melanoma were vaccinated 6 times over 12 weeks with one or both peptides in incomplete Freund's adjuvant and Hiltonol (poly-ICLC).","Adverse events (AEs) were coded based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) V.4.03, with provision for early study termination if dose-limiting toxicity (DLT) rates exceeded 33%.","The enrollment target was 12 participants evaluable for immune response to each peptide.","T-cell responses were assessed by interferon-\u03b3 ELISpot assay.","RESULTS: pBCAR3 peptides were immunogenic in vivo in mice, and in vitro in normal human donors, and T-cells specific for pBCAR3126-134 controlled outgrowth of a tumor xenograft.","The pIRS21097-1105 peptide was identified by mass spectrometry from human hepatocellular carcinoma tumors.","In the clinical trial, 15 participants were enrolled.","All had grade 1 or 2 treatment-related AEs, but there were no grade 3-4 AEs, DLTs or deaths on study.","T-cell responses were induced to the pIRS21097-1105 peptide in 5\/12 patients (42%, 90% CI 18% to 68%) and to the pBCAR3126-134 peptide in 2\/12 patients (17%, 90% CI 3% to 44%).","CONCLUSION: This study supports the safety and immunogenicity of vaccines containing the cancer-associated phosphopeptides pBCAR3126-134 and pIRS21097-1105, and the data support continued development of immune therapy targeting phosphopeptides.","Future studies will define ways to further enhance the magnitude and durability of phosphopeptide-specific immune responses.","TRIAL REGISTRATION NUMBER: NCT01846143."],"Aspect":"s","Summary":"All participants had grade 1 or 2 treatment-related adverse events, with no grade 3-4 adverse events, dose-limiting toxicities, or deaths on study.","Indexes":[13],"Sentences":["All had grade 1 or 2 treatment-related AEs, but there were no grade 3-4 AEs, DLTs or deaths on study."],"Revise":false}
{"PMID":"34046035","Document":["BACKGROUND: Ipilimumab improves survival for patients with metastatic malignant melanoma.","Combining a therapeutic cancer vaccine with ipilimumab may increase efficacy by providing enhanced anti-tumor immune responses.","UV1 consists of three synthetic long peptides from human telomerase reverse transcriptase (hTERT).","These peptides comprise epitopes recognized by T cells from cancer patients experiencing long-term survival following treatment with a first-generation hTERT vaccine, and generate long-lasting immune responses in cancer patients when used as monotherapy.","The objective of this trial was to investigate the safety and efficacy of combining UV1 with ipilimumab in metastatic melanoma.","PATIENTS AND METHODS: In this phase I\/IIa, single center trial [NCT02275416], patients with metastatic melanoma received repeated UV1 vaccinations, with GM-CSF as an adjuvant, in combination with ipilimumab.","Patients were evaluated for safety, efficacy and immune response.","Immune responses against vaccine peptides were monitored in peripheral blood by measuring antigen-specific proliferation and IFN-\u03b3 production.","RESULTS: Twelve patients were recruited.","Adverse events were mainly diarrhea, injection site reaction, pruritus, rash, nausea and fatigue.","Ten patients showed a Th1 immune response to UV1 peptides, occurring early and after few vaccinations.","Three patients obtained a partial response and one patient a complete response.","Overall survival was 50% at 5 years.","CONCLUSION: Treatment was well tolerated.","The rapid expansion of UV1-specific Th1 cells in the majority of patients indicates synergy between UV1 vaccine and CTLA-4 blockade.","This may have translated into clinical benefit, encouraging the combination of UV1 vaccination with standard of care treatment regimes containing ipilimumab\/CTLA-4 blocking antibodies."],"Aspect":"m","Summary":"The trial involved the combination of UV1 vaccine with ipilimumab, using repeated UV1 vaccinations with GM-CSF as an adjuvant.","Indexes":[1,4,5],"Sentences":["Combining a therapeutic cancer vaccine with ipilimumab may increase efficacy by providing enhanced anti-tumor immune responses.","The objective of this trial was to investigate the safety and efficacy of combining UV1 with ipilimumab in metastatic melanoma.","PATIENTS AND METHODS: In this phase I\/IIa, single center trial [NCT02275416], patients with metastatic melanoma received repeated UV1 vaccinations, with GM-CSF as an adjuvant, in combination with ipilimumab."],"Revise":false}
{"PMID":"37621406","Document":["PURPOSE: Neoadjuvant combination immune checkpoint blockade and intralesional oncolytic virotherapy have the potential to activate antitumor responses in patients with breast cancer.","EXPERIMENTAL DESIGN: Eligibility for this pilot phase I trial included patients with localized HER2-negative breast cancer who received systemic nivolumab and ipilimumab and intratumor talimogene laherparepvec (T-VEC; NCT04185311).","The primary objective was to evaluate the safety and adverse event profile of immunotherapy combined with T-VEC in patients with localized, HER2-negative breast cancer.","RESULTS: Six patients were enrolled, 4 having relapses after prior neoadjuvant chemotherapy and 2 who were previously untreated.","Toxicities included 1 patient having grade 3 hypotension and type 1 diabetes mellitus, 3 patients with hypothyroidism, and all patients having constitutional symptoms known to be associated with the administration of T-VEC.","One patient had a pathologic complete response, 3 patients had pathologic partial responses, 1 showed no significant response, and 1 had disease progression.","Biopsies demonstrated increased immune cell infiltration in samples from patients who responded to therapy.","CONCLUSIONS: This triple immunotherapy regimen provided responses in patients with advanced or relapsed HER2-negative breast cancer, at the expense of long-term toxicities.","SIGNIFICANCE: Systemic immune checkpoint blockade with a programmed death receptor 1 and a CTL antigen-4 blocking antibody, combined with intralesional oncolytic virotherapy, is a chemotherapy-free combination aimed at inducing an antitumor immune response locally and systemic immunity."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"34782430","Document":["BACKGROUND: A first-in-human, randomized pilot phase II clinical trial combining vaccines targeting overexpressed, non-mutated tumor blood vessel antigens (TBVA) and tyrosine kinase inhibitor dasatinib was conducted in human leukocyte antigen (HLA)-A2+ patients with advanced melanoma.","METHODS: Patient monocyte-derived type-1-polarized dendritic cells were loaded with HLA-A2-presented peptides derived from TBVA (DLK1, EphA2, HBB, NRP1, RGS5, TEM1) and injected intradermally as a vaccine into the upper extremities every other week.","Patients were randomized into one of two treatment arms receiving oral dasatinib (70\u2009mg two times per day) beginning in week 5 (Arm A) or in week 1 (Arm B).","Trial endpoints included T cell response to vaccine peptides (interferon-\u03b3 enzyme-linked immunosorbent spot), objective clinical response (Response Evaluation Criteria in Solid Tumors V.1.1) and exploratory tumor, blood and serum profiling of immune-associated genes\/proteins.","RESULTS: Sixteen patients with advanced-stage cutaneous (n=10), mucosal (n=1) or uveal (n=5) melanoma were accrued, 15 of whom had previously progressed on programmed cell death protein 1 (PD-1) blockade.","Of 13 evaluable patients, 6 patients developed specific peripheral blood T cell responses against \u22653 vaccine-associated peptides, with further evidence of epitope spreading.","All six patients with specific CD8+ T cell response to vaccine-targeted antigens exhibited evidence of T cell receptor (TCR) convergence in association with preferred clinical outcomes (four partial response and two stabilization of disease (SD)).","Seven patients failed to respond to vaccination (one SD and six progressive disease).","Patients in Arm B (immediate dasatinib) outperformed those in Arm A (delayed dasatinib) for immune response rate (IRR; 66.7% vs 28.6%), objective response rate (ORR) (66.7% vs 0%), overall survival (median 15.45 vs 3.47 months; p=0.0086) and progression-free survival (median 7.87 vs 1.97 months; p=0.063).","IRR (80% vs 25%) and ORR (60% vs 12.5%) was greater for females versus male patients.","Tumors in patients exhibiting response to treatment displayed (1) evidence of innate and adaptive immune-mediated inflammation and TCR convergence at baseline, (2) on-treatment transcriptional changes associated with reduced hypoxia\/acidosis\/glycolysis, and (3) increased inflammatory immune cell infiltration and tertiary lymphoid structure neogenesis.","CONCLUSIONS: Combined vaccination against TBVA plus dasatinib was safe and resulted in coordinating immunologic and\/or objective clinical responses in 6\/13 (46%) evaluable patients with melanoma, particularly those initiating treatment with both agents.","TRIAL REGISTRATION NUMBER: NCT01876212."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"31839677","Document":["BACKGROUND: Aiming to improve treatment options for BRAF wild-type melanoma, we previously conducted the DOC-MEK study of docetaxel with MEK inhibitor (MEKi) selumetinib or placebo, revealing trends to prolongation of progression-free survival (hazard ratio 0.75, P\u2009=\u20090.130), and improved response rates (32% vs 14%, P\u2009=\u20090.059) with docetaxel plus selumetinib.","NRAS status did not associate with outcome.","Here, the aim was to identify novel biomarkers of response to MEKi.","METHODS: A MEK 6 gene signature was quantified using NanoString and correlated with clinical outcomes.","Two components of the gene signature were investigated by gene silencing in BRAF\/NRAS wild-type melanoma cells.","RESULTS: In melanomas of patients on the selumetinib but not the placebo arm, two gene signature components, dual-specificity protein phosphatase 4 (DUSP4) and ETS translocation variant 4 (ETV4), were expressed more highly in responders than non-responders.","In vitro, ETV4 depletion inhibited cell survival but did not influence sensitivity to MEKi selumetinib or trametinib.","In contrast, DUSP4-depleted cells showed enhanced cell survival and increased resistance to both selumetinib and trametinib.","CONCLUSIONS: ETV4 and DUSP4 associated with clinical response to docetaxel plus selumetinib.","DUSP4 depletion induced MEKi resistance, suggesting that DUSP4 is not only a biomarker but also a mediator of MEKi sensitivity.","CLINICAL TRIAL REGISTRATION: DOC-MEK (EudraCT no: 2009-018153-23)."],"Aspect":"i","Summary":"The study quantified a MEK 6 gene signature using NanoString and correlated it with clinical outcomes, and investigated two components of the gene signature through gene silencing in BRAF\/NRAS wild-type melanoma cells.","Indexes":[3,4],"Sentences":["METHODS: A MEK 6 gene signature was quantified using NanoString and correlated with clinical outcomes.","Two components of the gene signature were investigated by gene silencing in BRAF\/NRAS wild-type melanoma cells."],"Revise":false}
{"PMID":"32157631","Document":["BACKGROUND: A randomized phase III trial comparing whole-brain radiotherapy (WBRT) to observation following definitive local treatment of intracranial melanoma metastases with neurosurgery and\/or stereotactic surgery (SRS) is underway.","OBJECTIVE: We sought to assess the pre-trial cost-effectiveness of WBRT, hippocampal-avoidant WBRT (HA-WBRT), and observation (SRS or surgery alone) for this population to guide trial data collection efforts and reduce decision uncertainty.","METHODS: A time-dependent Markov model followed patients treated with neurosurgery or SRS who received subsequent WBRT, HA-WBRT or observation over a 5-year time horizon.","Model inputs were sourced from published literature and results tested for robustness using probabilistic sensitivity analysis.","Value of information (VOI) analysis was undertaken to guide data collection for the randomized trial.","RESULTS: Over 5\u00a0years, the WBRT strategy produced 1.74\u00a0QALYs (2.38 life-years) at a mean cost of $40,128 (costs in 2017 Australian dollars); HA-WBRT produced 1.88\u00a0QALYs (2.38 life-years) and cost $42,977; and SRS\/surgery alone produced 1.65\u00a0QALYs (2.13 life-years) at a cost of $46,281.","Probabilistic sensitivity analysis showed HA-WBRT was the preferred strategy in 77% of simulations.","Cost-effectiveness results were most sensitive to utilities of the controlled-disease health state in the WBRT group, and costs of HA-WBRT.","The EVPI for a randomized trial was estimated at $6,888 per person.","CONCLUSIONS: HA-WBRT may be cost-effective for the treatment of melanoma brain metastases.","The results predicted in our model can be validated with prospective trial data when available."],"Aspect":"m","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"34287772","Document":["Background\u00a0The study determined the safety, pharmacokinetics\/pharmacodynamics (PK\/PD), and recommended Phase II dose of BCT-100 for arginine auxotrophic tumours in a non-Chinese population.","Methods This is a Phase I, 3\u2009+\u20093 dose-escalation, open-label, multi-centre study in two arginine auxotrophic cancers-Malignant Melanoma (MM) and Castration Resistant Prostate Cancer (CRPC).","Patients were enrolled to receive weekly intravenous BCT-100.","The dose cohorts were respectively 0.5\u00a0mg\/kg, 1.0\u00a0mg\/kg, 1.7\u00a0mg\/kg and 2.7\u00a0mg\/kg.","Results There were 14 MM and 9 CRPC patients, 16 males and 7 females with a\u00a0median age of 71.","No dose-limiting toxicities were reported.","Among all the AEs, 18 were drug-related (mostly were Grade 1).","Although there were individual variations in PKs amongst the patients in each cohort, the median arginine level was maintained at 2.5 \u00b5M (lower limit of quantification) in all 4 cohorts of patients after the second BCT-100 injection.","Therapeutic Arginine Depletion was found in the 1.7 and 2.7\u00a0mg\/kg\/week cohorts when anti-tumor activities were observed.","The two cohorts had a similar AUC (20,947 and 19,614\u00a0h*\u00b5g\/ml respectively).","Since the 2.7\u00a0mg\/kg\/week cohort had a more sustained arginine depletion for 2\u00a0weeks, the 2.7\u00a0mg\/kg\/week dose is chosen as the future phase II dose.","There were two complete remissions (1 MM & 1 CRPC), 1PR (MM) and 2 stable diseases with a disease control rate (CR\u2009+\u2009PR\u2009+\u2009SD) of 5\/23 (22%).","Conclusions BCT-100 is safe in a non-Chinese population and has anti-tumor activities in both MM and CRPC.","Weekly BCT-100 at 2.7\u00a0mg\/kg is defined as the optimal biological dose for future clinical phase II studies."],"Aspect":"a","Summary":"The study aims to determine the safety, pharmacokinetics\/pharmacodynamics (PK\/PD), and recommended Phase II dose of BCT-100 for arginine auxotrophic tumours in a non-Chinese population.","Indexes":[0],"Sentences":["Background\u00a0The study determined the safety, pharmacokinetics\/pharmacodynamics (PK\/PD), and recommended Phase II dose of BCT-100 for arginine auxotrophic tumours in a non-Chinese population."],"Revise":false}
{"PMID":"32725685","Document":["The efficacy and safety of nivolumab\u00a0+\u00a0ipilimumab combination therapy were retrospectively examined in Japanese patients with unresectable advanced melanoma in clinical practice.","Fifty-seven patients with advanced melanoma received the nivolumab\u00a0+\u00a0ipilimumab combination therapy.","The primary site was cutaneous, mucosal, uveal and unknown in 35, 16, two and four patients, respectively.","The overall response rate was 26.3%, with complete response observed in two (3.5%) patients, partial response in 13 (22.8%), stable disease in 12 (21.1%) and progressive disease in 30 (52.6%).","The response rate in the treatment-naive and prior systemic therapy group was 40.7% and 13.3%, respectively.","For those treated with a single immune checkpoint inhibitor followed by the nivolumab\u00a0+\u00a0ipilimumab combination therapy as second-line therapy after disease progression, the response rate was 18.8%.","Median progression-free survival (PFS) and overall survival (OS) in all patients was 3.3 and 14\u00a0months, respectively.","Median PFS in the treatment-naive and prior systemic therapy groups was 13 and 2\u00a0months, respectively.","Median OS was unreached in the treatment-naive group and was 6.3\u00a0months in prior systemic therapy groups.","There was no significant difference in PFS and OS for non-acral, acral and mucosal melanoma.","Adverse events occurred in 86% of patients; 56.1% were grade 3 or worse.","The response rate in an actual clinical setting, including the prior systemic therapy group, was lower than that in the global study and the Japanese phase II study.","However, in the treatment-naive group, the rate was equivalent to that in the Japanese phase II study.","PFS and OS in the treatment-naive group were comparable with those in the global study and Japanese phase II study, suggesting that the treatment was effective.","The proportion of grade 3 and 4 immune-related adverse events was as high as that in the global study and Japanese phase II study."],"Aspect":"a","Summary":"The study aims to examine the efficacy and safety of nivolumab plus ipilimumab combination therapy in Japanese patients with unresectable advanced melanoma.","Indexes":[0],"Sentences":["The efficacy and safety of nivolumab\u00a0+\u00a0ipilimumab combination therapy were retrospectively examined in Japanese patients with unresectable advanced melanoma in clinical practice."],"Revise":false}
{"PMID":"35552458","Document":["Few studies have examined cognitive responses to mailed precision prevention materials.","MC1R is a robust, well-described melanoma susceptibility marker.","The purpose was to assess cognitive responses to generic or precision prevention materials incorporating MC1R genetic risk.","Non-Hispanic White participants (n = 1134) enrolled in a randomized controlled trial received either precision prevention materials incorporating MC1R genetic risk (higher\/average) or generic prevention (standard) materials.","Six months after baseline, 808 (71.3%) participants reported on the amount of prevention materials read (5-point scale); believability and clarity of materials; intention to change preventive behaviors (7-point Likert scale); and recall of their MC1R genetic risk.","Comparisons were conducted using Kruskal-Wallis and chi-squared tests.","Overall, participants read most to all (Mdn = 4, IQR = 2) of the prevention materials, reported high believability (Mdn = 7, IQR = 1) and clarity (Mdn = 7, IQR = 1), and moderate intention to change preventive behaviors (Mdn = 5, IQR = 2).","Higher-risk participants reported slightly less clarity (Mdn = 6, IQR = 2) than either average-risk (Mdn = 6, IQR = 1, p = 2.50 \u00d7 10-3) or standard participants (Mdn = 7, IQR = 1, p = 2.30 \u00d7 10-5); and slightly less believability (Mdn = 6, IQR = 1) than standard participants (Mdn = 7, IQR = 1, p = .005).","Higher-risk participants were 2.21 times as likely (95% CI = 1.43-3.43) to misremember or forget their risk compared to average-risk participants; misremembering was observed only among higher-risk participants (14%).","Mailed precision prevention information were mostly read, highly believable and clear, and resulted in moderate levels of intention to change sun protection behaviors, bolstering the feasibility of population-level precision prevention.","Defensive reactions may explain lower clarity, believability, and higher incorrect risk recall among higher-risk participants.","Precision prevention uses an individual\u2019s genetics, environment, and\/or lifestyle to promote prevention behaviors.","However, if materials incorporating precision prevention information are not easily accessible, individuals may misinterpret or distrust findings.","Few studies have examined participant-reported believability and clarity of mailed precision prevention materials, how much they read, and whether they intend to change preventive behaviors.","We assessed genetic risk for melanoma by determining DNA variation at the MC1R gene, a known melanoma risk marker.","Participants were mailed either precision prevention materials conveying their MC1R genetic risk or generic (without genetic risk information) prevention materials.","Overall, participants read most of the materials, gave high believability and clarity scores, and reported moderate levels of intention to change preventive behavior.","However, participants at higher genetic risk had slightly lower believability and clarity scores than the generic group and were more likely to forget or misremember their genetic risk than participants at average genetic risk.","Among participants who correctly recalled their genetic risk, differences in believability diminished, while differences in clarity remained.","We conclude that precision prevention materials are highly believable and clear, but additional strategies may be necessary to maximize believability, clarity, and risk recall for individuals at a higher genetic risk."],"Aspect":"p","Summary":"The study involved 1134 Non-Hispanic White participants enrolled in a randomized controlled trial who were assigned to receive either precision prevention materials incorporating MC1R genetic risk (higher\/average) or generic prevention materials.","Indexes":[3],"Sentences":["Non-Hispanic White participants (n = 1134) enrolled in a randomized controlled trial received either precision prevention materials incorporating MC1R genetic risk (higher\/average) or generic prevention (standard) materials."],"Revise":false}
{"PMID":"33303685","Document":["The gut microbiome has been shown to influence the response of tumors to anti-PD-1 (programmed cell death-1) immunotherapy in preclinical mouse models and observational patient cohorts.","However, modulation of gut microbiota in cancer patients has not been investigated in clinical trials.","In this study, we performed a phase 1 clinical trial to assess the safety and feasibility of fecal microbiota transplantation (FMT) and reinduction of anti-PD-1 immunotherapy in 10 patients with anti-PD-1-refractory metastatic melanoma.","We observed clinical responses in three patients, including two partial responses and one complete response.","Notably, treatment with FMT was associated with favorable changes in immune cell infiltrates and gene expression profiles in both the gut lamina propria and the tumor microenvironment.","These early findings have implications for modulating the gut microbiota in cancer treatment."],"Aspect":"a","Summary":"The study aims to assess the safety and feasibility of fecal microbiota transplantation (FMT) and reinduction of anti-PD-1 immunotherapy in patients with anti-PD-1-refractory metastatic melanoma.","Indexes":[2],"Sentences":["In this study, we performed a phase 1 clinical trial to assess the safety and feasibility of fecal microbiota transplantation (FMT) and reinduction of anti-PD-1 immunotherapy in 10 patients with anti-PD-1-refractory metastatic melanoma."],"Revise":false}
{"PMID":"32877599","Document":["BACKGROUND: In the previously reported primary analysis of this phase 3 trial, 12 months of adjuvant dabrafenib plus trametinib resulted in significantly longer relapse-free survival than placebo in patients with resected stage III melanoma with BRAF V600E or V600K mutations.","To confirm the stability of the relapse-free survival benefit, longer-term data were needed.","METHODS: We randomly assigned 870 patients who had resected stage III melanoma with BRAF V600E or V600K mutations to receive 12 months of oral dabrafenib (at a dose of 150 mg twice daily) plus trametinib (2 mg once daily) or two matched placebos.","The primary end point was relapse-free survival.","Here, we report 5-year results for relapse-free survival and survival without distant metastasis as the site of the first relapse.","Overall survival was not analyzed, since the required number of events to trigger the final overall survival analysis had not been reached.","RESULTS: The minimum duration of follow-up was 59 months (median patient follow-up, 60 months for dabrafenib plus trametinib and 58 months for placebo).","At 5 years, the percentage of patients who were alive without relapse was 52% (95% confidence interval [CI], 48 to 58) with dabrafenib plus trametinib and 36% (95% CI, 32 to 41) with placebo (hazard ratio for relapse or death, 0.51; 95% CI, 0.42 to 0.61).","The percentage of patients who were alive without distant metastasis was 65% (95% CI, 61 to 71) with dabrafenib plus trametinib and 54% (95% CI, 49 to 60) with placebo (hazard ratio for distant metastasis or death, 0.55; 95% CI, 0.44 to 0.70).","No clinically meaningful between-group difference in the incidence or severity of serious adverse events was reported during the follow-up period.","CONCLUSIONS: In the 5-year follow-up of a phase 3 trial involving patients who had resected stage III melanoma with BRAF V600E or V600K mutations, 12 months of adjuvant therapy with dabrafenib plus trametinib resulted in a longer duration of survival without relapse or distant metastasis than placebo with no apparent long-term toxic effects.","(Funded by GlaxoSmithKline and Novartis; COMBI-AD ClinicalTrials.gov number, NCT01682083; EudraCT number, 2012-001266-15.",")."],"Aspect":"i","Summary":"Patients with resected stage III melanoma with BRAF V600E or V600K mutations were randomly assigned to receive 12 months of oral dabrafenib plus trametinib or two matched placebos.","Indexes":[2],"Sentences":["METHODS: We randomly assigned 870 patients who had resected stage III melanoma with BRAF V600E or V600K mutations to receive 12 months of oral dabrafenib (at a dose of 150 mg twice daily) plus trametinib (2 mg once daily) or two matched placebos."],"Revise":false}
{"PMID":"31664428","Document":["IMPORTANCE: Obesity is a cancer risk factor, and bariatric surgery in patients with obesity is associated with reduced cancer risk.","However, evidence of an association among obesity, bariatric surgery, and skin cancer, including melanoma, is limited.","OBJECTIVE: To investigate the association of bariatric surgery with skin cancer (squamous cell carcinoma and melanoma) and melanoma incidence.","DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized controlled trial, the Swedish Obese Subjects (SOS) study, is ongoing at 25 surgical departments and 480 primary health care centers in Sweden and was designed to examine outcomes after bariatric surgery.","The study included 2007 patients with obesity who underwent bariatric surgery and 2040 contemporaneously matched controls who received conventional obesity treatment.","Patients were enrolled between September 1, 1987, and January 31, 2001.","Data analysis was performed from June 29, 2018, to November 22, 2018.","INTERVENTIONS: Patients in the surgery group underwent gastric bypass (n\u2009=\u2009266), banding (n\u2009=\u2009376), or vertical banded gastroplasty (n\u2009=\u20091365).","The control group (n\u2009=\u20092040) received the customary treatment for obesity at their primary health care centers.","MAIN OUTCOMES AND MEASURES: The SOS study was cross-linked to the Swedish National Cancer Registry, the Cause of Death Registry, and the Registry of the Total Population for data on cancer incidence, death, and emigration.","RESULTS: The study included 4047 participants (mean [SD] age, 47.9 [6.1] years; 2867 [70.8%] female).","Information on cancer events was available for 4042 patients.","The study found that bariatric surgery was associated with a markedly reduced risk of melanoma (adjusted subhazard ratio, 0.43; 95% CI, 0.21-0.87; P\u2009=\u2009.02; median follow-up, 18.1 years) and risk of skin cancer in general (adjusted subhazard ratio, 0.59; 95% CI, 0.35-0.99; P\u2009=\u2009.047).","The skin cancer risk reduction was not associated with baseline body mass index or weight; insulin, glucose, lipid, and creatinine levels; diabetes; blood pressure; alcohol intake; or smoking.","CONCLUSIONS AND RELEVANCE: The results of this study suggest that bariatric surgery in individuals with obesity is associated with a reduced risk of skin cancer, including melanoma.","TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01479452."],"Aspect":"a","Summary":"The study aims to investigate the association of bariatric surgery with skin cancer (squamous cell carcinoma and melanoma) and melanoma incidence.","Indexes":[2],"Sentences":["OBJECTIVE: To investigate the association of bariatric surgery with skin cancer (squamous cell carcinoma and melanoma) and melanoma incidence."],"Revise":false}
{"PMID":"31895407","Document":["IMPORTANCE: Whether immune-related adverse events (irAEs) indicate drug activity in patients treated with immune checkpoint inhibitors remains unknown.","OBJECTIVE: To investigate the association between irAEs and recurrence-free survival (RFS) in the double-blind EORTC 1325\/KEYNOTE-054 clinical trial comparing pembrolizumab therapy and placebo for the treatment of patients with high-risk stage III melanoma.","DESIGN, SETTING, AND PARTICIPANTS: A total of 1019 adults with stage III melanoma were randomly assigned on a 1:1 ratio to receive treatment with pembrolizumab therapy or placebo.","Eligible patients were adults 18 years and older with complete resection of cutaneous melanoma metastatic to lymph nodes, classified with stage IIIA (at least 1 micrometastasis measuring >1 mm in greatest diameter), IIIB, or IIIC (without in-transit metastasis) cancer.","Patients were randomized from August 26, 2015, to November 14, 2016.","The clinical cutoff for the data set was October 2, 2017.","Analyses were then performed on the database, which was locked on November 28, 2017.","INTERVENTIONS: Participants were scheduled to receive 200 mg of pembrolizumab or placebo every 3 weeks for a total of 18 doses for approximately\u20091 year or until disease recurrence, unacceptable toxic effects, major protocol violation, or withdrawal of consent.","MAIN OUTCOMES AND MEASURES: The association between irAEs and RFS was estimated using a Cox model adjusted for sex, age, and AJCC-7 stage, with a time-varying covariate that had a value of 0 before irAE onset and 1 after irAE onset.","RESULTS: Of 1011 patients who began treatment with pembrolizumab therapy or placebo, 622 (61.5%) were men and 389 (38.5%) were women; 386 patients (38.2%) were aged 50 to 64 years, 377 (37.3%) were younger than 50 years, and 248 (24.5%) were 65 years and older.","Consistent with the reported main analysis in the intent-to-treat population, RFS was longer in the pembrolizumab arm compared with the placebo arm (hazard ratio [HR], 0.56; 98.4% CI, 0.43-0.74) among patients who started treatment.","The incidence of irAEs was 190 (37.4%) in the pembrolizumab arm (n\u2009=\u2009509) and 45 (9.0%) in the placebo arm (n\u2009=\u2009502); in each treatment group, the incidence was similar for men and women.","The occurrence of an irAE was associated with a longer RFS in the pembrolizumab arm (HR, 0.61; 95% CI, 0.39-0.95; P\u2009=\u2009.03) in both men and women.","However, in the placebo arm, this association was not significant.","Compared with the placebo arm, the reduction in the hazard of recurrence or death in the pembrolizumab arm was greater after the onset of an irAE than without or before an irAE (HR, 0.37; 95% CI, 0.24-0.57 vs HR, 0.61; 95% CI, 0.49-0.77, respectively; P\u2009=\u2009.03).","CONCLUSIONS AND RELEVANCE: In this study, the occurrence of an irAE was associated with a longer RFS in the pembrolizumab arm.","TRIAL REGISTRATIONS: ClinicalTrials.gov identifier: NCT02362594; EudraCT identifier: 2014-004944-37."],"Aspect":"p","Summary":"The study involved 1019 adults with stage III melanoma, including 622 men and 389 women, with ages ranging from younger than 50 years to 65 years and older.","Indexes":[2,9],"Sentences":["DESIGN, SETTING, AND PARTICIPANTS: A total of 1019 adults with stage III melanoma were randomly assigned on a 1:1 ratio to receive treatment with pembrolizumab therapy or placebo.","RESULTS: Of 1011 patients who began treatment with pembrolizumab therapy or placebo, 622 (61.5%) were men and 389 (38.5%) were women; 386 patients (38.2%) were aged 50 to 64 years, 377 (37.3%) were younger than 50 years, and 248 (24.5%) were 65 years and older."],"Revise":false}
{"PMID":"36738540","Document":["Survival of macroscopic stage III melanoma is poor.","Five-year overall survival and relapse-free survival rates for surgery alone range from 40 to 59% and 30 to-39%, respectively.","The current standard of care is therapeutic lymph node dissection (TLND) followed by a year of adjuvant systemic therapy.","Multiple phase 2 trials have shown that neo-adjuvant immunotherapy induces major pathologic response (MPR) rates (pathologic complete response (pCR): pCR, 0% viable tumour cells; near-pCR, <10% viable tumour cells), which translate into durable relapse free survival rates.","Single agent anti-PD-1 achieves 20-30% MPR, the combination of ipilimumab and nivolumab doubles the MPR rates to 50-60%.","The OpACIN trial demonstrated that neoadjuvant immunotherapy induced both higher numbers and a broader repertoire of tumour-resident T-cells in peripheral blood compared with adjuvant immunotherapy.","Very recently, the randomised phase 2 trial S1801\u00a0reported its first interim results.","S1801 compared TLND, followed by 18 courses of adjuvant pembrolizumab, to three courses of neoadjuvant pembrolizumab, followed by surgery and 15 adjuvant doses.","With a median follow-up of 14 months, a 23% EFS rate benefit was observed.","The ongoing phase 3 NADINA trial randomises patients between TLND\u00a0+\u00a0one year of adjuvant nivolumab (control arm) or 2 courses of neoadjuvant therapy with ipilimumab\u00a0+\u00a0nivolumab, followed by adjuvant therapy only for non-MPR patients.","There is rapid, consistent, and accumulating evidence generated from all phase 1 and phase 2 trials, indicating clinical superiority of neoadjuvant immunotherapy over adjuvant systemic therapy for macroscopic stage III melanoma.","Therefore, payers should consider neoadjuvant immunotherapy for reimbursement\u00a0as this approach is the best option for our patients, and classify it as the best medical practice."],"Aspect":"i","Summary":"The research methods include therapeutic lymph node dissection (TLND) followed by adjuvant systemic therapy, and neoadjuvant immunotherapy with agents such as anti-PD-1, ipilimumab, and nivolumab, comparing their effectiveness in trials like OpACIN, S1801, and NADINA.","Indexes":[2,3,4,5,7,9],"Sentences":["The current standard of care is therapeutic lymph node dissection (TLND) followed by a year of adjuvant systemic therapy.","Multiple phase 2 trials have shown that neo-adjuvant immunotherapy induces major pathologic response (MPR) rates (pathologic complete response (pCR): pCR, 0% viable tumour cells; near-pCR, <10% viable tumour cells), which translate into durable relapse free survival rates.","Single agent anti-PD-1 achieves 20-30% MPR, the combination of ipilimumab and nivolumab doubles the MPR rates to 50-60%.","The OpACIN trial demonstrated that neoadjuvant immunotherapy induced both higher numbers and a broader repertoire of tumour-resident T-cells in peripheral blood compared with adjuvant immunotherapy.","S1801 compared TLND, followed by 18 courses of adjuvant pembrolizumab, to three courses of neoadjuvant pembrolizumab, followed by surgery and 15 adjuvant doses.","The ongoing phase 3 NADINA trial randomises patients between TLND\u00a0+\u00a0one year of adjuvant nivolumab (control arm) or 2 courses of neoadjuvant therapy with ipilimumab\u00a0+\u00a0nivolumab, followed by adjuvant therapy only for non-MPR patients."],"Revise":false}
{"PMID":"37219686","Document":["PURPOSE: Genomic alterations of BRAF and NRAS are oncogenic drivers in malignant melanoma and other solid tumors.","Tovorafenib is an investigational, oral, selective, CNS-penetrant, small molecule, type II pan\u2011RAF inhibitor.","This first-in-human phase 1 study explored the safety and antitumor activity of tovorafenib.","METHODS: This two-part study in adult patients with relapsed or refractory advanced solid tumors included a dose escalation phase and a dose expansion phase including molecularly defined cohorts of patients with melanoma.","Primary objectives were to evaluate the safety of tovorafenib administered once every other day (Q2D) or once weekly (QW), and to determine the maximum-tolerated and recommended phase 2 dose (RP2D) on these schedules.","Secondary objectives included evaluation of antitumor activity and tovorafenib pharmacokinetics.","RESULTS: Tovorafenib was administered to 149 patients (Q2D n\u2009=\u2009110, QW n\u2009=\u200939).","The RP2D of tovorafenib was defined as 200\u00a0mg Q2D or 600\u00a0mg QW.","In the dose expansion phase, 58 (73%) of 80 patients in Q2D cohorts and 9 (47%) of 19 in the QW cohort had grade\u2009\u2265\u20093 adverse events.","The most common of these overall were anemia (14 patients, 14%) and maculo-papular rash (8 patients, 8%).","Responses were seen in 10 (15%) of 68 evaluable patients in the Q2D expansion phase, including in 8 of 16 (50%) patients with BRAF mutation-positive melanoma na\u00efve to RAF and MEK inhibitors.","In the QW dose expansion phase, there were no responses in 17 evaluable patients with NRAS mutation-positive melanoma na\u00efve to RAF and MEK inhibitors; 9 patients (53%) had a best response of stable disease.","QW dose administration was associated with minimal accumulation of tovorafenib in systemic circulation in the dose range of 400-800\u00a0mg.","CONCLUSIONS: The safety profile of both schedules was acceptable, with QW dosing at the RP2D of 600\u00a0mg QW preferred for future clinical studies.","Antitumor activity of tovorafenib in BRAF-mutated melanoma was promising and justifies continued clinical development across multiple settings.","GOV IDENTIFIER: NCT01425008."],"Aspect":"o","Summary":"Tovorafenib showed promising antitumor activity in BRAF-mutated melanoma, with a preferred dosing schedule of 600 mg QW for future studies.","Indexes":[10,13,14],"Sentences":["Responses were seen in 10 (15%) of 68 evaluable patients in the Q2D expansion phase, including in 8 of 16 (50%) patients with BRAF mutation-positive melanoma na\u00efve to RAF and MEK inhibitors.","CONCLUSIONS: The safety profile of both schedules was acceptable, with QW dosing at the RP2D of 600\u00a0mg QW preferred for future clinical studies.","Antitumor activity of tovorafenib in BRAF-mutated melanoma was promising and justifies continued clinical development across multiple settings."],"Revise":true}
{"PMID":"33444116","Document":["PURPOSE: Mucosal melanoma (MM) is a highly vascularized tumor with an extremely poor prognosis.","In this randomized, open-label, phase II study, we characterized the efficacy and safety of bevacizumab in combination with carboplatin plus paclitaxel (CPB) in patients with previously untreated advanced MM.","PATIENTS AND METHODS: Patients were randomly assigned in a 2:1 ratio to receive carboplatin (area under the curve, 5) plus paclitaxel (175 mg\/m2) once every 4 weeks in combination with (CPB arm, 5 mg\/kg) or without (CP arm) bevacizumab once every 2 weeks.","Progression-free survival (PFS) was the primary end point.","Secondary end points included overall survival (OS), objective response rate, and adverse events.","RESULTS: We recruited 114 patients to our study.","The median PFS was significantly longer in the CPB arm (4.8 months; 95% CI, 3.6 to 6.0 months) than in the CP arm (3.0 months; 95% CI, 1.7 to 4.3 months) (hazard ratio, 0.461; 95% CI, 0.306 to 0.695; P < .001).","Objective response rates were 19.7% and 13.2%, respectively (P = .384).","The median OS was also significantly longer in the CPB arm than in the CP arm (13.6 v 9.0 months; hazard ratio, 0.611; 95% CI, 0.407 to 0.917; P = .017).","No new safety signals were observed.","CONCLUSION: PFS and OS were significantly better in patients with metastatic MM who received bevacizumab in addition to CPB than in those who received CPB alone.","A phase III study should be performed to confirm these benefits (ClinicalTrials.gov identifier: NCT02023710)."],"Aspect":"s","Summary":"No new safety signals were observed.","Indexes":[9],"Sentences":["No new safety signals were observed."],"Revise":false}
{"PMID":"34287772","Document":["Background\u00a0The study determined the safety, pharmacokinetics\/pharmacodynamics (PK\/PD), and recommended Phase II dose of BCT-100 for arginine auxotrophic tumours in a non-Chinese population.","Methods This is a Phase I, 3\u2009+\u20093 dose-escalation, open-label, multi-centre study in two arginine auxotrophic cancers-Malignant Melanoma (MM) and Castration Resistant Prostate Cancer (CRPC).","Patients were enrolled to receive weekly intravenous BCT-100.","The dose cohorts were respectively 0.5\u00a0mg\/kg, 1.0\u00a0mg\/kg, 1.7\u00a0mg\/kg and 2.7\u00a0mg\/kg.","Results There were 14 MM and 9 CRPC patients, 16 males and 7 females with a\u00a0median age of 71.","No dose-limiting toxicities were reported.","Among all the AEs, 18 were drug-related (mostly were Grade 1).","Although there were individual variations in PKs amongst the patients in each cohort, the median arginine level was maintained at 2.5 \u00b5M (lower limit of quantification) in all 4 cohorts of patients after the second BCT-100 injection.","Therapeutic Arginine Depletion was found in the 1.7 and 2.7\u00a0mg\/kg\/week cohorts when anti-tumor activities were observed.","The two cohorts had a similar AUC (20,947 and 19,614\u00a0h*\u00b5g\/ml respectively).","Since the 2.7\u00a0mg\/kg\/week cohort had a more sustained arginine depletion for 2\u00a0weeks, the 2.7\u00a0mg\/kg\/week dose is chosen as the future phase II dose.","There were two complete remissions (1 MM & 1 CRPC), 1PR (MM) and 2 stable diseases with a disease control rate (CR\u2009+\u2009PR\u2009+\u2009SD) of 5\/23 (22%).","Conclusions BCT-100 is safe in a non-Chinese population and has anti-tumor activities in both MM and CRPC.","Weekly BCT-100 at 2.7\u00a0mg\/kg is defined as the optimal biological dose for future clinical phase II studies."],"Aspect":"i","Summary":"The study used a Phase I, 3+3 dose-escalation, open-label, multi-centre design to investigate the safety and pharmacokinetics\/pharmacodynamics of weekly intravenous BCT-100 in patients with arginine auxotrophic cancers, specifically Malignant Melanoma and Castration Resistant Prostate Cancer, with dose cohorts of 0.5 mg\/kg, 1.0 mg\/kg, 1.7 mg\/kg, and 2.7 mg\/kg.","Indexes":[1,2,3],"Sentences":["Methods This is a Phase I, 3\u2009+\u20093 dose-escalation, open-label, multi-centre study in two arginine auxotrophic cancers-Malignant Melanoma (MM) and Castration Resistant Prostate Cancer (CRPC).","Patients were enrolled to receive weekly intravenous BCT-100.","The dose cohorts were respectively 0.5\u00a0mg\/kg, 1.0\u00a0mg\/kg, 1.7\u00a0mg\/kg and 2.7\u00a0mg\/kg."],"Revise":false}
{"PMID":"35862871","Document":["PURPOSE: Combination treatment with BRAF and MEK inhibitors has demonstrated benefits on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the treatment of advanced BRAF V600-mutant melanoma.","Here, we report the 5-year update from the COLUMBUS trial (ClinicalTrials.gov identifier: NCT01909453).","METHODS: Patients with locally advanced unresectable or metastatic BRAF V600-mutant melanoma, untreated or progressed after first-line immunotherapy, were randomly assigned 1:1:1 to encorafenib 450 mg once daily plus binimetinib 45 mg twice daily, vemurafenib 960 mg twice daily, or encorafenib 300 mg once daily.","An updated analysis was conducted 65 months after the last patient was randomly assigned.","RESULTS: Five hundred seventy-seven patients were randomly assigned: 192 to encorafenib plus binimetinib, 191 to vemurafenib, and 194 to encorafenib.","The 5-year PFS and OS rates with encorafenib plus binimetinib were 23% and 35% overall and 31% and 45% in those with normal lactate dehydrogenase levels, respectively.","In comparison, the 5-year PFS and OS rates with vemurafenib were 10% and 21% overall and 12% and 28% in those with normal lactate dehydrogenase levels, respectively.","The median duration of response with encorafenib plus binimetinib was 18.6 months, with disease control achieved in 92.2% of patients.","In comparison, the median duration of response with vemurafenib was 12.3 months, with disease control achieved in 81.2% of patients.","Long-term follow-up showed no new safety concerns, and results were consistent with the known tolerability profile of encorafenib plus binimetinib.","Interactive visualization of the data presented in this article is available at COLUMBUS dashboard.","CONCLUSION: In this 5-year update of part 1 of the COLUMBUS trial, encorafenib plus binimetinib treatment demonstrated continued long-term benefits and a consistent safety profile in patients with BRAF V600-mutant melanoma."],"Aspect":"m","Summary":"The trial involved encorafenib administered at doses of 450 mg once daily and 300 mg once daily, combined with binimetinib at 45 mg twice daily, and vemurafenib at 960 mg twice daily.","Indexes":[2],"Sentences":["METHODS: Patients with locally advanced unresectable or metastatic BRAF V600-mutant melanoma, untreated or progressed after first-line immunotherapy, were randomly assigned 1:1:1 to encorafenib 450 mg once daily plus binimetinib 45 mg twice daily, vemurafenib 960 mg twice daily, or encorafenib 300 mg once daily."],"Revise":false}
{"PMID":"32152202","Document":["PURPOSE: We analyzed whole transcriptome sequencing in tumors from 23 patients with stage III or IV melanoma from a pilot trial of the anti-GD2 immunocytokine, hu14.18-IL2, to identify predictive immune and\/or tumor biomarkers in patients with melanoma at high risk for recurrence.","EXPERIMENTAL DESIGN: Patients were randomly assigned to receive the first of three monthly courses of hu14.18-IL2 immunotherapy either before (Group A) or after (Group B) complete surgical resection of all known diseases.","Tumors were evaluated by histology and whole transcriptome sequencing.","RESULTS: Tumor-infiltrating lymphocyte (TIL) levels directly associated with relapse-free survival (RFS) and overall survival (OS) in resected tumors from Group A, where early responses to the immunotherapy agent could be assessed.","TIL levels directly associated with a previously reported immune signature, which associated with RFS and OS, particularly in Group A tumors.","In Group A tumors, there were decreased cell-cycling gene RNA transcripts, but increased RNA transcripts for repair and growth genes.","We found that outcome (RFS and OS) was directly associated with several immune signatures and immune-related RNA transcripts and inversely associated with several tumor growth-associated transcripts, particularly in Group A tumors.","Most of these associations were not seen in Group B tumors.","CONCLUSIONS: We interpret these data to signify that both immunologic and tumoral cell processes, as measured by RNA-sequencing analyses detected shortly after initiation of hu14.18-IL2 therapy, are associated with long-term survival and could potentially be used as prognostic biomarkers in tumor resection specimens obtained after initiating neoadjuvant immunotherapy."],"Aspect":"m","Summary":"The medicine used is hu14.18-IL2 immunotherapy, administered in three monthly courses.","Indexes":[1],"Sentences":["EXPERIMENTAL DESIGN: Patients were randomly assigned to receive the first of three monthly courses of hu14.18-IL2 immunotherapy either before (Group A) or after (Group B) complete surgical resection of all known diseases."],"Revise":false}
{"PMID":"36029412","Document":["PURPOSE: Trial E1609 demonstrated superior overall survival with ipilimumab 3\u00a0mg\/kg (ipi3) compared to high-dose interferon (HDI) for patients with resected high-risk melanoma.","To inform treatment tolerability, we compared health-related quality of life (HRQoL), gastrointestinal (GI), and treatment-specific physical and cognitive\/emotional symptoms.","We also compared treatment-specific concerns between all arms.","METHODS: We assessed HRQoL using the Functional Assessment of Cancer Therapy-General, physical and cognitive\/emotional concerns using the FACT-Biologic Response Modifier subscale, and GI symptoms with the Functional Assessment of Chronic Illness Therapy-Diarrhea subscale pre-treatment and every 3 months.","The primary outcome was the difference in HRQoL at 3 months between ipi3\/ipi10 vs. HDI.","RESULTS: 549 patients (n\u2009=\u2009158 ipi3; n\u2009=\u2009191 ipi10; n\u2009=\u2009200 HDI) were analyzed.","3-month completion was 58.7%.","Compared to HDI, ipilimumab patients reported better HRQoL (ipi3\u2009=\u200987.5\u2009\u00b1\u200914.6 vs. HDI\u2009=\u200974.7\u2009\u00b1\u200915.4, p\u2009<\u2009.001; ipi10\u2009=\u200984.9\u2009\u00b1\u200916.5 vs. HDI, p\u2009<\u2009.001) and fewer physical (ipi3\u2009=\u200922.3\u2009\u00b1\u20094.6 vs. HDI\u2009=\u200917.1\u2009\u00b1\u20095.4, p\u2009<\u2009.001; ipi10\u2009=\u200921.8\u2009\u00b1\u20095.0 vs. HDI p\u2009<\u2009.001) and cognitive\/emotional (ipi3\u2009=\u200918.6\u2009\u00b1\u20094.4 vs. HDI\u2009=\u200915.0\u2009\u00b1\u20095.3, p\u2009<\u2009.001; ipi10\u2009=\u200917.7\u2009\u00b1\u20094.8 vs. HDI p\u2009<\u2009.001) concerns, but worse GI symptoms (ipi3\u2009=\u200940.8\u2009\u00b1\u20095.0 vs. HDI\u2009=\u200942.2\u2009\u00b1\u20092.9, p\u2009=\u2009.011; ipi10\u2009=\u200939.5\u2009\u00b1\u20097.0 vs. HDI, p\u2009<\u2009.001).","Fewer ipilimumab patients reported worsening treatment-specific concerns (e.g., 52% of ipi3 and 58% of ipi10 reported worsening fatigue vs. 82% HDI, p's\u2009<\u2009.001).","CONCLUSION: PROs demonstrated less toxicity of ipi3 compared to HDI and ipi10.","Priorities for symptom management among patients receiving ipilimumab include GI toxicities, fatigue, weakness, appetite loss, arthralgia, and depression.","TRIAL REGISTRATION: NCT01274338, January 11, 2011 (first posted date) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01274338?term=NCT01274338&draw=2&rank=1 ."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"31792256","Document":["The purpose was to evaluate the potential of diffusion-weighted-magnetic resonance imaging (DW-MRI) and 18F-fludeoxy-glucose-positron emission tomography integrated with CT (FDG-PET\/CT) for prediction of overall survival (OS) following AdCD40L-immunotherapy in patients with metastatic malignant melanoma (MMM).","Twenty-four patients with refractory MMM were treated with immunostimulatory AdCD40L gene therapy in a phase I\/IIa study.","Pre-therapeutic DW-MRI and FDG-PET\/CT were performed and then repeated at 5 and 9 weeks post-treatment.","Evaluation was conducted according to RECIST 1.1 and EORTC criteria.","Apparent diffusion coefficient (ADC), true diffusion coefficient (D), maximum standardized uptake value (SUVmax) were measured in the injected lesions.","Fold changes (F) in ADC (F ADC), D (F D), SUVmax (F SUVmax) were statistically assessed.","F D\u2009\u2265\u20091 and F ADC\u2009\u2265\u20091 were associated with better OS in scans at week 5 and 9 respectively.","F SUVmax was not correlated to OS.","F ADC\u2009\u2265\u20091 in both post-treatment scans and F D\u2009\u2265\u20091 at week 5 were related to a significant decrease of size of the injected lesions.","These results suggest that in patients with MMM treated with AdCD40l, functional parameters of DW-MRI are better early predictors of OS than the established metabolic and morphologic criteria for FDG-PET\/CT and MRI, respectively."],"Aspect":"a","Summary":"The study aims to evaluate the potential of diffusion-weighted-magnetic resonance imaging (DW-MRI) and 18F-fludeoxy-glucose-positron emission tomography integrated with CT (FDG-PET\/CT) for prediction of overall survival (OS) following AdCD40L-immunotherapy in patients with metastatic malignant melanoma (MMM).","Indexes":[0],"Sentences":["The purpose was to evaluate the potential of diffusion-weighted-magnetic resonance imaging (DW-MRI) and 18F-fludeoxy-glucose-positron emission tomography integrated with CT (FDG-PET\/CT) for prediction of overall survival (OS) following AdCD40L-immunotherapy in patients with metastatic malignant melanoma (MMM)."],"Revise":false}
{"PMID":"34243078","Document":["BACKGROUND: BRAF and MEK inhibitors combination, including dabrafenib (D) and trametinib (T) have transformed the treatment of BRAF V600-mutant advanced melanoma patients, including patients with brain metastasis (BM).","In a large phase IIIb, single-arm, open-label, multicenter\u00a0French study, we assessed safety, response to treatment, progression-free survival (PFS) and factors associated with progression, and stratified the population into risk groups.","METHODS: Patients with unresectable, advanced, BRAF V600-mutant melanoma were included, including those with the presence of BM, Eastern Cooperative Oncology Group Performance Status (ECOG PS) \u22642, elevated lactate dehydrogenase (LDH) or previous melanoma treatments.","Responses were determined locally, without central review.","PFS was estimated using the Kaplan-Meier analysis and modelled with multivariate Cox model.","Risk subgroups were identified using a regression tree analysis.","RESULTS: Between March 2015 and November 2016, 856 patients received at least one D\u00a0+\u00a0T dose.","Overall, 92% had stage IV melanoma, 38% ECOG PS \u22651, 32% BM\u00a0and 37.5% elevated LDH.","Median PFS was 8.02 months (95% confidence interval [CI] 7.33-8.77).","Significant factors associated with lower PFS were ECOG PS \u22651, elevated LDH, \u22653 metastatic sites\u00a0and presence of BM.","Patients with <3 metastatic sites, ECOG\u00a0=\u00a00 and no BM had the highest probability of PFS at 6 months (83%, 95% CI\u00a076-87) and 12 months (56%, 95% CI\u00a047-64), respectively.","CONCLUSIONS: This is the largest prospective study in advanced BRAF V600-mutant melanoma patients treated with D\u00a0+\u00a0T, conducted in conditions close to 'real-world practice'.","We confirm previous findings that LDH, ECOG PS and \u22653 metastatic sites are associated with shorter PFS, but the real-world setting introduces BM as a major prognostic factor."],"Aspect":"m","Summary":"The study involved the combination of dabrafenib (D) and trametinib (T) for treating BRAF V600-mutant advanced melanoma patients.","Indexes":[0,6],"Sentences":["BACKGROUND: BRAF and MEK inhibitors combination, including dabrafenib (D) and trametinib (T) have transformed the treatment of BRAF V600-mutant advanced melanoma patients, including patients with brain metastasis (BM).","RESULTS: Between March 2015 and November 2016, 856 patients received at least one D\u00a0+\u00a0T dose."],"Revise":false}
{"PMID":"36863095","Document":["BACKGROUND: Talimogene laherparepvec (T-VEC), a first-in-class oncolytic viral immunotherapy, enhances tumor-specific immune activation.","T-VEC combined with atezolizumab, which blocks inhibitor T-cell checkpoints, could provide greater benefit than either agent alone.","Safety\/efficacy of the combination was explored in patients with triple negative breast cancer (TNBC) or colorectal cancer (CRC) with liver metastases.","METHODS: In this phase Ib, multicenter, open-label, parallel cohort study of adults with TNBC or CRC with liver metastases, T-VEC (106 then 108 PFU\/ml; \u22644 ml) was administered into hepatic lesions via image-guided injection every 21 (\u00b13) days.","Atezolizumab 1200 mg was given on day 1 and every 21 (\u00b13) days thereafter.","Treatment continued until patients experienced dose-limiting toxicity (DLT), had complete response, progressive disease, needed alternative anticancer treatment, or withdrew due to an adverse event (AE).","The primary endpoint was DLT incidence, and secondary endpoints included efficacy and AEs.","RESULTS: Between 19 March 2018 and 6 November 2020, 11 patients with TNBC were enrolled (safety analysis set:\u00a0n\u00a0= 10); between 19 March 2018 and 16 October 2019, 25 patients with CRC were enrolled (safety analysis set: n\u00a0= 24).","For the 5 patients in the TNBC DLT analysis set, no patient had DLT; for the 18 patients in the CRC DLT analysis set, 3 (17%) had DLT, all serious AEs.","AEs were reported by 9 (90%) TNBC and 23 (96%) CRC patients, the majority with grade \u22653 [TNBC, 7 (70%); CRC, 13 (54%)], and 1 was fatal [CRC, 1 (4%)].","Evidence of efficacy was limited.","Overall response rate was 10% (95% confidence interval 0.3-44.5) for TNBC; one (10%) patient had a partial response.","For CRC, no patients had a response; 14 (58%) were unassessable.","CONCLUSIONS: The safety profile reflected known risks with T-VEC including risks of intrahepatic injection; no unexpected safety findings from addition of atezolizumab to T-VEC were observed.","Limited evidence of antitumor activity was observed."],"Aspect":"m","Summary":"The study used T-VEC (10^6 then 10^8 PFU\/ml; \u22644 ml) injected into hepatic lesions every 21 days and atezolizumab 1200 mg given on day 1 and every 21 days thereafter.","Indexes":[3,4],"Sentences":["METHODS: In this phase Ib, multicenter, open-label, parallel cohort study of adults with TNBC or CRC with liver metastases, T-VEC (106 then 108 PFU\/ml; \u22644 ml) was administered into hepatic lesions via image-guided injection every 21 (\u00b13) days.","Atezolizumab 1200 mg was given on day 1 and every 21 (\u00b13) days thereafter."],"Revise":false}
{"PMID":"37592104","Document":["In this randomized phase 2 trial, blockade of cytotoxic T-lymphocyte protein 4 (CTLA-4) with continuation of programmed death protein 1 (PD-1) blockade in patients with metastatic melanoma who had received front-line anti-PD-1 or therapy against programmed cell death 1 ligand 1 and whose tumors progressed was tested in comparison with CTLA-4 blockade alone.","Ninety-two eligible patients were randomly assigned in a 3:1 ratio to receive the combination of ipilimumab and nivolumab, or ipilimumab alone.","The primary endpoint was progression-free survival.","Secondary endpoints included the difference in CD8 T cell infiltrate among responding and nonresponding tumors, objective response rate, overall survival and toxicity.","The combination of nivolumab and ipilimumab resulted in a statistically significant improvement in progression-free survival over ipilimumab (hazard ratio\u2009=\u20090.63, 90% confidence interval (CI)\u2009=\u20090.41-0.97, one-sided P\u2009=\u20090.04).","Objective response rates were 28% (90% CI\u2009=\u200919-38%) and 9% (90% CI\u2009=\u20092-25%), respectively (one-sided P\u2009=\u20090.05).","Grade 3 or higher treatment-related adverse events occurred in 57% and 35% of patients, respectively, which is consistent with the known toxicity profile of these regimens.","The change in intratumoral CD8 T cell density observed in the present analysis did not reach statistical significance to support the formal hypothesis tested as a secondary endpoint.","In conclusion, primary resistance to PD-1 blockade therapy can be reversed in some patients with the combination of CTLA-4 and PD-1 blockade.","Clinicaltrials.gov identifier: NCT03033576 ."],"Aspect":"s","Summary":"Grade 3 or higher treatment-related adverse events occurred in 57% and 35% of patients, respectively.","Indexes":[6],"Sentences":["Grade 3 or higher treatment-related adverse events occurred in 57% and 35% of patients, respectively, which is consistent with the known toxicity profile of these regimens."],"Revise":false}
{"PMID":"35947391","Document":["IMPORTANCE: Medical second opinions are common, although little is known about the best processes for obtaining them.","This study assesses whether knowledge of a prior physician's diagnosis influences consulting physicians' diagnoses.","OBJECTIVE: To measure the extent to which dermatopathologists' diagnoses are influenced by prior diagnostic information from another dermatopathologist.","DESIGN, SETTING, AND PARTICIPANTS: Dermatopathologists were randomly assigned to interpret 1 slide set of 18 melanocytic skin biopsy specimens in 2 phases (5 slide sets totaling 90 cases).","Phase 1 interpretations were conducted without prior diagnostic information.","After a washout period of 12 or more months, dermatopathologists' phase 2 interpretations were conducted with their identical slide set; for a random subset of cases in phase 2, participants were shown prior diagnoses by other dermatopathologists that were either more or less severe than their own phase 1 diagnosis of the case.","Using the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis tool, cases ranged from class I (benign) to class V (\u2265pT1b invasive melanoma).","Data collection took place from August 2018 to March 2021, and data analysis was performed from March to December 2021.","INTERVENTION: Prior diagnoses were actual diagnoses from board-certified and\/or fellowship-trained dermatopathologists.","A prior diagnosis was always in a more severe or less severe diagnostic class than the participant's phase 1 interpretation; more or less severe was determined by the randomization scheme.","In the control condition of no prior diagnostic information, the participants were told that a prior diagnosis was not available.","MAIN OUTCOMES AND MEASURES: When exposure was to a prior diagnosis in a higher diagnostic class, the primary study outcome was whether a participant's diagnosis in phase 2 was in a higher diagnostic class than the participant's diagnosis in phase 1.","When exposure was to a prior diagnosis in a lower diagnostic class, the primary study outcome was whether a participant's diagnosis in phase 2 was in a lower diagnostic class than the participant's diagnosis in phase 1.","The effect of prior diagnostic information was measured using the relative risk (RR) of each outcome relative to the control condition of no prior diagnostic information, adjusted for the diagnostic class of the phase 1 diagnosis.","Prior to data collection, it was hypothesized that participants would be swayed in the direction of prior diagnostic information.","RESULTS: A total of 149 dermatopathologists (median [range] age, 47 years [34-76] years; 101 [68%] were male) provided 5322 interpretations of study cases.","Participants were more likely to increase the severity of their diagnosis when the prior diagnosis was of greater severity compared with when no prior diagnosis was provided (RR, 1.52; 95% CI, 1.34-1.73); likewise, participants gave less severe diagnoses when prior diagnoses were of lesser severity (RR, 1.38; 95% CI, 1.19-1.59).","Trends were similar among dermatopathologists who had previously stated they were \"not at all influenced\" by prior diagnoses.","Prior diagnoses also swayed dermatopathologists away from correct diagnoses.","CONCLUSIONS AND RELEVANCE: In this randomized controlled trial, despite the preference of most dermatopathologists to receive prior diagnoses when providing second opinions, this information swayed them away from a correct diagnosis to an incorrect diagnosis."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"38754916","Document":["BACKGROUND: Chimeric antigen receptor (CAR) T cell therapies specific for the CD19 and B-cell maturation antigen have become an approved standard of care worldwide for relapsed and refractory B-cell malignancies.","If CAR-T cell therapy for non-hematological malignancies is to achieve the same stage of clinical development, then iterative early-phase clinical testing can add value to the clinical development process for evaluating CAR-T cell products containing different CAR designs and manufactured under differing conditions.","METHODS: We conducted a phase 1 trial of third-generation GD2-specific CAR-T cell therapy, which has previously been tested in neuroblastoma patients.","In this study, the GD2-CAR-T therapy was evaluated for the first time in metastatic melanoma patients in combination with BRAF\/MEK inhibitor therapy, and as a monotherapy in patients with colorectal cancer and a patient with fibromyxoid sarcoma.","Feasibility and safety were determined and persistence studies, multiplex cytokine arrays on sera and detailed immune phenotyping of the original CAR-T products, the circulating CAR-T cells, and, in select patients, the tumor-infiltrating CAR-T cells were performed.","RESULTS: We demonstrate the feasibility of manufacturing CAR-T products at point of care for patients with solid cancer and show that a single intravenous infusion was well tolerated with no dose-limiting toxicities or severe adverse events.","In addition, we note significant improvements in CAR-T cell immune phenotype, and expansion when a modified manufacturing procedure was adopted for the latter 6 patients recruited to this 12-patient trial.","We also show evidence of CAR-T cell-mediated immune activity and in some patients expanded subsets of circulating myeloid cells after CAR-T cell therapy.","CONCLUSIONS: This is the first report of third-generation GD2-targeting CAR-T cells in patients with metastatic melanoma and other solid cancers such as colorectal cancer, showing feasibility, safety and immune activity, but limited clinical effect.","TRIAL REGISTRATION NUMBER: ACTRN12613000198729."],"Aspect":"p","Summary":"The study involved a 12-patient trial with metastatic melanoma patients, colorectal cancer patients, and a patient with fibromyxoid sarcoma.","Indexes":[3,6],"Sentences":["In this study, the GD2-CAR-T therapy was evaluated for the first time in metastatic melanoma patients in combination with BRAF\/MEK inhibitor therapy, and as a monotherapy in patients with colorectal cancer and a patient with fibromyxoid sarcoma.","In addition, we note significant improvements in CAR-T cell immune phenotype, and expansion when a modified manufacturing procedure was adopted for the latter 6 patients recruited to this 12-patient trial."],"Revise":false}
{"PMID":"38907159","Document":["Immune checkpoint inhibitors and BRAF-targeted therapy each improve survival in melanoma.","Immune changes early during targeted therapy suggest the mechanisms of each drug class could work synergistically.","In the non-comparative, randomized, phase 2 NeoTrio trial, we investigated whether targeted therapy could boost the proportion of patients achieving long-term recurrence-free survival with neoadjuvant immunotherapy in resectable stage III BRAFV600-mutant melanoma.","Sixty patients (42% females) were randomized to pembrolizumab alone (n\u2009=\u200920), sequential therapy (dabrafenib plus trametinib followed by pembrolizumab; n\u2009=\u200920) or concurrent (triple) therapy (n\u2009=\u200920), followed by surgery and adjuvant therapy.","The primary outcome was pathological response; secondary outcomes included radiographic response, recurrence-free survival, overall survival, surgical outcomes, peripheral blood and tumor analyses and safety.","The pathological response rate was 55% (11\/20; including six pathological complete responses (pCRs)) with pembrolizumab, 50% (10\/20; three pCRs) with sequential therapy and 80% (16\/20; ten pCRs) with concurrent therapy, which met the primary outcome in each arm.","Treatment-related adverse events affected 75-100% of patients during neoadjuvant treatment, with seven early discontinuations (all in the concurrent arm).","At 2\u2009years, event-free survival was 60% with pembrolizumab, 80% with sequential therapy and 71% with concurrent therapy.","Recurrences after major pathological response were more common in the targeted therapy arms, suggesting a reduction in response 'quality' when targeted therapy is added to neoadjuvant immunotherapy.","Risking the curative potential of immunotherapy in melanoma cannot be justified.","Pending longer follow-up, we suggest that immunotherapy and targeted therapy should not be combined in the neoadjuvant setting for melanoma.","ClinicalTrials.gov registration: NCT02858921 ."],"Aspect":"i","Summary":"The NeoTrio trial investigated the combination of targeted therapy (dabrafenib plus trametinib) with neoadjuvant immunotherapy (pembrolizumab) in patients with resectable stage III BRAFV600-mutant melanoma, randomizing patients to receive pembrolizumab alone, sequential therapy, or concurrent triple therapy.","Indexes":[2,3],"Sentences":["In the non-comparative, randomized, phase 2 NeoTrio trial, we investigated whether targeted therapy could boost the proportion of patients achieving long-term recurrence-free survival with neoadjuvant immunotherapy in resectable stage III BRAFV600-mutant melanoma.","Sixty patients (42% females) were randomized to pembrolizumab alone (n\u2009=\u200920), sequential therapy (dabrafenib plus trametinib followed by pembrolizumab; n\u2009=\u200920) or concurrent (triple) therapy (n\u2009=\u200920), followed by surgery and adjuvant therapy."],"Revise":false}
{"PMID":"32700090","Document":["BACKGROUND: New patterns of progression under immune-oncology (IO) antibodies (mAb) have been described such as pseudoprogression.","Except for melanoma, variations between studies reveal difficulties to establish their prevalence.","METHODS: This retrospective study enrolled patients participating in IO phase I trials at Gustave Roussy cancer center for solid tumors excluding melanoma.","Radiological assessment according to iRECIST was correlated with prospectively registered patient characteristics and outcomes.","Pseudoprogression (PsPD) was defined as RECIST-defined progression followed by stabilization or decrease at the next imaging, and dissociated response (DisR) as concomitant decrease in some tumor lesions and increase in others at a same timepoint.","RESULTS: Among 360 patients included, 74% received IO mAb combination: 45% with another IO mAb, 20% with targeted therapy and 10% with radiotherapy.","The overall response rate was 19.7%.","PsPD were observed in 10 (2.8%) patients and DisR in 12 (3.3%) patients.","Atypical responses (AR), including PsPD and DisR, were not associated with any patient's baseline characteristics.","Compare with typical responder patients, patients experiencing AR presented a shorter iPFS (HR 0.34; p\u2009<\u20090.001) and OS (HR 0.27; p\u2009=\u20090.026).","Among the 203 patients who progressed in 12\u00a0weeks, 80 (39.4%) patients were treated beyond progression.","PD was confirmed in 80% of cases, while 10% of patients presented a response.","CONCLUSION: Pseudoprogression and dissociated response are uncommon patterns of progression.","Their prevalence should be balanced with the rate of real progressing patients treated beyond progression.","Prognosis or on-treatment biomarkers are needed to identify early patients who will benefit from immunotherapy."],"Aspect":"p","Summary":"The study enrolled 360 patients with solid tumors (excluding melanoma) who participated in IO phase I trials, with 74% receiving IO mAb combination therapies.","Indexes":[2,5],"Sentences":["METHODS: This retrospective study enrolled patients participating in IO phase I trials at Gustave Roussy cancer center for solid tumors excluding melanoma.","RESULTS: Among 360 patients included, 74% received IO mAb combination: 45% with another IO mAb, 20% with targeted therapy and 10% with radiotherapy."],"Revise":false}
{"PMID":"32205463","Document":["PURPOSE: Preclinical data suggest that radiotherapy (RT) is beneficial in combination with immune checkpoint blockade.","Clinical trials have explored RT with single-agent immune checkpoint blockade, but no trials have reported RT with the combination of nivolumab and ipilimumab.","PATIENTS AND METHODS: We conducted a phase 1 study of patients with stage IV melanoma receiving nivolumab and ipilimumab with two different dose-fractionation schemes of RT.","Patients had at least one melanoma metastasis that would benefit from palliative RT and one metastasis that would not be irradiated.","Nivolumab 1 mg\/kg + ipilimumab 3 mg\/kg and extracranial RT with a dose of 30 Gy in 10 fractions was administered in Cohort A, and then 27 Gy in 3 fractions was administered in Cohort B.","The primary outcome was safety.","RESULTS: Twenty patients were treated (10 in each cohort).","The rates of treatment-related grade 3-4 adverse events in Cohort A and B were 40% and 30%, respectively.","There were no grade \u22653 adverse events attributed to RT.","Patients responded to treatment outside of the irradiated volume (Cohort A 5\/10; Cohort B 1\/9).","No evaluable patients had progression of irradiated metastases.","Immunologic changes were seen in the peripheral blood with increases in T-cell receptor diversity in some responding patients.","CONCLUSIONS: RT with nivolumab and ipilimumab was safe compared with historical data of nivolumab and ipilimumab alone.","Immunologic effects were observed in the peripheral blood.","Randomized studies are ongoing to assess whether RT increases the efficacy of nivolumab and ipilimumab."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"39374099","Document":["PURPOSE: Patients with BRAFV600\/NRASQ61 wild-type melanoma who progress after immune checkpoint inhibitors (ICIs) have a poor prognosis.","MEK inhibition has shown activity in this patient population but is associated with treatment-limiting skin toxicity.","Combining a BRAF inhibitor with a MEK inhibitor is associated with less skin toxicity.","METHODS: This phase II trial investigated trametinib (2 mg once daily) in patients with advanced BRAFV600\/NRASQ61 wild-type, ICI-refractory melanoma.","In case of treatment-limiting skin toxicity, low-dose dabrafenib (50 mg twice daily) was added to trametinib.","After a trial amendment, both drugs were combined up-front.","The confirmed objective response rate (cORR) served as the primary end point.","RESULTS: Twenty-four patients were included (50% male; median age 57 years; 92% Eastern Cooperative Oncology Group Performance Status 0-2; 75% stage IV-M1c\/stage IV-M1d; median number of prior therapies: two [range, 1-5]).","Three patients were enrolled before and 21 patients after the amendment, respectively.","Seven confirmed and one unconfirmed partial responses (PRs) were observed (cORR, 29.2%).","The median duration of response was 16.6 weeks (95% CI, 5.5 to 27.7).","Stable disease (SD) was the best response in an additional five patients.","Among the responding patients, genetic alterations causing mitogen-activated protein kinase (MAPK) pathway activation were documented in six patients.","The disease control rate in patients with MAPK pathway-activating alterations was 64.3% (five confirmed PR, one unconfirmed PR, and three SD).","The median progression-free survival was 13.3 weeks (95% CI, 3.5 to 23.1), and the median overall survival was 54.3 weeks (95% CI, 37.9 to 70.6).","Adding low-dose dabrafenib to trametinib effectively mitigated or prevented treatment-limiting trametinib-related skin toxicity.","CONCLUSION: The combination of trametinib plus low-dose dabrafenib demonstrated encouraging efficacy and effective mitigation of skin toxicity in patients with advanced, ICI-pretreated BRAFV600\/NRASQ61 wild-type melanoma patients.","MAPK pathway-activating alterations hold promise as a predictive biomarker."],"Aspect":"s","Summary":"Treatment-limiting skin toxicity was observed with MEK inhibition, but combining it with a BRAF inhibitor mitigated this side effect.","Indexes":[1,2,15],"Sentences":["MEK inhibition has shown activity in this patient population but is associated with treatment-limiting skin toxicity.","Combining a BRAF inhibitor with a MEK inhibitor is associated with less skin toxicity.","Adding low-dose dabrafenib to trametinib effectively mitigated or prevented treatment-limiting trametinib-related skin toxicity."],"Revise":false}
{"PMID":"34112708","Document":["PURPOSE: Phase II trials have shown encouraging activity with ipilimumab plus fotemustine and ipilimumab plus nivolumab in melanoma brain metastases.","We report the primary analysis and 4-year follow-up of the NIBIT-M2 study, the first phase III trial comparing these regimens with fotemustine in patients with melanoma with brain metastases.","PATIENTS AND METHODS: This phase III study recruited patients 18 years of age and older with BRAF wild-type or mutant melanoma, and active, untreated, asymptomatic brain metastases from nine centers, randomized (1:1:1) to fotemustine, ipilimumab plus fotemustine, or ipilimumab plus nivolumab.","The primary endpoint was overall survival (OS).","RESULTS: From January, 2013 to September, 2018, 27, 26, and 27 patients received fotemustine, ipilimumab plus fotemustine, and ipilimumab plus nivolumab.","Median OS was 8.5 months [95% confidence interval (CI), 4.8-12.2] in the fotemustine arm, 8.2 months (95% CI, 2.2-14.3) in the ipilimumab plus fotemustine arm (HR vs. fotemustine, 1.09; 95% CI, 0.59-1.99; P = 0.78), and 29.2 months (95% CI, 0-65.1) in the ipilimumab plus nivolumab arm (HR vs. fotemustine, 0.44; 95% CI, 0.22-0.87; P = 0.017).","Four-year survival rate was significantly higher for ipilimumab plus nivolumab than fotemustine [(41.0%; 95% CI, 20.6-61.4) vs. 10.9% (95% CI, 0-24.4; P = 0.015)], and was 10.3% (95% CI, 0-22.6) for ipilimumab plus fotemustine.","In the fotemustine, ipilimumab plus fotemustine, and ipilimumab plus nivolumab arms, respectively, 11 (48%), 18 (69%), and eight (30%) patients had treatment-related grade 3 or 4 adverse events, without treatment-related deaths.","CONCLUSIONS: Compared with fotemustine, ipilimumab plus nivolumab significantly improved overall and long-term survival of patients with melanoma with asymptomatic brain metastases."],"Aspect":"i","Summary":"Patients with melanoma and brain metastases were randomized to receive fotemustine, ipilimumab plus fotemustine, or ipilimumab plus nivolumab to compare the overall survival outcomes of these regimens.","Indexes":[2],"Sentences":["PATIENTS AND METHODS: This phase III study recruited patients 18 years of age and older with BRAF wild-type or mutant melanoma, and active, untreated, asymptomatic brain metastases from nine centers, randomized (1:1:1) to fotemustine, ipilimumab plus fotemustine, or ipilimumab plus nivolumab."],"Revise":false}
{"PMID":"32816891","Document":["PURPOSE: Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain, which redirects T cells to kill gp100-expressing tumor cells.","Here, we report a multicenter phase I\/II trial of tebentafusp in metastatic melanoma (NCT01211262) focusing on the mechanism of action of tebentafusp.","PATIENTS AND METHODS: Eighty-four patients with advanced melanoma received tebentafusp.","Treatment efficacy, treatment-related adverse events, and biomarker assessments were performed for blood-derived and tumor biopsy samples obtained at baseline and on-treatment.","RESULTS: Tebentafusp was generally well-tolerated and active in both patients with metastatic uveal melanoma and patients with metastatic cutaneous melanoma.","A 1-year overall survival rate of 65% was achieved for both patient cohorts.","On-treatment cytokine measurements were consistent with the induction of IFN\u03b3 pathway-related markers in the periphery and tumor.","Notably, tebentafusp induced an increase in serum CXCL10 (a T-cell attractant) and a reduction in circulating CXCR3+ CD8+ T cells together with an increase in cytotoxic T cells in the tumor microenvironment.","Furthermore, increased serum CXCL10 or the appearance of rash (likely due to cytotoxic T cells targeting gp100-expressing skin melanocytes) showed a positive association with patient survival.","CONCLUSIONS: These data suggest that redirecting T cells using a gp100-targeting TCR\/anti-CD3 bispecific fusion protein may provide benefit to patients with metastatic melanoma.","Furthermore, the activity observed in these two molecularly disparate melanoma classes hints at the broad therapeutic potential of tebentafusp."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"32157728","Document":["BACKGROUND: Skin cancer is a well-recognized public health issue, and primary prevention is the most effective strategy for reducing skin cancer risk.","The current recommendations are that behavioral counseling for sun safety measures is most beneficial and effective for children and adolescents and that targeting this population at primary and middle schools is the ideal intervention strategy to increase sun-protective behaviors and reduce UV exposure, sunburn incidence, and formation of new moles.","Numerous studies on the effectiveness of school-based sun safety interventions among elementary and middle school students have shown an increase in sun safety knowledge, attitudes, and behaviors following the intervention.","OBJECTIVE: To conduct a pilot feasibility study of \"Live Sun Smart!,\" (LSS) a school-based, multicomponent, interactive sun safety presentation, at changing sun safety knowledge, attitudes, and behaviors among middle school students.","METHODS: A non-randomized, single-group pretest-posttest interventional pilot study of the LSS program among children enrolled in grade 6.","RESULTS: After exposure to LSS, participants were more likely to give correct answers to knowledge-based sun safety questions and to report negative attitudes toward tanning.","Minimal and not significant changes were found in self-reported sun safety behaviors, though students did report an intention to change behaviors following the intervention.","Participants were satisfied with the program and believed it increased their sun safety knowledge.","CONCLUSION: Live Sun Smart!","appears to be an effective school-based, multicomponent sun safety program for improving sun safety knowledge and attitudes toward tanning among middle school students in this initial test of it.","The strengths and weaknesses of this pilot study have implications for future research."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"33191484","Document":["BACKGROUND: Cutaneous melanoma and distant organ metastasis has varying outcomes.","Considering all prognostic indicators in a prediction model might assist in selecting cases who could benefit from a personalized therapy strategy.","OBJECTIVE: This study aimed to develop and validate a prognostic model for patients with metastatic melanoma.","METHODS: A total of 1535 cases diagnosed with metastatic cutaneous melanoma (stage IV) were identified from the Surveillance, Epidemiology, and End Results database.","Patients were randomly divided into the training (n\u2009=\u20091023) and validation (n\u2009=\u2009512) cohorts.","A prognostic nomogram was established based predominantly on results from the competing-risk regression model for predicting cancer-specific death (CSD).","The area under the time-dependent receiver operating characteristic curve (AUC), calibration curves, and decision curve analyses (DCAs) were used to evaluate the nomogram.","RESULTS: No significant differences were observed in the clinical characteristics between the training and validation cohorts.","In the training cohort, patient-, tumor-, and treatment-related predictors of CSD for metastatic melanoma included age, sex, race, marital status, insurance, American Joint Committee on Cancer T and N stage, number of metastatic organs, surgical treatment, and chemotherapy.","All these factors were used for nomogram construction.","The time-dependent AUC values of the training and validation cohorts suggested a favorable performance and discrimination of the nomogram.","The 6-, 12-, and 18-month AUC values were 0.706, 0.700, and 0.706 in the training cohort, and 0.702, 0.670, and 0.656 in the validation cohort, respectively.","The calibration curves for the probability of death at 6, 12, and 18\u00a0months showed acceptable agreement between the values predicted by the nomogram and the observed outcomes in both cohorts.","DCA curves showed good positive net benefits in the prognostic model among most of the threshold probabilities at different time points (death at 6, 12, and 18\u00a0months).","Based on the total nomogram scores of each case, all patients were divided into the low-risk (n\u2009=\u2009511), intermediate-risk (n\u2009=\u2009512), and high-risk (n\u2009=\u2009512) groups, and the risk classification could identify cases with a high risk of death in both cohorts.","CONCLUSIONS: A predictive nomogram and a corresponding risk classification system for CSD in patients with metastatic melanoma were developed in this study, which may assist in patient counseling and in guiding clinical decision making for cases with metastatic melanoma."],"Aspect":"a","Summary":"The study aimed to develop and validate a prognostic model for patients with metastatic melanoma.","Indexes":[2],"Sentences":["OBJECTIVE: This study aimed to develop and validate a prognostic model for patients with metastatic melanoma."],"Revise":false}
{"PMID":"32083398","Document":["Vemurafenib is a BRAF kinase inhibitor indicated for the treatment of patients with BRAFV600 mutation-positive unresectable or metastatic melanoma and Erdheim-Chester disease.","This phase 1, open-label, single-arm study was designed to estimate absolute bioavailability of oral vemurafenib at steady state and to characterize the pharmacokinetics of a single intravenous microdose of 14 C-labeled vemurafenib in patients with BRAFV600 mutation-positive malignancies.","Patients received oral vemurafenib 960\u00a0mg twice daily on days\u00a01 through 28, with a single intravenous infusion of 14 C-labeled vemurafenib solution (3\u00a0mL, corresponding to a radioactive dose of 18.5\u00a0kBq and a vemurafenib dose of 20\u00a0\u00b5g) given on the morning of day\u00a021, immediately following the morning dose of oral vemurafenib.","A total of 6\u00a0patients were enrolled.","Four patients who received 14 C-labeled vemurafenib infusion were included in the pharmacokinetic and bioavailability analyses.","Geometric mean absolute bioavailability of oral vemurafenib at steady state, calculated as the ratio of dose-normalized area under the curve during the dosing interval (AUC\u03c4 ) following oral vemurafenib dose to dose-normalized AUC from time 0 extrapolated to infinity (AUC0-inf ) following vemurafenib intravenous dose, was 57.8%.","The majority of radioactivity (geometric mean 41%) was recovered in feces, and a small proportion (geometric mean 1.4%) was recovered in urine.","Treatment-emergent adverse events occurred in 5 of 6 (83%) patients and were all grade 1\/2 in severity, except for 1 grade-4 anaphylactic reaction occurring during infusion of 14 C-labeled vemurafenib, which was thought to be related to the excipient polysorbate 80 in the intravenous formulation."],"Aspect":"a","Summary":"The study aims to estimate the absolute bioavailability of oral vemurafenib at steady state and characterize the pharmacokinetics of a single intravenous microdose of 14 C-labeled vemurafenib in patients with BRAFV600 mutation-positive malignancies.","Indexes":[1],"Sentences":["This phase 1, open-label, single-arm study was designed to estimate absolute bioavailability of oral vemurafenib at steady state and to characterize the pharmacokinetics of a single intravenous microdose of 14 C-labeled vemurafenib in patients with BRAFV600 mutation-positive malignancies."],"Revise":false}
{"PMID":"37434093","Document":["AIM: The aim of this study was to construct and validate a nomogram to predict the 1-, 3- and 5-year overall survival (OS) in external ear melanoma (EEM) patients in the elderly based on the Surveillance, Epidemiology, and End Results (SEER) database.","METHODS: The information of patients diagnosed with EEM in the elderly between 2010 and 2014 was downloaded from the SEER database.","Univariable and multivariable Cox analyses were carried out to identify the independent characteristics, and the independent factors were further included to construct a nomogram.","The discriminative ability and calibration of the nomogram to predict OS were tested using C-index value, and calibration plots.","Based on the risk score of the nomogram, the patients were divided into high- and low-risk subgroup.","Finally, the survival differences of different subgroups were explored by Kaplan-Meier curves.","All statistical analyses were performed by R 4.2.0.","RESULTS: A total of 710 elderly EMM patients were included and randomly divided into training cohort and validation cohort.","Univariable Cox regression were used to identify age, race, sex, American Joint Committee on Cancer (AJCC), T, surgery, radiation, chemotherapy, and tumor size as independent risk factors.","Then, multivariable Cox model to determine significant risk factors was used to establish the selected factors.","A nomogram for predicting the 1-, 3- and 5-year OS was constructed using the independent variables including age, AJCC, T, surgery and chemotherapy.","The C-index values were 0.78 (95% CI 0.75-0.81) in training set and 0.72 (95% CI 0.66-0.78) in validation set.","The calibration curves were closer to ideal curves indicated the accurate predictive ability of this nomogram.","The elderly patients with EEM in the low-risk group showed a longer OS than patients in the high-risk group in both training and validation cohorts.","CONCLUSIONS: Our study established and validated a novel model to predict 1-, 3- and 5-year OS for EEM.","The individualized nomogram has a good prognostic ability and can be used as a new survival prediction tool for the elderly patients with EMM."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"35577503","Document":["BACKGROUND: This phase 1b study (NCT02323191) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of colony-stimulating factor-1 receptor-blocking monoclonal antibody (mAb) emactuzumab in combination with the programmed cell death-1 ligand (PD-L1)-blocking mAb atezolizumab in patients with advanced solid tumors na\u00efve or experienced for immune checkpoint blockers (ICBs).","METHODS: Emactuzumab (500-1350\u2009mg flat) and atezolizumab (1200\u2009mg flat) were administered intravenously every 3 weeks.","Dose escalation of emactuzumab was conducted using the 3+3 design up to the maximum tolerated dose (MTD) or optimal biological dose (OBD).","Extension cohorts to evaluate pharmacodynamics and clinical activity were conducted in metastatic ICB-naive urothelial bladder cancer (UBC) and ICB-pretreated melanoma (MEL), non-small cell lung cancer (NSCLC) and UBC patients.","RESULTS: Overall, 221 patients were treated.","No MTD was reached and the OBD was determined at 1000\u2009mg of emactuzumab in combination with 1200\u2009mg of atezolizumab.","Grade \u22653 treatment-related adverse events occurred in 25 (11.3%) patients of which fatigue and rash were the most common (14 patients (6.3%) each).","The confirmed objective response rate (ORR) was 9.8% for ICB-na\u00efve UBC, 12.5% for ICB-experienced NSCLC, 8.3% for ICB-experienced UBC and 5.6% for ICB-experienced MEL patients, respectively.","Tumor biopsy analyses demonstrated increased activated CD8 +tumor infiltrating T lymphocytes (TILs) associated with clinical benefit in ICB-na\u00efve UBC patients and less tumor-associated macrophage (TAM) reduction in ICB-experienced compared with ICB-na\u00efve patients.","CONCLUSION: Emactuzumab in combination with atezolizumab demonstrated a manageable safety profile with increased fatigue and skin rash over usual atezolizumab monotherapy.","A considerable ORR was particularly seen in ICB-experienced NSCLC patients.","Increase ofCD8 +TILs under therapy appeared to be associated with persistence of a TAM subpopulation."],"Aspect":"m","Summary":"The study used emactuzumab (500-1350 mg flat) and atezolizumab (1200 mg flat) administered intravenously every 3 weeks.","Indexes":[1,5],"Sentences":["METHODS: Emactuzumab (500-1350\u2009mg flat) and atezolizumab (1200\u2009mg flat) were administered intravenously every 3 weeks.","No MTD was reached and the OBD was determined at 1000\u2009mg of emactuzumab in combination with 1200\u2009mg of atezolizumab."],"Revise":false}
{"PMID":"34413169","Document":["BACKGROUND: We performed a clinical trial to evaluate safety and immunogenicity of a novel long peptide vaccine administered in combinations of incomplete Freund's adjuvant (IFA) and agonists for TLR3 (polyICLC) and TLR7\/8 (resiquimod).","We hypothesized that T cell responses to minimal epitope peptides (MEPs) within the long peptides would be enhanced compared with prior vaccines with MEP themselves and that T cell responses would be enhanced with TLR agonists, compared with IFA alone.","METHODS: Participants with resected stage IIB-IV melanoma were vaccinated with seven long melanoma peptides (LPV7) from tyrosinase, gp100, MAGE-A1, MAGE-A10, and NY-ESO-1, each containing a known MEP for CD8+ T cells, plus a tetanus helper peptide (Tet) restricted by Class II MHC.","Enrollment was guided by an adaptive design to one of seven adjuvant combinations.","Vaccines were administered at weeks 1, 2, 3, 6, 9, 12 at rotating injection sites.","T cell and IgG antibody (Ab) responses were measured with IFN-gamma ELIspot assay ex vivo and ELISA, respectively.","RESULTS: Fifty eligible participants were assigned to seven study groups, with highest enrollment on arm E (LPV7+Tet+IFA+polyICLC).","There was one dose-limiting toxicity (DLT) in Group E (grade 3 injection site reaction, 6% DLT rate).","All other treatment-related adverse events were grades 1-2.","The CD8+ T cell immune response rate (IRR) to MEPs was 18%, less than in prior studies using MEP vaccines in IFA.","The CD8+ T cell IRR trended higher for IFA-containing adjuvants (24%) than adjuvants containing only TLR agonists (6%).","Overall T cell IRR to full-length LPV7 was 30%; CD4+ T cell IRR to Tet was 40%, and serum Ab IRR to LPV7 was 84%.","These IRRs also trended higher for IFA-containing adjuvants (36% vs 18%, 48% vs 24%, and 97% vs 60%, respectively).","CONCLUSIONS: The LPV7 vaccine is safe with each of seven adjuvant strategies and induced T cell responses to CD8 MEPs ex vivo in a subset of patients but did not enhance IRRs compared with prior vaccines using short peptides.","Immunogenicity was supported more by IFA than by TLR agonists alone and may be enhanced by polyICLC plus IFA.","TRIAL REGISTRATION NUMBER: NCT02126579."],"Aspect":"s","Summary":"The observed side effects of the treatment included one dose-limiting toxicity (grade 3 injection site reaction), with all other treatment-related adverse events being grades 1-2.","Indexes":[7,8],"Sentences":["There was one dose-limiting toxicity (DLT) in Group E (grade 3 injection site reaction, 6% DLT rate).","All other treatment-related adverse events were grades 1-2."],"Revise":false}
{"PMID":"32448802","Document":["BACKGROUND: With immunotherapy gaining increasing approval for treatment of different tumor types, scientists rely on cutting edge methods for the monitoring of immune responses and biomarker development in patients.","Due to the lack of tools to efficiently detect rare circulating human tumor-specific CD4 T cells, their characterization in patients still remains very limited.","METHODS: We have used combinatorial staining strategies with peptide major histocompatibility complex class II (pMHCII) multimer constructs of different alleles to establish an optimized staining procedure for in vitro and direct ex-vivo visualization of tumor-specific CD4 T cells, in patient samples.","Furthermore, we have generated reversible multimers to achieve optimal cell staining and yet disassemble prior to in vitro cell expansion, thus preventing activation induced cell death.","RESULTS: We observed a vastly improved detection of tumor-specific, viral-specific and bacterial-specific cells with our optimization methods compared with the non-optimized staining procedure.","By increasing the variety of fluorochromes used to label the pMHCII multimers, we were also able to increase the parallel detection of different specificities within one sample, including antigen-specific CD8 T cells.","A decrease in cell viability was observed when using the full optimization method, but this was mitigated by the removal of neuraminidase and the use of reversible multimers.","CONCLUSION: This new optimized staining procedure represents an advance toward better detection and analysis of antigen-specific CD4 T cells.","It should facilitate state-of-the art precision monitoring of tumor-specific CD4 T cells and contribute to accelerate the use and the targeting of these cells in cancer immunotherapy."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"34817543","Document":["IMPORTANCE: Patient-led surveillance is a promising new model of follow-up care following excision of localized melanoma.","OBJECTIVE: To determine whether patient-led surveillance in patients with prior localized primary cutaneous melanoma is as safe, feasible, and acceptable as clinician-led surveillance.","DESIGN, SETTING, AND PARTICIPANTS: This was a pilot for a randomized clinical trial at 2 specialist-led clinics in metropolitan Sydney, Australia, and a primary care skin cancer clinic managed by general practitioners in metropolitan Newcastle, Australia.","The participants were 100 patients who had been treated for localized melanoma, owned a smartphone, had a partner to assist with skin self-examination (SSE), and had been routinely attending scheduled follow-up visits.","The study was conducted from November 1, 2018, to January 17, 2020, with analysis performed from September 1, 2020, to November 15, 2020.","INTERVENTION: Participants were randomized (1:1) to 6 months of patient-led surveillance (the intervention comprised usual care plus reminders to perform SSE, patient-performed dermoscopy, teledermatologist assessment, and fast-tracked unscheduled clinic visits) or clinician-led surveillance (the control was usual care).","MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of eligible and contacted patients who were randomized.","Secondary outcomes included patient-reported outcomes (eg, SSE knowledge, attitudes, and practices, psychological outcomes, other health care use) and clinical outcomes (eg, clinic visits, skin surgeries, subsequent new primary or recurrent melanoma).","RESULTS: Of 326 patients who were eligible and contacted, 100 (31%) patients (mean [SD] age, 58.7 [12.0] years; 53 [53%] men) were randomized to patient-led (n\u2009=\u200949) or clinician-led (n\u2009=\u200951) surveillance.","Data were available on patient-reported outcomes for 66 participants and on clinical outcomes for 100 participants.","Compared with clinician-led surveillance, patient-led surveillance was associated with increased SSE frequency (odds ratio [OR], 3.5; 95% CI, 0.9 to 14.0) and thoroughness (OR, 2.2; 95% CI, 0.8 to 5.7), had no detectable adverse effect on psychological outcomes (fear of cancer recurrence subscale score; mean difference, -1.3; 95% CI, -3.1 to 0.5), and increased clinic visits (risk ratio [RR], 1.5; 95% CI, 1.1 to 2.1), skin lesion excisions (RR, 1.1; 95% CI, 0.6 to 2.0), and subsequent melanoma diagnoses and subsequent melanoma diagnoses (risk difference, 10%; 95% CI, -2% to 23%).","New primary melanomas and 1 local recurrence were diagnosed in 8 (16%) of the participants in the intervention group, including 5 (10%) ahead of routinely scheduled visits; and in 3 (6%) of the participants in the control group, with none (0%) ahead of routinely scheduled visits (risk difference, 10%; 95% CI, 2% to 19%).","CONCLUSIONS AND RELEVANCE: This pilot of a randomized clinical trial found that patient-led surveillance after treatment of localized melanoma appears to be safe, feasible, and acceptable.","Experiences from this pilot study have prompted improvements to the trial processes for the larger trial of the same intervention.","TRIAL REGISTRATION: http:\/\/anzctr.org.au Identifier: ACTRN12616001716459."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"35998300","Document":["PURPOSE: The combination of talimogene laherparepvec (T-VEC) and pembrolizumab previously demonstrated an acceptable safety profile and an encouraging complete response rate (CRR) in patients with advanced melanoma in a phase Ib study.","We report the efficacy and safety from a phase III, randomized, double-blind, multicenter, international study of T-VEC plus pembrolizumab (T-VEC-pembrolizumab) versus placebo plus pembrolizumab (placebo-pembrolizumab) in patients with advanced melanoma.","METHODS: Patients with stage IIIB-IVM1c unresectable melanoma, na\u00efve to antiprogrammed cell death protein-1, were randomly assigned 1:1 to T-VEC-pembrolizumab or placebo-pembrolizumab.","T-VEC was administered at \u2264 4 \u00d7 106 plaque-forming unit (PFU) followed by \u2264 4 \u00d7 108 PFU 3 weeks later and once every 2 weeks until dose 5 and once every 3 weeks thereafter.","Pembrolizumab was administered intravenously 200 mg once every 3 weeks.","The dual primary end points were progression-free survival (PFS) per modified RECIST 1.1 by blinded independent central review and overall survival (OS).","Secondary end points included objective response rate per mRECIST, CRR, and safety.","Here, we report the primary analysis for PFS, the second preplanned interim analysis for OS, and the final analysis.","RESULTS: Overall, 692 patients were randomly assigned (346 T-VEC-pembrolizumab and 346 placebo-pembrolizumab).","T-VEC-pembrolizumab did not significantly improve PFS (hazard ratio, 0.86; 95% CI, 0.71 to 1.04; P = .13) or OS (hazard ratio, 0.96; 95% CI, 0.76 to 1.22; P = .74) compared with placebo-pembrolizumab.","The objective response rate was 48.6% for T-VEC-pembrolizumab (CRR 17.9%) and 41.3% for placebo-pembrolizumab (CRR 11.6%); the durable response rate was 42.2% and 34.1% for the arms, respectively.","Grade \u2265 3 treatment-related adverse events occurred in 20.7% of patients in the T-VEC-pembrolizumab arm and in 19.5% of patients in the placebo-pembrolizumab arm.","CONCLUSION: T-VEC-pembrolizumab did not significantly improve PFS or OS compared with placebo-pembrolizumab.","Safety results of the T-VEC-pembrolizumab combination were consistent with the safety profiles of each agent alone."],"Aspect":"o","Summary":"The study found that T-VEC-pembrolizumab did not significantly improve progression-free survival or overall survival compared to placebo-pembrolizumab.","Indexes":[9,12],"Sentences":["T-VEC-pembrolizumab did not significantly improve PFS (hazard ratio, 0.86; 95% CI, 0.71 to 1.04; P = .13) or OS (hazard ratio, 0.96; 95% CI, 0.76 to 1.22; P = .74) compared with placebo-pembrolizumab.","CONCLUSION: T-VEC-pembrolizumab did not significantly improve PFS or OS compared with placebo-pembrolizumab."],"Revise":false}
{"PMID":"35432383","Document":["The CSF-470 vaccine (VACCIMEL) plus BCG and GM-CSF as adjuvants has been assayed in cutaneous melanoma patients.","In the adjuvant randomized Phase II study CASVAC-0401, vaccinated patients had longer distant metastasis-free survival (DMFS) than those treated with IFN\u03b12b.","Five years after locking the data, an actualization was performed.","The benefit in DMFS was maintained in the vaccinated group versus the IFN\u03b12b-treated group (p = 0.035), with a median DMFS of 96 months for VACCIMEL and 13 months for IFN\u03b12b.","The favorable risk-benefit ratio was maintained.","DMFS was also analyzed as a single cohort in all the IIB, IIC, and III patients (n = 30) who had been treated with VACCIMEL.","The median DMFS was 169 months, and at 48 months follow-up, it was 71.4%, which was not statistically different from DMFS of previously published results obtained in adjuvancy with ipilimumab, pembrolizumab, nivolumab, or dabrafenib\/trametinib.","The possible toxicity of combining VACCIMEL with anti-immune checkpoint inhibitors (ICKi) was analyzed, especially since VACCIMEL was co-adjuvated with BCG in every vaccination.","A patient with in-transit metastases was studied to produce a proof of concept.","During treatment with VACCIMEL, the patient developed T-cell clones reactive towards tumor-associated antigens.","Three years after ending the VACCIMEL study, the patient progressed and was treated with ICKi.","During ICKi treatment, the patient did not reveal any toxicity due to previous BCG treatment.","When she recurred after a 4-year treatment with nivolumab, a biopsy was obtained and immunohistochemistry and RNA-seq were performed.","The tumor maintained expression of tumor-associated antigens and HLA-I and immune infiltration, with immunoreactive and immunosuppressive features.","VACCIMEL plus BCG and GM-CSF is an effective treatment in adjuvancy for stages IIB, IIC, and III cutaneous melanoma patients, and it is compatible with subsequent treatments with ICKi."],"Aspect":"p","Summary":"The study included 30 patients with cutaneous melanoma in stages IIB, IIC, and III, and mentioned one patient with in-transit metastases.","Indexes":[5,8],"Sentences":["DMFS was also analyzed as a single cohort in all the IIB, IIC, and III patients (n = 30) who had been treated with VACCIMEL.","A patient with in-transit metastases was studied to produce a proof of concept."],"Revise":false}
{"PMID":"33770575","Document":["BACKGROUND: Genetic aberrations in the cyclin-dependent kinase (CDK)4 pathway occur in 82% of patients with acral melanoma (AM), which is the predominant subtype of melanoma in China.","We aimed to evaluate the anti-tumour activity of palbociclib, a selective CDK4\/6 inhibitor, in patients with advanced AM with CDK4 pathway gene aberrations.","METHODS: In this phase II trial, patients with advanced AM with CDK4 or\/and CCND1 gain or\/and CDKN2A loss were treated with oral palbociclib (125\u00a0mg) on days 1-21 of a 28-day cycle.","The primary end-point was overall response rate (ORR).","Secondary end-points were progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs).","Whole-exome sequencing and multiplex immunohistochemistry of the available formalin-fixed, paraffin-embedded samples of nine patients were analysed to explore the predictive biomarkers of palbociclib response.","RESULTS: Fifteen patients were enrolled.","Three (20.0%) patients achieved tumour shrinkage at 8 weeks, including one with confirmed partial response.","At data cut-off date, treatment was ongoing for one patient.","The median PFS was 2.2\u00a0mo (range: 1.5-13.3\u00a0mo; 95% confidence interval [CI]: 1.9-2.5), and the median OS was 9.5\u00a0mo (range: 2.6-14.1\u00a0mo, 95% CI: 5.7-13.4).","Eight patients died due to disease progression.","The most common TRAEs were leukopenia (87%; Grade III\/IV, 27%), neutropenia (80%; grade III\/IV, 27%), and fatigue (53%; grade III\/IV, 7%).","Significant JAK2 deletions and SH2B3 amplifications were observed in patients who did not achieve any clinical benefit (CB) with palbociclib treatment.","MCM7 amplification or protein expression level was found to be associated with CB.","CONCLUSIONS: Palbociclib monotherapy demonstrated preliminary efficacy and an acceptable safety profile in advanced AM patients with CDK4 pathway aberrations.","Patients with amplification or high protein levels of MCM7 were more prone to benefit from palbociclib.","The JAK-STAT pathway might play a role in the mechanism of action of palbociclib in AM.","TRIAL REGISTRATION NUMBER: NCT03454919.","THE DATE OF REGISTRATION: March 6, 2018."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"33558721","Document":["Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in patients with macroscopic stage III melanoma in the phase 1b OpACIN ( NCT02437279 ) and phase 2 OpACIN-neo ( NCT02977052 ) studies1,2.","While the results are promising, data on the durability of these pathologic responses and baseline biomarkers for response and survival were lacking.","After a median follow-up of 4 years, none of the patients with a pathologic response (n\u2009=\u20097\/9 patients) in the OpACIN study had relapsed.","In OpACIN-neo (n\u2009=\u200986), the 2-year estimated relapse-free survival was 84% for all patients, 97% for patients achieving a pathologic response and 36% for nonresponders (P\u2009<\u20090.001).","High tumor mutational burden (TMB) and high interferon-gamma-related gene expression signature score (IFN-\u03b3 score) were associated with pathologic response and low risk of relapse; pRR was 100% in patients with high IFN-\u03b3 score\/high TMB; patients with high IFN-\u03b3 score\/low TMB or low IFN-\u03b3 score\/high TMB had pRRs of 91% and 88%; while patients with low IFN-\u03b3 score\/low TMB had a pRR of only 39%.","These data demonstrate long-term benefit in patients with a pathologic response and show the predictive potential of TMB and IFN-\u03b3 score.","Our findings provide a strong rationale for a randomized phase 3 study comparing neoadjuvant ipilimumab plus nivolumab versus standard adjuvant therapy with antibodies against the programmed cell death protein-1 (anti-PD-1) in macroscopic stage III melanoma."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"31839677","Document":["BACKGROUND: Aiming to improve treatment options for BRAF wild-type melanoma, we previously conducted the DOC-MEK study of docetaxel with MEK inhibitor (MEKi) selumetinib or placebo, revealing trends to prolongation of progression-free survival (hazard ratio 0.75, P\u2009=\u20090.130), and improved response rates (32% vs 14%, P\u2009=\u20090.059) with docetaxel plus selumetinib.","NRAS status did not associate with outcome.","Here, the aim was to identify novel biomarkers of response to MEKi.","METHODS: A MEK 6 gene signature was quantified using NanoString and correlated with clinical outcomes.","Two components of the gene signature were investigated by gene silencing in BRAF\/NRAS wild-type melanoma cells.","RESULTS: In melanomas of patients on the selumetinib but not the placebo arm, two gene signature components, dual-specificity protein phosphatase 4 (DUSP4) and ETS translocation variant 4 (ETV4), were expressed more highly in responders than non-responders.","In vitro, ETV4 depletion inhibited cell survival but did not influence sensitivity to MEKi selumetinib or trametinib.","In contrast, DUSP4-depleted cells showed enhanced cell survival and increased resistance to both selumetinib and trametinib.","CONCLUSIONS: ETV4 and DUSP4 associated with clinical response to docetaxel plus selumetinib.","DUSP4 depletion induced MEKi resistance, suggesting that DUSP4 is not only a biomarker but also a mediator of MEKi sensitivity.","CLINICAL TRIAL REGISTRATION: DOC-MEK (EudraCT no: 2009-018153-23)."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"32313721","Document":["The efficacy of immune checkpoint inhibitors has been shown to depend on preexisting antitumor immunity; thus, their combination with cancer vaccines is an attractive therapeutic approach.","Plasmacytoid dendritic cells (PDC) are strong inducers of antitumor responses and represent promising vaccine candidates.","We developed a cancer vaccine approach based on an allogeneic PDC line that functioned as a very potent antigen-presenting cell in pre-clinical studies.","In this phase Ib clinical trial, nine patients with metastatic stage IV melanoma received up to 60 million irradiated PDC line cells loaded with 4 melanoma antigens, injected subcutaneously at weekly intervals.","The primary endpoints were safety and tolerability.","The vaccine was well\u00a0tolerated and no serious vaccine-induced side effects were recorded.","Strikingly, there was no allogeneic response toward the vaccine, but a significant increase in the frequency of circulating anti-tumor specific T lymphocytes was observed in two patients, accompanied by a switch from a na\u00efve to memory phenotype, thus demonstrating priming of antigen-specific T-cells.","Signs of clinical activity were observed, including four stable diseases according to IrRC and vitiligo\u00efd lesions.","Four patients were still alive at week 48.","We also demonstrate the in vitro enhancement of specific T cell expansion induced by the synergistic combination of peptide-loaded PDC line with anti-PD-1, as compared to peptide-loaded PDC line alone.","Taken together, these clinical observations demonstrate the ability of the PDC line based-vaccine to prime and expand antitumor CD8+\u00a0responses in cancer patients.","Further trials should test the combination of this vaccine with immune checkpoint inhibitors."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"37377890","Document":["PURPOSE: Treatments are limited for metastatic melanoma and metastatic triple-negative breast cancer (mTNBC).","This pilot phase I trial (NCT03060356) examined the safety and feasibility of intravenous RNA-electroporated chimeric antigen receptor (CAR) T cells targeting the cell-surface antigen cMET.","EXPERIMENTAL DESIGN: Metastatic melanoma or mTNBC subjects had at least 30% tumor expression of cMET, measurable disease and progression on prior therapy.","Patients received up to six infusions (1 \u00d7 10e8 T cells\/dose) of CAR T cells without lymphodepleting chemotherapy.","Forty-eight percent of prescreened subjects met the cMET expression threshold.","Seven (3 metastatic melanoma, 4 mTNBC) were treated.","RESULTS: Mean age was 50 years (35-64); median Eastern Cooperative Oncology Group 0 (0-1); median prior lines of chemotherapy\/immunotherapy were 4\/0 for TNBC and 1\/3 for melanoma subjects.","Six patients experienced grade 1 or 2 toxicity.","Toxicities in at least 1 patient included anemia, fatigue, and malaise.","One subject had grade 1 cytokine release syndrome.","No grade 3 or higher toxicity, neurotoxicity, or treatment discontinuation occurred.","Best response was stable disease in 4 and disease progression in 3 subjects.","mRNA signals corresponding to CAR T cells were detected by RT-PCR in all patients' blood including in 3 subjects on day +1 (no infusion administered on this day).","Five subjects underwent postinfusion biopsy with no CAR T-cell signals seen in tumor.","Three subjects had paired tumor tissue; IHC showed increases in CD8 and CD3 and decreases in pS6 and Ki67.","CONCLUSIONS: Intravenous administration of RNA-electroporated cMET-directed CAR T cells is safe and feasible.","SIGNIFICANCE: Data evaluating CAR T therapy in patients with solid tumors are limited.","This pilot clinical trial demonstrates that intravenous cMET-directed CAR T-cell therapy is safe and feasible in patients with metastatic melanoma and metastatic breast cancer, supporting the continued evaluation of cellular therapy for patients with these malignancies."],"Aspect":"m","Summary":"The trial involved intravenous RNA-electroporated CAR T cells targeting cMET, with patients receiving up to six infusions of 1 \u00d7 10e8 T cells per dose.","Indexes":[1,3],"Sentences":["This pilot phase I trial (NCT03060356) examined the safety and feasibility of intravenous RNA-electroporated chimeric antigen receptor (CAR) T cells targeting the cell-surface antigen cMET.","Patients received up to six infusions (1 \u00d7 10e8 T cells\/dose) of CAR T cells without lymphodepleting chemotherapy."],"Revise":false}
{"PMID":"34780711","Document":["BACKGROUND: The dependence of the adaptive immune system on circadian rhythm is an emerging field of study with potential therapeutic implications.","We aimed to determine whether specific time-of-day patterns of immune checkpoint inhibitor infusions might alter melanoma treatment efficacy.","METHODS: Melanoma Outcomes Following Immunotherapy (MEMOIR) is a longitudinal study of all patients with melanoma who received ipilimumab, nivolumab, or pembrolizumab, or a combination of these at a single tertiary cancer centre (Winship Cancer Institute of Emory University, Atlanta, GA, USA).","For this analysis, we collected deidentified participant-level data from the MEMOIR database for adults (age \u226518 years) diagnosed with stage IV melanoma between 2012 and 2020.","Those who received fewer than four infusions were excluded.","Standard of care doses were used, with modifications at the treating physicians' discretion.","The primary outcome was overall survival, defined as death from any cause and indexed from date of first infusion of immune checkpoint inhibitor.","We calculated the association between overall survival and proportion of infusions of immune checkpoint inhibitors received after 1630 h (a composite time cutoff derived from seminal studies of the immune-circadian rhythm to represent onset of evening) using Cox regression and propensity score-matching on age, Eastern Cooperative Oncology Group performance status, serum lactate dehydrogenase concentration, and receipt of corticosteroids and radiotherapy.","Treatment-related adverse events that led to change or discontinuation of immune checkpoint inhibitors were also assessed.","FINDINGS: Between Jan 1, 2012, and Dec 31, 2020, 481 patients with melanoma received treatment with immune checkpoint inhibitors at the study centre, of whom 299 had stage IV disease and were included in this study; median follow-up was 27 months (IQR 14 to 47).","In the complete unmatched sample, 102 (34%) patients were female and 197 (66%) were male, with a median age of 61 years (IQR 51 to 72).","Every additional 20% of infusions of immune checkpoint inhibitors received after 1630 h (among all infusions received by a patient) conferred an overall survival hazard ratio (HR) of 1\u00b731 (95% CI 1\u00b700 to 1\u00b771; p=0\u00b7046).","A propensity score-matched analysis of patients who did (n=73) and did not (n=73) receive at least 20% of their infusions of immune checkpoint inhibitors after 1630 h (54 [37%] of 146 patients were women and 92 [63%] were men, with a median age of 58 years [IQR 48 to 68]) showed that having at least 20% of infusions in the evening was associated with shorter overall survival (median 4\u00b78 years [95% CI 3\u00b79 to not estimable] vs not reached; HR 2\u00b704 [1\u00b704 to 4\u00b700; p=0\u00b7038]).","This result remained robust to multivariable proportional hazards adjustment with (HR 1\u00b780 [1\u00b708 to 2\u00b798; p=0\u00b7023]) and without (2\u00b716 [1\u00b710 to 4\u00b725; p=0\u00b7025]) inclusion of the complete unmatched study sample.","The most common adverse events were colitis (54 [18%] of 299 patients), hepatitis (27 [9%]), and hypophysitis (15 [5%]), and there were no treatment-related deaths.","INTERPRETATION: Our findings are in line with an increasing body of evidence that adaptive immune responses are less robust when initially stimulated in the evening than if stimulated in the daytime.","Although prospective studies of the timing of immune checkpoint inhibitor infusions are warranted, efforts towards scheduling infusions before mid-afternoon could be considered in the multidisciplinary management of advanced melanoma.","FUNDING: National Institutes of Health, American Society for Radiation Oncology and Melanoma Research Alliance, and Winship Cancer Institute."],"Aspect":"s","Summary":"The most common adverse events were colitis (18%), hepatitis (9%), and hypophysitis (5%), with no treatment-related deaths.","Indexes":[8,14],"Sentences":["Treatment-related adverse events that led to change or discontinuation of immune checkpoint inhibitors were also assessed.","The most common adverse events were colitis (54 [18%] of 299 patients), hepatitis (27 [9%]), and hypophysitis (15 [5%]), and there were no treatment-related deaths."],"Revise":false}
{"PMID":"36634146","Document":["Blockade of vascular endothelial growth factor (VEGF) signaling with bevacizumab, a humanized anti-VEGF monoclonal antibody (mAb), or with receptor tyrosine kinase inhibitors, has improved progression-free survival and, in some indications, overall survival across several types of cancers by interrupting tumor angiogenesis.","However, the clinical benefit conferred by these therapies is variable, and tumors from treated patients eventually reinitiate growth.","Previously we demonstrated, in mouse tumor models, that galectin-1 (Gal1), an endogenous glycan-binding protein, preserves angiogenesis in anti-VEGF-resistant tumors by co-opting the VEGF receptor (VEGFR)2 signaling pathway in the absence of VEGF.","However, the relevance of these findings in clinical settings is uncertain.","Here, we explored, in a cohort of melanoma patients from AVAST-M, a multicenter, open-label, randomized controlled phase 3 trial of adjuvant bevacizumab versus standard surveillance, the role of circulating plasma Gal1 as part of a compensatory mechanism that orchestrates endothelial cell programs in bevacizumab-treated melanoma patients.","We found that increasing Gal1 levels over time in patients in the bevacizumab arm, but not in the observation arm, significantly increased their risks of recurrence and death.","Remarkably, plasma Gal1 was functionally active as it was able to reprogram endothelial cell biology, promoting migration, tubulogenesis, and VEGFR2 phosphorylation.","These effects were prevented by blockade of Gal1 using a newly developed fully human anti-Gal1 neutralizing mAb.","Thus, using samples from a large-scale clinical trial from stage II and III melanoma patients, we validated the clinical relevance of Gal1 as a potential mechanism of resistance to bevacizumab treatment."],"Aspect":"i","Summary":"The study explored the role of circulating plasma Gal1 in bevacizumab-treated melanoma patients by analyzing samples from the AVAST-M phase 3 trial.","Indexes":[4],"Sentences":["Here, we explored, in a cohort of melanoma patients from AVAST-M, a multicenter, open-label, randomized controlled phase 3 trial of adjuvant bevacizumab versus standard surveillance, the role of circulating plasma Gal1 as part of a compensatory mechanism that orchestrates endothelial cell programs in bevacizumab-treated melanoma patients."],"Revise":false}
{"PMID":"37845511","Document":["Patients with resected stage IIB\/C melanoma have high recurrence risk, similar to those with resected stage IIIA\/B disease.","The phase 3, double-blind CheckMate 76K trial assessed 790 patients with resected stage IIB\/C melanoma randomized 2:1 (stratified by tumor category) to nivolumab 480\u2009mg or placebo every 4\u2009weeks for 12\u2009months.","The primary endpoint was investigator-assessed recurrence-free survival (RFS).","Secondary endpoints included distant metastasis-free survival (DMFS) and safety.","At 7.8\u2009months of minimum follow-up, nivolumab significantly improved RFS versus placebo (hazard ratio (HR)\u2009=\u20090.42; 95% confidence interval (CI): 0.30-0.59; P\u2009<\u20090.0001), with 12-month RFS of 89.0% versus 79.4% and benefit observed across subgroups; DMFS was also improved (HR\u2009=\u20090.47; 95% CI: 0.30-0.72).","Treatment-related grade 3\/4 adverse events occurred in 10.3% (nivolumab) and 2.3% (placebo) of patients.","One treatment-related death (0.2%) occurred with nivolumab.","Nivolumab is an effective and generally well-tolerated adjuvant treatment in patients with resected stage IIB\/C melanoma.","ClinicalTrials.gov identifier: NCT04099251 ."],"Aspect":"p","Summary":"The phase 3 CheckMate 76K trial assessed 790 patients with resected stage IIB\/C melanoma randomized to nivolumab or placebo.","Indexes":[1],"Sentences":["The phase 3, double-blind CheckMate 76K trial assessed 790 patients with resected stage IIB\/C melanoma randomized 2:1 (stratified by tumor category) to nivolumab 480\u2009mg or placebo every 4\u2009weeks for 12\u2009months."],"Revise":false}
{"PMID":"34855329","Document":["Patients with advanced melanoma treated with immune checkpoint inhibitors can experience ongoing disease control after treatment discontinuation without subsequent systemic anticancer therapy.","We previously defined a novel outcome, treatment-free survival (TFS), as the time between protocol therapy cessation and subsequent therapy initiation\/death.","We assessed the effect of established prognostic variables [lactate dehydrogenase (LDH), programmed death ligand 1 status, BRAF mutation status, performance status, and sex] on TFS in different treatment scenarios: treatment until toxicity\/progression with frequent early cessation (nivolumab plus ipilimumab), treatment until toxicity\/progression with a well-tolerated regimen (nivolumab), and treatment for a short fixed duration (ipilimumab).","Data were pooled from 1077 patients with advanced melanoma treated in the CheckMate 069 and 067 trials.","TFS was defined as the area between the Kaplan-Meier curves for time to therapy cessation and time to subsequent therapy initiation\/death.","TFS was estimated by restricted mean (r-mean) survival time at 36\u2009months since randomization.","Clinically meaningful TFS (r-mean TFS 3.7-12.7\u2009months) was observed across all patient subgroups.","TFS was longest in patients treated with nivolumab plus ipilimumab.","The largest differences in r-mean TFS were observed with LDH in the nivolumab plus ipilimumab and ipilimumab treatment groups (TFS difference 4.7 and 4.9\u2009months, respectively).","In the nivolumab group, there was little difference in TFS across subgroups (r-mean TFS 3.7-5.5\u2009months).","TFS was sensitive to prognostic subgroup differences; however, duration of treatment affected the sensitivity of TFS.","These results provide further support for TFS as a clinical outcome measure."],"Aspect":"p","Summary":"The study involved 1077 patients with advanced melanoma treated in the CheckMate 069 and 067 trials.","Indexes":[3],"Sentences":["Data were pooled from 1077 patients with advanced melanoma treated in the CheckMate 069 and 067 trials."],"Revise":false}
{"PMID":"37268724","Document":["Brain metastases (BMs) are an emerging challenge in oncology due to increasing incidence and limited treatments.","Here, we present results of a single-arm, open-label, phase 2 trial evaluating intracranial efficacy of pembrolizumab, a programmed cell death protein 1 inhibitor, in 9 patients with untreated BMs (cohort A) and 48 patients with recurrent and progressive BMs (cohort B) across different histologies.","The primary endpoint was the proportion of patients achieving intracranial benefit, defined by complete response, partial response or stable disease.","The primary endpoint was met with an intracranial benefit rate of 42.1% (90% confidence interval (CI): 31-54%).","The median overall survival, a secondary endpoint, was 8.0 months (90% CI: 5.5-8.7 months) across both cohorts, 6.5 months (90% CI: 4.5-18.7 months) for cohort A and 8.1 months (90% CI: 5.3-9.6 months) for cohort B.","Seven patients (12.3%), encompassing breast, melanoma and sarcoma histologies, had overall survival greater than 2 years.","Thirty patients (52%; 90% CI: 41-64%) had one or more grade-3 or higher adverse events that were at least possibly treatment related.","Two patients had grade-4 adverse events (cerebral edema) that were deemed at least possibly treatment related.","These results suggest that programmed cell death protein 1 blockade may benefit a select group of patients with BMs, and support further studies to identify biomarkers and mechanisms of resistance.","ClinicalTrials.gov identifier: NCT02886585."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"32380428","Document":["INTRODUCTION: Until recently, adjuvant treatment options for stage III and IV resectable melanoma have been limited.","Patients were often managed through routine surveillance.","The phase III randomised controlled trial (RCT) CheckMate 238 (238) demonstrated the safety and efficacy of nivolumab as an adjuvant treatment for melanoma in patients with stage IIIB\/C or IV disease (American Joint Committee on Cancer [AJCC], 7th edition) versus ipilimumab.","The study objective was to estimate the relative efficacy, safety and health-related quality of life (HRQoL) between nivolumab and routine surveillance.","METHODS: Indirect treatment comparisons (ITCs) of nivolumab versus placebo were constructed using data from 238 and EORTC 18071.","EORTC 18071 is a phase III RCT comparing ipilimumab with placebo in patients with resected stage IIIA-IIIC melanoma (AJCC, 6th edition).","ITCs were performed using the Bucher comparison method and patient-level data for efficacy, safety and HRQoL.","RESULTS: For the efficacy outcomes, nivolumab performed significantly better than placebo for recurrence-free survival (hazard ratio [HR]: 0.53 [95% confidence interval {CI}: 0.41, 0.68]) and distant metastases-free survival (HR: 0.59 [95% CI: 0.44, 0.78]).","Safety ITCs indicated that patients receiving nivolumab had a greater hazard of experiencing an adverse event (AE) and AEs leading to treatment discontinuation, whereas there was a non-significant increased hazard of experiencing a serious AE.","HRQoL ITCs showed comparable time to deterioration in 14 of the 15 QLQ-C30 domains; only the dyspnoea domain significantly favoured placebo.","CONCLUSION: Nivolumab was associated with significantly improved efficacy outcomes versus placebo, whereas maintaining patient's overall HRQoL.","Across the different analysis and populations, there was a high level of consistency in the effect size."],"Aspect":"o","Summary":"Nivolumab significantly improved recurrence-free survival and distant metastases-free survival compared to placebo but had a greater hazard of adverse events.","Indexes":[7,8],"Sentences":["RESULTS: For the efficacy outcomes, nivolumab performed significantly better than placebo for recurrence-free survival (hazard ratio [HR]: 0.53 [95% confidence interval {CI}: 0.41, 0.68]) and distant metastases-free survival (HR: 0.59 [95% CI: 0.44, 0.78]).","Safety ITCs indicated that patients receiving nivolumab had a greater hazard of experiencing an adverse event (AE) and AEs leading to treatment discontinuation, whereas there was a non-significant increased hazard of experiencing a serious AE."],"Revise":false}
{"PMID":"35680383","Document":["PURPOSE: Although recombinant human interleukin-15 (rhIL-15) has generated much excitement as an immunotherapeutic agent for cancer, activity in human clinical trials has been modest to date, in part due to the risks of toxicity with significant dose escalation.","Since pulmonary metastases are a major site of distant failure in human and dog cancers, we sought to investigate inhaled rhIL-15 in dogs with naturally occurring lung metastases from osteosarcoma (OSA) or melanoma.","We hypothesized a favorable benefit\/risk profile given the concentrated delivery to the lungs with decreased systemic exposure.","EXPERIMENTAL DESIGN: We performed a phase I trial of inhaled rhIL-15 in dogs with gross pulmonary metastases using a traditional 3+3 cohort design.","A starting dose of 10 \u00b5g twice daily \u00d7 14 days was used based on human, non-human primate, and murine studies.","Safety, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) were the primary objectives, while response rates, progression-free and overall survival (OS), and pharmacokinetic and immune correlative analyses were secondary.","RESULTS: From October 2018 to December 2020, we enrolled 21 dogs with 18 dogs reaching the 28-day response assessment to be evaluable.","At dose level 5 (70 \u03bcg), we observed two DLTs, thereby establishing 50 \u00b5g twice daily \u00d7 14 days as the MTD and recommended phase 2 dose.","Among 18 evaluable dogs, we observed one complete response >1 year, one partial response with resolution of multiple target lesions, and five stable disease for an overall clinical benefit rate of 39%.","Plasma rhIL-15 quantitation revealed detectable and sustained rhIL-15 concentrations between 1-hour and 6 hour postnebulization.","Decreased pretreatment lymphocyte counts were significantly associated with clinical benefit.","Cytotoxicity assays of banked peripheral blood mononuclear cells revealed significant increases in peak cytotoxicity against canine melanoma and OSA targets that correlated with OS.","CONCLUSIONS: In this first-in-dog clinical trial of inhaled rhIL-15 in dogs with advanced metastatic disease, we observed promising clinical activity when administered as a monotherapy for only 14 days.","These data have significant clinical and biological implications for both dogs and humans with refractory lung metastases and support exploration of combinatorial therapies using inhaled rhIL-15."],"Aspect":"s","Summary":"At dose level 5 (70 \u03bcg), two dose-limiting toxicities were observed, establishing 50 \u00b5g twice daily \u00d7 14 days as the maximum tolerated dose.","Indexes":[7],"Sentences":["At dose level 5 (70 \u03bcg), we observed two DLTs, thereby establishing 50 \u00b5g twice daily \u00d7 14 days as the MTD and recommended phase 2 dose."],"Revise":false}
{"PMID":"35030011","Document":["PURPOSE: Preclinical data suggest the combination of an anti-programmed death receptor 1 antibody plus dabrafenib and trametinib to have superior antitumor activity compared with dabrafenib plus trametinib alone.","These observations are supported by translational evidence suggesting that immune checkpoint inhibitors plus targeted therapy may improve treatment outcomes in patients with BRAF V600-mutant metastatic melanoma.","COMBI-i is a phase III trial evaluating spartalizumab, an anti-programmed death receptor 1 antibody, in combination with dabrafenib and trametinib (sparta-DabTram), versus placebo plus dabrafenib and trametinib (placebo-DabTram) in patients with BRAF V600-mutant unresectable or metastatic melanoma.","METHODS: Patients received spartalizumab 400 mg intravenously every 4 weeks plus dabrafenib 150 mg orally twice daily and trametinib 2 mg orally once daily or placebo-DabTram.","Participants were age \u2265 18 years with unresectable or metastatic BRAF V600-mutant melanoma.","The primary end point was investigator-assessed progression-free survival.","Overall survival was a key secondary end point (ClinicalTrials.gov identifier: NCT02967692).","RESULTS: At data cutoff (July 1, 2020), the median progression-free survival was 16.2 months (95% CI, 12.7 to 23.9 months) in the sparta-DabTram arm versus 12.0 months (95% CI, 10.2 to 15.4 months) in the placebo-DabTram arm (hazard ratio, 0.82 [95% CI, 0.66 to 1.03]; P = .042 [one-sided; nonsignificant]).","The objective response rates were 69% (183 of 267 patients) versus 64% (170 of 265 patients), respectively.","Grade \u2265 3 treatment-related adverse events occurred in 55% (146 of 267) of patients in the sparta-DabTram arm and 33% (88 of 264) in the placebo-DabTram arm.","CONCLUSION: The study did not meet its primary end point; broad first-line use of sparta-DabTram is not supported by these results.","Further biomarker-driven investigation may identify patient subpopulations who could benefit from checkpoint inhibitor plus targeted therapy combinations."],"Aspect":"o","Summary":"The study found that the median progression-free survival was 16.2 months in the sparta-DabTram arm versus 12.0 months in the placebo-DabTram arm, but the primary end point was not met.","Indexes":[7,10],"Sentences":["RESULTS: At data cutoff (July 1, 2020), the median progression-free survival was 16.2 months (95% CI, 12.7 to 23.9 months) in the sparta-DabTram arm versus 12.0 months (95% CI, 10.2 to 15.4 months) in the placebo-DabTram arm (hazard ratio, 0.82 [95% CI, 0.66 to 1.03]; P = .042 [one-sided; nonsignificant]).","CONCLUSION: The study did not meet its primary end point; broad first-line use of sparta-DabTram is not supported by these results."],"Revise":false}
{"PMID":"33340807","Document":["INTRODUCTION: Skin cancer is the most common type of cancer and represents more than half of the diagnosed malignant tumors.","There are more than one million new cases per year in the United States and about 120.000 new cases in Brazil.","Cutaneous melanoma represents 5% of all primary cutaneous neoplasms; however, it has a worse prognosis.","Adequate treatment of the primary lesion is the main cure factor, with free surgical margins, thus avoiding recurrences of the lesion.","OBJECTIVES: The present study aims to evaluate and quantify the retraction of the surgical specimen in three moments, in-vivo, ex-vivo and in-vitro, and also evaluating possible factors related to retraction, such as formalin fixation, age, patient's gender, and lesion location.","METHODS: This is a prospective, single-center cohort that evaluated 145 surgical specimens from patients who underwent oncological surgery of cutaneous melanoma margins enlargement.","Lesions were marked with a standard brush, and surgical margins were measured with a sterile ruler, according to their initial staging.","After resection, new surgical specimens measurements were obtained, and, after fixation in formalin, the last measurement was performed.","The same oncological surgeon performed all procedures, and the same pathologist analyzed the specimens.","RESULTS: Regarding the area of the specimens, there was a general median retraction of 38.15% between in-vivo and ex-vivo (p\u00a0<\u00a00.001), and 43.97% between in-vivo and in-vitro.","When the measure of the specimen length (L) was evaluated, there was a 17% retraction between in-vivo and ex-vivo, and 20.42% between in-vivo and in-vitro, with statistical significance.","The younger population has a higher rate of retraction, and lesions on the back have a lower rate of shrinkage on the opposite of lower limbs that had higher shrinkage.","DISCUSSION: Corroborating the literature, this study showed an average shrinkage of 20.42% for length measurements between in-vivo and in-vitro, and the main predictors of greater or lesser retraction were age and location of the lesion.","It is also noted that the most considerable retraction occurs immediately after surgical resection, indicating that skin characteristics, such as degree of elasticity and tension, are determinant for the retraction.","Formalin action does not significantly impact retraction.","This study shows the importance of adequate treatment of the primary lesion, with adequate surgical margins, and that the measure measured by the pathologist, in general, represents 80% of the margins performed in the perioperative time."],"Aspect":"p","Summary":"The study evaluated 145 patients who underwent oncological surgery for cutaneous melanoma margins enlargement.","Indexes":[5],"Sentences":["METHODS: This is a prospective, single-center cohort that evaluated 145 surgical specimens from patients who underwent oncological surgery of cutaneous melanoma margins enlargement."],"Revise":false}
{"PMID":"34101300","Document":["To evaluate the feasibility of adoptive cell therapy (ACT) using ex vivo-expanded tumor-infiltrating lymphocytes (TILs) in Japanese patients with melanoma who failed immune-checkpoint inhibitor therapy, an open-label, single-arm, pilot study was conducted.","We investigated the immunological and genetic factors of the pretreatment tumor and expanded TILs that may be associated with the clinical response.","The treatment protocol comprised preparation of TIL culture, lympho-depleting non-myeloablative preconditioning with cyclophosphamide and fludarabine, TIL infusion, and intravenous administration of low-dose IL-2.","Three patients of clinical subtypes mucosal, superficial spreading, and acral melanoma underwent TIL-ACT.","Most severe adverse events, including fever and leukopenia, were manageable with the supportive regimen specified in the protocol, suggesting that the TIL-ACT regimen is suitable for Japanese patients with melanoma.","One patient showed a short-term partial response, one relatively long-stable disease, and one experienced disease progression.","Whole-exome and transcriptional sequencing of isolated tumor cells and immunohistochemical analyses before TIL-ACT revealed various immunostimulatory factors, including a high tumor mutation burden and immune cell-recruiting chemokines, as well as various immunosuppressive factors including TGF-\u03b2, VEGF, Wnt\/\u03b2-catenin, and MAPK signaling and epithelial-to-mesenchymal transition, which might influence the efficacy of TIL-ACT.","Our results imply mechanisms for the antitumor effect of and resistance to TIL-ACT.","Further studies of immune-resistant mechanisms of TIL-ACT are warranted.","This study is registered with the UMIN Clinical Trial Registry (UMIN 000011431)."],"Aspect":"p","Summary":"Three patients with clinical subtypes mucosal, superficial spreading, and acral melanoma underwent TIL-ACT.","Indexes":[3],"Sentences":["Three patients of clinical subtypes mucosal, superficial spreading, and acral melanoma underwent TIL-ACT."],"Revise":false}
{"PMID":"34774225","Document":["BACKGROUND: Combination nivolumab plus ipilimumab was efficacious in patients with asymptomatic melanoma brain metastases (MBM) in CheckMate 204, but showed low efficacy in patients with symptomatic MBM.","Here, we provide final 3-year follow-up data from the trial.","METHODS: This open-label, multicentre, phase 2 study (CheckMate 204) included adults (aged \u226518 years) with measurable MBM (0\u00b75-3\u00b70 cm in diameter).","Asymptomatic patients (cohort A) had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and no neurological symptoms or baseline corticosteroid use; symptomatic patients (cohort B) had an ECOG performance status of 0-2 with stable neurological symptoms and could be receiving low-dose dexamethasone.","Nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg was given intravenously every 3 weeks for four doses, followed by nivolumab 3 mg\/kg every 2 weeks for up to 2 years, until disease progression or unacceptable toxicity.","The primary endpoint was intracranial clinical benefit rate (complete responses, partial responses, or stable disease lasting \u22656 months) assessed in all treated patients.","Intracranial progression-free survival and overall survival were key secondary endpoints.","This study is registered with ClinicalTrials.gov, NCT02320058.","FINDINGS: Between Feb 19, 2015, and Nov 1, 2017, 119 (72%) of 165 screened patients were enrolled and treated: 101 patients were asymptomatic (cohort A; median follow-up 34\u00b73 months [IQR 14\u00b77-36\u00b74]) and 18 were symptomatic (cohort B; median follow-up 7\u00b75 months [1\u00b72-35\u00b72]).","Investigator-assessed intracranial clinical benefit was observed in 58 (57\u00b74% [95% CI 47\u00b72-67\u00b72]) of 101 patients in cohort A and three (16\u00b77% [3\u00b76-41\u00b74]) of 18 patients in cohort B; investigator-assessed objective response was observed in 54 (53\u00b75% [43\u00b73-63\u00b75]) patients in cohort A and three (16\u00b77% [3\u00b76-41\u00b74]) patients in cohort B.","33 (33%) patients in cohort A and three (17%) patients in cohort B had an investigator-assessed intracranial complete response.","For patients in cohort A, 36-month intracranial progression-free survival was 54\u00b71% (95% CI 42\u00b77-64\u00b71) and overall survival was 71\u00b79% (61\u00b78-79\u00b78).","For patients in cohort B, 36-month intracranial progression-free survival was 18\u00b79% (95% CI 4\u00b76-40\u00b75) and overall survival was 36\u00b76% (14\u00b70-59\u00b78).","The most common grade 3-4 treatment-related adverse events (TRAEs) were increased alanine aminotransferase and aspartate aminotransferase (15 [15%] of 101 patients each) in cohort A; no grade 3 TRAEs occurred in more than one patient each in cohort B, and no grade 4 events occurred.","The most common serious TRAEs were colitis, diarrhoea, hypophysitis, and increased alanine aminotransferase (five [5%] of each among the 101 patients in cohort A); no serious TRAE occurred in more than one patient each in cohort B.","There was one treatment-related death (myocarditis in cohort A).","INTERPRETATION: The durable 3-year response, overall survival, and progression-free survival rates for asymptomatic patients support first-line use of nivolumab plus ipilimumab.","Symptomatic disease in patients with MBM remains difficult to treat, but some patients achieve a long-term response with the combination.","FUNDING: Bristol Myers Squibb."],"Aspect":"a","Summary":"The study aims to investigate the efficacy and safety of combination nivolumab plus ipilimumab in patients with asymptomatic and symptomatic melanoma brain metastases (MBM).","Indexes":[0,5,6],"Sentences":["BACKGROUND: Combination nivolumab plus ipilimumab was efficacious in patients with asymptomatic melanoma brain metastases (MBM) in CheckMate 204, but showed low efficacy in patients with symptomatic MBM.","The primary endpoint was intracranial clinical benefit rate (complete responses, partial responses, or stable disease lasting \u22656 months) assessed in all treated patients.","Intracranial progression-free survival and overall survival were key secondary endpoints."],"Revise":false}
{"PMID":"37535056","Document":["PURPOSE: Disease progression during or after anti-PD-1-based treatment is common in advanced melanoma.","Sotigalimab is a CD40 agonist antibody with a unique epitope specificity and Fc receptor binding profile optimized for activation of CD40-expressing antigen-presenting cells.","Preclinical data indicated that CD40 agonists combined with anti-PD1 could overcome resistance to anti-PD-1.","PATIENTS AND METHODS: We conducted a multicenter, open-label, phase II trial to evaluate the combination of sotigalimab 0.3 mg\/kg and nivolumab 360 mg every 3 weeks in patients with advanced melanoma following confirmed disease progression on a PD-1 inhibitor.","The primary objective was to determine the objective response rate (ORR).","RESULTS: Thirty-eight subjects were enrolled and evaluable for safety.","Thirty-three were evaluable for activity.","Five confirmed partial responses (PR) were observed for an ORR of 15%.","Two PRs are ongoing at 45.9+ and 26+ months, whereas the other three responders relapsed at 41.1, 18.7, and 18.4 months.","The median duration of response was at least 26 months.","Two additional patients had stable disease for >6 months.","Thirty-four patients (89%) experienced at least one adverse event (AE), and 13% experienced a grade 3 AE related to sotigalimab.","The most common AEs were pyrexia, chills, nausea, fatigue, pruritus, elevated liver function, rash, vomiting, headache, arthralgia, asthenia, myalgia, and diarrhea.","There were no treatment-related SAEs, deaths, or discontinuation of sotigalimab due to AEs.","CONCLUSIONS: Sotigalimab plus nivolumab had a favorable safety profile consistent with the toxicity profiles of each agent.","The combination resulted in durable and prolonged responses in a subset of patients with anti-PD-1-resistant melanoma, warranting further evaluation in this setting.","See related commentary by Wu and Luke, p. 9."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"34021033","Document":["BACKGROUND: The adoptive transfer of tumor-infiltrating lymphocytes (TIL) has demonstrated robust efficacy in metastatic melanoma patients.","Tumor antigen-loaded dendritic cells (DCs) are believed to optimally activate antigen-specific T lymphocytes.","We hypothesized that the combined transfer of TIL, containing a melanoma antigen recognized by T cells 1 (MART-1) specific population, with MART-1-pulsed DC will result in enhanced proliferation and prolonged survival of transferred MART-1 specific T cells in vivo ultimately leading to improved clinical responses.","DESIGN: We tested the combination of TIL and DC in a phase II clinical trial of patients with advanced stage IV melanoma.","HLA-A0201 patients whose early TIL cultures demonstrated reactivity to MART-1 peptide were randomly assigned to receive TIL alone or TIL +DC pulsed with MART-1 peptide.","The primary endpoint was to evaluate the persistence of MART-1 TIL in the two arms.","Secondary endpoints were to evaluate clinical response and survival.","RESULTS: Ten patients were given TIL alone while eight patients received TIL+DC vaccine.","Infused MART-1 reactive CD8+ TIL were tracked in the blood over time by flow cytometry and results show good persistence in both arms, with no difference in the persistence of MART-1 between the two arms.","The objective response rate was 30% (3\/10) in the TIL arm and 50% (4\/8) in the TIL+DC arm.","All treatments were well tolerated.","CONCLUSIONS: The combination of TIL +DC showed no difference in the persistence of MART-1 TIL compared with TIL therapy alone.","Although more patients showed a clinical response to TIL+DC therapy, this study was not powered to resolve differences between groups.","TRIAL REGISTRATION NUMBER: NCT00338377."],"Aspect":"a","Summary":"The study aims to investigate whether the combined transfer of tumor-infiltrating lymphocytes (TIL) with dendritic cells (DCs) pulsed with MART-1 peptide enhances the proliferation and survival of MART-1 specific T cells and improves clinical responses in patients with advanced stage IV melanoma.","Indexes":[2,3,5,6],"Sentences":["We hypothesized that the combined transfer of TIL, containing a melanoma antigen recognized by T cells 1 (MART-1) specific population, with MART-1-pulsed DC will result in enhanced proliferation and prolonged survival of transferred MART-1 specific T cells in vivo ultimately leading to improved clinical responses.","DESIGN: We tested the combination of TIL and DC in a phase II clinical trial of patients with advanced stage IV melanoma.","The primary endpoint was to evaluate the persistence of MART-1 TIL in the two arms.","Secondary endpoints were to evaluate clinical response and survival."],"Revise":false}
{"PMID":"36881133","Document":["AIM: We have previously reported that polyfunctional T cell responses can be induced to the cancer testis antigen NY-ESO-1 in melanoma patients injected with mature autologous monocyte-derived dendritic cells (DCs) loaded with long NY-ESO-1-derived peptides together with \u03b1-galactosylceramide (\u03b1-GalCer), an agonist for type 1 Natural Killer T (NKT) cells.","OBJECTIVE: To assess whether inclusion of \u03b1-GalCer in autologous NY-ESO-1 long peptide-pulsed DC vaccines (DCV\u2009+\u2009\u03b1-GalCer) improves T cell responses when compared to peptide-pulsed DC vaccines without \u03b1-GalCer (DCV).","DESIGN, SETTING AND PARTICIPANTS: Single-centre blinded randomised controlled trial in patients\u2009\u2265\u200918\u00a0years old with histologically confirmed, fully resected stage II-IV malignant cutaneous melanoma, conducted between July 2015 and June 2018 at the Wellington Blood and Cancer Centre of the Capital and Coast District Health Board.","INTERVENTIONS: Stage I.","Patients were randomised to two cycles of DCV or DCV\u2009+\u2009\u03b1-GalCer (intravenous dose of 10\u2009\u00d7\u2009106 cells, interval of 28\u00a0days).","Stage II.","Patients assigned to DCV\u2009+\u2009\u03b1-GalCer were randomised to two further cycles of DCV\u2009+\u2009\u03b1-GalCer or observation, while patients initially assigned to DCV crossed over to two cycles of DCV\u2009+\u2009\u03b1-GalCer.","OUTCOME MEASURES: Primary: Area under the curve (AUC) of mean NY-ESO-1-specific T cell count detected by ex vivo IFN-\u03b3 ELISpot in pre- and post-treatment blood samples, compared between treatment arms at Stage I.","Secondary: Proportion of responders in each arm at Stage I; NKT cell count in each arm at Stage I; serum cytokine levels at Stage I; adverse events Stage I; T cell count for DCV\u2009+\u2009\u03b1-GalCer versus observation at Stage II, T cell count before versus after cross-over.","RESULTS: Thirty-eight patients gave written informed consent; 5 were excluded before randomisation due to progressive disease or incomplete leukapheresis, 17 were assigned to DCV, and 16 to DCV\u2009+\u2009\u03b1-GalCer.","The vaccines were well tolerated and associated with increases in mean total T cell count, predominantly CD4+ T cells, but the difference between the treatment arms was not statistically significant (difference\u2009-\u20096.85, 95% confidence interval,\u2009-\u200921.65 to 7.92; P\u2009=\u20090.36).","No significant improvements in T cell response were associated with DCV\u2009+\u2009\u03b1-GalCer with increased dosing, or in the cross-over.","However, the NKT cell response to \u03b1-GalCer-loaded vaccines was limited compared to previous studies, with mean circulating NKT cell levels not significantly increased in the DCV\u2009+\u2009\u03b1-GalCer arm and no significant differences in cytokine response between the treatment arms.","CONCLUSIONS: A high population coverage of NY-ESO-1-specific T cell responses was achieved with a good safety profile, but we failed to demonstrate that loading with \u03b1-GalCer provided an additional advantage to the T cell response with this cellular vaccine design.","CLINICAL TRIAL REGISTRATION: ACTRN12612001101875.","Funded by the Health Research Council of New Zealand."],"Aspect":"d","Summary":"\n\nThe treatment duration consisted of two cycles of either DCV or DCV\u2009+\u2009\u03b1-GalCer with an interval of 28 days, followed by two additional cycles in Stage II for certain patients.","Indexes":[4,5,6],"Sentences":["Patients were randomised to two cycles of DCV or DCV\u2009+\u2009\u03b1-GalCer (intravenous dose of 10\u2009\u00d7\u2009106 cells, interval of 28\u00a0days).","Stage II.","Patients assigned to DCV\u2009+\u2009\u03b1-GalCer were randomised to two further cycles of DCV\u2009+\u2009\u03b1-GalCer or observation, while patients initially assigned to DCV crossed over to two cycles of DCV\u2009+\u2009\u03b1-GalCer."],"Revise":true}
{"PMID":"32278771","Document":["PURPOSE: To assess efficacy of intravitreal ranibizumab injections and targeted panretinal photocoagulation (TRP) for radiation retinopathy-related macular edema.","DESIGN: Phase IIb, prospective, randomized clinical trial.","METHODS: Setting: Multicenter.","SUBJECTS: Forty eyes in 40 treatment-na\u00efve patients with radiation-induced macular edema and a resulting decrease in visual acuity ranging between 20\/25 and 20\/400 (Snellen equivalent).","INTERVENTION: Patients either received intravitreal 0.5\u00a0mg ranibizumab monthly, monthly ranibizumab with TRP, or 3\u00a0monthly ranibizumab (loading doses) followed by as-needed (PRN) injections and TRP.","After week 52, all subjects entered a treat-and-extend protocol for ranibizumab.","MainOutcomeMeasures: Mean Early Treatment Diabetic Maculopathy Study (ETDRS) BCVA change from baseline.","RESULTS: Mean patient age was 57 years (range, 22-80 years), ETDRS BCVA was 56.7 letters (20\/74 Snellen equivalent), and central macular thickness (CMT) was 423\u00a0\u03bcm (range, 183-826\u00a0\u03bcm).","Thirty-seven patients completed the month 12 visit (92.5%), at which time the change in mean BCVA was\u00a0+4.0 letters,\u00a0-1.9 letters, and\u00a0+0.9 letters in the monthly, monthly plus laser, and PRN plus laser cohorts, respectively.","There was a significant difference in mean BCVA at 1 year among all 3 cohorts (P < .001), as well as between cohorts in pairwise comparisons, with the most significant gains in the monthly group.","A total of 82.5% of the patients retained visual acuity of 20\/200 or better, and 20.0% improved 10 or more ETDRS letters.","CONCLUSIONS: Ranibizumab may improve vision and anatomy in patients with radiation retinopathy-related macular edema and prevent vision loss through 48\u00a0weeks of therapy.","Monthly injections were more effective than as-needed approach, and the addition of TRP yielded no therapeutic benefits."],"Aspect":"i","Summary":"Patients with radiation-induced macular edema were randomly assigned to receive intravitreal ranibizumab monthly, monthly ranibizumab with TRP, or 3 monthly ranibizumab followed by as-needed injections and TRP, in a phase IIb prospective, randomized clinical trial.","Indexes":[1,4],"Sentences":["DESIGN: Phase IIb, prospective, randomized clinical trial.","INTERVENTION: Patients either received intravitreal 0.5\u00a0mg ranibizumab monthly, monthly ranibizumab with TRP, or 3\u00a0monthly ranibizumab (loading doses) followed by as-needed (PRN) injections and TRP."],"Revise":false}
{"PMID":"35217280","Document":["Skin cancer is the most common cancer in the United States and among Caucasians worldwide, with more people diagnosed each year than all other cancers combined.","Basal cell cancer is the most common form with an estimated 4.3 million cases diagnosed annually, and treatment costs estimated at $4.8 billion.","The objective of this study was to compare efficacy of a topical solution consisting of 30% ascorbic acid in 95% dimethylsulfoxide with topical imiquimod in the treatment of basal cell carcinoma.","Twenty-five patients with 29 biopsy confirmed basal cell carcinomas were randomly assigned to receive either the topically applied ascorbic acid treatment twice daily for 8 weeks or topical imiquimod, a standard and well characterized topical treatment.","After 8 weeks, post-treatment biopsy of lesions showed complete resolution of 13\/15 (86.7%) in the ascorbic acid group, while 8\/14 (57.1%) lesions in the IMQ group were resolved (p\u00a0<\u00a00.05 Chi Square).","Topical ascorbic acid was superior at 8 weeks, and non-inferior at 12 weeks to topical imiquimod in the treatment of low risk nodular and superficial lesions.","In addition, ascorbic acid was associated with fewer adverse effects than imiquimod.","70% of patients in the imiquinod group showed residual hypopigmentation at 30mo follow up versus 0% in the ascorbate group."],"Aspect":"i","Summary":"The study compared the efficacy of a topical solution of 30% ascorbic acid in 95% dimethylsulfoxide with topical imiquimod in treating basal cell carcinoma by randomly assigning 25 patients to receive either treatment.","Indexes":[2,3],"Sentences":["The objective of this study was to compare efficacy of a topical solution consisting of 30% ascorbic acid in 95% dimethylsulfoxide with topical imiquimod in the treatment of basal cell carcinoma.","Twenty-five patients with 29 biopsy confirmed basal cell carcinomas were randomly assigned to receive either the topically applied ascorbic acid treatment twice daily for 8 weeks or topical imiquimod, a standard and well characterized topical treatment."],"Revise":false}
{"PMID":"39366752","Document":["BACKGROUND: HBM4003 is a novel anti-CTLA-4 heavy chain-only antibody, designed to enhance Treg ablation and antibody-dependent cell-mediated cytotoxicity while ensuring a manageable safety profile.","This phase I trial investigated the safety, pharmacokinetics, immunogenicity and preliminary efficacy of HBM4003 plus with anti-PD-1 antibody toripalimab in patients with advanced solid tumors, especially focusing on melanoma.","METHODS: The multicenter, open-label phase I trial was divided into two parts: dose-escalation phase (part 1) and dose-expansion phase (part 2).","In part 1, HBM4003 was administered at doses of 0.03, 0.1, 0.3\u2009mg\/kg in combination with toripalimab with fixed dosage of 240\u2009mg every 3 weeks.","The recommended phase II dose (RP2D) was used in the expansion phase.","Primary endpoints were safety and RP2D in part 1 and objective response rate (ORR) in part 2.","Biomarkers based on cytokines and multiplex immunofluorescence staining were explored.","RESULTS: A total of 40 patients received study treatment, including 36 patients treated with RP2D of HBM4003 0.3\u2009mg\/kg plus toripalimab 240\u2009mg every 3 week.","36 participants (90.0%) experienced at least one treatment-related adverse event (TRAE), of which 10 (25.0%) patients experienced grade \u22653 TRAEs and 5 (12.5%) experienced immune-mediated adverse events (irAEs) with maximum severity of grade 3.","No grade 4 or 5 irAEs occurred.","Efficacy analysis set included 32 melanoma patients treated with RP2D and with available post-baseline imaging data.","The ORRs of anti-PD-1\/PD-L1 treatment-na\u00efve subgroup and anti-PD-1\/PD-L1 treatment-failed subgroup were 33.3% and 5.9%, respectively.","In mucosal melanoma, the ORR of the two subgroups were 40.0% and 10.0%, respectively.","Baseline high Treg\/CD4+ratio in the tumor serves as an independent predictive factor for the efficacy of immunotherapy.","CONCLUSIONS: HBM4003 0.3\u2009mg\/kg plus toripalimab 240\u2009mg every 3 week demonstrated manageable safety in solid tumors and no new safety signal.","Limited data demonstrated promising antitumor activity, especially in PD-1 treatment-na\u00efve mucosal melanoma.","TRIAL REGISTRATION NUMBER: NCT04727164."],"Aspect":"m","Summary":"The trial investigated HBM4003 at doses of 0.03, 0.1, 0.3 mg\/kg in combination with toripalimab at a fixed dosage of 240 mg every 3 weeks.","Indexes":[3],"Sentences":["In part 1, HBM4003 was administered at doses of 0.03, 0.1, 0.3\u2009mg\/kg in combination with toripalimab with fixed dosage of 240\u2009mg every 3 weeks."],"Revise":false}
{"PMID":"31852717","Document":["Whereas systemic IL12 is associated with potentially life-threatening toxicity, intratumoral delivery of IL12 through tavokinogene telseplasmid electroporation (tavo) is safe and can induce tumor regression at distant sites.","The mechanism by which these responses are mediated is unknown but is presumed to result from a cellular immune response.","In a phase II clinical trial of tavo (NCT01502293), samples from 29 patients with cutaneous melanoma with in-transit disease were assessed for immune responses induced with this treatment.","Within the blood circulating immune cell population, we found that the frequencies of circulating PD-1+ CD4+ and CD8+ T cells declined with treatment.","Circulating immune responses to gp100 were also detected following treatment as measured by IFN\u03b3 ELISpot.","Patients with a greater antigen-specific circulating immune response also had higher numbers of CD8+ T cells within the tumor.","Clinical response was also associated with increased intratumoral CD3+ T cells.","Finally, intratumoral T-cell clonality and convergence were increased after treatment, indicating a focusing of the T-cell receptor repertoire.","These results indicated that local treatment with tavo can induce a systemic T-cell response and recruit T cells to the tumor microenvironment."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"34787471","Document":["OBJECTIVE: A qualitative sub-study was carried out within a larger phase II feasibility trial, to identify and describe the burden experienced by advanced melanoma patients participating in a clinical trial and the factors affecting their capacity to cope with the burden.","METHODS: Semi-structured interviews were conducted with fourteen patients with advanced melanoma recruited from National Health Service hospitals in the United Kingdom.","Qualitative analysis was undertaken using a framework analysis approach.","Normalisation process theory was applied to the concept of research participation burden in order to interpret and categorise findings.","RESULTS: Burdens of participation were identified as arising from making sense of the trial and treatment; arranging transport, appointment and prescriptions; enacting management strategies and enduring side effects; reflecting on trial documents and treatment efficacy, and emotional and mental effects of randomisation and treatment side effects.","Factors reported as influencing capacity include personal attributes and skills, physical and cognitive abilities and support network.","DISCUSSION: This is the first study to highlight the substantial burden faced by patients with advanced melanoma in a clinical trial and factors that may lessen or worsen the burden.","Consideration of identified burdens during trial design and execution will reduce the burden experienced by research participants."],"Aspect":"m","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"34608333","Document":["Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-based intralesional oncolytic immunotherapy approved for the treatment of unresectable melanoma.","The present, ongoing study aimed to estimate the treatment effect of neoadjuvant T-VEC on recurrence-free survival (RFS) of patients with advanced resectable melanoma.","An open-label, phase 2 trial (NCT02211131) was conducted in 150 patients with resectable stage IIIB-IVM1a melanoma who were randomized to receive T-VEC followed by surgery (arm 1, n\u2009=\u200976) or surgery alone (arm 2, n\u2009=\u200974).","The primary endpoint was a 2-year RFS in the intention-to-treat population.","Secondary and exploratory endpoints included overall survival (OS), pathological complete response (pCR), safety and biomarker analyses.","The 2-year RFS was 29.5% in arm 1 and 16.5% in arm 2 (overall hazard ratio (HR)\u2009=\u20090.75, 80% confidence interval (CI)\u2009=\u20090.58-0.96).","The 2-year OS was 88.9% for arm 1 and 77.4% for arm 2 (overall HR\u2009=\u20090.49, 80% CI\u2009=\u20090.30-0.79).","The RFS and OS differences between arms persisted at 3\u2009years.","In arm 1, 17.1% achieved a pCR.","Increased CD8+ density correlated with clinical outcomes in an exploratory analysis.","Arm 1 adverse events were consistent with previous reports for T-VEC.","The present study met its primary endpoint and estimated a 25% reduction in the risk of disease recurrence for neoadjuvant T-VEC plus surgery versus upfront surgery for patients with resectable stage IIIB-IVM1a melanoma."],"Aspect":"i","Summary":"The study conducted an open-label, phase 2 trial where patients with resectable stage IIIB-IVM1a melanoma were randomized to receive T-VEC followed by surgery or surgery alone to estimate the treatment effect of neoadjuvant T-VEC on recurrence-free survival.","Indexes":[1,2],"Sentences":["The present, ongoing study aimed to estimate the treatment effect of neoadjuvant T-VEC on recurrence-free survival (RFS) of patients with advanced resectable melanoma.","An open-label, phase 2 trial (NCT02211131) was conducted in 150 patients with resectable stage IIIB-IVM1a melanoma who were randomized to receive T-VEC followed by surgery (arm 1, n\u2009=\u200976) or surgery alone (arm 2, n\u2009=\u200974)."],"Revise":false}
{"PMID":"33285270","Document":["PURPOSE: The immunocytokine L19-IL2 delivers interleukin-2 to the tumor by exploiting the selective L19-dependent binding of extradomain B of fibronectin on tumor blood vessels.","In preclinical models, L19-IL2 has been shown to enhance the local and abscopal effects of radiation therapy.","The clinical safety of L19-IL2 monotherapy has been established previously.","In this study, the safety and tolerability of L19-IL2 after stereotactic body radiation therapy (SBRT) was assessed.","METHODS AND MATERIALS: Patients with oligometastatic solid tumors received radical SBRT to all visible metastases.","Within 1 week after SBRT, intravenous L19-IL2 using a 3 + 3 dose escalation design was administered.","Safety and tolerability were analyzed as the primary endpoint using the Common Terminology Criteria for Adverse Events 4.03 scoring system, with progression-free and overall survival as secondary endpoints.","RESULTS: A total of 6 patients in 2 L19-IL2 dose levels were included.","The 15 million International Units (Mio IU) dose level was well tolerated with no dose-limiting toxicity.","The most frequently reported adverse events were chills, noninfectious fever, fatigue, edema, erythema, pruritus, nausea\/vomiting, and cough and dyspnea.","Blood analysis revealed abnormalities in liver function tests, anemia, hypoalbuminemia, and hypokalemia.","At the second dose level (ie, 22.5 Mio IU), which is the recommended dose for L19-IL2 monotherapy, all 3 included patients experienced dose-limiting toxicity but recovered without sequelae.","We documented 2 long-term progression-free responders, both having non-small cell lung cancer as primary tumor.","CONCLUSIONS: Based on the results of this phase 1 clinical trial, the recommended phase 2 dose for SBRT combined with L19-IL2 is 15 Mio IU.","The therapeutic efficacy of this combination is currently being evaluated in the multicentric EU-funded phase 2 clinical trial, ImmunoSABR."],"Aspect":"p","Summary":"The study involved 6 patients with oligometastatic solid tumors.","Indexes":[4,7],"Sentences":["METHODS AND MATERIALS: Patients with oligometastatic solid tumors received radical SBRT to all visible metastases.","RESULTS: A total of 6 patients in 2 L19-IL2 dose levels were included."],"Revise":false}
{"PMID":"37561473","Document":["This randomized clinical trial presents the final 5-year follow-up results of neoadjuvant talimogene laherparepvec (T-VEC) plus surgery in patients with advanced melanoma."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"36596029","Document":["Skin malignant melanoma is one of the most aggressive skin tumors.","Superficial spreading melanoma (SSM) is the most common histological type, which can originate from different body skin sites, and some patients can still accumulate regional lymph nodes and even have distant metastasis in some cases.","This study used the relevant data from the monitoring, epidemiology and results database of the National Cancer Institute database to study the overall survival (OS) and cancer-specific survival (CSS) of SSM patients and established an SSM nomogram to evaluate the prognosis of patients.","A total of 13,922 patients were collected from the monitoring, epidemiology and results database of the National Cancer Institute and randomly divided into a training cohort (8353 cases) and a validation cohort (5569 cases).","Univariate and multivariate Cox regression analysis were used to determine prognostic factors, and these factors were used to construct OS and CSS nomograms for patients with SSM.","Finally, the discrimination and consistency of the nomogram model were evaluated by the consistency index (C-index), area under the curve (AUC) and calibration curve.","Multivariate Cox regression analysis suggested that age, sex, tumor site, the American joint committee on cancer T stage and the first primary melanoma were independent predictors of OS and CSS in patients with SSM and that the American joint committee on cancer N stage was also an independent predictor of CSS in patients with SSM.","Based on the above prognostic factors, this study constructed a predictive model.","The C-index of the model OS and CSS for this training cohort was 0.805 [95% CI: 0.793-0.817] and 0.896 [95% CI: 0.878-0.913], respectively.","The AUC values for 1-, 3-, and 5-year OS were 0.822, 0.820, and 0.821, respectively, and the AUC values for CSS were 0.914, 0.922, and 0.893, respectively.","The data indicated that both nomograms showed better predictive accuracy.","The calibration curves of the training cohort and the validation cohort were in good agreement.","The nomogram has superior predictive performance in predicting 1-, 3-, and 5-year OS and CSS prognosis in patients with SSM and can provide a reference for individualized treatment and clinical counseling of SSM."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"32534646","Document":["BACKGROUND: IMspire150 aimed to evaluate first-line combination treatment with BRAF plus MEK inhibitors and immune checkpoint therapy in BRAFV600 mutation-positive advanced or metastatic melanoma.","METHODS: IMspire150 was a randomised, double-blind, placebo-controlled phase 3 study done at 112 institutes in 20 countries.","Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma were randomly assigned 1:1 to 28-day cycles of atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) or atezolizumab placebo, vemurafenib, and cobimetinib (control group).","In cycle 1, all patients received vemurafenib and cobimetinib only; atezolizumab placebo was added from cycle 2 onward.","Randomisation was stratified by lactate dehydrogenase concentration and geographical region.","Blinding for atezolizumab was achieved by means of an identical intravenous placebo, and blinding for vemurafenib was achieved by means of a placebo tablet.","The primary outcome was investigator-assessed progression-free survival.","This trial (ClinicalTrials.gov, NCT02908672) is ongoing but no longer recruiting patients.","FINDINGS: Between Jan 13, 2017, and April 26, 2018, 777 patients were screened and 514 were enrolled and randomly assigned to the atezolizumab group (n=256) or control group (n=258).","At a median follow-up of 18\u00b79 months (IQR 10\u00b74-23\u00b78), progression-free survival as assessed by the study investigator was significantly prolonged with atezolizumab versus control (15\u00b71 vs 10\u00b76 months; hazard ratio [HR] 0\u00b778; 95% CI 0\u00b763-0\u00b797; p=0\u00b7025).","Common treatment-related adverse events (>30%) in the atezolizumab and control groups were blood creatinine phosphokinase increased (51\u00b73% vs 44\u00b78%), diarrhoea (42\u00b72% vs 46\u00b76%), rash (40\u00b79%, both groups), arthralgia (39\u00b71% vs 28\u00b71%), pyrexia (38\u00b77% vs 26\u00b70%), alanine aminotransferase increased (33\u00b79% vs 22\u00b78%), and lipase increased (32\u00b72% vs 27\u00b74%); 13% of patients in the atezolizumab group and 16% in the control group stopped all treatment because of adverse events.","INTERPRETATION: The addition of atezolizumab to targeted therapy with vemurafenib and cobimetinib was safe and tolerable and significantly increased progression-free survival in patients with BRAFV600 mutation-positive advanced melanoma.","FUNDING: F Hoffmann-La Roche and Genentech."],"Aspect":"p","Summary":"The study involved 514 patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma, randomly assigned to two groups: 256 to the atezolizumab group and 258 to the control group.","Indexes":[2,8],"Sentences":["Patients with unresectable stage IIIc-IV, BRAFV600 mutation-positive melanoma were randomly assigned 1:1 to 28-day cycles of atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) or atezolizumab placebo, vemurafenib, and cobimetinib (control group).","FINDINGS: Between Jan 13, 2017, and April 26, 2018, 777 patients were screened and 514 were enrolled and randomly assigned to the atezolizumab group (n=256) or control group (n=258)."],"Revise":false}
{"PMID":"35028656","Document":["BACKGROUND: Identifying the characteristics of persons who benefit more from behavioral interventions can help health care providers decide which individuals should be offered particular interventions because this is the subgroup of persons who are more likely to derive greater benefit from the intervention and refine the underlying constructs of the model guiding the intervention.","PURPOSE: This study evaluated possible demographic, medical, knowledge and attitudinal, and psychosocial variables that may moderate the impact of an online intervention, called mySmartSkin (MSS), on engagement in skin self-examination (SSE) and sun protection behaviors among melanoma survivors.","METHODS: Participants completed a baseline survey and were then randomized to the MSS condition or usual care.","Follow-up surveys were completed by participants at 8-, 24-, and 48-week postrandomization.","RESULTS: A greater impact of MSS on SSE was illustrated among participants with more phenotypic skin cancer risk factors and participants reporting lower baseline self-efficacy in conducting SSE.","A more favorable response of MSS on sun protection behaviors was shown when initial knowledge about abnormal lesions and sun protection barriers were high.","Greater use of MSS and more favorable evaluations of it were also associated with higher intervention response.","CONCLUSIONS: Future studies seeking to improve SSE and sun protection among melanoma survivors might benefit from focusing on survivors who report more skin cancer risk factors, lower self-efficacy in conducting SSE, less knowledge about what abnormal skin lesions look like, more perceived barriers to sun protection behaviors, and less worry about recurrence and cancer-related distress."],"Aspect":"m","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"32989226","Document":["BACKGROUND: Bromodomain and extra-terminal domain (BET) proteins are reported to be epigenetic anti-cancer drug targets.","This first-in-human study evaluated the safety, pharmacokinetics and preliminary anti-tumour activity of the BET inhibitor ODM-207 in patients with selected solid tumours.","METHODS: This was an open-label Phase 1 study comprised of a dose escalation part, and evaluation of the effect of food on pharmacokinetics.","ODM-207 was administered orally once daily.","The dose escalation part was initiated with a dose titration in the initial cohort, followed by a 3\u2009+\u20093 design.","RESULTS: Thirty-five patients were treated with ODM-207, of whom 12 (34%) had castrate-resistant prostate cancer.","One dose-limiting toxicity of intolerable fatigue was observed.","The highest studied dose achieved was 2\u2009mg\/kg due to cumulative toxicity observed beyond the dose-limiting toxicity (DLT) treatment window.","Common AEs included thrombocytopenia, asthenia, nausea, anorexia, diarrhoea, fatigue, and vomiting.","Platelet count decreased proportionally to exposure with rapid recovery upon treatment discontinuation.","No partial or complete responses were observed.","CONCLUSIONS: ODM-207 shows increasing exposure in dose escalation and was safe at doses up to 2\u2009mg\/kg but had a narrow therapeutic window.","CLINICAL TRIAL REGISTRATION: The clinical trial registration number is NCT03035591."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"38908858","Document":["BACKGROUND: Previous studies have suggested the potential synergistic antitumor activity when combining immune checkpoint inhibitors with anti-angiogenic agents in various solid tumors.","We aimed to assess the efficacy and safety of camrelizumab (a humanized programmed cell death-1 antibody) plus apatinib (a vascular endothelial growth factor receptor tyrosine kinase inhibitor) for patients with advanced mucosal melanoma (MM), and explore-related biomarkers.","METHODS: We conducted a single-center, open-label, single-arm, phase II study.","Patients with unresectable or recurrent\/metastatic MM received camrelizumab and apatinib.","The primary endpoint was the confirmed objective response rate (ORR).","RESULTS: Between April 2019 and June 2022, 32 patients were enrolled, with 50.0% previously received systemic therapy.","Among 28 patients with evaluable response, the confirmed ORR was 42.9%, the disease control rate was 82.1%, and the median progression-free survival (PFS) was 8.05 months.","The confirmed ORR was 42.9% (6\/14) in both treatment-na\u00efve and previously treated patients.","Notably, treatment-na\u00efve patients had a median PFS of 11.89 months, and those with prior treatment had a median PFS of 6.47 months.","Grade 3 treatment-related adverse events were transaminase elevation, rash, hyperbilirubinemia, proteinuria, hypertension, thrombocytopenia, hand-foot syndrome and diarrhea.","No treatment-related deaths were observed.","Higher tumor mutation burden (TMB), increased T-cell receptor (TCR) diversity, and altered receptor tyrosine kinase (RTK)\/RAS pathway correlated with better tumor response.","CONCLUSION: Camrelizumab plus apatinib provided promising antitumor activity with acceptable toxicity in patients with advanced MM.","TMB, TCR diversity and RTK\/RAS pathway genes were identified as potential predictive biomarkers and warrant further validation.","TRIAL REGISTRATION NUMBER: Chinese Clinical Trial Registry, ChiCTR1900023277."],"Aspect":"a","Summary":"The study aimed to assess the efficacy and safety of camrelizumab plus apatinib for patients with advanced mucosal melanoma (MM), and explore-related biomarkers.","Indexes":[1],"Sentences":["We aimed to assess the efficacy and safety of camrelizumab (a humanized programmed cell death-1 antibody) plus apatinib (a vascular endothelial growth factor receptor tyrosine kinase inhibitor) for patients with advanced mucosal melanoma (MM), and explore-related biomarkers."],"Revise":false}
{"PMID":"33947696","Document":["PURPOSE: In BRAF V600MUT metastatic melanoma, cyclin D-CDK4\/6-INK4-Rb pathway alterations are involved in resistance to MAPK inhibitors, suggesting a clinical benefit of cyclin-dependent kinase 4 (CDK4) inhibitors.","In this phase I-II study, we aimed to establish the MTD of palbociclib when added to vemurafenib.","PATIENTS AND METHODS: Patients with BRAF V600E\/KMUT metastatic melanoma harboring CDKN2A loss and RB1 expression were included and stratified into two groups according to previous BRAF inhibitor treatment (no:strata 1; yes:strata 2).","Treatment comprised palbociclib once daily for 14 days followed by a 7-day break + continuous dosing of vemurafenib.","The primary endpoint was the occurrence of dose-limiting toxicity (DLT), and the secondary endpoints included the best response, survival, pharmacokinetics, and tumor molecular profiling.","RESULTS: Eighteen patients were enrolled, with 15 in strata 2.","Characteristics at inclusion were American Joint Committee on Cancer stage IVM1c (N = 16; 88.9%), high lactate dehydrogenase (N = 9; 50.0%), and median number of previous treatments of 2.","One and 5 patients experienced DLT in strata 1 and 2, respectively, defining the MTD at palbociclib 25 mg and vemurafenib 960 mg in strata 2.","No significant evidence for drug-drug interactions was highlighted.","The median progression-free survival was 2.8 months, and 5 (27.8%) patients showed a clinical response.","The baseline differential mRNA expression analysis and in vitro data revealed the role of CHEK2 in the response to palbociclib.","CONCLUSIONS: Although the combination of palbociclib + fixed-dose vemurafenib did not allow an increased palbociclib dosage above 25 mg, a significant clinical benefit was achieved in pretreated patients with melanoma.","An association between the transcriptomic data and clinical response was highlighted."],"Aspect":"o","Summary":"The study determined the maximum tolerated dose of palbociclib in combination with vemurafenib and observed a significant clinical benefit in pretreated patients with melanoma.","Indexes":[7,11],"Sentences":["One and 5 patients experienced DLT in strata 1 and 2, respectively, defining the MTD at palbociclib 25 mg and vemurafenib 960 mg in strata 2.","CONCLUSIONS: Although the combination of palbociclib + fixed-dose vemurafenib did not allow an increased palbociclib dosage above 25 mg, a significant clinical benefit was achieved in pretreated patients with melanoma."],"Revise":false}
{"PMID":"36170791","Document":["BACKGROUND: Despite the poor prognosis associated with melanoma brain metastases (BM), data concerning these patients and their inclusion in clinical trials remains scarce.","We report here the efficacy results of a subgroup analysis in patients with BRAFV600-mutant melanoma and BM treated with BRAF and MEK inhibitors dabrafenib (D) and trametinib (T).","PATIENTS AND METHODS: This phase IIIb single-arm, open-label, multicenter, French study included patients with unresectable stage IIIc or IV BRAFV600-mutant melanoma with or without BM.","The present analysis focuses on patients with BM.","Response rates were determined clinically and\/or radiologically as per standard clinical practice.","Progression-free survival (PFS) was estimated using the Kaplan Meier analysis and modelled with multivariate Cox regression model.","Risk subgroups were identified using an exponential regression tree analysis.","Significance was set at p &lt; 0.05.","RESULTS: Between March 2015 and November 2016, 856 patients were included and 275 (32%) patients had BM.","Median PFS was 5.68 months (95% confidence interval [CI], 5.29-6.87).","Significant independent factors associated with shorter PFS were ECOG \u22651, elevated serum lactate dehydrogenase (LDH), \u22653 metastatic sites, and non-na\u00efve status.","The binary-split classification and regression tree modelling identified baseline LDH and ECOG status as major prognostic factors.","CONCLUSION: This is to date the largest, close to real-world, study in advanced BRAFV600-mutant melanoma patients with BM treated with D+T.","ECOG &gt;1, \u22653 metastatic sites and elevated LDH were associated with shorter PFS, a finding previously demonstrated only in patients without BM.","Further studies are warranted to determine the optimal treatment sequence in this population."],"Aspect":"o","Summary":"Among 275 patients with BRAFV600-mutant melanoma brain metastases (BM), median progression-free survival (PFS) was 5.68 months, with shorter PFS associated with ECOG \u22651, elevated LDH, \u22653 metastatic sites, and non-na\u00efve status.","Indexes":[8,9,10],"Sentences":["RESULTS: Between March 2015 and November 2016, 856 patients were included and 275 (32%) patients had BM.","Median PFS was 5.68 months (95% confidence interval [CI], 5.29-6.87).","Significant independent factors associated with shorter PFS were ECOG \u22651, elevated serum lactate dehydrogenase (LDH), \u22653 metastatic sites, and non-na\u00efve status."],"Revise":true}
{"PMID":"34780711","Document":["BACKGROUND: The dependence of the adaptive immune system on circadian rhythm is an emerging field of study with potential therapeutic implications.","We aimed to determine whether specific time-of-day patterns of immune checkpoint inhibitor infusions might alter melanoma treatment efficacy.","METHODS: Melanoma Outcomes Following Immunotherapy (MEMOIR) is a longitudinal study of all patients with melanoma who received ipilimumab, nivolumab, or pembrolizumab, or a combination of these at a single tertiary cancer centre (Winship Cancer Institute of Emory University, Atlanta, GA, USA).","For this analysis, we collected deidentified participant-level data from the MEMOIR database for adults (age \u226518 years) diagnosed with stage IV melanoma between 2012 and 2020.","Those who received fewer than four infusions were excluded.","Standard of care doses were used, with modifications at the treating physicians' discretion.","The primary outcome was overall survival, defined as death from any cause and indexed from date of first infusion of immune checkpoint inhibitor.","We calculated the association between overall survival and proportion of infusions of immune checkpoint inhibitors received after 1630 h (a composite time cutoff derived from seminal studies of the immune-circadian rhythm to represent onset of evening) using Cox regression and propensity score-matching on age, Eastern Cooperative Oncology Group performance status, serum lactate dehydrogenase concentration, and receipt of corticosteroids and radiotherapy.","Treatment-related adverse events that led to change or discontinuation of immune checkpoint inhibitors were also assessed.","FINDINGS: Between Jan 1, 2012, and Dec 31, 2020, 481 patients with melanoma received treatment with immune checkpoint inhibitors at the study centre, of whom 299 had stage IV disease and were included in this study; median follow-up was 27 months (IQR 14 to 47).","In the complete unmatched sample, 102 (34%) patients were female and 197 (66%) were male, with a median age of 61 years (IQR 51 to 72).","Every additional 20% of infusions of immune checkpoint inhibitors received after 1630 h (among all infusions received by a patient) conferred an overall survival hazard ratio (HR) of 1\u00b731 (95% CI 1\u00b700 to 1\u00b771; p=0\u00b7046).","A propensity score-matched analysis of patients who did (n=73) and did not (n=73) receive at least 20% of their infusions of immune checkpoint inhibitors after 1630 h (54 [37%] of 146 patients were women and 92 [63%] were men, with a median age of 58 years [IQR 48 to 68]) showed that having at least 20% of infusions in the evening was associated with shorter overall survival (median 4\u00b78 years [95% CI 3\u00b79 to not estimable] vs not reached; HR 2\u00b704 [1\u00b704 to 4\u00b700; p=0\u00b7038]).","This result remained robust to multivariable proportional hazards adjustment with (HR 1\u00b780 [1\u00b708 to 2\u00b798; p=0\u00b7023]) and without (2\u00b716 [1\u00b710 to 4\u00b725; p=0\u00b7025]) inclusion of the complete unmatched study sample.","The most common adverse events were colitis (54 [18%] of 299 patients), hepatitis (27 [9%]), and hypophysitis (15 [5%]), and there were no treatment-related deaths.","INTERPRETATION: Our findings are in line with an increasing body of evidence that adaptive immune responses are less robust when initially stimulated in the evening than if stimulated in the daytime.","Although prospective studies of the timing of immune checkpoint inhibitor infusions are warranted, efforts towards scheduling infusions before mid-afternoon could be considered in the multidisciplinary management of advanced melanoma.","FUNDING: National Institutes of Health, American Society for Radiation Oncology and Melanoma Research Alliance, and Winship Cancer Institute."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"34243078","Document":["BACKGROUND: BRAF and MEK inhibitors combination, including dabrafenib (D) and trametinib (T) have transformed the treatment of BRAF V600-mutant advanced melanoma patients, including patients with brain metastasis (BM).","In a large phase IIIb, single-arm, open-label, multicenter\u00a0French study, we assessed safety, response to treatment, progression-free survival (PFS) and factors associated with progression, and stratified the population into risk groups.","METHODS: Patients with unresectable, advanced, BRAF V600-mutant melanoma were included, including those with the presence of BM, Eastern Cooperative Oncology Group Performance Status (ECOG PS) \u22642, elevated lactate dehydrogenase (LDH) or previous melanoma treatments.","Responses were determined locally, without central review.","PFS was estimated using the Kaplan-Meier analysis and modelled with multivariate Cox model.","Risk subgroups were identified using a regression tree analysis.","RESULTS: Between March 2015 and November 2016, 856 patients received at least one D\u00a0+\u00a0T dose.","Overall, 92% had stage IV melanoma, 38% ECOG PS \u22651, 32% BM\u00a0and 37.5% elevated LDH.","Median PFS was 8.02 months (95% confidence interval [CI] 7.33-8.77).","Significant factors associated with lower PFS were ECOG PS \u22651, elevated LDH, \u22653 metastatic sites\u00a0and presence of BM.","Patients with <3 metastatic sites, ECOG\u00a0=\u00a00 and no BM had the highest probability of PFS at 6 months (83%, 95% CI\u00a076-87) and 12 months (56%, 95% CI\u00a047-64), respectively.","CONCLUSIONS: This is the largest prospective study in advanced BRAF V600-mutant melanoma patients treated with D\u00a0+\u00a0T, conducted in conditions close to 'real-world practice'.","We confirm previous findings that LDH, ECOG PS and \u22653 metastatic sites are associated with shorter PFS, but the real-world setting introduces BM as a major prognostic factor."],"Aspect":"o","Summary":"The study found that the median progression-free survival (PFS) for patients with advanced BRAF V600-mutant melanoma treated with dabrafenib and trametinib was 8.02 months, with significant factors associated with lower PFS including ECOG PS \u22651, elevated LDH, \u22653 metastatic sites, and presence of brain metastasis.","Indexes":[8,9],"Sentences":["Median PFS was 8.02 months (95% confidence interval [CI] 7.33-8.77).","Significant factors associated with lower PFS were ECOG PS \u22651, elevated LDH, \u22653 metastatic sites\u00a0and presence of BM."],"Revise":false}
{"PMID":"38754780","Document":["BACKGROUND: Neoadjuvant dabrafenib plus trametinib has a high pathological response rate and impressive short-term survival in patients with resectable stage III melanoma.","We report 5-year outcomes from the phase II NeoCombi trial.","PATIENTS AND METHODS: NeoCombi (NCT01972347) was a single-arm, open-label, single-centre, phase II trial.","Eligible patients were adults (aged \u226518 years) with histologically confirmed, resectable, RECIST-measurable, American Joint Committee on Cancer seventh edition clinical stage IIIB-C BRAF V600E\/K-mutant melanoma and Eastern Cooperative Oncology Group performance status \u22641.","Patients received 52 weeks of treatment with dabrafenib 150 mg (orally twice per day) plus trametinib 2 mg (orally once per day), with complete resection of the pre-therapy tumour bed at week 12.","RESULTS: Between 20 August 2014 and 19 April 2017, 35 patients were enrolled.","At data cut-off (17 August 2021), the median follow-up was 60 months [95% confidence interval (CI) 56-72 months].","Overall, 21 of 35 (60%) patients recurred, including 12 (57%) with first recurrence in locoregional sites (followed by later distant recurrence in 6) and 9 (43%) with first recurrence in distant sites, including 3 in the brain.","Most recurrences occurred within 2 years, with no recurrences beyond 3 years.","At 5 years, recurrence-free survival (RFS) was 40% (95% CI 27% to 60%), distant metastasis-free survival (DMFS) was 57% (95% CI 42% to 76%), and overall survival was 80% (95% CI 67% to 94%).","Five-year survival outcomes were stratified by pathological response: RFS was 53% with pathological complete response (pCR) versus 28% with non-pCR (P\u00a0= 0.087), DMFS was 59% versus 55% (P\u00a0= 0.647), and overall survival was 88% versus 71% (P\u00a0= 0.205), respectively.","CONCLUSIONS: Neoadjuvant dabrafenib plus trametinib has high pathological response rates in clinical stage III melanoma, but low rates of RFS, similar to those achieved with adjuvant targeted therapy alone.","Patients with a pCR to dabrafenib plus trametinib still had a high risk of recurrence, unlike that seen with immunotherapy where recurrences are rare."],"Aspect":"p","Summary":"The study involved 35 adult patients with resectable, stage IIIB-C BRAF V600E\/K-mutant melanoma and Eastern Cooperative Oncology Group performance status \u22641.","Indexes":[3,5],"Sentences":["Eligible patients were adults (aged \u226518 years) with histologically confirmed, resectable, RECIST-measurable, American Joint Committee on Cancer seventh edition clinical stage IIIB-C BRAF V600E\/K-mutant melanoma and Eastern Cooperative Oncology Group performance status \u22641.","RESULTS: Between 20 August 2014 and 19 April 2017, 35 patients were enrolled."],"Revise":false}
{"PMID":"31912791","Document":["BACKGROUND: We conducted a retrospective exploratory analysis to evaluate the effects of baseline tumour immune infiltrate on disease-free survival (DFS) outcomes in patients with fully resected stage IIC-IIIC melanoma receiving adjuvant vemurafenib monotherapy or placebo in the BRIM8 study.","PATIENTS AND METHODS: BRIM8 was a phase III, international, double-blind, randomised, placebo-controlled study.","Eligible patients with BRAFV600 mutation-positive, completely resected melanoma were randomly assigned to oral vemurafenib (960 mg twice daily) or matching placebo for 52 weeks.","The primary end point was DFS.","The association of CD8+ T-cell infiltration and programmed death ligand 1 (PD-L1) expression with DFS, as measured by immunohistochemistry, was explored retrospectively.","RESULTS: Four hundred ninety-eight patients were randomly assigned to receive adjuvant vemurafenib (n\u00a0= 250) or placebo (n\u00a0= 248); tumour samples were available for biomarker analysis for approximately 60% of patients.","In the pooled biomarker population, placebo-treated patients with <1% CD8+ T cells in the tumour centre had shorter median DFS than those with \u22651% CD8+ T cells (7.7 versus 47.8 months).","DFS benefit from vemurafenib versus placebo was greater in patients with <1% CD8+ T cells [hazard ratio (HR) 0.56; 95% confidence interval (CI) 0.34-0.92) than in patients with \u22651% CD8+ T cells (HR 0.77; 95% CI 0.48-1.22).","Likewise, median DFS was shorter among placebo-treated patients with <5% versus \u22655% PD-L1+ immune cells (IC) in the tumour (7.2 versus 47.8 months).","A greater DFS benefit with vemurafenib versus placebo was observed in patients with <5% PD-L1+IC (HR 0.36; 95% CI 0.24-0.56) than in patients with \u22655% PD-L1+IC (HR 0.99; 95% CI 0.58-1.69).","CONCLUSIONS: The presence of CD8+ T cells and PD-L1+IC are favourable prognostic factors for DFS.","Treatment with adjuvant vemurafenib may overcome the poor DFS prognosis associated with low CD8+ T-cell count or PD-L1 expression.","CLINICALTRIALS.","GOV IDENTIFIER: NCT01667419."],"Aspect":"i","Summary":"Eligible patients with BRAFV600 mutation-positive, completely resected melanoma were randomly assigned to oral vemurafenib or placebo for 52 weeks to evaluate disease-free survival outcomes.","Indexes":[0,2,3],"Sentences":["BACKGROUND: We conducted a retrospective exploratory analysis to evaluate the effects of baseline tumour immune infiltrate on disease-free survival (DFS) outcomes in patients with fully resected stage IIC-IIIC melanoma receiving adjuvant vemurafenib monotherapy or placebo in the BRIM8 study.","Eligible patients with BRAFV600 mutation-positive, completely resected melanoma were randomly assigned to oral vemurafenib (960 mg twice daily) or matching placebo for 52 weeks.","The primary end point was DFS."],"Revise":false}
{"PMID":"37956739","Document":["BACKGROUND: The outcome of patients with resectable mucosal melanoma is poor.","Toripalimab combined with axitinib has shown impressive results in metastatic mucosal melanoma with an objective response rate of 48.3% and a median progression-free survival of 7.5 months in a phase Ib trial.","It was hypothesized that this combination administered in the neoadjuvant setting might induce a pathologic response in resectable mucosal melanoma, so we conducted this trial.","PATIENTS AND METHODS: This single-arm phase II trial enrolled patients with resectable mucosal melanoma.","Patients received toripalimab 3 mg\/kg once every 2 weeks (Q2W) plus axitinib 5 mg two times a day (b.i.d.)","for 8 weeks as neoadjuvant therapy, then surgery and adjuvant toripalimab 3 mg\/kg Q2W starting 2 \u00b1 1weeks after surgery for 44 weeks.","The primary endpoint was the pathologic response rate according to the International Neoadjuvant Melanoma Consortium recommendations.","RESULTS: Between August 2019 and October 2021, 29 patients were enrolled and received treatment, of whom 24 underwent resection.","The median follow-up time was 34.2 months (95% confidence interval 20.4-48.0 months).","The pathologic response rate was 33.3% (8\/24; 4 pathological complete responses and 4 pathological partial responses).","The median event-free survival for all patients was 11.1 months (95% confidence interval 5.3-16.9 months).","The median overall survival was not reached.","Neoadjuvant therapy was tolerable with 8 (27.5%) grade 3-4 treatment-related adverse events and no treatment-related deaths.","Tissue samples of 17 patients at baseline and after surgery were collected (5 responders and 12 nonresponders).","Multiplex immunohistochemistry demonstrated a significant increase in CD3+ (P\u00a0= 0.0032) and CD3+CD8+ (P\u00a0= 0.0038) tumor-infiltrating lymphocytes after neoadjuvant therapy, particularly in pathological responders.","CONCLUSIONS: Neoadjuvant toripalimab combined with axitinib in resectable mucosal melanoma demonstrated a promising pathologic response rate with significantly increased infiltrating CD3+ and CD3+CD8+ T cells after therapy."],"Aspect":"m","Summary":"Patients received toripalimab 3 mg\/kg once every 2 weeks (Q2W) plus axitinib 5 mg two times a day (b.i.d.) for 8 weeks as neoadjuvant therapy, followed by adjuvant toripalimab 3 mg\/kg Q2W for 44 weeks.","Indexes":[4,5],"Sentences":["Patients received toripalimab 3 mg\/kg once every 2 weeks (Q2W) plus axitinib 5 mg two times a day (b.i.d.)","for 8 weeks as neoadjuvant therapy, then surgery and adjuvant toripalimab 3 mg\/kg Q2W starting 2 \u00b1 1weeks after surgery for 44 weeks."],"Revise":false}
{"PMID":"32313721","Document":["The efficacy of immune checkpoint inhibitors has been shown to depend on preexisting antitumor immunity; thus, their combination with cancer vaccines is an attractive therapeutic approach.","Plasmacytoid dendritic cells (PDC) are strong inducers of antitumor responses and represent promising vaccine candidates.","We developed a cancer vaccine approach based on an allogeneic PDC line that functioned as a very potent antigen-presenting cell in pre-clinical studies.","In this phase Ib clinical trial, nine patients with metastatic stage IV melanoma received up to 60 million irradiated PDC line cells loaded with 4 melanoma antigens, injected subcutaneously at weekly intervals.","The primary endpoints were safety and tolerability.","The vaccine was well\u00a0tolerated and no serious vaccine-induced side effects were recorded.","Strikingly, there was no allogeneic response toward the vaccine, but a significant increase in the frequency of circulating anti-tumor specific T lymphocytes was observed in two patients, accompanied by a switch from a na\u00efve to memory phenotype, thus demonstrating priming of antigen-specific T-cells.","Signs of clinical activity were observed, including four stable diseases according to IrRC and vitiligo\u00efd lesions.","Four patients were still alive at week 48.","We also demonstrate the in vitro enhancement of specific T cell expansion induced by the synergistic combination of peptide-loaded PDC line with anti-PD-1, as compared to peptide-loaded PDC line alone.","Taken together, these clinical observations demonstrate the ability of the PDC line based-vaccine to prime and expand antitumor CD8+\u00a0responses in cancer patients.","Further trials should test the combination of this vaccine with immune checkpoint inhibitors."],"Aspect":"m","Summary":"The trial involved the administration of up to 60 million irradiated PDC line cells loaded with 4 melanoma antigens, injected subcutaneously at weekly intervals.","Indexes":[3],"Sentences":["In this phase Ib clinical trial, nine patients with metastatic stage IV melanoma received up to 60 million irradiated PDC line cells loaded with 4 melanoma antigens, injected subcutaneously at weekly intervals."],"Revise":false}
{"PMID":"30965384","Document":["BACKGROUND: People with melanoma want and need effective interventions for living with fear of cancer recurrence (FCR).","OBJECTIVES: This study reports the 12-month outcomes of a brief, psychological intervention designed to reduce FCR in people at high risk of developing another primary melanoma compared with usual care.","METHODS: In this two-arm randomized controlled trial, adults previously diagnosed with stage 0, I or II melanoma were randomly allocated to the intervention (n = 80) or control (usual care) arm (n = 84).","The trial was registered with the Australian and New Zealand Clinical Trials Registry on 19 March 2013 (registration: ACTRN12613000304730).","The intervention comprised a 76-page psychoeducational resource and three individually tailored, telephone-based sessions with a psychologist, scheduled at specific time points around participants' dermatological appointments.","The primary outcome was the level of self-reported fear of new or recurrent melanoma assessed at 12 months postintervention using the severity subscale of the Fear of Cancer Recurrence Inventory.","RESULTS: Compared with the control arm, the intervention group reported significantly lower FCR at 12 months postintervention; the between-group mean difference was -1\u00b741 for FCR severity [95% confidence interval (CI) -2\u00b76 to -0\u00b72; P\u00a0=\u00a00\u00b702] and -1\u00b732 for FCR triggers (95% CI -2\u00b76 to -0\u00b702; P\u00a0=\u00a00\u00b704).","The odds ratio for FCR severity scores \u226513 (54% intervention, 63% control) was 0\u00b759 (95% CI 0\u00b730-1\u00b714, P\u00a0=\u00a00\u00b712).","There were no differences between groups in secondary outcomes, such as anxiety, depression or health-related quality of life.","CONCLUSIONS: The previously reported 6-month benefits of this brief, patient-centred psychological intervention in reducing FCR were found to continue 12 months postintervention, with no known adverse effects, supporting implementation as part of routine melanoma care."],"Aspect":"a","Summary":"This study aims to report the 12-month outcomes of a brief, psychological intervention designed to reduce fear of cancer recurrence (FCR) in people at high risk of developing another primary melanoma compared with usual care.","Indexes":[1],"Sentences":["OBJECTIVES: This study reports the 12-month outcomes of a brief, psychological intervention designed to reduce FCR in people at high risk of developing another primary melanoma compared with usual care."],"Revise":false}
{"PMID":"35069538","Document":["Anti-melanoma differentiation-associated gene 5 (MDA5) antibody, a dermatomyositis (DM)-specific antibody, is strongly associated with interstitial lung disease (ILD).","Patients with idiopathic inflammatory myopathy (IIM) who are anti-MDA5 antibody positive [anti-MDA5 (+)] often experience chest symptoms during the active disease phase.","These symptoms are primarily explained by respiratory failure; nevertheless, cardiac involvement can also be symptomatic.","Thus, the aim of this study was to investigate cardiac involvement in anti-MDA5 (+) DM.","A total of 63 patients with IIM who underwent electrocardiography (ECG) and ultrasound cardiography (UCG) during the active disease phase from 2016 to 2021 [anti-MDA5 (+) group, n = 21; anti-MDA5-negative (-) group, n = 42] were enrolled in the study, and their clinical charts were retrospectively reviewed.","The ECG and UCG findings were compared between the anti-MDA5 (+) and anti-MDA5 (-) groups.","All anti-MDA5 (+) patients had DM with ILD.","The anti-MDA5 (+) group showed more frequent skin ulcerations and lower levels of leukocytes, muscle enzymes, and electrolytes (Na, K, Cl, and Ca) than the anti-MDA5 (-) group.","According to the ECG findings obtained during the active disease phase, the T wave amplitudes were significantly lower for the anti-MDA5 (+) group than for the anti-MDA5 (-) group (I, II, and V4-6 lead; p < 0.01; aVF and V3, p < 0.05).","However, the lower amplitudes were restored during the remission phase.","Except for the E wave, A wave and Sep e', the UCG results showed no significant differences between the groups.","Four patients with anti-MDA5 (+) DM had many leads with lower T wave and cardiac abnormalities (heart failure, diastolic dysfunction, myocarditis) on and after admission.","Though anti-MDA5 (+) patients clinically improved after immunosuppressive therapy, some of their ECG findings did not fully recover in remission phase.","In conclusion, anti-MDA5 (+) DM appears to show cardiac involvement (electrical activity and function) during the active phase.","Further studies are necessary to clarify the actual cardiac condition and mechanism of these findings in patients with anti-MDA5 (+) DM."],"Aspect":"o","Summary":"Patients with anti-MDA5 positive dermatomyositis often show signs of cardiac involvement, including abnormal electrical activity and potential cardiac dysfunction, during the active phase of the disease.","Indexes":[3,8,10,11,13],"Sentences":["Thus, the aim of this study was to investigate cardiac involvement in anti-MDA5 (+) DM.","According to the ECG findings obtained during the active disease phase, the T wave amplitudes were significantly lower for the anti-MDA5 (+) group than for the anti-MDA5 (-) group (I, II, and V4-6 lead; p < 0.01; aVF and V3, p < 0.05).","Except for the E wave, A wave and Sep e', the UCG results showed no significant differences between the groups.","Four patients with anti-MDA5 (+) DM had many leads with lower T wave and cardiac abnormalities (heart failure, diastolic dysfunction, myocarditis) on and after admission.","In conclusion, anti-MDA5 (+) DM appears to show cardiac involvement (electrical activity and function) during the active phase."],"Revise":true}
{"PMID":"36881133","Document":["AIM: We have previously reported that polyfunctional T cell responses can be induced to the cancer testis antigen NY-ESO-1 in melanoma patients injected with mature autologous monocyte-derived dendritic cells (DCs) loaded with long NY-ESO-1-derived peptides together with \u03b1-galactosylceramide (\u03b1-GalCer), an agonist for type 1 Natural Killer T (NKT) cells.","OBJECTIVE: To assess whether inclusion of \u03b1-GalCer in autologous NY-ESO-1 long peptide-pulsed DC vaccines (DCV\u2009+\u2009\u03b1-GalCer) improves T cell responses when compared to peptide-pulsed DC vaccines without \u03b1-GalCer (DCV).","DESIGN, SETTING AND PARTICIPANTS: Single-centre blinded randomised controlled trial in patients\u2009\u2265\u200918\u00a0years old with histologically confirmed, fully resected stage II-IV malignant cutaneous melanoma, conducted between July 2015 and June 2018 at the Wellington Blood and Cancer Centre of the Capital and Coast District Health Board.","INTERVENTIONS: Stage I.","Patients were randomised to two cycles of DCV or DCV\u2009+\u2009\u03b1-GalCer (intravenous dose of 10\u2009\u00d7\u2009106 cells, interval of 28\u00a0days).","Stage II.","Patients assigned to DCV\u2009+\u2009\u03b1-GalCer were randomised to two further cycles of DCV\u2009+\u2009\u03b1-GalCer or observation, while patients initially assigned to DCV crossed over to two cycles of DCV\u2009+\u2009\u03b1-GalCer.","OUTCOME MEASURES: Primary: Area under the curve (AUC) of mean NY-ESO-1-specific T cell count detected by ex vivo IFN-\u03b3 ELISpot in pre- and post-treatment blood samples, compared between treatment arms at Stage I.","Secondary: Proportion of responders in each arm at Stage I; NKT cell count in each arm at Stage I; serum cytokine levels at Stage I; adverse events Stage I; T cell count for DCV\u2009+\u2009\u03b1-GalCer versus observation at Stage II, T cell count before versus after cross-over.","RESULTS: Thirty-eight patients gave written informed consent; 5 were excluded before randomisation due to progressive disease or incomplete leukapheresis, 17 were assigned to DCV, and 16 to DCV\u2009+\u2009\u03b1-GalCer.","The vaccines were well tolerated and associated with increases in mean total T cell count, predominantly CD4+ T cells, but the difference between the treatment arms was not statistically significant (difference\u2009-\u20096.85, 95% confidence interval,\u2009-\u200921.65 to 7.92; P\u2009=\u20090.36).","No significant improvements in T cell response were associated with DCV\u2009+\u2009\u03b1-GalCer with increased dosing, or in the cross-over.","However, the NKT cell response to \u03b1-GalCer-loaded vaccines was limited compared to previous studies, with mean circulating NKT cell levels not significantly increased in the DCV\u2009+\u2009\u03b1-GalCer arm and no significant differences in cytokine response between the treatment arms.","CONCLUSIONS: A high population coverage of NY-ESO-1-specific T cell responses was achieved with a good safety profile, but we failed to demonstrate that loading with \u03b1-GalCer provided an additional advantage to the T cell response with this cellular vaccine design.","CLINICAL TRIAL REGISTRATION: ACTRN12612001101875.","Funded by the Health Research Council of New Zealand."],"Aspect":"m","Summary":"The trial involved \u03b1-galactosylceramide (\u03b1-GalCer) used with autologous NY-ESO-1 long peptide-pulsed DC vaccines (DCV + \u03b1-GalCer) at an intravenous dose of 10 \u00d7 10^6 cells, with an interval of 28 days.","Indexes":[1,4],"Sentences":["OBJECTIVE: To assess whether inclusion of \u03b1-GalCer in autologous NY-ESO-1 long peptide-pulsed DC vaccines (DCV\u2009+\u2009\u03b1-GalCer) improves T cell responses when compared to peptide-pulsed DC vaccines without \u03b1-GalCer (DCV).","Patients were randomised to two cycles of DCV or DCV\u2009+\u2009\u03b1-GalCer (intravenous dose of 10\u2009\u00d7\u2009106 cells, interval of 28\u00a0days)."],"Revise":true}
{"PMID":"38908858","Document":["BACKGROUND: Previous studies have suggested the potential synergistic antitumor activity when combining immune checkpoint inhibitors with anti-angiogenic agents in various solid tumors.","We aimed to assess the efficacy and safety of camrelizumab (a humanized programmed cell death-1 antibody) plus apatinib (a vascular endothelial growth factor receptor tyrosine kinase inhibitor) for patients with advanced mucosal melanoma (MM), and explore-related biomarkers.","METHODS: We conducted a single-center, open-label, single-arm, phase II study.","Patients with unresectable or recurrent\/metastatic MM received camrelizumab and apatinib.","The primary endpoint was the confirmed objective response rate (ORR).","RESULTS: Between April 2019 and June 2022, 32 patients were enrolled, with 50.0% previously received systemic therapy.","Among 28 patients with evaluable response, the confirmed ORR was 42.9%, the disease control rate was 82.1%, and the median progression-free survival (PFS) was 8.05 months.","The confirmed ORR was 42.9% (6\/14) in both treatment-na\u00efve and previously treated patients.","Notably, treatment-na\u00efve patients had a median PFS of 11.89 months, and those with prior treatment had a median PFS of 6.47 months.","Grade 3 treatment-related adverse events were transaminase elevation, rash, hyperbilirubinemia, proteinuria, hypertension, thrombocytopenia, hand-foot syndrome and diarrhea.","No treatment-related deaths were observed.","Higher tumor mutation burden (TMB), increased T-cell receptor (TCR) diversity, and altered receptor tyrosine kinase (RTK)\/RAS pathway correlated with better tumor response.","CONCLUSION: Camrelizumab plus apatinib provided promising antitumor activity with acceptable toxicity in patients with advanced MM.","TMB, TCR diversity and RTK\/RAS pathway genes were identified as potential predictive biomarkers and warrant further validation.","TRIAL REGISTRATION NUMBER: Chinese Clinical Trial Registry, ChiCTR1900023277."],"Aspect":"o","Summary":"The study found that camrelizumab plus apatinib showed promising antitumor activity with an objective response rate of 42.9% and acceptable toxicity in patients with advanced mucosal melanoma.","Indexes":[6,12],"Sentences":["Among 28 patients with evaluable response, the confirmed ORR was 42.9%, the disease control rate was 82.1%, and the median progression-free survival (PFS) was 8.05 months.","CONCLUSION: Camrelizumab plus apatinib provided promising antitumor activity with acceptable toxicity in patients with advanced MM."],"Revise":false}
{"PMID":"36265502","Document":["BACKGROUND: Patients with stage IIB or IIC melanoma who undergo surgery alone are at a substantial risk for disease recurrence.","Adjuvant pembrolizumab significantly improved recurrence-free survival versus placebo in stage IIB or IIC melanoma in the first interim analysis of the KEYNOTE-716 trial.","Here, we report results from the secondary endpoint of distant metastasis-free survival (prespecified third interim analysis), and recurrence-free survival with longer follow-up.","METHODS: KEYNOTE-716 is a multicentre, double-blind, placebo-controlled, crossover or rechallenge, randomised, phase 3 trial done at 160 academic medical centres and hospitals across 16 countries.","Eligible patients were aged 12 years and older with newly-diagnosed, completely resected, and histologically confirmed stage IIB (T3b or T4a) or IIC (T4b) cutaneous melanoma; negative sentinel lymph node biopsy; and an Eastern Cooperative Oncology Group performance status of 0-1.","Patients were randomly assigned (1:1) to receive either 200 mg of pembrolizumab (2 mg\/kg up to a maximum of 200 mg in paediatric patients) or placebo, both intravenously, every 3 weeks for 17 cycles (part 1) or until disease recurrence or unacceptable toxicity.","Eligible patients with disease recurrence could receive further treatment with pembrolizumab in the part 2 crossover or rechallenge phase.","Randomisation was done using an interactive response technology system and stratified by T category and paediatric status.","The primary endpoint was investigator-assessed recurrence-free survival (assessed here with longer follow-up), and we report the prespecified third interim analysis of distant metastasis-free survival (secondary endpoint).","Efficacy analyses were done in the intention-to-treat population (all patients who were randomly assigned, according to assigned group) and safety was assessed in all patients who were randomly assigned and received at least one dose of trial treatment, according to the treatment received.","KEYNOTE-716 is registered at ClinicalTrials.gov, NCT03553836, and has completed recruitment.","FINDINGS: Between Sept 23, 2018, and Nov 4, 2020, 976 patients were randomly assigned to receive pembrolizumab (n=487) or placebo (n=489).","At a median follow-up of 27\u00b74 months (IQR 23\u00b71-31\u00b77), median distant metastasis-free survival was not reached (95% CI not reached [NR]-NR) in either group.","Pembrolizumab significantly improved distant metastasis-free survival (hazard ratio [HR] 0\u00b764, 95% CI 0\u00b747-0\u00b788, p=0\u00b70029) versus placebo.","Median recurrence-free survival was 37\u00b72 months (95% CI NR-NR) in the pembrolizumab group and not reached in the placebo group (95% CI NR-NR).","The risk of recurrence remained lower with pembrolizumab versus placebo (HR 0\u00b764, 95% CI 0\u00b750-0\u00b784).","The most common grade 3 or worse adverse events were hypertension (16 [3%] of 483 patients in the pembrolizumab group vs 17 [4%] of 486 patients in the placebo group), diarrhoea (eight [2%] vs one [&lt;1%]), rash (seven [1%] vs two [&lt;1%]), autoimmune hepatitis (seven [1%] vs two [&lt;1%]), and increased lipase (six [1%] vs eight [2%]).","Treatment-related serious adverse events occurred in 49 (10%) patients in the pembrolizumab group and 11 (2%) patients in the placebo group.","No treatment-related deaths were reported.","INTERPRETATION: Adjuvant pembrolizumab is an efficacious treatment option for resected stage IIB and IIC melanoma, with significant improvement in distant-metastasis free survival versus placebo and continued reduction in the risk of recurrence with an adverse event profile consistent with previous studies of pembrolizumab.","The overall benefit-risk of pembrolizumab continues to be positive in the adjuvant setting.","FUNDING: Merck Sharp &amp; Dohme, a subsidiary of Merck &amp; Co."],"Aspect":"a","Summary":"The study aims to evaluate the efficacy of adjuvant pembrolizumab in improving recurrence-free survival and distant metastasis-free survival in patients with stage IIB or IIC melanoma compared to placebo.","Indexes":[0,8],"Sentences":["BACKGROUND: Patients with stage IIB or IIC melanoma who undergo surgery alone are at a substantial risk for disease recurrence.","The primary endpoint was investigator-assessed recurrence-free survival (assessed here with longer follow-up), and we report the prespecified third interim analysis of distant metastasis-free survival (secondary endpoint)."],"Revise":false}
{"PMID":"33962356","Document":["BACKGROUND: Clinical trials enroll patients with specific diseases based on certain pre-defined eligibility criteria.","Disease registries are crucial to evaluate the efficacy and safety of new expensive oncology medicines in broad non-trial patient populations.","METHODS: We provide detailed information on the structure, including variables, and the scientific results from a nation-wide Danish database covering advanced melanoma, illustrating the importance of continuous real-world data registration.","Disease status and treatment-related information on all patients with American Joint Committee on Cancer (AJCC) 8th edition stage III or IV melanoma candidates to medical treatment in Denmark are prospectively registered in the Danish Metastatic Melanoma Database (DAMMED).","RESULTS: By January 1st, 2021, DAMMED includes 4156 patients and 7420 treatment regimens.","Response rates and survival data from published randomized clinical trial data are compared with real-world efficacy data from DAMMED and presented.","Overall, nine independent manuscripts highlighting similarities and discrepancies between real-world and clinical trial results are already reported to date.","CONCLUSION: Nation-wide disease registries take into consideration the complexity of daily clinical practice.","We show a concrete example of how disease registries can complement clinical trials' information, improving clinical practice, and support health-related technology assessment."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"34853302","Document":["Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring activating BRAF mutations.","Previous preclinical studies suggested that an intermittent dosing of these drugs could delay the emergence of resistance.","Contrary to expectations, the first published phase 2 randomized study comparing continuous versus intermittent schedule of dabrafenib (BRAFi) plus trametinib (MEKi) demonstrated a detrimental effect of the \"on-off\" schedule.","Here we report confirmatory data from the Phase II randomized open-label clinical trial comparing the antitumoral activity of the standard schedule versus an intermittent combination of vemurafenib (BRAFi) plus cobimetinib (MEKi) in advanced BRAF mutant melanoma patients (NCT02583516).","The trial did not meet its primary endpoint of progression free survival (PFS) improvement.","Our results show that the antitumor activity of the experimental intermittent schedule of vemurafenib plus cobimetinib is not superior to the standard continuous schedule.","Detection of BRAF mutation in cell free tumor DNA has prognostic value for survival and its dynamics has an excellent correlation with clinical response, but not with progression.","NGS analysis demonstrated de novo mutations in resistant cases."],"Aspect":"m","Summary":"The trial involved vemurafenib (BRAFi) plus cobimetinib (MEKi).","Indexes":[3],"Sentences":["Here we report confirmatory data from the Phase II randomized open-label clinical trial comparing the antitumoral activity of the standard schedule versus an intermittent combination of vemurafenib (BRAFi) plus cobimetinib (MEKi) in advanced BRAF mutant melanoma patients (NCT02583516)."],"Revise":true}
{"PMID":"38838446","Document":["BACKGROUND: The safety profile of adjuvant pembrolizumab was evaluated in a pooled analysis of 4 phase 3 clinical trials.","METHODS: Patients had completely resected stage IIIA, IIIB, or IIIC melanoma per American Joint Committee on Cancer, 7th edition, criteria (AJCC-7; KEYNOTE-054); stage IIB or IIC melanoma per AJCC-8 (KEYNOTE-716); stage IB, II, or IIIA non-small cell lung cancer per AJCC-7 (PEARLS\/KEYNOTE-091); or postnephrectomy\/metastasectomy clear cell renal cell carcinoma at increased risk of recurrence (KEYNOTE-564).","Patients received adjuvant pembrolizumab 200\u00a0mg (2\u00a0mg\/kg up to 200\u00a0mg for pediatric patients) or placebo every 3 weeks for approximately 1 year.","Adverse events (AEs) were summarized for patients who received \u2265\u00a01 dose of treatment.","RESULTS: Data were pooled from 4125 patients treated with pembrolizumab (n\u00a0=\u00a02060) or placebo (n\u00a0=\u00a02065).","Median (range) duration of treatment was 11.1 months (0.0-18.9) with pembrolizumab and 11.2 months (0.0-18.1) with placebo.","Treatment-related AEs occurred in 78.6\u00a0% (1620\/2060) of patients in the pembrolizumab group (grade 3-5, 16.3\u00a0% [336\/2060]) and 58.7\u00a0% (1212\/2065) in the placebo group (grade 3-5, 3.5\u00a0% [72\/2065]).","Immune-mediated AEs (e.g.","adrenal insufficiency, hypophysitis, and thyroiditis) occurred in 36.2\u00a0% (746\/2060) of patients in the pembrolizumab group (grade 3-5, 8.6\u00a0% [177\/2060]) and 8.4\u00a0% (174\/2065) in the placebo group (grade 3-5, 1.1\u00a0% [23\/2065]).","Of patients with \u2265\u00a01 immune-mediated AE or infusion reaction, systemic corticosteroids were required for 35.2\u00a0% (268\/761) and 20.2\u00a0% (39\/193) of patients in the pembrolizumab and placebo groups, respectively.","CONCLUSIONS: Adjuvant pembrolizumab demonstrated a manageable safety profile that was comparable to prior reports in advanced disease."],"Aspect":"s","Summary":"In this study treatment-related adverse events (AEs) occurred in 78.6% of patients in the pembrolizumab group and 56% in the placebo group while immune-mediated AEs such as adrenal insufficiency, hypophysitis, thyroiditis or infusion reactions occurred in 36.2% of the pembrolizumab group and 8,4% in the placebo group. ","Indexes":[6,7,8,9],"Sentences":["Treatment-related AEs occurred in 78.6\u00a0% (1620\/2060) of patients in the pembrolizumab group (grade 3-5, 16.3\u00a0% [336\/2060]) and 58.7\u00a0% (1212\/2065) in the placebo group (grade 3-5, 3.5\u00a0% [72\/2065]).","Immune-mediated AEs (e.g.","adrenal insufficiency, hypophysitis, and thyroiditis) occurred in 36.2\u00a0% (746\/2060) of patients in the pembrolizumab group (grade 3-5, 8.6\u00a0% [177\/2060]) and 8.4\u00a0% (174\/2065) in the placebo group (grade 3-5, 1.1\u00a0% [23\/2065]).","Of patients with \u2265\u00a01 immune-mediated AE or infusion reaction, systemic corticosteroids were required for 35.2\u00a0% (268\/761) and 20.2\u00a0% (39\/193) of patients in the pembrolizumab and placebo groups, respectively."],"Revise":true}
{"PMID":"33947696","Document":["PURPOSE: In BRAF V600MUT metastatic melanoma, cyclin D-CDK4\/6-INK4-Rb pathway alterations are involved in resistance to MAPK inhibitors, suggesting a clinical benefit of cyclin-dependent kinase 4 (CDK4) inhibitors.","In this phase I-II study, we aimed to establish the MTD of palbociclib when added to vemurafenib.","PATIENTS AND METHODS: Patients with BRAF V600E\/KMUT metastatic melanoma harboring CDKN2A loss and RB1 expression were included and stratified into two groups according to previous BRAF inhibitor treatment (no:strata 1; yes:strata 2).","Treatment comprised palbociclib once daily for 14 days followed by a 7-day break + continuous dosing of vemurafenib.","The primary endpoint was the occurrence of dose-limiting toxicity (DLT), and the secondary endpoints included the best response, survival, pharmacokinetics, and tumor molecular profiling.","RESULTS: Eighteen patients were enrolled, with 15 in strata 2.","Characteristics at inclusion were American Joint Committee on Cancer stage IVM1c (N = 16; 88.9%), high lactate dehydrogenase (N = 9; 50.0%), and median number of previous treatments of 2.","One and 5 patients experienced DLT in strata 1 and 2, respectively, defining the MTD at palbociclib 25 mg and vemurafenib 960 mg in strata 2.","No significant evidence for drug-drug interactions was highlighted.","The median progression-free survival was 2.8 months, and 5 (27.8%) patients showed a clinical response.","The baseline differential mRNA expression analysis and in vitro data revealed the role of CHEK2 in the response to palbociclib.","CONCLUSIONS: Although the combination of palbociclib + fixed-dose vemurafenib did not allow an increased palbociclib dosage above 25 mg, a significant clinical benefit was achieved in pretreated patients with melanoma.","An association between the transcriptomic data and clinical response was highlighted."],"Aspect":"m","Summary":"The study involved palbociclib administered once daily for 14 days followed by a 7-day break at a maximum tolerated dose (MTD) of 25 mg, combined with continuous dosing of vemurafenib at 960 mg.","Indexes":[1,3,7],"Sentences":["In this phase I-II study, we aimed to establish the MTD of palbociclib when added to vemurafenib.","Treatment comprised palbociclib once daily for 14 days followed by a 7-day break + continuous dosing of vemurafenib.","One and 5 patients experienced DLT in strata 1 and 2, respectively, defining the MTD at palbociclib 25 mg and vemurafenib 960 mg in strata 2."],"Revise":false}
{"PMID":"33464969","Document":["OBJECTIVE: In narratives, characters often face threats where they either live (survivor narratives) or die (death narratives).","Both outcomes have the potential to persuade, and are frequently utilised in mass communication campaigns, yet more research is needed examining the relative effectiveness and underlying mechanisms of each strategy.","DESIGN: U.S. adults (N\u2009=\u20091010) were randomly assigned to a 2 (survivor, death) \u00d7 2 (non-foreshadowed, foreshadowed) \u00d7 2 (within-study replication: narrative 1, narrative 2) between-participants experiment with melanoma stories as stimuli.","MAIN OUTCOME MEASURES: Intentions to engage in sun safe behaviour and skin self-examination behaviour were assessed in the pre- and posttest, and then transformed into change scores.","RESULTS: Death narratives increased sun safe behaviour intentions.","Consistent with the entertainment overcoming resistance model, foreshadowed death narratives were found to increase sun safe behaviour intentions via increased transportation and decreased counterarguing.","CONCLUSION: Compared to survivor narratives, death narratives increase intentions to engage in sun safe behaviour.","The findings offer support for character death as a key feature of narrative persuasion, and narrative transportation and counterarguing as important mediational pathways."],"Aspect":"o","Summary":"Death narratives increased sun safe behaviour intentions compared to survivor narratives.","Indexes":[4,6],"Sentences":["RESULTS: Death narratives increased sun safe behaviour intentions.","CONCLUSION: Compared to survivor narratives, death narratives increase intentions to engage in sun safe behaviour."],"Revise":false}
{"PMID":"33417511","Document":["PURPOSE: This study aimed to assess the efficacy of the combination of nivolumab (nivo) plus ipilimumab (ipi) as a first-line therapy with respect to the 12-month overall survival (OS) in patients with metastatic uveal melanoma (MUM) who are not eligible for liver resection.","METHODS: This was a single-arm, phase II trial led by the Spanish Multidisciplinary Melanoma Group (GEM) on nivo plus ipi for systemic treatment-na\u00efve patients of age > 18 years, with histologically confirmed MUM, Eastern Cooperative Oncology Group-PS 0\/1, and confirmed progressive metastatic disease (M1).","Nivo (1 mg\/kg once every 3 weeks) and ipi (3 mg\/kg once every 3 weeks) were administered during four inductions, followed by nivo (3 mg\/kg once every 2 weeks) until progressive disease, toxicity, or withdrawal.","The primary end point was 12-month OS.","OS, progression-free survival (PFS), and overall response rate were evaluated every 6 weeks using RECIST (v1.1).","Safety was also evaluated.","Logistic regression and Cox proportional hazard models comprising relevant clinical factors were used to evaluate the potential association with response to treatment and survival.","Cytokines were quantified in serum samples for their putative role in immune modulation\/angiogenesis and\/or earlier evidence of involvement in immunotherapy.","RESULTS: A total of 52 patients with a median age of 59 years (range, 26-84 years) were enrolled.","Overall, 78.8%, 56%, and 32% of patients had liver M1, extra-liver M1, and elevated lactate dehydrogenase.","Stable disease was the most common outcome (51.9%).","The primary end point was 12-month OS, which was 51.9% (95% CI, 38.3 to 65.5).","The median OS and PFS were 12.7 months and 3.0 months, respectively.","PFS was influenced by higher LDH values.","CONCLUSIONS: Nivo plus ipi in the first-line setting for MUM showed a modest improvement in OS over historical benchmarks of chemotherapy, with a manageable toxicity profile."],"Aspect":"a","Summary":"This study aimed to assess the efficacy of the combination of nivolumab plus ipilimumab as a first-line therapy with respect to the 12-month overall survival (OS) in patients with metastatic uveal melanoma (MUM) who are not eligible for liver resection.","Indexes":[0],"Sentences":["PURPOSE: This study aimed to assess the efficacy of the combination of nivolumab (nivo) plus ipilimumab (ipi) as a first-line therapy with respect to the 12-month overall survival (OS) in patients with metastatic uveal melanoma (MUM) who are not eligible for liver resection."],"Revise":false}
{"PMID":"31515719","Document":["PURPOSE: Prospective data are lacking on long-term morbidity of inguinal lymphadenectomy including the influence of extent of surgery, use of radiotherapy, and patient factors.","The aim of this study is to evaluate the effects of these factors on patient outcome, quality of life (QOL), regional symptoms, and limb volumes after inguinal or ilio-inguinal lymphadenectomy for melanoma.","METHODS: Analysis of the subgroup of patients with inguinal lymph node field relapse of melanoma, treated by inguinal or ilio-inguinal lymphadenectomy in the ANZMTG\/TROG randomized trial of adjuvant radiotherapy versus observation.","RESULTS: Sixty-nine patients, 46 having undergone inguinal and 23 ilio-inguinal lymphadenectomy, with median follow-up of 73\u00a0months were analyzed.","Mean limb volume increased rapidly after surgery (7% by 3\u00a0months) and continued to increase for at least another 18\u00a0months.","Patients with body mass index (BMI)\u2009\u2265\u200925\u00a0kg\/m2 had greater limb volume increase than normal-weight patients (13.3% versus 6.9%, P\u2009=\u20090.030).","QOL improved over the first 18\u00a0months, but despite initial improvement, regional symptoms persisted long term.","Type of surgery (inguinal or ilio-inguinal lymphadenectomy) had no demonstrably significant effect on limb volume (9.9% versus 13.4%, P\u2009=\u20090.35), QOL (P\u2009=\u20090.68), or regional symptoms (P\u2009=\u20090.65).","There was no difference in overall survival between inguinal and ilio-inguinal lymphadenectomy [hazard ratio (HR)\u20090.75, 95% confidence interval (CI) 0.40-1.40, P\u2009=\u20090.43].","CONCLUSIONS: Inguinal lymphadenectomy for melanoma is a potentially morbid procedure with significant increases in limb volume.","Patients report reasonable QOL but may have ongoing regional symptoms.","Overweight\/obesity is associated with poorer QOL, increased limb volume, and regional symptoms."],"Aspect":"p","Summary":"The study involved 69 patients with melanoma, who underwent inguinal (46 patients) or ilio-inguinal (23 patients) lymphadenectomy.","Indexes":[3],"Sentences":["RESULTS: Sixty-nine patients, 46 having undergone inguinal and 23 ilio-inguinal lymphadenectomy, with median follow-up of 73\u00a0months were analyzed."],"Revise":false}
{"PMID":"33020648","Document":["Immune and targeted therapies achieve long-term survival in metastatic melanoma; however, new treatment strategies are needed to improve patients' outcomes1,2.","We report on the efficacy, safety and biomarker analysis from the single-arm safety run-in (part 1; n\u2009=\u20099) and biomarker (part 2; n\u2009=\u200927) cohorts of the randomized, placebo-controlled, phase\u20093 COMBI-i trial (NCT02967692) of the anti-PD-1 antibody spartalizumab, in combination with the BRAF inhibitor dabrafenib and MEK inhibitor trametinib.","Patients (n\u2009=\u200936) had previously untreated BRAF V600-mutant unresectable or metastatic melanoma.","In part\u20091, the recommended phase\u20093 regimen was identified based on the incidence of dose-limiting toxicities (DLTs; primary endpoint): 400\u2009mg of spartalizumab every 4\u2009weeks plus 150\u2009mg of dabrafenib twice daily plus 2\u2009mg of trametinib once daily.","Part\u20092 characterized changes in PD-L1 levels and CD8+ cells following treatment (primary endpoint), and analyzed additional biomarkers.","Assessments of efficacy and safety were key secondary endpoints (median follow-up, 24.3\u2009months).","Spartalizumab plus dabrafenib and trametinib led to an objective response rate (ORR) of 78%, including 44% complete responses (CRs).","Grade\u2009\u22653 treatment-related adverse events (TRAEs) were experienced by 72% of patients.","All patients had temporary dose modifications, and 17% permanently discontinued all three study drugs due to TRAEs.","Early progression-free survival (PFS) events were associated with low tumor mutational burden\/T cell-inflamed gene expression signature (GES) or high immunosuppressive tumor microenvironment (TME) GES levels at baseline; an immunosuppressive TME may also preclude CR.","Overall, the efficacy, safety and on-treatment biomarker modulations associated with spartalizumab plus dabrafenib and trametinib are promising, and biomarkers that may predict long-term benefit were identified."],"Aspect":"o","Summary":"Spartalizumab combined with dabrafenib and trametinib demonstrated a 78% objective response rate, including 44% complete responses, while early progression-free survival events were linked to baseline tumor mutational burden and tumor microenvironment characteristics.","Indexes":[6,9],"Sentences":["Spartalizumab plus dabrafenib and trametinib led to an objective response rate (ORR) of 78%, including 44% complete responses (CRs).","Early progression-free survival (PFS) events were associated with low tumor mutational burden\/T cell-inflamed gene expression signature (GES) or high immunosuppressive tumor microenvironment (TME) GES levels at baseline; an immunosuppressive TME may also preclude CR."],"Revise":true}
{"PMID":"32752904","Document":["Aim: We tested the safety and immunogenicity of a novel vaccine in patients with resected high-risk melanoma.","Patients & methods: HLA-A2-positive patients with resected Stage II-IV melanoma were randomized to receive up to three vaccinations of melanoma-associated peptide (MART-1a) combined with a\u00a0stable\u00a0oil-in-water emulsion (SE) either with the Toll-like receptor 4\u00a0agonist glucopyranosyl lipid A (GLA-SE-Schedule 1) or alone (SE-Schedule 2).","Safety and immunogenicity of the vaccines were monitored.","Results: A total of\u00a023 patients were registered.","No treatment-related grade 3 or higher adverse events were observed.","Increases in MART-1a-specific T cells were seen in 70 and 63% of Schedule 1 and Schedule 2 patients, respectively.","Conclusion: Both vaccine schedules were well-tolerated and resulted in an increase in MART-1a-specific T cells.","Clinical Trial registration: NCT02320305 (ClinicalTrials.gov)."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"33127652","Document":["PURPOSE: Increased \u03b2-adrenergic receptor (\u03b2-AR) signaling has been shown to promote the creation of an immunosuppressive tumor microenvironment (TME).","Preclinical studies have shown that abrogation of this signaling pathway, particularly \u03b22-AR, provides a more favorable TME that enhances the activity of anti-PD-1 checkpoint inhibitors.","We hypothesize that blocking stress-related immunosuppressive pathways would improve tumor response to immune checkpoint inhibitors in patients.","Here, we report the results of dose escalation of a nonselective \u03b2-blocker (propranolol) with pembrolizumab in patients with metastatic melanoma.","PATIENTS AND METHODS: A 3 + 3 dose escalation study for propranolol twice a day with pembrolizumab (200 mg every 3 weeks) was completed.","The primary objective was to determine the recommended phase II dose (RP2D).","Additional objectives included safety, antitumor activity, and biomarker analyses.","Responders were defined as patients with complete or partial response per immune-modified RECIST at 6 months.","RESULTS: Nine patients with metastatic melanoma received increasing doses of propranolol in cohorts of 10, 20, and 30 mg twice a day.","No dose-limiting toxicities were observed.","Most common treatment-related adverse events (TRAEs) were rash, fatigue, and vitiligo, observed in 44% patients.","One patient developed two grade \u22653 TRAEs.","Objective response rate was 78%.","While no significant changes in treatment-associated biomarkers were observed, an increase in IFN\u03b3 and a decrease in IL6 was noted in responders.","CONCLUSIONS: Combination of propranolol with pembrolizumab in treatment-na\u00efve metastatic melanoma is safe and shows very promising activity.","Propranolol 30 mg twice a day was selected as RP2D in addition to pembrolizumab based on safety, tolerability, and preliminary antitumor activity."],"Aspect":"s","Summary":"Most common treatment-related adverse events (TRAEs) were rash, fatigue, and vitiligo, observed in 44% patients.","Indexes":[10],"Sentences":["Most common treatment-related adverse events (TRAEs) were rash, fatigue, and vitiligo, observed in 44% patients."],"Revise":false}
{"PMID":"34710570","Document":["BACKGROUND: Modulating the DNA damage response and repair (DDR) pathways is a promising strategy for boosting cancer immunotherapy.","Ceralasertib (AZD6738) is an oral inhibitor of the serine\/threonine protein kinase ataxia telangiectasia and Rad3-related protein, which is crucial for DDR.","PATIENTS AND METHODS: This phase II trial evaluated ceralasertib plus durvalumab for the treatment of patients with metastatic melanoma who had failed anti-programmed cell death protein 1 therapy.","RESULTS: Among the 30 patients, we observed an overall response rate of 31.0% and a disease control rate of 63.3%.","Responses were evident across patients with acral, mucosal, and cutaneous melanoma.","The median duration of response was 8.8 months (range, 3.8-11.7 months).","The median progression-free survival was 7.1 months (95% confidence interval, 3.6-10.6 months), and the median overall survival was 14.2 months (95% confidence interval, 9.3-19.1 months).","Common adverse events were largely hematologic and manageable with dose interruptions and reductions.","Exploratory biomarker analysis suggested that tumors with an immune-enriched microenvironment or alterations in the DDR pathway were more likely to respond to the study treatment.","CONCLUSION: We conclude that ceralasertib in combination with durvalumab has promising antitumor activity among patients with metastatic melanoma who have failed anti-programmed cell death protein 1 therapy, and constitute a population with unmet needs."],"Aspect":"s","Summary":"Common adverse events were largely hematologic and manageable with dose interruptions and reductions.","Indexes":[7],"Sentences":["Common adverse events were largely hematologic and manageable with dose interruptions and reductions."],"Revise":false}
{"PMID":"31270835","Document":["BACKGROUND: Melanoma is a globally significant and highly prevalent disease, with Breslow thickness widely recognized as the most important histologic indicator of prognosis.","In the newest edition of the AJCC Cancer Staging Manual, changes have been made to the definition of stages based on Breslow thickness.","It is therefore imperative we accurately measure the Breslow thickness in a standardized fashion.","METHODS: Our study aimed to identify the optimal number of levels required to measure Breslow thickness.","We reviewed archived cases of previously diagnosed invasive melanomas and assessed whether there was a change of T stage with the greater number of levels examined.","RESULTS: In our series of 54 cases, 10 (18.5%) cases were upgraded as additional levels were examined, statistically significant at the threshold of three levels.","CONCLUSIONS: Our data suggests the optimal number of levels to examine is 3, with no benefit seen in further levels up to 10."],"Aspect":"o","Summary":"The study found that examining three levels is optimal for measuring Breslow thickness in melanoma cases, with no additional benefit from examining further levels up to ten.","Indexes":[5,6],"Sentences":["RESULTS: In our series of 54 cases, 10 (18.5%) cases were upgraded as additional levels were examined, statistically significant at the threshold of three levels.","CONCLUSIONS: Our data suggests the optimal number of levels to examine is 3, with no benefit seen in further levels up to 10."],"Revise":false}
{"PMID":"35866644","Document":["OBJECTIVES AND DESIGN: The MELFO (MELanoma FOllow-up) study is an international phase III randomized controlled trial comparing an experimental low-intensity schedule against current national guidelines.","BACKGROUND: Evidence-based guidelines for the follow-up of sentinel node-negative melanoma patients are lacking.","METHODS: Overall, 388 adult patients diagnosed with sentinel node-negative primary melanoma patients were randomized in cancer centers in the Netherlands and United Kingdom between 2006 and 2016.","The conventional schedule group (control: n=196) was reviewed as per current national guidelines.","The experimental schedule group (n=192) was reviewed in a reduced-frequency schedule.","Quality of life was the primary outcome measurement.","Detection rates and survival outcomes were recorded.","Patient satisfaction rates and compliance with allocated schedules were compared.","RESULTS: At 5 years, both arms expressed high satisfaction with their regimens (>97%).","This study found no significant group effect on any patient-reported outcome measure scores between the follow-up protocols.","In total, 75\/388 (19.4%) patients recurred, with no difference in incidence found between the 2 arms (hazard ratio=0.87, 95% confidence interval: 0.54-1.39, P =0.57).","Self-examination was the method of detection for 25 experimental patients and 32 control patients (75.8% vs. 76.2%; P =0.41).","This study found no difference in any survival outcomes between the 2 study arms (disease-free survival: hazard ratio=1.00, 95% confidence interval: 0.49-2.07, P =0.99).","CONCLUSIONS: A reduced-intensity, American Joint Committee on Cancer (AJCC) stage-adjusted follow-up schedule for sentinel node-negative melanoma patients is a safe strategy, and patient self-examination is effective for recurrence detection with no evidence of diagnostic delay.","Patients' acceptance is very high."],"Aspect":"p","Summary":"The study involved 388 adult patients from cancer centers in the Netherlands and United Kingdom between 2006 and 2016  diagnosed with sentinel node-negative primary melanoma, randomized into two groups: 196 in the conventional schedule group and 192 in the experimental schedule group","Indexes":[2,3,6],"Sentences":["METHODS: Overall, 388 adult patients diagnosed with sentinel node-negative primary melanoma patients were randomized in cancer centers in the Netherlands and United Kingdom between 2006 and 2016.","The conventional schedule group (control: n=196) was reviewed as per current national guidelines.","Detection rates and survival outcomes were recorded."],"Revise":true}
{"PMID":"32923156","Document":["Development of T cell-directed immune checkpoint inhibitors (ICI) has revolutionized metastatic melanoma (MM) therapy, but <50% of treated patients experience durable responses.","This phase I trial (NCT01946373) investigates the safety\/feasibility of tumor-infiltrating lymphocyte (TIL) adoptive cell therapy (ACT) combined with dendritic cell (DC) vaccination in MM patients progressing on ICI.","An initial cohort (5 patients) received TIL therapy alone to evaluate safety and allow for optimization of TIL expansion protocols.","A second cohort (first-in-man, 5 patients) received TIL combined with autologous tumor lysate-loaded DC vaccination.","All patients received cyclophosphamide\/fludarabine preconditioning prior to, and intravenous (i.v.)","IL-2 after, TIL transfer.","The DC vaccine was given as five intradermal injections after TIL and IL-2 administration.","[18F]-FDG PET\/CT radiology was performed to evaluate clinical response, according to RECIST 1.1 (on the CT part).","Immunological monitoring was performed by flow cytometry and T-cell receptor (TCR) sequencing.","In the safety\/optimization cohort, all patients had a mixed response or stable disease, but none durable.","In the combination cohort, two patients experienced complete responses (CR) that are still ongoing (>36 and >18\u00a0months, respectively).","In addition, two patients had partial responses (PR), one still ongoing (>42\u00a0months) with only a small bone-lesion remaining, and one of short duration (<4\u00a0months).","One patient died early during treatment and did not receive DC.","Long-lasting persistency of the injected TILs was demonstrated in blood.","In summary, we report clinical responses by TIL therapy combined with DC vaccination in 4 out of 4 treated MM patients who previously failed ICI."],"Aspect":"m","Summary":"The study utilized tumor-infiltrating lymphocyte (TIL) therapy in combination with autologous tumor lysate-loaded dendritic cell (DC) vaccination, with cyclophosphamide and fludarabine as preconditioning agents and intravenous IL-2 administered post-TIL transfer.","Indexes":[1,4,5,6],"Sentences":["This phase I trial (NCT01946373) investigates the safety\/feasibility of tumor-infiltrating lymphocyte (TIL) adoptive cell therapy (ACT) combined with dendritic cell (DC) vaccination in MM patients progressing on ICI.","All patients received cyclophosphamide\/fludarabine preconditioning prior to, and intravenous (i.v.)","IL-2 after, TIL transfer.","The DC vaccine was given as five intradermal injections after TIL and IL-2 administration."],"Revise":true}
{"PMID":"36195819","Document":["AIMS: Human health is intrinsically linked with planetary health.","But planetary resources are currently being degraded and this poses an existential threat to human health and the sustainability of our healthcare systems.","The aims of this study were to (1) describe an approach to integrate environmental impacts in a cost analysis; and (2) demonstrate this approach by estimating select environmental impacts alongside traditional health system and other costs using the example of the pilot MEL-SELF randomised controlled trial of patient-led melanoma surveillance.","METHODS: Economic costs were calculated alongside a randomised trial using standard cost analysis methodology from a societal perspective.","Environmental impacts were calculated using a type of carbon footprinting methodology called process-based life cycle analysis.","This method considers three scopes of carbon emissions: Scope 1, which occur directly from the intervention; Scope 2, which occur indirectly from the intervention's energy use; and Scope 3, which occur indirectly because of the value chain of the intervention.","In this study we only included emissions from patient transport to attend their melanoma clinic over the study period of 6 months.","RESULTS: The environmental impact per participant across allocated groups for patient transport to their melanoma clinic was estimated to be 10 kg carbon dioxide equivalent.","Economic costs across the allocated groups indicated substantial health system costs, out-of-pocket costs, and productivity losses associated with melanoma surveillance.","The largest cost contributor was health system costs, and the most expensive category of health system cost was hospital admission.","CONCLUSION: Calculating environmental impacts is worthwhile and feasible within a cost analysis framework.","Further work is needed to address outstanding conceptual and practical issues so that a comprehensive assessment of environmental impacts can be considered alongside economic costs in health technology assessments."],"Aspect":"a","Summary":"The study aims to integrate environmental impacts in a cost analysis and demonstrate this approach using a randomized controlled trial of patient-led melanoma surveillance.","Indexes":[2],"Sentences":["The aims of this study were to (1) describe an approach to integrate environmental impacts in a cost analysis; and (2) demonstrate this approach by estimating select environmental impacts alongside traditional health system and other costs using the example of the pilot MEL-SELF randomised controlled trial of patient-led melanoma surveillance."],"Revise":false}
{"PMID":"33340807","Document":["INTRODUCTION: Skin cancer is the most common type of cancer and represents more than half of the diagnosed malignant tumors.","There are more than one million new cases per year in the United States and about 120.000 new cases in Brazil.","Cutaneous melanoma represents 5% of all primary cutaneous neoplasms; however, it has a worse prognosis.","Adequate treatment of the primary lesion is the main cure factor, with free surgical margins, thus avoiding recurrences of the lesion.","OBJECTIVES: The present study aims to evaluate and quantify the retraction of the surgical specimen in three moments, in-vivo, ex-vivo and in-vitro, and also evaluating possible factors related to retraction, such as formalin fixation, age, patient's gender, and lesion location.","METHODS: This is a prospective, single-center cohort that evaluated 145 surgical specimens from patients who underwent oncological surgery of cutaneous melanoma margins enlargement.","Lesions were marked with a standard brush, and surgical margins were measured with a sterile ruler, according to their initial staging.","After resection, new surgical specimens measurements were obtained, and, after fixation in formalin, the last measurement was performed.","The same oncological surgeon performed all procedures, and the same pathologist analyzed the specimens.","RESULTS: Regarding the area of the specimens, there was a general median retraction of 38.15% between in-vivo and ex-vivo (p\u00a0<\u00a00.001), and 43.97% between in-vivo and in-vitro.","When the measure of the specimen length (L) was evaluated, there was a 17% retraction between in-vivo and ex-vivo, and 20.42% between in-vivo and in-vitro, with statistical significance.","The younger population has a higher rate of retraction, and lesions on the back have a lower rate of shrinkage on the opposite of lower limbs that had higher shrinkage.","DISCUSSION: Corroborating the literature, this study showed an average shrinkage of 20.42% for length measurements between in-vivo and in-vitro, and the main predictors of greater or lesser retraction were age and location of the lesion.","It is also noted that the most considerable retraction occurs immediately after surgical resection, indicating that skin characteristics, such as degree of elasticity and tension, are determinant for the retraction.","Formalin action does not significantly impact retraction.","This study shows the importance of adequate treatment of the primary lesion, with adequate surgical margins, and that the measure measured by the pathologist, in general, represents 80% of the margins performed in the perioperative time."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"39386211","Document":["INTRODUCTION: Point-of-care (POC) manufacturing of chimeric antigen receptor (CAR) modified T cell has expanded rapidly over the last decade.","In addition to the use of CD19 CAR T cells for hematological diseases, there is a growing interest in targeting a variety of tumor-associated epitopes.","METHODS: Here, we report the manufacturing and characterization of autologous anti-CD20 CAR T cells from melanoma patients within phase I clinical trial (NCT03893019).","Using a second-generation lentiviral vector for the production of the CD20 CAR T cells on the CliniMACS Prodigy\u00ae.","RESULTS: We demonstrated consistency in cell composition and functionality of the products manufactured at two different production sites.","The T cell purity was >98.5%, a CD4\/CD8 ratio between 2.5 and 5.5 and transduction rate between 34% and 61% on day 12 (harvest).","Median expansion rate was 53-fold (range, 42-65-fold) with 1.7-3.8\u00d7109 CAR T cells at harvest, a sufficient number for the planned dose escalation steps (1\u00d7105\/kg, 1\u00d7106\/kg, 1\u00d7107\/kg BW).","Complementary research of some of the products pointed out that the CAR+ cells expressed mainly central memory T-cell phenotype.","All tested CAR T cell products were capable to translate into T cell activation upon engagement of CAR target cells, indicated by the increase in pro-inflammatory cytokine release and by the increase in CAR T cell amplification.","Notably, there were some interindividual, cell-intrinsic differences at the level of cytokine release and amplification.","CAR-mediated T cell activation depended on the level of CAR cognate antigen.","DISCUSSION: In conclusion, the CliniMACS Prodigy\u00ae platform is well suited for decentralized POC manufacturing of anti-CD20 CAR T cells and may be likewise applicable for the rapid and automated manufacturing of CAR T cells directed against other targets.","CLINICAL TRIAL REGISTRATION: https:\/\/clinicaltrials.gov\/study\/NCT03893019?cond=Melanoma&term=NCT03893019&rank=1, identifier NCT03893019."],"Aspect":"a","Summary":"The study aims to report the manufacturing and characterization of autologous anti-CD20 CAR T cells from melanoma patients within a phase I clinical trial (NCT03893019).","Indexes":[2],"Sentences":["METHODS: Here, we report the manufacturing and characterization of autologous anti-CD20 CAR T cells from melanoma patients within phase I clinical trial (NCT03893019)."],"Revise":false}
{"PMID":"35678233","Document":["Checkpoint immunotherapies (CPIs) have improved outcomes for metastatic melanoma patients, with objective response rates to combination ipilimumab and nivolumab of ~58%.","Preclinical data suggest that histone deacetylase (HDAC) inhibition enhances antitumor immune activity and may augment CPI.","In a phase Ib open-label pilot trial (NCT03565406), patients with therapy-naive metastatic melanoma were treated with the class I\/IV HDAC inhibitor mocetinostat orally three times a week in combination with nivolumab and ipilimumab every 3 weeks for 12 weeks followed by 12-week maintenance cycles of nivolumab every 2 weeks and mocetinostat at the same dose and schedule as induction.","The endpoints of the trial were safety, definition of a recommended phase 2 dose, preliminary assessment of response, and correlative marker determination.","Patient PBMC and serum samples collected at baseline and on-treatment were assessed by flow cytometry and Luminex assays for immune correlates.","Ten patients were treated: nine with 70-mg and one with 50-mg mocetinostat.","In the 70-mg cohort, eight patients had objective responses.","The patient in the 50-mg cohort had an early progression of disease.","All patients had grade 2 or higher toxicities, and six had grades 3 and 4 toxicities.","Patient PBMC showed significant decreases in myeloid-derived suppressor cells and trends towards reduced anti-inflammatory monocyte phenotypes.","Patient serum showed significant upregulation of granzyme A and TNF and trends towards increased granzyme B and IFN\u03b3.","Collectively, combining CPI and mocetinostat had favorable response rates but with high levels of toxicity.","Assessment of immune correlates supports a shift away from immunosuppressive phenotypes towards enhanced immune responses."],"Aspect":"s","Summary":"All patients had grade 2 or higher toxicities, with six experiencing grades 3 and 4 toxicities.","Indexes":[8],"Sentences":["All patients had grade 2 or higher toxicities, and six had grades 3 and 4 toxicities."],"Revise":false}
{"PMID":"34764195","Document":["UNLABELLED: We conducted a randomized phase III trial to evaluate whether adjuvant pembrolizumab for one year (647 patients) improved recurrence-free survival (RFS) or overall survival (OS) in comparison with high-dose IFN\u03b1-2b for one year or ipilimumab for up to three years (654 patients), the approved standard-of-care adjuvant immunotherapies at the time of enrollment for patients with high-risk resected melanoma.","At a median follow-up of 47.5 months, pembrolizumab was associated with significantly longer RFS than prior standard-of-care adjuvant immunotherapies [HR, 0.77; 99.62% confidence interval (CI), 0.59-0.99; P = 0.002].","There was no statistically significant association with OS among all patients (HR, 0.82; 96.3% CI, 0.61-1.09; P = 0.15).","Proportions of treatment-related adverse events of grades 3 to 5 were 19.5% with pembrolizumab, 71.2% with IFN\u03b1-2b, and 49.2% with ipilimumab.","Therefore, adjuvant pembrolizumab significantly improved RFS but not OS compared with the prior standard-of-care immunotherapies for patients with high-risk resected melanoma.","SIGNIFICANCE: Adjuvant PD-1 blockade therapy decreases the rates of recurrence, but not survival, in patients with surgically resectable melanoma, substituting the prior standard-of-care immunotherapies for this cancer.","See related commentary by Smithy and Shoushtari, p. 599.","This article is highlighted in the In This Issue feature, p. 587."],"Aspect":"m","Summary":"The trial compared pembrolizumab for one year with high-dose IFN\u03b1-2b for one year or ipilimumab for up to three years.","Indexes":[0],"Sentences":["UNLABELLED: We conducted a randomized phase III trial to evaluate whether adjuvant pembrolizumab for one year (647 patients) improved recurrence-free survival (RFS) or overall survival (OS) in comparison with high-dose IFN\u03b1-2b for one year or ipilimumab for up to three years (654 patients), the approved standard-of-care adjuvant immunotherapies at the time of enrollment for patients with high-risk resected melanoma."],"Revise":false}
{"PMID":"31425478","Document":["Despite an established history of intraocular antivascular endothelial growth factor (anti-VEGF) agents therapy in a variety of ocular pathologies as well as other cancer forms, use in the primary treatment of uveal melanoma has not been well assessed.","This was a two-stage therapeutic and exploratory phase II, non-randomised, single centre trial involving intraocular treatment with 0.5 mg in 0.05 ml of ranibizumab via six intravitreous injections over 6 months in patients with primary ocular melanoma that otherwise required radical surgery because of tumour size.","Seven patients were recruited with a median age of 66 years.","At baseline, the longest basal diameter was 15.1 mm (mean, range 10-20.4 mm) with a height measured by ultrasonography of 9.2 mm (mean, range 6.6-12.7 mm).","No patients achieved complete or partial response at any visit.","All required enucleation.","Histopathological analysis revealed mixed cell melanoma in 5\/7 (71%) and spindle cell morphology in 2\/7 (29%) with ciliary body involvement in 4\/7 (57%) and the presence of closed loops also in 4\/7 (57%).","Genetic analysis demonstrated loss of chromosome 3 in 5\/7 (71%) but abnormalities in chromosome 1,6 or 8 in all cases.","Our study was terminated early as alternative treatments were clearly superior for local tumour control.","There continues to be a role of intravitreal anti-VEGF for the treatment of the sequelae of local radiotherapy in the form of radiation retinopathy and so these agents may be used as adjuncts in the treatment of uveal melanoma rather than as a primary treatment."],"Aspect":"o","Summary":"No patients achieved complete or partial response to ranibizumab therapy, and all patients required enucleation.","Indexes":[4,5],"Sentences":["No patients achieved complete or partial response at any visit.","All required enucleation."],"Revise":false}
{"PMID":"36229663","Document":["In patients with previously treated metastatic uveal melanoma, the historical 1\u2009year overall survival rate is 37% with a median overall survival of 7.8\u2009months.","We conducted a multicenter, single-arm, open-label phase 2 study of tebentafusp, a soluble T cell receptor bispecific (gp100\u00d7CD3), in 127 patients with treatment-refractory metastatic uveal melanoma (NCT02570308).","The primary endpoint was the estimation of objective response rate based on RECIST (Response Evaluation Criteria in Solid Tumours) v1.1.","Secondary objectives included safety, overall survival, progression-free survival and disease control rate.","All patients had at least one treatment-related adverse event, with rash (87%), pyrexia (80%) and pruritus (67%) being the most common.","Toxicity was mostly mild to moderate in severity but was greatly reduced in incidence and intensity after the initial three doses.","Despite a low overall response rate of 5% (95% CI: 2-10%), the 1\u2009year overall survival rate was 62% (95% CI: 53-70%) with a median overall survival of 16.8\u2009months (95% CI: 12.9-21.3), suggesting benefit beyond traditional radiographic-based response criteria.","In an exploratory analysis, early on-treatment reduction in circulating tumour DNA was strongly associated with overall survival, even in patients with radiographic progression.","Our findings indicate that tebentafusp has promising clinical activity with an acceptable safety profile in patients with previously treated metastatic uveal melanoma, and data suggesting ctDNA as an early indicator of clinical benefit from tebentafusp need confirmation in a randomized trial."],"Aspect":"o","Summary":"Tebentafusp demonstrated a 1-year overall survival rate of 62% with a median overall survival of 16.8 months in patients with previously treated metastatic uveal melanoma, suggesting benefit beyond traditional response criteria.","Indexes":[6],"Sentences":["Despite a low overall response rate of 5% (95% CI: 2-10%), the 1\u2009year overall survival rate was 62% (95% CI: 53-70%) with a median overall survival of 16.8\u2009months (95% CI: 12.9-21.3), suggesting benefit beyond traditional radiographic-based response criteria."],"Revise":false}
{"PMID":"32885874","Document":["The educational effectiveness of dermoscopy image-based self-learning on a computer for medical students has not been well examined.","To assess the effect of an image-based self-learning session on the dermoscopic diagnostic performance for malignant melanoma (MM), basal cell carcinoma, melanocytic nevus and seborrheic keratosis (SK) on non-acral regions in comparison with a conventional classroom-style lecture, 114 fourth-year medical students (mean age, 23.7\u00a0years; male\u00a0:\u00a0female, 73:41) were enrolled.","The subjects were randomly assigned to either a self-learning to lecture (SL) or lecture to self-learning (LS) group to receive a 15-min image-based self-learning computer session and a 15-min video lecture session in different orders.","The user interface of the digital content was the same as that on a website (https:\/\/dz-image.casio.jp).","Diagnostic performance was determined using the total number of correct answers for the four diseases and by malignancy prediction in examination A (before training), B (after receiving one session) and C (after receiving both sessions).","The examinations were all unique and contained five dermoscopic images each of the four diseases.","The total number of correct answers and malignancy prediction results for examination B were significantly higher in the SL group than in LS (11.6 and 15.2 vs 10.1 and 13.4, respectively; both P\u00a0<\u00a00.01), with no remarkable differences for examination C (13.5 and 16.8 vs 13.3 and 16.4, respectively; P\u00a0=\u00a00.62 and P\u00a0=\u00a00.21).","In subanalyses, the number of correct answers for SK in examination B was significantly higher in the SL group (3.6 vs. 1.8, P\u00a0<\u00a00.01), while that for MM was significantly lower (2.2 vs 3.0, P\u00a0<\u00a00.01).","Diagnostic performance was comparable between sexes for examination B.","In conclusion, computer-assisted dermoscopy image-based self-learning may be a suitable and non-inferior alternative to classroom-style instruction for medical students within an ultra-short training period."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"34413145","Document":["There is a need for in\u00a0vivo diagnostic imaging probes that can noninvasively measure tumor-infiltrating CD8+ leukocytes.","Such imaging probes could be used to predict early response to cancer immunotherapy, help select effective single or combination immunotherapies, and facilitate the development of new immunotherapies or immunotherapy combinations.","This study was designed to optimize conditions for performing CD8 PET imaging with 89Zr-Df-IAB22M2C and determine whether CD8 PET imaging could provide a safe and effective noninvasive method of visualizing the whole-body biodistribution of CD8+ leukocytes.","Methods: We conducted a phase 1 first-in-humans PET imaging study using an anti-CD8 radiolabeled minibody, 89Zr-Df-IAB22M2C, to detect whole-body and tumor CD8+ leukocyte distribution in patients with metastatic solid tumors.","Patients received 111 MBq of 89Zr-Df-IAB22M2C followed by serial PET scanning over 5-7 d. A 2-stage design included a dose-escalation phase and a dose-expansion phase.","Biodistribution, radiation dosimetry, and semiquantitative evaluation of 89Zr-Df-IAB22M2C uptake were performed in all patients.","Results: Fifteen subjects with metastatic melanoma, non-small cell lung cancer, and hepatocellular carcinoma were enrolled.","No drug-related adverse events or abnormal laboratory results were noted except for a transient increase in antidrug antibodies in 1 subject.","89Zr-Df-IAB22M2C accumulated in tumors and CD8-rich tissues (e.g., spleen, bone marrow, nodes), with maximum uptake at 24-48 h after injection and low background activity in CD8-poor tissues (e.g., muscle and lung).","Radiotracer uptake in tumors was noted in 10 of 15 subjects, including 7 of 8 subjects on immunotherapy, 1 of 2 subjects on targeted therapy, and 2 of 5 treatment-na\u00efve subjects.","In 3 patients with advanced melanoma or hepatocellular carcinoma on immunotherapy, posttreatment CD8 PET\/CT scans demonstrated increased 89Zr-Df-IAB22M2C uptake in tumor lesions, which correlated with response.","Conclusion: CD8 PET imaging with 89Zr-Df-IAB22M2C is safe and has the potential to visualize the whole-body biodistribution of CD8+ leukocytes in tumors and reference tissues, and may predict early response to immunotherapy."],"Aspect":"i","Summary":"The study conducted a phase 1 first-in-humans PET imaging using an anti-CD8 radiolabeled minibody, 89Zr-Df-IAB22M2C, to detect whole-body and tumor CD8+ leukocyte distribution in patients with metastatic solid tumors.","Indexes":[3],"Sentences":["Methods: We conducted a phase 1 first-in-humans PET imaging study using an anti-CD8 radiolabeled minibody, 89Zr-Df-IAB22M2C, to detect whole-body and tumor CD8+ leukocyte distribution in patients with metastatic solid tumors."],"Revise":false}
{"PMID":"38583422","Document":["INTRODUCTION: Naked DNA vaccination could be a powerful and safe strategy to mount antigen-specific cellular immunity.","We designed a phase I clinical trial to investigate the toxicity of naked DNA vaccines encoding CD8+ T-cell epitope from tumor-associated antigen MART-1 in patients with advanced melanoma.","METHODS: This dose escalating phase Ia clinical trial investigates the toxicity and immunological response upon naked DNA vaccines encoding a CD8+ T-cell epitope from the tumor-associated antigen MART-1, genetically linked to the gene encoding domain 1 of subunit-tetanus toxin fragment C in patients with advanced melanoma (inoperable stage IIIC-IV, AJCC 7th edition).","The vaccine was administrated via intradermal application using a permanent make-up or tattoo device.","Safety was monitored according to CTCAE v.3.0 and skin biopsies and blood samples were obtained for immunologic monitoring.","RESULTS: Nine pretreated, HLA-A*0201-positive patients with advanced melanoma expressing MART-1 and MHC class I, with a good performance status, and adequate organ function, were included.","With a median follow-up of 5.9 months, DNA vaccination was safe, without treatment-related deaths.","Common treatment-emergent adverse events of any grade were dermatologic reactions at the vaccination site (100%) and pain (56%).","One patient experienced grade 4 toxicity, most likely related to tumor progression.","One patient (11%) achieved stable disease, lasting 353 days.","Immune analysis showed no increase in vaccine-induced T cell response in peripheral blood of 5 patients, but did show a MART-1 specific CD8+ T cell response at the tattoo administration site.","The maximum dose administered was 2 mg due to lack of clinical activity.","CONCLUSION: We showed that the developed DNA vaccine, applied using a novel intradermal application strategy, can be administered safely.","Further research with improved vaccine formats is required to show possible clinical benefit of DNA vaccination."],"Aspect":"p","Summary":"The study involved 9 pretreated, HLA-A*0201-positive patients with advanced melanoma expressing MART-1 and MHC class I, with a good performance status, and adequate organ function.","Indexes":[5],"Sentences":["RESULTS: Nine pretreated, HLA-A*0201-positive patients with advanced melanoma expressing MART-1 and MHC class I, with a good performance status, and adequate organ function, were included."],"Revise":false}
{"PMID":"33303575","Document":["Antitumor immunity is impaired in obese mice.","Mechanistic insight into this observation remains sparse and whether it is recapitulated in patients with cancer is unclear because clinical studies have produced conflicting and controversial findings.","We addressed this by analyzing data from patients with a diverse array of cancer types.","We found that survival after immunotherapy was not accurately predicted by body mass index or serum leptin concentrations.","However, oxidized low-density lipoprotein (ox-LDL) in serum was identified as a suppressor of T-cell function and a driver of tumor cytoprotection mediated by heme oxygenase-1 (HO-1).","Analysis of a human melanoma gene expression database showed a clear association between higher HMOX1 (HO-1) expression and reduced progression-free survival.","Our in vivo experiments using mouse models of both melanoma and breast cancer revealed HO-1 as a mechanism of resistance to anti-PD1 immunotherapy but also exposed HO-1 as a vulnerability that could be exploited therapeutically using a small-molecule inhibitor.","In conclusion, our clinical data have implicated serum ox-LDL as a mediator of therapeutic resistance in patients with cancer, operating as a double-edged sword that both suppressed T-cell immunity and simultaneously induced HO-1-mediated tumor cell protection.","Our studies also highlight the therapeutic potential of targeting HO-1 during immunotherapy, encouraging further translational development of this combination approach.See article by Kuehm et al., p. 227."],"Aspect":"m","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"31358540","Document":["PURPOSE: Atezolizumab [anti-programmed death-ligand 1 (PD-L1)] selectively targets PD-L1 to block its interaction with receptors programmed death 1 and B7.1, thereby reinvigorating antitumor T-cell activity.","We evaluated the long-term safety and activity of atezolizumab, along with biological correlates of clinical activity endpoints, in a cohort of patients with melanoma in an ongoing phase Ia study (NCT01375842).","PATIENTS AND METHODS: Patients with unresectable or metastatic melanoma were enrolled to receive atezolizumab 0.1 to 20 mg\/kg or \u226510 mg\/kg every 3 weeks.","Primary study objectives were safety and tolerability.","Secondary objectives included investigator-assessed efficacy measures; pharmacodynamic and predictive biomarkers of antitumor activity were explored.","RESULTS: Forty-five patients were enrolled and were evaluable for safety.","Most treatment-related adverse events (AE) were grade 1\/2 (60%).","Fatigue (44%), pruritus (20%), pyrexia (18%), and rash (18%) were the most common treatment-related AEs of any grade.","No treatment-related deaths occurred.","Overall response rate was 30% among 43 efficacy- evaluable patients, with a median duration of response of 62 months [95% CI, 35-not estimable (NE)].","Clinically meaningful long-term survival was observed, with a median overall survival of 23 months (95% CI, 9-66).","Baseline biomarkers of tumor immunity [PD-L1 expression on immune cells, T effector (Teff), and antigen presentation gene signatures) and tumor mutational burden (TMB) were associated with improved response, progression-free survival, and overall survival.","CONCLUSIONS: Atezolizumab was well tolerated, with durable responses and survival in patients with melanoma.","PD-L1 expression, TMB, and Teff signatures may indicate improved benefit with atezolizumab in these patients."],"Aspect":"m","Summary":"Atezolizumab was administered at doses ranging from 0.1 to 20 mg\/kg or \u226510 mg\/kg every 3 weeks.","Indexes":[2],"Sentences":["PATIENTS AND METHODS: Patients with unresectable or metastatic melanoma were enrolled to receive atezolizumab 0.1 to 20 mg\/kg or \u226510 mg\/kg every 3 weeks."],"Revise":false}
{"PMID":"39374099","Document":["PURPOSE: Patients with BRAFV600\/NRASQ61 wild-type melanoma who progress after immune checkpoint inhibitors (ICIs) have a poor prognosis.","MEK inhibition has shown activity in this patient population but is associated with treatment-limiting skin toxicity.","Combining a BRAF inhibitor with a MEK inhibitor is associated with less skin toxicity.","METHODS: This phase II trial investigated trametinib (2 mg once daily) in patients with advanced BRAFV600\/NRASQ61 wild-type, ICI-refractory melanoma.","In case of treatment-limiting skin toxicity, low-dose dabrafenib (50 mg twice daily) was added to trametinib.","After a trial amendment, both drugs were combined up-front.","The confirmed objective response rate (cORR) served as the primary end point.","RESULTS: Twenty-four patients were included (50% male; median age 57 years; 92% Eastern Cooperative Oncology Group Performance Status 0-2; 75% stage IV-M1c\/stage IV-M1d; median number of prior therapies: two [range, 1-5]).","Three patients were enrolled before and 21 patients after the amendment, respectively.","Seven confirmed and one unconfirmed partial responses (PRs) were observed (cORR, 29.2%).","The median duration of response was 16.6 weeks (95% CI, 5.5 to 27.7).","Stable disease (SD) was the best response in an additional five patients.","Among the responding patients, genetic alterations causing mitogen-activated protein kinase (MAPK) pathway activation were documented in six patients.","The disease control rate in patients with MAPK pathway-activating alterations was 64.3% (five confirmed PR, one unconfirmed PR, and three SD).","The median progression-free survival was 13.3 weeks (95% CI, 3.5 to 23.1), and the median overall survival was 54.3 weeks (95% CI, 37.9 to 70.6).","Adding low-dose dabrafenib to trametinib effectively mitigated or prevented treatment-limiting trametinib-related skin toxicity.","CONCLUSION: The combination of trametinib plus low-dose dabrafenib demonstrated encouraging efficacy and effective mitigation of skin toxicity in patients with advanced, ICI-pretreated BRAFV600\/NRASQ61 wild-type melanoma patients.","MAPK pathway-activating alterations hold promise as a predictive biomarker."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"37378632","Document":["PURPOSE: Cancer vaccines represent a novel treatment modality with a complementary mode of action addressing a crucial bottleneck for checkpoint inhibitor (CPI) efficacy.","CPIs are expected to release brakes in T-cell responses elicited by vaccination, leading to more robust immune responses.","Increased antitumor T-cell responses may confer increased antitumor activity in patients with less immunogenic tumors, a subgroup expected to achieve reduced benefit from CPIs alone.","In this trial, a telomerase-based vaccine was combined with pembrolizumab to assess the safety and clinical activity in patients with melanoma.","PATIENTS AND METHODS: Thirty treatment-na\u00efve patients with advanced melanoma were enrolled.","Patients received intradermal injections of UV1 with adjuvant GM-CSF at two dose levels, and pembrolizumab according to the label.","Blood samples were assessed for vaccine-induced T-cell responses, and tumor tissues were collected for translational analyses.","The primary endpoint was safety, with secondary objectives including progression-free survival (PFS), overall survival (OS), and objective response rate (ORR).","RESULTS: The combination was considered safe and well-tolerated.","Grade 3 adverse events were observed in 20% of patients, with no grade 4 or 5 adverse events reported.","Vaccination-related adverse events were mostly mild injection site reactions.","The median PFS was 18.9 months, and the 1- and 2-year OS rates were 86.7% and 73.3%, respectively.","The ORR was 56.7%, with 33.3% achieving complete responses.","Vaccine-induced immune responses were observed in evaluable patients, and inflammatory changes were detected in posttreatment biopsies.","CONCLUSIONS: Encouraging safety and preliminary efficacy were observed.","Randomized phase II trials are currently ongoing."],"Aspect":"i","Summary":"Thirty treatment-na\u00efve advanced melanoma patients received a telomerase-based vaccine (UV1) with GM-CSF and pembrolizumab, with blood and tumor samples collected for immunological and translational analyses to assess safety and efficacy.","Indexes":[4,5,6],"Sentences":["PATIENTS AND METHODS: Thirty treatment-na\u00efve patients with advanced melanoma were enrolled.","Patients received intradermal injections of UV1 with adjuvant GM-CSF at two dose levels, and pembrolizumab according to the label.","Blood samples were assessed for vaccine-induced T-cell responses, and tumor tissues were collected for translational analyses."],"Revise":true}
{"PMID":"32467299","Document":["BACKGROUND: A pilot study of stereotactic body radiation therapy (SBRT) followed by high-dose interleukin-2 (IL-2) showed a higher than anticipated objective response rate (ORR) among patients with metastatic melanoma (MM).","We performed a prospective randomized study to determine if the ORR of SBRT + IL-2 was greater than IL-2 monotherapy in patients with advanced melanoma.","METHODS: Patients with MM who had adequate physiological reserve for IL-2 and at least one site suitable for SBRT were eligible.","There was a 1:1 randomization to SBRT + IL-2 or IL-2 monotherapy.","Patients received one or two doses of SBRT (20\u2009Gy per fraction) with the last dose administered 3 days before starting the first cycle of IL-2.","IL-2 (600,000 IU per kg via intravenous bolus infusion) was given every 8\u2009hours for a maximum of 14 doses with a second cycle after a 2-week rest.","Responding patients received up to six IL-2 cycles.","Patients assigned to IL-2 monotherapy who exhibited progression of melanoma after cycle 2 were allowed to crossover and receive SBRT and additional IL-2.","Response Evaluation Criteria in Solid Tumors 1.1 criteria were applied to non-irradiated lesions for response assessment.","RESULTS: 44 patients were included in the analysis.","The ORR in the SBRT + IL-2 group was 54%: 21% complete response (CR), 33% partial response (PR), 21% stable disease (SD) and 25% progressive disease (PD).","The ORR in patients receiving IL-2 monotherapy was 35%: 15% CR, 20% PR, 25% SD and 40% PD.","Seven patients assigned to IL-2 subsequently received SBRT + IL-2.","One CR and two PRs were observed in the crossover group.","There was no difference in progression-free or overall survival (OS).","At 5 years the OS was 26% in the SBRT + IL-2 group and 25% in the IL-2 monotherapy group.","The disease control rate (DCR) was higher in the SBRT + IL-2 group (75% vs 60%, p=0.34).","CONCLUSIONS: SBRT + IL-2 induced more objective responses with a higher DCR compared to IL-2 monotherapy in MM.","IL-2 monotherapy resulted in a significantly higher ORR than anticipated.","Some patients in the crossover group also achieved objective responses.","TRIAL REGISTRATION NUMBER: NCT01416831."],"Aspect":"d","Summary":"The treatment duration involved cycles of IL-2 administered every 8 hours for a maximum of 14 doses, with a second cycle after a 2-week rest, and up to six cycles for responding patients.","Indexes":[5,6],"Sentences":["IL-2 (600,000 IU per kg via intravenous bolus infusion) was given every 8\u2009hours for a maximum of 14 doses with a second cycle after a 2-week rest.","Responding patients received up to six IL-2 cycles."],"Revise":false}
{"PMID":"35190519","Document":["Treatment for advanced melanoma after progression on immunotherapy is limited.","This phase II trial (NCT03422445) was conducted to evaluate the efficacy and safety of apatinib plus temozolomide in patients with advanced melanoma after failure of immunotherapy.","Patients with unresectable stage III or stage IV melanoma after progression on immunotherapy were treated with temozolomide 300 mg on days 1-5 and apatinib 500 mg daily every 28-day cycle until disease progression or intolerable toxicities.","Besides immunotherapy, prior chemotherapy, targeted therapy, and clinical trials were allowed.","The primary endpoint was progression-free survival.","Secondary endpoints were objective response rate, disease control rate, overall survival, and safety.","Of 29 patients, 28 (96.6%) had metastatic diseases, and the predominant subtypes were mucosal [12 (41.4%)] and acral melanoma [eight (27.6%)].","Five (17.2%) patients showed BRAF, CKIT, or NRAS mutation.","Five achieved confirmed partial response, with an objective response rate of 17.2%.","The disease control rate was 82.8%.","The median progression-free survival was 5.0 months [95% confidence interval (CI): 4.7-5.3], and the median overall survival was 10.1 months (95% CI: 5.1-15.0).","Grade 3-4 treatment-related adverse events included proteinuria [four (13.8%)], thrombocytopenia [two (6.9%)], hypertension [one (3.4%)], and hyperbilirubinemia [one (3.4%)].","No treatment-related death occurred.","Apatinib plus temozolomide demonstrated promising efficacy and manageable safety profile in patients with advanced melanoma after progression on immunotherapy."],"Aspect":"p","Summary":"The study involved 29 patients with unresectable stage III or stage IV melanoma after progression on immunotherapy, of which 28 (96.6%) had metastatic diseases, with mucosal (12 patients, 41.4%) and acral melanoma (8 patients, 27.6%) being the predominant subtypes, and 5 (17.2%) patients had BRAF, CKIT, or NRAS mutation.","Indexes":[6,7],"Sentences":["Of 29 patients, 28 (96.6%) had metastatic diseases, and the predominant subtypes were mucosal [12 (41.4%)] and acral melanoma [eight (27.6%)].","Five (17.2%) patients showed BRAF, CKIT, or NRAS mutation."],"Revise":false}
{"PMID":"38506710","Document":["PURPOSE: Personalized vaccines targeting multiple neoantigens (nAgs) are a promising strategy for eliciting a diversified antitumor T-cell response to overcome tumor heterogeneity.","NOUS-PEV is a vector-based personalized vaccine, expressing 60 nAgs and consists of priming with a nonhuman Great Ape Adenoviral vector (GAd20) followed by boosts with Modified Vaccinia Ankara.","Here, we report data of a phase Ib trial of NOUS-PEV in combination with pembrolizumab in treatment-na\u00efve patients with metastatic melanoma (NCT04990479).","PATIENTS AND METHODS: The feasibility of this approach was demonstrated by producing, releasing, and administering to 6 patients 11 of 12 vaccines within 8 weeks from biopsy collection to GAd20 administration.","RESULTS: The regimen was safe, with no treatment-related serious adverse events observed and mild vaccine-related reactions.","Vaccine immunogenicity was demonstrated in all evaluable patients receiving the prime\/boost regimen, with detection of robust neoantigen-specific immune responses to multiple neoantigens comprising both CD4 and CD8 T cells.","Expansion and diversification of vaccine-induced T-cell receptor (TCR) clonotypes was observed in the posttreatment biopsies of patients with clinical response, providing evidence of tumor infiltration by vaccine-induced neoantigen-specific T cells.","CONCLUSIONS: These findings indicate the ability of NOUS-PEV to amplify and broaden the repertoire of tumor-reactive T cells to empower a diverse, potent, and durable antitumor immune response.","Finally, a gene signature indicative of the reduced presence of activated T cells together with very poor expression of the antigen-processing machinery genes has been identified in pretreatment biopsies as a potential biomarker of resistance to the treatment."],"Aspect":"i","Summary":"The study involved a phase Ib trial of administering the personalized vaccine NOUS-PEV, which consists of priming with a nonhuman Great Ape Adenoviral vector (GAd20) followed by boosts with Modified Vaccinia Ankara in combination with pembrolizumab to treatment-na\u00efve patients with metastatic melanoma. ","Indexes":[1,2],"Sentences":["NOUS-PEV is a vector-based personalized vaccine, expressing 60 nAgs and consists of priming with a nonhuman Great Ape Adenoviral vector (GAd20) followed by boosts with Modified Vaccinia Ankara.","Here, we report data of a phase Ib trial of NOUS-PEV in combination with pembrolizumab in treatment-na\u00efve patients with metastatic melanoma (NCT04990479)."],"Revise":true}
{"PMID":"32044885","Document":["Predicting the response to PD-1\/PD-L1 immune checkpoint blockade in patients with metastatic melanoma remains challenging.","In this study, we have investigated for the relationships between PD-L1 expression, PD-L1 copy number variations, and the response to anti-PD-1 therapies.","We studied the formalin-fixed paraffin-embedded tumor samples of 36 patients with metastatic melanoma using PD-L1 immunohistochemistry (IHC) and PD-L1\/chromosome 9 fluorescent in situ hybridization (FISH).","PD-L1 IHC was positive in 3 patients (8.33%, with >5% stained tumor cells) and PD-L1 FISH test revealed 5 (13.8%) PD-L1 amplifications, 8 (22.2%) PD-L1 gains, and 2 (5.5%) PD-L1 losses.","Among 14 responders and 13 nonresponders to anti-PD-1 immunotherapy, we concluded that there was no significant relationship between PD-L1 expression, PD-L1 copy number variations, and the response to anti-PD-1 therapies.","In our study, the determination of PD-L1 expression using IHC and PD-L1 copy number using FISH was insufficient to predict the response to PD-1\/PD-L1 immune checkpoint blockade in patients with advanced melanomas."],"Aspect":"a","Summary":"The study aims to investigate the relationships between PD-L1 expression, PD-L1 copy number variations, and the response to anti-PD-1 therapies in patients with metastatic melanoma.","Indexes":[1],"Sentences":["In this study, we have investigated for the relationships between PD-L1 expression, PD-L1 copy number variations, and the response to anti-PD-1 therapies."],"Revise":false}
{"PMID":"35648432","Document":["IMPORTANCE: Previous systematic reviews and meta-analyses have concluded that given data paucity, a comparison of reflectance confocal microscopy (RCM) with dermoscopy is complex.","They recommend comparative prospective studies in a real-world setting of suspect lesions.","OBJECTIVE: To test the hypothesis that RCM reduces unnecessary lesion excision by more than 30% and identifies all melanoma lesions thicker than 0.5 mm at baseline.","DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial included 3165 patients enrolled from 3 dermatology referral centers in Italy between January 2017 and December 2019, with a mean (SD) follow-up of 9.6 (6.9) months (range, 1.9-37.0 months).","The consecutive sample of 3165 suspect lesions determined through dermoscopy were eligible for inclusion (10 patients refused).","Diagnostic analysis included 3078 patients (48 lost, 39 refused excision).","Data were analyzed between April and September 2021.","INTERVENTIONS: Patients were randomly assigned 1:1 to standard therapeutic care (clinical and dermoscopy evaluation) with or without adjunctive RCM.","Information available guided prospective clinical decision-making (excision or follow-up).","MAIN OUTCOMES AND MEASURES: Hypotheses were defined prior to study initiation.","All lesions excised (baseline and follow-up) were registered, including histopathological diagnoses\/no change at dermoscopy follow-up (with or without adjunctive RCM).","Number needed to excise (total number of excised lesions\/number of melanomas) and Breslow thickness of delayed diagnosed melanomas were calculated based on real-life, prospective, clinical decision-making.","RESULTS: Among the 3165 participants, 1608 (50.8%) were male, and mean (SD) age was 49.3 (14.9) years.","When compared with standard therapeutic care only, adjunctive RCM was associated with a higher positive predictive value (18.9 vs 33.3), lower benign to malignant ratio (3.7:1.0 vs 1.8:1.0), and a number needed to excise reduction of 43.4% (5.3 vs 3.0).","All lesions (n\u2009=\u200915) with delayed melanoma diagnoses were thinner than 0.5 mm.","CONCLUSIONS AND RELEVANCE: This randomized clinical trial shows that adjunctive use of RCM for suspect lesions reduces unnecessary excisions and assures the removal of aggressive melanomas at baseline in a real-life, clinical decision-making application for referral centers with RCM.","TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04789421."],"Aspect":"o","Summary":"Adjunctive use of reflectance confocal microscopy (RCM) reduces unnecessary lesion excision by 43.4% and helps identify melanoma lesions.","Indexes":[13],"Sentences":["When compared with standard therapeutic care only, adjunctive RCM was associated with a higher positive predictive value (18.9 vs 33.3), lower benign to malignant ratio (3.7:1.0 vs 1.8:1.0), and a number needed to excise reduction of 43.4% (5.3 vs 3.0)."],"Revise":false}
{"PMID":"35069538","Document":["Anti-melanoma differentiation-associated gene 5 (MDA5) antibody, a dermatomyositis (DM)-specific antibody, is strongly associated with interstitial lung disease (ILD).","Patients with idiopathic inflammatory myopathy (IIM) who are anti-MDA5 antibody positive [anti-MDA5 (+)] often experience chest symptoms during the active disease phase.","These symptoms are primarily explained by respiratory failure; nevertheless, cardiac involvement can also be symptomatic.","Thus, the aim of this study was to investigate cardiac involvement in anti-MDA5 (+) DM.","A total of 63 patients with IIM who underwent electrocardiography (ECG) and ultrasound cardiography (UCG) during the active disease phase from 2016 to 2021 [anti-MDA5 (+) group, n = 21; anti-MDA5-negative (-) group, n = 42] were enrolled in the study, and their clinical charts were retrospectively reviewed.","The ECG and UCG findings were compared between the anti-MDA5 (+) and anti-MDA5 (-) groups.","All anti-MDA5 (+) patients had DM with ILD.","The anti-MDA5 (+) group showed more frequent skin ulcerations and lower levels of leukocytes, muscle enzymes, and electrolytes (Na, K, Cl, and Ca) than the anti-MDA5 (-) group.","According to the ECG findings obtained during the active disease phase, the T wave amplitudes were significantly lower for the anti-MDA5 (+) group than for the anti-MDA5 (-) group (I, II, and V4-6 lead; p < 0.01; aVF and V3, p < 0.05).","However, the lower amplitudes were restored during the remission phase.","Except for the E wave, A wave and Sep e', the UCG results showed no significant differences between the groups.","Four patients with anti-MDA5 (+) DM had many leads with lower T wave and cardiac abnormalities (heart failure, diastolic dysfunction, myocarditis) on and after admission.","Though anti-MDA5 (+) patients clinically improved after immunosuppressive therapy, some of their ECG findings did not fully recover in remission phase.","In conclusion, anti-MDA5 (+) DM appears to show cardiac involvement (electrical activity and function) during the active phase.","Further studies are necessary to clarify the actual cardiac condition and mechanism of these findings in patients with anti-MDA5 (+) DM."],"Aspect":"p","Summary":"The study involved 63 patients with idiopathic inflammatory myopathy (IIM), divided into two groups: 21 patients in the anti-MDA5 (+) group and 42 patients in the anti-MDA5 (-) group.","Indexes":[4],"Sentences":["A total of 63 patients with IIM who underwent electrocardiography (ECG) and ultrasound cardiography (UCG) during the active disease phase from 2016 to 2021 [anti-MDA5 (+) group, n = 21; anti-MDA5-negative (-) group, n = 42] were enrolled in the study, and their clinical charts were retrospectively reviewed."],"Revise":false}
{"PMID":"37414215","Document":["BACKGROUND: While neoadjuvant immunotherapy for melanoma has shown promising results, the data have been limited by a relatively short follow-up time, with most studies reporting 2-year outcomes.","The goal of this study was to determine long-term outcomes for stage III\/IV melanoma patients treated with neoadjuvant and adjuvant programmed cell death receptor 1 (PD-1) inhibition.","PATIENTS AND METHODS: This is a follow-up study of a previously published phase Ib clinical trial of 30 patients with resectable stage III\/IV cutaneous melanoma who received one dose of 200 mg IV neoadjuvant pembrolizumab 3 weeks before surgical resection, followed by 1 year of adjuvant pembrolizumab.","The primary outcomes were 5-year overall survival (OS), 5-year recurrence-free survival (RFS), and recurrence patterns.","RESULTS: We report updated results at 5 years of follow-up with a median follow-up of 61.9 months.","No deaths occurred in patients with a major pathological response (MPR, <10% viable tumor) or complete pathological response (pCR, no viable tumor) (n\u00a0= 8), compared to a 5-year OS of 72.8% for the remainder of the cohort (P\u00a0= 0.12).","Two of eight patients with a pCR or MPR had a recurrence.","Of the patients with >10% viable tumor remaining, 8 of 22 patients (36%) had a recurrence.","Additionally, the median time to recurrence was 3.9 years for patients with \u226410% viable tumor and 0.6 years for patients with >10% viable tumor (P\u00a0= 0.044).","CONCLUSIONS: The 5-year results from this trial represent the longest follow-up of a single-agent neoadjuvant PD-1 trial to date.","Response to neoadjuvant therapy continues to be an important prognosticator with regard to OS and RFS.","Additionally, recurrences in patients with pCR occur later and are salvageable, with a 5-year OS of 100%.","These results demonstrate the long-term efficacy of single-agent neoadjuvant\/adjuvant PD-1 blockade in patients with a pCR and the importance of long-term follow-up for these patients.","TRIAL REGISTRATION: Clinicaltrials.gov, NCT02434354."],"Aspect":"m","Summary":"The trial used pembrolizumab administered as a single dose of 200 mg IV in a neoadjuvant setting followed by 1 year of adjuvant pembrolizumab.","Indexes":[2],"Sentences":["PATIENTS AND METHODS: This is a follow-up study of a previously published phase Ib clinical trial of 30 patients with resectable stage III\/IV cutaneous melanoma who received one dose of 200 mg IV neoadjuvant pembrolizumab 3 weeks before surgical resection, followed by 1 year of adjuvant pembrolizumab."],"Revise":false}
{"PMID":"37427883","Document":["BACKGROUND\/AIMS: The aim of our study was to develop and validate a nomogram to predict cancer-specific survival and make a risk stratification system for primary gastrointestinal melanoma.","MATERIALS AND METHODS: Patients with primary gastrointestinal melanoma in the Surveillance, Epidemiology, and End Results database between 2000 and 2018 were included and randomly divided into the training and validation cohort (8:2).","A prediction nomogram of cancer-specific survival was constructed based on the risk factors identified in the multivariate Cox regression.","Calibration curve, time-dependent receiver operating characteristic, and decision curve analysis were performed.","Further, a risk stratification system was developed based on the nomogram.","RESULTS: A total of 433 patients were included.","The nomogram was constructed based on age, site, and tumor size, Surveillance, Epidemiology, and End Results (SEER) stage, and therapy.","The area under the curves of the nomogram predicting 6-, 12-, and 18-month cancer-specific survival were 0.789, 0.757, and 0.726 for the internal validation and 0.796, 0.763, and 0.795 for the external validation.","Calibration curves and decision curve analysis were performed.","Further, patients were divided into 2 risk subgroups.","The Kaplan-Meier analysis and the log-rank test showed that the risk stratification made well differentiation of patients with different risks of cancerspecific survival.","CONCLUSION: We developed and validated a practical prediction model of cancer-specific survival and a risk stratification system for patients with primary gastrointestinal melanoma, which might be available in clinical practices."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"37930123","Document":["PURPOSE: Preclinical studies show that activation of AMP kinase by phenformin can augment the cytotoxic effect and RAF inhibitors in BRAF V600-mutated melanoma.","We conducted a phase Ib dose-escalation trial of phenformin with standard dose dabrafenib\/trametinib in patients with metastatic BRAF V600-mutated melanoma.","EXPERIMENTAL DESIGN: We used a 3+3 dose-escalation design which explored phenformin doses between 50 and 200 mg twice daily.","Patients also received standard dose dabrafenib\/trametinib.","We measured phenformin pharmacokinetics and assessed the effect of treatment on circulating myeloid-derived suppressor cells (MDSC).","RESULTS: A total of 18 patients were treated at dose levels ranging from 50 to 200 mg twice daily.","The planned dose-escalation phase had to be cancelled because of the COVID 19 pandemic.","The most common toxicities were nausea\/vomiting; there were two cases of reversible lactic acidosis.","Responses were seen in 10 of 18 patients overall (56%) and in 2 of 8 patients who had received prior therapy with RAF inhibitor.","Pharmacokinetic data confirmed drug bioavailability.","MDSCs were measured in 7 patients treated at the highest dose levels and showed MDSC levels declined on study drug in 6 of 7 patients.","CONCLUSIONS: We identified the recommended phase II dose of phenformin as 50 mg twice daily when administered with dabrafenib\/trametinib, although some patients will require short drug holidays.","We observed a decrease in MDSCs, as predicted by preclinical studies, and may enhance immune recognition of melanoma cells.","SIGNIFICANCE: This is the first trial using phenformin in combination with RAF\/MEK inhibition in patients with BRAF V600-mutated melanoma.","This is a novel strategy, based on preclinical data, to increase pAMPK while blocking the MAPK pathway in melanoma.","Our data provide justification and a recommended dose for a phase II trial."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"38402687","Document":["BACKGROUND: Pain is common in patients with cancer.","The World Health Organisation recommends paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) for mild pain and combined with other agents for moderate\/severe pain.","This study estimated associations of NSAIDs with recurrence-free survival (RFS), distant metastasis-free survival (DMFS) and the incidence of immune-related adverse events (irAEs) in high-risk patients with resected melanoma in the EORTC 1325\/KEYNOTE-054 phase III clinical trial.","PATIENTS AND METHODS: Patients with AJCC7 stage IIIA, IIIB or IIIC resected melanoma were randomized to receive 200\u00a0mg of adjuvant pembrolizumab (N\u00a0=\u00a0514) or placebo (N\u00a0=\u00a0505) 3-weekly for one year or until recurrence.","As previously reported, pembrolizumab prolonged RFS and DMFS.","NSAID use was defined as administration between 7 days pre-randomization and starting treatment.","Multivariable Cox and Fine and Gray models were used to estimate hazard ratios (HRs) for associations of NSAIDs with RFS, DMFS and irAEs.","RESULTS: Of 1019 patients randomized, 59 and 44 patients in the pembrolizumab and placebo arms, respectively, used NSAIDs.","NSAIDs were not associated with RFS (HR 0.91, 95% CI 0.58-1.43) or DMFS in the pembrolizumab (HR 1.03, 95% CI 0.65-1.66) or placebo arms (for RFS, HR 0.76, 95% CI 0.48-1.20; for DMFS, HR 0.80, 95% CI 0.49-1.31).","NSAIDs were associated with the incidence of irAEs in the placebo arm (HR 3.06, 95% CI 1.45-6.45) but not in the pembrolizumab arm (HR 0.94, 95% CI 0.58-1.53).","CONCLUSION: NSAIDs were not associated with efficacy outcomes nor the risk of irAEs in patients with resected high-risk stage III melanoma receiving adjuvant pembrolizumab."],"Aspect":"m","Summary":"The trial involved pembrolizumab administered at a dose of 200 mg every 3 weeks for one year or until recurrence.","Indexes":[3],"Sentences":["PATIENTS AND METHODS: Patients with AJCC7 stage IIIA, IIIB or IIIC resected melanoma were randomized to receive 200\u00a0mg of adjuvant pembrolizumab (N\u00a0=\u00a0514) or placebo (N\u00a0=\u00a0505) 3-weekly for one year or until recurrence."],"Revise":false}
{"PMID":"32877599","Document":["BACKGROUND: In the previously reported primary analysis of this phase 3 trial, 12 months of adjuvant dabrafenib plus trametinib resulted in significantly longer relapse-free survival than placebo in patients with resected stage III melanoma with BRAF V600E or V600K mutations.","To confirm the stability of the relapse-free survival benefit, longer-term data were needed.","METHODS: We randomly assigned 870 patients who had resected stage III melanoma with BRAF V600E or V600K mutations to receive 12 months of oral dabrafenib (at a dose of 150 mg twice daily) plus trametinib (2 mg once daily) or two matched placebos.","The primary end point was relapse-free survival.","Here, we report 5-year results for relapse-free survival and survival without distant metastasis as the site of the first relapse.","Overall survival was not analyzed, since the required number of events to trigger the final overall survival analysis had not been reached.","RESULTS: The minimum duration of follow-up was 59 months (median patient follow-up, 60 months for dabrafenib plus trametinib and 58 months for placebo).","At 5 years, the percentage of patients who were alive without relapse was 52% (95% confidence interval [CI], 48 to 58) with dabrafenib plus trametinib and 36% (95% CI, 32 to 41) with placebo (hazard ratio for relapse or death, 0.51; 95% CI, 0.42 to 0.61).","The percentage of patients who were alive without distant metastasis was 65% (95% CI, 61 to 71) with dabrafenib plus trametinib and 54% (95% CI, 49 to 60) with placebo (hazard ratio for distant metastasis or death, 0.55; 95% CI, 0.44 to 0.70).","No clinically meaningful between-group difference in the incidence or severity of serious adverse events was reported during the follow-up period.","CONCLUSIONS: In the 5-year follow-up of a phase 3 trial involving patients who had resected stage III melanoma with BRAF V600E or V600K mutations, 12 months of adjuvant therapy with dabrafenib plus trametinib resulted in a longer duration of survival without relapse or distant metastasis than placebo with no apparent long-term toxic effects.","(Funded by GlaxoSmithKline and Novartis; COMBI-AD ClinicalTrials.gov number, NCT01682083; EudraCT number, 2012-001266-15.",")."],"Aspect":"o","Summary":"At 5 years, the percentage of patients who were alive without relapse was 52% with dabrafenib plus trametinib and 36% with placebo, indicating a longer duration of survival without relapse or distant metastasis with the combination therapy.","Indexes":[7,10],"Sentences":["At 5 years, the percentage of patients who were alive without relapse was 52% (95% confidence interval [CI], 48 to 58) with dabrafenib plus trametinib and 36% (95% CI, 32 to 41) with placebo (hazard ratio for relapse or death, 0.51; 95% CI, 0.42 to 0.61).","CONCLUSIONS: In the 5-year follow-up of a phase 3 trial involving patients who had resected stage III melanoma with BRAF V600E or V600K mutations, 12 months of adjuvant therapy with dabrafenib plus trametinib resulted in a longer duration of survival without relapse or distant metastasis than placebo with no apparent long-term toxic effects."],"Revise":false}
{"PMID":"36564126","Document":["BACKGROUND: Intratumoral administration of V937, a bioselected, genetically unmodified coxsackievirus A21, has previously demonstrated antitumor activity in patients with advanced melanoma as monotherapy and in combination with the programmed cell death 1 (PD-1) antibody pembrolizumab.","We report results from an open-label, single-arm, phase 1b study (NCT02307149) evaluating V937 plus the cytotoxic T-lymphocyte antigen 4 inhibitor ipilimumab in patients with advanced melanoma.","METHODS: Adult patients (aged \u226518 years) with histologically confirmed metastatic or unresectable stage IIIB\/C or IV melanoma received intratumoral V937 on days 1, 3, 5, 8, and 22 and every 3 weeks (Q3W) thereafter for up to 19 sets of injections plus intravenous ipilimumab 3\u2009mg\/kg Q3W administered for four doses starting on day 22.","Imaging was performed at screening, on days 43 and 106 and every 6 weeks thereafter; response was assessed by immune-related response criteria per investigator assessment.","Primary endpoints were safety in all treated patients and objective response rate (ORR) in all treated patients and in patients with disease that progressed on prior anti-PD-1 therapy.","RESULTS: Fifty patients were enrolled and treated.","ORR was 30% (95% CI 18% to 45%) among all treated patients, 47% (95% CI 23% to 72%) among patients who had not received prior anti-PD-1 therapy, and 21% (95% CI 9% to 39%) among patients who had experienced disease progression on prior anti-PD-1 therapy.","Tumor regression occurred in injected and non-injected lesions.","Median immune-related progression-free survival was 6.2 months (95%\u2009CI 3.5 to 9.0 months), and median overall survival was 45.1 months (95%\u2009CI 28.3 months to not reached).","The most common treatment-related adverse events (AEs) were pruritus (n=25, 50%), fatigue (n=22, 44%), and diarrhea (n=16, 32%).","There were no V937-related dose-limiting toxicities and no treatment-related grade 5 AEs.","Treatment-related grade 3 or 4 AEs, all of which were considered related to ipilimumab, occurred in 14% of patients (most commonly dehydration, diarrhea, and hepatotoxicity in 4% each).","CONCLUSIONS: Responses associated with intratumoral V937 plus ipilimumab were robust, including in the subgroup of patients who had experienced disease progression on prior anti-PD-1 therapy.","Toxicities were manageable and consistent with those of the individual monotherapies."],"Aspect":"i","Summary":"Adult patients with advanced melanoma received intratumoral V937 on specific days and every 3 weeks thereafter, combined with intravenous ipilimumab 3 mg\/kg every 3 weeks for four doses starting on day 22.","Indexes":[2,4],"Sentences":["METHODS: Adult patients (aged \u226518 years) with histologically confirmed metastatic or unresectable stage IIIB\/C or IV melanoma received intratumoral V937 on days 1, 3, 5, 8, and 22 and every 3 weeks (Q3W) thereafter for up to 19 sets of injections plus intravenous ipilimumab 3\u2009mg\/kg Q3W administered for four doses starting on day 22.","Primary endpoints were safety in all treated patients and objective response rate (ORR) in all treated patients and in patients with disease that progressed on prior anti-PD-1 therapy."],"Revise":true}
{"PMID":"37307514","Document":["PURPOSE: To address the paucity of data in patients with historically poor outcomes, we conducted the single-arm phase IIIb CheckMate 401 study to evaluate the safety and efficacy of nivolumab plus ipilimumab followed by nivolumab monotherapy in clinically diverse patient populations with advanced melanoma.","METHODS: Treatment-naive patients with unresectable stage III-IV melanoma received nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg once every 3 weeks (four doses) followed by nivolumab 3 mg\/kg (240 mg following a protocol amendment) once every 2 weeks for \u226424 months.","The primary end point was the incidence of grade 3-5 select treatment-related adverse events (TRAEs).","Overall survival (OS) was a secondary end point.","Outcomes were evaluated in subgroups defined by Eastern Cooperative Oncology Group performance status (ECOG PS), brain metastasis status, and melanoma subtype.","RESULTS: In total, 533 patients received at least one dose of study drug.","Grade 3-5 select TRAEs affecting the GI (16%), hepatic (15%), endocrine (11%), skin (7%), renal (2%), and pulmonary (1%) systems occurred in the all-treated population; similar incidence rates were observed across all subgroups.","At 21.6 months' median follow-up, 24-month OS rates were 63% in the all-treated population, 44% in the ECOG PS 2 subgroup (including patients with cutaneous melanoma only), 71% in the brain metastasis subgroup, 36% in the ocular\/uveal melanoma subgroup, and 38% in the mucosal melanoma subgroup.","CONCLUSION: Nivolumab plus ipilimumab followed by nivolumab monotherapy was tolerable in patients with advanced melanoma and poor prognostic characteristics.","Efficacy was similar between the all-treated population and patients with brain metastases.","Reduced efficacy was observed in patients with ECOG PS 2, ocular\/uveal melanoma, and\/or mucosal melanoma, highlighting the continued need for novel treatment options for these difficult-to-treat patients."],"Aspect":"s","Summary":"Grade 3-5 select treatment-related adverse events (TRAEs) occurred, affecting the GI (16%), hepatic (15%), endocrine (11%), skin (7%), renal (2%), and pulmonary (1%) systems.","Indexes":[6],"Sentences":["Grade 3-5 select TRAEs affecting the GI (16%), hepatic (15%), endocrine (11%), skin (7%), renal (2%), and pulmonary (1%) systems occurred in the all-treated population; similar incidence rates were observed across all subgroups."],"Revise":false}
{"PMID":"36197494","Document":["BACKGROUND: Recurrence-free survival (RFS) and overall survival (OS) data for adjuvant nivolumab versus placebo (proxy for routine surveillance) in patients with high-risk, resected melanoma are lacking.","This post hoc, indirect treatment comparison (ITC) used pooled data from the phase 3 EORTC 18,071 (ipilimumab vs. placebo) and CheckMate 238 (nivolumab vs. ipilimumab) trials to assess RFS and OS with nivolumab versus placebo and the numbers needed to treat (NNT) over 4\u00a0years.","METHODS: Patients with resected stage IIIB-C cutaneous melanoma (American Joint Committee on Cancer seventh edition) were included.","Inverse probability treatment weighting (IPTW) was used to balance baseline characteristics.","RFS NNTs were calculated for nivolumab versus ipilimumab and placebo.","OS NNTs were calculated for nivolumab versus placebo.","To adjust for different post-recurrence treatments, the difference in post-recurrence survival between the two ipilimumab arms was added to OS of the placebo arm.","RESULTS: This ITC included 278, 643, and 365 patients treated with nivolumab, ipilimumab, and placebo, respectively.","Following IPTW, nivolumab was associated with improved RFS versus placebo (hazard ratio [HR]: 0.49; 95% confidence interval [CI] 0.39-0.61) and ipilimumab (HR: 0.69; 95% CI 0.56-0.85).","RFS NNT was 4.2 for nivolumab versus placebo and 8.9 for nivolumab versus ipilimumab.","After post-recurrence survival adjustment, weighted 4-year OS rates were 75.8% for nivolumab and 64.1% for placebo; OS NNT for nivolumab versus placebo was 8.5.","CONCLUSIONS: In patients with resected stage IIIB-C cutaneous melanoma in this ITC, nivolumab improved RFS versus placebo and ipilimumab, and OS versus placebo after post-recurrence survival adjustment."],"Aspect":"i","Summary":"Inverse probability treatment weighting (IPTW) was used to balance baseline characteristics, and recurrence-free survival (RFS) and overall survival (OS) numbers needed to treat (NNT) were calculated for nivolumab versus ipilimumab and placebo, with adjustments for post-recurrence survival.","Indexes":[2,3,4,5,6],"Sentences":["METHODS: Patients with resected stage IIIB-C cutaneous melanoma (American Joint Committee on Cancer seventh edition) were included.","Inverse probability treatment weighting (IPTW) was used to balance baseline characteristics.","RFS NNTs were calculated for nivolumab versus ipilimumab and placebo.","OS NNTs were calculated for nivolumab versus placebo.","To adjust for different post-recurrence treatments, the difference in post-recurrence survival between the two ipilimumab arms was added to OS of the placebo arm."],"Revise":true}
{"PMID":"38547774","Document":["AIMS: The MAPK pathway is constitutively activated in uveal melanoma (UM).","Selumetinib (AZD6244, ARRY-142886), a MEK inhibitor, has shown limited activity as monotherapy in metastatic UM.","Pre-clinical studies support synergistic cytotoxic activity for MEK inhibitors combined with taxanes, and here we sought to assess the clinical efficacy of combining selumetinib and paclitaxel.","PATIENTS AND METHODS: Seventy-seven patients with metastatic UM who had not received prior chemotherapy were randomised to selumetinib alone, or combined with paclitaxel with or without interruption in selumetinib two days before paclitaxel.","The primary endpoint was progression free survival (PFS).","After amendment, the combination arms were combined for analysis and the sample size adjusted to detect a hazard ratio (HR): 0.55, 80% power at 1-sided 5% significance level.","RESULTS: The median PFS in the combination arms was 4.8 months (95% CI: 3.8 - 5.6) compared with 3.4 months (2.0 - 3.9) in the selumetinib arm (HR 0.62 [90% CI 0.41 - 0.92], 1-sided p-value = 0.022).","ORR was 14% and 4% in the combination and monotherapy arms respectively.","Median OS was 9 months for the combination and was not significantly different from selumetinib alone (10 months) with HR of 0.98 [90% CI 0.58 - 1.66], 1-sided p-value =\u00a00.469.","Toxicity was in keeping with the known profiles of the agents involved.","CONCLUSIONS: SelPac met its primary endpoint, demonstrating an improvement in PFS for combination selumetinib and paclitaxel.","No improvement in OS was observed, and the modest improvement in PFS is not practice changing."],"Aspect":"s","Summary":"Toxicity was in keeping with the known profiles of the agents involved.","Indexes":[9],"Sentences":["Toxicity was in keeping with the known profiles of the agents involved."],"Revise":false}
{"PMID":"32428937","Document":["The pomegranate phenolics are reported to have cutaneous benefits and to be effective in treating skin disorders, including hyperpigmentation.","In this context, a preparation method was developed by which to obtain phenolic-rich pomegranate peel extract.","Sinapic acid was presented as the major pomegranate peel phenolics, followed by gallic and ellagic acids, and 4 additional phenolics.","The extract exhibited strong antioxidant activity with an in vitro tyrosinase inhibitory effect.","The skin hyperpigmentation treating potency was confirmed by the suppression of cellular melanogenesis through tyrosinase and TRP-2 inhibitions as examined in the B16F10 melanoma cells.","Cellular antioxidant and proliferative activities of the extract toward human dermal fibroblasts were evidenced, as well as an inhibitory effect against MMP-2.","The extract was developed into the stable serum and mask.","The products were proved to be non-irritated in 30 Thai volunteers participating in a single application closed patch test.","A split-face, randomized, double-blind, placebo-controlled test of the skin lightening effect was evaluated in the 30 volunteers over 28 consecutive daily treatments and monitored by the Mexameter MX 18.","The active serum and mask were better in facial skin lightening efficacy than the placebo (p\u2009<\u20090.005).","That was in accordance with the sensory evaluation scored by the volunteers.","Phenolic-rich pomegranate peel extract is evidenced as a safe herbal derived material promising for skin hyperpigmentation treatment.","Supportive information regarding chemical and biological profiles is presented with the confirmed safety and cutaneous benefits in volunteers."],"Aspect":"i","Summary":"A split-face, randomized, double-blind, placebo-controlled test was conducted to evaluate the skin lightening effect of phenolic-rich pomegranate peel extract in 30 volunteers over 28 consecutive daily treatments.","Indexes":[8],"Sentences":["A split-face, randomized, double-blind, placebo-controlled test of the skin lightening effect was evaluated in the 30 volunteers over 28 consecutive daily treatments and monitored by the Mexameter MX 18."],"Revise":false}
{"PMID":"38319662","Document":["IMPORTANCE: While smoking is associated with a decreased incidence of cutaneous melanoma, the association of smoking with melanoma progression and death is not well defined.","OBJECTIVE: To determine the association of smoking with survival in patients with early-stage primary cutaneous melanoma.","DESIGN, SETTING, AND PARTICIPANTS: This cohort study performed a post hoc analysis of data derived from the randomized, multinational first and second Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II).","Participants were accrued for MSLT-I from January 20, 1994, to March 29, 2002; MSLT-II, from December 21, 2004, to March 31, 2014.","Median follow-up was 110.0 (IQR, 53.4-120.0) months for MSLT-I and 67.6 (IQR, 25.8-110.2) months for MSLT-II.","Patients aged 18 to 75 years with clinical stages I or II melanoma with a Breslow thickness of 1.00 mm or greater or Clark level IV to V and available standard prognostic and smoking data were included.","Analyses were performed from October 4, 2022, to March 31, 2023.","EXPOSURE: Current, former, and never smoking.","MAIN OUTCOMES AND MEASURES: Melanoma-specific survival of patients with current, former, and never smoking status was assessed for the entire cohort and for nodal observation and among subgroups with sentinel lymph node biopsy (SLNB)-negative and SLNB-positive findings.","RESULTS: Of 6279 included patients, 3635 (57.9%) were men, and mean (SD) age was 52.7 (13.4) years.","The most common tumor location was an extremity (2743 [43.7%]), and mean (SD) Breslow thickness was 2.44 (2.06) mm.","Smoking status included 1077 (17.2%) current, 1694 (27.0%) former, and 3508 (55.9%) never.","Median follow-up was 78.4 (IQR, 30.5-119.6) months.","Current smoking was associated with male sex, younger age, trunk site, thicker tumors, tumor ulceration, and SLNB positivity.","Current smoking was associated with a greater risk of melanoma-associated death by multivariable analysis for the entire study (hazard ratio [HR],\u20091.48 [95% CI, 1.26-1.75]; P\u2009<\u2009.001).","Former smoking was not.","The increased risk of melanoma-specific mortality associated with current smoking was greatest for patients with SLNB-negative melanoma (HR,\u20091.85 [95% CI, 1.35-2.52]; P\u2009<\u2009.001), but also present for patients with SLNB-positive melanoma (HR,\u20091.29 [95% CI, 1.04-1.59]; P\u2009=\u2009.02) and nodal observation (HR,\u20091.68 [95% CI, 1.09-2.61]; P\u2009=\u2009.02).","Smoking at least 20 cigarettes\/d doubled the risk of death due to melanoma for patients with SLNB-negative disease (HR, 2.06 [95% CI, 1.36-3.13]; P\u2009<\u2009.001).","CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that patients with clinical stage I and II melanoma who smoked had a significantly increased risk of death due to melanoma.","Smoking status should be assessed at time of melanoma diagnosis and may be considered a risk factor for disease progression."],"Aspect":"o","Summary":"Current and not former smoking was associated with an increased risk of melanoma-specific mortality in both patients with SLNB-positive and -negative melanoma, but in particular patients with SNLB-negative disease were affected where smoking 20 cigarettes\/d doubled the risk of death. ","Indexes":[14,16,17],"Sentences":["Current smoking was associated with a greater risk of melanoma-associated death by multivariable analysis for the entire study (hazard ratio [HR],\u20091.48 [95% CI, 1.26-1.75]; P\u2009<\u2009.001).","The increased risk of melanoma-specific mortality associated with current smoking was greatest for patients with SLNB-negative melanoma (HR,\u20091.85 [95% CI, 1.35-2.52]; P\u2009<\u2009.001), but also present for patients with SLNB-positive melanoma (HR,\u20091.29 [95% CI, 1.04-1.59]; P\u2009=\u2009.02) and nodal observation (HR,\u20091.68 [95% CI, 1.09-2.61]; P\u2009=\u2009.02).","Smoking at least 20 cigarettes\/d doubled the risk of death due to melanoma for patients with SLNB-negative disease (HR, 2.06 [95% CI, 1.36-3.13]; P\u2009<\u2009.001)."],"Revise":true}
{"PMID":"35753087","Document":["BACKGROUND: Ripretinib, a broad-spectrum KIT and platelet-derived growth factor receptor A switch-control tyrosine kinase inhibitor, is approved for the treatment of adult patients with advanced gastrointestinal stromal tumor as \u2265 fourth-line therapy.","We present the efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma enrolled in the expansion phase of the ripretinib phase I study.","PATIENTS AND METHODS: Patients with KIT-altered metastatic melanoma were enrolled and treated with ripretinib at the recommended phase II dose of 150 mg once daily in 28-day cycles.","Investigator-assessed responses according to Response Evaluation Criteria In Solid Tumors version 1.1 were carried out on day 1 of cycles 3, 5, 7, every three cycles thereafter, and at a final study visit.","RESULTS: A total of 26 patients with KIT-altered metastatic melanoma (25 with KIT mutations, 1 with KIT-amplification) were enrolled.","Patients had received prior immunotherapy (n\u00a0= 23, 88%) and KIT inhibitor therapy (n\u00a0= 9, 35%).","Confirmed objective response rate (ORR) was 23% [95% confidence interval (CI) 9%-44%; one complete and five partial responses] with a median duration of response of 9.1 months (range, 6.9-31.3 months).","Median progression-free survival (mPFS) was 7.3 months (95% CI 1.9-13.6 months).","Patients without prior KIT inhibitor therapy had a higher ORR and longer mPFS (n\u00a0= 17, ORR 29%, mPFS 10.2 months) than those who had received prior KIT inhibitor treatment (n\u00a0= 9, ORR 11%, mPFS 2.9 months).","The most common treatment-related treatment-emergent adverse events (TEAEs) of any grade in \u226515% of patients were increased lipase, alopecia, actinic keratosis, myalgia, arthralgia, decreased appetite, fatigue, hyperkeratosis, nausea, and palmar-plantar erythrodysesthesia syndrome.","There were no grade \u22654 treatment-related TEAEs.","CONCLUSIONS: In this phase I study, ripretinib demonstrated encouraging efficacy and a well-tolerated safety profile in patients with KIT-altered metastatic melanoma, suggesting ripretinib may have a clinically meaningful role in treating these patients."],"Aspect":"o","Summary":"Ripretinib showed a confirmed objective response rate (ORR) of 23% with a median duration of response of 9.1 months and a median progression-free survival (mPFS) of 7.3 months in patients with KIT-altered metastatic melanoma.","Indexes":[6,7],"Sentences":["Confirmed objective response rate (ORR) was 23% [95% confidence interval (CI) 9%-44%; one complete and five partial responses] with a median duration of response of 9.1 months (range, 6.9-31.3 months).","Median progression-free survival (mPFS) was 7.3 months (95% CI 1.9-13.6 months)."],"Revise":false}
{"PMID":"38614074","Document":["KEYNOTE-9421 is a randomized phase II adjuvant study in patients with resected stage III melanoma investigating a personalized neoantigen mRNA vaccine in combination with anti-PD-1.","The study gave a clear signal of superiority for the vaccine plus anti-PD-1 in relapse-free and distant-metastasis-free survival but is not yet conclusive, and important questions remain."],"Aspect":"a","Summary":"The study aims to investigate the efficacy of a personalized neoantigen mRNA vaccine in combination with anti-PD-1 in patients with resected stage III melanoma.","Indexes":[0],"Sentences":["KEYNOTE-9421 is a randomized phase II adjuvant study in patients with resected stage III melanoma investigating a personalized neoantigen mRNA vaccine in combination with anti-PD-1."],"Revise":false}
{"PMID":"35842199","Document":["BACKGROUND: No standard of care for mucosal melanoma (MM) in the adjuvant setting has been established.","Meanwhile, relapse-free survival (RFS) is only \u223c5 months after surgery alone.","This phase II trial aimed to compare toripalimab versus high-dose interferon-\u03b12b (HDI) as an adjuvant therapy for resected MM.","PATIENTS AND METHODS: From July 2017 to May 2019, 145 patients with resected MM were randomized (1 : 1) to receive HDI (n\u00a0= 72) or toripalimab (n\u00a0= 73) for 1 year until disease relapse\/distant metastasis, unacceptable toxicity, or withdrawal of consent.","The primary endpoint was RFS.","The secondary endpoints included distant metastasis-free survival (DMFS), overall survival (OS), and safety.","RESULTS: After a median follow-up of 26.3 months, the number of RFS, OS, and DMFS events was 51 versus 46, 33 versus 29, and 49 versus 44 in the toripalimab arm and the HDI arm, respectively.","The median RFS was 13.6 [95% confidence interval (CI) 8.31-19.02] months and 13.9 (95% CI 8.28-19.61) months in the toripalimab arm and the HDI arm, respectively.","The DMFS was not significantly different between the two arms [hazard ratio (HR) 1.00; 95% CI 0.65-1.54].","The median OS was 35.1 months (95% CI 27.93 months-not reached) in the toripalimab arm, with no significant difference in all-cause death (HR 1.11, 95% CI 0.66-1.84) for the two arms.","The median sums of the patients' actual infusion doses were 3672 mg and 1054.5 MIU in the toripalimab arm and the HDI arm, respectively.","The incidence of treatment-emergent adverse events with a grade \u22653 was much higher in the HDI arm than in the toripalimab arm (87.5% versus 27.4%).","CONCLUSIONS: Toripalimab showed a similar RFS and a more favorable safety profile than HDI, both better than historical data, suggesting that toripalimab might be the better treatment option.","However, additional translational studies and better treatment regimens are still warranted to improve the clinical outcome of MM."],"Aspect":"s","Summary":"The incidence of treatment-emergent adverse events with a grade \u22653 was much higher in the HDI arm than in the toripalimab arm.","Indexes":[11],"Sentences":["The incidence of treatment-emergent adverse events with a grade \u22653 was much higher in the HDI arm than in the toripalimab arm (87.5% versus 27.4%)."],"Revise":false}
{"PMID":"32366871","Document":["Advanced melanoma remains a disease with poor prognosis.","Several serologic markers have been investigated to help monitoring and prognostication, but to date only lactate dehydrogenase (LDH) has been validated as a standard prognostic factor biomarker for this disease by the American Joint Committee on Cancer.","In this work, we built a semi-mechanistic model to explore the relationship between the time course of several circulating biomarkers and overall or progression free survival in advanced melanoma patients treated with adjuvant high-dose interferon-[Formula: see text].","Additionally, due to the adverse interferon tolerability, a semi-mechanistic model describing the side effects of the treatment in the absolute neutrophil counts is proposed in order to simultaneously analyze the benefits and toxic effects of this treatment.","The results of our analysis suggest that the relative change from baseline of LDH was the most significant predictor of the overall survival of the patients.","Unfortunately, there was no significant difference in the proportion of patients with elevated serum biomarkers between the patients who recurred and those who remained free of disease.","Still, we believe that the modelling framework presented in this work of circulating biomarkers and adverse effects could constitute an additional strategy for disease monitoring in advance melanoma patients."],"Aspect":"m","Summary":"The treatment involved adjuvant high-dose interferon.","Indexes":[2],"Sentences":["In this work, we built a semi-mechanistic model to explore the relationship between the time course of several circulating biomarkers and overall or progression free survival in advanced melanoma patients treated with adjuvant high-dose interferon-[Formula: see text]."],"Revise":false}
{"PMID":"31664428","Document":["IMPORTANCE: Obesity is a cancer risk factor, and bariatric surgery in patients with obesity is associated with reduced cancer risk.","However, evidence of an association among obesity, bariatric surgery, and skin cancer, including melanoma, is limited.","OBJECTIVE: To investigate the association of bariatric surgery with skin cancer (squamous cell carcinoma and melanoma) and melanoma incidence.","DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized controlled trial, the Swedish Obese Subjects (SOS) study, is ongoing at 25 surgical departments and 480 primary health care centers in Sweden and was designed to examine outcomes after bariatric surgery.","The study included 2007 patients with obesity who underwent bariatric surgery and 2040 contemporaneously matched controls who received conventional obesity treatment.","Patients were enrolled between September 1, 1987, and January 31, 2001.","Data analysis was performed from June 29, 2018, to November 22, 2018.","INTERVENTIONS: Patients in the surgery group underwent gastric bypass (n\u2009=\u2009266), banding (n\u2009=\u2009376), or vertical banded gastroplasty (n\u2009=\u20091365).","The control group (n\u2009=\u20092040) received the customary treatment for obesity at their primary health care centers.","MAIN OUTCOMES AND MEASURES: The SOS study was cross-linked to the Swedish National Cancer Registry, the Cause of Death Registry, and the Registry of the Total Population for data on cancer incidence, death, and emigration.","RESULTS: The study included 4047 participants (mean [SD] age, 47.9 [6.1] years; 2867 [70.8%] female).","Information on cancer events was available for 4042 patients.","The study found that bariatric surgery was associated with a markedly reduced risk of melanoma (adjusted subhazard ratio, 0.43; 95% CI, 0.21-0.87; P\u2009=\u2009.02; median follow-up, 18.1 years) and risk of skin cancer in general (adjusted subhazard ratio, 0.59; 95% CI, 0.35-0.99; P\u2009=\u2009.047).","The skin cancer risk reduction was not associated with baseline body mass index or weight; insulin, glucose, lipid, and creatinine levels; diabetes; blood pressure; alcohol intake; or smoking.","CONCLUSIONS AND RELEVANCE: The results of this study suggest that bariatric surgery in individuals with obesity is associated with a reduced risk of skin cancer, including melanoma.","TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01479452."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"33982452","Document":["BACKGROUND: Checkpoint inhibitors (CPI) in combination with cell-based vaccines may produce synergistic antitumor immunity.","The primary analysis of the randomized and blinded phase IIb trial in resected stage III\/IV melanoma demonstrated TLPLDC is safe and improved 24-month disease-free survival (DFS) in the per treatment (PT) analysis.","Here, we examine efficacy within pre-specified and exploratory subgroups.","METHODS: Stage III\/IV patients rendered disease-free by surgery were randomized 2:1 to TLPLDC vaccine versus placebo.","The pre-specified PT analysis included only patients completing the primary vaccine\/placebo series at 6\u00a0months.","Kaplan-Meier analysis was used to compare 24-month DFS among subgroups.","RESULTS: There were no clinicopathologic differences between subgroups except stage IV patients were more likely to receive CPI.","In stage IV patients, 24-month DFS was 43% for vaccine versus 0% for placebo (p\u00a0=\u00a00.098) in the ITT analysis and 73% versus 0% (p\u00a0=\u00a00.002) in the PT analysis.","There was no significant difference in 24-month DFS when stratified by use of immunotherapy or CPI.","For patients with resected recurrent disease, 24-month DFS was 88.9% versus 33.3% (p\u00a0=\u00a00.013) in the PT analysis.","All benefit from vaccination was in the PT analysis; no benefit was found in patients receiving up to three doses.","CONCLUSION: The TLPLDC vaccine improved DFS in patients completing the primary vaccine series, particularly in the resected stage IV patients.","The efficacy of the TLPLDC vaccine will be confirmed in a phase III study evaluating adjuvant TLPLDC + CPI versus Placebo + CPI in resected stage IV melanoma patients."],"Aspect":"p","Summary":"The study involved stage III\/IV melanoma patients rendered disease-free by surgery, randomized 2:1 to TLPLDC vaccine versus placebo.","Indexes":[3],"Sentences":["METHODS: Stage III\/IV patients rendered disease-free by surgery were randomized 2:1 to TLPLDC vaccine versus placebo."],"Revise":false}
{"PMID":"32157631","Document":["BACKGROUND: A randomized phase III trial comparing whole-brain radiotherapy (WBRT) to observation following definitive local treatment of intracranial melanoma metastases with neurosurgery and\/or stereotactic surgery (SRS) is underway.","OBJECTIVE: We sought to assess the pre-trial cost-effectiveness of WBRT, hippocampal-avoidant WBRT (HA-WBRT), and observation (SRS or surgery alone) for this population to guide trial data collection efforts and reduce decision uncertainty.","METHODS: A time-dependent Markov model followed patients treated with neurosurgery or SRS who received subsequent WBRT, HA-WBRT or observation over a 5-year time horizon.","Model inputs were sourced from published literature and results tested for robustness using probabilistic sensitivity analysis.","Value of information (VOI) analysis was undertaken to guide data collection for the randomized trial.","RESULTS: Over 5\u00a0years, the WBRT strategy produced 1.74\u00a0QALYs (2.38 life-years) at a mean cost of $40,128 (costs in 2017 Australian dollars); HA-WBRT produced 1.88\u00a0QALYs (2.38 life-years) and cost $42,977; and SRS\/surgery alone produced 1.65\u00a0QALYs (2.13 life-years) at a cost of $46,281.","Probabilistic sensitivity analysis showed HA-WBRT was the preferred strategy in 77% of simulations.","Cost-effectiveness results were most sensitive to utilities of the controlled-disease health state in the WBRT group, and costs of HA-WBRT.","The EVPI for a randomized trial was estimated at $6,888 per person.","CONCLUSIONS: HA-WBRT may be cost-effective for the treatment of melanoma brain metastases.","The results predicted in our model can be validated with prospective trial data when available."],"Aspect":"i","Summary":"The study used a time-dependent Markov model to follow patients treated with neurosurgery or SRS who received subsequent WBRT, HA-WBRT, or observation over a 5-year time horizon.","Indexes":[2],"Sentences":["METHODS: A time-dependent Markov model followed patients treated with neurosurgery or SRS who received subsequent WBRT, HA-WBRT or observation over a 5-year time horizon."],"Revise":false}
{"PMID":"33639003","Document":["Full skin examination (FSE) may improve the detection of malignant melanoma (MM).","The objective of this study was to assess the safety of targeted lesion examination (TLE) compared with FSE in our Pigmented Lesion Clinic (PLC).","Patients attending the PLC were randomized in a 2\u00a0:\u00a01 ratio to FSE (intervention) or TLE (standard care).","Demographic details and risk factors were documented, and the time taken to perform FSE and TLE was noted.","Of 763 participants, 520 were assigned to FSE and 243 were assigned to TLE.","On average, FSE took 4.02\u00a0min and TLE took 30\u00a0s to perform.","Of the 520 participants assigned to FSE, 37 (7.1%) had incidental findings, of whom 12 patients (2.3%) had additional lesions biopsied.","No additional melanomas were detected that would have been missed by use of the standard protocol.","This study suggests that in low-risk patients referred to a PLC with a lesion of concern, the possibility of missing incidental cutaneous malignancies using lesion-directed examination is low."],"Aspect":"i","Summary":"Patients attending the Pigmented Lesion Clinic (PLC) were randomized in a 2:1 ratio to full skin examination (FSE) or targeted lesion examination (TLE) to assess the safety of TLE compared with FSE.","Indexes":[1,2],"Sentences":["The objective of this study was to assess the safety of targeted lesion examination (TLE) compared with FSE in our Pigmented Lesion Clinic (PLC).","Patients attending the PLC were randomized in a 2\u00a0:\u00a01 ratio to FSE (intervention) or TLE (standard care)."],"Revise":false}
{"PMID":"34295326","Document":["There is limited experience of PD-1 antibody combined with other therapies in children.","We aimed to explore the antitumor activity and safety of PD-1 antibody monotherapy or combination with other regimens in relapsed or refractory pediatric cancer.","This is a retrospective-case study conducted in two Chinese expert centers.","The primary objective of this study was to describe the overall response rate (ORR) and disease control rate (DCR).","Secondary objectives included characterizing toxicities.","Of the 22 pediatric patients with cancer who received PD-1 inhibitors, the median follow-up for all patients after the commencement of PD-1 therapy with or without other regimens was 12.3 months (0 - 43 months).","PD-1 antibody monotherapy demonstrated antitumor activity in a population of pediatric patients with Hodgkin lymphoma (HL), with an objective response rate (ORR) and disease control rate (DCR) of 83.3% (3CR and 2PR) and 100%, respectively.","However, no objective response was observed in patients with melanoma or Burkitt lymphoma evaluated in this study.","We reviewed responses for patients with chemotherapy, decitabine or everolimus combination therapies with PD-1 antibodies, and found that PD-1 antibody combined with decitabine showed potential efficacy in pediatric patients with advanced embryonal rhabdomyosarcoma and lymphoepitheliomatoid-like carcinoma.","There were no severe treatment-related adverse events (TRAEs) directly attributed to PD-1 antibody monotherapy in Asian pediatric patients with lower incidence of hematologic toxicity and nonhematologic toxicity.","The Grade \u22653 TRAEs were attributed to the combination chemotherapy."],"Aspect":"o","Summary":"The study found that PD-1 antibody monotherapy showed antitumor activity in pediatric patients with Hodgkin lymphoma, while combination with decitabine showed potential efficacy in advanced embryonal rhabdomyosarcoma and lymphoepitheliomatoid-like carcinoma.","Indexes":[6,8],"Sentences":["PD-1 antibody monotherapy demonstrated antitumor activity in a population of pediatric patients with Hodgkin lymphoma (HL), with an objective response rate (ORR) and disease control rate (DCR) of 83.3% (3CR and 2PR) and 100%, respectively.","We reviewed responses for patients with chemotherapy, decitabine or everolimus combination therapies with PD-1 antibodies, and found that PD-1 antibody combined with decitabine showed potential efficacy in pediatric patients with advanced embryonal rhabdomyosarcoma and lymphoepitheliomatoid-like carcinoma."],"Revise":false}
{"PMID":"38657233","Document":["IFx-Hu2.0 was designed to encode part of the Emm55 protein contained within a plasmid in a formulation intended for transfection into mammalian cells.","IFx-Hu2.0 promotes both adaptive and innate immune responses in animal studies.","Furthermore, previous studies have demonstrated safety\/efficacy in equine, canine, and murine species.","We present the first-in-human study of IFx-Hu2.0, administered by intralesional injection into melanoma tumors of seven patients with stage III\/IV unresectable melanoma.","No dose-limiting toxicities attributable to IFx-Hu2.0 were observed.","Grade 1\/2 injection site reactions were observed in five of seven patients.","IgG and IgM responses to Emm55 peptides and known melanoma antigens were seen in the peripheral blood, suggesting that IFx-Hu2.0 acts as an individualized \"in situ vaccine.\"","Three of four patients previously refractory to anti-PD1 experienced clinical benefit upon subsequent anti-PD1-based treatment.","Therefore, this approach is feasible, and clinical\/correlative outcomes warrant further investigation for treating patients with metastatic melanoma with an immune priming agent."],"Aspect":"a","Summary":"The study aims to investigate the feasibility and clinical outcomes of using IFx-Hu2.0 as an intralesional injection in patients with stage III\/IV unresectable melanoma.","Indexes":[3,8],"Sentences":["We present the first-in-human study of IFx-Hu2.0, administered by intralesional injection into melanoma tumors of seven patients with stage III\/IV unresectable melanoma.","Therefore, this approach is feasible, and clinical\/correlative outcomes warrant further investigation for treating patients with metastatic melanoma with an immune priming agent."],"Revise":false}
{"PMID":"38566437","Document":["BACKGROUND: Treatment decisions in metastatic melanoma (MM) are highly dependent on patient preferences and require the patients' involvement.","The complexity of treatment options with their individual advantages and disadvantages is often overwhelming.","We therefore developed an online patient decision aid (PtDA) to facilitate shared decision making (SDM).","METHODS: To evaluate the PtDA we conducted a two-armed, twocenter, prospective, open randomized controlled trial with MM patients who were facing a decision about first-line treatment.","The patients were allotted randomly in a 1:1 ratio to an intervention group (IG) with access to the PtDA before discussion with a physician or to a control group (CG) without access to the PtDA.","The primary endpoint was knowledge about the options for first-line treatment (multiple-choice test, 10 items, range 0-40 points).","The secondary endpoints were the SDM (third-party ratings of audio recordings of the treatment discussions) and satisfaction with the decision at the follow-up visit.","RESULTS: Of the 128 randomized patients, 120 completed the baseline questionnaire and were analyzed (59% male, median age 66 years).","The primary endpoint, i.e., the mean difference in knowledge after discussion with a physician, differed significantly between the IG and the CG (-3.22, 95% CI [-6.32; -0.12], p = 0.042).","No differences were found for the secondary endpoints, SDM and satisfaction with the decision.","The patients in the IG rated the PtDA as very useful.","CONCLUSION: The PtDA improved the knowledge of patients with MM about the options for treatment.","Both groups were highly satisfied with their treatment decisions.","However, additional physician training seems necessary to promote SDM."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"32885874","Document":["The educational effectiveness of dermoscopy image-based self-learning on a computer for medical students has not been well examined.","To assess the effect of an image-based self-learning session on the dermoscopic diagnostic performance for malignant melanoma (MM), basal cell carcinoma, melanocytic nevus and seborrheic keratosis (SK) on non-acral regions in comparison with a conventional classroom-style lecture, 114 fourth-year medical students (mean age, 23.7\u00a0years; male\u00a0:\u00a0female, 73:41) were enrolled.","The subjects were randomly assigned to either a self-learning to lecture (SL) or lecture to self-learning (LS) group to receive a 15-min image-based self-learning computer session and a 15-min video lecture session in different orders.","The user interface of the digital content was the same as that on a website (https:\/\/dz-image.casio.jp).","Diagnostic performance was determined using the total number of correct answers for the four diseases and by malignancy prediction in examination A (before training), B (after receiving one session) and C (after receiving both sessions).","The examinations were all unique and contained five dermoscopic images each of the four diseases.","The total number of correct answers and malignancy prediction results for examination B were significantly higher in the SL group than in LS (11.6 and 15.2 vs 10.1 and 13.4, respectively; both P\u00a0<\u00a00.01), with no remarkable differences for examination C (13.5 and 16.8 vs 13.3 and 16.4, respectively; P\u00a0=\u00a00.62 and P\u00a0=\u00a00.21).","In subanalyses, the number of correct answers for SK in examination B was significantly higher in the SL group (3.6 vs. 1.8, P\u00a0<\u00a00.01), while that for MM was significantly lower (2.2 vs 3.0, P\u00a0<\u00a00.01).","Diagnostic performance was comparable between sexes for examination B.","In conclusion, computer-assisted dermoscopy image-based self-learning may be a suitable and non-inferior alternative to classroom-style instruction for medical students within an ultra-short training period."],"Aspect":"o","Summary":"Computer-assisted dermoscopy image-based self-learning showed non-inferior outcomes compared to classroom-style instruction for medical students in a short training period.","Indexes":[6,9],"Sentences":["The total number of correct answers and malignancy prediction results for examination B were significantly higher in the SL group than in LS (11.6 and 15.2 vs 10.1 and 13.4, respectively; both P\u00a0<\u00a00.01), with no remarkable differences for examination C (13.5 and 16.8 vs 13.3 and 16.4, respectively; P\u00a0=\u00a00.62 and P\u00a0=\u00a00.21).","In conclusion, computer-assisted dermoscopy image-based self-learning may be a suitable and non-inferior alternative to classroom-style instruction for medical students within an ultra-short training period."],"Revise":false}
{"PMID":"37270692","Document":["PURPOSE: The combination of encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor) has demonstrated clinical efficacy with an acceptable safety profile in patients with BRAFV600E\/K-mutant metastatic melanoma.","We evaluated the efficacy and safety of encorafenib plus binimetinib in patients with BRAFV600E-mutant metastatic non-small-cell lung cancer (NSCLC).","METHODS: In this ongoing, open-label, single-arm, phase II study, patients with BRAFV600E-mutant metastatic NSCLC received oral encorafenib 450 mg once daily plus binimetinib 45 mg twice daily in 28-day cycles.","The primary end point was confirmed objective response rate (ORR) by independent radiology review (IRR).","Secondary end points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival, time to response, and safety.","RESULTS: At data cutoff, 98 patients (59 treatment-na\u00efve and 39 previously treated) with BRAFV600E-mutant metastatic NSCLC received encorafenib plus binimetinib.","Median duration of treatment was 9.2 months with encorafenib and 8.4 months with binimetinib.","ORR by IRR was 75% (95% CI, 62 to 85) in treatment-na\u00efve and 46% (95% CI, 30 to 63) in previously treated patients; median DOR was not estimable (NE; 95% CI, 23.1 to NE) and 16.7 months (95% CI, 7.4 to NE), respectively.","DCR after 24 weeks was 64% in treatment-na\u00efve and 41% in previously treated patients.","Median PFS was NE (95% CI, 15.7 to NE) in treatment-na\u00efve and 9.3 months (95% CI, 6.2 to NE) in previously treated patients.","The most frequent treatment-related adverse events (TRAEs) were nausea (50%), diarrhea (43%), and fatigue (32%).","TRAEs led to dose reductions in 24 (24%) and permanent discontinuation of encorafenib plus binimetinib in 15 (15%) patients.","One grade 5 TRAE of intracranial hemorrhage was reported.","Interactive visualization of the data presented in this article is available at the PHAROS dashboard (https:\/\/clinical-trials.dimensions.ai\/pharos\/).","CONCLUSION: For patients with treatment-na\u00efve and previously treated BRAFV600E-mutant metastatic NSCLC, encorafenib plus binimetinib showed a meaningful clinical benefit with a safety profile consistent with that observed in the approved indication in melanoma."],"Aspect":"p","Summary":"The study involved 98 patients with BRAFV600E-mutant metastatic NSCLC, including 59 treatment-na\u00efve and 39 previously treated patients.","Indexes":[5],"Sentences":["RESULTS: At data cutoff, 98 patients (59 treatment-na\u00efve and 39 previously treated) with BRAFV600E-mutant metastatic NSCLC received encorafenib plus binimetinib."],"Revise":false}
{"PMID":"31901705","Document":["BACKGROUND: BRAF\/MEK inhibitor combinations are established treatments for BRAF V600-mutant melanoma based on demonstrated benefits on progression-free survival (PFS) and overall survival (OS).","Here, we report an updated analysis of the COLUMBUS\u00a0(COmbined LGX818 [encorafenib] Used with MEK162 [binimetinib] in\u00a0BRAF\u00a0mutant Unresectable Skin cancer) trial with long-term follow-up.","METHODS: In part 1 of the COLUMBUS trial, 577 patients with advanced\/metastatic BRAF V600-mutant melanoma, untreated or progressed after first-line immunotherapy, were randomised 1:1:1 to 450\u00a0mg of encorafenib QD\u00a0+\u00a045\u00a0mg of binimetinib BID (COMBO450) vs 960\u00a0mg of vemurafenib BID (VEM) or 300\u00a0mg of encorafenib ENCO QD (ENCO300).","An updated analysis was conducted that included PFS, OS, objective response rate, safety and tolerability\u00a0and analyses of results by prognostic subgroups.","RESULTS: At data cutoff, there were 116, 113\u00a0and 138 deaths in the COMBO450, ENCO300\u00a0and VEM treatment arms, respectively.","The median OS was 33.6 months (95% confidence interval [CI], 24.4-39.2) for COMBO450, 23.5 months (95% CI, 19.6-33.6) for ENCO300\u00a0and 16.9 months (95% CI, 14.0-24.5) for VEM.","Compared with VEM, COMBO450 decreased the risk of death by 39% (hazard ratio [HR], 0.61; 95% CI, 0.48-0.79).","The updated median PFS for COMBO450 was 14.9 months (95% CI, 11.0-20.2), ENCO300 was 9.6 months (95% CI, 7.4-14.8)\u00a0and VEM was 7.3 months (95% CI, 5.6-7.9).","PFS was longer for COMBO450 vs VEM (HR, 0.51; 95% CI, 0.39-0.67).","Landmark OS and PFS results show consistent results for each year analysed.","Subgroups all favoured COMBO450 vs VEM.","CONCLUSIONS: Updated PFS and OS results for COMBO450 from the COLUMBUS trial demonstrate a long-term benefit in patients with advanced BRAF V600-mutated melanoma."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"37643378","Document":["PURPOSE: BRAF V600 mutation is detected in 5%-10% of pediatric high-grade gliomas (pHGGs), and effective treatments are limited.","In previous trials, dabrafenib as monotherapy or in combination with trametinib demonstrated activity in children and adults with relapsed\/refractory BRAF V600-mutant HGG.","METHODS: This phase II study evaluated dabrafenib plus trametinib in patients with relapsed\/refractory BRAF V600-mutant pHGG.","The primary objective was overall response rate (ORR) by independent review by Response Assessment in Neuro-Oncology criteria.","Secondary objectives included ORR by investigator determination, duration of response (DOR), progression-free survival, overall survival (OS), and safety.","RESULTS: A total of 41 pediatric patients with previously treated BRAF V600-mutant HGG were enrolled.","At primary analysis, median follow-up was 25.1 months, and 51% of patients remained on treatment.","Sixteen of 20 discontinuations were due to progressive disease in this relapsed\/refractory pHGG population.","Independently assessed ORR was 56% (95% CI, 40 to 72).","Median DOR was 22.2 months (95% CI, 7.6 months to not reached [NR]).","Fourteen deaths were reported.","Median OS was 32.8 months (95% CI, 19.2 months to NR).","The most common all-cause adverse events (AEs) were pyrexia (51%), headache (34%), and dry skin (32%).","Two patients (5%) had AEs (both rash) leading to discontinuation.","CONCLUSION: In relapsed\/refractory BRAF V600-mutant pHGG, dabrafenib plus trametinib improved ORR versus previous trials of chemotherapy in molecularly unselected patients with pHGG and was associated with durable responses and encouraging survival.","These findings suggest that dabrafenib plus trametinib is a promising targeted therapy option for children and adolescents with relapsed\/refractory BRAF V600-mutant HGG."],"Aspect":"m","Summary":"The study evaluated dabrafenib plus trametinib as a treatment for patients with relapsed\/refractory BRAF V600-mutant pHGG.","Indexes":[1,2,14,15],"Sentences":["In previous trials, dabrafenib as monotherapy or in combination with trametinib demonstrated activity in children and adults with relapsed\/refractory BRAF V600-mutant HGG.","METHODS: This phase II study evaluated dabrafenib plus trametinib in patients with relapsed\/refractory BRAF V600-mutant pHGG.","CONCLUSION: In relapsed\/refractory BRAF V600-mutant pHGG, dabrafenib plus trametinib improved ORR versus previous trials of chemotherapy in molecularly unselected patients with pHGG and was associated with durable responses and encouraging survival.","These findings suggest that dabrafenib plus trametinib is a promising targeted therapy option for children and adolescents with relapsed\/refractory BRAF V600-mutant HGG."],"Revise":false}
{"PMID":"36099927","Document":["BACKGROUND: The IMMUNED trial previously showed significant improvements in recurrence-free survival for adjuvant nivolumab plus ipilimumab as well as for adjuvant nivolumab alone in patients with stage IV melanoma with no evidence of disease after resection or radiotherapy.","Here, we report the final analysis, including overall survival data.","METHODS: IMMUNED was an investigator-sponsored, double-blind, placebo-controlled, three-arm, phase 2 trial conducted in 20 academic medical centres in Germany.","Eligible patients were aged 18-80 years with stage IV melanoma with no evidence of disease after surgery or radiotherapy.","Patients were randomly assigned (1:1:1) to either nivolumab plus ipilimumab (nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg every 3 weeks for four doses followed by nivolumab 3 mg\/kg every 2 weeks), nivolumab monotherapy (nivolumab 3 mg\/kg every 2 weeks), or matching placebo, for up to 1 year.","The primary endpoint was recurrence-free survival in the intention-to-treat population.","Secondary endpoints were time-to-recurrence, overall survival, progression-free survival or recurrence-free survival 2 (in patients in the placebo group who crossed over to nivolumab monotherapy after experiencing disease recurrence), and safety endpoints.","This trial is registered on ClinicalTrials.gov (NCT02523313), and is complete.","FINDINGS: Between Sept 2, 2015, and Nov 20, 2018, 175 patients were enrolled in the study, and 167 were randomly assigned to receive either nivolumab plus ipilimumab (n=56), nivolumab plus ipilimumab-matching placebo (n=59), or double placebo control (n=52).","At a median follow-up of 49\u00b72 months (IQR 34\u00b79-58\u00b71), 4-year recurrence-free survival was 64\u00b72% (95% CI 49\u00b72-75\u00b79) in the nivolumab plus ipilimumab group, 31\u00b74% (19\u00b77-43\u00b78) in the nivolumab alone group, and 15\u00b70% (6\u00b77-26\u00b76) in the placebo group.","The hazard ratio (HR) for recurrence for the nivolumab plus ipilimumab group versus placebo was 0\u00b725 (97\u00b75% CI 0\u00b713-0\u00b748; p<0\u00b70001), and for the nivolumab group versus placebo was 0\u00b760 (0\u00b736-1\u00b700; p=0\u00b7024).","Median overall survival was not reached in any treatment group.","The HR for overall survival was significantly in favour of the nivolumab plus ipilimumab group versus placebo (HR 0\u00b741; 95% CI 0\u00b717-0\u00b799; p=0\u00b7040), but not for the nivolumab group versus placebo (HR 0\u00b775; 0\u00b736-1\u00b756; p=0\u00b744).","4-year overall survival was 83\u00b78% (95% CI 68\u00b78-91\u00b79) in the nivolumab plus ipilimumab group, 72\u00b76% (57\u00b74-83\u00b72) in the nivolumab alone group, and 63\u00b71% (46\u00b79-75\u00b76) in the placebo group.","The median progression-free survival or recurrence-free survival 2 of patients in the placebo group who crossed over to nivolumab monotherapy after experiencing disease recurrence was not reached (95% CI 21\u00b72 months to not reached).","Rates of grade 3-4 treatment-related adverse events remained largely unchanged compared with our previous report, occurring in 71% (95% CI 57-82) of the nivolumab plus ipilimumab group, and 29% (95% CI 17-42) of patients receiving nivolumab alone.","There were no treatment-related deaths.","INTERPRETATION: Both active regimens continued to show significantly improved recurrence-free survival compared with placebo in patients with stage IV melanoma with no evidence of disease who were at high risk of recurrence.","Overall survival was significantly improved for patients receiving nivolumab plus ipilimumab compared with placebo.","Use of subsequent anti-PD-1-based therapy was high in patients in the placebo group after recurrence and most likely impacted the overall survival comparison of nivolumab alone versus placebo.","The recurrence-free and overall survival benefit of nivolumab plus ipilimumab over placebo reinforces the change of practice already initiated for the treatment of patients with stage IV melanoma with no evidence of disease.","FUNDING: Bristol-Myers Squibb."],"Aspect":"d","Summary":"The treatment duration was up to 1 year, with patients receiving either nivolumab plus ipilimumab or nivolumab monotherapy for the specified duration.","Indexes":[4],"Sentences":["Patients were randomly assigned (1:1:1) to either nivolumab plus ipilimumab (nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg every 3 weeks for four doses followed by nivolumab 3 mg\/kg every 2 weeks), nivolumab monotherapy (nivolumab 3 mg\/kg every 2 weeks), or matching placebo, for up to 1 year."],"Revise":true}
{"PMID":"36450385","Document":["BACKGROUND: Adjuvant therapy for high-risk resected melanoma with programmed cell-death 1 blockade results in a median relapse-free survival (RFS) of 5 years.","The addition of low dose ipilimumab (IPI) to a regimen of adjuvant nivolumab (NIVO) in CheckMate-915 did not result in increased RFS.","A pilot phase II adjuvant study of either standard dose or low dose IPI with NIVO was conducted at two centers to evaluate RFS with correlative biomarker studies.","METHODS: Patients with resected stages IIIB\/IIIC\/IV melanoma received either IPI 3\u2009mg\/kg and NIVO 1\u2009mg\/kg (cohort 4) or IPI 1\u2009mg\/kg and NIVO 3\u2009mg\/kg (cohorts 5 and 6) induction therapy every 3\u2009weeks for 12 weeks, followed by maintenance NIVO.","In an amalgamated subset of patients across cohorts, peripheral T cells at baseline and on-treatment were assessed by flow cytometry and RNA sequencing for exploratory biomarkers.","RESULTS: High rates of grade 3-4 adverse events precluded completion of induction therapy in 50%, 35% and 7% of the patients in cohorts 4, 5 and 6, respectively.","At a median of 63.9 months of follow-up, 16\/56 patients (29%) relapsed.","For all patients, at 5\u2009years, RFS was 71% (95% CI: 60 to 84), and overall survival was 94% (95% CI: 88 to 100).","Expansion of CD3+CD4+CD38+CD127-GARP- T cells, an on-treatment increase in CD39 expression in CD8+ T\u2009cells, and T-cell expression of phosphorylated signal-transducer-and-activator-of-transcription (STAT)2 and STAT5 were associated with relapse.","CONCLUSIONS: Adjuvant IPI\/NIVO at the induction doses used resulted in promising relapse-free and overall survival, although with a high rate of grade 3-4 adverse events.","Biomarker analyses highlight an association of ectoenzyme-expressing T cells and STAT signaling pathways with relapse, warranting future validation.","TRIAL REGISTRATION NUMBER: NCT01176474 and NCT02970981."],"Aspect":"p","Summary":"The study involved patients with resected stages IIIB\/IIIC\/IV melanoma who received different doses of ipilimumab (IPI) and nivolumab (NIVO).","Indexes":[3],"Sentences":["METHODS: Patients with resected stages IIIB\/IIIC\/IV melanoma received either IPI 3\u2009mg\/kg and NIVO 1\u2009mg\/kg (cohort 4) or IPI 1\u2009mg\/kg and NIVO 3\u2009mg\/kg (cohorts 5 and 6) induction therapy every 3\u2009weeks for 12 weeks, followed by maintenance NIVO."],"Revise":false}
{"PMID":"33861486","Document":["LESSONS LEARNED: This study suggests that trametinib has significant clinical activity in non-V600 BRAF mutation and BRAF fusion metastatic melanoma, albeit in a small cohort.","All patients with metastatic melanoma should undergo sequencing of the BRAF gene to identify noncanonical BRAF mutations that may indicate benefit from treatment with trametinib.","BACKGROUND: Non-V600 BRAF mutations and BRAF fusions in aggregate occur in approximately 5% of all melanomas.","Inhibition of the mitogen-activated protein kinase (MAPK) pathway has been implicated as a possible treatment strategy for these patients.","METHODS: In this open-label, multicenter, phase II study, patients with advanced melanoma harboring mutations in BRAF outside V600 (non-V600) or BRAF fusions received trametinib 2.0 mg daily.","Patients were divided into cohorts based on the intrinsic catalytic activity of BRAF mutation (high, cohort A; low\/unknown, cohort B).","The primary endpoint was objective response rate (ORR) for patients in cohort A; secondary endpoints included ORR in cohort B, safety, and survival in both treatment arms.","RESULTS: Among all patients, the ORR was 33% (three of nine patients), including 67% in cohort A and 17% in cohort B.","Two patients had stable disease as best response, and six patients had some degree of tumor shrinkage.","The median progression-free survival (PFS) was 7.3 months.","Treatment-related adverse events occurred in all patients (100%); most (89%) were grade 1-2.","CONCLUSION: In contrast to recently described tumor-agnostic studies in a genetically similar population, trametinib had considerable activity in a small population of patients with melanoma harboring BRAF non-V600 mutations and fusions, providing rationale for sequencing in search of these genomic alterations."],"Aspect":"o","Summary":"This study found that trametinib showed significant clinical activity in patients with non-V600 BRAF mutation and BRAF fusion metastatic melanoma, with an overall response rate of 33%.","Indexes":[0,7],"Sentences":["LESSONS LEARNED: This study suggests that trametinib has significant clinical activity in non-V600 BRAF mutation and BRAF fusion metastatic melanoma, albeit in a small cohort.","RESULTS: Among all patients, the ORR was 33% (three of nine patients), including 67% in cohort A and 17% in cohort B."],"Revise":false}
{"PMID":"31664428","Document":["IMPORTANCE: Obesity is a cancer risk factor, and bariatric surgery in patients with obesity is associated with reduced cancer risk.","However, evidence of an association among obesity, bariatric surgery, and skin cancer, including melanoma, is limited.","OBJECTIVE: To investigate the association of bariatric surgery with skin cancer (squamous cell carcinoma and melanoma) and melanoma incidence.","DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized controlled trial, the Swedish Obese Subjects (SOS) study, is ongoing at 25 surgical departments and 480 primary health care centers in Sweden and was designed to examine outcomes after bariatric surgery.","The study included 2007 patients with obesity who underwent bariatric surgery and 2040 contemporaneously matched controls who received conventional obesity treatment.","Patients were enrolled between September 1, 1987, and January 31, 2001.","Data analysis was performed from June 29, 2018, to November 22, 2018.","INTERVENTIONS: Patients in the surgery group underwent gastric bypass (n\u2009=\u2009266), banding (n\u2009=\u2009376), or vertical banded gastroplasty (n\u2009=\u20091365).","The control group (n\u2009=\u20092040) received the customary treatment for obesity at their primary health care centers.","MAIN OUTCOMES AND MEASURES: The SOS study was cross-linked to the Swedish National Cancer Registry, the Cause of Death Registry, and the Registry of the Total Population for data on cancer incidence, death, and emigration.","RESULTS: The study included 4047 participants (mean [SD] age, 47.9 [6.1] years; 2867 [70.8%] female).","Information on cancer events was available for 4042 patients.","The study found that bariatric surgery was associated with a markedly reduced risk of melanoma (adjusted subhazard ratio, 0.43; 95% CI, 0.21-0.87; P\u2009=\u2009.02; median follow-up, 18.1 years) and risk of skin cancer in general (adjusted subhazard ratio, 0.59; 95% CI, 0.35-0.99; P\u2009=\u2009.047).","The skin cancer risk reduction was not associated with baseline body mass index or weight; insulin, glucose, lipid, and creatinine levels; diabetes; blood pressure; alcohol intake; or smoking.","CONCLUSIONS AND RELEVANCE: The results of this study suggest that bariatric surgery in individuals with obesity is associated with a reduced risk of skin cancer, including melanoma.","TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01479452."],"Aspect":"i","Summary":"The study involved a nonrandomized controlled trial where patients with obesity underwent bariatric surgery (gastric bypass, banding, or vertical banded gastroplasty) or received conventional obesity treatment, with data analysis performed to examine outcomes.","Indexes":[3,4,7,8],"Sentences":["DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized controlled trial, the Swedish Obese Subjects (SOS) study, is ongoing at 25 surgical departments and 480 primary health care centers in Sweden and was designed to examine outcomes after bariatric surgery.","The study included 2007 patients with obesity who underwent bariatric surgery and 2040 contemporaneously matched controls who received conventional obesity treatment.","INTERVENTIONS: Patients in the surgery group underwent gastric bypass (n\u2009=\u2009266), banding (n\u2009=\u2009376), or vertical banded gastroplasty (n\u2009=\u20091365).","The control group (n\u2009=\u20092040) received the customary treatment for obesity at their primary health care centers."],"Revise":false}
{"PMID":"32761987","Document":["BACKGROUND: Compared with other cancers, melanoma has the longest delays measured as the median time to patient presentation for care from symptom onset.","Time to presentation for care is a key determinant of outcomes, including disease stage, prognosis, and treatment.","METHODS: Melanoma survivors with localized disease and their skin check partners enrolled in two sequential randomized control trials of skin self-examination (SSE) training.","In Phase 1, the pair read a workbook in the office and had quarterly total body skin examinations with a study dermatologist.","In Phase 2, materials were mailed to pairs, whose surveillance was with a community physician.","SSE knowledge, performance (frequency and extent), and identification of concerning moles were compared between phases.","RESULTS: Among 341 patients, 197 received the workbook and the others were controls.","Knowledge in performing SSE was higher for the workbook relative to controls in both phases.","The SSE frequency ranged from 2.38 to 5.97 times in 9\u00a0months.","Patients randomized to the workbook in both phases performed significantly more SSE than controls at 9\u00a0months (P\u00a0<\u00a0.05).","In both phases, trained survivors performed significantly more SSEs on the scalp than controls at 9 and 18\u00a0months (P\u00a0<\u00a0.05).","Phase 1 survivors performed significantly more SSEs on the abdomen, buttocks, and soles of the feet than controls, but this did not occur in Phase 2.","Finally, in both phases, survivors trained with the workbook resulted in greater detection of suspicious lesions and melanomas.","CONCLUSIONS: These findings justify the benefits of remote SSE training for patients as an adjunct to provider-administered screening."],"Aspect":"m","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"33407577","Document":["BACKGROUND: Studies carried out in vitro and in a mouse model have shown that BRAF inhibitors enhance the effects of IFN-\u03b1 on BRAFV600E melanoma cells through the inhibition of ERK.","Therefore, the combination of vemurafenib and IFN-\u03b1 in patients with BRAFV600E melanoma may provide therapeutic benefits; MEK inhibition may prevent the reactivation of the MAPK pathway induced by BRAF inhibitor resistance.","PATIENTS AND METHODS: In a phase I study, adult patients with advanced BRAFV600-mutated melanoma were treated with vemurafenib\u2009+\u2009PEG-IFN-\u03b1-2b or vemurafenib\u2009+\u2009cobimetinib\u2009+\u2009PEG-IFN-\u03b1-2b, to assess the safety of the combination and the upregulation of IFN-\u03b1\/\u03b2 receptor-1 (IFNAR1).","RESULTS: Eight patients were treated; 59 adverse events with four serious ones (three related to study treatments) were reported.","Patients with a pre-treatment IFNAR1 expression on\u2009\u2264\u200935% melanoma cells had a median progression-free survival of 12.0\u00a0months (range: 5.6-18.4\u00a0months) and a median overall survival of 31.0\u00a0months (range: 19.8-42.2\u00a0months), while patients with a pre-treatment IFNAR1 expression on\u2009>\u200935% of melanoma cells had a median progression-free survival of 4.0\u00a0months (range: 0-8.8; p\u2009=\u20090.03), and a median overall survival of 5\u00a0months (p\u2009=\u20090.02).","Following treatment, responders had higher levels of growth-suppressor genes, including GAS1 and DUSP1, and genes involved in a metabolically robust immune response, including FAP.","CONCLUSION: Our study supports the overall safety of the vemurafenib\u2009+\u2009PEG-IFN-\u03b1-2b\u2009+\u2009cobimetinib combination.","IFNAR1 expression levels correlated with response to treatment, including survival.","Vemurafenib\u2009+\u2009PEG-IFN-\u03b1-2b\u2009+\u2009cobimetinib would have difficulty finding a niche in the current treatment scenario for advanced melanoma, but we speculate that our findings may contribute to identify subjects particularly responsive to treatment.","TRIAL REGISTRATION: The study was registered at clinicaltrials.gov (NCT01959633).","Registered 10 October 2013, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01959633."],"Aspect":"a","Summary":"The study aims to assess the safety of the combination of vemurafenib and PEG-IFN-\u03b1-2b or vemurafenib + cobimetinib + PEG-IFN-\u03b1-2b and the upregulation of IFN-\u03b1\/\u03b2 receptor-1 (IFNAR1) in patients with advanced BRAFV600-mutated melanoma.","Indexes":[2],"Sentences":["PATIENTS AND METHODS: In a phase I study, adult patients with advanced BRAFV600-mutated melanoma were treated with vemurafenib\u2009+\u2009PEG-IFN-\u03b1-2b or vemurafenib\u2009+\u2009cobimetinib\u2009+\u2009PEG-IFN-\u03b1-2b, to assess the safety of the combination and the upregulation of IFN-\u03b1\/\u03b2 receptor-1 (IFNAR1)."],"Revise":false}
{"PMID":"36625227","Document":["Skin cancer is the most common cancer in the United States, and early detection of melanoma may lead to diagnosis of thinner and more treatable cancers, resulting in improved survival rates.","This study examined the effects of message interactivity (high vs. low) and imagery (cartoon, real human character, or customized imagery preference) on accuracy of identifying abnormal skin lesions (ASL) and skin self-examination (SSE) intention.","This study employed a 3 (cartoon character vs. real person vs. customization) x 2 (high interactivity vs. low interactivity) between-subjects online experimental design.","Participants at risk for skin cancer were randomly assigned to one of the six conditions and completed a survey after reviewing the educational materials.","Univariate analyses were conducted to detect group differences on the accuracy of identifying ASL and intention to conduct SSE in the next 3\u00a0months.","Among 321 participants who completed the study, the mean age was 36.61\u00a0years, 56.7% were females, 76.1% had a college or higher degree, and over 60% self-identified as non-Hispanic White.","Individuals in the high interactivity and customization group (compared to the low interactivity and cartoon group) were more likely to accurately identify ASL.","Individuals in the high interactivity and customization or low interactivity and real person imagery groups (compared to the low interactivity and cartoon group) reported higher intention to conduct SSE in the next 3\u00a0months.","These results suggest that customization and interactivity may be beneficial for educational programs or intervention design to improve both melanoma identification and SSE intention."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"36100309","Document":["BACKGROUND: A vaccine containing 6 melanoma-associated peptides to stimulate helper T cells (6MHP) is safe, immunogenic, and clinically active.","A phase I\/II trial was designed to evaluate safety and immunogenicity of 6MHP vaccines plus programmed death 1 (PD-1) blockade.","PARTICIPANTS AND METHODS: Participants with advanced melanoma received 6MHP vaccines in an incomplete Freund's adjuvant (6 vaccines over 12 weeks).","Pembrolizumab was administered intravenously every 3 weeks.","Tumor biopsies at baseline and day 22 were analyzed by multiplex immunohistochemistry.","Primary end points were safety (Common Terminology Criteria for Adverse Events V.4.03) and immunogenicity (ex vivo interferon-\u03b3 ELISpot assay).","Additional end points included changes in the tumor microenvironment (TME) and clinical outcomes.","RESULTS: Twenty-two eligible participants were treated: 6 na\u00efve to PD-1 antibody (Ab) and 16 PD-1 Ab-experienced.","Median follow-up was 24.4 months.","Most common treatment-related adverse events (any grade) included injection site reactions, fatigue, anemia, lymphopenia, fever, elevated aspartate aminotransferase, pruritus, and rash.","Treatment-related dose-limiting toxicities were observed in 3 (14%) participants, which did not cross the study safety bound.","A high durable T cell response (Rsp) to 6MHP was detected in only one participant, but twofold T cell Rsps to 6MHP were detected in 7\/22 (32%; 90% CI (16% to 52%)) by week 13.","Objective clinical responses were observed in 23% (1 complete response, 4 partial responses), including 4\/6 PD-1 Ab-na\u00efve (67%) and 1\/16 PD-1 Ab-experienced (6%).","Overall survival (OS) was longer for PD-1 Ab-na\u00efve than Ab-experienced participants (HR 6.3 (90% CI (2.1 to 28.7)).","In landmark analyses at 13 weeks, OS was also longer for those with T cell Rsps (HR 6.5 (90% CI (2.1 to 29.2)) and for those with objective clinical responses.","TME evaluation revealed increased densities of CD8+ T cells, CD20+ B cells, and Tbet+ cells by day 22.","CONCLUSIONS: Treatment with the 6MHP vaccine plus pembrolizumab was safe, increased intratumoral lymphocytes, and induced T cell Rsps associated with prolonged OS.","The low T cell Rsp rate in PD-1 Ab-experienced participants corroborates prior murine studies that caution against delaying cancer vaccines until after PD-1 blockade.","The promising objective response rate and OS in PD-1 Ab-na\u00efve participants support consideration of a larger study in that setting."],"Aspect":"o","Summary":"The study found that treatment with the 6MHP vaccine plus pembrolizumab was safe, increased intratumoral lymphocytes, and induced T cell responses associated with prolonged overall survival.","Indexes":[11,13,16],"Sentences":["A high durable T cell response (Rsp) to 6MHP was detected in only one participant, but twofold T cell Rsps to 6MHP were detected in 7\/22 (32%; 90% CI (16% to 52%)) by week 13.","Overall survival (OS) was longer for PD-1 Ab-na\u00efve than Ab-experienced participants (HR 6.3 (90% CI (2.1 to 28.7)).","CONCLUSIONS: Treatment with the 6MHP vaccine plus pembrolizumab was safe, increased intratumoral lymphocytes, and induced T cell Rsps associated with prolonged OS."],"Revise":false}
{"PMID":"32062691","Document":["PURPOSE: This study aimed to determine the safety, tolerability, and recommended phase II doses of trametinib plus uprosertib (GSK2141795) in patients with solid tumors likely to be sensitive to MEK and\/or AKT inhibition.","METHODS: This was a phase I, open-label, dose-escalation, and dose-expansion study in patients with triple-negative breast cancer or BRAF-wild type advanced melanoma.","The primary outcome of the expansion study was investigator-assessed response.","Among 126 enrolled patients, 63 received continuous oral daily dosing of trametinib and uprosertib, 29 received various alternative dosing schedules, and 34 were enrolled into expansion cohorts.","Doses tested in the expansion cohort were trametinib 1.5\u00a0mg once daily (QD)\u2009+\u2009uprosertib 50\u00a0mg QD.","RESULTS: Adverse events (AEs) were consistent with those reported in monotherapy studies but occurred at lower doses and with greater severity.","Diarrhea was the most common dose-limiting toxicity; diarrhea and rash were particularly difficult to tolerate.","Overall, 59% and 6% of patients reported AEs with a maximum severity of grade 3 and 4, respectively.","Poor tolerability prevented adequate delivery of uprosertib with trametinib at a concentration predicted to have clinical activity.","The study was terminated early based on futility in the continuous-dosing expansion cohorts and a lack of pharmacological or therapeutic advantage with intermittent dosing.","The objective response rate was\u2009<\u20095% (1 complete response, 5 partial responses).","CONCLUSIONS: Continuous and intermittent dosing of trametinib in combination with uprosertib was not tolerated, and minimal clinical activity was observed in all schedules tested."],"Aspect":"s","Summary":"Diarrhea and rash were particularly difficult to tolerate, with 59% and 6% of patients reporting adverse events with a maximum severity of grade 3 and 4, respectively.","Indexes":[5,6,7],"Sentences":["RESULTS: Adverse events (AEs) were consistent with those reported in monotherapy studies but occurred at lower doses and with greater severity.","Diarrhea was the most common dose-limiting toxicity; diarrhea and rash were particularly difficult to tolerate.","Overall, 59% and 6% of patients reported AEs with a maximum severity of grade 3 and 4, respectively."],"Revise":false}
{"PMID":"34021033","Document":["BACKGROUND: The adoptive transfer of tumor-infiltrating lymphocytes (TIL) has demonstrated robust efficacy in metastatic melanoma patients.","Tumor antigen-loaded dendritic cells (DCs) are believed to optimally activate antigen-specific T lymphocytes.","We hypothesized that the combined transfer of TIL, containing a melanoma antigen recognized by T cells 1 (MART-1) specific population, with MART-1-pulsed DC will result in enhanced proliferation and prolonged survival of transferred MART-1 specific T cells in vivo ultimately leading to improved clinical responses.","DESIGN: We tested the combination of TIL and DC in a phase II clinical trial of patients with advanced stage IV melanoma.","HLA-A0201 patients whose early TIL cultures demonstrated reactivity to MART-1 peptide were randomly assigned to receive TIL alone or TIL +DC pulsed with MART-1 peptide.","The primary endpoint was to evaluate the persistence of MART-1 TIL in the two arms.","Secondary endpoints were to evaluate clinical response and survival.","RESULTS: Ten patients were given TIL alone while eight patients received TIL+DC vaccine.","Infused MART-1 reactive CD8+ TIL were tracked in the blood over time by flow cytometry and results show good persistence in both arms, with no difference in the persistence of MART-1 between the two arms.","The objective response rate was 30% (3\/10) in the TIL arm and 50% (4\/8) in the TIL+DC arm.","All treatments were well tolerated.","CONCLUSIONS: The combination of TIL +DC showed no difference in the persistence of MART-1 TIL compared with TIL therapy alone.","Although more patients showed a clinical response to TIL+DC therapy, this study was not powered to resolve differences between groups.","TRIAL REGISTRATION NUMBER: NCT00338377."],"Aspect":"p","Summary":"The study involved 18 patients with advanced stage IV melanoma, with 10 receiving TIL alone and 8 receiving TIL + DC vaccine.","Indexes":[7],"Sentences":["RESULTS: Ten patients were given TIL alone while eight patients received TIL+DC vaccine."],"Revise":false}
{"PMID":"32448802","Document":["BACKGROUND: With immunotherapy gaining increasing approval for treatment of different tumor types, scientists rely on cutting edge methods for the monitoring of immune responses and biomarker development in patients.","Due to the lack of tools to efficiently detect rare circulating human tumor-specific CD4 T cells, their characterization in patients still remains very limited.","METHODS: We have used combinatorial staining strategies with peptide major histocompatibility complex class II (pMHCII) multimer constructs of different alleles to establish an optimized staining procedure for in vitro and direct ex-vivo visualization of tumor-specific CD4 T cells, in patient samples.","Furthermore, we have generated reversible multimers to achieve optimal cell staining and yet disassemble prior to in vitro cell expansion, thus preventing activation induced cell death.","RESULTS: We observed a vastly improved detection of tumor-specific, viral-specific and bacterial-specific cells with our optimization methods compared with the non-optimized staining procedure.","By increasing the variety of fluorochromes used to label the pMHCII multimers, we were also able to increase the parallel detection of different specificities within one sample, including antigen-specific CD8 T cells.","A decrease in cell viability was observed when using the full optimization method, but this was mitigated by the removal of neuraminidase and the use of reversible multimers.","CONCLUSION: This new optimized staining procedure represents an advance toward better detection and analysis of antigen-specific CD4 T cells.","It should facilitate state-of-the art precision monitoring of tumor-specific CD4 T cells and contribute to accelerate the use and the targeting of these cells in cancer immunotherapy."],"Aspect":"m","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"35635631","Document":["BACKGROUND: Targeting the MDM2-p53 interaction using AMG\u00a0232 is synergistic with MAPK inhibitors (MAPKi) in preclinical melanoma models.","We postulated that AMG\u00a0232 plus MAPKi is safe and more effective than MAPKi alone in TP53-wild type, MAPKi-na\u00efve metastatic melanoma.","METHODS: Patients were treated with increasing (120\u00a0mg, 180\u00a0mg, 240\u00a0mg) oral doses of AMG\u00a0232 (seven-days-on, 15-days-off, 21-day cycle) plus dabrafenib (D) and trametinib (T) (Arm 1, BRAFV600-mutant) or T alone (Arm 2, BRAFV600-wild type).","Patients were treated for seven days with AMG\u00a0232 alone before adding T\u00b1D.","Safety and efficacy were assessed using CTCAE\u00a0v4.0 and RECIST\u00a0v1.1 criteria, respectively.","Pharmacokinetic (PK) analysis was performed at baseline and steady-state levels\u00a0for AMG 232.","RESULTS: 31 patients were enrolled.","Ten and 21 patients were enrolled in Arm 1 and Arm 2, respectively.","The most common AMG\u00a0232-related adverse events (AEs) were nausea (87%), diarrhea (77%), and fatigue (74%).","Seven patients (23%) were withdrawn from the study due to AMG\u00a0232-related AEs.","Three dose-limiting AEs occurred (Arm 1, 180\u00a0mg, nausea; Arm 2, 240\u00a0mg, grade 3 pulmonary embolism; Arm 2, 180\u00a0mg, grade 4 thrombocytopenia).","AMG\u00a0232 PK exposures were not altered when AMG\u00a0232 was combined with T\u00b1D.","Objective responses were seen in 8\/10 (Arm 1) and 3\/20 (Arm 2) evaluable patients.","The median progression-free survival for Arm 1 and Arm 2 was 19.0 months-not reached and 2.8 months, respectively.","CONCLUSION: The maximum tolerated dose of AMG\u00a0232 for both arms was 120\u00a0mg. AMG\u00a0232 plus T\u00b1D exhibited a favorable PK profile.","Although objective responses occurred in both arms, adding AMG\u00a0232 to T\u00b1D did not confer additional clinical benefit."],"Aspect":"s","Summary":"The most common AMG 232-related adverse events were nausea (87%), diarrhea (77%), and fatigue (74%), with some patients experiencing severe side effects like pulmonary embolism and thrombocytopenia. Seven patients (23%) were withdrawn from the study due to AMG 232-related AEs. ","Indexes":[8,9,10],"Sentences":["The most common AMG\u00a0232-related adverse events (AEs) were nausea (87%), diarrhea (77%), and fatigue (74%).","Seven patients (23%) were withdrawn from the study due to AMG\u00a0232-related AEs.","Three dose-limiting AEs occurred (Arm 1, 180\u00a0mg, nausea; Arm 2, 240\u00a0mg, grade 3 pulmonary embolism; Arm 2, 180\u00a0mg, grade 4 thrombocytopenia)."],"Revise":true}
{"PMID":"32728218","Document":["Treating patients\u00a0who have\u00a0cancer with vaccines that stimulate a targeted immune response is conceptually appealing, but cancer vaccine trials have not been successful in late-stage patients with treatment-refractory tumours1,2.","We are testing melanoma FixVac (BNT111)-an intravenously administered liposomal RNA (RNA-LPX) vaccine, which targets four non-mutated, tumour-associated antigens that are prevalent in melanoma-in an ongoing, first-in-human, dose-escalation phase I trial in patients with advanced melanoma (Lipo-MERIT trial, ClinicalTrials.gov identifier NCT02410733).","We report here data from an exploratory interim analysis that show that melanoma FixVac, alone or in combination with blockade of the checkpoint inhibitor PD1, mediates durable objective responses in checkpoint-inhibitor (CPI)-experienced patients with unresectable melanoma.","Clinical responses are accompanied by the induction of strong CD4+ and CD8+ T cell immunity against the vaccine antigens.","The antigen-specific cytotoxic T-cell responses in some responders reach magnitudes typically reported for adoptive T-cell therapy, and are durable.","Our findings indicate that RNA-LPX vaccination is a potent immunotherapy in patients with CPI-experienced melanoma, and suggest the general utility of non-mutant shared tumour antigens as targets for cancer vaccination."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"37921680","Document":["BACKGROUND: Immune checkpoint inhibitors control effector mechanisms and work to restore downregulated T-cells in patients with melanoma.","Examples of such include programmed death-1 inhibitors and lymphocyte-activating gene 3 inhibitors.","The combination of nivolumab, a programmed death-1 inhibitor, and relatlimab-rmbw, a lymphocyte-activating gene 3 inhibitor, has shown antitumor activity and improved progression-free survival in patients with unresectable or metastatic melanoma.","MECHANISM OF ACTION PHARMACOKINETICS\/PHARMACODYNAMICS: The fixed-dose combination of nivolumab and relatlimab immunotherapy is approved for adults and pediatrics 12 years of age or older with metastatic or unresectable melanoma.","Volume of distribution is 6.6 L for relatlimab and nivolumab, and half-life is 27 and 26 days, respectively.","Clearance at steady state is 7.6 mL\/h for nivolumab and 5.5 mL\/h for relatlimab.","Sex, age, race, and mild hepatic\/renal impairment had no clinical effect on clearance.","The exposure-response relationship and pharmacodynamic response for the safety and effectiveness of nivolumab\/relatlimab-rmbw have not been fully characterized.","Safety concerns include severe and fatal immune-mediated adverse reactions, infusion-related reactions, and complications of allogeneic hematopoietic stem cell transplantation, and fetal toxicity.","Dosing is determined by patient's age and weight.","Solution is infused over a 30-minute timeframe.","CLINICAL TRIALS: In the RELATIVITY-047 trial, patients received nivolumab or nivolumab\/relatlimab-rmbw.","Results showed superiority of dual therapy over monotherapy with a progression-free survival of 10.1 months (95% CI, 6.4-15.7) compared with 4.6 months (95% CI, 3.4-5.6) and hazard ratio of 0.75 (95% CI, 0.62-0.92); P = 0.006, respectively.","No safety concerns were observed compared with monotherapy with treatment-related adverse events occurring in 18.9% of patients on combination therapy compared with 9.7% on nivolumab alone.","THERAPEUTIC ADVANCE: The novel mechanism and improvement in progression-free survival compared with standard of care highlight the therapeutic advancement of nivolumab\/relatlimab-rmbw in the treatment of unresectable and metastatic melanoma."],"Aspect":"a","Summary":"The study aims to evaluate the efficacy and safety of the combination therapy of nivolumab and relatlimab-rmbw compared to nivolumab monotherapy in patients with unresectable or metastatic melanoma.","Indexes":[2,11,12,13],"Sentences":["The combination of nivolumab, a programmed death-1 inhibitor, and relatlimab-rmbw, a lymphocyte-activating gene 3 inhibitor, has shown antitumor activity and improved progression-free survival in patients with unresectable or metastatic melanoma.","CLINICAL TRIALS: In the RELATIVITY-047 trial, patients received nivolumab or nivolumab\/relatlimab-rmbw.","Results showed superiority of dual therapy over monotherapy with a progression-free survival of 10.1 months (95% CI, 6.4-15.7) compared with 4.6 months (95% CI, 3.4-5.6) and hazard ratio of 0.75 (95% CI, 0.62-0.92); P = 0.006, respectively.","No safety concerns were observed compared with monotherapy with treatment-related adverse events occurring in 18.9% of patients on combination therapy compared with 9.7% on nivolumab alone."],"Revise":false}
{"PMID":"38767650","Document":["PURPOSE: The Adaptively Dosed ImmunoTherapy Trial (ADAPT-IT;NCT03122522) investigated adaptive ipilimumab discontinuation in melanoma based on early radiographic assessment.","Initial findings indicated similar effectiveness compared with conventional nivolumab-ipilimumab (nivo-ipi).","Exploratory biomarker analyses and final clinical results are now reported.","PATIENTS AND METHODS: Patients with unresectable melanoma received two doses of nivo-ipi.","Radiographic assessment at Week 6 informed continuation of ipilimumab before nivolumab maintenance.","The primary endpoint was overall response rate at Week 12.","Plasma was assayed for circulating tumor DNA and 10 cytokines using a multiplex immunoassay.","Flow cytometry of peripheral blood mononuclear cells was performed with an 11-color panel.","RESULTS: Among the treated patients, expansion of proliferating T-cell populations was observed in responders and nonresponders.","Baseline IL6 levels were low in patients achieving an objective radiographic response (median 1.30 vs. 2.86 pg\/mL; P = 0.025).","High baseline IL6 levels were associated with short progression-free survival [PFS; HR = 1.24, 95% confidence interval (CI), 1.01-1.52; P = 0.041].","At Week 6, patients with response had lower average tumor variant allele fractions than nonresponders (median 0.000 vs. 0.019; P = 0.014).","Greater increases in average variant allele fractions from baseline to Week 6 correlated with short PFS (HR = 1.11, 95% CI, 1.01-1.21; P = 0.023).","Week 12 overall response rate was 47% (95% CI, 35%-59%) with a median follow-up of 34 months among survivors.","Median PFS was 21 months (95% CI, 10-not reached); 76% of responses (95% CI, 64%-91%) persisted at 36 months.","CONCLUSIONS: Adaptively dosed nivo-ipi responses are durable and resemble historical data for conventional nivo-ipi.","Baseline IL6 and circulating tumor DNA changes during treatment warrant further study as biomarkers of nivo-ipi response."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"33625104","Document":["Nearly 10% of patients with high-risk early-stage melanoma will develop satellite or in-transit metastases (ITM), classified as stage III disease similar to lymph node metastases.","The pivotal registration trials of the CTLA-4 antibody ipilimumab, and the PD-1 antibodies nivolumab and pembrolizumab, also included patients with unresectable stage III disease.","However, there has been no analysis of patients with ITM, and anecdotal retrospective small series have indicated a potential lesser effect.","This study aimed to identify patients with unresectable ITM within the randomized trials, and to determine response, progression-free survival and overall survival.","The pivotal phase III randomized intervention trials that included melanoma patients with ITM, with or without nodal metastasis, and were treated with ipilimumab, nivolumab or pembrolizumab was identified.","The datasets from each trial were then searched to identify the specific details of the investigated patient population for a pooled analysis.","The primary endpoint was complete response rate.","Seven trials that included stage III patients, and with accessible datasets, were identified.","There was a total of 4711 patients, however, no patients with ITM could be identified, as this data was not captured by the case report forms.","Evidence from prospective clinical trials on the use of immunotherapy in patients with ITM is lacking.","We recommend pooling data from multiple institutions to examine efficacy of available drug therapies in this patient population, but more importantly, prospective clinical trials of locoregional treatments with or without systemic drug therapies are required."],"Aspect":"i","Summary":"The study identified pivotal phase III randomized intervention trials including melanoma patients with unresectable in-transit metastases (ITM) treated with ipilimumab, nivolumab, or pembrolizumab, and searched accessible datasets for detailed patient information to conduct a pooled analysis, with the primary endpoint being the complete response rate.","Indexes":[3,4,5,6],"Sentences":["This study aimed to identify patients with unresectable ITM within the randomized trials, and to determine response, progression-free survival and overall survival.","The pivotal phase III randomized intervention trials that included melanoma patients with ITM, with or without nodal metastasis, and were treated with ipilimumab, nivolumab or pembrolizumab was identified.","The datasets from each trial were then searched to identify the specific details of the investigated patient population for a pooled analysis.","The primary endpoint was complete response rate."],"Revise":true}
{"PMID":"34243078","Document":["BACKGROUND: BRAF and MEK inhibitors combination, including dabrafenib (D) and trametinib (T) have transformed the treatment of BRAF V600-mutant advanced melanoma patients, including patients with brain metastasis (BM).","In a large phase IIIb, single-arm, open-label, multicenter\u00a0French study, we assessed safety, response to treatment, progression-free survival (PFS) and factors associated with progression, and stratified the population into risk groups.","METHODS: Patients with unresectable, advanced, BRAF V600-mutant melanoma were included, including those with the presence of BM, Eastern Cooperative Oncology Group Performance Status (ECOG PS) \u22642, elevated lactate dehydrogenase (LDH) or previous melanoma treatments.","Responses were determined locally, without central review.","PFS was estimated using the Kaplan-Meier analysis and modelled with multivariate Cox model.","Risk subgroups were identified using a regression tree analysis.","RESULTS: Between March 2015 and November 2016, 856 patients received at least one D\u00a0+\u00a0T dose.","Overall, 92% had stage IV melanoma, 38% ECOG PS \u22651, 32% BM\u00a0and 37.5% elevated LDH.","Median PFS was 8.02 months (95% confidence interval [CI] 7.33-8.77).","Significant factors associated with lower PFS were ECOG PS \u22651, elevated LDH, \u22653 metastatic sites\u00a0and presence of BM.","Patients with <3 metastatic sites, ECOG\u00a0=\u00a00 and no BM had the highest probability of PFS at 6 months (83%, 95% CI\u00a076-87) and 12 months (56%, 95% CI\u00a047-64), respectively.","CONCLUSIONS: This is the largest prospective study in advanced BRAF V600-mutant melanoma patients treated with D\u00a0+\u00a0T, conducted in conditions close to 'real-world practice'.","We confirm previous findings that LDH, ECOG PS and \u22653 metastatic sites are associated with shorter PFS, but the real-world setting introduces BM as a major prognostic factor."],"Aspect":"s","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"36923305","Document":["PURPOSE: Mavorixafor is an oral, selective inhibitor of the CXCR4 chemokine receptor that modulates immune cell trafficking.","A biomarker-driven phase Ib study (NCT02823405) was conducted in 16 patients with melanoma to investigate the hypothesis that mavorixafor favorably modulates immune cell profiles in the tumor microenvironment (TME) and to evaluate the safety of mavorixafor alone and in combination with pembrolizumab.","EXPERIMENTAL DESIGN: Serial biopsies of melanoma lesions were assessed after 3 weeks of mavorixafor monotherapy and after 6 weeks of combination treatment for immune cell markers by NanoString analysis for gene expression and by multiplexed immunofluorescent staining for in situ protein expression.","Serum samples taken at biopsy timepoints were evaluated for key chemokine and cytokine alterations using the Myriad Rules Based Medicine multiplex immunoassays.","RESULTS: Within the TME, mavorixafor alone increased CD8+ T-cell infiltration, granzyme B signal, antigen presentation machinery, and both tumor inflammatory signature (TIS) and IFN\u03b3\u00a0gene expression signature scores.","Increases in the key serum cytokines CXCL9 and CXCL10 were further enhanced when mavorixafor was combined with pembrolizumab.","Adverse events (AE), as assessed by the investigator according to NCI Common Terminology Criteria for Adverse Events (v4.03), related to either mavorixafor or pembrolizumab (\u226515%) were diarrhea, fatigue, maculopapular rash, and dry eye.","Reported AEs were all \u2264 grade 3.","CONCLUSION\/DISCUSSION: Treatment with single-agent mavorixafor resulted in enhanced immune cell infiltration and activation in the TME, leading to increases in TIS and IFN\u03b3 gene signatures.","Mavorixafor as a single agent, and in combination with pembrolizumab, has an acceptable safety profile.","These data support further investigation of the use of mavorixafor for patients unresponsive to checkpoint inhibitors.","SIGNIFICANCE: Despite survival improvements in patients with melanoma treated with checkpoint inhibitor therapy, a significant unmet medical need exists for therapies that enhance effectiveness.","We propose that mavorixafor sensitizes the melanoma tumor microenvironment and enhances the activity of checkpoint inhibitors, and thereby may translate to a promising treatment for broader patient populations."],"Aspect":"o","Summary":"Mavorixafor alone increased immune cell infiltration and activation in the tumor microenvironment, leading to increases in TIS and IFN\u03b3 gene signatures.","Indexes":[4,8],"Sentences":["RESULTS: Within the TME, mavorixafor alone increased CD8+ T-cell infiltration, granzyme B signal, antigen presentation machinery, and both tumor inflammatory signature (TIS) and IFN\u03b3\u00a0gene expression signature scores.","CONCLUSION\/DISCUSSION: Treatment with single-agent mavorixafor resulted in enhanced immune cell infiltration and activation in the TME, leading to increases in TIS and IFN\u03b3 gene signatures."],"Revise":false}
{"PMID":"31581055","Document":["BACKGROUND: Limited data are available on nivolumab in challenging subgroups with advanced melanoma.","We report outcomes of nivolumab after prior ipilimumab in patients who are typically excluded from clinical trials.","PATIENTS AND METHODS: In this phase II, single-arm, open-label, multicentre study (CheckMate 172), patients with advanced melanoma who progressed on or after ipilimumab received nivolumab 3\u00a0mg\/kg, every 2 weeks for up to 2 years.","The primary objective was incidence of grade \u22653, treatment-related select adverse events (AEs).","RESULTS: At a minimum follow-up of 18 months, grade \u22653 treatment-related select AEs with the most variation across subgroups were diarrhoea and colitis (1.1% [n\u00a0=\u00a011] and 0.3% [n\u00a0=\u00a03] for the total population [n\u00a0=\u00a01008]; 0.6% [n\u00a0=\u00a01] and 0.6% [n\u00a0=\u00a01] for patients with an asymptomatic central nervous system [CNS] metastasis [n\u00a0=\u00a0165; 16.4%]; 4.5% [n\u00a0=\u00a03] and 3.0% [n\u00a0=\u00a02] for patients with an Eastern Cooperative Oncology Group performance status [ECOG PS] of 2 [n\u00a0=\u00a066; 6.5%]; 2.4% [n\u00a0=\u00a02] and 0% for those who experienced a grade 3\/4 immune-related AE [irAE] with prior ipilimumab [n\u00a0=\u00a084; 8.3%]; and 0% and 0% for autoimmune disease [n\u00a0=\u00a025; 2.5%], respectively).","Median overall survival was 21.4 months in the total population and was 11.6, 2.4, 21.5, and 18.6 months in patients with a CNS metastasis, ECOG PS 2, a grade 3\/4 irAE with prior ipilimumab, and autoimmune disease, respectively.","CONCLUSIONS: In this large, phase II clinical trial of patients with advanced melanoma who progressed on or after ipilimumab, nivolumab demonstrated a safety profile consistent with that of prior clinical trials.","ClinicalTrials.gov ID: NCT02156804."],"Aspect":"d","Summary":"The treatment duration was up to 2 years, with nivolumab administered every 2 weeks.","Indexes":[2],"Sentences":["PATIENTS AND METHODS: In this phase II, single-arm, open-label, multicentre study (CheckMate 172), patients with advanced melanoma who progressed on or after ipilimumab received nivolumab 3\u00a0mg\/kg, every 2 weeks for up to 2 years."],"Revise":true}
{"PMID":"34817543","Document":["IMPORTANCE: Patient-led surveillance is a promising new model of follow-up care following excision of localized melanoma.","OBJECTIVE: To determine whether patient-led surveillance in patients with prior localized primary cutaneous melanoma is as safe, feasible, and acceptable as clinician-led surveillance.","DESIGN, SETTING, AND PARTICIPANTS: This was a pilot for a randomized clinical trial at 2 specialist-led clinics in metropolitan Sydney, Australia, and a primary care skin cancer clinic managed by general practitioners in metropolitan Newcastle, Australia.","The participants were 100 patients who had been treated for localized melanoma, owned a smartphone, had a partner to assist with skin self-examination (SSE), and had been routinely attending scheduled follow-up visits.","The study was conducted from November 1, 2018, to January 17, 2020, with analysis performed from September 1, 2020, to November 15, 2020.","INTERVENTION: Participants were randomized (1:1) to 6 months of patient-led surveillance (the intervention comprised usual care plus reminders to perform SSE, patient-performed dermoscopy, teledermatologist assessment, and fast-tracked unscheduled clinic visits) or clinician-led surveillance (the control was usual care).","MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of eligible and contacted patients who were randomized.","Secondary outcomes included patient-reported outcomes (eg, SSE knowledge, attitudes, and practices, psychological outcomes, other health care use) and clinical outcomes (eg, clinic visits, skin surgeries, subsequent new primary or recurrent melanoma).","RESULTS: Of 326 patients who were eligible and contacted, 100 (31%) patients (mean [SD] age, 58.7 [12.0] years; 53 [53%] men) were randomized to patient-led (n\u2009=\u200949) or clinician-led (n\u2009=\u200951) surveillance.","Data were available on patient-reported outcomes for 66 participants and on clinical outcomes for 100 participants.","Compared with clinician-led surveillance, patient-led surveillance was associated with increased SSE frequency (odds ratio [OR], 3.5; 95% CI, 0.9 to 14.0) and thoroughness (OR, 2.2; 95% CI, 0.8 to 5.7), had no detectable adverse effect on psychological outcomes (fear of cancer recurrence subscale score; mean difference, -1.3; 95% CI, -3.1 to 0.5), and increased clinic visits (risk ratio [RR], 1.5; 95% CI, 1.1 to 2.1), skin lesion excisions (RR, 1.1; 95% CI, 0.6 to 2.0), and subsequent melanoma diagnoses and subsequent melanoma diagnoses (risk difference, 10%; 95% CI, -2% to 23%).","New primary melanomas and 1 local recurrence were diagnosed in 8 (16%) of the participants in the intervention group, including 5 (10%) ahead of routinely scheduled visits; and in 3 (6%) of the participants in the control group, with none (0%) ahead of routinely scheduled visits (risk difference, 10%; 95% CI, 2% to 19%).","CONCLUSIONS AND RELEVANCE: This pilot of a randomized clinical trial found that patient-led surveillance after treatment of localized melanoma appears to be safe, feasible, and acceptable.","Experiences from this pilot study have prompted improvements to the trial processes for the larger trial of the same intervention.","TRIAL REGISTRATION: http:\/\/anzctr.org.au Identifier: ACTRN12616001716459."],"Aspect":"p","Summary":"The study involved 100 patients who had been treated for localized melanoma, with a mean age of 58.7 years, and 53% of them were men.","Indexes":[3,8],"Sentences":["The participants were 100 patients who had been treated for localized melanoma, owned a smartphone, had a partner to assist with skin self-examination (SSE), and had been routinely attending scheduled follow-up visits.","RESULTS: Of 326 patients who were eligible and contacted, 100 (31%) patients (mean [SD] age, 58.7 [12.0] years; 53 [53%] men) were randomized to patient-led (n\u2009=\u200949) or clinician-led (n\u2009=\u200951) surveillance."],"Revise":false}
{"PMID":"32591862","Document":["BACKGROUND: Autologous monocyte-derived mRNA co-electroporated dendritic cells with mRNA encoding CD40 ligand (CD40L), CD70 and a constitutively activated TLR4 (caTLR4) (referred to as TriMixDC-MEL) have anti-tumor activity in advanced melanoma patients.","We investigated the safety and activity of adjuvant TriMixDC-MEL in stage III\/IV melanoma patients.","MATERIALS AND METHODS: Forty-one patients were randomly assigned to treatment with TriMixDC-MEL (n\u2009=\u200921) and standard follow-up (n\u2009=\u200920).","\"Cross-over\" was allowed at the time of non-salvageable recurrence.","The primary endpoint was the percentage of patients alive and disease-free at 1-year.","For a subset of patients, (formalin-fixed paraffin-embedded), tumor tissue samples were available for mRNA expression profiling and PD-L1 immunohistochemical staining.","RESULTS: Baseline characteristics were well balanced.","One-year after randomization, 71% of patients in the study arm were alive and free of disease compared to 35% in the control arm.","After a median follow-up of 53\u00a0months (range 3-67), 23 patients experienced a non-salvageable melanoma recurrence (TriMixDC-Mel arm n\u2009=\u20099 and control arm n\u2009=\u200914).The median time to non-salvageable recurrence was superior in the TriMixDC-MEL arm (median 8\u00a0months (range 1-6) vs. not reached; log-rank p 0.044).","TriMixDC-MEL-related adverse events (AE) consisted of transient local skin reactions, flu-like symptoms and post-infusion chills.","No grade\u2009\u2265\u20093 AE's occurred.","The mRNA expression profiling revealed four genes (STAT2, TPSAB1, CD9 and CSF2) as potential predictive biomarkers.","CONCLUSION: TriMixDC-MEL id\/iv as adjuvant therapy is tolerable and may improve the 1-year disease-free survival rate.","Combination of optimized autologous monocyte-derived DC-formulations warrants further investigation in combination with currently approved adjuvant therapy options."],"Aspect":"a","Summary":"The study aims to investigate the safety and activity of adjuvant TriMixDC-MEL in stage III\/IV melanoma patients.","Indexes":[1],"Sentences":["We investigated the safety and activity of adjuvant TriMixDC-MEL in stage III\/IV melanoma patients."],"Revise":false}
{"PMID":"37401516","Document":["BACKGROUND: Here we report clinical risk factors and event rates for the development of new non-melanoma skin cancer (NMSC) in a randomized, double-blind, placebo-controlled trial of the irreversible ornithine decarboxylase (ODC) inhibitor, difluromethylornithine (DFMO), over a 3-5-year follow-up.","METHODS: 147 placebo patients (white; mean age 60.2 years; 60% male) were evaluated for event rates and association of initial skin biomarkers and baseline patient characteristics with the development of squamous cell (SCC) and basal cell (BCC) carcinomas.","RESULTS: Post-study evaluation (median follow-up 4.4 years) indicates the measures of prior NMSCs ( P \u2005\u2264\u20050.001), prior BCCs ( P \u2005\u2264\u20050.001), prior SCCs ( P \u2005=\u20050.011), prior tumor rate ( P \u2005=\u20050.002), hemoglobin ( P \u2005=\u20050.022), and gender ( P \u2005=\u20050.045) as significant predictors for new NMSC development.","Similarly, all measures of prior BCCs and NMSCs ( P \u2005<\u20050.001), prior tumor rate ( P \u2005=\u20050.014), and SCCs in the prior 2 years ( P \u2005=\u20050.047) were statistically significant predictors for new BCC development.","Total prior NMSCs and those in the prior 5 years ( P \u2005<\u20050.001), total prior SCCs and those in the prior 5 years ( P \u2005<\u20050.001), total prior BCCs and those in the prior 5 years ( P \u2005\u2264\u20050.001), prior tumor rate ( P \u2005=\u20050.011) as well as age ( P \u2005=\u20050.008), hemoglobin ( P \u2005=\u20050.002), and gender ( P \u2005=\u20050.003) were statistically significant predictors of new SCC development.","TPA-induced ODC activity at baseline showed no statistically significant association with the development of new NMSC ( P \u2005=\u20050.35), new BCCs ( P \u2005=\u20050.62), or new SCCs ( P \u2005=\u20050.25).","CONCLUSION: In the studied population, the history of and rate at which prior NMSCs occur are predictive and should be controlled for in future NMSC prevention trials."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"35395069","Document":["UNLABELLED: The effects of aspirin on melanoma are unclear, with studies reporting conflicting results.","Data from two periods of the ASPirin in Reducing Events in the Elderly (ASPREE) study; the randomized placebo-controlled trial period examining daily 100 mg aspirin in older adults with a median follow-up of 4.7 years, and the second period, an additional 2 years of observational follow-up, were utilized in this secondary analysis to examine whether aspirin exposure is associated with a reduced cutaneous melanoma incidence.","All melanoma cases were adjudicated and Cox proportional hazards models were used to compare incidence between randomized treatment groups.","ASPREE recruited 19,114 participants with a median age of 74 years.","During the trial period, 170 individuals (76 aspirin, 94 placebo) developed an invasive melanoma, and no significant effect of aspirin was observed on incident melanoma [HR = 0.81; 95% confidence interval (CI), 0.60-1.10].","Including the additional 2 years of observational follow-up (median follow-up of 6.3 years), 268 individuals (119 aspirin, 149 placebo) developed an invasive melanoma, and similar results were observed (HR = 0.81; 95% CI, 0.63-1.03).","A reduced number of events was observed with aspirin among females in a subgroup analysis (HR = 0.65; 95% CI, 0.44-0.92); however, the interaction effect with males (HR = 0.92; 95% CI, 0.68-1.25) was nonsignificant (P = 0.17).","Our findings from this randomized trial do not provide strong support that aspirin is associated with a reduced risk of invasive melanoma in older individuals.","Additional studies are required to further explore this relationship.","PREVENTION RELEVANCE: Melanoma prevention is an important strategy to improve outcomes and while preventive efforts have largely focused on sun protection, the role of potential chemopreventive agents such as aspirin warrants investigation."],"Aspect":"d","Summary":"The trial period lasted 4.7 years, with an additional 2 years of observational follow-up.","Indexes":[1,5],"Sentences":["Data from two periods of the ASPirin in Reducing Events in the Elderly (ASPREE) study; the randomized placebo-controlled trial period examining daily 100 mg aspirin in older adults with a median follow-up of 4.7 years, and the second period, an additional 2 years of observational follow-up, were utilized in this secondary analysis to examine whether aspirin exposure is associated with a reduced cutaneous melanoma incidence.","Including the additional 2 years of observational follow-up (median follow-up of 6.3 years), 268 individuals (119 aspirin, 149 placebo) developed an invasive melanoma, and similar results were observed (HR = 0.81; 95% CI, 0.63-1.03)."],"Revise":false}
{"PMID":"32559817","Document":["The aim was to provide evidence on systemically treated patients with advanced melanoma not represented in phase III trials to support clinical decision-making.","Analysis were performed on advanced melanoma patients diagnosed between 2014 and 2017 in the Netherlands, treated with immune- or targeted therapy, who met \u22651 trial exclusion criteria.","These criteria were derived from the KEYNOTE-006 and CHECKMATE-067\/-066 phase III trials.","Prognostic importance of factors associated with overall survival (OS) was assessed with the Kaplan-Meier method, Cox models, predicted OS probabilities of prognostic subgroups and a conditional inference survival tree (CIST).","A nationwide population-based registry was used as data source.","Of 2536 systemically treated patients with advanced melanoma, 1004 (40%) patients were ineligible for phase IIII trials.","Ineligible patients had a poorer median OS (mOS) compared to eligible patients (8.8 vs 23\u2009months).","Eligibility criteria strongly associated with OS in systemically treated ineligible patients were Eastern Cooperative Oncology Group Performance Score (ECOG PS) \u22652, brain metastases (BM) and lactate dehydrogenase (LDH) of >500\u2009U\/L.","Patients with ECOG PS of \u22652 with or without symptomatic BM had a predicted mOS of 6.5 and 11.3 months and a 3-year survival probability of 9.3% and 23.6%, respectively.","The CIST showed the strongest prognostic covariate for survival was LDH, followed by ECOG PS.","The prognosis of patients with LDH of >500\u2009U\/L is poor, but long-term survival is possible.","The prognosis of ineligible patients with advanced melanoma in real-world was very heterogeneous and highly dependent on LDH value, ECOG PS and symptomatic BM."],"Aspect":"m","Summary":"The article mentions the use of immune- or targeted therapy for treating advanced melanoma.","Indexes":[1],"Sentences":["Analysis were performed on advanced melanoma patients diagnosed between 2014 and 2017 in the Netherlands, treated with immune- or targeted therapy, who met \u22651 trial exclusion criteria."],"Revise":false}
{"PMID":"32259264","Document":["IMPORTANCE: Long noncoding RNAs (lncRNAs) are involved in innate and adaptive immunity in cancer by mediating the functional state of immunologic cells, pathways, and genes.","However, whether lncRNAs are associated with immune molecular classification and clinical outcomes of cancer immunotherapy is largely unknown.","OBJECTIVES: To explore lncRNA-based immune subtypes associated with survival and response to cancer immunotherapy and to present a novel lncRNA score for immunotherapy prediction using computational algorithms.","DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, an individual patient analysis based on a phase 2, single-arm clinical trial and multicohort was performed from June 25 through September 30, 2019.","Data are from the phase 2 IMvigor210 trial and from The Cancer Genome Atlas (TCGA).","The study analyzed lncRNA and genomic data of 348 patients with bladder cancer from the IMvigor210 trial and 71 patients with melanoma from TCGA who were treated with immunotherapy.","In addition, a pancancer multicohort that included 2951 patients was obtained from TCGA.","MAIN OUTCOMES AND MEASURES: The primary end point was overall survival (OS).","RESULTS: Among 348 patients from the IMvigor210 trial (272 [78.2%] male) and 71 patients with melanoma from TCGA (mean [SD] age, 58.3 [13.4] years; 37 [52.1%] female), 4 distinct classes with statistically significant differences in OS (median months, not reached vs 9.6 vs 8.1 vs 6.7 months; P\u2009=\u2009.002) were identified.","The greatest OS benefit was obtained in the immune-active class, as characterized by the immune-functional lncRNA signature and high CTL infiltration.","Patients with low vs high lncRNA scores had statistically significantly longer OS (hazard ratio, 0.32; 95% CI, 0.24-0.42; P\u2009<\u2009.001) in the IMvigor210 trial and across various cancer types.","The lncRNA score was associated with immunotherapeutic OS benefit in the IMvigor210 trial cohort (area under the curve [AUC], 0.79 at 12 months and 0.77 at 20 months) and in TCGA melanoma cohort (AUC, 0.87 at 24 months), superior tumor alteration burden, programmed cell death ligand 1 (PD-L1) expression, and cytotoxic T-lymphocyte (CTL) infiltration.","Addition of the lncRNA score to the combination of tumor alteration burden, PD-L1 expression, and CTL infiltration to build a novel multiomics algorithm correlated more strongly with OS in the IMvigor210 trial cohort (AUC, 0.81 at 12 months and 0.80 at 20 months).","CONCLUSIONS AND RELEVANCE: This study identifies novel lncRNA-based immune classes in cancer immunotherapy and recommends immunotherapy for patients in the immune-active class.","In addition, the study recommends that the lncRNA score should be integrated into multiomic panels for precision immunotherapy."],"Aspect":"i","Summary":"The study analyzed lncRNA and genomic data of patients with bladder cancer and melanoma who were treated with immunotherapy using computational algorithms to explore lncRNA-based immune subtypes and predict survival and response to immunotherapy.","Indexes":[2,5],"Sentences":["OBJECTIVES: To explore lncRNA-based immune subtypes associated with survival and response to cancer immunotherapy and to present a novel lncRNA score for immunotherapy prediction using computational algorithms.","The study analyzed lncRNA and genomic data of 348 patients with bladder cancer from the IMvigor210 trial and 71 patients with melanoma from TCGA who were treated with immunotherapy."],"Revise":true}
{"PMID":"33303685","Document":["The gut microbiome has been shown to influence the response of tumors to anti-PD-1 (programmed cell death-1) immunotherapy in preclinical mouse models and observational patient cohorts.","However, modulation of gut microbiota in cancer patients has not been investigated in clinical trials.","In this study, we performed a phase 1 clinical trial to assess the safety and feasibility of fecal microbiota transplantation (FMT) and reinduction of anti-PD-1 immunotherapy in 10 patients with anti-PD-1-refractory metastatic melanoma.","We observed clinical responses in three patients, including two partial responses and one complete response.","Notably, treatment with FMT was associated with favorable changes in immune cell infiltrates and gene expression profiles in both the gut lamina propria and the tumor microenvironment.","These early findings have implications for modulating the gut microbiota in cancer treatment."],"Aspect":"p","Summary":"The study involved 10 patients with anti-PD-1-refractory metastatic melanoma.","Indexes":[2],"Sentences":["In this study, we performed a phase 1 clinical trial to assess the safety and feasibility of fecal microbiota transplantation (FMT) and reinduction of anti-PD-1 immunotherapy in 10 patients with anti-PD-1-refractory metastatic melanoma."],"Revise":false}
{"PMID":"34782430","Document":["BACKGROUND: A first-in-human, randomized pilot phase II clinical trial combining vaccines targeting overexpressed, non-mutated tumor blood vessel antigens (TBVA) and tyrosine kinase inhibitor dasatinib was conducted in human leukocyte antigen (HLA)-A2+ patients with advanced melanoma.","METHODS: Patient monocyte-derived type-1-polarized dendritic cells were loaded with HLA-A2-presented peptides derived from TBVA (DLK1, EphA2, HBB, NRP1, RGS5, TEM1) and injected intradermally as a vaccine into the upper extremities every other week.","Patients were randomized into one of two treatment arms receiving oral dasatinib (70\u2009mg two times per day) beginning in week 5 (Arm A) or in week 1 (Arm B).","Trial endpoints included T cell response to vaccine peptides (interferon-\u03b3 enzyme-linked immunosorbent spot), objective clinical response (Response Evaluation Criteria in Solid Tumors V.1.1) and exploratory tumor, blood and serum profiling of immune-associated genes\/proteins.","RESULTS: Sixteen patients with advanced-stage cutaneous (n=10), mucosal (n=1) or uveal (n=5) melanoma were accrued, 15 of whom had previously progressed on programmed cell death protein 1 (PD-1) blockade.","Of 13 evaluable patients, 6 patients developed specific peripheral blood T cell responses against \u22653 vaccine-associated peptides, with further evidence of epitope spreading.","All six patients with specific CD8+ T cell response to vaccine-targeted antigens exhibited evidence of T cell receptor (TCR) convergence in association with preferred clinical outcomes (four partial response and two stabilization of disease (SD)).","Seven patients failed to respond to vaccination (one SD and six progressive disease).","Patients in Arm B (immediate dasatinib) outperformed those in Arm A (delayed dasatinib) for immune response rate (IRR; 66.7% vs 28.6%), objective response rate (ORR) (66.7% vs 0%), overall survival (median 15.45 vs 3.47 months; p=0.0086) and progression-free survival (median 7.87 vs 1.97 months; p=0.063).","IRR (80% vs 25%) and ORR (60% vs 12.5%) was greater for females versus male patients.","Tumors in patients exhibiting response to treatment displayed (1) evidence of innate and adaptive immune-mediated inflammation and TCR convergence at baseline, (2) on-treatment transcriptional changes associated with reduced hypoxia\/acidosis\/glycolysis, and (3) increased inflammatory immune cell infiltration and tertiary lymphoid structure neogenesis.","CONCLUSIONS: Combined vaccination against TBVA plus dasatinib was safe and resulted in coordinating immunologic and\/or objective clinical responses in 6\/13 (46%) evaluable patients with melanoma, particularly those initiating treatment with both agents.","TRIAL REGISTRATION NUMBER: NCT01876212."],"Aspect":"m","Summary":"The trial involved vaccine which is monocyte-derived type-1-polarized dendritic cells loaded with HLA-A2-presented peptides derived from TBVA (DLK1, EphA2, HBB, NRP1, RGS5, TEM1) every other week and the use of dasatinib at a dosage of 70 mg twice per day.","Indexes":[1,2],"Sentences":["METHODS: Patient monocyte-derived type-1-polarized dendritic cells were loaded with HLA-A2-presented peptides derived from TBVA (DLK1, EphA2, HBB, NRP1, RGS5, TEM1) and injected intradermally as a vaccine into the upper extremities every other week.","Patients were randomized into one of two treatment arms receiving oral dasatinib (70\u2009mg two times per day) beginning in week 5 (Arm A) or in week 1 (Arm B)."],"Revise":true}
{"PMID":"37651676","Document":["PURPOSE: Despite marked advances in the treatment of unresectable or metastatic melanoma, the need for novel therapies remains.","Bempegaldesleukin (BEMPEG), a pegylated interleukin-2 (IL-2) cytokine prodrug, demonstrated efficacy in the phase II PIVOT-02 trial.","PIVOT IO 001 (ClinicalTrials.gov identifier: NCT03635983) is a phase III, randomized, open-label study that builds on the PIVOT-02 results in first-line melanoma.","METHODS: Patients with previously untreated, unresectable, or metastatic melanoma were randomly assigned 1:1 to receive BEMPEG plus nivolumab (NIVO) or NIVO monotherapy.","Primary end points were objective response rate (ORR) and progression-free survival (PFS) by blinded independent central review and overall survival (OS).","Secondary and exploratory end points included additional efficacy measures, safety, and pharmacokinetics (PKs) and pharmacodynamics analyses.","RESULTS: In 783 patients (n = 391, BEMPEG plus NIVO; n = 392, NIVO monotherapy), the median follow-up was 11.6 months in the intent-to-treat population.","The ORR with BEMPEG plus NIVO was 27.7% versus 36.0% with NIVO (two-sided P = .0311).","The median PFS with BEMPEG plus NIVO was 4.17 months (95% CI, 3.52 to 5.55) versus 4.99 months (95% CI, 4.14 to 7.82) with NIVO (hazard ratio [HR], 1.09; 97% CI, 0.88 to 1.35; P = .3988).","The median OS was 29.67 months (95% CI, 22.14 to not reached [NR]) with BEMPEG plus NIVO versus 28.88 months (95% CI, 21.32 to NR) with NIVO (HR, 0.94; 99.929% CI, 0.59 to 1.48; P = .6361).","Grade 3-4 treatment-related adverse events (AEs) and serious AE rates were higher with the combination (21.7% and 10.1%, respectively) versus NIVO (11.5% and 5.5%, respectively).","BEMPEG PK exposure and absolute lymphocyte count changes after BEMPEG plus NIVO were comparable between PIVOT IO 001 and PIVOT-02.","CONCLUSION: The PIVOT IO 001 study did not meet its primary end points of ORR, PFS, and OS.","Increased toxicity was observed with BEMPEG plus NIVO versus NIVO."],"Aspect":"s","Summary":"Increased toxicity, including higher rates of grade 3-4 treatment-related adverse events (AEs) and serious AEs, was observed with BEMPEG plus NIVO versus NIVO.","Indexes":[10,13],"Sentences":["Grade 3-4 treatment-related adverse events (AEs) and serious AE rates were higher with the combination (21.7% and 10.1%, respectively) versus NIVO (11.5% and 5.5%, respectively).","Increased toxicity was observed with BEMPEG plus NIVO versus NIVO."],"Revise":false}
{"PMID":"32761328","Document":["BACKGROUND: Ocular melanoma is the most common primary intraocular malignancy and has a very poor prognosis once liver metastases occur.","The aim of this study was to prospectively assess the efficacy and safety of percutaneous hepatic perfusion with melphalan (M-PHP) using the new second-generation (GEN 2) hemofiltration system in patients with ocular melanoma metastases confined to the liver.","METHODS: Prospective, single-center, single-arm, phase II study including patients with unresectable ocular melanoma metastases confined to the liver.","Treatment consisted of two M-PHP procedures at 6-8 weeks interval.","Procedures were performed using the CHEMOSAT (GEN 2) system with 3 mg\/kg melphalan.","Primary endpoints were overall response rate (ORR) and best overall response (BOR).","Secondary endpoints included overall survival (OS), progression-free survival (PFS), hepatic PFS (hPFS), and safety.","RESULTS: Sixty-four M-PHP procedures were performed in 35 patients between February 2014 and June 2017.","The ORR was 72%.","BOR was as follows: complete response in 3%, partial response in 69%, stable disease in 13%, and progressive disease in 16%.","There was no treatment-related mortality.","Fourteen serious adverse events occurred.","At a median follow-up of 19.1 months (range 5.6-69.5), median OS was 19.1 months and was significantly longer in responders than in nonresponders (27.5 vs. 11.9 months, p < 0.001).","The 1- and 2-year OS was 77% and 43%, respectively.","PFS and hPFS were 7.6 and 11.2 months, respectively.","CONCLUSIONS: M-PHP using the GEN 2 filter can achieve a high ORR and prolonged survival in patients with liver-only ocular melanoma metastases."],"Aspect":"m","Summary":"The treatment involved melphalan administered at a dose of 3 mg\/kg using the CHEMOSAT (GEN 2) system.","Indexes":[4],"Sentences":["Procedures were performed using the CHEMOSAT (GEN 2) system with 3 mg\/kg melphalan."],"Revise":false}
{"PMID":"36668984","Document":["OBJECTIVE: The aim of this study was to develop a pretreatment magnetic resonance imaging (MRI)-based radiomics model for disease-free survival (DFS) prediction in patients with uveal melanoma (UM).","METHODS: We randomly assigned 85 patients with UM into 2 cohorts: training (n = 60) and validation (n = 25).","The radiomics model was built from significant features that were selected from the training cohort by applying a least absolute shrinkage and selection operator to pretreatment MRI scans.","Least absolute shrinkage and selection operator regression and the Cox proportional hazard model were used to construct a radiomics score (rad-score).","Patients were divided into a low- or a high-risk group based on the median of the rad-score.","The Kaplan-Meier analysis was used to evaluate the association between the rad-score and DFS.","A nomogram incorporating the rad-score and MRI features was plotted to individually estimate DFS.","The model's discrimination power was assessed using the concordance index.","RESULTS: The radiomics model with 15 optimal radiomics features based on MRI performed well in stratifying patients into the high- or a low-risk group of DFS in both the training and validation cohorts (log-rank test, P = 0.009 and P = 0.02, respectively).","Age, basal diameter, and height were selected as significant clinical and MRI features.","The nomogram showed good predictive performance with concordance indices of 0.741 (95% confidence interval, 0.637-0.845) and 0.912 (95% confidence interval, 0.847-0.977) in the training and validation cohorts, respectively.","Calibration curves demonstrated good agreement.","CONCLUSION: The developed clinical-radiomics model may be a powerful predictor of the DFS of patients with UM, thereby providing evidence for preoperative risk stratification."],"Aspect":"o","Summary":"The developed radiomics model based on MRI effectively stratified patients with uveal melanoma into high- or low-risk groups for disease-free survival in both training and validation cohorts.","Indexes":[8],"Sentences":["RESULTS: The radiomics model with 15 optimal radiomics features based on MRI performed well in stratifying patients into the high- or a low-risk group of DFS in both the training and validation cohorts (log-rank test, P = 0.009 and P = 0.02, respectively)."],"Revise":false}
{"PMID":"37592104","Document":["In this randomized phase 2 trial, blockade of cytotoxic T-lymphocyte protein 4 (CTLA-4) with continuation of programmed death protein 1 (PD-1) blockade in patients with metastatic melanoma who had received front-line anti-PD-1 or therapy against programmed cell death 1 ligand 1 and whose tumors progressed was tested in comparison with CTLA-4 blockade alone.","Ninety-two eligible patients were randomly assigned in a 3:1 ratio to receive the combination of ipilimumab and nivolumab, or ipilimumab alone.","The primary endpoint was progression-free survival.","Secondary endpoints included the difference in CD8 T cell infiltrate among responding and nonresponding tumors, objective response rate, overall survival and toxicity.","The combination of nivolumab and ipilimumab resulted in a statistically significant improvement in progression-free survival over ipilimumab (hazard ratio\u2009=\u20090.63, 90% confidence interval (CI)\u2009=\u20090.41-0.97, one-sided P\u2009=\u20090.04).","Objective response rates were 28% (90% CI\u2009=\u200919-38%) and 9% (90% CI\u2009=\u20092-25%), respectively (one-sided P\u2009=\u20090.05).","Grade 3 or higher treatment-related adverse events occurred in 57% and 35% of patients, respectively, which is consistent with the known toxicity profile of these regimens.","The change in intratumoral CD8 T cell density observed in the present analysis did not reach statistical significance to support the formal hypothesis tested as a secondary endpoint.","In conclusion, primary resistance to PD-1 blockade therapy can be reversed in some patients with the combination of CTLA-4 and PD-1 blockade.","Clinicaltrials.gov identifier: NCT03033576 ."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"33471137","Document":["BACKGROUND: Limited data are available on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with preexisting autoimmune diseases (PAD).","METHODS: Retrospective study of patients with PAD referred for rheumatologic evaluation prior to starting or during immunotherapy between January 2013 and July 2019 from 10 academic sites across Canada.","Data were extracted by chart review using a standardized form.","RESULTS: Twenty-seven patients with PAD on ICI therapy were identified.","The most common PADs were rheumatoid arthritis (30%), psoriasis\/psoriatic arthritis (30%), inflammatory bowel disease (IBD, 15%) and axial spondyloarthritis (11%), and the most frequently observed cancers were lung cancer and melanoma.","All patients received anti-PD-1 therapies, and 2 received additional sequential anti-CTLA-4 therapy.","PAD exacerbations occurred in 52% over a median (IQR) follow-up of 11.0 (6.0-17.5) months, with 14% being severe, 57% requiring corticosteroids, 50% requiring immunosuppression and 14% requiring ICI discontinuation.","Flares were generally more frequent and severe in patients who previously required more intensive immunosuppression (i.e., biologics).","Flares occurred despite background immunosuppression at the time of ICI initiation.","In patients with preexisting psoriasis, IBD and axial spondyloarthritis, rheumatic immune-related adverse events (irAEs), mostly polyarthritis and tenosynovitis, were frequently observed.","Tumor progression was not associated with exposure to immunosuppressive drugs before or after ICI initiation and was numerically less frequent in patients with irAEs.","CONCLUSION: PAD exacerbations in the context of ICI treatment are common, although generally mild, and occur despite background immunosuppression.","Exacerbations are more frequent and severe in patients on more intensive immunosuppressive therapies pre-immunotherapy."],"Aspect":"o","Summary":"Preexisting autoimmune disease exacerbations occurred in 52% of patients receiving anti-PD-1 therapy, with flares being more frequent and severe in those previously on intensive immunosuppression, while tumor progression was not associated with immunosuppressive drug use and was less frequent in patients with immune-related adverse events.","Indexes":[6,7,10],"Sentences":["PAD exacerbations occurred in 52% over a median (IQR) follow-up of 11.0 (6.0-17.5) months, with 14% being severe, 57% requiring corticosteroids, 50% requiring immunosuppression and 14% requiring ICI discontinuation.","Flares were generally more frequent and severe in patients who previously required more intensive immunosuppression (i.e., biologics).","Tumor progression was not associated with exposure to immunosuppressive drugs before or after ICI initiation and was numerically less frequent in patients with irAEs."],"Revise":true}
{"PMID":"31704549","Document":["AIM OF STUDY: The aim of the study was to assess the impact of treatment with adjuvant vemurafenib monotherapy on health-related quality of life (HRQOL) in patients with resected stage IIC-IIIC melanoma.","METHODS: The phase 3 BRIM8 study (NCT01667419) randomised patients with BRAFV600 mutation-positive resected stage IIC-IIIC melanoma to 960\u00a0mg of vemurafenib twice daily or matching placebo for 52 weeks (13\u00a0\u00d7\u00a028-day cycles).","Patients completed the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) version 3\u00a0at baseline, cycle 1 (days 1, 15 and 22), cycle 2 (days 1 and 15), day 1 of every subsequent 4-week cycle, the end-of-treatment visit and each visit during the follow-up period.","RESULTS: Completion rates for the EORTC QLQ-C30 questionnaire were high (>80%).","There was a mean decline in the global health status (GHS)\/quality of life (QOL) score of 17.4 (\u00b122.9) and 17.3 (\u00b124.1) points at days 15 and 22 of cycle 1, respectively, among vemurafenib-treated patients who recovered to approximately 10 points below baseline for the remainder of the treatment period.","A similar trend was observed in all functional scales except for cognitive function (<10-point change from baseline at all visits) and in the symptom scores for appetite loss, fatigue and pain.","As observed for the GHS\/QOL score, all scores rapidly returned to baseline after completion of planned vemurafenib treatment or treatment discontinuation.","CONCLUSIONS: The schedule of HRQOL assessments allowed for an accurate and complete evaluation of the impact of acute treatment-related symptoms.","Vemurafenib-treated patients experience clinically meaningful moderate worsening in some treatment- or disease-related symptoms and GHS\/QOL that resolve over time."],"Aspect":"s","Summary":"Vemurafenib-treated patients experience clinically meaningful moderate worsening in some treatment- or disease-related symptoms and GHS\/QOL that resolve over time.","Indexes":[8],"Sentences":["Vemurafenib-treated patients experience clinically meaningful moderate worsening in some treatment- or disease-related symptoms and GHS\/QOL that resolve over time."],"Revise":false}
{"PMID":"32369107","Document":["Immune and molecular profiling of CD8 T cells of patients receiving DC vaccines expressing three full-length melanoma antigens (MAs) was performed.","Antigen expression levels in DCs had no significant impact on T cell or clinical responses.","Patients who received checkpoint blockade before DC vaccination had higher baseline MA-specific CD8 T cell responses but no evidence for improved functional responses to the vaccine.","Patients who showed the best clinical responses had low PD-1 expression on MA-specific T cells before and after DC vaccination; however, blockade of PD-1 during antigen presentation by DC had minimal functional impact on PD-1high MA-specific T cells.","Gene and protein expression analyses in lymphocytes and tumor samples identified critical immunoregulatory pathways, including CTLA-4 and PD-1.","High immune checkpoint gene expression networks correlated with inferior clinical outcomes.","Soluble serum PD-L2 showed suggestive positive association with improved outcome.","These findings show that checkpoint molecular pathways are critical for vaccine outcomes and suggest specific sequencing of vaccine combinations."],"Aspect":"a","Summary":"The study aims to investigate the immune and molecular profiling of CD8 T cells in patients receiving DC vaccines expressing three full-length melanoma antigens.","Indexes":[0],"Sentences":["Immune and molecular profiling of CD8 T cells of patients receiving DC vaccines expressing three full-length melanoma antigens (MAs) was performed."],"Revise":false}
{"PMID":"38395969","Document":["Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients.","In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB\/C melanoma were randomized to adjuvant treatment with nDCs (n\u2009=\u200999) or placebo (n\u2009=\u200949).","Active treatment consisted of intranodally injected autologous CD1c+ conventional and plasmacytoid DCs loaded with tumor antigens.","The primary endpoint was the 2-year recurrence-free survival (RFS) rate, whereas the secondary endpoints included median RFS, 2-year and median overall survival, adverse event profile, and immunological response The 2-year RFS rate was 36.8% in the nDC treatment group and 46.9% in the control group (p\u2009=\u20090.31).","Median RFS was 12.7 months vs 19.9 months, respectively (hazard ratio 1.25; 90% CI: 0.88-1.79; p\u2009=\u20090.29).","Median overall survival was not reached in both treatment groups (hazard ratio 1.32; 90% CI: 0.73-2.38; p\u2009=\u20090.44).","Grade 3-4 study-related adverse events occurred in 5% and 6% of patients.","Functional antigen-specific T cell responses could be detected in 67.1% of patients tested in the nDC treatment group vs 3.8% of patients tested in the control group (p\u2009<\u20090.001).","In conclusion, while adjuvant nDC treatment in stage IIIB\/C melanoma patients generated specific immune responses and was well tolerated, no benefit in RFS was observed."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"35658604","Document":["Background: Oncogenic BRAF mutations are commonly found in advanced differentiated thyroid cancer (DTC), and reports have shown efficacy of BRAF inhibitors in these tumors.","We investigated the difference in response between dabrafenib monotherapy and dabrafenib + trametinib therapy in patients with BRAF-mutated radioactive iodine refractory DTC.","Methods: In this open-label randomized phase 2 multicenter trial, patients aged \u226518 years with BRAF-mutated radioactive iodine refractory DTC with progressive disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 within 13 months before enrollment were eligible.","Patients were randomly assigned to receive dabrafenib alone or dabrafenib + trametinib.","The primary endpoint was objective response rate by modified RECIST (minor response of -20% to -29%, partial and complete response) within the first 24 weeks of therapy.","Trial Registration Number: NCT01723202.","Results: A total of 53 patients were enrolled.","The objective response rate (modified RECIST) was 42% (11\/26 [95% confidence interval {CI} 23-63%]) with dabrafenib versus 48% (13\/27 [CI 29-68%]) with dabrafenib + trametinib (p\u2009=\u20090.67).","Objective response rate (RECIST 1.1) was 35% (9\/26 [CI 17-56%]) with dabrafenib and 30% (8\/27 [CI 14-51%]) with dabrafenib + trametinib.","Most common treatment-related adverse events included skin and subcutaneous tissue disorders (17\/26, 65%), fever (13\/26, 50%), hyperglycemia (12\/26, 46%) with dabrafenib alone and fever (16\/27, 59%), nausea, chills, fatigue (14\/27, 52% each) with dabrafenib + trametinib.","There were no treatment-related deaths.","Conclusions: Combination dabrafenib + trametinib was not superior in efficacy compared to dabrafenib monotherapy in patients with BRAF-mutated radioiodine refractory progressive DTC."],"Aspect":"i","Summary":"Patients with BRAF-mutated radioactive iodine refractory DTC were randomly assigned to receive dabrafenib alone or dabrafenib + trametinib in an open-label randomized phase 2 multicenter trial.","Indexes":[1,2,3],"Sentences":["We investigated the difference in response between dabrafenib monotherapy and dabrafenib + trametinib therapy in patients with BRAF-mutated radioactive iodine refractory DTC.","Methods: In this open-label randomized phase 2 multicenter trial, patients aged \u226518 years with BRAF-mutated radioactive iodine refractory DTC with progressive disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 within 13 months before enrollment were eligible.","Patients were randomly assigned to receive dabrafenib alone or dabrafenib + trametinib."],"Revise":false}
{"PMID":"37142291","Document":["Talimogene laherparepvec (T-VEC) plus ipilimumab has demonstrated greater antitumor activity versus ipilimumab alone, without additional toxicity, in patients with advanced melanoma.","Here, we report the 5-year outcomes from a randomized phase II study.","These data provide the longest efficacy and safety follow-up for patients with melanoma treated with a combination of an oncolytic virus and a checkpoint inhibitor.Eligible patients with unresectable stage IIIB\u2012IV melanoma were randomized 1:1 to receive T-VEC plus ipilimumab or ipilimumab alone.","T-VEC was administered intralesionally at 106 plaque-forming units (PFU)\/mL in week 1, followed by 108 PFU\/mL in week 4 and every 2 weeks thereafter.","Ipilimumab (3 mg\/kg every 3 weeks; \u22644 doses) was administered intravenously starting at week 1 in the ipilimumab arm and week 6 in the combination arm.","The primary end point was investigator-assessed objective response rate (ORR) per immune-related response criteria; key secondary end points included durable response rate (DRR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety.Overall, 198 patients were randomized to receive the combination (n=98) or ipilimumab (n=100).","The combination improved the ORR versus ipilimumab (35.7% vs 16.0%; OR 2.9; 95% CI 1.5 to 5.7; p=0.003).","DRR was 33.7% and 13.0% (unadjusted OR 3.4; 95% CI 1.7 to 7.0; descriptive p=0.001), respectively.","Among the objective responders, the median DOR was 69.2 months (95% CI 38.5 to not estimable) with the combination and was not reached with ipilimumab.","Median PFS was 13.5 months with the combination and 6.4 months with ipilimumab (HR 0.78; 95% CI 0.55 to 1.09; descriptive p=0.14).","Estimated 5-year OS was 54.7% (95% CI 43.9 to 64.2) in the combination arm and 48.4% (95% CI 37.9 to 58.1) in the ipilimumab arm.","Forty-seven (48.0%) and 65 (65.0%) patients in the combination and ipilimumab arms, respectively, received subsequent therapies.","No new safety signals were reported.At the 5-year follow-up, the improved response rates observed with T-VEC plus ipilimumab were durable.","This is the first randomized controlled study of the combination of an oncolytic virus and a checkpoint inhibitor that meets its primary end point.Trial registration number: NCT01740297."],"Aspect":"i","Summary":"The study involved a randomized phase II trial where patients with unresectable stage IIIB\u2012IV melanoma received either T-VEC plus ipilimumab or ipilimumab alone, with T-VEC administered intralesionally and ipilimumab given intravenously.","Indexes":[2,3,4],"Sentences":["These data provide the longest efficacy and safety follow-up for patients with melanoma treated with a combination of an oncolytic virus and a checkpoint inhibitor.Eligible patients with unresectable stage IIIB\u2012IV melanoma were randomized 1:1 to receive T-VEC plus ipilimumab or ipilimumab alone.","T-VEC was administered intralesionally at 106 plaque-forming units (PFU)\/mL in week 1, followed by 108 PFU\/mL in week 4 and every 2 weeks thereafter.","Ipilimumab (3 mg\/kg every 3 weeks; \u22644 doses) was administered intravenously starting at week 1 in the ipilimumab arm and week 6 in the combination arm."],"Revise":false}
{"PMID":"35596181","Document":["BACKGROUND: Anti-programmed cell death receptor-1 (PD-1) monotherapy is the standard treatment for metastatic melanoma in current.","Camrelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody whose safety and efficacy have not been reported in advanced Asian melanoma patients.","METHODS: This phase I study investigated the safety, activity, and pharmacokinetics of camrelizumab in Chinese patients with advanced melanoma.","The study included two phases, the dose-escalation phase (\"3\u2009+\u20093\" design at 60\u2009mg, 200\u2009mg, and 400\u2009mg) and the dose-expansion phase.","RESULTS: No dose-limiting toxicities were recorded over the dose-escalation phase, and the maximum tolerated dose was not reached.","The most common treatment-related adverse events (TRAEs) in 36 patients were reactive cutaneous capillary endothelial proliferation, followed by rash, fever, hypothyroidism, hyperthyroidism, vitiligo, and fatigue.","Five grade 3 or above TRAEs were reported (13.9%), including two cases of elevated \u03b3-glutamyltransferase and blood triglycerides without clinical symptoms, and one liver injury recovered after symptomatic treatment.","The confirmed overall response rate was 13.9% (95%CI: 4.7, 29.5%) and disease control rate was 38.9% (95%CI: 23.1, 56.5%).","The median progression-free survival was 1.8\u2009months (95%CI: 1.1, 2.4) and the median overall survival was 11.1\u2009months (95%CI: 6.8, 15.4).","CONCLUSIONS: Camrelizumab had acceptable tolerability and similar anti-tumor activity compared with other anti-PD-1 antibodies in advanced Asian melanoma patients.","TRIAL REGISTRATION: ClinicalTrials.gov identification: NCT02738489.","Registered on 14\/04\/2016, prospectively registered."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"33303685","Document":["The gut microbiome has been shown to influence the response of tumors to anti-PD-1 (programmed cell death-1) immunotherapy in preclinical mouse models and observational patient cohorts.","However, modulation of gut microbiota in cancer patients has not been investigated in clinical trials.","In this study, we performed a phase 1 clinical trial to assess the safety and feasibility of fecal microbiota transplantation (FMT) and reinduction of anti-PD-1 immunotherapy in 10 patients with anti-PD-1-refractory metastatic melanoma.","We observed clinical responses in three patients, including two partial responses and one complete response.","Notably, treatment with FMT was associated with favorable changes in immune cell infiltrates and gene expression profiles in both the gut lamina propria and the tumor microenvironment.","These early findings have implications for modulating the gut microbiota in cancer treatment."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"32376721","Document":["BACKGROUND: CTLA-4 blockade with ipilimumab is Food and Drug Administration-approved for melanoma as a monotherapy and has been shown to modulate the circulating T-cell repertoire.","We have previously reported clinical trials combining CTLA-4 blockade with granulocyte-macrophage colony-stimulating factor (GM-CSF) in metastatic melanoma patients and in metastatic castration resistant prostate cancer (mCRPC) patients.","Here, we investigate the effect that cancer type has on circulating T cells in metastatic melanoma and mCRPC patients, treated with ipilimumab and GM-CSF.","METHODS: We used next-generation sequencing of T-cell receptors (TCR) to compare the circulating T cells of melanoma and mCRPC patients receiving the same treatment with ipilimumab and GM-CSF by Wilcoxon rank sum test.","Flow cytometry was utilized to investigate specific T-cell populations.","TCR sequencing results were correlated with each T-cell subpopulation by Spearman's rank correlation coefficient.","Of note, 14 metastatic melanoma patients had samples available for TCR sequencing and 21 had samples available for flow cytometry analysis; 37 mCRPC patients had samples available for sequencing of whom 22 have TCR data available at both timepoints; 20 of these patients had samples available for flow cytometry analysis and 16 had data available at both timepoints.","RESULTS: While melanoma and mCRPC patients had similar pretreatment circulating T-cell counts, treatment induces greater expansion of circulating T cells in melanoma patients.","Metastatic melanoma patients have a higher proportion of clones that increased more than fourfold after the treatment compared with mCRPC patients (18.9% vs 11.0%, p=0.017).","Additionally, melanoma patients compared with mCRPC patients had a higher ratio of convergent frequency (1.22 vs 0.60, p=0.012).","Decreases in clonality induced by treatment are associated with baseline CD8+ T-cell counts in both patient groups, but are more pronounced in the melanoma patients (r=-0.81, p<0.001\u2009vs r=-0.59, p=0.02).","TRIAL REGISTRATION NUMBERS: NCT00064129; NCT01363206."],"Aspect":"i","Summary":"The study investigated the effect of cancer type on circulating T cells in metastatic melanoma and mCRPC patients treated with ipilimumab and GM-CSF using next-generation sequencing of T-cell receptors and flow cytometry.","Indexes":[2,3,4],"Sentences":["Here, we investigate the effect that cancer type has on circulating T cells in metastatic melanoma and mCRPC patients, treated with ipilimumab and GM-CSF.","METHODS: We used next-generation sequencing of T-cell receptors (TCR) to compare the circulating T cells of melanoma and mCRPC patients receiving the same treatment with ipilimumab and GM-CSF by Wilcoxon rank sum test.","Flow cytometry was utilized to investigate specific T-cell populations."],"Revise":false}
{"PMID":"36089578","Document":["BACKGROUND: This clinical trial evaluated a novel telomerase-targeting therapeutic cancer vaccine, UV1, in combination with ipilimumab, in patients with metastatic melanoma.","Translational research was conducted on patient-derived blood and tissue samples with the goal of elucidating the effects of treatment on the T cell receptor repertoire and tumor microenvironment.","METHODS: The trial was an open-label, single-center phase I\/IIa study.","Eligible patients had unresectable metastatic melanoma.","Patients received up to 9 UV1 vaccinations and four ipilimumab infusions.","Clinical responses were assessed according to RECIST 1.1.","Patients were followed up for progression-free survival (PFS) and overall survival (OS).","Whole-exome and RNA sequencing, and multiplex immunofluorescence were performed on the biopsies.","T cell receptor (TCR) sequencing was performed on the peripheral blood and tumor tissues.","RESULTS: Twelve patients were enrolled in the study.","Vaccine-specific immune responses were detected in 91% of evaluable patients.","Clinical responses were observed in four patients.","The mPFS was 6.7\u00a0months, and the mOS was 66.3\u00a0months.","There was no association between baseline tumor mutational burden, neoantigen load, IFN-\u03b3 gene signature, tumor-infiltrating lymphocytes, and response to therapy.","Tumor telomerase expression was confirmed in all available biopsies.","Vaccine-enriched TCR clones were detected in blood and biopsy, and an increase in the tumor IFN-\u03b3 gene signature was detected in clinically responding patients.","CONCLUSION: Clinical responses were observed irrespective of established predictive biomarkers for checkpoint inhibitor efficacy, indicating an added benefit of the vaccine-induced T cells.","The clinical and immunological read-out warrants further investigation of UV1 in combination with checkpoint inhibitors.","Trial registration Clinicaltrials.gov identifier: NCT02275416.","Registered October 27, 2014. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02275416?term=uv1&draw=2&rank=6."],"Aspect":"i","Summary":"The study was an open-label, single-center phase I\/IIa trial where eligible patients with unresectable metastatic melanoma received up to 9 UV1 vaccinations and four ipilimumab infusions, with clinical responses assessed according to RECIST 1.1.","Indexes":[2,3,4,5],"Sentences":["METHODS: The trial was an open-label, single-center phase I\/IIa study.","Eligible patients had unresectable metastatic melanoma.","Patients received up to 9 UV1 vaccinations and four ipilimumab infusions.","Clinical responses were assessed according to RECIST 1.1."],"Revise":false}
{"PMID":"37536936","Document":["BACKGROUND: The tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is made by ex vivo priming matured autologous dendritic cells (DCs) with yeast cell wall particles (YCWPs) loaded with autologous tumor lysate (TL).","The tumor lysate, particle only (TLPO) vaccine uses autologous TL-loaded YCWPs coated with silicate for in vivo DC loading.","Here we report the 36-month prespecified analyses of this prospective, randomized, double-blind trial investigating the ability of the TLPO and TLPLDC (\u00b1granulocyte-colony stimulating factor (G-CSF)) vaccines to prevent melanoma recurrence in high-risk patients.","METHODS: Patients with clinically disease-free stage III\/IV melanoma were randomized 2:1 initially to TLPLDC versus placebo (n=124) and subsequently TLPO versus TLPLDC (n=63).","All patients were randomized and blinded; however, the placebo control arm was replaced in the second randomization scheme with another novel vaccine; some analyses in this paper therefore reflect a combination of the two randomization schemes.","Patients receiving the TLPLDC vaccine were further divided by their method of DC harvest (with or without G-CSF pretreatment); this was not randomized.","The use of standard of care checkpoint inhibitors was not stratified between groups.","Safety was assessed and Kaplan-Meier and log-rank analyses compared disease-free (DFS) and overall survival (OS).","RESULTS: After combining the two randomization processes, a total of 187 patients were allocated between treatment arms: placebo (n=41), TLPLDC (n=103), or TLPO (n=43).","The allocation among arms created by the addition of patients from the two separate randomization schemes does not reflect concurrent randomization among all treatment arms.","TLPLDC was further divided by use of G-CSF in DC harvest: no G-CSF (TLPLDC) (n=47) and with G-CSF (TLPLDC+G) (n=56).","Median follow-up was 35.8 months.","Only two patients experienced a related adverse event \u2265grade 3, one each in the TLPLDC+G\u2009and placebo arms.","DFS was 27.2% (placebo), 55.4% (TLPLDC), 22.9% (TLPLDC+G), and 60.9% (TLPO) (p<0.001).","OS was 62.5% (placebo), 93.6% (TLPLDC), 57.7% (TLPLDC+G), and 94.6% (TLPO) (p=0.002).","CONCLUSIONS: The TLPO and TLPLDC (without G-CSF) vaccines were associated with improved DFS and OS in this clinical trial.","Given production and manufacturing advantages, the efficacy of the TLPO vaccine will be confirmed in a phase 3 trial.","TRIAL REGISTRATION NUMBER: NCT02301611."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":true}
{"PMID":"35940183","Document":["BACKGROUND: Targeted therapy and immunotherapy have shown intracranial activity in melanoma with CNS metastases, but there remains an unmet need, particularly for patients with symptomatic CNS metastases.","We aimed to evaluate atezolizumab in combination with cobimetinib or vemurafenib plus cobimetinib in patients with melanoma with CNS metastases.","METHODS: TRICOTEL was a multicentre, open-label, single-arm, phase 2 study done in two cohorts: a BRAFV600 wild-type cohort and a BRAFV600 mutation-positive cohort, recruited at 21 hospitals and oncology centres in Brazil, France, Germany, Hungary, Italy, Spain, and Switzerland.","Eligible patients were aged 18 years or older with previously untreated metastatic melanoma, CNS metastases of 5 mm or larger in at least one dimension, and an Eastern Cooperative Oncology Group performance status of 2 or less.","Patients in the BRAFV600 wild-type cohort received intravenous atezolizumab (840 mg, days 1 and 15 of each 28-day cycle) plus oral cobimetinib (60 mg once daily, days 1-21).","Patients in the BRAFV600 mutation-positive cohort received intravenous atezolizumab (840 mg, days 1 and 15 of each 28-day cycle) plus oral vemurafenib (720 mg twice daily) plus oral cobimetinib (60 mg once daily, days 1-21); atezolizumab was withheld in cycle 1.","Treatment was continued until progression, toxicity, or death.","The primary outcome was intracranial objective response rate confirmed by assessments at least 4 weeks apart, as assessed by independent review committee (IRC) using modified Response Evaluation Criteria in Solid Tumours version 1.1.","Because of early closure of the BRAFV600 wild-type cohort, the primary endpoint of intracranial objective response rate by IRC assessment was not done in this cohort; intracranial objective response rate by investigator assessment was reported instead.","Efficacy and safety were analysed in all patients who received at least one dose of study medication.","This trial is closed to enrolment and is registered with ClinicalTrials.gov, NCT03625141.","FINDINGS: Between Dec 13, 2018, and Dec 7, 2020, 65 patients were enrolled in the BRAFV600 mutation-positive cohort; the BRAFV600 wild-type cohort was closed early after enrolment of 15 patients.","Median follow-up was 9\u00b77 months (IQR 6\u00b73-15\u00b70) for the BRAFV600 mutation-positive cohort and 6\u00b72 months (3\u00b75-23\u00b70) for the BRAFV600 wild-type cohort.","Intracranial objective response rate was 42% (95% CI 29-54) by IRC assessment in the BRAFV600 mutation-positive cohort and 27% (95% CI 8-55) by investigator assessment in the BRAFV600 wild-type cohort.","Treatment-related grade 3 or worse adverse events occurred in 41 (68%) of 60 patients who received atezolizumab plus vemurafenib plus cobimetinib in the BRAFV600 mutation-positive cohort, the most common of which were lipase increased (15 [25%] of 60 patients) and blood creatine phosphokinase increased (ten [17%]).","Eight (53%) of 15 patients treated with atezolizumab plus cobimetinib in the BRAFV600 wild-type cohort had treatment-related grade 3 or worse adverse events, most commonly anaemia (two [13%]) and dermatitis acneiform (two [13%]).","Treatment-related serious adverse events occurred in 14 (23%) of 60 patients in the BRAFV600 mutation-positive cohort and two (13%) of 15 in the BRAFV600 wild-type cohort.","One death in the BRAFV600 mutation-positive cohort (limbic encephalitis) was considered to be related to atezolizumab treatment.","INTERPRETATION: Adding atezolizumab to vemurafenib plus cobimetinib provided promising intracranial activity in patients with BRAFV600-mutated melanoma with CNS metastases.","FUNDING: F Hoffmann-La Roche."],"Aspect":"m","Summary":"The study evaluated atezolizumab (840 mg, days 1 and 15 of each 28-day cycle) plus oral cobimetinib (60 mg once daily, days 1-21) in the BRAFV600 wild-type cohort, and atezolizumab (840 mg, days 1 and 15 of each 28-day cycle) plus oral vemurafenib (720 mg twice daily) plus oral cobimetinib (60 mg once daily, days 1-21) in the BRAFV600 mutation-positive cohort.","Indexes":[4,5],"Sentences":["Patients in the BRAFV600 wild-type cohort received intravenous atezolizumab (840 mg, days 1 and 15 of each 28-day cycle) plus oral cobimetinib (60 mg once daily, days 1-21).","Patients in the BRAFV600 mutation-positive cohort received intravenous atezolizumab (840 mg, days 1 and 15 of each 28-day cycle) plus oral vemurafenib (720 mg twice daily) plus oral cobimetinib (60 mg once daily, days 1-21); atezolizumab was withheld in cycle 1."],"Revise":false}
{"PMID":"38246194","Document":["BACKGROUND: Checkpoint inhibitors are standard adjuvant treatment for stage IIB-IV resected melanoma, but many patients recur.","Our study aimed to evaluate whether mRNA-4157 (V940), a novel mRNA-based individualised neoantigen therapy, combined with pembrolizumab, improved recurrence-free survival and distant metastasis-free survival versus pembrolizumab monotherapy in resected high-risk melanoma.","METHODS: We did an open-label, randomised, phase 2b, adjuvant study of mRNA-4157 plus pembrolizumab versus pembrolizumab monotherapy in patients, enrolled from sites in the USA and Australia, with completely resected high-risk cutaneous melanoma.","Patients with completely resected melanoma (stage IIIB-IV) were assigned 2:1 to receive open-label mRNA-4157 plus pembrolizumab or pembrolizumab monotherapy.","mRNA-4157 was administered intramuscularly (maximum nine doses) and pembrolizumab intravenously (maximum 18 doses) in 3-week cycles.","The primary endpoint was recurrence-free survival in the intention-to-treat population.","This ongoing trial is registered at ClinicalTrials.gov, NCT03897881.","FINDINGS: From July 18, 2019, to Sept 30, 2021, 157 patients were assigned to mRNA-4157 plus pembrolizumab combination therapy (n=107) or pembrolizumab monotherapy (n=50); median follow-up was 23 months and 24 months, respectively.","Recurrence-free survival was longer with combination versus monotherapy (hazard ratio [HR] for recurrence or death, 0\u00b7561 [95% CI 0\u00b7309-1\u00b7017]; two-sided p=0\u00b7053), with lower recurrence or death event rate (24 [22%] of 107 vs 20 [40%] of 50); 18-month recurrence-free survival was 79% (95% CI 69\u00b70-85\u00b76) versus 62% (46\u00b79-74\u00b73).","Most treatment-related adverse events were grade 1-2.","Grade \u22653 treatment-related adverse events occurred in 25% of patients in the combination group and 18% of patients in the monotherapy group, with no mRNA-4157-related grade 4-5 events.","Immune-mediated adverse event frequency was similar for the combination (37 [36%]) and monotherapy (18 [36%]) groups.","INTERPRETATION: Adjuvant mRNA-4157 plus pembrolizumab prolonged recurrence-free survival versus pembrolizumab monotherapy in patients with resected high-risk melanoma and showed a manageable safety profile.","These results provide evidence that an mRNA-based individualised neoantigen therapy might be beneficial in the adjuvant setting.","FUNDING: Moderna in collaboration with Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway, NJ, USA."],"Aspect":"p","Summary":"The study involved 157 patients with completely resected high-risk cutaneous melanoma (stage IIIB-IV), with 107 assigned to mRNA-4157 plus pembrolizumab and 50 assigned to pembrolizumab monotherapy.","Indexes":[3,7],"Sentences":["Patients with completely resected melanoma (stage IIIB-IV) were assigned 2:1 to receive open-label mRNA-4157 plus pembrolizumab or pembrolizumab monotherapy.","FINDINGS: From July 18, 2019, to Sept 30, 2021, 157 patients were assigned to mRNA-4157 plus pembrolizumab combination therapy (n=107) or pembrolizumab monotherapy (n=50); median follow-up was 23 months and 24 months, respectively."],"Revise":false}
{"PMID":"32753545","Document":["UNLABELLED: Treatment of metastatic melanoma with autologous tumor infiltrating lymphocytes (TILs) is currently applied in several centers.","Robust and remarkably consistent overall response rates, of around 50% of treated patients, have been observed across hospitals, including a substantial fraction of durable, complete responses.","PURPOSE: Execute a phase I\/II feasibility study with TIL therapy in metastatic melanoma at the Netherlands Cancer Institute, with the goal to assess feasibility and potential value of a randomized phase III trial.","EXPERIMENTAL: Ten patients were treated with TIL therapy.","Infusion products and peripheral blood samples were phenotypically characterized and neoantigen reactivity was assessed.","Here, we present long-term clinical outcome and translational data on neoantigen reactivity of the T cell products.","RESULTS: Five out of 10 patients, who were all anti-PD-1 na\u00efve at time of treatment, showed an objective clinical response, including two patients with a complete response that are both ongoing for more than 7 years.","Immune monitoring demonstrated that neoantigen-specific T cells were detectable in TIL infusion products from three out of three patients analyzed.","For six out of the nine neoantigen-specific T cell responses detected in these TIL products, T cell response magnitude increased significantly in the peripheral blood compartment after therapy, and neoantigen-specific T cells were detectable for up to 3 years after TIL infusion.","CONCLUSION: The clinical results from this study confirm the robustness of TIL therapy in metastatic melanoma and the potential role of neoantigen-specific T cell reactivity.","In addition, the data from this study supported the rationale to initiate an ongoing multicenter phase III TIL trial."],"Aspect":"i","Summary":"The study conducted a phase I\/II feasibility trial where ten patients with metastatic melanoma were treated with autologous tumor infiltrating lymphocytes (TILs) therapy.","Indexes":[2,3],"Sentences":["PURPOSE: Execute a phase I\/II feasibility study with TIL therapy in metastatic melanoma at the Netherlands Cancer Institute, with the goal to assess feasibility and potential value of a randomized phase III trial.","EXPERIMENTAL: Ten patients were treated with TIL therapy."],"Revise":false}
{"PMID":"32534242","Document":["PURPOSE: This study (NCT02083354) assessed the efficacy and safety of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.","METHOD: Overall, 77 patients of East Asian origin (including 61 from Mainland China) with unresectable or metastatic BRAF V600-mutant cutaneous melanoma were enrolled.","Prior treatment was allowed except with BRAF\/MEK inhibitors.","Patients received dabrafenib 150\u00a0mg twice daily and trametinib 2\u00a0mg once daily.","The primary end-point was objective response rate (ORR) using Response Evaluation Criteria in Solid Tumours 1.1.","Secondary end-points were duration of response (DOR), progression-free survival (PFS), overall survival (OS), pharmacokinetics and safety.","RESULTS: At data cutoff (February 23, 2018; median follow-up, 8.3 months), treatment was ongoing in 36 patients (47%).","The median age was 52 years; 32% of patients had elevated lactate dehydrogenase, and 84% had received prior systemic therapy.","ORR was 61% (95% confidence interval: 49.2-72.0), with four patients (5%) achieving complete response.","Median DOR and PFS were 11.3 and 7.9 months, respectively.","Median OS was not reached.","The most common adverse event (AE) of any grade was pyrexia (56%).","Grade \u2265III AEs occurred in 29 patients (38%).","The most common grade \u2265III AEs were pyrexia (8%) and anaemia (6%).","AEs led to permanent discontinuation in five patients (6.5%).","Mean Cmax for dabrafenib and trametinib was 3560 and 11.5\u00a0ng\/mL (day 1) and 2680 and 27.1\u00a0ng\/mL (day 15), respectively.","CONCLUSION: These results support the efficacy and tolerability of dabrafenib in combination with trametinib in East Asian patients with unresectable or metastatic BRAF V600-mutant cutaneous melanoma."],"Aspect":"d","Summary":"Unknown.","Indexes":[],"Sentences":[],"Revise":false}
{"PMID":"34287772","Document":["Background\u00a0The study determined the safety, pharmacokinetics\/pharmacodynamics (PK\/PD), and recommended Phase II dose of BCT-100 for arginine auxotrophic tumours in a non-Chinese population.","Methods This is a Phase I, 3\u2009+\u20093 dose-escalation, open-label, multi-centre study in two arginine auxotrophic cancers-Malignant Melanoma (MM) and Castration Resistant Prostate Cancer (CRPC).","Patients were enrolled to receive weekly intravenous BCT-100.","The dose cohorts were respectively 0.5\u00a0mg\/kg, 1.0\u00a0mg\/kg, 1.7\u00a0mg\/kg and 2.7\u00a0mg\/kg.","Results There were 14 MM and 9 CRPC patients, 16 males and 7 females with a\u00a0median age of 71.","No dose-limiting toxicities were reported.","Among all the AEs, 18 were drug-related (mostly were Grade 1).","Although there were individual variations in PKs amongst the patients in each cohort, the median arginine level was maintained at 2.5 \u00b5M (lower limit of quantification) in all 4 cohorts of patients after the second BCT-100 injection.","Therapeutic Arginine Depletion was found in the 1.7 and 2.7\u00a0mg\/kg\/week cohorts when anti-tumor activities were observed.","The two cohorts had a similar AUC (20,947 and 19,614\u00a0h*\u00b5g\/ml respectively).","Since the 2.7\u00a0mg\/kg\/week cohort had a more sustained arginine depletion for 2\u00a0weeks, the 2.7\u00a0mg\/kg\/week dose is chosen as the future phase II dose.","There were two complete remissions (1 MM & 1 CRPC), 1PR (MM) and 2 stable diseases with a disease control rate (CR\u2009+\u2009PR\u2009+\u2009SD) of 5\/23 (22%).","Conclusions BCT-100 is safe in a non-Chinese population and has anti-tumor activities in both MM and CRPC.","Weekly BCT-100 at 2.7\u00a0mg\/kg is defined as the optimal biological dose for future clinical phase II studies."],"Aspect":"m","Summary":"The study investigated BCT-100, administered weekly at doses of 0.5 mg\/kg, 1.0 mg\/kg, 1.7 mg\/kg, and 2.7 mg\/kg, with the recommended Phase II dose being 2.7 mg\/kg\/week.","Indexes":[2,3,10,13],"Sentences":["Patients were enrolled to receive weekly intravenous BCT-100.","The dose cohorts were respectively 0.5\u00a0mg\/kg, 1.0\u00a0mg\/kg, 1.7\u00a0mg\/kg and 2.7\u00a0mg\/kg.","Since the 2.7\u00a0mg\/kg\/week cohort had a more sustained arginine depletion for 2\u00a0weeks, the 2.7\u00a0mg\/kg\/week dose is chosen as the future phase II dose.","Weekly BCT-100 at 2.7\u00a0mg\/kg is defined as the optimal biological dose for future clinical phase II studies."],"Revise":false}
{"PMID":"35842199","Document":["BACKGROUND: No standard of care for mucosal melanoma (MM) in the adjuvant setting has been established.","Meanwhile, relapse-free survival (RFS) is only \u223c5 months after surgery alone.","This phase II trial aimed to compare toripalimab versus high-dose interferon-\u03b12b (HDI) as an adjuvant therapy for resected MM.","PATIENTS AND METHODS: From July 2017 to May 2019, 145 patients with resected MM were randomized (1 : 1) to receive HDI (n\u00a0= 72) or toripalimab (n\u00a0= 73) for 1 year until disease relapse\/distant metastasis, unacceptable toxicity, or withdrawal of consent.","The primary endpoint was RFS.","The secondary endpoints included distant metastasis-free survival (DMFS), overall survival (OS), and safety.","RESULTS: After a median follow-up of 26.3 months, the number of RFS, OS, and DMFS events was 51 versus 46, 33 versus 29, and 49 versus 44 in the toripalimab arm and the HDI arm, respectively.","The median RFS was 13.6 [95% confidence interval (CI) 8.31-19.02] months and 13.9 (95% CI 8.28-19.61) months in the toripalimab arm and the HDI arm, respectively.","The DMFS was not significantly different between the two arms [hazard ratio (HR) 1.00; 95% CI 0.65-1.54].","The median OS was 35.1 months (95% CI 27.93 months-not reached) in the toripalimab arm, with no significant difference in all-cause death (HR 1.11, 95% CI 0.66-1.84) for the two arms.","The median sums of the patients' actual infusion doses were 3672 mg and 1054.5 MIU in the toripalimab arm and the HDI arm, respectively.","The incidence of treatment-emergent adverse events with a grade \u22653 was much higher in the HDI arm than in the toripalimab arm (87.5% versus 27.4%).","CONCLUSIONS: Toripalimab showed a similar RFS and a more favorable safety profile than HDI, both better than historical data, suggesting that toripalimab might be the better treatment option.","However, additional translational studies and better treatment regimens are still warranted to improve the clinical outcome of MM."],"Aspect":"d","Summary":"Patients received treatment for 1 year or until disease relapse, distant metastasis, unacceptable toxicity, or withdrawal of consent.","Indexes":[3],"Sentences":["PATIENTS AND METHODS: From July 2017 to May 2019, 145 patients with resected MM were randomized (1 : 1) to receive HDI (n\u00a0= 72) or toripalimab (n\u00a0= 73) for 1 year until disease relapse\/distant metastasis, unacceptable toxicity, or withdrawal of consent."],"Revise":true}
